<SEC-DOCUMENT>0000719135-21-000029.txt : 20210331
<SEC-HEADER>0000719135-21-000029.hdr.sgml : 20210331
<ACCEPTANCE-DATETIME>20210331163132
ACCESSION NUMBER:		0000719135-21-000029
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		88
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210331
DATE AS OF CHANGE:		20210331

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Apyx Medical Corp
		CENTRAL INDEX KEY:			0000719135
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				112644611
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31885
		FILM NUMBER:		21793864

	BUSINESS ADDRESS:	
		STREET 1:		5115 ULMERTON ROAD
		CITY:			CLEARWATER
		STATE:			FL
		ZIP:			33760
		BUSINESS PHONE:		7273842323

	MAIL ADDRESS:	
		STREET 1:		5115 ULMERTON ROAD
		CITY:			CLEARWATER
		STATE:			FL
		ZIP:			33760

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BOVIE MEDICAL Corp
		DATE OF NAME CHANGE:	20150319

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BOVIE MEDICAL CORP
		DATE OF NAME CHANGE:	19990216

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AN CON GENETICS INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>apyx-20201231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:3619fb04-76d2-4e32-a22c-67723657dfe5,g:73c9cb31-492e-4d91-a8e4-50624d0c0cae,d:db46c8b71d7d4a27b277b6db52f68e8e--><html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:apyx="http://apyxmedical.com/20201231" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>apyx-20201231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV80L2ZyYWc6YTcxNWU2Nzc0ZTRjNDA4NjgyZGMyZTQyMjNiOGM4NjgvdGFibGU6MWI1YjlmMjNiOTBkNGRiNjgwYTE3YzEwODVjNGQ4NjkvdGFibGVyYW5nZToxYjViOWYyM2I5MGQ0ZGI2ODBhMTdjMTA4NWM0ZDg2OV8yLTEtMS0xLTA_478ac2cb-7551-4575-8f41-52727e8d1acb">0000719135</ix:nonNumeric><ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV80L2ZyYWc6YTcxNWU2Nzc0ZTRjNDA4NjgyZGMyZTQyMjNiOGM4NjgvdGFibGU6MWI1YjlmMjNiOTBkNGRiNjgwYTE3YzEwODVjNGQ4NjkvdGFibGVyYW5nZToxYjViOWYyM2I5MGQ0ZGI2ODBhMTdjMTA4NWM0ZDg2OV81LTEtMS0xLTA_7b680101-1e4f-417b-a1a7-88a3240ca088">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV80L2ZyYWc6YTcxNWU2Nzc0ZTRjNDA4NjgyZGMyZTQyMjNiOGM4NjgvdGFibGU6MWI1YjlmMjNiOTBkNGRiNjgwYTE3YzEwODVjNGQ4NjkvdGFibGVyYW5nZToxYjViOWYyM2I5MGQ0ZGI2ODBhMTdjMTA4NWM0ZDg2OV8xNi0xLTEtMS0w_36981a18-5556-43fb-887b-ffd807d0f3f0">FY</ix:nonNumeric><ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV80L2ZyYWc6YTcxNWU2Nzc0ZTRjNDA4NjgyZGMyZTQyMjNiOGM4NjgvdGFibGU6MWI1YjlmMjNiOTBkNGRiNjgwYTE3YzEwODVjNGQ4NjkvdGFibGVyYW5nZToxYjViOWYyM2I5MGQ0ZGI2ODBhMTdjMTA4NWM0ZDg2OV8xNy0xLTEtMS0w_d204c6c8-1a67-4a9c-9970-375e5adce881">2020</ix:nonNumeric><ix:nonNumeric contextRef="i79cf41051ed34d12a5fa5d78feeeef12_D20200101-20201231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzEwOTk1MTE2MzcxMDk_cf9a545e-25f8-4790-a167-4803e9a50ffa">P1Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="apyx-20201231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="id55f6de3007948b69061635a4640b62b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i7ed1b671dc694c3ca5cd5bc47208993d_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ib31d35568ba546f9a9d4089583b98733_I20210329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96df8138377f4df5b064ec7bcc292732_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96fdd56f4a934deb9be8b429dd443450_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56b0b5fc07294eaa8b9b7c9c449eee1a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67c608a0d0d84f82b2791e369dd406ef_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd03c7764245458ba14ccb5108168190_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00df6877cb2d4b75a1a4abee0d94d57f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id992bd2f876c4b41b9cacd2ed36d028b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1b9838e537a4797bfd3b3f72116ce4a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3251c9a7258d4e12930f0fe7a2b79ff9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib71a81c6cf874b9f8f5abe1afdc8701d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cae677daf3a4680b30b757dd83c4a07_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a3d8fad4cc642db8994868640f75384_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bb3f044ef5d488f992a3c49afc08bf0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e0b3ac3abbb4da6ba6ebb3596d95da5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bd3c576836a42909e45df1e4cbe6038_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1386a67ac59644f3bcf3f6f4a0040e4f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i868214ceea314396813754fb0220fc1f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b9e760795d04740980adf4105f44066_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d4c03e853084e12b45168c562e7aeac_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09376f8c140d4e28b47971c939c7a4fb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a1a44a54fd4403d892b074c44ed1d4d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i45882c1ec2804d9e9753f1f3e2754339_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">apyx:ApyxSYMedicalDevicesNingboCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bc128762b18423fb747675dee1c2b38_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cbbd8dbe42a42989174fca0d2219d64_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ided82545571a4ee3959a92c88503da8a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id16feebf7b354586bb519173e63e4a13_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia212175fe18e4aa78e12bf752ae2656e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f6eeb41de814d65b926757c9f6c1659_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">apyx:ComputerEquipmentandSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9461cea186574f9d99826a2a0dc1e166_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">apyx:ComputerEquipmentandSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i373f3e4cf9074d1eaadacf5820f14dc7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ToolsDiesAndMoldsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37622543d9574bb98c9c743b9e441331_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ToolsDiesAndMoldsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b779b72fb924855b2f72a574d145bd7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">apyx:RenuvionJPlasmaGeneratorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i981157b059a44725985cef208243fc13_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">apyx:MountingFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8df0935c0bc549ebafb864ba67aab0d3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">apyx:AccessoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67552fb7889b46aebef782a87a2fa29c_D20180830-20180830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-30</xbrli:startDate><xbrli:endDate>2018-08-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice559c8f3fad43108151f29c47e8b650_D20180830-20180830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apyx:SymmetrySurgicalInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">apyx:ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-30</xbrli:startDate><xbrli:endDate>2018-08-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f29cae9fd29439fa7f042f1814f46aa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apyx:SymmetrySurgicalInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">apyx:ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf67c4dec56341a2a59058b71b03ea9c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apyx:SymmetrySurgicalInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">apyx:ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e0b17e778314c9c90e0d88fd0f6dd2b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63baacc6f0574a6e8bf0b19a1687afb0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">apyx:ChineseSupplierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0a28971628c45e3b9e9d97e753d9756_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7edc49dacbe457c9d33e24e671deb98_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a54987fec4e4d109be138c336d48d57_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee3b318d7e9f4b0a847b69cbdeb233ce_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3f4327a210e4a4da700fd1022432191_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19401a17feaf403f899024675a2ec439_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4036b967bee44ae799da3bf97a2bdb7f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22cf6c2b0fa640009153ca8537851d59_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fb285bd8adc40a4b2a0c9d050a1f420_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0306c2a7b1164d41a4a0dca8f17a1e2a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40e12307801b4ccb8c56cf5e4fd98ec4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">apyx:ComputerEquipmentandSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id798580ebbff4f89bc905e8051c3b2b2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">apyx:ComputerEquipmentandSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6680d593e9440dbbfd54f5193fbf907_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22cabb993e2b4682a7111b3d2814c1c0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e903bdd325546128d4b5baaaa0369ec_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ToolsDiesAndMoldsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f57e20923764c72859b130e5896e87f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ToolsDiesAndMoldsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i810adca1ebab41a5a9488ebb3154fda3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">apyx:SophiaBulgariaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0363bd7ae504408f83e9148242c28770_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i672dd521a5844f22a7fa22968f746eed_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fc3ec19ac0e4ed4895cf47c5da6347f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="apyx:LeaseArrangementsAxis">apyx:LeaseRemeasurementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6241803215ac41d1bca740510e6f9f94_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="apyx:LeaseArrangementsAxis">apyx:LeaseRemeasurementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia07cd0c04ff44e70938ff407067b900c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="apyx:LeaseArrangementsAxis">apyx:LeaseExecutionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i796972f9750c4ee3b870255ed2cedf91_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="apyx:LeaseArrangementsAxis">apyx:LeaseExecutionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib92bbe0f312c4b5ba37e35fb5203b324_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12dd582368554dba97b8aa9e153c5b2b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:OptionOnSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47bce2e772fe46be81b0517aa210b5d9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:OptionOnSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ae0b3b25b524ed89da35d0c86ded00e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:CoVenturerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42b2e2edfea349f6bef6deafaa0b9c9f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:CoVenturerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2101546a5f04f93a9393b9ac203e960_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:CoVenturerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i324ce5f416944371b0b0f1514f0a8c83_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:CoVenturerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33ad88dc3b434353b50eb3acfab694d4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24f804d243d24666a8bc91f19e0bc3dc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a42214a67b14472a2d145b68faf883b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">apyx:LargestCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a14786bb32f4b7fbd8311532b5e461e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">apyx:LargestCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ccc3072ced640849dd9bbd33abe34e5_I20011231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apyx:A2001ExecutiveandEmployeeStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2001-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2069ea94eb1477bb94891296fd7ccf0_I20071030"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apyx:A2003ExecutiveandEmployeeStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2007-10-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79cf41051ed34d12a5fa5d78feeeef12_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ec1168e4e6e457abbce2a3267321f39_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c9befc04c0e430b8f6bffceacc59a9d_I20120731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apyx:TwoThousandTwelveShareIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2012-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f01e109bd104360a674e88733aec92b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apyx:TwoThousandTwelveShareIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief0094005e77442fa9d4b4c6c22a8df0_I20150731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apyx:TwoThousandFifteenExecutiveAndEmployeeStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4bc94f07ff84f97b245be704259861e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apyx:TwoThousandFifteenExecutiveAndEmployeeStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74bbca955e6f4c6e8758ac942298fe99_I20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apyx:A2017ExecutiveandEmployeeStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04da05110f984d449da3c74c6a62b472_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apyx:A2017ExecutiveandEmployeeStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i865b7f7fe4ac4cfba2d0d6c0001de126_I20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apyx:A2019ShareIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8dcd8a8a5fd54b70a6dd5754aceae3b0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apyx:A2019ShareIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib625f4dfee414563bb1127dd3c30d6a0_D20200129-20200129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-29</xbrli:startDate><xbrli:endDate>2020-01-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7505016b032b4f8aaffab34edef82f38_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffb306c7379244eab19d37d41fd043d9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i938276f948f8476088fcafef6b8fa346_I20151031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7261616081a40bbad79158817e1fdf0_D20151001-20151031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-10-01</xbrli:startDate><xbrli:endDate>2015-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>apyx:segment</xbrli:measure></xbrli:unit><xbrli:context id="i594539d6cfd54e88904eebbf46eef99a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:AdvancedEnergyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a77d1947a3942e4b0d3b8009af417c4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:OEMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a90fc59d66d4c82b190fa272723dc6d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d507772bdc84e94aa1f1e2764c3a5b4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:AdvancedEnergyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacc05ae73fc84dee92f50cd7192ca9e1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:OEMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief62b70f9e3643ea9918e4763977575f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i661eca8a002a4cb2af895f3f5c9a5ec2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd1b12aeda3f4c229577e1cc6e8722a7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7e4bbf7a2034449bae0430f14b14d54_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i515759e8c6ae472bb639c3e78b1b52f8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="idb46c8b71d7d4a27b277b6db52f68e8e_1"></div><div style="min-height:31.5pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.283%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:22pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:22pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:22pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xL2ZyYWc6ZDFhY2YxMTYzNWZmNDZmZjk3NTNlM2EwOWI4YjI4MDYvdGV4dHJlZ2lvbjpkMWFjZjExNjM1ZmY0NmZmOTc1M2UzYTA5YjhiMjgwNl8yMzA0_7d34ea68-d3ee-4e63-a7b6-aa8d704c7f26">10-K</ix:nonNumeric> </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.620%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.505%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.136%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.139%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:DocumentAnnualReport" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xL2ZyYWc6ZDFhY2YxMTYzNWZmNDZmZjk3NTNlM2EwOWI4YjI4MDYvdGFibGU6MjRmMTczMzc1YThjNDI2ZThhMGVlZjFiMzIzOWVhZDMvdGFibGVyYW5nZToyNGYxNzMzNzVhOGM0MjZlOGEwZWVmMWIzMjM5ZWFkM18wLTAtMS0xLTUzNTM_b87a2e7a-b6da-417b-a81d-7120dee48679">&#9746;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">For the fiscal year ended </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xL2ZyYWc6ZDFhY2YxMTYzNWZmNDZmZjk3NTNlM2EwOWI4YjI4MDYvdGFibGU6MjRmMTczMzc1YThjNDI2ZThhMGVlZjFiMzIzOWVhZDMvdGFibGVyYW5nZToyNGYxNzMzNzVhOGM0MjZlOGEwZWVmMWIzMjM5ZWFkM18xLTMtMS0xLTUzNDM_e73745f5-892d-4397-ac35-db76d24798ab"><ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xL2ZyYWc6ZDFhY2YxMTYzNWZmNDZmZjk3NTNlM2EwOWI4YjI4MDYvdGFibGU6MjRmMTczMzc1YThjNDI2ZThhMGVlZjFiMzIzOWVhZDMvdGFibGVyYW5nZToyNGYxNzMzNzVhOGM0MjZlOGEwZWVmMWIzMjM5ZWFkM18xLTMtMS0xLTUzNDM_f50335ad-d8ee-4a9a-a747-60cc3b333237">December 31</ix:nonNumeric>, 2020</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">or</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xL2ZyYWc6ZDFhY2YxMTYzNWZmNDZmZjk3NTNlM2EwOWI4YjI4MDYvdGFibGU6MjRmMTczMzc1YThjNDI2ZThhMGVlZjFiMzIzOWVhZDMvdGFibGVyYW5nZToyNGYxNzMzNzVhOGM0MjZlOGEwZWVmMWIzMjM5ZWFkM181LTAtMS0xLTUzNTE_ee1f9495-8914-4ad2-a463-6027ea1e0bbf">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">For the transition period from _____ to _____</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Commission File Number: </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xL2ZyYWc6ZDFhY2YxMTYzNWZmNDZmZjk3NTNlM2EwOWI4YjI4MDYvdGFibGU6MjRmMTczMzc1YThjNDI2ZThhMGVlZjFiMzIzOWVhZDMvdGFibGVyYW5nZToyNGYxNzMzNzVhOGM0MjZlOGEwZWVmMWIzMjM5ZWFkM183LTMtMS0xLTUzNDY_878551e3-e96f-4aa0-a503-b190dff3ace8">0-12183</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:114pt"><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><img src="apyx-20201231_g1.jpg" alt="apyx-20201231_g1.jpg" style="height:145px;margin-bottom:5pt;vertical-align:text-bottom;width:223px"/></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xL2ZyYWc6ZDFhY2YxMTYzNWZmNDZmZjk3NTNlM2EwOWI4YjI4MDYvdGFibGU6MDM0OTAwOGYxZDU5NGVlZDk3MWU5MDcwN2YyMDhjZDgvdGFibGVyYW5nZTowMzQ5MDA4ZjFkNTk0ZWVkOTcxZTkwNzA3ZjIwOGNkOF8xLTAtMS0xLTUzNjA_8cd6747c-4543-4aaa-813d-cd8fe074c277">APYX MEDICAL CORPORATION</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Exact name of registrant as specified in its charter)</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.989%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xL2ZyYWc6ZDFhY2YxMTYzNWZmNDZmZjk3NTNlM2EwOWI4YjI4MDYvdGFibGU6ZWE3NWY4ZjIyMDFiNDMxMjgxYWI5MGNiYjUyNjkzYjEvdGFibGVyYW5nZTplYTc1ZjhmMjIwMWI0MzEyODFhYjkwY2JiNTI2OTNiMV8wLTAtMS0xLTM1NzE_da21b49b-7e89-4443-9d59-fd42f1033362">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xL2ZyYWc6ZDFhY2YxMTYzNWZmNDZmZjk3NTNlM2EwOWI4YjI4MDYvdGFibGU6ZWE3NWY4ZjIyMDFiNDMxMjgxYWI5MGNiYjUyNjkzYjEvdGFibGVyYW5nZTplYTc1ZjhmMjIwMWI0MzEyODFhYjkwY2JiNTI2OTNiMV8wLTItMS0xLTM1NzQ_97ad472e-1045-42bd-b209-48d708f3cd1b">11-2644611</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xL2ZyYWc6ZDFhY2YxMTYzNWZmNDZmZjk3NTNlM2EwOWI4YjI4MDYvdGV4dHJlZ2lvbjpkMWFjZjExNjM1ZmY0NmZmOTc1M2UzYTA5YjhiMjgwNl8xMDk5NTExNjMwMTYz_f06309c8-b2bf-4a72-a91d-a79362125f18">5115 Ulmerton Road</ix:nonNumeric>, <ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xL2ZyYWc6ZDFhY2YxMTYzNWZmNDZmZjk3NTNlM2EwOWI4YjI4MDYvdGV4dHJlZ2lvbjpkMWFjZjExNjM1ZmY0NmZmOTc1M2UzYTA5YjhiMjgwNl8xMDk5NTExNjMwMTY0_9f0e038f-dd31-431c-a9f2-73ee5d80ed4e">Clearwater</ix:nonNumeric>, <ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xL2ZyYWc6ZDFhY2YxMTYzNWZmNDZmZjk3NTNlM2EwOWI4YjI4MDYvdGV4dHJlZ2lvbjpkMWFjZjExNjM1ZmY0NmZmOTc1M2UzYTA5YjhiMjgwNl8xMDk5NTExNjMwMTY1_f7fb3ff6-26dc-460d-9a5f-a9896964ea6f">FL</ix:nonNumeric> <ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xL2ZyYWc6ZDFhY2YxMTYzNWZmNDZmZjk3NTNlM2EwOWI4YjI4MDYvdGV4dHJlZ2lvbjpkMWFjZjExNjM1ZmY0NmZmOTc1M2UzYTA5YjhiMjgwNl8xMDk5NTExNjMwMTY3_61c479be-e785-43db-aa26-d8e03d796c72">33760</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices, zip code)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xL2ZyYWc6ZDFhY2YxMTYzNWZmNDZmZjk3NTNlM2EwOWI4YjI4MDYvdGV4dHJlZ2lvbjpkMWFjZjExNjM1ZmY0NmZmOTc1M2UzYTA5YjhiMjgwNl8xMDk5NTExNjMwMTc0_5a13ec2b-6dc8-4c1b-918d-37f38ec11a82">727</ix:nonNumeric>) <ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xL2ZyYWc6ZDFhY2YxMTYzNWZmNDZmZjk3NTNlM2EwOWI4YjI4MDYvdGV4dHJlZ2lvbjpkMWFjZjExNjM1ZmY0NmZmOTc1M2UzYTA5YjhiMjgwNl8xMDk5NTExNjMwMTc4_3e55319a-dc3c-4ade-bbc0-99178635dcb6">384-2323</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Issuer&#8217;s telephone number)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:31.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.061%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.061%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.748%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each Class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each Exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xL2ZyYWc6ZDFhY2YxMTYzNWZmNDZmZjk3NTNlM2EwOWI4YjI4MDYvdGFibGU6Y2Y5YTFhNGQ1M2Q3NDgzNmEwZWUyOWMyZTAzNmU0ZGEvdGFibGVyYW5nZTpjZjlhMWE0ZDUzZDc0ODM2YTBlZTI5YzJlMDM2ZTRkYV8xLTAtMS0xLTM1NjQ_e3545a24-b8fd-4949-97f9-a9da170c7972">Common Stock, $.001 Par Value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xL2ZyYWc6ZDFhY2YxMTYzNWZmNDZmZjk3NTNlM2EwOWI4YjI4MDYvdGFibGU6Y2Y5YTFhNGQ1M2Q3NDgzNmEwZWUyOWMyZTAzNmU0ZGEvdGFibGVyYW5nZTpjZjlhMWE0ZDUzZDc0ODM2YTBlZTI5YzJlMDM2ZTRkYV8xLTItMS0xLTM1Njc_60891eff-60f9-4b97-9259-c4d0d6d0ff39">APYX</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xL2ZyYWc6ZDFhY2YxMTYzNWZmNDZmZjk3NTNlM2EwOWI4YjI4MDYvdGFibGU6Y2Y5YTFhNGQ1M2Q3NDgzNmEwZWUyOWMyZTAzNmU0ZGEvdGFibGVyYW5nZTpjZjlhMWE0ZDUzZDc0ODM2YTBlZTI5YzJlMDM2ZTRkYV8xLTQtMS0xLTM1Njk_8e2ffc62-471c-4f12-94fe-778b7d49f1f8">NASDAQ Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered under Section 12(g) of the Exchange Act: None</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes: </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xL2ZyYWc6ZDFhY2YxMTYzNWZmNDZmZjk3NTNlM2EwOWI4YjI4MDYvdGV4dHJlZ2lvbjpkMWFjZjExNjM1ZmY0NmZmOTc1M2UzYTA5YjhiMjgwNl80OTQ3ODAyMzI3MzQz_db619411-0287-470e-b983-1bf18f5e43e5">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#253;</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes: </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xL2ZyYWc6ZDFhY2YxMTYzNWZmNDZmZjk3NTNlM2EwOWI4YjI4MDYvdGV4dHJlZ2lvbjpkMWFjZjExNjM1ZmY0NmZmOTc1M2UzYTA5YjhiMjgwNl80OTQ3ODAyMzI3MzQ0_b7e6b391-801c-46c5-9a15-7ce17fad559c">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#253;</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xL2ZyYWc6ZDFhY2YxMTYzNWZmNDZmZjk3NTNlM2EwOWI4YjI4MDYvdGV4dHJlZ2lvbjpkMWFjZjExNjM1ZmY0NmZmOTc1M2UzYTA5YjhiMjgwNl80OTQ3ODAyMzI3MzQ1_3d895b85-2be9-41aa-8597-948da99ecb40">Yes</ix:nonNumeric>: </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#253;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">o</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xL2ZyYWc6ZDFhY2YxMTYzNWZmNDZmZjk3NTNlM2EwOWI4YjI4MDYvdGV4dHJlZ2lvbjpkMWFjZjExNjM1ZmY0NmZmOTc1M2UzYTA5YjhiMjgwNl80OTQ3ODAyMzI3MzQ3_427d3571-3e79-4889-bfb2-7e1d0aa6de61">Yes</ix:nonNumeric>: </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#253;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">o</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act (Check one):</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.560%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.726%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">o</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">o</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xL2ZyYWc6ZDFhY2YxMTYzNWZmNDZmZjk3NTNlM2EwOWI4YjI4MDYvdGFibGU6NzJhMzg0NWExNTMxNDI1ZmIyY2UzMzI0MjgyMjQ3ZDAvdGFibGVyYW5nZTo3MmEzODQ1YTE1MzE0MjVmYjJjZTMzMjQyODIyNDdkMF8xLTAtMS0xLTUxOTg_63c1562f-c7de-496b-b1a0-5f920203ce8e">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">&#253;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" format="ixt:booleantrue" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xL2ZyYWc6ZDFhY2YxMTYzNWZmNDZmZjk3NTNlM2EwOWI4YjI4MDYvdGFibGU6NzJhMzg0NWExNTMxNDI1ZmIyY2UzMzI0MjgyMjQ3ZDAvdGFibGVyYW5nZTo3MmEzODQ1YTE1MzE0MjVmYjJjZTMzMjQyODIyNDdkMF8xLTQtMS0xLTM1NDQ_702750e9-042e-42fa-818a-3ed5c3fcebba">&#253;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xL2ZyYWc6ZDFhY2YxMTYzNWZmNDZmZjk3NTNlM2EwOWI4YjI4MDYvdGFibGU6NzJhMzg0NWExNTMxNDI1ZmIyY2UzMzI0MjgyMjQ3ZDAvdGFibGVyYW5nZTo3MmEzODQ1YTE1MzE0MjVmYjJjZTMzMjQyODIyNDdkMF8yLTQtMS0xLTM1NDA_16252790-0b83-4b74-ae3e-cfbdf9fac90e">o</ix:nonNumeric></span></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">o</span></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant has &#64257;led a report on and attestation to its management&#8217;s assessment of the e&#64256;ectiveness of its internal control over &#64257;nancial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting &#64257;rm that prepared or issued its audit report.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:IcfrAuditorAttestationFlag" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xL2ZyYWc6ZDFhY2YxMTYzNWZmNDZmZjk3NTNlM2EwOWI4YjI4MDYvdGFibGU6NzJhMzg0NWExNTMxNDI1ZmIyY2UzMzI0MjgyMjQ3ZDAvdGFibGVyYW5nZTo3MmEzODQ1YTE1MzE0MjVmYjJjZTMzMjQyODIyNDdkMF80LTQtMS0xLTUzNTU_291faf13-e7c9-41e8-9e48-4ee01a3443a7">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes: </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" format="ixt:booleanfalse" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xL2ZyYWc6ZDFhY2YxMTYzNWZmNDZmZjk3NTNlM2EwOWI4YjI4MDYvdGV4dHJlZ2lvbjpkMWFjZjExNjM1ZmY0NmZmOTc1M2UzYTA5YjhiMjgwNl80OTQ3ODAyMzI3MzQ2_81da8888-5c2f-4b68-854e-22782e1bb27d">&#253;</ix:nonNumeric></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The aggregate market value of the common stock held by non-affiliates and non-voting equity held by non-affiliates computed by reference to the price at which the common stock was last sold, or the average bid and asked prices of such common stock as of June 30, 2020, the registrant&#8217;s most recently completed second fiscal quarter, was approximately $<ix:nonFraction unitRef="usd" contextRef="i7ed1b671dc694c3ca5cd5bc47208993d_I20200630" decimals="-5" format="ixt:numdotdecimal" name="dei:EntityPublicFloat" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xL2ZyYWc6ZDFhY2YxMTYzNWZmNDZmZjk3NTNlM2EwOWI4YjI4MDYvdGV4dHJlZ2lvbjpkMWFjZjExNjM1ZmY0NmZmOTc1M2UzYTA5YjhiMjgwNl80OTQ3ODAyMzI3MzQ5_4ae6ba27-7d28-49c3-9e53-2fa83f3ab915">189.8</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of March 2</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">9, 2021, <ix:nonFraction unitRef="shares" contextRef="ib31d35568ba546f9a9d4089583b98733_I20210329" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xL2ZyYWc6ZDFhY2YxMTYzNWZmNDZmZjk3NTNlM2EwOWI4YjI4MDYvdGV4dHJlZ2lvbjpkMWFjZjExNjM1ZmY0NmZmOTc1M2UzYTA5YjhiMjgwNl85MzQ1ODQ4ODM4NTc5_1f22652d-c40e-4a59-9566-2d9d73230d86">34,317,863</ix:nonFraction> share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">s of the registrant&#8217;s $.001 par value common stock were outstanding.</span></div><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.283%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="height:13.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="idb46c8b71d7d4a27b277b6db52f68e8e_7"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO ANNUAL REPORT ON FORM 10-K</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2020 </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part I</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_16">Business</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_16">2</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_19">Risk Factors</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_19">7</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1B</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_22">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_22">15</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_25">Properties</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_25">15</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_28">Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_28">15</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_31">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_31">16</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part II</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_37">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_37">17</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_40">Selected Financial Data</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_40">19</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_43">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_43">20</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_46">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_46">28</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_49">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_49">29</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_154">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_154">54</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_157">Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_157">55</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9B</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_160">Other Information</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_160">56</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part III</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_166">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_166">57</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_169">Executive Compensation Discussion and Analysis</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_169">62</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_172">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_172">71</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 13</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_175">Certain Relationships and Related Transactions and Director Independence</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_175">74</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 14</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_178">Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_178">74</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part IV</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 15</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_184">Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_184">75</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Signatures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><div id="idb46c8b71d7d4a27b277b6db52f68e8e_10"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cautionary Notes Regarding </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Statements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have included or incorporated by reference into this report, and from time to time may make in our public filings, press releases or other public statements, certain statements that may constitute forward-looking statements. These include without limitation those under &#8220;Business&#8221; in Part I, Item 1, &#8220;Risk Factors&#8221; in Part I, Item 1A, &#8220;Legal Proceedings&#8221; in Part I, Item 3, &#8220;Management's Discussion and Analysis of Financial Condition and Results of Operations&#8221; in Part II, Item 7, and &#8220;Quantitative and Qualitative Disclosures about Market Risk&#8221; in Part II, Item 7A. In addition, our management my make forward-looking statements to analysts, investors, representatives of the media and others. These forward-looking statements are not historical facts and represent only our beliefs regarding future events, many of which, by their nature, are inherently uncertain and beyond our control. We may, in some cases, use words such as &#8220;project&#8221;, &#8220;believe&#8221;, &#8220;anticipate&#8221;, &#8220;plan&#8221;, &#8220;expect&#8221;, &#8220;estimate&#8221;, &#8220;intend&#8221;, &#8220;should&#8221;, &#8220;would&#8221;, &#8220;could&#8221;, &#8220;potentially&#8221;, &#8220;may&#8221; or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the &#8220;safe harbor&#8221; provisions of the Private Securities Litigation Reform Act of 1995, we are identifying important factors that, individually or in the aggregate, could cause actual results to differ materially from those contained in any forward- looking statements made by us. Any such forward-looking statements are qualified by reference to the following cautionary statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements in this report are subject to a number of risks and uncertainties, some of which are beyond our control, including, among other things: </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in general economic, business or demographic conditions or trends in the U.S. or throughout the world or changes in the political environment, including changes in GDP, interest rates and inflation;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to conclude a sufficient number of attractive growth projects, deploy growth capital in amounts consistent with our objectives in the prosecution of those and achieve targeted risk-adjusted returns on any growth project, including the commercialization of our Helium Plasma Technology;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the regulatory environment, including our ability to gain requisite approval from the Food and Drug Administration and other governmental and regulatory bodies, both domestically and internationally, and the ability to estimate compliance costs, comply with any changes thereto, rates implemented by regulators, and our relationships and rights under, and contracts with, governmental agencies and authorities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruptions or other extraordinary or force majeure events and the ability to insure against losses resulting from such events or disruptions, including disruptions caused by COVID-19 or other global pandemics;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sudden or extreme volatility in commodity prices and availability;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in competitive dynamics affecting our business and the medical device industry as a whole;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">technological innovations leading to increased competition in the medical device industry;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in healthcare policy;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to make alternate arrangements to account for any disruptions or shutdowns that may affect suppliers&#8217; facilities or the operations upon which our business is dependent;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continued aggressive EPA state regulation of Ethylene oxide sterilization (EtO) commercial plants resulting in additional plant closures, leading to a reduced availability of our handpieces, which are commercially sterilized;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to implement operating and internal growth strategies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">environmental risks, including the impact of climate change and weather conditions;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of weather events, including potentially hurricanes, tornadoes and/or seasonal extremes;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unplanned outages and/or failures of technical and mechanical systems;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cybersecurity breaches impacting critical systems or data;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">work interruptions or other labor stoppages;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our actual results, performance, prospects or opportunities could differ materially from those expressed in or implied by the forward-looking statements. A description of risks that could cause our actual results to differ appears under the caption &#8220;Risk Factors&#8221; in Part I, Item 1A and elsewhere in this report. It is not possible to predict or identify all risk factors and you should not consider that description to be a complete discussion of all potential risks or uncertainties that could cause actual results to differ.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In light of these risks, uncertainties and assumptions, you should not place undue reliance on any forward-looking statements. The forward-looking events discussed in this report may not occur. These forward-looking statements are made as of the date of this report. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">information, future events or otherwise. You should, however, consult further disclosures we may make in future filings with the Securities and Exchange Commission. Past performance is not an indicator of future results.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii</span></div></div></div><div id="idb46c8b71d7d4a27b277b6db52f68e8e_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="idb46c8b71d7d4a27b277b6db52f68e8e_16"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. Business</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apyx Medical Corporation (&#8220;Company&#8221;, &#8220;Apyx Medical&#8221;, &#8220;we&#8221;, &#8220;us&#8221;, or &#8220;our&#8221;) was incorporated in 1982, under the laws of the State of Delaware and has its principal executive office at 5115 Ulmerton Road, Clearwater, FL 33760.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an advanced energy technology company with a passion for elevating people&#8217;s lives through innovative products in the cosmetic and surgical markets.  Known for our innovative Helium Plasma Technology, Apyx is solely focused on bringing transformative solutions to the physicians and patients we serve. Our Helium Plasma Technology is marketed and sold as Renuvion&#174; in the cosmetic surgery market and J-Plasma&#174; in the hospital surgical market. Renuvion&#174; offers plastic surgeons, fascial plastic surgeons and cosmetic physicians a unique ability to provide controlled heat to the tissue to achieve their desired results. The J-Plasma&#174; system allows surgeons to operate with a high level of precision, and virtually eliminating unintended tissue trauma. We also leverage our deep expertise and decades of experience in unique waveforms through original equipment manufacturing (OEM) agreements with other medical device manufacturers. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2018, we closed on a definitive asset purchase agreement with Specialty Surgical Instrumentation Inc., a Tennessee Corporation and wholly owned subsidiary of Symmetry Surgical Inc. (&#8220;Symmetry&#8221;), pursuant to which we divested and sold our electrosurgical "Core" business segment and related intellectual property, including the Bovie&#174; brand and trademarks, to Symmetry for gross proceeds of $97 million in cash. The divestiture and sale of our Core business segment to Symmetry has allowed us to further focus on our strategic objective of commercializing our Helium Plasma Technology, including the expansion of our Renuvion&#174; brand in the cosmetic surgery market.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our objective is to achieve profitable, sustainable growth by increasing our market share in the Advanced Energy category, including the commercialization of products that have the potential to be transformational with respect to the results they produce for surgeons and patients. In order to achieve this objective, we plan to leverage our long history in the industry, along with the reputation for quality and reliability that our brand enjoys within the medical community.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our revenues were affected by the continued impacts of the COVID-19 pandemic, in the latter half of 2020 we saw strong utilization of our Renuvion&#174; handpieces from existing customers in the U.S., along with shipments to several new customers in our international markets, which helped to offset sluggish global demand for capital equipment.  Throughout the year, we continued our efforts to support our customers during this challenging time. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we were also pleased to see overall improvements in our Advanced Energy business trends during the third and fourth quarters, demand for handpieces remains uneven across, and within, the primary markets that we serve, and global demand trends for generator adoption remain in the early stages of recovery.  Although the timing of a return to a more normalized environment remains uncertain, we remain cautiously optimistic with respect to the continued recovery of the cosmetic and plastic surgery market. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the ongoing effects of the COVID-19 pandemic, we continued to see trends leading to year-over-year growth in our U.S. Advanced Energy business in the fourth quarter 2020, and year-over-year growth in our international Advanced Energy business in early 2021. We remain well-capitalized and well-positioned to weather the continued impacts of COVID-19, while investing in our primary initiatives to drive strong, long-term growth in the global cosmetic and plastic surgery market as the recovery continues.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Subsidiaries</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apyx Bulgaria, EOOD is a wholly owned limited liability company incorporated under Bulgarian law, located in Sofia, Bulgaria. It is engaged in the business of development and manufacturing of our advanced energy&#160;generators, as well as the manufacturing of disposable hand piece subassemblies and OEM generators and accessories.  The facility also distributes products directly to customers in certain international markets and provides warranty and repair services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Industry</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cosmetic surgery market is a special segment of the medical field which is involved in the restoration, reconstruction, or alteration of the human body so as to enhance the body&#8217;s appearance. The market for cosmetic surgery includes surgical, minimally invasive, and nonsurgical cosmetic procedures. This market is expected to have steady growth year over year and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">this growth is driven by social and cultural factors such as the influence of social media, peer pressure for appearance and beauty, and increasing disposable income.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that Apyx Medical has sustainable, competitive advantages in the cosmetic market for several reasons: our long history of developing unique energy devices to meet the needs of physicians, our unique Helium Plasma Technology, and our outstanding product quality supported by strong engineering and research and development capabilities.   We believe that our equipment and devices have, and will continue to improve, the lives of doctors and their patients.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on our intellectual property that we have developed or acquired over the years including patents, trade secrets, technical innovations and various licensing agreements to provide our future growth and build our competitive position. We have been issued 39 patents in the United States and 27 foreign patents. We have 13 pending patent applications in the United States and 36 pending foreign applications. We have 8 U.S. registered trademarks and 1 pending U.S. trademark application. As we continue to expand our intellectual property portfolio, we believe it is critical for us to continue to invest in filing patent applications to protect our technology, inventions and improvements. However, we can give no assurance that competitors will not infringe on our patent rights or otherwise create similar or non-infringing competing products that are technically patentable in their own right.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing and Suppliers</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to producing the most technically advanced and highest quality products of their kind available on the market. We manufacture the majority of our products on our premises in Clearwater, Florida and at our facility located in Sofia, Bulgaria, both of which are certified under the ISO international quality standards and are subject to continuing regulation and routine inspections by the FDA to ensure compliance with regulations relating to our quality system, medical device complaint reporting, and adherence to FDA restrictions on promotion and advertising. In addition, we are subject to regulations under the Occupational Safety and Health Act, the Environmental Protection Act and other federal, state and local regulations, as well as international laws and regulations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apyx Bulgaria, EOOD operates an approximately 20,000 square foot, ISO13485 certified and FDA registered manufacturing facility located in the capital city of Sofia, which houses manufacturing, development and assembly operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain collaborative arrangements with three foreign suppliers, including our contract component manufacturer located in Ningbo, China, under which we request the development of certain products which we purchase pursuant to purchase orders. Our purchase order commitments are never more than one year in duration and are supported by our sales forecasts.  During late 2019, we entered into a joint venture with our Chinese supplier to establish a foundation for the manufacturing and sale of our products into the Chinese market. The joint venture is in the early stages of startup, and accordingly, the activity associated with it is not material.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Backlog</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The value of unshipped factory orders is not material.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employees</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, we had 266 full-time employees world-wide, of whom 4 were executive officers, 30 were supervisory personnel, 34 were sales personnel and 198 were technical support, administrative and production employees. None of our current employees are covered by a collective bargaining agreement and we have never experienced a work stoppage. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The implementation of our growth strategy largely depends on our ability to hire, train, and retain our sales professionals. We train our sales professionals to thoroughly understand our Helium Plasma Technology and the marketplace in which we compete, including how our technologies can increase our customer's revenue and the results they are able to achieve for their patients. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our compensation programs are designed to align the compensation of our employees with our performance, and to provide the proper incentives to attract, retain and motivate them to achieve superior results. The structure of our compensation programs balances incentive earnings for both short-term and long-term performance, specifically:</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We offer wages that are competitive and consistent with employee positions, skill levels, experience, knowledge and geographic location; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We work with both local and nationally recognized outside compensation and benefits consulting firms to independently evaluate the effectiveness of our executive and non-executive compensation and benefit programs and to provide benchmarking against our peers within our industry; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may provide our non-hourly U.S-based employees long term incentives in the form of stock options; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Annual increases and incentive compensation are based on merit, which is communicated to employees at the time of hiring and documented through our talent management process as part of our annual review procedures and upon internal transfer and/or promotion; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">All employees are eligible for health insurance, paid and unpaid leaves, a retirement plan, and life and disability/accident coverage. We also offer a variety of voluntary benefits that allow employees to select the options that meet their needs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The health and safety of our employees is our highest priority, and this is consistent with our operating philosophy.  In our response to the COVID-19 pandemic around the globe, we supported our employees and their families by:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Adding work from home flexibility; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Adjusting attendance policies to encourage those who are sick to stay home; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increasing cleaning protocols; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Establishing new physical distancing procedures for employees who need to be onsite; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Providing additional personal protective equipment and cleaning supplies; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Implementing protocols to address actual and suspected COVID-19 cases and potential exposure; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Limiting all domestic and international non-essential travel for all employees; and </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Requiring masks to be worn at all locations where allowed by local law.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Two Business Segments </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have two reportable segments: Advanced Energy and OEM. The Corporate and Other category includes certain unallocated corporate and administrative costs which are not specifically attributed to any reportable segment. Net assets are shared, therefore, not allocated to the reportable segments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2020, o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ur OEM segment contributed 19.8% of our consolidated total revenue and our Advanced Energy segment contributed 80.2% of our consolidated total revenue.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Advanced Energy Segment</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product portfolio consists of our Helium Plasma Technology that is marketed and sold as Renuvion&#174; in the cosmetic surgery market and J-Plasma&#174; in the hospital surgical market. Renuvion&#174; offers plastic surgeons, facial plastic surgeons and cosmetic physicians a unique ability to provide controlled heat to the tissue to achieve their desired results. The J-Plasma&#174; system allows surgeons to operate with a high level of precision</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> virtually eliminating unintended tissue trauma. This technology has U.S. FDA clearance, CE mark, and clearance for sale in multiple other countries and is generally indicated for the cutting, coagulation and ablation of soft tissue. The system consists of an electrosurgical generator unit ("ESU"), a handpiece and a supply of helium gas. The proprietary radiofrequency ("RF") energy is delivered to the handpiece by the ESU and used to energize an electrode. When helium gas passes over the energized electrode, helium plasma is generated which allows for conduction of the RF energy from the electrode to the patient in the form of a precise helium plasma beam. The energy delivered to the patient via the helium plasma beam is very precise and cooler in temperature in comparison to other surgical energy modalities such as standard RF monopolar energy. This technology has been the subject of thirty eight peer-reviewed journal articles, book chapters, abstracts, and posters. It also continues to be the subject of numerous presentations at traditional and cosmetic surgery conferences around the world.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This technology initially received FDA clearance in 2012 and a CE mark in December 2014, which enables us to sell the product in the European Union. In 2014, we created and trained a direct sales force dedicated to sell this technology. In 2015, we continued the commercialization process for our Helium Plasma Technology with a multi-faceted strategy designed to accelerate adoption of the product. This strategy primarily involved deployment of a dedicated sales force, developing product line extensions and expanding the specialties in which this technology can become the &#8220;standard of care&#8220; for certain procedures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, we continued our full-scale commercialization efforts for Renuvion&#174;. As of December 31, 2020 we had a direct sales force of 31 field-based selling professionals and utilized 2 independent sales agencies. We also had 5 sales managers. This selling organization is focused on the use of Renuvion&#174; in the cosmetic surgery market. In addition, we have invested in training programs and marketing-related activities to support accelerated adoption of Renuvion&#174; into physicians' practices.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From 2015 through 2020, we launched numerous new extensions to our Helium Plasma product lines in an effort to target new surgical procedures, users, and markets.   Most notably, in early 2020 we launched our Renuvion&#174; APR handpieces which were designed with improved ergonomics and usability for our Renuvion&#174; customers. As a result of our sales, marketing and product development initiatives, we have significantly increased the number of physicians using our Helium Plasma Technology by expanding usage to include the cosmetic surgery market in the U.S., and the cosmetic surgery market as well as the surgical oncology market outside the U.S..</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to assist us in leveraging our Helium Plasma Technology's precision and effectiveness in multiple surgical specialties, in 2019 we added 4 additional doctors to our Medical Advisory Board, which currently consists</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of 5 mem</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">bers representing the plastic surgery, facial plastic surgery, and cosmetic procedure specialties.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial strategy in the U.S. is primarily focused on advancing the usage of Renuvion&#174; in the cosmetic surgery market. In our international markets, we focus on both the cosmetic surgery, and on our J-Plasma&#174; technology for the surgical oncology market. We continue to develop a clinical and regulatory strategy, and corresponding marketing campaigns, to support our market focus. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to make substantial investments in the development and marketing of our Renuvion&#174; technology for the long-term benefit of the Company and its stakeholders, and this may adversely affect our short-term profitability and cash flows, particularly over the next 12 to 18 months. While we believe that these investments have the potential to generate additional </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">revenues and profits in the future, there can be no assurance that our Helium Plasma Technology will continue to be successful or that such future revenues and profitability will be realized.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Customers</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., we primarily sell our Renuvion&#174; products through our direct sales force to physicians, cosmetic surgery offices and surgical centers.</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside of the U.S., all of our products are sold primarily through our distributor network.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Products</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Advanced Energy Products consist of our Helium Plasma Technology lines (Renuvion&#174; and J-Plasma&#174;). These product lines consist of a multifunction generator, a handpiece and a supply of helium gas. Radiofrequency ("RF") energy is delivered to the handpiece by the generator and used to energize an electrode. When helium gas passes over the energized electrode, helium plasma is generated which allows for conduction of the RF energy from the electrode to the patient in the form of a precise helium plasma beam. The energy delivered to the patient via the helium plasma beam is very precise and cooler in temperature in comparison to other surgical energy modalities such as standard RF monopolar energy. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Helium Plasma Generator</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In early 2020, we launched the newest versions of our Helium Plasma generator &#8211; The Renuvion System 3 and J-Plasma System 3 generators. These are high frequency electrosurgical generators that can be used for delivery of RF energy and/or helium plasma to cut, coagulate and ablate soft tissue during open and laparoscopic surgical procedures.  These new generators were built for use with our Renuvion APR handpieces and feature enhanced capabilities such as a joule counter, capable of displaying energy delivered to the patient, and new Auto-Bipolar functionality, which expands surgical capabilities of the system.  These new product releases continue to expand the procedure base for our Helium Plasma Technology by providing surgeons with the tools they need to access additional anatomic locations and perform specific procedures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disposable Portfolio</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer a variety of different hand pieces for open and laparoscopic procedures. The helium-based plasma generated from these devices has been shown to provide increased precision and control and cause less thermal damage to tissue than CO2 laser, argon plasma and RF energy products currently available on the market. The technology has a general indication and can be used for cutting, coagulating and ablating soft tissue. The two primary specialties that are targeted are the cosmetic surgery and surgical oncology markets. The advantages of helium plasma continue to be studied throughout the medical and scientific communities. We believe that surgical applications are just one area of opportunity for this technology. During 2020, we launched our new generation APR hand pieces, designed specifically for percutaneous use, with improved ergonomics and safety features. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Competition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, we are the only company with helium-based plasma and retractable blade products. However, there are RF based competitors, argon plasma competitors, and CO2 laser competitors for our target market. We believe our competitive position did not change in 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OEM Segment </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We leverage our expertise in the design, development and manufacturing of electrosurgical equipment by producing generators and related accessories for large, well-known medical device manufacturers through original equipment manufacturing ("OEM") agreements, as well as start-up companies with the need for our energy-based designs.  In connection with the Asset Purchase Agreement with Symmetry Surgical, we entered into a Manufacturing and Supply Agreement for a ten-year term, whereby we will manufacture certain products and sell to them at agreed upon prices.  Revenue, costs and expenses resulting from this agreement are reported in our Consolidated Statements of Operations as a component of income or loss from operations of our OEM reporting segment. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="idb46c8b71d7d4a27b277b6db52f68e8e_19"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A. Risk Factors </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to risks and uncertainties in the ordinary course of business, important risk factors that may affect us are discussed below. Additional risks not presently known to us, or that we currently believe are immaterial, may also significantly impact or impair our business operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulatory Compliance Risk</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Approval and Monitoring</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many countries where we sell medical devices subject our technologies to their own approval and other regulatory requirements regarding performance, safety, and quality.  The global regulatory environment is increasingly unpredictable and stringent. Countries that did not have regulatory requirements for medical devices have established such requirements in recent years, and other countries have expanded, or plan to expand, their existing regulations. While there are efforts at some harmonization of global regulations, requirements continue to differ significantly among countries. We expect that as this global regulatory environment continues to evolve, it could impact the cost, the time needed to approve, and ultimately, our ability to maintain existing approvals or obtain future approvals for our products. Regulations of the U.S. FDA and other regulatory agencies in and outside the U.S. impose significant compliance and monitoring obligations on our business.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory approval delays due to COVID-19 </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19 may impede clinical trials and slow down regulatory actions. It could adversely affect the entire clinical trial spectrum from enrollment to data analysis. Assuming patients enroll, clinical trials may face disruptions to protocol schedules for treatment and follow-up visits. Reports from Europe have noted overwhelmed facilities where all non-critical visits have been postponed or canceled. Many U.S. hospitals have followed suit to limit exposure and allow for care of COVID-19 patients. Deviations from trial protocols could present challenges when it comes time to analyze the related data set. Some clinics may stop allowing clinical trial monitors on site. Without reconciling the data, we may be unable to "lock" the trial database, an essential step that precedes the analysis of the data. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on regular interaction and guidance from the FDA, European Medicines Agency (EMA), and other regulatory bodies to plan research and development activities across all stages. Due to the COVID-19 pandemic, the FDA and worldwide regulatory bodies have a great deal of resources dedicated to COVID-19 related matters, resulting in disruption in their ability to fully support the regulatory approval process.  As resources continue to be diverted, regulatory approvals will more and more become non-essential matters until the pandemic is under control. Delays of approvals, clearances, inspections, and meetings are currently being experienced and will continue for the foreseeable future.  Postponement of these interactions could delay us from bringing new products to market.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to costly and complex laws and governmental regulations and any adverse regulatory action may materially adversely affect our financial condition and business operations. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a part of the regulatory process of obtaining marketing clearance for new products and new indications for existing products, we conduct and participate in numerous clinical trials with a variety of study designs, patient populations, and trial endpoints. Unfavorable or inconsistent clinical data from existing or future clinical trials, or the market&#8217;s or FDA&#8217;s perception of this clinical data, may adversely impact our ability to obtain product approvals, our position in, and share of, the markets in which we participate.  We cannot guarantee that we will be able to obtain or maintain marketing clearance for our new products or enhancements or modifications to existing products, and the failure to maintain approvals or obtain approval or clearance could have a material adverse effect on our business, results of operations, financial condition and cash flows. Even if we are able to obtain approval or clearance, it may:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">take a significant amount of time; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require the expenditure of considerable resources; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">involve rigorous clinical and pre-clinical testing, as well as increased post-market surveillance; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">involve modifications, repairs, corrections, or replacements of our products; and </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit the proposed intended uses of our products. </span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before and after a product is commercially released, we have ongoing responsibilities under the U.S. FDA, Health Canada, Australia, Brazil, EU, and other applicable world-wide government agency regulations. For instance, many of our processes and facilities, as well as those of our suppliers, are also subject to periodic audits to determine compliance with applicable regulations. The results of these audits can include major inspectional observations, warning letters, or other forms of enforcement. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA were to conclude that we are not in compliance with applicable laws or regulations, or that any of our medical products are ineffective or pose an unreasonable health risk, they could ban such medical products, seize adulterated or misbranded medical products, order a recall, repair, replacement, correction, or refund of such products, refuse to grant pending pre-market approval applications, refuse to issue export certificates for foreign governments, or require us to notify health professionals and others that the devices present unreasonable risks of substantial harm to the public health. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and other non-U.S. government agencies may also assess civil or criminal penalties against us, our officers or employees and impose operating restrictions on a company-wide basis. The FDA may also recommend prosecution to the Department of Justice. Any adverse regulatory action, depending on its magnitude, may restrict us from effectively marketing and selling our products and limit our ability to obtain future pre-market clearances or approvals, and could result in a substantial modification to our business practices and operations. These potential consequences, as well as any adverse outcome from government investigations, could have a material adverse effect on our business, results of operations, financial condition, and cash flows. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the FDA has taken the position  that device manufacturers are prohibited from promoting their products other than for the uses and indications set forth in the cleared product labeling. Any failure to comply could subject us to significant civil or criminal exposure, administrative obligations and costs, other potential penalties from, and/or agreements with, the federal government. Governmental regulations worldwide have, and may continue to become, increasingly stringent and customary. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the EU, a single regulatory approval process exists, and conformity with the legal requirements is represented by the CE Mark. To obtain a CE Mark, defined products must meet minimum standards of performance, safety, and quality (i.e., the essential requirements), and then, according to their classification, comply with one or more of a selection of conformity assessment routes. The competent authorities of the EU countries separately regulate the clinical research for medical devices and the market surveillance of products once they are placed on the market. A new Medical Device Regulation ("EU MDR") was published by the EU in 2017, which imposes significant additional premarket and postmarket requirements. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The EU MDR represents the first major changes to the EU medical device regulatory environment, has significantly raised the compliance bar for the medical device industry, and will cause significant changes to the regulatory obligations of manufacturers, importers and distributors involved in the medical device distribution chain.  Classification has changed for some product categories, and strict new requirements have been imposed on clinical data, risk management, post market surveillance, and supplier management.  Penalties for regulatory non-compliance could be severe, including fines and revocation or suspension of a company&#8217;s business license, and criminal sanctions. The regulation initially provided a three-year implementation period to May 2020, but that timeline was delayed to May 2021 due to COVID-19 and its impact on audits and technical file review by Notified Bodies. After that time, medical devices marketed in the EU will require certification according to these new requirements, except for devices with valid CE certificates, issued pursuant to the Medical Device Directives before May 2020, which can be placed in the market until May 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside of the EU, regulations vary significantly from country to country and are becoming increasingly stringent and country specific. Territories and countries around the world continue to develop their own unique regulatory requirements, and these individual governments are passing laws that enforce these new regulations, and also impose fees, to register products in their country.  The time and effort required to obtain approval to market products may be longer or shorter than that required in the U.S. or the EU. Certain European countries outside of the EU, and other countries around the world do not recognize the CE mark certification or FDA clearance and have their own regulatory requirements to register and sell products in these territories. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Environmental Regulation</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:3.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The medical device industry continues to be the subject of intense scrutiny and stringent regulation and the demand for green, sustainable products is rapidly increasing.  There are increasing requirements for efficient and accurate processes for hazardous substance handling, supplier disclosures, and regulatory reporting in order to comply with numerous global health and environmental regulatory requirements and restrictions, including but not limited to: </span></div><div style="margin-bottom:3.75pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Restriction on Hazardous Substances (RoHS) Directive </span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Packaging and Packing Waste Directive</span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">REACH Regulation</span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Proposition 65</span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Hazardous Air Pollutants: Ethylene Oxide</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compliance with existing and future environmental regulations may have an impact on the manufacturing and sterilization of our medical devices.  Environmental regulations in the U.S. and EU limit or prohibit the use of certain chemicals, substances and materials in the manufacture of our medical devices such as Prop 65 in California and others in the EU such as REACH, RoHS, and WEEE Directive.  With the current global concerns over climate change and the tangible effects human beings are having on the environment, there is no doubt that the amount of environmental legislation is primed to increase still further, with the EU being at the forefront of this movement. </span></div><div style="margin-bottom:3.75pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ethylene oxide (EtO) is used to sterilize approximately 50% of medical devices in the U.S.  While some alternative methods currently exist, potential device incompatibility issues exist with these alternatives.  The U.S. Environmental Protection Agency (EPA) classified EtO as a carcinogen after linking it to cases of breast cancer, lymphoma and leukemia. Currently, shortages due to current closures are not expected, but any additional commercial sterilization facility closures could result in shortages for certain devices.  Our devices are not currently impacted by these closures, however, it is unknown if the current EtO facilities utilized by Apyx Medical could be impacted in the future.</span></div><div style="margin-bottom:3.75pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA is closely monitoring the supply chain effects of closures and potential closures of certain facilities that use EtO to sterilize medical devices prior to their use, and, is concerned about the future availability of sterile medical devices and the potential for medical device shortages that might impact patient care. However, they do not have oversight authority over EtO emissions, which is within the purview of the EPA.</span></div><div style="margin-bottom:3.75pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations and those of certain third-party suppliers involve the use of substances subject to these laws and regulations, primarily those used in manufacturing and sterilization processes. If we or our suppliers violate these environmental laws and regulations, facilities could be shut down and violators could be fined, criminally charged or otherwise sanctioned. Furthermore, environmental laws outside of the U.S. are becoming more stringent, resulting in increased costs and compliance burdens. In addition, certain environmental laws assess liability on current or previous owners or operators of real property for the costs of investigation, removal or remediation of hazardous substances or materials at their properties or at properties which they have disposed of hazardous substances. In addition to cleanup actions brought by governmental authorities, private parties could bring personal injury or other claims due to the presence of, or exposure to, hazardous substances. The ultimate cost of site cleanup and timing of future cash outflows is difficult to predict, given the uncertainties regarding the extent of the required cleanup, the interpretation of applicable laws and regulations, and alternative cleanup methods. The costs of complying with current or future environmental protection and health and safety laws and regulations, or liabilities arising from past or future releases of, or exposures to, hazardous substances, may exceed our estimates, or have a material adverse effect on our business, results of operations, financial condition, and cash flows.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-Corruption Regulation</span></div><div style="margin-bottom:3.75pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we grow our international presence and global operations, we will be increasingly exposed to statutes, anti-corruption trade policies, economic sanctions and other restrictions imposed by the United States and other foreign governments and organizations, including the U.S. Foreign Corrupt Practices Act, or the FCPA, and other federal statutes and regulations, including those established by the Office of Foreign Assets Control, or OFAC. In addition, other foreign statutes, such as the U.K. Bribery Act of 2010, or the Bribery Act, prohibits both domestic and international bribery, as well as bribery across both private and public sectors. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="margin-bottom:3.75pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have implemented policies and procedures designed to ensure compliance by our directors, officers, employees, representatives, consultants and agents with the FCPA, OFAC restrictions, the Bribery Act and other export control, anti-corruption, anti-money-laundering and anti-terrorism laws and regulations. However, there can be no assurance that our policies and procedures are or will be sufficient to prevent violations from occurring.  Violations of the FCPA, OFAC restrictions, the Bribery Act or other export control, anti-corruption, anti-money laundering and anti-terrorism laws or regulations may result in severe criminal or civil sanctions, and we may be subject to other liabilities, which could have a material adverse effect on our reputation, financial condition, and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Our Business</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manufacture the majority of our products at our Clearwater, Florida and Sofia, Bulgaria facilities. Components, labor-intensive assemblies and sub-assemblies, and sterilization services are outsourced to third parties and produced to our specifications.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also dependent on OEM customers who have no legal obligation to purchase products from us. Should such customers fail to give us purchase orders for products after development, our future business could be negatively affected. Furthermore, no assurance can be given that such customers will give sufficient high priority to our products. Finally, disagreements or disputes may arise between us and our customers, which could adversely affect production and sales of our products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to successfully introduce new products or fail to keep pace with competitive advances in technology, our business, financial condition, results of operations and cash flows could be adversely affected. In addition, our research and development efforts rely upon investments and alliances, and we cannot guarantee that any previous or future investments or alliances will be successful.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development activities are an essential component of our efforts to develop new and innovative products for introduction in the marketplace. New and improved products play a critical role in our sales growth. We continue to place emphasis on the development of proprietary products, such as our J-Plasma&#174;/Renuvion&#174; technology, and product improvements to complement and expand our existing product lines. We maintain close working relationships with physicians and medical personnel in hospitals and universities who assist in product research and areas of development. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These activities are primarily conducted internally and are expensed as incurred. Expenses include direct expenses for wages, materials, and services associated with the development of our products, net of any reimbursements from customers. Research and development expenses do not include any portion of general and administrative expenses. Our research and development activities are conducted at our Clearwater, Florida and Sofia, Bulgaria facilities. We expect to continue making future investments to enable us to develop and market new technologies and products to further our strategic objectives and strengthen our existing business. However, we cannot guarantee that any of our previous or future investments in both facilities will be successful or that our new products will gain market acceptance, the failure of which would have a material adverse effect on our business and results of operations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount expended by us on research and development of our products during the years 2020 and 2019, totaled approximately $3.9 million and $3.7 million, respectively. We have invested substantial resources in the development and marketing of our Advanced Energy product technologies but have not incurred any direct costs relating to environmental regulations or requirements. For 2021, we expect to invest approximately 10% to 15% of revenue for research and development activities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we are successful in developing new, or enhancing our existing products, there are various circumstances that could prevent their successful commercialization.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to successfully commercialize our products will depend on a number of factors, any of which could delay or prevent commercialization, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to obtain the necessary regulatory clearances or approvals for expanded indications, new products, or product modifications;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we are unable to demonstrate, if required, the safety and efficacy of new products with data from preclinical studies and clinical trials;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our product is determined to be ineffective or unsafe following approval, and is removed from the market or we are required to perform additional research and development to further prove the safety and effectiveness of the product before re-entry into the market;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the regulatory approvals of our new products are delayed or denied, or we are required to conduct further research and development of our products prior to receiving regulatory approval;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we are unable to build and maintain a sales and marketing group to successfully launch and sell our new products;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we are required to allocate available funds to litigation matters;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the needs of our physicians or their patients are not sufficiently met;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we are unable to manufacture the quantity of products needed, in accordance with quality manufacturing standards, to meet market demand;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competition from other products or technologies prevents or reduces market acceptance of our products;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we do not have, and cannot obtain, the intellectual property rights needed to manufacture or market our products without infringing on another company&#8217;s patents; or</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we are unsuccessful in defending against patent infringement, or other intellectual property rights claims, that could be brought against us, our products or technologies;</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The failure to successfully commercialize our products will have a material and adverse effect on the future growth of our business, financial condition and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect our patents or other proprietary rights, or if we infringe on the patents or other proprietary rights of others, our competitiveness and business prospects may be materially damaged.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been issued 39 patents in the United States and 27 foreign patents. We have 13 pending patent applications in the United States and 36 pending foreign applications. Our intellectual property portfolio for our J-Plasma&#174;/Renuvion&#174; products continues to grow on an annual basis.  We intend to continue to seek legal protection, primarily through patents, for our proprietary technology. Seeking patent protection is a lengthy and costly process and there can be no assurance that patents will be issued from any pending applications, or that any claims allowed from existing or pending patents will be sufficiently broad or strong to protect our proprietary technology. There is also no guarantee that any patents we hold will not be challenged, invalidated or circumvented, or that the patent rights granted will provide competitive advantages to us. Our competitors have developed, and may continue to develop and obtain, patents for technologies that are similar or superior to our technologies. In addition, the laws of foreign jurisdictions in which we develop, manufacture or sell our products may not protect our intellectual property rights to the same extent as the laws of the United States.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse outcomes in current or future legal disputes regarding patent and other intellectual property rights could result in the loss of our intellectual property rights, subject us to significant liabilities to third parties, require us to seek licenses from third parties on terms that may not be reasonable or favorable to us, prevent us from manufacturing, importing or selling our products, or compel us to redesign our products to avoid infringing third parties&#8217; intellectual property. As a result, our product offerings may be delayed, and we may be unable to meet customers&#8217; requirements in a timely manner. Regardless of the merit of any related legal proceeding, we have incurred in the past, and may be required to incur in the future, substantial costs to prosecute, enforce or defend our intellectual property rights. Even in the absence of infringement by our products on third parties&#8217; intellectual property rights, or litigation related to trade secrets, we have elected in the past, and may in the future, elect to enter into settlements to avoid the costs and risks of protracted litigation and the diversion of resources and management&#8217;s attention. If the terms of settlements entered into with certain of our competitors are not observed or enforced, we may suffer further costs and risks. Any of these circumstances could have a material adverse effect on our business, financial condition, results of operations or cash flows.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to patent, copyright, and trademark protection, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect our trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our consultants, vendors, and our former or current employees.  Despite these efforts, however, any of these parties may breach those agreements and disclose our trade secrets and other unpatented or unregistered proprietary information, and once disclosed, we are likely to lose trade secret protection. Monitoring unauthorized uses and disclosures of our trade secrets is difficult, and we cannot be certain that the steps we have taken to protect our intellectual property will be effective. In addition, our remedies may not be sufficient to cover our losses. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In 2020, the Coronavirus&#160;outbreak&#160;was declared a pandemic by the World Health Organization and spread to the United States and many other parts of the world and may&#160;continue to&#160;adversely affect our business operations, employee availability, financial condition, results of operations and cash flows&#160;for an extended period of time.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outbreak of COVID-19 continues to grow both in the U.S. and globally, and related government and private sector responsive actions may&#160;continue to&#160;adversely affect our business operations. It is impossible to predict the effect and ultimate impact of the COVID-19 pandemic as the situation continues to evolve.&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ongoing&#160;significant reductions&#160;in business-related activities could result in&#160;further&#160;loss of sales and profits, as well as other material adverse effects. The extent of the impact of COVID-19 worldwide on our business, financial results, liquidity and cash flows will depend largely on future developments, including new information that may emerge concerning the severity and action taken to contain or prevent further spread within the U.S. and the related impact on consumer confidence and spending, all of which are highly uncertain and cannot be predicted.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As COVID-19 continues and persists for an extended period of time,&#160;there&#160;may&#160;be significant and material disruptions to our supply chain and operations, and delays in the manufacturing and shipment of our products, which may have a material adverse effect on our business, financial condition, results of operations and cash flows.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have been, and may in the future, become subject to litigation proceedings that could materially and adversely affect our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The medical device industry is characterized by frequent claims and litigation, and we are and may become subject to various claims, lawsuits and proceedings in the ordinary course of our business, including claims by current or former employees, distributors and competitors, and with respect to our products and product liability claims, lawsuits and proceedings. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in a number of legal actions relating to the use of our technology. The outcomes of these legal actions are not within our complete control and may not be known for prolonged periods of time. In the opinion of management, the Company has meritorious defenses, and such claims are adequately covered by insurance, or are not expected, individually or in the aggregate, to result in a material, adverse effect on our financial condition, results of operations and cash flows. However, in the event that damages exceed the aggregate coverage limits of our policy, or if our insurance carriers disclaim coverage, we believe it is possible that costs associated with these claims could have a material adverse impact on our consolidated financial position, results of operations and cash flows (see below </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3:  Legal Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on certain suppliers, subcontractors, and manufacturers for raw materials and other products and are vulnerable to fluctuations in the availability and price of such products and services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in the price, availability and quality of the raw materials (including plastics and other petroleum-based materials, along with precious metals) and subcontracting services we use in our manufacturing could have a negative effect on our cost of sales and our ability to meet the demands of our customers. Inability to meet the demands of our customers could result in the loss of future sales.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the costs to manufacture our products depend in part on the market prices of the raw materials used to produce them. We may not be able to pass along to our customers all or a portion of our higher costs of raw materials due to competitive and market pressures, which could decrease our earnings and profitability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have collaborative arrangements with three key foreign suppliers under which we request the development of certain items and components, which we purchase pursuant to purchase orders. Our purchase order commitments are never more than one year in duration and are supported by our sales forecasts. The majority of our raw materials are purchased from sole-source suppliers. While we believe we could ultimately procure other sources for these components, should we experience any significant disruptions in this key supply chain, there are no assurances that we could do so in a timely manner which could render us unable to meet the demands of our customers, resulting in a material and adverse effect on our business and results of operations.   </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our manufacturing facilities are located in Clearwater, Florida and Sofia, Bulgaria and could be affected due to multiple weather risks, including risks to our Florida facility from hurricanes and similar phenomena.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our manufacturing facilities are located in Clearwater, Florida and Sofia, Bulgaria and could be affected by multiple weather </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">risks, most notably hurricanes in Clearwater, Florida. Although we carry property and casualty insurance and business interruption insurance, future possible disruptions of operations or damage to property, plant and equipment due to hurricanes or other weather risks could result in impaired production and affect our ability to meet our commitments to our customers and impair important business relationships, the loss of which could adversely affect our operations and profitability. We do, however, maintain a backup generator at our Clearwater facility, are working to establish deeper redundancies between both facilities, and have a disaster recovery plan in place to help mitigate this risk.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quality Management and Product Liability </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:3.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our business depends on the quality of our products, and we have global processes, procedures and programs that are intended to help us maintain the highest possible level of quality.  We operate in an industry susceptible to significant product liability claims; these claims may be brought by individuals seeking relief on their own behalf or purporting to represent a class.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Quality problems and product liability claims could lead to recalls or safety alerts, reputational harm, adverse verdicts or costly settlements, and could have a material adverse effect on our business, results of operations, financial condition and cash flows.</span></div><div><span><br/></span></div><div style="margin-bottom:3.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quality is extremely important to us and our customers due to the impact on patients, and the serious and potentially costly consequences of product failure. Our business exposes us to potential product liability risks that are inherent in the design, manufacture, and marketing of medical devices. If they were to occur, component failures, manufacturing nonconformances, design defects, off-label use, or inadequate disclosure of product-related risks or product related information, could result in an unsafe condition, injury to, or even death of, a patient. These problems could lead to recall or issuance of safety notices relating to our products and could result in product liability claims and lawsuits, including class actions. Further, we may be exposed to unpredictable or accelerated changes in demand for certain of our products in connection with COVID-19, and its related impacts could impact production of products that could increase the risk of regulatory enforcement actions, product defects or related claims, as well as adversely impact our customer relationships and reputation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Industry</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The energy-based medical device industry in the aesthetics market is highly competitive and we may be unable to compete effectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The energy-based medical device industry for the aesthetics market is highly competitive. Many competitors in this industry are well-established, do a substantially greater amount of business, and have greater financial resources and facilities than we do.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have invested and continue to invest, substantial resources to develop and monetize our J-Plasma&#174;/Renuvion&#174; technology. We believe we must continue to develop new applications for our products and obtain new indications for use in order to stay competitive. If we are unable to gain acceptance of our technology in the marketplace, or obtain new indications for use, our business and results of operations and cash flows may be materially and adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Part of our strategy depends on developing strong working relationships with key plastic surgeons, cosmetic physicians and other healthcare professionals.  The guidance we get from these relationships is important from both a commercialization strategy and product development standpoint.  Without these relationships, the development and commercialization of our products could suffer which could have a material adverse impact on our business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Stock</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market price of our stock has been and may continue to be highly volatile.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is listed on The NASDAQ Stock Market LLC under the ticker symbol &#8220;APYX&#8221;. The market price of our stock has been, and may continue to be, highly volatile and announcements by us or by third parties may have a significant impact on our stock price. These announcements may include:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our listing status on the The NASDAQ Stock Market LLC;</span></div><div style="padding-left:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our operating results falling below the expectations of public market analysts and investors;</span></div><div style="padding-left:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">developments in our relationships with or developments affecting our major customers;</span></div><div style="padding-left:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">negative regulatory action or regulatory non-approval with respect to our new products;</span></div><div style="padding-left:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">government regulation, governmental investigations, or audits related to us or to our products;</span></div><div style="padding-left:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">developments related to our patents or other proprietary rights or those of our competitors and</span></div><div style="padding-left:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes in the position of securities analysts with respect to our stock.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The stock market has from time-to-time experienced extreme price and volume fluctuations, which have particularly affected the market prices for the medical technology sector companies, and which have often been unrelated to their operating performance. These broad market fluctuations may adversely affect the market price of our common stock. In addition, future sales by our security holders may lower the price of our common stock, which could result in losses to our stockholders.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have no present intention to pay dividends on our common stock and, even if we change that policy, we may be unable to pay dividends on it. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently do not anticipate paying any dividends on our common stock in the foreseeable future. We currently intend to retain future earnings, if any, to finance operations and invest in our business. Any declaration and payment of future dividends to holders of our common stock will be at the discretion of our board of directors and will depend on many factors, including our financial condition, earnings, capital requirements, level of indebtedness, statutory and contractual restrictions applying to the payment of dividends, and other considerations that our board of directors deems relevant.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we change that policy and commence paying dividends, we will not be obligated to continue paying those dividends, and our stockholders will not be guaranteed, or have contractual or other rights, to receive dividends. If we commence paying dividends in the future, our board of directors may decide, at its discretion, at any time, to decrease the number of dividends, otherwise modify or repeal the dividend policy or discontinue entirely the payment of dividends. Under Delaware law, our board of directors may not authorize the payment of a dividend unless it is paid out of our statutory surplus.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exercise of options issued by us will dilute the ownership interest of existing stockholders.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, our outstanding stock options to our employees, officers, directors and consultants amounted to  4,938,943 shares of our common stock, representing approximately 14.4% of our outstanding common stock.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exercise of some or all of our stock options will dilute the ownership interests of existing stockholders. Any sales in the public market of the common stock issuable upon such conversion or exercise could adversely affect prevailing market prices of our common stock.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risks</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may, in the future, identify deficiencies in controls over financial reporting. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have successfully remediated the control deficiencies that led to the material weaknesses reported in 2018 and 2019, as disclosed, in Part II, Item 9A, there can be no assurance that the remedial measures taken will prevent future control deficiencies or material weaknesses from occurring. If we identify additional material weaknesses in our internal controls over financial reporting in the future, our ability to analyze, record and report financial information free of material misstatements, and to prepare our financial statements within the time periods specified by the rules and forms of the SEC, will likely be adversely affected. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are at risk of being the victim of a cyber-attack or a security breach that may expose confidential customer, product and Company data or compromise our internal IT infrastructure.  This could lead to liabilities resulting from failure to comply </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">with US and foreign data security and privacy regulations and negative impacts to our business operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We store in our computer systems and network various elements of data and information related to our customers, products and company that could be compromised as the result of a cyber-attack or security breach.   If an individual or group of individuals, including a Company employee, were to compromise confidential information, or if customer confidential information is inappropriately disclosed due to a security breach of our computer systems, system failures or otherwise, we may face substantial liabilities or incur penalties in connection with any violation of applicable privacy laws or regulations.   We also rely heavily on our internal systems, network and data.  Any attacks on our IT infrastructure could have a significant impact on our daily manufacturing and customer service functions which could result in a material adverse impact on our financial results. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is dependent on the security of our IT networks and those of our customers. Internal or external attacks on any of those could disrupt the normal operations of our engagements and impede our ability to provide critical services to our customers, thereby subjecting us to liability under our contracts. Additionally, our business involves the use, storage and transmission of information about our employees, our customers and clients of our customers. While we take measures to protect the security of, and unauthorized access to, our systems, as well as the privacy of personal and proprietary information, it is possible that our security controls over our systems, as well as other security practices we follow or those systems of our customers into which we operate and rely upon, may not prevent the improper access to or disclosure of personally identifiable or proprietary information. Such disclosure could harm our reputation and subject us to liability under our contracts and laws that protect personal data, resulting in increased costs or loss of revenue.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data privacy is subject to frequently changing rules and regulations, which sometimes conflict among the various jurisdictions and countries in which we operate and continue to develop in ways which we cannot predict. We are subject to U.S. federal and state laws regarding data privacy and security including Section 5 of the Federal Trade Commission Act, or FTC Act. We are also subject to foreign data privacy and security laws, including the Global Data Protection Regulation, or GDPR, the European Union-wide legal framework to govern data collection, use and sharing and related consumer privacy rights. The GDPR includes significant penalties for non-compliance. Our failure to adhere to, or successfully implement processes in response to, changing regulatory requirements in this area could result in legal liability or impairment to our reputation in the marketplace, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in U.S. trade policies could significantly increase the cost of imported goods into the United States, which may materially reduce our sales or profitability. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in U.S. trade policy could trigger retaliatory actions by affected countries, resulting in "trade wars," in increased costs for goods imported into the United States, which may reduce customer demand for these products if the parties having to pay those tariffs increase their prices, or in trading partners limiting their trade with the United States. If these consequences are realized, the volume of economic activity in the United States, may be materially reduced. Such a reduction may materially and adversely affect our sales volumes. Further, the realization of these matters may increase our cost of goods and, if those costs cannot be passed on to our customers, our business and profits may be materially and adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="idb46c8b71d7d4a27b277b6db52f68e8e_22"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1B. Unresolved Staff Comments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None</span></div><div style="text-align:justify"><span><br/></span></div><div id="idb46c8b71d7d4a27b277b6db52f68e8e_25"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. Properties</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently own and maintain a 60,000 square foot facility which consists of office, warehousing, manufacturing and research space located at 5115 Ulmerton Rd., Clearwater, Florida. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apyx Bulgaria EOOD leases approximately 20,000 square feet of office, warehousing and manufacturing facilities located in Sofia, Bulgaria. The rental cost of the facility is approximately $10,000 per month.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="idb46c8b71d7d4a27b277b6db52f68e8e_28"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. Legal Proceedings</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 18 of Notes to Consolidated Financial Statements in Part II, Item 8 of this Form 10-K.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="idb46c8b71d7d4a27b277b6db52f68e8e_31"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. Mine Safety Disclosures</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="idb46c8b71d7d4a27b277b6db52f68e8e_34"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div style="text-align:justify"><span><br/></span></div><div id="idb46c8b71d7d4a27b277b6db52f68e8e_37"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock currently is traded on the NASDAQ Stock Market LLC. As of March&#160;29, 2021, we had approxim</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ately 600 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stockholders of record. Since many stockholders choose to hold their shares under the name of their brokerage firm, we estimate that the ac</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tual number of stockholders was over 3,500 stockholders. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Authorized for Issuance Under Equity Compensation Plans</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:30.131%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.334%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.334%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.335%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Securities to be Issued Upon Exercise of Outstanding Options, Warrants and Rights<br/>(a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price of Outstanding Options, Warrants and Rights<br/>(b)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans (excluding securities reflected in column (a))<br/>(c)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation plans approved by security holders</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,872,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,351,369&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation plans not approved by security holders </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,938,943&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.46&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,351,369&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Represents inducement grants for new hires</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividend Policy</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid any cash dividends on our common stock and we currently do not anticipate paying cash dividends in the foreseeable future. We currently expect to retain any future earnings to fund the operation and expansion of our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Five Year Performance Graph </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following line graph compares the cumulative total return of our common shares with the cumulative total return of the Russell 2000 Stock Index and the Russell 3000 Stock Index. The line graph assumes, in each case, an initial investment of $100 on December&#160;31, 2016, based on the market prices at the end of each fiscal year through and including December&#160;31, 2020, and reinvestment of dividends.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><img src="apyx-20201231_g2.jpg" alt="apyx-20201231_g2.jpg" style="height:480px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:35.942%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2016</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2017</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apyx Medical Corporation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.42&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180.49&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235.64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.54&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russell 2000 Index</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russell 3000 Index</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><div id="idb46c8b71d7d4a27b277b6db52f68e8e_40"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. Selected Financial Data </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Required.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="idb46c8b71d7d4a27b277b6db52f68e8e_43"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should read the following discussion and analysis in conjunction with our consolidated financial statements and related notes contained elsewhere in this report. This discussion contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of a variety of factors discussed in this report and those discussed in other documents we file with the SEC. In light of these risks, uncertainties and assumptions, readers are cautioned not to place undue reliance on such forward-looking statements. These forward-looking statements represent beliefs and assumptions as of the date of this report. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change. Past performance does not guarantee future results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Executive Level Overview</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an advanced energy technology company with a passion for elevating people&#8217;s lives through innovative products in the cosmetic and surgical markets. Known for our innovative Helium Plasma Technology, Apyx is solely focused on bringing transformative solutions to the physicians and patients it serves. Our Helium Plasma Technology is marketed and sold as Renuvion&#174; in the cosmetic surgery market and J-Plasma&#174; in the hospital surgical market. Renuvion&#174; offers plastic surgeons, fascial plastic surgeons and cosmetic physicians a unique ability to provide controlled heat toe tissue to achieve their desired results. The J-Plasma&#174; system allows surgeons to operate with a high level of precision, virtually eliminating unintended tissue trauma. We also leverage our deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in our Annual Report on Form 10-K for the year ended December 31, 2019 ("2019 Form 10-K"), an outbreak of a novel strain of the coronavirus, COVID-19, was identified in China and subsequently recognized as a pandemic by the World Health Organization. The COVID-19 outbreak continues to severely restrict the level of economic activity around the world. In response to the COVID-19 outbreak the governments of many countries, states, cities and other geographic regions have taken preventative or protective actions, such as imposing restrictions on travel and business operations and advising or requiring individuals to limit or forego their time outside of their homes. Temporary closures of businesses in some jurisdictions were ordered, and numerous other businesses closed permanently.  Many other businesses continue to be operated at reduced capacity.   </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ongoing significant reductions in business-related activities could result in further loss of sales and profits and other material adverse effects. The extent of the impact of COVID-19 on our business, financial results, liquidity and cash flows will depend largely on future developments, including new information that may emerge concerning actions taken to contain or prevent further spread of the virus, or its newly forming variants, within the U.S. and the related impact on consumer confidence and spending, all of which are highly uncertain and cannot be predicted.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our revenues were affected by the continued impacts of the COVID-19 pandemic, in the latter half of 2020 we saw strong utilization of our Renuvion&#174; handpieces from existing customers in the U.S., along with shipments to several new customers in our international markets, which helped to offset sluggish global demand for capital equipment.  Throughout the year, we continued our efforts to support our customers during this challenging time. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we were also pleased to see overall improvements in our Advanced Energy business trends during the third and fourth quarters, demand for handpieces remains uneven across, and within, the primary markets that we serve, and global demand trends for generator adoption remain in the early stages of recovery.  Although the timing of a return to a more normalized environment remains uncertain, we remain cautiously optimistic with respect to the continued recovery of the cosmetic and plastic surgery market. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We source the components used in our products from a variety of suppliers and we have collaborative arrangements with three key foreign suppliers. At this time our suppliers have experienced no significant disruptions as a result of COVID-19. We have experienced minor delays in our procurement from these suppliers as a result of the availability of shipping from third party freight carriers. These delays have not, to date, had a significant impact on our operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to COVID-19, we took action in these key areas:</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued</span></div><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Protecting the Health and Safety of our Employees: To reduce the risk to our employees and their families to potential exposure to COVID-19, we required that all non-essential employees work remotely until further notice. We also split the shifts of our manufacturing personnel to allow for adequate social distancing, and require all personnel to utilize personal protective equipment while on site at our facilities. We also significantly reduced business travel and outside access to our facilities.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Maintaining Engagement of or Sales Team and Our Customers: In addition to the initiatives we put in place to protect health and safety for all employees, we focused our direct sales team on remaining in close contact with their existing surgeon customers to do everything they can to provide them with support during this difficult time. With this goal in mind, we  implemented additional training for our sales reps in order to sharpen their ability to engage with our customers virtually. In addition to engaging with existing customers via virtual methods, our reps also continued to target and reach out to prospective customers, and outside the U.S., we continued to monitor the activities of our distributor partners and helped them navigate the challenges they faced as a result of the slower demand they have seen in their respective countries.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Operating Expenses: We continued to take preemptive steps to curtail spending, including implementing hiring restrictions, reducing most discretionary spending, reducing capital expenditures, and delaying certain R&amp;D projects and clinical research studies.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Governmental Policy: On March 27, 2020, the U.S. government enacted the CARES Act to provide relief from COVID-19. We have taken advantage of certain provisions of the CARES Act which are applicable to us, including utilizing net operating loss (NOL) carryback provisions. We expect that utilizing these provisions will significantly help mitigate the working capital impact COVID-19 has had on our sales and operations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first two months of 2020, our plans to host new Physician Mentor Programs, or &#8220;PMPs,&#8221; and expand our presence and educational programming at industry conferences and trade shows proceeded as expected. Our events planned for March, through the present time, however, were canceled or postponed due to COVID-19. In lieu of this in-person programming, our sales, marketing and field clinical teams have been very active in engaging with our customers - and prospects - around the world. We have hosted educational events virtually where we featured some of our leading clinician customers speaking on a wide range of topics, including side-by-side results comparing Renuvion&#174; to a leading competitor's technology.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our virtual educational events have also included case studies to illustrate how our leading clinician customers have adopted Renuvion&#174;, their strategies for marketing and selling to new patients, and their thoughts on pricing and return on investment. We hosted the first installment of a planned series of webinars designed to assist our customers and prospects with opening their practices post-COVID 19. We also engaged with clinician customers outside the U.S. including hosting multiple continuing education training sessions on J-Plasma&#174; and Renuvion&#174; with our current international distributors and conducting multiple calls with groups of international prospects interested in learning about our Renuvion&#174; technology.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, we continued to drive sales in our Advanced Energy business by increasing the adoption and utilization of our handpieces in the U.S. cosmetic surgery market and fulfilling demand from distributors in our international markets. Management estimates that our products have been sold in more than 55 countries. As of December 31, 2020, we had a direct sales force of 31 field-based selling professionals and utilized 2 independent sales agencies. We also had 5 sales managers. This selling organization is focused on the use of Renuvion&#174; in the cosmetic surgery market. In addition, we have invested in training programs and marketing-related activities to support accelerated adoption of Renuvion&#174; into physicians' practices.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our continued investment and focus on the following strategic initiatives in 2020 and beyond will position the Company for long-term growth in the cosmetic surgery market:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">To formalize our regulatory strategy to pursue specific clinical indications that will enable us to sell our Renuvion&#174; products for targeted procedures</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">To secure new clinical evidence demonstrating the safety and efficacy of our Helium Plasma Technology</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">To provide enhanced physician and practice support for our cosmetic surgery customers</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">To improve our manufacturing capabilities and efficiencies</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued</span></div><div><span><br/></span></div></div><div style="padding-left:18pt"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In regards to our operating segments, our results are aggregated into reportable segments only if they exhibit similar economic characteristics. In addition to similar economic characteristics, we also consider the following factors in determining the reportable segments: the nature of business activities, the management structure directly accountable to our chief operating decision maker for operating and administrative activities, availability of discrete financial information, and information presented to the Board of Directors and investors. Asset information is not reviewed by the chief operating decision maker by segment and is not available by segment and, accordingly, we have not presented a measure of assets by reportable segment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reportable segments are disclosed as principally organized and managed as two operating segments: Advanced Energy and OEM.  "Corporate &amp; Other" includes certain unallocated corporate and administrative costs which are not specifically attributed to any reportable segment. The OEM segment is primarily development and manufacturing contract and product driven, and all related expenses are recorded as cost of sales, therefore no segment specific operating expenses are incurred.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strongly encourage investors to visit our website: </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.apyxmedical.com</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;to view the most current news and to review our filings with the Securities and Exchange Commission.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.576%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended<br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales by Reportable Segment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced Energy</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,676&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OEM</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,497&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,711&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,235&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales by Domestic and International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,812&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,899&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,651&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,711&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,235&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue decreased by 1.9% or approximately $(0.5) million for the year ended December&#160;31, 2020 when compared with 2019. Advanced Energy segment sales decreased 2.0% or approximately $(0.5) million for the year ended December&#160;31, 2020 when compared with 2019. The impact of COVID-19 resulted in decreased demand for our products, both domestically and internationally throughout 2020, although sales began to recover late in the second quarter, and through the end of the year, as many of our customers resumed operations in a limited capacity. We continue to see improved demand domestically for our products from pre-COVID-19 levels and have experienced improvements internationally, driven primarily by entry into new markets, the largest of which was Brazil. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The OEM product line consists of proprietary products designed specifically for third party equipment manufacturers. Revenue for this product line decreased (1.1)% or approximately $(0.1) million when compared to 2019.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">International sales represented approximately 32.1% and 30.6% of total revenues for the years ended December 31, 2020 and 2019, respectively. Management estimates our products have been sold in more than 55 countries through local dealers coordinated by sales and marketing personnel through our facilities in Clearwater, Florida and Sofia, Bulgaria.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued</span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gross Profit</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.576%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended<br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,207&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,141&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.576%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,504&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,094&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our gross profit margin as a percentage of sales decreased by 4.4% during the year ended December&#160;31, 2020 compared with 2019. During the second quarter, we reassessed our forecasted product mix due to COVID-19, increased availability of our newer handpiece designs, and improved timing of product registrations in some of our foreign markets. As a result, certain products were reduced to a lower carrying value, and some components were also written off as it was determined to cease further production on these models. This resulted in a decrease in gross profit of approximately $0.3 million which is reflective of small recoveries on the impairments later in the year through the manufacture and sale of handpieces utilizing the impaired components. The remaining decrease in gross profit margin is driven by product mix within our Advanced Energy segment</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, offset by improved product margins in our Advanced Energy segment as a result of our continued manufacturing efficiency initiatives and introduction of newer product models.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued</span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Costs and Expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.576%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended<br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,920&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,731&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our expenditures for R&amp;D related activities increased by 5.1% or approximately $0.2 million for the year ended December&#160;31, 2020, compared with 2019. This increase was primarily due to continued spending on our two investigational device exemption (IDE) clinical studies, which had applications submitted to the FDA in late 2019.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Professional services</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.576%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended<br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,350&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,507&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Professional services expenses decreased 13.6% for the year ended December&#160;31, 2020, compared with 2019. The change was primarily attributable to decreases in legal expense ($0.7 million) associated with our now settled class action lawsuit, a decrease in Medical Advisory Board consulting fees ($0.5 million), and a decrease in option expense related to options granted to our Medical Advisory Board physicians ($0.3 million), as additional grants did not occur in 2020. These decreases were partially offset by an increase in accounting and auditing fees ($0.5 million) related to recent financial statement restatements, the change in our independent accountants and reaudit of the 2019 consolidated financial statements, and continued efforts to remediate our internal control deficiencies and material weaknesses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salaries and related costs</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.576%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended<br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and related expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,630&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,025&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, salaries and related expenses increased approximately 4.3% or approximately $0.6 million compared to 2019. The increase was primarily attributable to additional employee stock option grants in 2020, which drove an increase in employee stock option expense of $1.2 million in 2020. This increase was partially offset by lower bonus expense during 2020 of approximately $0.6 million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expenses</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.576%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended<br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SG&amp;A expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,687&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expense decreased by 14.7% or approximately $2.0 million for the year ended December&#160;31, 2020, compared with 2019.&#160;The decrease is primarily related to decreases in travel and entertainment expense ($1.2 million), advertising including show fees and related costs ($0.6 million), regulatory registration and related quality audit expenses ($0.4 </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued</span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million), and commissions on Advanced Energy sales ($0.2 million), all of which are associated with restricted travel, decreased sales activity, or delayed regulatory activity as a result of COVID-19. These decreases were partially offset by higher bad debt expense ($0.4 million).</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Income</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.576%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended<br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,392&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income decreased (82.7)% for the year ended December 31, 2020 as compared with the prior year. This decrease is due to a lower yield, as well as a lower average balance, on our investments in U.S. Treasury securities included in cash and cash equivalents.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income (Loss), net</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.576%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended<br/>December 31,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (loss), net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(351)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (loss), net increased 236.5% for the year ended December 31, 2020, as compared with the prior year. This increase is primarily due to the receipt of refunds on tariffs paid in the prior year during the first quarter of 2020, combined with the recognition of a joint and several liability for not collecting and remitting payroll taxes related to stock option exercises in the prior year.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax benefit was approximately $7.5 million, with an effective tax rate of 38.7%, for the year ended December 31, 2020 as compared to an income tax benefit of approximately $0.1 million, with an effective tax rate of 0.7%, in 2019. For the year ended December 31, 2020, the effective tax rate differs from the statutory rate primarily due to the release of the valuation allowance on our Federal NOL from 2019 as a result of the CARES Act, partially offset by a valuation allowance on our State NOL for 2020 and accrued interest and penalties on our uncertain tax positions. For the year ended December 31, 2019, the effective tax rate differs from the statutory rate primarily due to the valuation allowance on our Federal and State NOL for 2019 and accrued interest and penalties on our uncertain tax positions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the U.S. government enacted the CARES Act to provide relief from COVID-19. The CARES Act includes a provision that allows companies to carryback NOLs generated in the period 2018 through 2020 to prior years. As a result, we released the full valuation allowance of approximately $3.7 million on our Federal NOL carryforward from 2019 during the first quarter of 2020. In 2020, our income tax benefit is composed primarily of a benefit of $3.7 million associated with the current year net loss and $3.7 million associated with the release of the valuation allowance on the net operating loss from 2019 from the CARES Act. In 2019, our income tax benefit is composed primarily of return to provision adjustments related to the 2018 tax year (benefit of approximately $0.3 million), partially offset by the accrual of interest and penalties on our uncertain tax positions (expense of approximately $0.2 million).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to receive refunds of approximately $7.5 million during 2021 related to the carryback of our 2020 and 2019 pre-tax losses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued</span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2020, we had approximately $41.9 million in cash and cash equivalents as compared to approximately $58.8  in cash and cash equivalents at December 31, 2019.  Our working capital at December 31, 2020 was approximately $56.9 million compared with $64.4 million at December 31, 2019. The decrease in working capital at December 31, 2020 was primarily due to the net loss incurred by the Company in 2020, excluding non-cash activity, comprised primarily of stock-based compensation expense.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2020, net cash used in operating activities was approximately $16.0 million compared with net cash used in operating activities of approximately $18.5 million in 2019.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities for the year ended December 31, 2020, was $0.6 million, related to purchases of capital equipment. Net cash from investing activities for the year ended December 31, 2019 was $60.5 million, primarily related to the maturity of short-term investments and reinvestment in cash equivalents, as well as approximately $1.3 million in purchases of capital equipment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, we had purchase commitments for inventories totaling approximately $1.9 million, substantially all of which is expected to be purchased by the end of 2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP), we have adopted various accounting policies. Our most significant accounting policies are disclosed in Note 2 to the consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Our estimates and assumptions, including those related to inventories, legal proceedings, research and development, warranty obligations, product liability, sales returns and discounts, stock-based compensation and income taxes are updated as appropriate, which in most cases is at least quarterly. We base our estimates on historical experience, or various assumptions that are believed to be reasonable under the circumstances and the results form the basis for making judgments about the reported values of assets, liabilities, revenues and expenses. Actual results may materially differ from these estimates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimates are considered to be critical if they meet both of the following criteria: (1) the estimate requires assumptions about material matters that are uncertain at the time the accounting estimates are made and (2) other materially different estimates could have been reasonably made or material changes in the estimates are reasonably likely to occur from period to period. Our critical accounting estimates include the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our stock option plans, options to purchase common shares of the Company may be granted to employees, officers and directors of the Company by the Board of Directors. We account for stock options in accordance with FASB ASC Topic 718-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation-Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, with compensation expense recognized over the vesting period. Options are valued using the Black-Scholes model, which includes a number of estimates that affect the amount of our expense. We have determined that the most critical of these estimates are the estimates of expected life and volatility used in the calculations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected life</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For employee stock-based compensation awards, we estimate the expected life of awards utilizing the SEC's simplified method. We utilize this method, as we have not historically granted stock-based compensation awards to employees in sufficient volumes to determine a reasonable estimate of the life of awards. For awards granted to non-employees, we calculate expected life using a combination of past exercise behavior, the contractual term and expected remaining exercise behavior.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Volatility</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued</span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the volatility by utilizing the historical volatility of our stock over the period of the awards expected life. The SEC allows us to include periods in excess of the useful life if we determine that they provide a more reasonable basis for the volatility of our stock. Additionally, ASC 718-10 allows us to exclude periods from the volatility if they pertain to events or circumstances that in our judgment are specific to us and if the event or transaction is not reasonably expected to occur again during the expected term of the awards. We have not included any additional periods, nor disregarded any periods, in calculating our volatility.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable Allowance</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a reserve for uncollectible accounts receivable. When evaluating the adequacy of the allowance for doubtful accounts, we analyze specific unremitted customer balances for known collectability issues, review historical bad debt experience, customer credit worthiness and economic trends, and we make estimates in connection with establishing the allowance for doubtful accounts, including the future impacts of current trends. Changes in estimates are reflected in the period they are made. If the financial condition of our customers deteriorates, resulting in an inability to make payments, additional allowances may be required.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventory Obsolescence Allowance</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a reserve for excess and obsolete inventory resulting from the potential inability to sell our products at prices in excess of current carrying costs. The markets in which we operate are highly competitive, with new products and surgical procedures introduced on an ongoing basis. Such marketplace changes may cause our products to become obsolete. We make estimates regarding the future recoverability of the costs of these products and record a provision for excess and obsolete inventories based on historical experience and expected future trends. If actual product life cycles, product demand or acceptance of new product introductions are less favorable than projected by management, additional inventory write-downs may be required, which would unfavorably affect future operating results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation Contingencies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with authoritative guidance, we record a liability in our consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible, but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the consolidated financial statements. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded; actual results may differ from these estimates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes includes federal, foreign, state and local income taxes currently payable and those deferred because of temporary differences between the financial statement and tax bases of assets and liabilities. Deferred tax assets or liabilities are computed based on the difference between the financial statement and income tax bases of assets and liabilities using enacted marginal tax rates. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. Deferred income tax expenses or credits are based on the changes in the asset or liability from period to period.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of historical losses exclusive of discontinued operations, and our expectation to continue to generate losses in the near future, we recorded a valuation allowance on the our deferred tax asset. Exclusive of the carryback provisions of the CARES ACT and the associated income tax benefit recognized in 2020, we do not anticipate recording an income tax benefit related to these deferred tax assets. We will reassess the realization of deferred tax assets each reporting period and will be able to reduce the valuation allowance to the extent the financial results of continuing operations improve, and it becomes more likely than not that the deferred tax assets will be realizable. As management expects the Company to continue to generate losses in the foreseeable future after 2020, we will continue to record a valuation allowance on the net deferred tax assets balance as of December 31, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the financial statement impact of an uncertain tax position taken or expected to be taken on an income tax return at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized in the financial statements unless it is more likely than not of being sustained.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued</span></div><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inflation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inflation has not materially impacted the operations of our Company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">We have no off-balance sheet arrangements at this time.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 4 of the Notes to Consolidated Financial Statements.</span></div><div style="text-align:justify"><span><br/></span></div><div id="idb46c8b71d7d4a27b277b6db52f68e8e_46"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not required.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="idb46c8b71d7d4a27b277b6db52f68e8e_49"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 8. Financial Statements and Supplementary Data </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO FINANCIAL INFORMATION</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:93.043%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.757%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Report of Independent Registered Public Accounting Firm</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_52">30</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_55">Consolidated Balance Sheets at December 31, 2020 and 2019</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_55">31</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_61">Consolidated Statements of Operations for the years ended December 31, 2020 and 2019</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_61">32</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_64">Consolidated Statements of Changes in Equity for the years ended December 31, 2020 and 2019</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_64">33</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_67">Consolidated Statements of Cash Flows for the years ended December 31, 2020 and 2019</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_67">34</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_70">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_70">35</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="idb46c8b71d7d4a27b277b6db52f68e8e_52"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Report of Independent Registered Public Accounting Firm</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To the Stockholders and the Board of Directors of Apyx Medical Corporation</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Opinion on the Financial Statements</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have audited the accompanying consolidated balance sheets of Apyx Medical Corporation and its subsidiaries (the Company) as of December 31, 2020 and 2019, the related consolidated statements of operations, changes in equity and cash flows for the years then ended, and the related notes to the consolidated financial statements (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Basis for Opinion</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Critical Audit Matters</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ RSM US LLP</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have served as the Company's auditor since 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Orlando, Florida</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March 31, 2021</span></div><div><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="idb46c8b71d7d4a27b277b6db52f68e8e_55"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands, except share and per share data)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfMy0xLTEtMS0w_27307a98-2162-449d-b230-1c543ccce7d0">41,915</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfMy0zLTEtMS0w_86be10df-52e4-48e5-994d-090d8389cbe3">58,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts receivable, net of allowance of $<ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNi0wLTEtMS0wL3RleHRyZWdpb246NTViYWNjN2VjMmExNGY0MmI3ZmY5YWI1MTY5NDllZjNfMTA5OTUxMTYyNzg0NA_ff0a8256-4df8-4806-a58b-64b07d45a582">300</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNi0wLTEtMS0wL3RleHRyZWdpb246NTViYWNjN2VjMmExNGY0MmI3ZmY5YWI1MTY5NDllZjNfMTA5OTUxMTYyNzg1MQ_5283322c-bc0f-42d4-9eca-7482fc68acb5">273</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNi0xLTEtMS0w_d93e2d5b-c25e-4c0c-bfcb-3ca68eab5049">8,399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNi0zLTEtMS0w_ee5e3a05-faad-40be-a499-882bae056e47">7,987</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNy0xLTEtMS0xMzI_0c603164-0ced-4ab7-b355-3dd62ddea1c9">7,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" name="us-gaap:IncomeTaxesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNy0zLTEtMS0xMzI_58b18cae-28c1-413e-a0d1-906949b5996f">426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNy0xLTEtMS0w_f206da9c-f99b-4b17-af39-5ec31cf19a89">1,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNy0zLTEtMS0w_92fbbfcd-dcb8-41fc-8b3e-ae723781c155">1,233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net of provision for obsolescence of $<ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" name="apyx:ProvisionForObsolescenceInventory" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfOC0wLTEtMS0wL3RleHRyZWdpb246MGZhMGIwZjQwYjRiNDU3Njk0ZmZmOWFiNzNkYjAzM2FfMTA5OTUxMTYyNzg0Nw_329d841a-7bf1-4241-bfcc-9a17b233f0d9">388</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" name="apyx:ProvisionForObsolescenceInventory" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfOC0wLTEtMS0wL3RleHRyZWdpb246MGZhMGIwZjQwYjRiNDU3Njk0ZmZmOWFiNzNkYjAzM2FfMTA5OTUxMTYyNzg1NA_ab6b87a2-83c4-4acf-8f7c-00d0ec6819d7">392</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfOC0xLTEtMS0w_4cca3aee-7d29-4124-894f-9247db909628">4,051</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfOC0zLTEtMS0w_ff6e7fc7-4f50-4133-89cb-332a14b21604">5,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfMTAtMS0xLTEtMA_83116c5e-4a2a-4327-8a1c-696db5d24cc8">2,795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfMTAtMy0xLTEtMA_2eab3fdc-bbe9-406f-966e-4712416f38e1">3,207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfMTItMS0xLTEtMA_bf9daa06-d018-481b-a1f2-d50990675378">66,089</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfMTItMy0xLTEtMA_1ebdfc9e-6db4-4a81-87bf-4a38ebc9a1d9">76,733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfMTMtMS0xLTEtMA_d497df63-e174-4cea-915d-143509ba3381">6,541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfMTMtMy0xLTEtMA_4db7410f-3646-45bb-ac94-94aaade11d22">6,618</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfMTQtMS0xLTEtMA_d734a495-e0fe-4d86-9a11-a56bda26f72e">237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfMTQtMy0xLTEtMA_1d25f005-da66-4935-834b-a6fa368a85c7">350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfMTgtMS0xLTEtMA_d4915c8f-87ed-4d24-a5e7-0ac4b95d0324">437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfMTgtMy0xLTEtMA_8a36d548-7a44-43b0-8293-1cb8fe8c4d87">653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfMTktMS0xLTEtMA_b0d22643-2b74-40a3-8f99-78e21e74e2fa">807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfMTktMy0xLTEtMA_494107ae-1173-496c-aedc-3b00b323ea51">391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfMjEtMS0xLTEtMA_a96c96ad-4de0-4130-a15b-fedcbb653cf7">74,111</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfMjEtMy0xLTEtMA_74d257ec-7c3b-4c4f-8e88-e9da6066f5a4">84,745</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND EQUITY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfMjYtMS0xLTEtMA_c2cefb9e-40c9-4751-9aaa-799328e92941">1,511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfMjYtMy0xLTEtMA_830ec1de-aa4d-477f-8fdb-ecdf0f568565">2,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfMjctMS0xLTEtMA_df72342b-87ed-41ee-bf54-75be41d6669c">7,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfMjctMy0xLTEtMA_1b684e2b-627b-4ff2-a70b-907220b4a159">9,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfMzEtMS0xLTEtMA_07c598a3-ae60-45ef-bc68-3fbfe2a3b21d">126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfMzEtMy0xLTEtMA_a8b86100-477c-410f-b9e9-cb7ef19769b3">108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of finance lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfMzItMS0xLTEtMA_00566cd9-8be2-4c64-9bf2-fe1b3ba7403b">238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfMzItMy0xLTEtMA_e4414655-df57-4d0e-8ba0-cbfa1f3d63a5">229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related party note payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DueToRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfMzMtMS0xLTEtMA_3222110c-abbd-4c45-b6f4-1fb70db3d949">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" name="us-gaap:DueToRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfMzMtMy0xLTEtMA_ccc5b199-31a2-4405-b209-140226372943">140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNDAtMS0xLTEtMA_c3b4f8bc-e5df-4f0b-8c3f-afd58ce9338c">9,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNDAtMy0xLTEtMA_5c843e95-b52b-4d10-ae00-4573dc9f2f03">12,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNDItMS0xLTEtMA_69881be3-3e30-40fb-9517-b73b0e48e7b6">129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNDItMy0xLTEtMA_c749d053-9c8f-4f81-9adb-74cc6fd5f83d">235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term finance lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNDMtMS0xLTEtMA_593bd6bc-36b8-4edc-a82f-5e6321abdecf">183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNDMtMy0xLTEtMA_166354ca-f18c-4dc0-9221-6037b68ede6a">421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNDQtMS0xLTEtMA_1a495784-42f0-4b5a-ac30-31795daf4a84">621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNDQtMy0xLTEtODI_e4550917-d979-408e-9858-d9330b502bf2">405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNDUtMS0xLTEtMA_398d7667-deac-4ad4-bbd0-90c60e88f05e">166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNDUtMy0xLTEtMA_527b05fd-d142-4157-9f13-fde39ae3965f">114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNDctMS0xLTEtMA_94b12e4a-494a-4f5e-a6bd-a2697f02b48b">10,252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNDctMy0xLTEtMA_fa21e73f-713b-40a1-824d-635267a657a8">13,486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMMITMENTS AND CONTINGENCIES (NOTE 18)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNDktMS0xLTEtMA_411378e8-15c4-4c8e-bddf-19523483d842"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNDktMy0xLTEtMA_9f2d9288-cb24-47da-904d-25ed265549e5"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EQUITY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNTEtMC0xLTEtMC90ZXh0cmVnaW9uOjRlOWQzMjk0NDE5ZjRlZjg5YzhhOTRkOWViOWMyMGIzXzEwOTk1MTE2Mjc5Nzk_7df126f3-3fce-41ed-b2f9-e8e741d6b3d6"><ix:nonFraction unitRef="usdPerShare" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNTEtMC0xLTEtMC90ZXh0cmVnaW9uOjRlOWQzMjk0NDE5ZjRlZjg5YzhhOTRkOWViOWMyMGIzXzEwOTk1MTE2Mjc5Nzk_ad802057-8772-407e-9e8c-126c54b8bb28">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNTEtMC0xLTEtMC90ZXh0cmVnaW9uOjRlOWQzMjk0NDE5ZjRlZjg5YzhhOTRkOWViOWMyMGIzXzEwOTk1MTE2Mjc5OTI_126cebd6-cf09-4ee0-9205-96b19bdc8547"><ix:nonFraction unitRef="shares" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNTEtMC0xLTEtMC90ZXh0cmVnaW9uOjRlOWQzMjk0NDE5ZjRlZjg5YzhhOTRkOWViOWMyMGIzXzEwOTk1MTE2Mjc5OTI_3ff0a23f-9a94-491b-aba8-332b822a32de">75,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNTEtMC0xLTEtMC90ZXh0cmVnaW9uOjRlOWQzMjk0NDE5ZjRlZjg5YzhhOTRkOWViOWMyMGIzXzEwOTk1MTE2MjgwMDU_8e500aa4-4daf-429b-9cfc-abe9f84c676d"><ix:nonFraction unitRef="shares" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNTEtMC0xLTEtMC90ZXh0cmVnaW9uOjRlOWQzMjk0NDE5ZjRlZjg5YzhhOTRkOWViOWMyMGIzXzEwOTk1MTE2MjgwMDU_d96729ff-c38b-4b8e-8d0a-381fa5646079">34,289,222</ix:nonFraction></ix:nonFraction> issued and outstanding as of December 31, 2020, and <ix:nonFraction unitRef="shares" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNTEtMC0xLTEtMC90ZXh0cmVnaW9uOjRlOWQzMjk0NDE5ZjRlZjg5YzhhOTRkOWViOWMyMGIzXzEwOTk1MTE2MjgwMTg_aea57991-f1a7-42aa-a817-c7a58822a749">34,312,527</ix:nonFraction> issued and <ix:nonFraction unitRef="shares" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNTEtMC0xLTEtMC90ZXh0cmVnaW9uOjRlOWQzMjk0NDE5ZjRlZjg5YzhhOTRkOWViOWMyMGIzXzEwOTk1MTE2MjgwMzE_e06ff0c9-6e4d-431a-b4dc-e84f9f53ee49">34,169,952</ix:nonFraction> outstanding as of December 31, 2019</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNTEtMS0xLTEtMA_ff912ace-7338-45ba-ae2b-e43dd010c80d">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNTEtMy0xLTEtMA_b7101feb-eba7-4c26-ade5-33b7f3a68300">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNTItMS0xLTEtMA_dc361b27-6f2f-42ae-8313-3994ff8c89ac">61,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNTItMy0xLTEtMA_12b6048e-910e-4580-ad83-ee125414ee31">56,708</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNTMtMS0xLTEtMA_0099245f-6357-4255-a742-45d96f2b9c96">2,621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNTMtMy0xLTEtMA_12b7348f-c60d-4345-a4e2-4646a7abaa45">14,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNTQtMS0xLTEtMA_0ff4c242-71f7-45c1-b40d-1c3a10812695">63,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNTQtMy0xLTEtMA_78a84f77-d7cc-4777-bff7-36b7c9eb5dbd">71,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNTUtMS0xLTEtMTA0_aeb40917-cc49-4401-b57c-c25665de255a">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNTUtMy0xLTEtMTA0_b9d455a0-a343-4177-9689-76a41b6955b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNTctMS0xLTEtMzU4Mw_8858a148-a59e-4a66-a96c-862812ae8764">63,859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNTctMy0xLTEtMzU4Nw_d9d59025-a1af-47c1-9a0e-29cd6e85afe0">71,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities and equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNTUtMS0xLTEtMA_b7c5c7ef-ed03-4881-90d5-f50b4af93004">74,111</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNTUtMy0xLTEtMA_7b947b3d-d084-4303-9904-aeca407da9d1">84,745</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of the consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><div id="idb46c8b71d7d4a27b277b6db52f68e8e_61"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands, except per share data)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfMi0xLTEtMS0w_5a7fe1d4-cd29-4ce0-ac62-fb28c289faab">27,711</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfMi0zLTEtMS0w_e46fab52-816a-4334-aa9b-09b1626dca9a">28,235</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfMy0xLTEtMS0w_43fe5483-43bf-40db-945b-d6c8f10b62ac">10,207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfMy0zLTEtMS0w_4939e319-1450-4cb8-8504-5e200c27be5e">9,141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfNC0xLTEtMS0w_4cb51c6c-5f95-4cd7-80b2-e6e84367bca6">17,504</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfNC0zLTEtMS0w_3d2cbd80-6bd6-4a22-b405-28d7d0735f6a">19,094</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other costs and expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfNi0xLTEtMS0w_13b94bdd-1b15-4e1c-8488-401816fcbf5b">3,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfNi0zLTEtMS0w_3340eae1-8a08-433a-aede-9f133d7fda4f">3,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfessionalFees" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfNy0xLTEtMS0w_7f02cc0e-fe63-473f-af2c-6b7830fae72e">7,350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfessionalFees" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfNy0zLTEtMS0w_e4688dd1-dbcf-4d7f-bffc-caa3206f98aa">8,507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and related costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SalariesAndWages" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfOC0xLTEtMS0w_169cb689-1672-4766-bef5-7b93dbfaf253">14,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SalariesAndWages" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfOC0zLTEtMS0w_9c0a1d9e-53ef-4564-af1e-40bbaa026525">14,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfOS0xLTEtMS0w_be1b3c1b-1f84-4f09-8795-27afd1e16c68">11,687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfOS0zLTEtMS0w_e577f7b6-963c-40f6-b0c9-abb0e9bfafe1">13,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total other costs and expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfMTEtMS0xLTEtMA_8b0b6a75-43a0-47ba-8e17-a1ae00cc8f4b">37,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfMTEtMy0xLTEtMA_c8b88149-87af-4ef1-9d0b-52bd5c977941">39,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfMTItMS0xLTEtMA_3a230f04-31f9-45d8-a7ca-09327aa096ff"><ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfMTItMS0xLTEtMA_da81baf8-76ae-40ec-9b58-9738333a2341">20,083</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfMTItMy0xLTEtMA_f73228c6-30b2-4c16-920d-6c052219dc8a">20,869</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfMTQtMS0xLTEtMA_c7657e66-8386-4e7e-824d-a561df032472">241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfMTQtMy0xLTEtMA_e68c09ac-f5d8-40aa-8ce7-95937e9a5486">1,392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfMTUtMS0xLTEtMA_1bd644f3-dcf3-469b-8f91-da7a0d5de2c7">46</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfMTUtMy0xLTEtMA_17d69843-1b2a-42cf-871d-6985806143bb">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (loss), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfMTgtMS0xLTEtMA_199383b5-a389-4415-866c-7e2252c43233">479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfMTgtMy0xLTEtMA_c7cacc41-63b5-4bb1-b8df-e6be788de916">351</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total other income, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfMjEtMS0xLTEtMA_3f6285d0-979e-4d84-a11c-3823111f4af6">674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfMjEtMy0xLTEtMA_81ec758b-fb50-4017-abbb-9225046f4b5a">1,033</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfMjItMS0xLTEtMA_2c25f35c-c171-47ec-b47c-3b75439ff59b">19,409</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfMjItMy0xLTEtMA_11227ec3-da8a-478b-9c6a-35b9ff3b30ca">19,836</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfMjMtMS0xLTEtMA_03a6a7dc-ab3a-4c7a-bdbb-a3d2b3b725e1">7,503</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfMjMtMy0xLTEtMA_aae979e1-15eb-4df6-93e5-a40dfd2e8ba2">130</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfMjQtMS0xLTEtMA_b8aa7559-8a56-4d49-8318-262b9a47a925">11,906</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfMjQtMy0xLTEtMA_70d34d50-ce0e-40b6-91b2-8da3c4bf23ee">19,706</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfMjUtMS0xLTEtMA_3f5e0059-8aff-4207-bb33-d6d3f739f0ab">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfMjUtMy0xLTEtMA_def018c7-2afa-41a5-b73f-fb9901d1475e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss attributable to stockholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfMjYtMS0xLTEtMA_bead852b-9fe2-4bb1-9624-d752b940aafa">11,896</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfMjYtMy0xLTEtMA_2c31e165-b1eb-416d-b730-af5e89196e4d">19,706</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and Diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfMzEtMS0xLTEtMA_b1a97deb-fb87-42c5-b9ad-248234c16d93">0.35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfMzEtMy0xLTEtMA_2a45bf55-dce6-4518-b6ac-91f28346304d">0.58</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of shares outstanding - basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfNDItMS0xLTEtMA_bd47576c-9cf7-46c5-9e38-1ec3a7d8d020">34,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfNDItMy0xLTEtMA_377f7bed-86e1-4b85-b1cc-de38b8fdcf19">34,069</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of the consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><div id="idb46c8b71d7d4a27b277b6db52f68e8e_64"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.455%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.457%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Par Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retained Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-controlling interest equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total  Equity</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance<br/>December 31, 2018</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i96fdd56f4a934deb9be8b429dd443450_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMjItNS0xLTEtMA_7942230e-8684-497d-8844-99632625b730">33,705</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96fdd56f4a934deb9be8b429dd443450_I20181231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMjItNy0xLTEtMA_eaf8c387-1fc1-4239-8863-f172ae0e63e5">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b0b5fc07294eaa8b9b7c9c449eee1a_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMjItOS0xLTEtMA_53b05c0a-9c8e-44d2-a1b9-e10852c4a84f">52,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67c608a0d0d84f82b2791e369dd406ef_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMjItMTEtMS0xLTA_ab32d2bf-d031-496b-970c-2a7c8d65acd5">34,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd03c7764245458ba14ccb5108168190_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMjItMTMtMS0xLTA_a8ab873e-c5c1-493e-94d3-7ce213923abd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00df6877cb2d4b75a1a4abee0d94d57f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMjItMTUtMS0xLTA_62e80886-8517-4fc0-91fc-ada9719a7324">87,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares issued on stock options exercised for cash</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id992bd2f876c4b41b9cacd2ed36d028b_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMjMtNS0xLTEtMA_67a873dd-06ff-47dc-ba97-17877582141d">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1b9838e537a4797bfd3b3f72116ce4a_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMjMtOS0xLTEtMA_ae40eb6f-c85f-46c1-bfe1-9e30a9134d36">207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMjMtMTUtMS0xLTA_23076b27-1b95-4676-9b8e-173a4d2a1123">207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1b9838e537a4797bfd3b3f72116ce4a_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMjgtOS0xLTEtMA_d6302fc9-7239-4828-a33b-a5730f3e95dc">3,581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMjgtMTUtMS0xLTA_d1c1d7fa-615f-444a-801c-a3514e6ce5d5">3,581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares issued on net settlement of stock options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id992bd2f876c4b41b9cacd2ed36d028b_D20190101-20191231" decimals="-3" name="apyx:StockSwapToAcquireOptionsShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMjktNS0xLTEtMA_f8421414-31d4-4c55-9d9a-92c3ad9c124c">223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested restricted stock issued</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id992bd2f876c4b41b9cacd2ed36d028b_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMzAtNS0xLTEtMA_b75a8e82-f685-46d2-99d6-091ae3888949">181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3251c9a7258d4e12930f0fe7a2b79ff9_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMzMtMTEtMS0xLTA_89f053db-b9aa-4e11-9451-0a1709ac15bf">19,706</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMzMtMTUtMS0xLTA_1bd3144a-4b42-4422-8c6f-58bfcab85d05">19,706</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance<br/>December 31, 2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib71a81c6cf874b9f8f5abe1afdc8701d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMzQtNS0xLTEtMA_d0751714-403b-4f06-83fc-81333c56ca6f">34,170</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib71a81c6cf874b9f8f5abe1afdc8701d_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMzQtNy0xLTEtMA_32ae4276-3cea-479f-8ef2-dccf4093ec52">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cae677daf3a4680b30b757dd83c4a07_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMzQtOS0xLTEtMA_800eca9b-1517-4899-b4f9-5144ec468b9c">56,708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a3d8fad4cc642db8994868640f75384_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMzQtMTEtMS0xLTA_f0562a43-7a78-4d51-950d-83fce31721ba">14,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bb3f044ef5d488f992a3c49afc08bf0_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMzQtMTMtMS0xLTA_b1c76dba-b97e-44e7-8b55-18c0f798422f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMzQtMTUtMS0xLTA_ea7ad58c-bbbb-4b1a-93c5-957232212773">71,259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions from non-controlling interest</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e0b3ac3abbb4da6ba6ebb3596d95da5_D20200101-20201231" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMzUtMTMtMS0xLTIyNw_4e99fa6d-35b6-4655-9175-8e07692507ac">148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMzUtMTUtMS0xLTIyNw_b973a557-b4bc-404f-bede-779afbdb13c4">148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares issued on stock options exercised for cash</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8bd3c576836a42909e45df1e4cbe6038_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMzYtNS0xLTEtMjI3_2120e36c-cc59-407d-b01d-c611cd636ded">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1386a67ac59644f3bcf3f6f4a0040e4f_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMzYtOS0xLTEtMjI3_085cf4a0-8e5a-45fd-b622-0a2e8b3263d9">148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMzYtMTUtMS0xLTIyNw_406784b1-5138-4cdd-95e1-705e1c97c7f6">148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1386a67ac59644f3bcf3f6f4a0040e4f_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMzctOS0xLTEtMjI3_2d4608ea-42e6-4f2b-a006-ce77d4ffe291">4,210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMzctMTUtMS0xLTIyNw_b6ce3a61-0ef4-4f5d-9cd5-e614f48f3b6f">4,210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares issued on net settlement of stock options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8bd3c576836a42909e45df1e4cbe6038_D20200101-20201231" decimals="-3" name="apyx:StockSwapToAcquireOptionsShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMzgtNS0xLTEtMjI3_b118002c-aee6-4fef-8981-02ff6d21fbfc">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested restricted stock issued</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8bd3c576836a42909e45df1e4cbe6038_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMzktNS0xLTEtMjI3_7d61d952-fded-4844-993b-49d8bd3ca51f">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i868214ceea314396813754fb0220fc1f_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfNDAtMTEtMS0xLTIyNw_fab8cf41-d846-4f44-aa9f-cbcc6f9b6f47">11,896</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1e0b3ac3abbb4da6ba6ebb3596d95da5_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfNDAtMTMtMS0xLTIyNw_51e922f0-a69c-437a-806c-6aaeb30fc95f">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfNDAtMTUtMS0xLTIyNw_bd098300-204c-4258-aff2-773fee773cf3">11,906</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance<br/>December 31, 2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1b9e760795d04740980adf4105f44066_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfNDEtNS0xLTEtMjI3_9cca7727-d4cd-465f-995e-565fdf135d59">34,289</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b9e760795d04740980adf4105f44066_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfNDEtNy0xLTEtMjI3_a78e3c84-ffa1-48a0-90f8-8a1f9c734b9f">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d4c03e853084e12b45168c562e7aeac_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfNDEtOS0xLTEtMjI3_2e424aa4-b378-45c3-8b09-a1b20c552ab3">61,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09376f8c140d4e28b47971c939c7a4fb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfNDEtMTEtMS0xLTIyNw_04a6d0fb-7258-42b1-9502-e3cde896eed5">2,621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a1a44a54fd4403d892b074c44ed1d4d_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfNDEtMTMtMS0xLTIyNw_e06681fb-f9e9-428b-86e3-84282beb549c">138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfNDEtMTUtMS0xLTIyNw_af59ae5d-9f69-43d4-8010-d3115de5e163">63,859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of the consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="idb46c8b71d7d4a27b277b6db52f68e8e_67"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands) </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.352%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMy0xLTEtMS0w_ffa866a1-9948-4de0-839d-ed2a55b82a49">11,906</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMy0zLTEtMS0w_e9480eab-25a7-4c15-9dae-b7aa4ddd5604">19,706</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfNy0xLTEtMS0w_3d5e71aa-9753-4569-91f1-168e56fe2860">887</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfNy0zLTEtMS0w_036eeae0-0277-4ccc-8739-c4e6c613a6a0">754</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for inventory obsolescence</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" name="apyx:ProvisionForInventoryObsolescence" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfOC0xLTEtMS0w_b7ccee32-ee91-406b-9d43-3282e8840481">506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" name="apyx:ProvisionForInventoryObsolescence" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfOC0zLTEtMS0w_edccfb6f-d4c9-46df-b0e6-b89c383d98d9">132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for product warranties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" name="us-gaap:ProductWarrantyExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfOS0xLTEtMS0w_093c03ac-69ee-4ce7-93e4-6d654149e0c5">215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" name="us-gaap:ProductWarrantyExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfOS0zLTEtMS0w_e4e905f6-c9dc-454d-a71d-d8dfbe3f0ba5">321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on disposal of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:GainLossOnDispositionOfAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMTAtMS0xLTEtMA_1c3e0143-ee5e-4b03-8eae-691af6a0a6d3">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:GainLossOnDispositionOfAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMTAtMy0xLTEtMA_6edc0f9a-8f5e-4841-9337-275d9d56472c">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMTEtMS0xLTEtMA_2a554c68-b5c4-434c-a7ab-80b7d4151ff3">4,210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMTEtMy0xLTEtMA_4981fcb9-d509-4a1d-aad7-89edc5a8fbbe">3,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized and unrealized gains on short term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMTQtMS0xLTEtMA_30464bef-5429-4d3b-895b-648dec9a2f08">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" name="us-gaap:GainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMTQtMy0xLTEtMA_ef52ef74-6fc3-4744-b02e-f64c7181e247">164</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision (benefit) for allowance for doubtful accounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMTUtMS0xLTEtMA_f60ae142-e86c-491e-9a87-d20a92af3729">262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMTUtMy0xLTEtMA_53bd53b7-474b-4872-8b64-56b16f877ed1">163</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in current assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMTgtMS0xLTEtMA_6aa69be4-24f8-44e8-a0ea-cb8fc3a00b69">558</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMTgtMy0xLTEtMA_1e70e763-3925-4608-a1ba-7e9d5fc6cc44">3,970</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMTktMS0xLTEtMA_11994be3-c5d8-4690-be02-517110ce6338">7,228</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMTktMy0xLTEtMA_b02a78e1-dc04-47dc-872a-d2944df2d1e6">180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMjAtMS0xLTEtMA_0e8c6a2f-2fda-4690-8c27-8ef069a19a41">27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMjAtMy0xLTEtMA_fc872d73-508f-4b22-92e3-502e2008c1bd">586</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMjEtMS0xLTEtMA_32daa676-827f-456e-b950-43d5da6444b5">615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMjEtMy0xLTEtMA_13c477c2-802d-49cb-937d-6e58a6faaa47">2,367</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMjMtMS0xLTEtMA_8b3c4cd0-a152-4716-88d8-129cd943a627">965</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMjMtMy0xLTEtMA_4a2b31bf-1658-4624-b040-3b5f02e49f5e">1,054</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMjUtMS0xLTEtMA_01f1ae98-08ad-44fb-9575-3a5ca77af864">2,090</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMjUtMy0xLTEtMA_70bc26ca-13b7-43b4-b65d-307d76420264">2,370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMjgtMS0xLTEtMA_fff61d77-a87a-4a4a-b63a-b4b7d1fbef6e">16,066</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMjgtMy0xLTEtMA_1f34c740-c89d-470d-94a6-99277c700692">18,475</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMzAtMS0xLTEtMA_68e35276-1000-420b-b29e-9f966535811c">581</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMzAtMy0xLTEtMA_3b7d8669-71d8-4257-bffd-97da4fe8f729">1,301</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMzItMS0xLTEtMA_a7f10575-97a0-497b-979f-5d6e080b9849">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMzItMy0xLTEtMA_8f3f16b8-2f64-4a5d-80df-9e67195547c9">18,884</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMzMtMS0xLTEtMA_8428d5a4-ef4f-4b0c-a030-301a5b75c23f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMzMtMy0xLTEtMA_0eca8896-c107-46b6-9a5c-55c855a5ef86">80,726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash (used in) provided by investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMzQtMS0xLTEtMA_43402628-8a5c-4439-a2a0-96a72ac18388">581</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMzQtMy0xLTEtMA_afbe7c76-323b-44fa-b31e-599e44bd3939">60,541</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from stock option exercises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" name="apyx:ProceedsFromStockOptionsExercisedAndWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMzctMS0xLTEtMA_bf9cf70c-02e3-4a63-acab-7c186a1016ab">148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" name="apyx:ProceedsFromStockOptionsExercisedAndWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMzctMy0xLTEtMA_2f7f9095-98d3-45ad-a5b8-83a1f9c13993">207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of related party note payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" name="us-gaap:RepaymentsOfRelatedPartyDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMzgtMS0xLTEtMjkx_d4c534ec-4d80-4c89-b85c-c0b9de74480d">140</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:RepaymentsOfRelatedPartyDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMzgtMy0xLTEtMzYxNw_d5075f0e-1050-43c3-8a4b-c6ad08e09a6c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of finance lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" name="apyx:RepaymentofFinanceLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMzgtMS0xLTEtMA_1c97e890-f5fd-4426-a1a4-1510fc8ae9ba">229</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" name="apyx:RepaymentofFinanceLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMzgtMy0xLTEtMA_c8c47fc2-a1a3-47b1-a8b2-f38f4068820d">60</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contributions from non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromMinorityShareholders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMzktMS0xLTEtMA_7778480f-93be-43b2-b63e-6e38176cddd6">148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromMinorityShareholders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMzktMy0xLTEtMA_d8a504bc-a4db-4223-8cb5-38291ad5f184">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash (used in) provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfNDMtMS0xLTEtMA_ff0bcae3-b200-41b5-b12f-349e249f7c76">73</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfNDMtMy0xLTEtMA_da6d64ce-2694-418e-83f9-308979764561">147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effect of exchange rates on cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfNDQtMS0xLTEtMA_a1e28dd1-c1f7-4399-be99-8435155a6d93">177</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfNDQtMy0xLTEtMA_d9d3054d-8c45-4950-967b-2ae758af3603">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfNDUtMS0xLTEtMA_a8e76f3d-5e88-4be4-9d59-1fa1608ca78e">16,897</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfNDUtMy0xLTEtMA_f4c5fb3d-697c-4106-8c33-6fc5429ad446">42,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and cash equivalents, beginning of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfNDYtMS0xLTEtMA_b751ad2b-2d05-4076-a785-9faa151dd924">58,812</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00df6877cb2d4b75a1a4abee0d94d57f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfNDYtMy0xLTEtMA_e34fde87-acc3-434a-bd01-2876a3ead491">16,596</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and cash equivalents, end of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfNDctMS0xLTEtMA_c5446f13-913a-4259-aa2d-df3b1cd9db38">41,915</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfNDctMy0xLTEtMA_1365fce9-e88b-4d03-a44b-3707fac33eea">58,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfNTEtMS0xLTEtMA_6e8e154a-f201-4490-9a1b-a0b03a850f6b">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfNTEtMy0xLTEtMA_af985ef1-c257-4dbf-88b3-75e50fbf710a">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxesPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfNTItMS0xLTEtMA_b7f30652-b0c4-44f0-a29f-6bb08a3a933e">82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxesPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfNTItMy0xLTEtMA_fd587e07-7a93-4fec-82e6-8ab82597a6e9">325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non cash operating and investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfer of other assets to fixed assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="apyx:NonCashTransferOfOtherAssetsToFixedAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfNTUtMS0xLTEtMA_e59e705c-9975-4b30-8719-eae52e26dc30">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" name="apyx:NonCashTransferOfOtherAssetsToFixedAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfNTUtMy0xLTEtMA_e804d839-adcb-4a2a-9691-6980f6f3456d">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfer of inventory to fixed assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" name="apyx:NonCashTransfersOfInventoryToFromFixedAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfNTYtMS0xLTEtMA_02132dbd-855c-479f-8e96-e6da776f287a">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" name="apyx:NonCashTransfersOfInventoryToFromFixedAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfNTYtMy0xLTEtMA_20c8aace-793b-41e7-8c28-ae102cc734f1">277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of the consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><div id="idb46c8b71d7d4a27b277b6db52f68e8e_70"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><div><span><br/></span></div><div id="idb46c8b71d7d4a27b277b6db52f68e8e_73"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 1. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83My9mcmFnOjg5NjA5ZGI5NzlmZDQ2YzM5MDQ5MmYyZTNjNjJiNWQ2L3RleHRyZWdpb246ODk2MDlkYjk3OWZkNDZjMzkwNDkyZjJlM2M2MmI1ZDZfMTI1NA_ff6d252f-7576-4b69-9099-0d0b5b0ad64d" continuedAt="ie6a63b7d1d7b499382ef39e524e62291" escape="true">DESCRIPTION OF BUSINESS&#160;</ix:nonNumeric></span></div><div style="text-align:justify;text-indent:42.75pt"><span><br/></span></div><ix:continuation id="ie6a63b7d1d7b499382ef39e524e62291"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apyx Medical Corporation (&#8220;Company", "Apyx", "it" and similar terms) was incorporated in 1982, under the laws of the State of Delaware and has its principal executive office at 5115 Ulmerton Road, Clearwater, FL 33760.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is an advanced energy technology company with a passion for elevating people&#8217;s lives through innovative products in the cosmetic and surgical markets. Known for its innovative Helium Plasma Technology, Apyx is solely focused on bringing transformative solutions to the physicians and patients they serve. It's Helium Plasma Technology is marketed and sold as Renuvion&#174; in the cosmetic surgery market and J-Plasma&#174; in the hospital surgical market. Renuvion&#174; offers plastic surgeons, fascial plastic surgeons and cosmetic physicians a unique ability to provide controlled heat to the tissue to achieve their desired results. The J-Plasma&#174; system allows surgeons to operate with a high level of precision, virtually eliminating unintended tissue trauma. The Company also leverages its deep expertise and decades of experience in unique waveforms through original equipment manufacturing (OEM) agreements with other medical device manufacturers.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="idb46c8b71d7d4a27b277b6db52f68e8e_76"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 2. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMTY3ODQ_d12b6993-e47c-4028-b2f8-cbf4869903f0" continuedAt="i628d5452d29045e7abd06bbcc4c0ceab" escape="true">SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i628d5452d29045e7abd06bbcc4c0ceab" continuedAt="i078499813c414dbc95884a18d66b371a">&#160;</ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i078499813c414dbc95884a18d66b371a" continuedAt="ib0033fdfb8714b4284c417587d431759"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMTY4NzA_28232f0a-37a6-4955-80ef-8a0acc7d758d" continuedAt="ic1bd88b076b447b4bf82d05e3272d55a" escape="true">Consolidated Financial Statements</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic1bd88b076b447b4bf82d05e3272d55a">The accompanying consolidated financial statements include the accounts of Apyx, its wholly owned subsidiary, Apyx Bulgaria, EOOD, and its <ix:nonFraction unitRef="number" contextRef="i45882c1ec2804d9e9753f1f3e2754339_I20201231" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMTA5OTUxMTY1MDMxNQ_57d44797-3b2d-49ee-a36f-ff35071f4587">51</ix:nonFraction>% owned subsidiary, Apyx SY Medical Devices (Ningbo) Co., Ltd. (collectively, "Apyx," or the &#8220;Company&#8221;). All significant intercompany transactions and balances have been eliminated in consolidation.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMTY3OTY_5d08ff91-a56b-48d3-96d4-f56e0003ff63" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates in the Preparation of Financial Statements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. The reported amounts of revenues and expenses during the reporting period may be affected by the estimates and assumptions the Company is required to make.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMTY4MDg_a98f1baa-7968-4a7d-b533-9fd9585b70fa" continuedAt="i190155a5ed9a438d8e3b7ba6aff2a6bf" escape="true">Cash and Cash Equivalents</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="i190155a5ed9a438d8e3b7ba6aff2a6bf">Holdings of highly liquid investments with original maturities of three months or less from the date of purchase are considered to be cash equivalents. As of December 31, 2020 and 2019, all of the Company&#8217;s U.S. Treasury Bills have original maturities of three months or less and are included in cash and cash equivalents.</ix:continuation>  </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMTY4MDY_2a732bb9-5daf-4a73-ba19-0a45ca8f7e30" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of trade accounts receivable. With respect to cash, the Company frequently maintains cash and cash equivalent balances in excess of federally insured limits; it has not experienced any losses in such accounts.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMTY4NjA_29bc863d-e662-4981-a046-e58658835642" continuedAt="i5c528e44e71c424fa1444a87e01d2162" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trade Accounts Receivable and Allowance for Doubtful Accounts</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's standard credit terms for billings range from net <ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" format="ixt-sec:durday" name="apyx:SalesDiscountBillingTermsLowerLimit" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMzM5NA_ff81a243-8442-42fa-868e-e800f6bc2efb">10</ix:nonNumeric> days to net <ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" format="ixt-sec:durday" name="apyx:SalesDiscountBillingTermsUpperLimit" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMzQwNA_5f9d4959-3ac4-48fa-af75-66727c35cd00">90</ix:nonNumeric> days, depending on the customer agreement. Accounts receivable are determined to be past due if payments are not made in accordance with such agreements and an allowance is generally recorded for accounts that become three months past due, or sooner if there are other indicators that the receivables may not be recovered. Customary collection efforts are initiated, and receivables are written off when the Company determines they are not collectible and abandons these collection efforts.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5c528e44e71c424fa1444a87e01d2162">The Company evaluates the allowance for doubtful accounts on a regular basis for adequacy based upon its periodic review of the collectability of the receivables in light of historical experience, adverse situations that may affect its customers&#8217; ability to pay and prevailing economic conditions. This evaluation is inherently subjective, as it requires estimates that are susceptible to significant revision as more information becomes available.</ix:continuation> Management believes that the allowances for doubtful accounts of approximately $<ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfNDQwMQ_83a318b9-5002-4931-b56d-aa0a8a1b4fab"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfNDQwMQ_f22477c2-aac3-44eb-908a-7cafc9abc348">0.3</ix:nonFraction></ix:nonFraction> million at December&#160;31, 2020 and 2019, are adequate to provide for possible bad debts.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ib0033fdfb8714b4284c417587d431759" continuedAt="i066253a46b0c4b8880c203a8640ca454"><ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMTY3NDk_5ad8975d-0933-45f3-b17e-df92194c51c0" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are allocated to manufactured inventory based upon labor hours. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company monitors inventory usage to determine if the carrying value of any items should be adjusted due to lack of demand for the item and adjusts inventory for estimated obsolescence or unusable inventory equal to the difference between the cost of inventory and the estimated net realizable value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMTY4MjQ_b1d21de0-1edc-40ae-8a20-7b5e5e482712" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Depreciation and amortization are provided for using the straight-line method over the estimated useful lives of the assets. The amortization of leasehold improvements is based on the shorter of the lease term or the life of the improvement. Betterments and major improvements, which extend the life of the asset, are capitalized, whereas maintenance and repairs and routine improvements are expensed as incurred. The estimated useful lives are: buildings and improvements, <ix:nonNumeric contextRef="i0bc128762b18423fb747675dee1c2b38_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMjE5OTAyMzI3ODkwMw_91e79db8-d291-4f37-ba9a-ed110c80f112">39</ix:nonNumeric> years; machinery and equipment, <ix:nonNumeric contextRef="i1cbbd8dbe42a42989174fca0d2219d64_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMjE5OTAyMzI3OTAyMA_0fda99e4-57cf-45bf-913a-126bb7615bb1">3</ix:nonNumeric>-<ix:nonNumeric contextRef="ided82545571a4ee3959a92c88503da8a_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMjE5OTAyMzI3OTAyNA_bde87ddc-bdf0-41a4-af46-33dbe11675c2">10</ix:nonNumeric> years; furniture and fixtures, <ix:nonNumeric contextRef="id16feebf7b354586bb519173e63e4a13_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMjE5OTAyMzI3ODk4MQ_96fc3343-3582-4b24-86b3-4a31f71239bd">5</ix:nonNumeric>-<ix:nonNumeric contextRef="ia212175fe18e4aa78e12bf752ae2656e_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMjE5OTAyMzI3ODk4NQ_848f591a-b00b-4ac0-907c-7b326fe6b65a">10</ix:nonNumeric> years;  computer equipment and software, <ix:nonNumeric contextRef="i7f6eeb41de814d65b926757c9f6c1659_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMjE5OTAyMzI3OTA5Nw_7ba2d8ef-6dd3-4363-b33e-7c2910681957">3</ix:nonNumeric>-<ix:nonNumeric contextRef="i9461cea186574f9d99826a2a0dc1e166_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMjE5OTAyMzI3OTEwMQ_1cad51a5-e4e6-46e8-a070-5cbec5b3b36f">5</ix:nonNumeric> years; and molds, <ix:nonNumeric contextRef="i373f3e4cf9074d1eaadacf5820f14dc7_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMjE5OTAyMzI3OTAwOA_acd1638f-abe7-49c6-bf9b-dd1ae88d843d">7</ix:nonNumeric>-<ix:nonNumeric contextRef="i37622543d9574bb98c9c743b9e441331_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMjE5OTAyMzI3OTAxMg_d26ee61e-1275-4527-a3e9-42860a7db830">15</ix:nonNumeric> years.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMTY4MTc_de02e79a-fb4d-4238-907c-437c4ba6462e" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Valuation of Long-Lived Assets</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews long-lived assets for recoverability if events or changes in circumstances indicate that the assets may have been impaired. This circumstance exists when the carrying amount of the asset exceeds the sum of the undiscounted cash flows expected to result from its use and eventual disposition. In those cases, an impairment loss is recognized to the extent that the assets&#8217; carrying amount exceeds its fair value. Any impairment losses are not restored in the future if the fair value increases. At December&#160;31, 2020, the Company believes the remaining carrying values of its long-lived assets are recoverable.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="us-gaap:StandardProductWarrantyPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMTY4NzU_303ae309-bd21-4527-baba-524a5b72dd53" continuedAt="if831cd61f3ae4d148c5134305313ab34" escape="true">Product Warranties</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if831cd61f3ae4d148c5134305313ab34">The Company provides a <ix:nonNumeric contextRef="i0b779b72fb924855b2f72a574d145bd7_D20200101-20201231" format="ixt-sec:durwordsen" name="apyx:ProductWarranty" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMTA5OTUxMTY1MDM0NQ_1a5f9e34-f78c-4ce6-8ac4-dc43d2bf4dc9">four year</ix:nonNumeric> limited warranty on end-user sales of its Renuvion&#174;/J-Plasma&#174; generators, a <ix:nonNumeric contextRef="i981157b059a44725985cef208243fc13_D20200101-20201231" format="ixt-sec:durwordsen" name="apyx:ProductWarranty" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMTA5OTUxMTY1MDM0NA_37d44102-fb6a-44a9-8426-6f4f5c253825">two year</ix:nonNumeric> warranty on mounting fixtures, and a <ix:nonNumeric contextRef="i8df0935c0bc549ebafb864ba67aab0d3_D20200101-20201231" format="ixt-sec:durwordsen" name="apyx:ProductWarranty" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMTA5OTUxMTY1MDM1OA_d681a705-4a4c-405a-98a5-8b26beb5a05c">one-year</ix:nonNumeric> warranty on certain accessories. The Company estimates and provides for future costs for product warranties in cost of sales at the time revenue is recognized. The Company bases its product warranty costs on related material costs, repair labor costs and shipping costs. The Company estimates the future cost of product warranties by considering historical material, repair labor, and shipping costs, and applying the experience rates to the outstanding warranty period for products sold. It is reasonably possible that actual results could differ from those estimates.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMTY4MDA_ee322f26-c8f0-478e-b284-e5b699c6a088" continuedAt="i36b3496842b54f5fac2898b13f658ace" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration that the Company expects to receive for those goods or services. To recognize revenue, the Company (i) identifies the contract(s) with a customer; (ii) identifies the performance obligations in the contract; (iii) determines the transaction price; (iv) allocates the transaction price to the performance obligations in the contract; and (v) recognizes revenue when, or as, it satisfies the performance obligation(s). For sales of the Company's Advanced Energy products (Renuvion&#174;/J-Plasma&#174;), this is at a point in time when title has been transferred to the customer, which is generally at the time of shipment or receipt by customer for FOB destination terms. For sales of products under its OEM agreements, the Company recognizes revenue over time when no alternative use exists for the manufactured goods and the Company has rights to payment. Presently, the Company does not stock any significant completed goods under its OEM agreements, accordingly, the recognition of revenue under these agreements approximates point in time recognition. The following policies apply to its major categories of revenue transactions:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">The majority of sales to customers are evidenced by firm purchase orders. Generally, title and the risks and rewards of ownership are transferred to the customer when the product is shipped. Payment by the customer is due under fixed payment terms.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div></div><ix:continuation id="i066253a46b0c4b8880c203a8640ca454" continuedAt="id64a2022db3448da82ccb2afcef562db"><ix:continuation id="i36b3496842b54f5fac2898b13f658ace" continuedAt="i4a65eb9ea1ee447ca1e858f8bff2e333"><div style="margin-bottom:3pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Product returns are only accepted at the Company's discretion and in accordance with its &#8220;Returned Goods Policy&#8221;. Historically, the level of product returns has not been significant. Accruals for sales returns, rebates and allowances are made as a reduction of revenue based upon an analysis of historical customer returns and credits, rebates, discounts and current market conditions.</span></div><div style="margin-bottom:3pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">The terms of sale to customers generally do not include any obligations to perform future services. Limited warranties are generally provided for sales and provisions for warranty are provided at the time of product sale based upon an analysis of historical data.</span></div></ix:continuation><div style="margin-bottom:3pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4a65eb9ea1ee447ca1e858f8bff2e333" continuedAt="i99fa593a9db14b089bee2b5c6afbf0a7">&#8226;</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt"><ix:continuation id="i99fa593a9db14b089bee2b5c6afbf0a7">In connection with the execution of OEM supply agreements, the Company may enter into an accompanying product development agreement. If the Company enters into a product development agreement, and development of the goods does not represent a performance obligation on a standalone basis, the Company defers the development fees billed to customers and the associated costs. At December 31, 2020 and 2019, respectively, the Company had recorded approximately $<ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfNDk0NzgwMjM0NzQ3MA_a693c448-ebb6-4c08-aa6e-9984c3a6335d">0.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMTA5NDg_727a48bd-0dce-443e-be1b-0f4eee51814b">0.4</ix:nonFraction> million of contract liabilities and $<ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfNDk0NzgwMjM0NzQ4NA_4691ac86-9948-4fc8-9a25-d423abae148a">0.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMTA5Nzk_eb2895d3-8ca9-4ee3-bfc4-8e9c6ed25b23">0.1</ix:nonFraction> million of contract assets related to the deferral of revenues and expenses under these agreements. Recognition of the deferred billings and costs will occur as the Company performs on the accompanying supply arrangements.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMTY4NjE_06d96eb3-0038-457b-a691-ea8e15dcb29b" continuedAt="i9df987dda87a4ac08d4cf18703893809" escape="true">Advertising Costs</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9df987dda87a4ac08d4cf18703893809">Advertising costs are expensed as incurred.</ix:continuation> The amounts of advertising costs, including trade shows, were approximately $<ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdvertisingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMTEyMTg_644a898d-6586-4e70-be0e-292ebfcb0e3e">0.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdvertisingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMTEyMjI_e2cf8a3e-75b1-4f01-9e97-810951b6bdad">1.5</ix:nonFraction> million for the years ended December&#160;31, 2020 and 2019, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMTY4NTU_1328a765-b6d2-42e9-99c4-e1597c94d87c" continuedAt="i30f5293582af4448b9783f820e05e2e5" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for stock-based compensation in accordance with FASB ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation-Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. FASB ASC 718 requires recognizing compensation expense for all share-based payment awards made to employees, directors and non-employees based upon the awards&#8217; grant date fair value. It accounts for forfeitures as they occur. The standard covers employee stock options, restricted stock and other equity awards. The Company utilizes a Black-Scholes model to estimate the grant date fair value of stock option awards. For employee and director awards, compensation expense is recognized on a straight-line basis over the vesting periods. For  non-employee awards, compensation expense is recorded for non-forfeitable, fully vested awards at the grant date. For other awards granted to non-employees, compensation cost is recognized as services are provided, which approximates a straight-line basis over the vesting period.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="us-gaap:LegalCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMTY4NjQ_17cb336e-4df6-4e42-8027-17db37548aad" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation Contingencies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with authoritative guidance, the Company accrues a liability in its consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible, but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the consolidated financial statements. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded; actual results may differ from those estimates.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMTY4Mjc_97afdcdb-be94-4a1d-aaf9-5f5410f40665" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income (Loss) Per Share</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company computes basic (loss) earnings attributable to common stockholders per share by dividing net (loss) income attributable to common stockholders by the weighted average number of common shares outstanding for the reporting period. Diluted (loss) earnings per share attributable to common stockholders gives effect to all potential dilutive shares outstanding during the period. The number of dilutive shares is calculated using the treasury stock method which reduces the effective number of shares by the amount of shares the Company could purchase with the proceeds of assumed exercises. Anti-dilutive units are excluded from the calculation of diluted shares. In periods of loss, all potentially dilutive units are anti-dilutive and are excluded from the calculation of diluted income (loss) per share.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMTY3NjE_de85e4b6-cd1b-4213-95c8-37fd98ef0755" continuedAt="i3993f8799e074ba0b5d6e15548b11889" escape="true">Research and Development Costs</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3993f8799e074ba0b5d6e15548b11889">Research and development expenses are charged to operations as incurred.</ix:continuation> </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div></div><ix:continuation id="id64a2022db3448da82ccb2afcef562db" continuedAt="i4e589f6aaef14b7aa4ea01391f45c552"><ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMTY3NzY_9cc5dbf5-05d0-4205-8d68-3a2b6e5dcf1f" continuedAt="i30701c8c87f74380b7ae58f6d79fe62d" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the liability method of accounting for income taxes as set forth in FASB ASC Topic 740, "Income Taxes".  Under the liability method, deferred taxes are determined based on temporary differences between the financial statement and tax bases of assets and liabilities using tax rates expected to be in effect during the years in which the deferred taxes reverse.  The Company accounts for interest and penalties on income taxes as income tax expense. A valuation allowances is recorded when it is more likely than not that a tax benefit will not be realized.  In determining the need for valuation allowances the Company considers projected future taxable income, the timing of reversals of temporary differences, and the availability of tax planning strategies.  As of December 31, 2020 and 2019, the Company recorded a valuation allowance on the net deferred tax asset. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the realizability of deferred tax assets each reporting period and will be able to reduce the valuation allowance to the extent the financial results of continuing operations improve, and it becomes more likely than not that the deferred tax assets will be realizable. As Management expects the Company to continue to generate losses in the foreseeable future after 2020, the Company will continue to record a full valuation allowance on the net deferred tax assets as of December 31, 2020. As a result of the CARES ACT, during 2020, the Company released the valuation allowance on the Federal NOLs that can now be carried back to prior taxable years.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i30701c8c87f74380b7ae58f6d79fe62d">The Company assesses the financial statement impact of an uncertain tax position taken or expected to be taken on an income tax return at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority.  An uncertain income tax position will not be recognized in the financial statements unless it is more likely than not of being sustained.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMTY3ODM_ad0e7065-8ee4-48b4-8f6a-437f2379a1b9" continuedAt="i16d8df937406478dbbe869e720ff371e" escape="true">Foreign Currency Transactions</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i16d8df937406478dbbe869e720ff371e">The functional currency of Apyx Bulgaria is the U.S.&#160;dollar. The monetary assets and liabilities that are denominated in a currency other than U.S. dollar are remeasured into U.S.&#160;dollars at the exchange rate on the balance sheet date, while nonmonetary items are remeasured at historical rates. Revenue and expenses are remeasured at weighted average exchange rates during the period. Transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency are included in selling, general and administrative expenses in the Consolidated Statements of Operations and were not material for the years ended December 31, 2020 and 2019.</ix:continuation> </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><div id="idb46c8b71d7d4a27b277b6db52f68e8e_1722"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">NOTE 3. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="us-gaap:AccountingChangesAndErrorCorrectionsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNzIyL2ZyYWc6OTE2Y2MxZjkzOGFjNDc5ZGJmZDUxNGI0Y2RiZmZhZmUvdGV4dHJlZ2lvbjo5MTZjYzFmOTM4YWM0NzlkYmZkNTE0YjRjZGJmZmFmZV80OTQ3ODAyMzI3MjY3_904ba55e-f855-4afb-b9b0-87e58a469f93" continuedAt="i11a4523713884ea1ae7debd8b90fce8e" escape="true">CHANGE IN ACCOUNTING POLICY</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:justify"><ix:continuation id="i30f5293582af4448b9783f820e05e2e5"><ix:continuation id="i11a4523713884ea1ae7debd8b90fce8e"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, the Company began granting stock option awards deeper within the organization. It does not have sufficient experience with grants to these employees and has experienced challenges in developing reliable forfeiture estimates at the grant date. Accounting for revising the forfeiture estimates has been burdensome. Accounting Standards Codification 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation- Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, prescribes two methods for accounting for forfeitures on stock option awards, either the estimation method utilized by the Company previously, or by accounting for forfeitures as they occur. On January 1, 2020, the Company made an accounting policy election change and began accounting for forfeitures on stock option awards using actual forfeitures. This accounting policy election change was made on a retrospective basis. However, the changes to the current and prior period were determined to be immaterial and there have been no changes to previously reported results as a result of the change.</span></ix:continuation></ix:continuation></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><div id="idb46c8b71d7d4a27b277b6db52f68e8e_79"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 4. &#160;&#160;&#160;&#160;<ix:continuation id="i4e589f6aaef14b7aa4ea01391f45c552" continuedAt="ie73e8a7c246c4cd7b308cd25ba3044d0">RECENT ACCOUNTING PRONOUNCEMENTS</ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ie73e8a7c246c4cd7b308cd25ba3044d0"><ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83OS9mcmFnOmNiZjRlY2NkM2VjMTRlNWU4OTQ3NDZhNmRhNGI0YmIxL3RleHRyZWdpb246Y2JmNGVjY2QzZWMxNGU1ZTg5NDc0NmE2ZGE0YjRiYjFfMjIzMw_942da197-8315-4c6f-879d-78adb25ae8a6" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments&#8212;Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 326). The update changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, contract assets, held-to-maturity debt securities and loans, and requires entities to use a new forward-looking expected loss model that will result in the earlier recognition of allowance for losses. This update, as originally issued, was effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 326),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Derivatives and Hedging </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 815), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">and Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 842) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Effective Dates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which deferred the effective dates of these standards for Smaller Reporting Companies until fiscal years beginning after December 15, 2022. The Company currently expects to continue to qualify as a Smaller Reporting Company, based upon the current SEC definition and, as a result, will be utilizing the deferred elective date. While the Company is in the process of determining the effects of the adoption of the standard on the consolidated financial statements, it does not expect the impact to be material.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on the Company's consolidated financial statements or disclosures.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="idb46c8b71d7d4a27b277b6db52f68e8e_91"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 5. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV85MS9mcmFnOjhiNTA4Y2FkYTBhZTQ4YjNhNDZhYmQzYTE5ZDIwNWIyL3RleHRyZWdpb246OGI1MDhjYWRhMGFlNDhiM2E0NmFiZDNhMTlkMjA1YjJfMjI4MQ_302abc66-1726-48db-94ca-0eb9ea2bca78" continuedAt="i972a342a6fc44f118a79b2651a365c71" escape="true">DISPOSITION OF THE CORE BUSINESS</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><ix:continuation id="i972a342a6fc44f118a79b2651a365c71" continuedAt="if296b9f2303744fd914d5dc8497e787f"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2018, the Company closed on a definitive asset purchase agreement (the "Asset Purchase Agreement") with Specialty Surgical Instrumentation Inc., a Tennessee Corporation and wholly owned subsidiary of Symmetry Surgical Inc. (&#8220;Symmetry&#8221;), pursuant to which the Company divested and sold the Company's electrosurgical "Core" business segment and related intellectual property, including the Bovie</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> brand and trademarks, to Symmetry for gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="i67552fb7889b46aebef782a87a2fa29c_D20180830-20180830" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromDivestitureOfBusinesses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV85MS9mcmFnOjhiNTA4Y2FkYTBhZTQ4YjNhNDZhYmQzYTE5ZDIwNWIyL3RleHRyZWdpb246OGI1MDhjYWRhMGFlNDhiM2E0NmFiZDNhMTlkMjA1YjJfNTA0_5861dab8-6c4d-4ce9-b920-fc31d2051e59">97</ix:nonFraction> million in cash.</span></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="if296b9f2303744fd914d5dc8497e787f">In connection with the Asset Purchase Agreement, the Company entered into an Electro Surgical Disposables and Accessories, Cauteries and Other Products Supply Agreement with Symmetry for a <ix:nonNumeric contextRef="ice559c8f3fad43108151f29c47e8b650_D20180830-20180830" format="ixt-sec:durwordsen" name="apyx:AssetPurchaseAgreementTerm" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV85MS9mcmFnOjhiNTA4Y2FkYTBhZTQ4YjNhNDZhYmQzYTE5ZDIwNWIyL3RleHRyZWdpb246OGI1MDhjYWRhMGFlNDhiM2E0NmFiZDNhMTlkMjA1YjJfMTA5OTUxMTYzMzY5OA_aec0783e-b7c1-4d5f-8fd0-2cd08abb0c64">four-year</ix:nonNumeric> term, whereby it will manufacture certain Core products and sell them to Symmetry at agreed upon prices. Any activity resulting from this agreement is netted and reported in the Consolidated Statements of Operations as other income (loss). Core activity for 2020 amounted to $<ix:nonFraction unitRef="usd" contextRef="i1f29cae9fd29439fa7f042f1814f46aa_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV85MS9mcmFnOjhiNTA4Y2FkYTBhZTQ4YjNhNDZhYmQzYTE5ZDIwNWIyL3RleHRyZWdpb246OGI1MDhjYWRhMGFlNDhiM2E0NmFiZDNhMTlkMjA1YjJfNTQ5NzU1ODE0NDcxNA_7d986ebe-8e36-449c-81d6-09858d0d573e">9.4</ix:nonFraction>&#160;million with cost of sales equivalents of $<ix:nonFraction unitRef="usd" contextRef="i1f29cae9fd29439fa7f042f1814f46aa_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV85MS9mcmFnOjhiNTA4Y2FkYTBhZTQ4YjNhNDZhYmQzYTE5ZDIwNWIyL3RleHRyZWdpb246OGI1MDhjYWRhMGFlNDhiM2E0NmFiZDNhMTlkMjA1YjJfNTQ5NzU1ODE0NDcyOA_0e29ddae-0385-4566-a31f-3e8892c4777a">8.1</ix:nonFraction>&#160;million and other related expenses of $<ix:nonFraction unitRef="usd" contextRef="i1f29cae9fd29439fa7f042f1814f46aa_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV85MS9mcmFnOjhiNTA4Y2FkYTBhZTQ4YjNhNDZhYmQzYTE5ZDIwNWIyL3RleHRyZWdpb246OGI1MDhjYWRhMGFlNDhiM2E0NmFiZDNhMTlkMjA1YjJfNTQ5NzU1ODE0NDc0Mg_4a94eab0-2049-4e17-9d39-e08b1bbf8dfc">0.8</ix:nonFraction>&#160;million for net other income of $<ix:nonFraction unitRef="usd" contextRef="i1f29cae9fd29439fa7f042f1814f46aa_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV85MS9mcmFnOjhiNTA4Y2FkYTBhZTQ4YjNhNDZhYmQzYTE5ZDIwNWIyL3RleHRyZWdpb246OGI1MDhjYWRhMGFlNDhiM2E0NmFiZDNhMTlkMjA1YjJfNTQ5NzU1ODE0NDc1Ng_bc46ded4-8a43-4669-99e9-72fcd6cec624">0.5</ix:nonFraction>&#160;million.  Core activity in 2019 amounted to&#160;$<ix:nonFraction unitRef="usd" contextRef="ibf67c4dec56341a2a59058b71b03ea9c_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV85MS9mcmFnOjhiNTA4Y2FkYTBhZTQ4YjNhNDZhYmQzYTE5ZDIwNWIyL3RleHRyZWdpb246OGI1MDhjYWRhMGFlNDhiM2E0NmFiZDNhMTlkMjA1YjJfMTA2NA_d4dbb938-5978-44ec-a7f4-efbfa2ef9d95">9.4</ix:nonFraction> million&#160;with cost of sales equivalents of&#160;$<ix:nonFraction unitRef="usd" contextRef="ibf67c4dec56341a2a59058b71b03ea9c_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV85MS9mcmFnOjhiNTA4Y2FkYTBhZTQ4YjNhNDZhYmQzYTE5ZDIwNWIyL3RleHRyZWdpb246OGI1MDhjYWRhMGFlNDhiM2E0NmFiZDNhMTlkMjA1YjJfMTA4OQ_f9ba1353-c0be-454d-88e9-eab9b6476ca6">8.8</ix:nonFraction> million&#160;and related operating expenses of&#160;$<ix:nonFraction unitRef="usd" contextRef="ibf67c4dec56341a2a59058b71b03ea9c_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV85MS9mcmFnOjhiNTA4Y2FkYTBhZTQ4YjNhNDZhYmQzYTE5ZDIwNWIyL3RleHRyZWdpb246OGI1MDhjYWRhMGFlNDhiM2E0NmFiZDNhMTlkMjA1YjJfMTEyNg_daa93bb5-1b8f-4a03-93d5-819452c0169c">0.5</ix:nonFraction> million for net other income of $<ix:nonFraction unitRef="usd" contextRef="ibf67c4dec56341a2a59058b71b03ea9c_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV85MS9mcmFnOjhiNTA4Y2FkYTBhZTQ4YjNhNDZhYmQzYTE5ZDIwNWIyL3RleHRyZWdpb246OGI1MDhjYWRhMGFlNDhiM2E0NmFiZDNhMTlkMjA1YjJfNTQ5NzU1ODE0NDc3MA_fbac1de3-c998-4b43-bab6-0068396f6b31">0.1</ix:nonFraction>&#160;million.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><div id="idb46c8b71d7d4a27b277b6db52f68e8e_1729"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 6. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="us-gaap:MinorityInterestDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNzI5L2ZyYWc6ZTBlZjUzNzJjZTAzNDRhYmJlN2U3ZjJjZmUyZTY5ZjkvdGV4dHJlZ2lvbjplMGVmNTM3MmNlMDM0NGFiYmU3ZTdmMmNmZTJlNjlmOV80OTQ3ODAyMzI1Nzky_23b18923-e17b-4277-bfb8-105bc39971b9" continuedAt="i50738e9f31d84eb79c9d67e37de71eb3" escape="true">INTEREST IN JOINT VENTURE INVESTMENT</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i50738e9f31d84eb79c9d67e37de71eb3"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Company executed a joint venture agreement with its Chinese supplier ("China JV"). The agreement requires the Company to make a capital contribution into the newly formed entity of approximately&#160;$<ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="apyx:NoncontrollingInterestRequiredCapitalContribution" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNzI5L2ZyYWc6ZTBlZjUzNzJjZTAzNDRhYmJlN2U3ZjJjZmUyZTY5ZjkvdGV4dHJlZ2lvbjplMGVmNTM3MmNlMDM0NGFiYmU3ZTdmMmNmZTJlNjlmOV8xMDk5NTExNjI4NTE4_e6aeeabd-e7a4-4890-9957-e6c6841c10e8">357,000</ix:nonFraction>, of which approximately $<ix:nonFraction unitRef="usd" contextRef="i8e0b17e778314c9c90e0d88fd0f6dd2b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNzI5L2ZyYWc6ZTBlZjUzNzJjZTAzNDRhYmJlN2U3ZjJjZmUyZTY5ZjkvdGV4dHJlZ2lvbjplMGVmNTM3MmNlMDM0NGFiYmU3ZTdmMmNmZTJlNjlmOV8yMTk5MDIzMjU1OTAy_bf146f5d-658c-4616-8bfe-f122ac1756d2">154,000</ix:nonFraction> was contributed during the year ended December 31, 2020. As of the date of these consolidated financial statements, the joint venture has not commenced principal operations. </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="apyx:NoncontrollingInterestTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNzI5L2ZyYWc6ZTBlZjUzNzJjZTAzNDRhYmJlN2U3ZjJjZmUyZTY5ZjkvdGV4dHJlZ2lvbjplMGVmNTM3MmNlMDM0NGFiYmU3ZTdmMmNmZTJlNjlmOV80OTQ3ODAyMzI1Nzkz_8f504f5a-eb56-43e8-94d6-0128e52b8a5e" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the Company's ownership interest in its <ix:nonFraction unitRef="number" contextRef="i63baacc6f0574a6e8bf0b19a1687afb0_I20201231" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNzI5L2ZyYWc6ZTBlZjUzNzJjZTAzNDRhYmJlN2U3ZjJjZmUyZTY5ZjkvdGV4dHJlZ2lvbjplMGVmNTM3MmNlMDM0NGFiYmU3ZTdmMmNmZTJlNjlmOV8yMTk5MDIzMjU2MTQy_fa68d5c9-dd1d-442b-8a37-ae9d45da6575">51</ix:nonFraction>% owned China JV were as follows:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.712%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.088%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended<br/>December 31, 2020</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning interest in China JV</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0a28971628c45e3b9e9d97e753d9756_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNzI5L2ZyYWc6ZTBlZjUzNzJjZTAzNDRhYmJlN2U3ZjJjZmUyZTY5ZjkvdGFibGU6OWFiNTdjOTZlODJkNGMwOWE0Nzg4ZDdkOWRmZTM2YTcvdGFibGVyYW5nZTo5YWI1N2M5NmU4MmQ0YzA5YTQ3ODhkN2Q5ZGZlMzZhN18yLTEtMS0xLTM3ODc_ace8bdf0-53c5-4061-9541-68547b61349d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contributions </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e0b17e778314c9c90e0d88fd0f6dd2b_D20200101-20201231" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNzI5L2ZyYWc6ZTBlZjUzNzJjZTAzNDRhYmJlN2U3ZjJjZmUyZTY5ZjkvdGFibGU6OWFiNTdjOTZlODJkNGMwOWE0Nzg4ZDdkOWRmZTM2YTcvdGFibGVyYW5nZTo5YWI1N2M5NmU4MmQ0YzA5YTQ3ODhkN2Q5ZGZlMzZhN18zLTEtMS0xLTM3ODc_a0bf1291-2b48-4c0f-950b-048e48e1b34e">154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Apyx</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e0b17e778314c9c90e0d88fd0f6dd2b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNzI5L2ZyYWc6ZTBlZjUzNzJjZTAzNDRhYmJlN2U3ZjJjZmUyZTY5ZjkvdGFibGU6OWFiNTdjOTZlODJkNGMwOWE0Nzg4ZDdkOWRmZTM2YTcvdGFibGVyYW5nZTo5YWI1N2M5NmU4MmQ0YzA5YTQ3ODhkN2Q5ZGZlMzZhN180LTEtMS0xLTM3ODc_43be2c47-6781-4791-a4ba-288305f8af78">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending interest in China JV</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7edc49dacbe457c9d33e24e671deb98_I20201231" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNzI5L2ZyYWc6ZTBlZjUzNzJjZTAzNDRhYmJlN2U3ZjJjZmUyZTY5ZjkvdGFibGU6OWFiNTdjOTZlODJkNGMwOWE0Nzg4ZDdkOWRmZTM2YTcvdGFibGVyYW5nZTo5YWI1N2M5NmU4MmQ0YzA5YTQ3ODhkN2Q5ZGZlMzZhN181LTEtMS0xLTM3ODc_c7801231-1ea7-496b-a130-699c07c75436">144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><div id="idb46c8b71d7d4a27b277b6db52f68e8e_97"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 7. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV85Ny9mcmFnOmZiNmQ0NzhlYTQyMzQ0NjVhYzdkMzYyYWZlODZiYmRjL3RleHRyZWdpb246ZmI2ZDQ3OGVhNDIzNDQ2NWFjN2QzNjJhZmU4NmJiZGNfNzI_fcbb0d87-1a4e-497a-bf74-540565420ca7" continuedAt="ia156976753af4aa9b6717f3bdbf3ec6c" escape="true">INVENTORIES</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ia156976753af4aa9b6717f3bdbf3ec6c"><ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV85Ny9mcmFnOmZiNmQ0NzhlYTQyMzQ0NjVhYzdkMzYyYWZlODZiYmRjL3RleHRyZWdpb246ZmI2ZDQ3OGVhNDIzNDQ2NWFjN2QzNjJhZmU4NmJiZGNfNzQ_6c82dae9-61a4-4348-9cd0-74c50e6eecf8" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterials" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV85Ny9mcmFnOmZiNmQ0NzhlYTQyMzQ0NjVhYzdkMzYyYWZlODZiYmRjL3RhYmxlOmZiMjdiOGZkZmMwOTRjNzc4MGE4M2UyNWFkZGFlY2E2L3RhYmxlcmFuZ2U6ZmIyN2I4ZmRmYzA5NGM3NzgwYTgzZTI1YWRkYWVjYTZfMS0xLTEtMS0w_fe760009-9364-49e1-8376-b0142cfd1704">2,243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterials" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV85Ny9mcmFnOmZiNmQ0NzhlYTQyMzQ0NjVhYzdkMzYyYWZlODZiYmRjL3RhYmxlOmZiMjdiOGZkZmMwOTRjNzc4MGE4M2UyNWFkZGFlY2E2L3RhYmxlcmFuZ2U6ZmIyN2I4ZmRmYzA5NGM3NzgwYTgzZTI1YWRkYWVjYTZfMS0zLTEtMS0w_af07127e-0aeb-434f-9e7f-271f24d1fab1">2,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcess" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV85Ny9mcmFnOmZiNmQ0NzhlYTQyMzQ0NjVhYzdkMzYyYWZlODZiYmRjL3RhYmxlOmZiMjdiOGZkZmMwOTRjNzc4MGE4M2UyNWFkZGFlY2E2L3RhYmxlcmFuZ2U6ZmIyN2I4ZmRmYzA5NGM3NzgwYTgzZTI1YWRkYWVjYTZfMi0xLTEtMS0w_bb2903e3-3c88-48ce-9112-d0ac90b909da">1,109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcess" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV85Ny9mcmFnOmZiNmQ0NzhlYTQyMzQ0NjVhYzdkMzYyYWZlODZiYmRjL3RhYmxlOmZiMjdiOGZkZmMwOTRjNzc4MGE4M2UyNWFkZGFlY2E2L3RhYmxlcmFuZ2U6ZmIyN2I4ZmRmYzA5NGM3NzgwYTgzZTI1YWRkYWVjYTZfMi0zLTEtMS0w_8410f60b-88a2-4029-ac6b-6f1c56c66064">1,209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoods" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV85Ny9mcmFnOmZiNmQ0NzhlYTQyMzQ0NjVhYzdkMzYyYWZlODZiYmRjL3RhYmxlOmZiMjdiOGZkZmMwOTRjNzc4MGE4M2UyNWFkZGFlY2E2L3RhYmxlcmFuZ2U6ZmIyN2I4ZmRmYzA5NGM3NzgwYTgzZTI1YWRkYWVjYTZfMy0xLTEtMS0w_e3019878-eb86-4537-b381-93a3b95808b9">1,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoods" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV85Ny9mcmFnOmZiNmQ0NzhlYTQyMzQ0NjVhYzdkMzYyYWZlODZiYmRjL3RhYmxlOmZiMjdiOGZkZmMwOTRjNzc4MGE4M2UyNWFkZGFlY2E2L3RhYmxlcmFuZ2U6ZmIyN2I4ZmRmYzA5NGM3NzgwYTgzZTI1YWRkYWVjYTZfMy0zLTEtMS0w_88740204-1586-4667-904e-5c8221bcc47f">1,316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross inventories</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV85Ny9mcmFnOmZiNmQ0NzhlYTQyMzQ0NjVhYzdkMzYyYWZlODZiYmRjL3RhYmxlOmZiMjdiOGZkZmMwOTRjNzc4MGE4M2UyNWFkZGFlY2E2L3RhYmxlcmFuZ2U6ZmIyN2I4ZmRmYzA5NGM3NzgwYTgzZTI1YWRkYWVjYTZfNC0xLTEtMS0w_128d9aac-a15d-4144-aec5-b03d96ad6029">4,439</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV85Ny9mcmFnOmZiNmQ0NzhlYTQyMzQ0NjVhYzdkMzYyYWZlODZiYmRjL3RhYmxlOmZiMjdiOGZkZmMwOTRjNzc4MGE4M2UyNWFkZGFlY2E2L3RhYmxlcmFuZ2U6ZmIyN2I4ZmRmYzA5NGM3NzgwYTgzZTI1YWRkYWVjYTZfNC0zLTEtMS0w_e223459f-a4e1-4b6e-85d1-fe8832f807fe">5,460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: provision for obsolescence</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" name="us-gaap:InventoryValuationReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV85Ny9mcmFnOmZiNmQ0NzhlYTQyMzQ0NjVhYzdkMzYyYWZlODZiYmRjL3RhYmxlOmZiMjdiOGZkZmMwOTRjNzc4MGE4M2UyNWFkZGFlY2E2L3RhYmxlcmFuZ2U6ZmIyN2I4ZmRmYzA5NGM3NzgwYTgzZTI1YWRkYWVjYTZfNS0xLTEtMS0w_1e5e5818-9445-4375-a067-368d7714461e">388</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" name="us-gaap:InventoryValuationReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV85Ny9mcmFnOmZiNmQ0NzhlYTQyMzQ0NjVhYzdkMzYyYWZlODZiYmRjL3RhYmxlOmZiMjdiOGZkZmMwOTRjNzc4MGE4M2UyNWFkZGFlY2E2L3RhYmxlcmFuZ2U6ZmIyN2I4ZmRmYzA5NGM3NzgwYTgzZTI1YWRkYWVjYTZfNS0zLTEtMS0w_279736fc-a0ee-4c94-b117-3693907b81ed">392</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV85Ny9mcmFnOmZiNmQ0NzhlYTQyMzQ0NjVhYzdkMzYyYWZlODZiYmRjL3RhYmxlOmZiMjdiOGZkZmMwOTRjNzc4MGE4M2UyNWFkZGFlY2E2L3RhYmxlcmFuZ2U6ZmIyN2I4ZmRmYzA5NGM3NzgwYTgzZTI1YWRkYWVjYTZfNi0xLTEtMS0w_704a6085-cb1d-4344-875e-cc2944fc8014">4,051</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV85Ny9mcmFnOmZiNmQ0NzhlYTQyMzQ0NjVhYzdkMzYyYWZlODZiYmRjL3RhYmxlOmZiMjdiOGZkZmMwOTRjNzc4MGE4M2UyNWFkZGFlY2E2L3RhYmxlcmFuZ2U6ZmIyN2I4ZmRmYzA5NGM3NzgwYTgzZTI1YWRkYWVjYTZfNi0zLTEtMS0w_98b8194f-05cd-4acf-9963-1b7dd91a2616">5,068</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, the Company reassessed its forecasted product mix due to COVID-19, increased availability of newer handpiece designs, and improved timing of product registrations in some of our foreign markets. As a result, certain products were reduced to a lower carrying value, and some components were also written down as the Company determined to cease further production on these older models. The total impairment was approximately $<ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWriteDown" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV85Ny9mcmFnOmZiNmQ0NzhlYTQyMzQ0NjVhYzdkMzYyYWZlODZiYmRjL3RleHRyZWdpb246ZmI2ZDQ3OGVhNDIzNDQ2NWFjN2QzNjJhZmU4NmJiZGNfNDk0NzgwMjMyNjkwMw_9815fe3e-1fd1-4f52-95a5-a39c513bde3d">400,000</ix:nonFraction> and is included in cost of sales in the accompanying Consolidated Statement of Operations for 2020. Later in 2020, the Company's forecasts were revised, and it subsequently utilized a portion of the written down components and approximately $<ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="apyx:InventoryWriteDownReversals" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV85Ny9mcmFnOmZiNmQ0NzhlYTQyMzQ0NjVhYzdkMzYyYWZlODZiYmRjL3RleHRyZWdpb246ZmI2ZDQ3OGVhNDIzNDQ2NWFjN2QzNjJhZmU4NmJiZGNfNDk0NzgwMjMyNjkxMw_3d0ce480-ae5c-438f-babf-b91d2dfceee5">100,000</ix:nonFraction> of the impairment was recovered through the sale of the corresponding manufactured handpieces.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><div id="idb46c8b71d7d4a27b277b6db52f68e8e_100"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 8. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDAvZnJhZzowMmUyN2NjNmEzYWY0MGNjYWE0N2ZkMTg0ODRiZGNjYS90ZXh0cmVnaW9uOjAyZTI3Y2M2YTNhZjQwY2NhYTQ3ZmQxODQ4NGJkY2NhXzM0MQ_6962a832-f553-442b-a336-4c0fa95fdce2" continuedAt="ibc1259162ae5447f89a9e047e9dc50ee" escape="true">PROPERTY AND EQUIPMENT</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ibc1259162ae5447f89a9e047e9dc50ee"><ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDAvZnJhZzowMmUyN2NjNmEzYWY0MGNjYWE0N2ZkMTg0ODRiZGNjYS90ZXh0cmVnaW9uOjAyZTI3Y2M2YTNhZjQwY2NhYTQ3ZmQxODQ4NGJkY2NhXzMzNg_0aa44c10-07b3-4fe6-86ea-4b55f3639150" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a54987fec4e4d109be138c336d48d57_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDAvZnJhZzowMmUyN2NjNmEzYWY0MGNjYWE0N2ZkMTg0ODRiZGNjYS90YWJsZTplMjBkMTMzMzMwZDE0ZGY1YTI0ZTBhNDQ3YjJhMDM1MC90YWJsZXJhbmdlOmUyMGQxMzMzMzBkMTRkZjVhMjRlMGE0NDdiMmEwMzUwXzEtMS0xLTEtMA_8450e626-41fb-462e-ac50-26e3fef4a0d7">1,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee3b318d7e9f4b0a847b69cbdeb233ce_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDAvZnJhZzowMmUyN2NjNmEzYWY0MGNjYWE0N2ZkMTg0ODRiZGNjYS90YWJsZTplMjBkMTMzMzMwZDE0ZGY1YTI0ZTBhNDQ3YjJhMDM1MC90YWJsZXJhbmdlOmUyMGQxMzMzMzBkMTRkZjVhMjRlMGE0NDdiMmEwMzUwXzEtMy0xLTEtMA_a4ba3cc9-9aea-4f4d-9822-5973e3533ce5">1,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3f4327a210e4a4da700fd1022432191_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDAvZnJhZzowMmUyN2NjNmEzYWY0MGNjYWE0N2ZkMTg0ODRiZGNjYS90YWJsZTplMjBkMTMzMzMwZDE0ZGY1YTI0ZTBhNDQ3YjJhMDM1MC90YWJsZXJhbmdlOmUyMGQxMzMzMzBkMTRkZjVhMjRlMGE0NDdiMmEwMzUwXzItMS0xLTEtMA_4945f298-c5d2-4a7f-b11a-0f1867003943">4,454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19401a17feaf403f899024675a2ec439_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDAvZnJhZzowMmUyN2NjNmEzYWY0MGNjYWE0N2ZkMTg0ODRiZGNjYS90YWJsZTplMjBkMTMzMzMwZDE0ZGY1YTI0ZTBhNDQ3YjJhMDM1MC90YWJsZXJhbmdlOmUyMGQxMzMzMzBkMTRkZjVhMjRlMGE0NDdiMmEwMzUwXzItMy0xLTEtMA_e6046326-959e-4db6-b30c-12b2b49490f1">4,423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4036b967bee44ae799da3bf97a2bdb7f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDAvZnJhZzowMmUyN2NjNmEzYWY0MGNjYWE0N2ZkMTg0ODRiZGNjYS90YWJsZTplMjBkMTMzMzMwZDE0ZGY1YTI0ZTBhNDQ3YjJhMDM1MC90YWJsZXJhbmdlOmUyMGQxMzMzMzBkMTRkZjVhMjRlMGE0NDdiMmEwMzUwXzMtMS0xLTEtMA_7e459c54-26b1-47fe-b7c4-6cd5e549851a">2,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf6c2b0fa640009153ca8537851d59_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDAvZnJhZzowMmUyN2NjNmEzYWY0MGNjYWE0N2ZkMTg0ODRiZGNjYS90YWJsZTplMjBkMTMzMzMwZDE0ZGY1YTI0ZTBhNDQ3YjJhMDM1MC90YWJsZXJhbmdlOmUyMGQxMzMzMzBkMTRkZjVhMjRlMGE0NDdiMmEwMzUwXzMtMy0xLTEtMA_0f3321d4-81ff-4354-898e-0d7306f2b7e4">2,187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fb285bd8adc40a4b2a0c9d050a1f420_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDAvZnJhZzowMmUyN2NjNmEzYWY0MGNjYWE0N2ZkMTg0ODRiZGNjYS90YWJsZTplMjBkMTMzMzMwZDE0ZGY1YTI0ZTBhNDQ3YjJhMDM1MC90YWJsZXJhbmdlOmUyMGQxMzMzMzBkMTRkZjVhMjRlMGE0NDdiMmEwMzUwXzQtMS0xLTEtMA_f47ceb02-764f-4049-951e-1c223a59605d">290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0306c2a7b1164d41a4a0dca8f17a1e2a_I20191231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDAvZnJhZzowMmUyN2NjNmEzYWY0MGNjYWE0N2ZkMTg0ODRiZGNjYS90YWJsZTplMjBkMTMzMzMwZDE0ZGY1YTI0ZTBhNDQ3YjJhMDM1MC90YWJsZXJhbmdlOmUyMGQxMzMzMzBkMTRkZjVhMjRlMGE0NDdiMmEwMzUwXzQtMy0xLTEtMA_814ecdd8-dbc8-4a77-af58-9d0b100db346">292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e12307801b4ccb8c56cf5e4fd98ec4_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDAvZnJhZzowMmUyN2NjNmEzYWY0MGNjYWE0N2ZkMTg0ODRiZGNjYS90YWJsZTplMjBkMTMzMzMwZDE0ZGY1YTI0ZTBhNDQ3YjJhMDM1MC90YWJsZXJhbmdlOmUyMGQxMzMzMzBkMTRkZjVhMjRlMGE0NDdiMmEwMzUwXzUtMS0xLTEtMA_98ea14be-206e-4133-9ff2-768babfe84c3">1,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id798580ebbff4f89bc905e8051c3b2b2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDAvZnJhZzowMmUyN2NjNmEzYWY0MGNjYWE0N2ZkMTg0ODRiZGNjYS90YWJsZTplMjBkMTMzMzMwZDE0ZGY1YTI0ZTBhNDQ3YjJhMDM1MC90YWJsZXJhbmdlOmUyMGQxMzMzMzBkMTRkZjVhMjRlMGE0NDdiMmEwMzUwXzUtMy0xLTEtMA_5544933d-94b3-449c-8541-bee5e0a64ae1">1,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6680d593e9440dbbfd54f5193fbf907_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDAvZnJhZzowMmUyN2NjNmEzYWY0MGNjYWE0N2ZkMTg0ODRiZGNjYS90YWJsZTplMjBkMTMzMzMwZDE0ZGY1YTI0ZTBhNDQ3YjJhMDM1MC90YWJsZXJhbmdlOmUyMGQxMzMzMzBkMTRkZjVhMjRlMGE0NDdiMmEwMzUwXzYtMS0xLTEtMA_a7a50fdb-58dc-4409-bf3e-07ef42f29f8a">156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cabb993e2b4682a7111b3d2814c1c0_I20191231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDAvZnJhZzowMmUyN2NjNmEzYWY0MGNjYWE0N2ZkMTg0ODRiZGNjYS90YWJsZTplMjBkMTMzMzMwZDE0ZGY1YTI0ZTBhNDQ3YjJhMDM1MC90YWJsZXJhbmdlOmUyMGQxMzMzMzBkMTRkZjVhMjRlMGE0NDdiMmEwMzUwXzYtMy0xLTEtMA_b4bd636f-a5c4-4f9e-883e-677b505c6924">156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e903bdd325546128d4b5baaaa0369ec_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDAvZnJhZzowMmUyN2NjNmEzYWY0MGNjYWE0N2ZkMTg0ODRiZGNjYS90YWJsZTplMjBkMTMzMzMwZDE0ZGY1YTI0ZTBhNDQ3YjJhMDM1MC90YWJsZXJhbmdlOmUyMGQxMzMzMzBkMTRkZjVhMjRlMGE0NDdiMmEwMzUwXzctMS0xLTEtMA_10b09b72-9dd6-4812-b070-c39fd059a5f5">813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f57e20923764c72859b130e5896e87f_I20191231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDAvZnJhZzowMmUyN2NjNmEzYWY0MGNjYWE0N2ZkMTg0ODRiZGNjYS90YWJsZTplMjBkMTMzMzMwZDE0ZGY1YTI0ZTBhNDQ3YjJhMDM1MC90YWJsZXJhbmdlOmUyMGQxMzMzMzBkMTRkZjVhMjRlMGE0NDdiMmEwMzUwXzctMy0xLTEtMA_113a10d0-185c-467f-9ec3-835b7b9b8c57">805</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDAvZnJhZzowMmUyN2NjNmEzYWY0MGNjYWE0N2ZkMTg0ODRiZGNjYS90YWJsZTplMjBkMTMzMzMwZDE0ZGY1YTI0ZTBhNDQ3YjJhMDM1MC90YWJsZXJhbmdlOmUyMGQxMzMzMzBkMTRkZjVhMjRlMGE0NDdiMmEwMzUwXzgtMS0xLTEtMA_f5c9e591-48a3-416d-b463-6195286e9d52">10,931</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDAvZnJhZzowMmUyN2NjNmEzYWY0MGNjYWE0N2ZkMTg0ODRiZGNjYS90YWJsZTplMjBkMTMzMzMwZDE0ZGY1YTI0ZTBhNDQ3YjJhMDM1MC90YWJsZXJhbmdlOmUyMGQxMzMzMzBkMTRkZjVhMjRlMGE0NDdiMmEwMzUwXzgtMy0xLTEtMA_f9be2228-18f6-4add-a9cf-994456fcd87d">10,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDAvZnJhZzowMmUyN2NjNmEzYWY0MGNjYWE0N2ZkMTg0ODRiZGNjYS90YWJsZTplMjBkMTMzMzMwZDE0ZGY1YTI0ZTBhNDQ3YjJhMDM1MC90YWJsZXJhbmdlOmUyMGQxMzMzMzBkMTRkZjVhMjRlMGE0NDdiMmEwMzUwXzktMS0xLTEtMA_3f458d39-7338-4235-a1e5-1461808b56da">4,813</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDAvZnJhZzowMmUyN2NjNmEzYWY0MGNjYWE0N2ZkMTg0ODRiZGNjYS90YWJsZTplMjBkMTMzMzMwZDE0ZGY1YTI0ZTBhNDQ3YjJhMDM1MC90YWJsZXJhbmdlOmUyMGQxMzMzMzBkMTRkZjVhMjRlMGE0NDdiMmEwMzUwXzktMy0xLTEtMA_55b5e1fb-0f39-4e9f-a574-d2c754d1761f">4,403</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment in service</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" format="ixt:numdotdecimal" name="apyx:Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDAvZnJhZzowMmUyN2NjNmEzYWY0MGNjYWE0N2ZkMTg0ODRiZGNjYS90YWJsZTplMjBkMTMzMzMwZDE0ZGY1YTI0ZTBhNDQ3YjJhMDM1MC90YWJsZXJhbmdlOmUyMGQxMzMzMzBkMTRkZjVhMjRlMGE0NDdiMmEwMzUwXzEwLTEtMS0xLTA_5f6d2b61-833e-4e5a-8fd6-ed7dccfce17a">6,118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="apyx:Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDAvZnJhZzowMmUyN2NjNmEzYWY0MGNjYWE0N2ZkMTg0ODRiZGNjYS90YWJsZTplMjBkMTMzMzMwZDE0ZGY1YTI0ZTBhNDQ3YjJhMDM1MC90YWJsZXJhbmdlOmUyMGQxMzMzMzBkMTRkZjVhMjRlMGE0NDdiMmEwMzUwXzEwLTMtMS0xLTA_84557429-16d7-4ed9-8399-0df98e35ad9e">6,469</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDAvZnJhZzowMmUyN2NjNmEzYWY0MGNjYWE0N2ZkMTg0ODRiZGNjYS90YWJsZTplMjBkMTMzMzMwZDE0ZGY1YTI0ZTBhNDQ3YjJhMDM1MC90YWJsZXJhbmdlOmUyMGQxMzMzMzBkMTRkZjVhMjRlMGE0NDdiMmEwMzUwXzExLTEtMS0xLTA_ce5d8f74-c4b1-40be-8550-c3e8e89e0d0a">423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDAvZnJhZzowMmUyN2NjNmEzYWY0MGNjYWE0N2ZkMTg0ODRiZGNjYS90YWJsZTplMjBkMTMzMzMwZDE0ZGY1YTI0ZTBhNDQ3YjJhMDM1MC90YWJsZXJhbmdlOmUyMGQxMzMzMzBkMTRkZjVhMjRlMGE0NDdiMmEwMzUwXzExLTMtMS0xLTA_7131cab5-a853-4e07-80f8-1b5ea78dc8ae">149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDAvZnJhZzowMmUyN2NjNmEzYWY0MGNjYWE0N2ZkMTg0ODRiZGNjYS90YWJsZTplMjBkMTMzMzMwZDE0ZGY1YTI0ZTBhNDQ3YjJhMDM1MC90YWJsZXJhbmdlOmUyMGQxMzMzMzBkMTRkZjVhMjRlMGE0NDdiMmEwMzUwXzEyLTEtMS0xLTA_fe60a876-def6-4226-97ea-5a4e4fc1a436">6,541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDAvZnJhZzowMmUyN2NjNmEzYWY0MGNjYWE0N2ZkMTg0ODRiZGNjYS90YWJsZTplMjBkMTMzMzMwZDE0ZGY1YTI0ZTBhNDQ3YjJhMDM1MC90YWJsZXJhbmdlOmUyMGQxMzMzMzBkMTRkZjVhMjRlMGE0NDdiMmEwMzUwXzEyLTMtMS0xLTA_50f16a86-b8ea-42c0-8db9-018641db1f7c">6,618</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDAvZnJhZzowMmUyN2NjNmEzYWY0MGNjYWE0N2ZkMTg0ODRiZGNjYS90ZXh0cmVnaW9uOjAyZTI3Y2M2YTNhZjQwY2NhYTQ3ZmQxODQ4NGJkY2NhXzE1MQ_9e77e0d4-16ed-4046-8737-3e3f6a024157"><ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDAvZnJhZzowMmUyN2NjNmEzYWY0MGNjYWE0N2ZkMTg0ODRiZGNjYS90ZXh0cmVnaW9uOjAyZTI3Y2M2YTNhZjQwY2NhYTQ3ZmQxODQ4NGJkY2NhXzE1MQ_e11e9955-fa01-446d-a2b5-a0a53492255b">0.7</ix:nonFraction></ix:nonFraction> million for the years ended December&#160;31, 2020 and 2019. Depreciation expense is included within cost of goods sold and selling, general and administrative expense in the Consolidated Statements of Operations.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="idb46c8b71d7d4a27b277b6db52f68e8e_103"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 9. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="us-gaap:LesseeFinanceLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90ZXh0cmVnaW9uOjMxNWMzNTEzNmNlYTQxNTA4MDJkNWZlMmY5MGFjM2FjXzIxNjA_415d8d63-fec5-46c3-b437-24fefb0da9c6" continuedAt="ief27198dae344f2eb9409550499ba6c3" escape="true"><ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90ZXh0cmVnaW9uOjMxNWMzNTEzNmNlYTQxNTA4MDJkNWZlMmY5MGFjM2FjXzIxNjk_5bc9c1d5-cf3d-4799-84e4-e603203c77a4" continuedAt="i5800120795f840b9b9d245eb7f5bd5eb" escape="true">LEASES</ix:nonNumeric></ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ief27198dae344f2eb9409550499ba6c3" continuedAt="i7585c1bfd8b34cba81f621908336d097"><ix:continuation id="i5800120795f840b9b9d245eb7f5bd5eb" continuedAt="ic60ff8a242c042418a06cd0d07c85440"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not recognize leases with terms less than twelve months in duration, or that have variable only payments, in its Consolidated Balance Sheet as right-of-use assets and lease liabilities. The Company has adopted the practical expedient which allows for the Company to not separate lease and non-lease components of contracts. Accordingly, non-lease components are included in the measurement of the Company's lease liabilities and right-of-use assets. If the Company is aware of the implicit rate in leases, the Company determines the operating lease liability using the implicit rate. For those leases where the Company is not aware of the implicit rate in the lease, the Company utilizes an incremental borrowing rate of <ix:nonFraction unitRef="number" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="2" name="apyx:LesseeDiscountRateIncrementalBorrowingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90ZXh0cmVnaW9uOjMxNWMzNTEzNmNlYTQxNTA4MDJkNWZlMmY5MGFjM2FjXzQ5NDc4MDIzMjc0MDU_9e01f04f-62af-40b7-8815-1fb9fed1b454">4.00</ix:nonFraction>%, which is indicative of its collateralized borrowing rate. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases its facility in Sofia, Bulgaria and vehicles in Clearwater, Florida under non-cancelable operating lease agreements. The Company's lease on the Bulgaria facility includes rent escalation over the term of the lease. Rent expense on the lease is accounted for on a straight-line basis over the lease term. During 2019, the Bulgaria facility lease was extended for an additional <ix:nonNumeric contextRef="i810adca1ebab41a5a9488ebb3154fda3_I20191231" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90ZXh0cmVnaW9uOjMxNWMzNTEzNmNlYTQxNTA4MDJkNWZlMmY5MGFjM2FjXzEzMTI_e7395b44-1b74-4ea6-9b3c-e34a71bfa465">2</ix:nonNumeric> years. In accordance with operating lease guidance under Topic 842, the extension was accounted for as a lease modification and the right-of-use asset and lease liability were remeasured at the modification date. These operating leases have terms expiring through December 2022. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance Leases</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, the Company entered into non-cancelable finance leases for certain computer equipment and a vehicle in Clearwater, Florida. These finance leases have terms expiring through August 2023. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90ZXh0cmVnaW9uOjMxNWMzNTEzNmNlYTQxNTA4MDJkNWZlMmY5MGFjM2FjXzIxNzI_8fd87f67-597c-44b5-8de0-86cae190b9d0" continuedAt="ie91b7ffcd7374c688bdb27aa43a3c50f" escape="true">Information about the Company&#8217;s lease costs are as follows:</ix:nonNumeric></span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i7585c1bfd8b34cba81f621908336d097"><ix:continuation id="ic60ff8a242c042418a06cd0d07c85440"><ix:continuation id="ie91b7ffcd7374c688bdb27aa43a3c50f"><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended <br/>December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTphMDVmNjBhNDNjOTY0NTQzOTFlMGFmMzk5M2NkNTFiOC90YWJsZXJhbmdlOmEwNWY2MGE0M2M5NjQ1NDM5MWUwYWYzOTkzY2Q1MWI4XzItMS0xLTEtNDk4_9790dcfb-e32d-4ad2-817d-36f1335b48aa">124</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTphMDVmNjBhNDNjOTY0NTQzOTFlMGFmMzk5M2NkNTFiOC90YWJsZXJhbmdlOmEwNWY2MGE0M2M5NjQ1NDM5MWUwYWYzOTkzY2Q1MWI4XzItMS0xLTEtMA_d55179f9-3844-4e70-933c-371fb6c56d89">115</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease costs:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTphMDVmNjBhNDNjOTY0NTQzOTFlMGFmMzk5M2NkNTFiOC90YWJsZXJhbmdlOmEwNWY2MGE0M2M5NjQ1NDM5MWUwYWYzOTkzY2Q1MWI4XzQtMS0xLTEtNDk4_c9784021-e88a-4ac9-bfc8-44363ea84924">216</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTphMDVmNjBhNDNjOTY0NTQzOTFlMGFmMzk5M2NkNTFiOC90YWJsZXJhbmdlOmEwNWY2MGE0M2M5NjQ1NDM5MWUwYWYzOTkzY2Q1MWI4XzQtMS0xLTEtMA_3a564c04-4c5e-4c36-b2f9-a367d936c406">57</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTphMDVmNjBhNDNjOTY0NTQzOTFlMGFmMzk5M2NkNTFiOC90YWJsZXJhbmdlOmEwNWY2MGE0M2M5NjQ1NDM5MWUwYWYzOTkzY2Q1MWI4XzUtMS0xLTEtNDk4_bcd21d35-5de9-49b3-bcf9-69f13e309dd0">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTphMDVmNjBhNDNjOTY0NTQzOTFlMGFmMzk5M2NkNTFiOC90YWJsZXJhbmdlOmEwNWY2MGE0M2M5NjQ1NDM5MWUwYWYzOTkzY2Q1MWI4XzUtMS0xLTEtMA_56e0fcc0-2d1d-4d6d-89f8-bec7155327f2">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTphMDVmNjBhNDNjOTY0NTQzOTFlMGFmMzk5M2NkNTFiOC90YWJsZXJhbmdlOmEwNWY2MGE0M2M5NjQ1NDM5MWUwYWYzOTkzY2Q1MWI4XzYtMS0xLTEtNDk4_8a77813b-4d0f-4821-ad92-81cc99f2cd9f">13</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTphMDVmNjBhNDNjOTY0NTQzOTFlMGFmMzk5M2NkNTFiOC90YWJsZXJhbmdlOmEwNWY2MGE0M2M5NjQ1NDM5MWUwYWYzOTkzY2Q1MWI4XzYtMS0xLTEtMA_30cef4a5-e5c7-4796-b0af-ef00a7e3aaac">16</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease costs</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTphMDVmNjBhNDNjOTY0NTQzOTFlMGFmMzk5M2NkNTFiOC90YWJsZXJhbmdlOmEwNWY2MGE0M2M5NjQ1NDM5MWUwYWYzOTkzY2Q1MWI4XzctMS0xLTEtNDk4_4f73dc27-e6ed-4bf5-bbe5-8eb585d80dbc">375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTphMDVmNjBhNDNjOTY0NTQzOTFlMGFmMzk5M2NkNTFiOC90YWJsZXJhbmdlOmEwNWY2MGE0M2M5NjQ1NDM5MWUwYWYzOTkzY2Q1MWI4XzctMS0xLTEtMA_52f35355-cc40-443a-a3e6-51bcaffbe841">196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and non-cash information related to our leases are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended <br/>December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended <br/>December 31, 2019<br/></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non cash information:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets capitalized and lease liabilities recognized upon adoption of Topic 842</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0363bd7ae504408f83e9148242c28770_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTo2YjI0NzYwNDFhNGU0ZTRiOGRiMmI5YWExMDFjOTYxYy90YWJsZXJhbmdlOjZiMjQ3NjA0MWE0ZTRlNGI4ZGIyYjlhYTEwMWM5NjFjXzMtMS0xLTEtMzgxOA_dc0796b1-187b-412e-99c5-959c5f08a4e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0363bd7ae504408f83e9148242c28770_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTo2YjI0NzYwNDFhNGU0ZTRiOGRiMmI5YWExMDFjOTYxYy90YWJsZXJhbmdlOjZiMjQ3NjA0MWE0ZTRlNGI4ZGIyYjlhYTEwMWM5NjFjXzMtMi0xLTEtMzgxOA_6f461003-9e01-4b66-bc56-953e1a9427f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i672dd521a5844f22a7fa22968f746eed_D20190101-20191231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTo2YjI0NzYwNDFhNGU0ZTRiOGRiMmI5YWExMDFjOTYxYy90YWJsZXJhbmdlOjZiMjQ3NjA0MWE0ZTRlNGI4ZGIyYjlhYTEwMWM5NjFjXzMtMS0xLTEtMA_f7352d48-e3ec-4792-9cdd-48dda9a86b2e">212</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i672dd521a5844f22a7fa22968f746eed_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTo2YjI0NzYwNDFhNGU0ZTRiOGRiMmI5YWExMDFjOTYxYy90YWJsZXJhbmdlOjZiMjQ3NjA0MWE0ZTRlNGI4ZGIyYjlhYTEwMWM5NjFjXzMtMi0xLTEtMA_fe1d59b4-605c-4f69-9962-aed107de7da5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets capitalized and lease liabilities recognized upon lease remeasurement</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fc3ec19ac0e4ed4895cf47c5da6347f_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTo2YjI0NzYwNDFhNGU0ZTRiOGRiMmI5YWExMDFjOTYxYy90YWJsZXJhbmdlOjZiMjQ3NjA0MWE0ZTRlNGI4ZGIyYjlhYTEwMWM5NjFjXzQtMS0xLTEtMzgxOA_ef707aad-2ab5-4910-9911-03e7da4f5dac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fc3ec19ac0e4ed4895cf47c5da6347f_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTo2YjI0NzYwNDFhNGU0ZTRiOGRiMmI5YWExMDFjOTYxYy90YWJsZXJhbmdlOjZiMjQ3NjA0MWE0ZTRlNGI4ZGIyYjlhYTEwMWM5NjFjXzQtMi0xLTEtMzgxOA_59c92f11-19c5-48db-b1af-02950495dba1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6241803215ac41d1bca740510e6f9f94_D20190101-20191231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTo2YjI0NzYwNDFhNGU0ZTRiOGRiMmI5YWExMDFjOTYxYy90YWJsZXJhbmdlOjZiMjQ3NjA0MWE0ZTRlNGI4ZGIyYjlhYTEwMWM5NjFjXzQtMS0xLTEtMA_89f72fd6-de19-4a2c-88c0-d07790ce1369">207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6241803215ac41d1bca740510e6f9f94_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTo2YjI0NzYwNDFhNGU0ZTRiOGRiMmI5YWExMDFjOTYxYy90YWJsZXJhbmdlOjZiMjQ3NjA0MWE0ZTRlNGI4ZGIyYjlhYTEwMWM5NjFjXzQtMi0xLTEtMA_e982ca0a-f7cb-4604-9623-88c5135659f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets capitalized and lease liabilities recognized upon execution of lease</span></td><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia07cd0c04ff44e70938ff407067b900c_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTo2YjI0NzYwNDFhNGU0ZTRiOGRiMmI5YWExMDFjOTYxYy90YWJsZXJhbmdlOjZiMjQ3NjA0MWE0ZTRlNGI4ZGIyYjlhYTEwMWM5NjFjXzUtMS0xLTEtMzgxOA_f7e2f4c8-99db-49e3-8abb-b1a71b3a2aaf">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia07cd0c04ff44e70938ff407067b900c_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTo2YjI0NzYwNDFhNGU0ZTRiOGRiMmI5YWExMDFjOTYxYy90YWJsZXJhbmdlOjZiMjQ3NjA0MWE0ZTRlNGI4ZGIyYjlhYTEwMWM5NjFjXzUtMi0xLTEtMzgxOA_c8dd4ffc-9297-42dc-b43b-8ca95dd585d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i796972f9750c4ee3b870255ed2cedf91_D20190101-20191231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTo2YjI0NzYwNDFhNGU0ZTRiOGRiMmI5YWExMDFjOTYxYy90YWJsZXJhbmdlOjZiMjQ3NjA0MWE0ZTRlNGI4ZGIyYjlhYTEwMWM5NjFjXzUtMS0xLTEtMA_10a0530e-7c40-4de4-8333-4a2ed9eeeb55">28</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i796972f9750c4ee3b870255ed2cedf91_D20190101-20191231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTo2YjI0NzYwNDFhNGU0ZTRiOGRiMmI5YWExMDFjOTYxYy90YWJsZXJhbmdlOjZiMjQ3NjA0MWE0ZTRlNGI4ZGIyYjlhYTEwMWM5NjFjXzUtMi0xLTEtMA_ca62ea35-ea24-4e70-978b-ffe0cb0e6d2a">710</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash information:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTo2YjI0NzYwNDFhNGU0ZTRiOGRiMmI5YWExMDFjOTYxYy90YWJsZXJhbmdlOjZiMjQ3NjA0MWE0ZTRlNGI4ZGIyYjlhYTEwMWM5NjFjXzgtMS0xLTEtMzgxOA_dcbad5f9-78ff-4fcb-8cac-2b0227abf1ed">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" name="apyx:FinanceLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTo2YjI0NzYwNDFhNGU0ZTRiOGRiMmI5YWExMDFjOTYxYy90YWJsZXJhbmdlOjZiMjQ3NjA0MWE0ZTRlNGI4ZGIyYjlhYTEwMWM5NjFjXzgtMi0xLTEtMzgxOA_e922ddd6-7310-45ff-9099-48eab7e2dc91">251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTo2YjI0NzYwNDFhNGU0ZTRiOGRiMmI5YWExMDFjOTYxYy90YWJsZXJhbmdlOjZiMjQ3NjA0MWE0ZTRlNGI4ZGIyYjlhYTEwMWM5NjFjXzgtMS0xLTEtMA_194ceb44-e57e-4e30-81e3-82442ccc3e76">106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" name="apyx:FinanceLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTo2YjI0NzYwNDFhNGU0ZTRiOGRiMmI5YWExMDFjOTYxYy90YWJsZXJhbmdlOjZiMjQ3NjA0MWE0ZTRlNGI4ZGIyYjlhYTEwMWM5NjFjXzgtMi0xLTEtMA_db0fb052-9516-4f54-b6eb-d91c77fb6550">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about the Company&#8217;s weighted average remaining lease terms and discount rate assumptions are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.160%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended <br/>December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended <br/>December 31, 2019<br/></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZToxZmJjYzZlZDc1ZTg0YWYwYmE5NzIyYzhkOGI5NzhiNi90YWJsZXJhbmdlOjFmYmNjNmVkNzVlODRhZjBiYTk3MjJjOGQ4Yjk3OGI2XzItMS0xLTEtMzgzMQ_bc68e691-47f4-49d2-9a5c-f6e496492f1c">2.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZToxZmJjYzZlZDc1ZTg0YWYwYmE5NzIyYzhkOGI5NzhiNi90YWJsZXJhbmdlOjFmYmNjNmVkNzVlODRhZjBiYTk3MjJjOGQ4Yjk3OGI2XzItMi0xLTEtMzgzMQ_75a6f06d-ba1b-48ac-b5a0-1ffc68937d39">1.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZToxZmJjYzZlZDc1ZTg0YWYwYmE5NzIyYzhkOGI5NzhiNi90YWJsZXJhbmdlOjFmYmNjNmVkNzVlODRhZjBiYTk3MjJjOGQ4Yjk3OGI2XzItMS0xLTEtMA_c92cde3b-435c-419a-8022-facaabd30c31">3.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZToxZmJjYzZlZDc1ZTg0YWYwYmE5NzIyYzhkOGI5NzhiNi90YWJsZXJhbmdlOjFmYmNjNmVkNzVlODRhZjBiYTk3MjJjOGQ4Yjk3OGI2XzItMi0xLTEtMA_ef971720-a460-4b96-8c93-0842c306c4dc">2.7</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZToxZmJjYzZlZDc1ZTg0YWYwYmE5NzIyYzhkOGI5NzhiNi90YWJsZXJhbmdlOjFmYmNjNmVkNzVlODRhZjBiYTk3MjJjOGQ4Yjk3OGI2XzMtMS0xLTEtMzgzMQ_ebcd1079-ab60-47ac-953f-9e79450dccde">4.03</ix:nonFraction>%</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="2" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZToxZmJjYzZlZDc1ZTg0YWYwYmE5NzIyYzhkOGI5NzhiNi90YWJsZXJhbmdlOjFmYmNjNmVkNzVlODRhZjBiYTk3MjJjOGQ4Yjk3OGI2XzMtMi0xLTEtMzgzMQ_0565f976-3df9-4021-9f9d-271f86eb7029">4.00</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZToxZmJjYzZlZDc1ZTg0YWYwYmE5NzIyYzhkOGI5NzhiNi90YWJsZXJhbmdlOjFmYmNjNmVkNzVlODRhZjBiYTk3MjJjOGQ4Yjk3OGI2XzMtNC0xLTEtMzgyNw_388b9493-f01e-4eda-8fb8-ad6d7c7c0176">4.04</ix:nonFraction>%</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="2" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZToxZmJjYzZlZDc1ZTg0YWYwYmE5NzIyYzhkOGI5NzhiNi90YWJsZXJhbmdlOjFmYmNjNmVkNzVlODRhZjBiYTk3MjJjOGQ4Yjk3OGI2XzMtNS0xLTEtMzgyOQ_9c5bd173-b29b-4a15-b82e-dc51f8a4056e">4.00</ix:nonFraction>%</span></td></tr></table></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90ZXh0cmVnaW9uOjMxNWMzNTEzNmNlYTQxNTA4MDJkNWZlMmY5MGFjM2FjXzIxNjI_be6c21e0-d0b4-4376-9a5a-1b8be6dbe3a9" escape="true"><ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90ZXh0cmVnaW9uOjMxNWMzNTEzNmNlYTQxNTA4MDJkNWZlMmY5MGFjM2FjXzIxNjc_7b699c18-fc7b-4513-bdad-a66563fa24ab" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of December 31, 2020 are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:76.319%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.190%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.191%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTpiNTAyMTJjZjg1YzM0ODIwOWYxNGMzYWI2MDcwN2JiYS90YWJsZXJhbmdlOmI1MDIxMmNmODVjMzQ4MjA5ZjE0YzNhYjYwNzA3YmJhXzItMS0xLTEtMA_1bdc0b26-47e7-49e6-806d-df53b4479b4f">134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTpiNTAyMTJjZjg1YzM0ODIwOWYxNGMzYWI2MDcwN2JiYS90YWJsZXJhbmdlOmI1MDIxMmNmODVjMzQ4MjA5ZjE0YzNhYjYwNzA3YmJhXzItMi0xLTEtMA_d8a8aab8-2f09-4b9f-8b05-1c8449bfc338">236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTpiNTAyMTJjZjg1YzM0ODIwOWYxNGMzYWI2MDcwN2JiYS90YWJsZXJhbmdlOmI1MDIxMmNmODVjMzQ4MjA5ZjE0YzNhYjYwNzA3YmJhXzMtMS0xLTEtMA_9654796b-eced-48ac-a720-13dd7e6274dc">131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTpiNTAyMTJjZjg1YzM0ODIwOWYxNGMzYWI2MDcwN2JiYS90YWJsZXJhbmdlOmI1MDIxMmNmODVjMzQ4MjA5ZjE0YzNhYjYwNzA3YmJhXzMtMi0xLTEtMA_ad94ac79-14df-4a4c-8425-b36c2242ad69">183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTpiNTAyMTJjZjg1YzM0ODIwOWYxNGMzYWI2MDcwN2JiYS90YWJsZXJhbmdlOmI1MDIxMmNmODVjMzQ4MjA5ZjE0YzNhYjYwNzA3YmJhXzQtMS0xLTEtMA_21fd6d14-3c37-41e1-8fe0-300b21b4aa66">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTpiNTAyMTJjZjg1YzM0ODIwOWYxNGMzYWI2MDcwN2JiYS90YWJsZXJhbmdlOmI1MDIxMmNmODVjMzQ4MjA5ZjE0YzNhYjYwNzA3YmJhXzQtMi0xLTEtMA_30d9a4cb-927c-49b3-8e6a-cbdf9d23f500">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTpiNTAyMTJjZjg1YzM0ODIwOWYxNGMzYWI2MDcwN2JiYS90YWJsZXJhbmdlOmI1MDIxMmNmODVjMzQ4MjA5ZjE0YzNhYjYwNzA3YmJhXzctMS0xLTEtMA_aca1beb9-4f1c-4c3d-9d01-66cd07809332">265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTpiNTAyMTJjZjg1YzM0ODIwOWYxNGMzYWI2MDcwN2JiYS90YWJsZXJhbmdlOmI1MDIxMmNmODVjMzQ4MjA5ZjE0YzNhYjYwNzA3YmJhXzctMi0xLTEtMA_93807528-90f5-49cc-8536-5eedf873a2e6">437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTpiNTAyMTJjZjg1YzM0ODIwOWYxNGMzYWI2MDcwN2JiYS90YWJsZXJhbmdlOmI1MDIxMmNmODVjMzQ4MjA5ZjE0YzNhYjYwNzA3YmJhXzgtMS0xLTEtMA_df9e388d-a874-45f3-8aa7-6ec7a9a41bd1">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTpiNTAyMTJjZjg1YzM0ODIwOWYxNGMzYWI2MDcwN2JiYS90YWJsZXJhbmdlOmI1MDIxMmNmODVjMzQ4MjA5ZjE0YzNhYjYwNzA3YmJhXzgtMi0xLTEtMA_5f8e7941-3bf3-4c81-b514-95831067e26d">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTpiNTAyMTJjZjg1YzM0ODIwOWYxNGMzYWI2MDcwN2JiYS90YWJsZXJhbmdlOmI1MDIxMmNmODVjMzQ4MjA5ZjE0YzNhYjYwNzA3YmJhXzktMS0xLTEtMA_028c822e-cec7-421f-862a-82e433238feb">255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTpiNTAyMTJjZjg1YzM0ODIwOWYxNGMzYWI2MDcwN2JiYS90YWJsZXJhbmdlOmI1MDIxMmNmODVjMzQ4MjA5ZjE0YzNhYjYwNzA3YmJhXzktMi0xLTEtMA_a4069214-1336-447d-b678-f84e087a83a0">421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion of lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTpiNTAyMTJjZjg1YzM0ODIwOWYxNGMzYWI2MDcwN2JiYS90YWJsZXJhbmdlOmI1MDIxMmNmODVjMzQ4MjA5ZjE0YzNhYjYwNzA3YmJhXzEwLTEtMS0xLTA_8c37660e-a616-4a25-8637-fc4f10bb0f49">126</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTpiNTAyMTJjZjg1YzM0ODIwOWYxNGMzYWI2MDcwN2JiYS90YWJsZXJhbmdlOmI1MDIxMmNmODVjMzQ4MjA5ZjE0YzNhYjYwNzA3YmJhXzEwLTItMS0xLTA_e70efe33-6d0a-4208-a4e5-e60303ad53bd">238</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTpiNTAyMTJjZjg1YzM0ODIwOWYxNGMzYWI2MDcwN2JiYS90YWJsZXJhbmdlOmI1MDIxMmNmODVjMzQ4MjA5ZjE0YzNhYjYwNzA3YmJhXzExLTEtMS0xLTA_d1b9353f-e7c0-49fe-9dca-dd58df2ff7c0">129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTpiNTAyMTJjZjg1YzM0ODIwOWYxNGMzYWI2MDcwN2JiYS90YWJsZXJhbmdlOmI1MDIxMmNmODVjMzQ4MjA5ZjE0YzNhYjYwNzA3YmJhXzExLTItMS0xLTA_b10881a5-4f11-408c-b485-5f96be2a341a">183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric></ix:continuation></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><div id="idb46c8b71d7d4a27b277b6db52f68e8e_106"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 10. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDYvZnJhZzo5NjQyNWFiNjYxODQ0MmRhOGExNDIzNzEyM2RkNDAxNi90ZXh0cmVnaW9uOjk2NDI1YWI2NjE4NDQyZGE4YTE0MjM3MTIzZGQ0MDE2XzE0MA_1c5a7bb1-fded-4fdd-98d3-7f5afed9e2d4" continuedAt="i7bfaec4ba2dc4ae4aa7a8c268c10c63b" escape="true">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i7bfaec4ba2dc4ae4aa7a8c268c10c63b"><ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="apyx:AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDYvZnJhZzo5NjQyNWFiNjYxODQ0MmRhOGExNDIzNzEyM2RkNDAxNi90ZXh0cmVnaW9uOjk2NDI1YWI2NjE4NDQyZGE4YTE0MjM3MTIzZGQ0MDE2XzE0Mg_9adc989e-128d-426e-aa0d-04183cdab433" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:64.492%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.737%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.739%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" name="us-gaap:AccruedSalariesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDYvZnJhZzo5NjQyNWFiNjYxODQ0MmRhOGExNDIzNzEyM2RkNDAxNi90YWJsZTpmNTdmZWU5YmYzZWY0MGNjODJiMWU1MjQ2NDg5MWUwYy90YWJsZXJhbmdlOmY1N2ZlZTliZjNlZjQwY2M4MmIxZTUyNDY0ODkxZTBjXzItMS0xLTEtMA_0e88d65d-8798-476d-8ee3-90b07a078fd9">808</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" name="us-gaap:AccruedSalariesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDYvZnJhZzo5NjQyNWFiNjYxODQ0MmRhOGExNDIzNzEyM2RkNDAxNi90YWJsZTpmNTdmZWU5YmYzZWY0MGNjODJiMWU1MjQ2NDg5MWUwYy90YWJsZXJhbmdlOmY1N2ZlZTliZjNlZjQwY2M4MmIxZTUyNDY0ODkxZTBjXzItMy0xLTEtMA_62ef4847-e882-4e20-b397-91fcb550ce52">694</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued bonus</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" name="us-gaap:AccruedBonusesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDYvZnJhZzo5NjQyNWFiNjYxODQ0MmRhOGExNDIzNzEyM2RkNDAxNi90YWJsZTpmNTdmZWU5YmYzZWY0MGNjODJiMWU1MjQ2NDg5MWUwYy90YWJsZXJhbmdlOmY1N2ZlZTliZjNlZjQwY2M4MmIxZTUyNDY0ODkxZTBjXzMtMS0xLTEtMA_477c15cf-f3dc-4fd3-962d-26eac5b3c3db">811</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedBonusesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDYvZnJhZzo5NjQyNWFiNjYxODQ0MmRhOGExNDIzNzEyM2RkNDAxNi90YWJsZTpmNTdmZWU5YmYzZWY0MGNjODJiMWU1MjQ2NDg5MWUwYy90YWJsZXJhbmdlOmY1N2ZlZTliZjNlZjQwY2M4MmIxZTUyNDY0ODkxZTBjXzMtMy0xLTEtMA_64f1dab6-2933-4689-bc0e-4f9c02756229">1,306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued commissions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedSalesCommissionCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDYvZnJhZzo5NjQyNWFiNjYxODQ0MmRhOGExNDIzNzEyM2RkNDAxNi90YWJsZTpmNTdmZWU5YmYzZWY0MGNjODJiMWU1MjQ2NDg5MWUwYy90YWJsZXJhbmdlOmY1N2ZlZTliZjNlZjQwY2M4MmIxZTUyNDY0ODkxZTBjXzQtMS0xLTEtMA_3c0ae541-29be-40b3-ba32-8fee29ca8a7c">1,001</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" name="us-gaap:AccruedSalesCommissionCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDYvZnJhZzo5NjQyNWFiNjYxODQ0MmRhOGExNDIzNzEyM2RkNDAxNi90YWJsZTpmNTdmZWU5YmYzZWY0MGNjODJiMWU1MjQ2NDg5MWUwYy90YWJsZXJhbmdlOmY1N2ZlZTliZjNlZjQwY2M4MmIxZTUyNDY0ODkxZTBjXzQtMy0xLTEtMA_b7766cc5-b480-422e-842b-fbf6a9020f56">877</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product warranties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" name="us-gaap:ProductWarrantyAccrualClassifiedCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDYvZnJhZzo5NjQyNWFiNjYxODQ0MmRhOGExNDIzNzEyM2RkNDAxNi90YWJsZTpmNTdmZWU5YmYzZWY0MGNjODJiMWU1MjQ2NDg5MWUwYy90YWJsZXJhbmdlOmY1N2ZlZTliZjNlZjQwY2M4MmIxZTUyNDY0ODkxZTBjXzUtMS0xLTEtMA_f9a3764d-7c94-4d47-8b45-4dfe18206836">498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" name="us-gaap:ProductWarrantyAccrualClassifiedCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDYvZnJhZzo5NjQyNWFiNjYxODQ0MmRhOGExNDIzNzEyM2RkNDAxNi90YWJsZTpmNTdmZWU5YmYzZWY0MGNjODJiMWU1MjQ2NDg5MWUwYy90YWJsZXJhbmdlOmY1N2ZlZTliZjNlZjQwY2M4MmIxZTUyNDY0ODkxZTBjXzUtMy0xLTEtMA_3aa560e2-6cac-4ed6-970a-822838956acf">452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product liability claim insurance deductibles</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" name="us-gaap:AccruedInsuranceCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDYvZnJhZzo5NjQyNWFiNjYxODQ0MmRhOGExNDIzNzEyM2RkNDAxNi90YWJsZTpmNTdmZWU5YmYzZWY0MGNjODJiMWU1MjQ2NDg5MWUwYy90YWJsZXJhbmdlOmY1N2ZlZTliZjNlZjQwY2M4MmIxZTUyNDY0ODkxZTBjXzYtMS0xLTEtMA_7a9d3edf-00a4-484d-87b1-88d0cb56956c">435</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedInsuranceCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDYvZnJhZzo5NjQyNWFiNjYxODQ0MmRhOGExNDIzNzEyM2RkNDAxNi90YWJsZTpmNTdmZWU5YmYzZWY0MGNjODJiMWU1MjQ2NDg5MWUwYy90YWJsZXJhbmdlOmY1N2ZlZTliZjNlZjQwY2M4MmIxZTUyNDY0ODkxZTBjXzYtMy0xLTEtMA_1d0933ba-efe6-469c-82b9-fdf9775e2e6f">1,170</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDYvZnJhZzo5NjQyNWFiNjYxODQ0MmRhOGExNDIzNzEyM2RkNDAxNi90YWJsZTpmNTdmZWU5YmYzZWY0MGNjODJiMWU1MjQ2NDg5MWUwYy90YWJsZXJhbmdlOmY1N2ZlZTliZjNlZjQwY2M4MmIxZTUyNDY0ODkxZTBjXzctMS0xLTEtMA_29e5fa66-0e07-42ac-a8d0-801634d7cdae">222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDYvZnJhZzo5NjQyNWFiNjYxODQ0MmRhOGExNDIzNzEyM2RkNDAxNi90YWJsZTpmNTdmZWU5YmYzZWY0MGNjODJiMWU1MjQ2NDg5MWUwYy90YWJsZXJhbmdlOmY1N2ZlZTliZjNlZjQwY2M4MmIxZTUyNDY0ODkxZTBjXzctMy0xLTEtMA_de28496d-397e-4426-a265-1dc523589bd8">1,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joint and several payroll liability</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" format="ixt:numdotdecimal" name="apyx:JointAndSeveralPayrollLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDYvZnJhZzo5NjQyNWFiNjYxODQ0MmRhOGExNDIzNzEyM2RkNDAxNi90YWJsZTpmNTdmZWU5YmYzZWY0MGNjODJiMWU1MjQ2NDg5MWUwYy90YWJsZXJhbmdlOmY1N2ZlZTliZjNlZjQwY2M4MmIxZTUyNDY0ODkxZTBjXzgtMS0xLTEtMA_b6abb2eb-2fb6-4d27-a97a-f9bf3d7d98c0">1,027</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="apyx:JointAndSeveralPayrollLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDYvZnJhZzo5NjQyNWFiNjYxODQ0MmRhOGExNDIzNzEyM2RkNDAxNi90YWJsZTpmNTdmZWU5YmYzZWY0MGNjODJiMWU1MjQ2NDg5MWUwYy90YWJsZXJhbmdlOmY1N2ZlZTliZjNlZjQwY2M4MmIxZTUyNDY0ODkxZTBjXzgtMy0xLTEtMA_ac416e34-20cc-4384-9c47-c9ec66364cb7">1,045</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" format="ixt:numdotdecimal" name="apyx:UncertainTaxPositionsLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDYvZnJhZzo5NjQyNWFiNjYxODQ0MmRhOGExNDIzNzEyM2RkNDAxNi90YWJsZTpmNTdmZWU5YmYzZWY0MGNjODJiMWU1MjQ2NDg5MWUwYy90YWJsZXJhbmdlOmY1N2ZlZTliZjNlZjQwY2M4MmIxZTUyNDY0ODkxZTBjXzktMS0xLTEtMA_0690a7b0-8d6a-42b3-bccb-0ab4ee135333">1,658</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="apyx:UncertainTaxPositionsLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDYvZnJhZzo5NjQyNWFiNjYxODQ0MmRhOGExNDIzNzEyM2RkNDAxNi90YWJsZTpmNTdmZWU5YmYzZWY0MGNjODJiMWU1MjQ2NDg5MWUwYy90YWJsZXJhbmdlOmY1N2ZlZTliZjNlZjQwY2M4MmIxZTUyNDY0ODkxZTBjXzktMy0xLTEtMA_a481db5a-4c87-40b2-ba15-fa2063ab77fd">1,491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales tax payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" name="us-gaap:SalesAndExciseTaxPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDYvZnJhZzo5NjQyNWFiNjYxODQ0MmRhOGExNDIzNzEyM2RkNDAxNi90YWJsZTpmNTdmZWU5YmYzZWY0MGNjODJiMWU1MjQ2NDg5MWUwYy90YWJsZXJhbmdlOmY1N2ZlZTliZjNlZjQwY2M4MmIxZTUyNDY0ODkxZTBjXzEwLTEtMS0xLTIxMjM_6839b413-3c6e-4628-9c16-26a9be5813ed">591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" name="us-gaap:SalesAndExciseTaxPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDYvZnJhZzo5NjQyNWFiNjYxODQ0MmRhOGExNDIzNzEyM2RkNDAxNi90YWJsZTpmNTdmZWU5YmYzZWY0MGNjODJiMWU1MjQ2NDg5MWUwYy90YWJsZXJhbmdlOmY1N2ZlZTliZjNlZjQwY2M4MmIxZTUyNDY0ODkxZTBjXzEwLTMtMS0xLTIxMjM_3713ab88-9d97-4ce4-b622-14823a4fe1a6">492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses and current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" name="apyx:OtherAccruedExpensesAndLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDYvZnJhZzo5NjQyNWFiNjYxODQ0MmRhOGExNDIzNzEyM2RkNDAxNi90YWJsZTpmNTdmZWU5YmYzZWY0MGNjODJiMWU1MjQ2NDg5MWUwYy90YWJsZXJhbmdlOmY1N2ZlZTliZjNlZjQwY2M4MmIxZTUyNDY0ODkxZTBjXzEwLTEtMS0xLTA_23ecdea7-6fc6-46be-b656-bca9aa52fc29">227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" name="apyx:OtherAccruedExpensesAndLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDYvZnJhZzo5NjQyNWFiNjYxODQ0MmRhOGExNDIzNzEyM2RkNDAxNi90YWJsZTpmNTdmZWU5YmYzZWY0MGNjODJiMWU1MjQ2NDg5MWUwYy90YWJsZXJhbmdlOmY1N2ZlZTliZjNlZjQwY2M4MmIxZTUyNDY0ODkxZTBjXzEwLTMtMS0xLTA_67def09b-30e1-4f7b-9963-86bfd97612a3">486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDYvZnJhZzo5NjQyNWFiNjYxODQ0MmRhOGExNDIzNzEyM2RkNDAxNi90YWJsZTpmNTdmZWU5YmYzZWY0MGNjODJiMWU1MjQ2NDg5MWUwYy90YWJsZXJhbmdlOmY1N2ZlZTliZjNlZjQwY2M4MmIxZTUyNDY0ODkxZTBjXzExLTEtMS0xLTA_df72342b-87ed-41ee-bf54-75be41d6669c">7,278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDYvZnJhZzo5NjQyNWFiNjYxODQ0MmRhOGExNDIzNzEyM2RkNDAxNi90YWJsZTpmNTdmZWU5YmYzZWY0MGNjODJiMWU1MjQ2NDg5MWUwYy90YWJsZXJhbmdlOmY1N2ZlZTliZjNlZjQwY2M4MmIxZTUyNDY0ODkxZTBjXzExLTMtMS0xLTA_24e78c1c-d1ca-43f1-b316-5efac586a47a">9,396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="idb46c8b71d7d4a27b277b6db52f68e8e_109"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 11. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="us-gaap:ProductWarrantyDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDkvZnJhZzpmODk3MWM2ZmZlODk0MzA1OTcwZTcxNWVmMjU4ZmUyYS90ZXh0cmVnaW9uOmY4OTcxYzZmZmU4OTQzMDU5NzBlNzE1ZWYyNThmZTJhXzExOQ_00ffdc69-ca6a-4abb-9635-6f6869963d07" continuedAt="iad56c0904b0d4b6e896aa912afcf915b" escape="true">PRODUCT WARRANTIES</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="iad56c0904b0d4b6e896aa912afcf915b"><ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDkvZnJhZzpmODk3MWM2ZmZlODk0MzA1OTcwZTcxNWVmMjU4ZmUyYS90ZXh0cmVnaW9uOmY4OTcxYzZmZmU4OTQzMDU5NzBlNzE1ZWYyNThmZTJhXzExNw_909f89ad-0f61-48a6-b0c6-bc6810746e50" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product warranty activity consisted of the following for the years ended:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:72.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.695%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" name="us-gaap:StandardProductWarrantyAccrual" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDkvZnJhZzpmODk3MWM2ZmZlODk0MzA1OTcwZTcxNWVmMjU4ZmUyYS90YWJsZToxMTBhN2NlOGNhYmI0OTA4YTVmZGNjN2ZjNjY3ZTk2YS90YWJsZXJhbmdlOjExMGE3Y2U4Y2FiYjQ5MDhhNWZkY2M3ZmM2NjdlOTZhXzEtMS0xLTEtMA_1b2f86ac-3177-4675-a568-c81b2c719cb5">452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00df6877cb2d4b75a1a4abee0d94d57f_I20181231" decimals="-3" name="us-gaap:StandardProductWarrantyAccrual" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDkvZnJhZzpmODk3MWM2ZmZlODk0MzA1OTcwZTcxNWVmMjU4ZmUyYS90YWJsZToxMTBhN2NlOGNhYmI0OTA4YTVmZGNjN2ZjNjY3ZTk2YS90YWJsZXJhbmdlOjExMGE3Y2U4Y2FiYjQ5MDhhNWZkY2M3ZmM2NjdlOTZhXzEtMy0xLTEtMA_49d3e50f-9bda-4347-86f6-f160ce305011">348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for product warranties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" name="us-gaap:StandardProductWarrantyAccrualWarrantiesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDkvZnJhZzpmODk3MWM2ZmZlODk0MzA1OTcwZTcxNWVmMjU4ZmUyYS90YWJsZToxMTBhN2NlOGNhYmI0OTA4YTVmZGNjN2ZjNjY3ZTk2YS90YWJsZXJhbmdlOjExMGE3Y2U4Y2FiYjQ5MDhhNWZkY2M3ZmM2NjdlOTZhXzItMS0xLTEtMA_8d73b33f-7dc0-4fb2-b7ed-f501cccd0a2b">215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" name="us-gaap:StandardProductWarrantyAccrualWarrantiesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDkvZnJhZzpmODk3MWM2ZmZlODk0MzA1OTcwZTcxNWVmMjU4ZmUyYS90YWJsZToxMTBhN2NlOGNhYmI0OTA4YTVmZGNjN2ZjNjY3ZTk2YS90YWJsZXJhbmdlOjExMGE3Y2U4Y2FiYjQ5MDhhNWZkY2M3ZmM2NjdlOTZhXzItMy0xLTEtMA_dd582574-0713-4512-b474-0f650e5ef6b9">321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product warranty expenses incurred</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" name="us-gaap:StandardProductWarrantyAccrualPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDkvZnJhZzpmODk3MWM2ZmZlODk0MzA1OTcwZTcxNWVmMjU4ZmUyYS90YWJsZToxMTBhN2NlOGNhYmI0OTA4YTVmZGNjN2ZjNjY3ZTk2YS90YWJsZXJhbmdlOjExMGE3Y2U4Y2FiYjQ5MDhhNWZkY2M3ZmM2NjdlOTZhXzMtMS0xLTEtMA_952246c5-a5fa-4df1-af70-ebdffbc6adf8">169</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" name="us-gaap:StandardProductWarrantyAccrualPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDkvZnJhZzpmODk3MWM2ZmZlODk0MzA1OTcwZTcxNWVmMjU4ZmUyYS90YWJsZToxMTBhN2NlOGNhYmI0OTA4YTVmZGNjN2ZjNjY3ZTk2YS90YWJsZXJhbmdlOjExMGE3Y2U4Y2FiYjQ5MDhhNWZkY2M3ZmM2NjdlOTZhXzMtMy0xLTEtMA_ebb36b23-b7ec-4dfc-adc8-328f22f7057b">217</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product warranties</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" name="us-gaap:StandardProductWarrantyAccrual" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDkvZnJhZzpmODk3MWM2ZmZlODk0MzA1OTcwZTcxNWVmMjU4ZmUyYS90YWJsZToxMTBhN2NlOGNhYmI0OTA4YTVmZGNjN2ZjNjY3ZTk2YS90YWJsZXJhbmdlOjExMGE3Y2U4Y2FiYjQ5MDhhNWZkY2M3ZmM2NjdlOTZhXzQtMS0xLTEtMA_e19d679d-9a31-4c51-84fd-74606167430a">498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" name="us-gaap:StandardProductWarrantyAccrual" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDkvZnJhZzpmODk3MWM2ZmZlODk0MzA1OTcwZTcxNWVmMjU4ZmUyYS90YWJsZToxMTBhN2NlOGNhYmI0OTA4YTVmZGNjN2ZjNjY3ZTk2YS90YWJsZXJhbmdlOjExMGE3Y2U4Y2FiYjQ5MDhhNWZkY2M3ZmM2NjdlOTZhXzQtMy0xLTEtMA_19a46ba7-40bc-473b-8be4-08d9c729c7d9">452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div id="idb46c8b71d7d4a27b277b6db52f68e8e_112"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 12. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="apyx:JointandSeveralPayrollLiabilityTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMTIvZnJhZzo0ODQzMDJiZTNkMGE0ZDI3OWYzZTNhN2RmM2I2YTJjNS90ZXh0cmVnaW9uOjQ4NDMwMmJlM2QwYTRkMjc5ZjNlM2E3ZGYzYjZhMmM1Xzg2NA_bfc91baa-dc53-4bca-b36f-8b88c945d220" continuedAt="i09270a451327492cb573c802bd0488f4" escape="true">JOINT AND SEVERAL PAYROLL LIABILITY</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i09270a451327492cb573c802bd0488f4">During 2017, 2018 and 2019, the Company improperly calculated and reported the amount of income to certain employees, and did not collect and remit the correct amount of its employees' portion of income and payroll taxes, related to stock option exercises as required by the IRS. Due to IRS statutory requirements, the Company has joint and several liability for the full amount that was not withheld and remitted to the proper taxing authorities. This amount of the liability was approximately $<ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-5" format="ixt:numdotdecimal" name="apyx:JointAndSeveralPayrollLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMTIvZnJhZzo0ODQzMDJiZTNkMGE0ZDI3OWYzZTNhN2RmM2I2YTJjNS90ZXh0cmVnaW9uOjQ4NDMwMmJlM2QwYTRkMjc5ZjNlM2E3ZGYzYjZhMmM1XzEwOTk1MTE2MzExOTI_1362ba98-3fa1-41c9-a9ae-54f7d29d70bb"><ix:nonFraction unitRef="usd" contextRef="ib92bbe0f312c4b5ba37e35fb5203b324_I20191231" decimals="-5" format="ixt:numdotdecimal" name="apyx:JointAndSeveralPayrollLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMTIvZnJhZzo0ODQzMDJiZTNkMGE0ZDI3OWYzZTNhN2RmM2I2YTJjNS90ZXh0cmVnaW9uOjQ4NDMwMmJlM2QwYTRkMjc5ZjNlM2E3ZGYzYjZhMmM1XzEwOTk1MTE2MzExOTI_ccb9531c-0002-45e9-90cb-aed51d7a198d">1.0</ix:nonFraction></ix:nonFraction>&#160;million at December 31, 2020 and 2019. Included in other income (loss), net in the accompanying Consolidated Statements of Operations for 2019 is approximately $<ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="apyx:JointAndSeveralPayrollExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMTIvZnJhZzo0ODQzMDJiZTNkMGE0ZDI3OWYzZTNhN2RmM2I2YTJjNS90ZXh0cmVnaW9uOjQ4NDMwMmJlM2QwYTRkMjc5ZjNlM2E3ZGYzYjZhMmM1XzEwOTk1MTE2MzE0Njc_fcc679e3-d035-49e2-bb5b-faf4bd227368">0.3</ix:nonFraction>&#160;million related to the liability. If the Company can establish that its employees have in fact paid these obligations, either presently or in the future, it will be relieved of its liability.</ix:continuation> </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><div id="idb46c8b71d7d4a27b277b6db52f68e8e_115"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 13. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMTUvZnJhZzo5MTcyZjJmY2ZmMzY0MDRlOWVmYzM4YzUwNWQyNTM4ZS90ZXh0cmVnaW9uOjkxNzJmMmZjZmYzNjQwNGU5ZWZjMzhjNTA1ZDI1MzhlXzQwOQ_275a9471-c777-49d6-ab1e-b69087d202e3" continuedAt="i3faeb517f252481895d353f4071eda3f" escape="true">EARNINGS (LOSS) PER SHARE</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i3faeb517f252481895d353f4071eda3f"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings (loss) per share (&#8220;basic EPS&#8221;) is computed by dividing the net income or loss by the weighted average number of common shares outstanding for the reporting period. Diluted earnings per share (&#8220;diluted EPS&#8221;) gives effect to all dilutive potential shares outstanding. As the Company is in a net loss position for all periods presented, all potential shares outstanding are anti-dilutive. <ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMTUvZnJhZzo5MTcyZjJmY2ZmMzY0MDRlOWVmYzM4YzUwNWQyNTM4ZS90ZXh0cmVnaW9uOjkxNzJmMmZjZmYzNjQwNGU5ZWZjMzhjNTA1ZDI1MzhlXzQwMw_f985d748-249d-49b2-9b97-d662a3b1b7df" continuedAt="i3d27f08f204149598e5eb2e8a8858463" escape="true">The following table provides the computation of basic and diluted earnings (loss) per share.</ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:5pt"><ix:continuation id="i3d27f08f204149598e5eb2e8a8858463"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:72.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.695%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Numerators:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to stockholders</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMTUvZnJhZzo5MTcyZjJmY2ZmMzY0MDRlOWVmYzM4YzUwNWQyNTM4ZS90YWJsZTpiMmU0YzA3ZDliYjk0MjZmODU3ODMxYWU0OTExYjdjNS90YWJsZXJhbmdlOmIyZTRjMDdkOWJiOTQyNmY4NTc4MzFhZTQ5MTFiN2M1XzUtMS0xLTEtMA_1585dd87-3361-4f84-b9e8-4d151e5cb248">11,896</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMTUvZnJhZzo5MTcyZjJmY2ZmMzY0MDRlOWVmYzM4YzUwNWQyNTM4ZS90YWJsZTpiMmU0YzA3ZDliYjk0MjZmODU3ODMxYWU0OTExYjdjNS90YWJsZXJhbmdlOmIyZTRjMDdkOWJiOTQyNmY4NTc4MzFhZTQ5MTFiN2M1XzUtMy0xLTEtMA_c02ed9b7-f8ac-45f6-be8b-cb5a598a249b">19,706</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average shares outstanding - basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMTUvZnJhZzo5MTcyZjJmY2ZmMzY0MDRlOWVmYzM4YzUwNWQyNTM4ZS90YWJsZTpiMmU0YzA3ZDliYjk0MjZmODU3ODMxYWU0OTExYjdjNS90YWJsZXJhbmdlOmIyZTRjMDdkOWJiOTQyNmY4NTc4MzFhZTQ5MTFiN2M1XzIwLTEtMS0xLTA_ea06bd82-3756-4669-87c0-2e50d7fdb2f5">34,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMTUvZnJhZzo5MTcyZjJmY2ZmMzY0MDRlOWVmYzM4YzUwNWQyNTM4ZS90YWJsZTpiMmU0YzA3ZDliYjk0MjZmODU3ODMxYWU0OTExYjdjNS90YWJsZXJhbmdlOmIyZTRjMDdkOWJiOTQyNmY4NTc4MzFhZTQ5MTFiN2M1XzIwLTMtMS0xLTA_837c523c-65aa-43ac-8326-df44910890ce">34,069</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss per share - basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMTUvZnJhZzo5MTcyZjJmY2ZmMzY0MDRlOWVmYzM4YzUwNWQyNTM4ZS90YWJsZTpiMmU0YzA3ZDliYjk0MjZmODU3ODMxYWU0OTExYjdjNS90YWJsZXJhbmdlOmIyZTRjMDdkOWJiOTQyNmY4NTc4MzFhZTQ5MTFiN2M1XzM3LTEtMS0xLTA_b1a97deb-fb87-42c5-b9ad-248234c16d93">0.35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMTUvZnJhZzo5MTcyZjJmY2ZmMzY0MDRlOWVmYzM4YzUwNWQyNTM4ZS90YWJsZTpiMmU0YzA3ZDliYjk0MjZmODU3ODMxYWU0OTExYjdjNS90YWJsZXJhbmdlOmIyZTRjMDdkOWJiOTQyNmY4NTc4MzFhZTQ5MTFiN2M1XzM3LTMtMS0xLTA_2a45bf55-dce6-4518-b6ac-91f28346304d">0.58</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Anti-dilutive instruments excluded from diluted loss per common share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i12dd582368554dba97b8aa9e153c5b2b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMTUvZnJhZzo5MTcyZjJmY2ZmMzY0MDRlOWVmYzM4YzUwNWQyNTM4ZS90YWJsZTpiMmU0YzA3ZDliYjk0MjZmODU3ODMxYWU0OTExYjdjNS90YWJsZXJhbmdlOmIyZTRjMDdkOWJiOTQyNmY4NTc4MzFhZTQ5MTFiN2M1XzU1LTEtMS0xLTA_dfa6506b-6153-4727-8dff-094d9408a92e">4,939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i47bce2e772fe46be81b0517aa210b5d9_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMTUvZnJhZzo5MTcyZjJmY2ZmMzY0MDRlOWVmYzM4YzUwNWQyNTM4ZS90YWJsZTpiMmU0YzA3ZDliYjk0MjZmODU3ODMxYWU0OTExYjdjNS90YWJsZXJhbmdlOmIyZTRjMDdkOWJiOTQyNmY4NTc4MzFhZTQ5MTFiN2M1XzU1LTMtMS0xLTA_cd842f5f-b158-463c-aae6-7ffd432db77b">3,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><div id="idb46c8b71d7d4a27b277b6db52f68e8e_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 14.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMTgvZnJhZzpmMmMwNTJkMjlmY2Q0M2FlOWUzZjhmZjRjY2NjZjNlNy90ZXh0cmVnaW9uOmYyYzA1MmQyOWZjZDQzYWU5ZTNmOGZmNGNjY2NmM2U3XzE0Mzc_8021c24d-313d-481b-b8e0-68f0e826a18c" continuedAt="ibe7638978cae467aac6f0ddbab6549bf" escape="true">FINANCIAL INSTRUMENTS</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibe7638978cae467aac6f0ddbab6549bf">Cash and Cash Equivalents at December 31, 2020 and 2019, respectively, consisted of approximately $<ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Cash" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMTgvZnJhZzpmMmMwNTJkMjlmY2Q0M2FlOWUzZjhmZjRjY2NjZjNlNy90ZXh0cmVnaW9uOmYyYzA1MmQyOWZjZDQzYWU5ZTNmOGZmNGNjY2NmM2U3XzEwOTk1MTE2MzA1MTY_8ab60cd7-b3bf-4c84-b9e5-76d48456d073">2,250,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Cash" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMTgvZnJhZzpmMmMwNTJkMjlmY2Q0M2FlOWUzZjhmZjRjY2NjZjNlNy90ZXh0cmVnaW9uOmYyYzA1MmQyOWZjZDQzYWU5ZTNmOGZmNGNjY2NmM2U3XzExMw_e6bce8ee-da48-49a8-a418-62babfdc8b8c">2,237,000</ix:nonFraction> in cash and $<ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMTgvZnJhZzpmMmMwNTJkMjlmY2Q0M2FlOWUzZjhmZjRjY2NjZjNlNy90ZXh0cmVnaW9uOmYyYzA1MmQyOWZjZDQzYWU5ZTNmOGZmNGNjY2NmM2U3XzEwOTk1MTE2MzA1Mjg_ed55e8e8-4eb5-40fc-9afc-0d6229190d1a">39,665,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMTgvZnJhZzpmMmMwNTJkMjlmY2Q0M2FlOWUzZjhmZjRjY2NjZjNlNy90ZXh0cmVnaW9uOmYyYzA1MmQyOWZjZDQzYWU5ZTNmOGZmNGNjY2NmM2U3XzEyOA_d082b763-949f-43bc-ab65-a7b459317102">56,575,000</ix:nonFraction> in U.S. Treasury Securities with maturities of 3 months or less.</ix:continuation> </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><div id="idb46c8b71d7d4a27b277b6db52f68e8e_121"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 15. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90ZXh0cmVnaW9uOjdmMjM2M2MzYTgzMzRkYzA4MTM0MzYxMjZjYzY4NWU3XzI1ODg_f507d5b0-7fdb-44b0-a051-ed6fc0665ec1" continuedAt="i900a06420c4b4882af9c01f724a8f623" escape="true">INCOME TAXES</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i900a06420c4b4882af9c01f724a8f623" continuedAt="if9b7cc2457474fdf8118e52f3d48ddd8"><ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90ZXh0cmVnaW9uOjdmMjM2M2MzYTgzMzRkYzA4MTM0MzYxMjZjYzY4NWU3XzI1ODY_d57fadbc-d469-442b-a5bb-46ef1cb366d0" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of the provision for income taxes are as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.964%"><tr><td style="width:1.0%"></td><td style="width:66.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.547%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo1MzU2YmE3MjBkMTI0MjZmODY3MGM2Yzk2MmE4NGM5NS90YWJsZXJhbmdlOjUzNTZiYTcyMGQxMjQyNmY4NjcwYzZjOTYyYTg0Yzk1XzItMS0xLTEtMA_e8f4ebe1-8489-4948-b383-ea0b9904ecb2">3,682</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo1MzU2YmE3MjBkMTI0MjZmODY3MGM2Yzk2MmE4NGM5NS90YWJsZXJhbmdlOjUzNTZiYTcyMGQxMjQyNmY4NjcwYzZjOTYyYTg0Yzk1XzItMy0xLTEtMA_32d4553c-927c-4b31-b0de-f2a76ed4fec0">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo1MzU2YmE3MjBkMTI0MjZmODY3MGM2Yzk2MmE4NGM5NS90YWJsZXJhbmdlOjUzNTZiYTcyMGQxMjQyNmY4NjcwYzZjOTYyYTg0Yzk1XzMtMS0xLTEtMA_6b788fbf-d4e0-48e9-863b-8f81c7425f23">120</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo1MzU2YmE3MjBkMTI0MjZmODY3MGM2Yzk2MmE4NGM5NS90YWJsZXJhbmdlOjUzNTZiYTcyMGQxMjQyNmY4NjcwYzZjOTYyYTg0Yzk1XzMtMy0xLTEtMA_e4fa0f4b-7a72-4f84-ab9a-dd634745e7d6">205</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo1MzU2YmE3MjBkMTI0MjZmODY3MGM2Yzk2MmE4NGM5NS90YWJsZXJhbmdlOjUzNTZiYTcyMGQxMjQyNmY4NjcwYzZjOTYyYTg0Yzk1XzQtMS0xLTEtMA_05bdccbc-a66d-4942-846f-73237fed6849">37</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo1MzU2YmE3MjBkMTI0MjZmODY3MGM2Yzk2MmE4NGM5NS90YWJsZXJhbmdlOjUzNTZiYTcyMGQxMjQyNmY4NjcwYzZjOTYyYTg0Yzk1XzQtMy0xLTEtMA_8a6034d3-e3f8-4a60-a337-13e4e4e08a67">87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo1MzU2YmE3MjBkMTI0MjZmODY3MGM2Yzk2MmE4NGM5NS90YWJsZXJhbmdlOjUzNTZiYTcyMGQxMjQyNmY4NjcwYzZjOTYyYTg0Yzk1XzUtMS0xLTEtMA_80ba231e-675f-457b-8af8-ae5af2b60278">3,839</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo1MzU2YmE3MjBkMTI0MjZmODY3MGM2Yzk2MmE4NGM5NS90YWJsZXJhbmdlOjUzNTZiYTcyMGQxMjQyNmY4NjcwYzZjOTYyYTg0Yzk1XzUtMy0xLTEtMA_353c122f-c12f-41c8-867f-6f3dcde6fa11">130</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Release of valuation allowance due to CARES Act</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="apyx:CARESActIncomeTaxExpenseBenefitValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo1MzU2YmE3MjBkMTI0MjZmODY3MGM2Yzk2MmE4NGM5NS90YWJsZXJhbmdlOjUzNTZiYTcyMGQxMjQyNmY4NjcwYzZjOTYyYTg0Yzk1XzctMS0xLTEtMzg2NQ_1329db28-14b3-4df3-b708-d237614756ac">3,664</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="apyx:CARESActIncomeTaxExpenseBenefitValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo1MzU2YmE3MjBkMTI0MjZmODY3MGM2Yzk2MmE4NGM5NS90YWJsZXJhbmdlOjUzNTZiYTcyMGQxMjQyNmY4NjcwYzZjOTYyYTg0Yzk1XzctMy0xLTEtMzg2Nw_545b6a32-7d95-4463-b763-fdbb91c1d1e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="apyx:CurrentIncomeTaxExpenseBenefitAfterValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo1MzU2YmE3MjBkMTI0MjZmODY3MGM2Yzk2MmE4NGM5NS90YWJsZXJhbmdlOjUzNTZiYTcyMGQxMjQyNmY4NjcwYzZjOTYyYTg0Yzk1XzgtMS0xLTEtMzg2NQ_d32de340-ae0f-46c5-b70a-099fc47af10b">7,503</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" sign="-" name="apyx:CurrentIncomeTaxExpenseBenefitAfterValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo1MzU2YmE3MjBkMTI0MjZmODY3MGM2Yzk2MmE4NGM5NS90YWJsZXJhbmdlOjUzNTZiYTcyMGQxMjQyNmY4NjcwYzZjOTYyYTg0Yzk1XzgtMy0xLTEtMzg2Nw_448dcf26-7452-4954-af6c-527e418a6d53">130</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo1MzU2YmE3MjBkMTI0MjZmODY3MGM2Yzk2MmE4NGM5NS90YWJsZXJhbmdlOjUzNTZiYTcyMGQxMjQyNmY4NjcwYzZjOTYyYTg0Yzk1XzctMS0xLTEtMA_43770109-dee6-4073-b3f3-f0583fc7a2a0">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo1MzU2YmE3MjBkMTI0MjZmODY3MGM2Yzk2MmE4NGM5NS90YWJsZXJhbmdlOjUzNTZiYTcyMGQxMjQyNmY4NjcwYzZjOTYyYTg0Yzk1XzctMy0xLTEtMA_4202c2c8-a029-4ae9-a5e3-02689347f40d">3,989</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo1MzU2YmE3MjBkMTI0MjZmODY3MGM2Yzk2MmE4NGM5NS90YWJsZXJhbmdlOjUzNTZiYTcyMGQxMjQyNmY4NjcwYzZjOTYyYTg0Yzk1XzgtMS0xLTEtMA_a1d6749b-05ff-41db-b49f-796c5ae8d94b">1,004</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo1MzU2YmE3MjBkMTI0MjZmODY3MGM2Yzk2MmE4NGM5NS90YWJsZXJhbmdlOjUzNTZiYTcyMGQxMjQyNmY4NjcwYzZjOTYyYTg0Yzk1XzgtMy0xLTEtMA_37a55291-206f-4f6f-a013-7bc2d4f2cf6e">741</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo1MzU2YmE3MjBkMTI0MjZmODY3MGM2Yzk2MmE4NGM5NS90YWJsZXJhbmdlOjUzNTZiYTcyMGQxMjQyNmY4NjcwYzZjOTYyYTg0Yzk1XzEwLTEtMS0xLTA_b6f2d135-041e-4b4b-b6b0-90cef1d24f08">1,029</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo1MzU2YmE3MjBkMTI0MjZmODY3MGM2Yzk2MmE4NGM5NS90YWJsZXJhbmdlOjUzNTZiYTcyMGQxMjQyNmY4NjcwYzZjOTYyYTg0Yzk1XzEwLTMtMS0xLTA_fe863261-9e34-4ac4-b79e-92b23d64d28e">4,730</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="apyx:IncomeTaxExpenseBenefitValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo1MzU2YmE3MjBkMTI0MjZmODY3MGM2Yzk2MmE4NGM5NS90YWJsZXJhbmdlOjUzNTZiYTcyMGQxMjQyNmY4NjcwYzZjOTYyYTg0Yzk1XzEyLTEtMS0xLTA_d1c8f555-eb05-43d8-affb-4702c12ba0fa">1,029</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="apyx:IncomeTaxExpenseBenefitValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo1MzU2YmE3MjBkMTI0MjZmODY3MGM2Yzk2MmE4NGM5NS90YWJsZXJhbmdlOjUzNTZiYTcyMGQxMjQyNmY4NjcwYzZjOTYyYTg0Yzk1XzEyLTMtMS0xLTA_87e9e19f-15b9-49dc-9818-c24a1da4f261">4,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total provision for income tax</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo1MzU2YmE3MjBkMTI0MjZmODY3MGM2Yzk2MmE4NGM5NS90YWJsZXJhbmdlOjUzNTZiYTcyMGQxMjQyNmY4NjcwYzZjOTYyYTg0Yzk1XzE0LTEtMS0xLTA_b6e1cb38-84cd-49b0-8de5-1dce7415bbfb">7,503</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo1MzU2YmE3MjBkMTI0MjZmODY3MGM2Yzk2MmE4NGM5NS90YWJsZXJhbmdlOjUzNTZiYTcyMGQxMjQyNmY4NjcwYzZjOTYyYTg0Yzk1XzE0LTMtMS0xLTA_5debeb81-835a-438a-818a-f95c00ac32a4">130</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90ZXh0cmVnaW9uOjdmMjM2M2MzYTgzMzRkYzA4MTM0MzYxMjZjYzY4NWU3XzI1OTM_b0dad329-0858-4bbb-9a30-866b47ca327b" escape="true"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a reconciliation of the statutory federal income tax rate to the Company's effective tax rate:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.029%"><tr><td style="width:1.0%"></td><td style="width:67.053%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.569%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.440%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal tax provision</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTpmNGY2ZTZiMzJmMjQ0OGU5OWE4MzRjMmYwOTJhMjdmYi90YWJsZXJhbmdlOmY0ZjZlNmIzMmYyNDQ4ZTk5YTgzNGMyZjA5MmEyN2ZiXzItMS0xLTEtMA_e7c6aac3-770a-443c-9824-341690c1cd8b">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTpmNGY2ZTZiMzJmMjQ0OGU5OWE4MzRjMmYwOTJhMjdmYi90YWJsZXJhbmdlOmY0ZjZlNmIzMmYyNDQ4ZTk5YTgzNGMyZjA5MmEyN2ZiXzItMy0xLTEtMA_660ae1ff-d1c0-46e0-a199-0d938512c10a">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes (net of federal benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTpmNGY2ZTZiMzJmMjQ0OGU5OWE4MzRjMmYwOTJhMjdmYi90YWJsZXJhbmdlOmY0ZjZlNmIzMmYyNDQ4ZTk5YTgzNGMyZjA5MmEyN2ZiXzMtMS0xLTEtMA_25843662-d1b1-4994-94b1-7b31fc8b0f96">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTpmNGY2ZTZiMzJmMjQ0OGU5OWE4MzRjMmYwOTJhMjdmYi90YWJsZXJhbmdlOmY0ZjZlNmIzMmYyNDQ4ZTk5YTgzNGMyZjA5MmEyN2ZiXzMtMy0xLTEtMA_d82593ab-5b7a-4f3f-8908-71469ab1b150">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTpmNGY2ZTZiMzJmMjQ0OGU5OWE4MzRjMmYwOTJhMjdmYi90YWJsZXJhbmdlOmY0ZjZlNmIzMmYyNDQ4ZTk5YTgzNGMyZjA5MmEyN2ZiXzUtMS0xLTEtMA_9277d018-caf0-4739-8c3a-da52d55a299c">5.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTpmNGY2ZTZiMzJmMjQ0OGU5OWE4MzRjMmYwOTJhMjdmYi90YWJsZXJhbmdlOmY0ZjZlNmIzMmYyNDQ4ZTk5YTgzNGMyZjA5MmEyN2ZiXzUtMy0xLTEtMA_4108838c-5865-43c0-94f0-00954268923c">23.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOL carryback from CARES Act</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="3" name="apyx:EffectiveIncomeTaxRateReconciliationCARESActNetOperatingLossCarryforwardsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTpmNGY2ZTZiMzJmMjQ0OGU5OWE4MzRjMmYwOTJhMjdmYi90YWJsZXJhbmdlOmY0ZjZlNmIzMmYyNDQ4ZTk5YTgzNGMyZjA5MmEyN2ZiXzctMS0xLTEtMzg3MQ_59e22906-5422-472a-87fd-9377f1c7e923">18.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="3" format="ixt:zerodash" name="apyx:EffectiveIncomeTaxRateReconciliationCARESActNetOperatingLossCarryforwardsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTpmNGY2ZTZiMzJmMjQ0OGU5OWE4MzRjMmYwOTJhMjdmYi90YWJsZXJhbmdlOmY0ZjZlNmIzMmYyNDQ4ZTk5YTgzNGMyZjA5MmEyN2ZiXzctMy0xLTEtMzg3Mw_49e41035-c076-44e3-8439-950a6919fc0e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTpmNGY2ZTZiMzJmMjQ0OGU5OWE4MzRjMmYwOTJhMjdmYi90YWJsZXJhbmdlOmY0ZjZlNmIzMmYyNDQ4ZTk5YTgzNGMyZjA5MmEyN2ZiXzctMS0xLTEtMA_66b4fba0-04ed-4b5f-93fa-164e37a27874">1.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTpmNGY2ZTZiMzJmMjQ0OGU5OWE4MzRjMmYwOTJhMjdmYi90YWJsZXJhbmdlOmY0ZjZlNmIzMmYyNDQ4ZTk5YTgzNGMyZjA5MmEyN2ZiXzctMy0xLTEtMA_397e350a-e20a-452e-a15a-ee97f2e9d68f">0.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductions" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTpmNGY2ZTZiMzJmMjQ0OGU5OWE4MzRjMmYwOTJhMjdmYi90YWJsZXJhbmdlOmY0ZjZlNmIzMmYyNDQ4ZTk5YTgzNGMyZjA5MmEyN2ZiXzgtMS0xLTEtMA_51082198-d5ee-4e94-8e69-b535fa72a6a1">38.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductions" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTpmNGY2ZTZiMzJmMjQ0OGU5OWE4MzRjMmYwOTJhMjdmYi90YWJsZXJhbmdlOmY0ZjZlNmIzMmYyNDQ4ZTk5YTgzNGMyZjA5MmEyN2ZiXzgtMy0xLTEtMA_32d84137-3535-4178-971c-9fcfbaad3042">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90ZXh0cmVnaW9uOjdmMjM2M2MzYTgzMzRkYzA4MTM0MzYxMjZjYzY4NWU3XzI1NjU_3cd1b758-9dfa-4f36-93f5-630137904b8e" continuedAt="ib23d6c1a75004a36b7b923fa56c43dec" escape="true">Major components of the Company&#8217;s deferred tax assets (liabilities) are as follows: </ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div></div><ix:continuation id="if9b7cc2457474fdf8118e52f3d48ddd8" continuedAt="i0dd87b09e01e48fda0262d969e71b047"><div style="margin-bottom:5pt;margin-top:5pt"><ix:continuation id="ib23d6c1a75004a36b7b923fa56c43dec"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.352%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss and credit carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo0ZTI1NjdiZGNjMjg0NDYxOTQ5OTFiYmZhMDAxNjE3MS90YWJsZXJhbmdlOjRlMjU2N2JkY2MyODQ0NjE5NDk5MWJiZmEwMDE2MTcxXzItMS0xLTEtMA_17bf95a8-8b43-4a78-89a3-22d565c581bc">1,888</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo0ZTI1NjdiZGNjMjg0NDYxOTQ5OTFiYmZhMDAxNjE3MS90YWJsZXJhbmdlOjRlMjU2N2JkY2MyODQ0NjE5NDk5MWJiZmEwMDE2MTcxXzItMy0xLTEtMA_3a745ca0-d32c-4df1-8667-30babb198f56">4,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo0ZTI1NjdiZGNjMjg0NDYxOTQ5OTFiYmZhMDAxNjE3MS90YWJsZXJhbmdlOjRlMjU2N2JkY2MyODQ0NjE5NDk5MWJiZmEwMDE2MTcxXzMtMS0xLTEtMA_7e852fec-7034-4af2-b210-171accdb837b">1,603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo0ZTI1NjdiZGNjMjg0NDYxOTQ5OTFiYmZhMDAxNjE3MS90YWJsZXJhbmdlOjRlMjU2N2JkY2MyODQ0NjE5NDk5MWJiZmEwMDE2MTcxXzMtMy0xLTEtMA_be4fb0bd-dc30-4b57-bba8-860da8300b35">1,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo0ZTI1NjdiZGNjMjg0NDYxOTQ5OTFiYmZhMDAxNjE3MS90YWJsZXJhbmdlOjRlMjU2N2JkY2MyODQ0NjE5NDk5MWJiZmEwMDE2MTcxXzYtMS0xLTEtMA_779390ba-0bf0-4b36-98cd-f80d70954141">745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo0ZTI1NjdiZGNjMjg0NDYxOTQ5OTFiYmZhMDAxNjE3MS90YWJsZXJhbmdlOjRlMjU2N2JkY2MyODQ0NjE5NDk5MWJiZmEwMDE2MTcxXzYtMy0xLTEtMA_53a983f2-5b57-4938-be9e-60b5daf485b9">1,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo0ZTI1NjdiZGNjMjg0NDYxOTQ5OTFiYmZhMDAxNjE3MS90YWJsZXJhbmdlOjRlMjU2N2JkY2MyODQ0NjE5NDk5MWJiZmEwMDE2MTcxXzctMS0xLTEtMA_c050e7b5-4fc5-4316-bf97-183d73901b72">4,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo0ZTI1NjdiZGNjMjg0NDYxOTQ5OTFiYmZhMDAxNjE3MS90YWJsZXJhbmdlOjRlMjU2N2JkY2MyODQ0NjE5NDk5MWJiZmEwMDE2MTcxXzctMy0xLTEtMA_dbb97eac-a178-44c0-bbfa-173b1358e404">6,916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo0ZTI1NjdiZGNjMjg0NDYxOTQ5OTFiYmZhMDAxNjE3MS90YWJsZXJhbmdlOjRlMjU2N2JkY2MyODQ0NjE5NDk5MWJiZmEwMDE2MTcxXzgtMS0xLTEtMA_479f6525-aa0e-4daa-b32c-baa8f45ca281">3,837</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo0ZTI1NjdiZGNjMjg0NDYxOTQ5OTFiYmZhMDAxNjE3MS90YWJsZXJhbmdlOjRlMjU2N2JkY2MyODQ0NjE5NDk5MWJiZmEwMDE2MTcxXzgtMy0xLTEtMA_99fe4e61-fc42-4852-9461-3d260843214b">6,472</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets, net of valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo0ZTI1NjdiZGNjMjg0NDYxOTQ5OTFiYmZhMDAxNjE3MS90YWJsZXJhbmdlOjRlMjU2N2JkY2MyODQ0NjE5NDk5MWJiZmEwMDE2MTcxXzktMS0xLTEtMA_e1b6e50e-ab16-4cb6-bb78-1a8d78218d35">399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo0ZTI1NjdiZGNjMjg0NDYxOTQ5OTFiYmZhMDAxNjE3MS90YWJsZXJhbmdlOjRlMjU2N2JkY2MyODQ0NjE5NDk5MWJiZmEwMDE2MTcxXzktMy0xLTEtMA_c3f7d0e9-418d-4a7c-89f7-d7e207bc9112">444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo0ZTI1NjdiZGNjMjg0NDYxOTQ5OTFiYmZhMDAxNjE3MS90YWJsZXJhbmdlOjRlMjU2N2JkY2MyODQ0NjE5NDk5MWJiZmEwMDE2MTcxXzEyLTEtMS0xLTA_2ac815ab-2d11-4364-bcf2-33798c066e56">278</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo0ZTI1NjdiZGNjMjg0NDYxOTQ5OTFiYmZhMDAxNjE3MS90YWJsZXJhbmdlOjRlMjU2N2JkY2MyODQ0NjE5NDk5MWJiZmEwMDE2MTcxXzEyLTMtMS0xLTA_526e3968-51c4-4f72-b0eb-f6468eeed09c">245</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo0ZTI1NjdiZGNjMjg0NDYxOTQ5OTFiYmZhMDAxNjE3MS90YWJsZXJhbmdlOjRlMjU2N2JkY2MyODQ0NjE5NDk5MWJiZmEwMDE2MTcxXzE0LTEtMS0xLTA_bd62a931-34bc-4cd5-9fb5-a78b25e1ef6a">121</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo0ZTI1NjdiZGNjMjg0NDYxOTQ5OTFiYmZhMDAxNjE3MS90YWJsZXJhbmdlOjRlMjU2N2JkY2MyODQ0NjE5NDk5MWJiZmEwMDE2MTcxXzE0LTMtMS0xLTM4NzU_4562b58a-6aa8-4f02-addd-816712b45c49">199</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo0ZTI1NjdiZGNjMjg0NDYxOTQ5OTFiYmZhMDAxNjE3MS90YWJsZXJhbmdlOjRlMjU2N2JkY2MyODQ0NjE5NDk5MWJiZmEwMDE2MTcxXzE1LTEtMS0xLTA_9c2dc4a7-16e6-4088-9736-b846cd003d02">399</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo0ZTI1NjdiZGNjMjg0NDYxOTQ5OTFiYmZhMDAxNjE3MS90YWJsZXJhbmdlOjRlMjU2N2JkY2MyODQ0NjE5NDk5MWJiZmEwMDE2MTcxXzE1LTMtMS0xLTA_152c741a-e98d-4636-970d-8e5504cb559e">444</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo0ZTI1NjdiZGNjMjg0NDYxOTQ5OTFiYmZhMDAxNjE3MS90YWJsZXJhbmdlOjRlMjU2N2JkY2MyODQ0NjE5NDk5MWJiZmEwMDE2MTcxXzE2LTEtMS0xLTA_0128e8d2-9c07-4fbf-8ad1-5fcc70358a98">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo0ZTI1NjdiZGNjMjg0NDYxOTQ5OTFiYmZhMDAxNjE3MS90YWJsZXJhbmdlOjRlMjU2N2JkY2MyODQ0NjE5NDk5MWJiZmEwMDE2MTcxXzE2LTMtMS0xLTA_9ac4503b-a17c-4a62-8055-93f7ad3a86ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the U.S. government enacted the CARES Act to provide relief from COVID-19. The CARES Act includes a provision that allows companies to carryback net operating losses (NOL&#8217;s) generated in the period 2018 through 2020 to prior years. In conjunction with the disposition of the Core business in 2018, the Company generated a significant amount of taxable income in 2018. Subsequent to this, the Company generated NOLs in 2019 and 2020. For the NOLs generated in 2019, the Company previously recorded a full valuation allowance on the deferred tax assets associated with the NOL due to realization not being probable under then existing tax law. The CARES Act makes these assets realizable and, as of the date of the CARES Act, the Company has recognized an income tax benefit of approximately $<ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="apyx:CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90ZXh0cmVnaW9uOjdmMjM2M2MzYTgzMzRkYzA4MTM0MzYxMjZjYzY4NWU3XzEwOTk1MTE2MzYzMzA_a7ab007b-f34d-4029-bfdc-4e118712e4bb">3.7</ix:nonFraction>&#160;million associated with the release of the valuation allowance on its Federal NOL deferred tax asset from 2019. Additionally, using the provisions of the CARES Act, the Company is carrying back its 2020 Federal NOL of approximately $<ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="apyx:CARESActEffectiveIncomeTaxRateReconciliationFederalNetOperatingLossCarryforwardsAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90ZXh0cmVnaW9uOjdmMjM2M2MzYTgzMzRkYzA4MTM0MzYxMjZjYzY4NWU3XzEwOTk1MTE2MzYzNDQ_bbd19a2a-10f4-468a-8de7-786d8bd031b8">3.7</ix:nonFraction>&#160;million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all positive and negative evidence regarding the realization of deferred tax assets, including past operating results and future sources of taxable income. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers the earnings of Apyx Bulgaria, EOOD to be indefinitely invested outside the United States on the basis of estimates that future domestic cash generation will be sufficient to meet future domestic cash needs and our specific plans for reinvestment of those subsidiary earnings. It has not recorded a deferred tax liability related to the U.S. Federal and State income taxes and foreign withholding taxes on the undistributed earnings of Apyx Bulgaria, EOOD indefinitely invested outside the United States. If it decides to repatriate the foreign earnings, the Company will need to adjust its income tax provision in the period it determines that the earnings will no longer be indefinitely invested outside the United States.&#160; </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the financial statement impact of an uncertain tax position taken or expected to be taken on an income tax return at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An uncertain income tax position will not be recognized in the financial statements unless it is more likely than not of being sustained. As of December 31, 2020 and 2019, the Company has recorded a liability of approximately $<ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90ZXh0cmVnaW9uOjdmMjM2M2MzYTgzMzRkYzA4MTM0MzYxMjZjYzY4NWU3XzE4Njc_0b4d5cf7-5417-4b0d-899a-a852f33b5d8c"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90ZXh0cmVnaW9uOjdmMjM2M2MzYTgzMzRkYzA4MTM0MzYxMjZjYzY4NWU3XzE4Njc_10f811de-c644-48cf-9189-1b05638eb98a">1.3</ix:nonFraction></ix:nonFraction> million related to uncertain tax positions and accrued approximately $<ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90ZXh0cmVnaW9uOjdmMjM2M2MzYTgzMzRkYzA4MTM0MzYxMjZjYzY4NWU3XzcxNDY4MjU1ODkzOTg_df0c13b7-6e43-4446-a4a7-335b30df4d06">0.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90ZXh0cmVnaW9uOjdmMjM2M2MzYTgzMzRkYzA4MTM0MzYxMjZjYzY4NWU3XzE5MjI_1f83a5d8-9741-4711-ab84-43a76684d652">0.2</ix:nonFraction> million, respectively, of interest and penalties on these positions. It is expected that the change in unrecognized tax benefits within the next 12 months will not be significant.  </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90ZXh0cmVnaW9uOjdmMjM2M2MzYTgzMzRkYzA4MTM0MzYxMjZjYzY4NWU3XzI1ODM_aec17595-4541-4414-8a7c-40b6a2e8c212" escape="true"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a roll-forward of the Company's total gross unrecognized tax benefits, not including interest and penalties, for the years ended December 31:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:79.093%"><tr><td style="width:1.0%"></td><td style="width:58.604%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.018%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.569%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.570%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Tax Benefits</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning of year balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTpiNGY4ZWE5MDE0MDg0MGZjYWRjZGFiMGZhMDE2MWI2Mi90YWJsZXJhbmdlOmI0ZjhlYTkwMTQwODQwZmNhZGNkYWIwZmEwMTYxYjYyXzEtMi0xLTEtMA_c9e20297-e213-43c8-91b5-5bcb81b9957a">1,313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00df6877cb2d4b75a1a4abee0d94d57f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTpiNGY4ZWE5MDE0MDg0MGZjYWRjZGFiMGZhMDE2MWI2Mi90YWJsZXJhbmdlOmI0ZjhlYTkwMTQwODQwZmNhZGNkYWIwZmEwMTYxYjYyXzItNC0xLTEtNTM2Nw_0c15f714-c8f8-4463-8040-96547ea2a3db">1,313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions of tax positions related to the current year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTpiNGY4ZWE5MDE0MDg0MGZjYWRjZGFiMGZhMDE2MWI2Mi90YWJsZXJhbmdlOmI0ZjhlYTkwMTQwODQwZmNhZGNkYWIwZmEwMTYxYjYyXzItMi0xLTEtMA_15c0fc01-9f98-4a6b-9e1b-ccd782b4528d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTpiNGY4ZWE5MDE0MDg0MGZjYWRjZGFiMGZhMDE2MWI2Mi90YWJsZXJhbmdlOmI0ZjhlYTkwMTQwODQwZmNhZGNkYWIwZmEwMTYxYjYyXzMtNC0xLTEtNTM2Nw_9f4dd9de-3219-4772-bc9c-a8fafcde6a7f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions of tax positions related to the prior year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTpiNGY4ZWE5MDE0MDg0MGZjYWRjZGFiMGZhMDE2MWI2Mi90YWJsZXJhbmdlOmI0ZjhlYTkwMTQwODQwZmNhZGNkYWIwZmEwMTYxYjYyXzMtMi0xLTEtMA_436c5a37-a0d0-408a-a79b-a36c1deed3ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTpiNGY4ZWE5MDE0MDg0MGZjYWRjZGFiMGZhMDE2MWI2Mi90YWJsZXJhbmdlOmI0ZjhlYTkwMTQwODQwZmNhZGNkYWIwZmEwMTYxYjYyXzQtNC0xLTEtNTM2Nw_66aaa0a2-b72a-41e7-97c2-55e831472092">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases for tax positions related to prior year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTpiNGY4ZWE5MDE0MDg0MGZjYWRjZGFiMGZhMDE2MWI2Mi90YWJsZXJhbmdlOmI0ZjhlYTkwMTQwODQwZmNhZGNkYWIwZmEwMTYxYjYyXzQtMi0xLTEtMA_05120607-d09d-422b-af3a-8301909490a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTpiNGY4ZWE5MDE0MDg0MGZjYWRjZGFiMGZhMDE2MWI2Mi90YWJsZXJhbmdlOmI0ZjhlYTkwMTQwODQwZmNhZGNkYWIwZmEwMTYxYjYyXzUtNC0xLTEtNTM2Nw_59db85ac-c53a-41b2-ac01-1ad88d3a2805">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">End of year balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTpiNGY4ZWE5MDE0MDg0MGZjYWRjZGFiMGZhMDE2MWI2Mi90YWJsZXJhbmdlOmI0ZjhlYTkwMTQwODQwZmNhZGNkYWIwZmEwMTYxYjYyXzUtMi0xLTEtMA_546730f4-28ea-401c-9558-4d52f4e15853">1,313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTpiNGY4ZWE5MDE0MDg0MGZjYWRjZGFiMGZhMDE2MWI2Mi90YWJsZXJhbmdlOmI0ZjhlYTkwMTQwODQwZmNhZGNkYWIwZmEwMTYxYjYyXzYtNC0xLTEtNTM2Nw_736bcbb8-9c1b-462b-9f04-bdb783da2be1">1,313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0dd87b09e01e48fda0262d969e71b047">The Company is subject to U.S. federal and state income tax examination.  The Company&#8217;s 2017 through 2019 U.S. federal income tax returns are subject to examination by the Internal Revenue Service.  The Company&#8217;s state income tax returns are subject to examination for the 2016 through 2019 tax years.</ix:continuation></span></div><div><span><br/></span></div><div><span><br/></span></div><div id="idb46c8b71d7d4a27b277b6db52f68e8e_127"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 16. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjcvZnJhZzplY2EwOWM4ODg5MmE0Njk1ODc3MDBkMTEzNjIwYTBkNS90ZXh0cmVnaW9uOmVjYTA5Yzg4ODkyYTQ2OTU4NzcwMGQxMTM2MjBhMGQ1XzkzNA_3ad78e67-17f2-4177-ba5a-ea7b728664e4" continuedAt="i1ecc6523fe9940a09c3f474895ad41af" escape="true">RETIREMENT PLAN</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i1ecc6523fe9940a09c3f474895ad41af"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides a tax-qualified profit-sharing retirement plan under section 401(k) of the Internal Revenue Code for the benefit of eligible employees with an accumulation of funds for retirement on a tax-deferred basis and provides for annual discretionary contribution to individual trust funds.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All employees are eligible to participate upon completing three months of service. The employees may make voluntary contributions to the plan up to the maximum percentage allowed by the Internal Revenue Code. Vesting in employee matching contributions is graded and depends on the years of service. After <ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" format="ixt-sec:durwordsen" name="apyx:DefinedContributionPlanEmployersMatchingContributionVestingPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjcvZnJhZzplY2EwOWM4ODg5MmE0Njk1ODc3MDBkMTEzNjIwYTBkNS90ZXh0cmVnaW9uOmVjYTA5Yzg4ODkyYTQ2OTU4NzcwMGQxMTM2MjBhMGQ1XzY0MQ_222b8728-1acc-43e9-af08-798fd7e778f2">three years</ix:nonNumeric> from their date of hire, the employees are <ix:nonFraction unitRef="number" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="INF" name="apyx:DefinedContributionPlanEmployersMatchingContributionVestingPercentageAfterThreeYears" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjcvZnJhZzplY2EwOWM4ODg5MmE0Njk1ODc3MDBkMTEzNjIwYTBkNS90ZXh0cmVnaW9uOmVjYTA5Yzg4ODkyYTQ2OTU4NzcwMGQxMTM2MjBhMGQ1XzY4Nw_ca936040-be55-475f-b1b3-cf451a01078f">100</ix:nonFraction>% vested. The Company makes matching contributions of <ix:nonFraction unitRef="number" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjcvZnJhZzplY2EwOWM4ODg5MmE0Njk1ODc3MDBkMTEzNjIwYTBkNS90ZXh0cmVnaW9uOmVjYTA5Yzg4ODkyYTQ2OTU4NzcwMGQxMTM2MjBhMGQ1Xzc0Mg_ab2b03e7-0b06-4ec0-929f-7455a6f84656">50</ix:nonFraction>% of the employee contributions up to a total of <ix:nonFraction unitRef="number" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="2" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjcvZnJhZzplY2EwOWM4ODg5MmE0Njk1ODc3MDBkMTEzNjIwYTBkNS90ZXh0cmVnaW9uOmVjYTA5Yzg4ODkyYTQ2OTU4NzcwMGQxMTM2MjBhMGQ1Xzc5Mg_85a6945d-29f9-4805-9b85-ebbda268f926">3</ix:nonFraction>% of participant payroll. Matching contributions made by the Company totaled approximately $<ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjcvZnJhZzplY2EwOWM4ODg5MmE0Njk1ODc3MDBkMTEzNjIwYTBkNS90ZXh0cmVnaW9uOmVjYTA5Yzg4ODkyYTQ2OTU4NzcwMGQxMTM2MjBhMGQ1Xzg3MA_ddd509c3-1b55-4e4e-894e-43d035fb831d"><ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjcvZnJhZzplY2EwOWM4ODg5MmE0Njk1ODc3MDBkMTEzNjIwYTBkNS90ZXh0cmVnaW9uOmVjYTA5Yzg4ODkyYTQ2OTU4NzcwMGQxMTM2MjBhMGQ1Xzg3MA_e6707246-b4c5-40ec-b37a-f9fdd9ae09f8">0.3</ix:nonFraction></ix:nonFraction> million for each of the years ended December&#160;31, 2020 and 2019, respectively.</span></div></ix:continuation><div><span><br/></span></div><div id="idb46c8b71d7d4a27b277b6db52f68e8e_133"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 17. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzMvZnJhZzozNzkyMTk1YzY4ZDQ0OTdjYmFkYzZkNWRkNWM5NjBjYi90ZXh0cmVnaW9uOjM3OTIxOTVjNjhkNDQ5N2NiYWRjNmQ1ZGQ1Yzk2MGNiXzY1Ng_e5639371-b369-4176-8576-e85814387ec5" continuedAt="i855b0b7feb584ac8b7448b2c3f107d90" escape="true">RELATED PARTY TRANSACTIONS</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i855b0b7feb584ac8b7448b2c3f107d90"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several relatives of Nikolay Shilev, Apyx Bulgaria&#8217;s Managing Director, are considered related parties. Teodora Shileva, Mr. Shilev&#8217;s spouse, is an employee of the Company working in the accounting department. Antoaneta Dimitrova Shileva-Tor</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">omanova, Mr. Shilev&#8217;s sister, is the manager of human resources. Svetoslav Shilev, Mr. Shilev&#8217;s son, is a quality manager in the quality assurance department. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as part of the purchase of the Apyx Bulgaria manufacturing facility, Mr. Shilev was issued a note payable for $<ix:nonFraction unitRef="usd" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayableRelatedPartiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzMvZnJhZzozNzkyMTk1YzY4ZDQ0OTdjYmFkYzZkNWRkNWM5NjBjYi90ZXh0cmVnaW9uOjM3OTIxOTVjNjhkNDQ5N2NiYWRjNmQ1ZGQ1Yzk2MGNiXzU3Mw_42b7ca02-268d-484f-b878-fcdb9c6c5b77">0.1</ix:nonFraction> million, which was paid in full on October 20, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The partner in the Company's China joint venture is also a supplie</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r of the Company. For the years ended December 31, 2020 and 2019, the Company made purchases from this supplier of approximately $<ix:nonFraction unitRef="usd" contextRef="i8ae0b3b25b524ed89da35d0c86ded00e_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzMvZnJhZzozNzkyMTk1YzY4ZDQ0OTdjYmFkYzZkNWRkNWM5NjBjYi90ZXh0cmVnaW9uOjM3OTIxOTVjNjhkNDQ5N2NiYWRjNmQ1ZGQ1Yzk2MGNiXzEwOTk1MTE2Mjk0NTM_3f053f04-759a-4e88-9d5c-87e75d92d4f8">1,441,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i42b2e2edfea349f6bef6deafaa0b9c9f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzMvZnJhZzozNzkyMTk1YzY4ZDQ0OTdjYmFkYzZkNWRkNWM5NjBjYi90ZXh0cmVnaW9uOjM3OTIxOTVjNjhkNDQ5N2NiYWRjNmQ1ZGQ1Yzk2MGNiXzEwOTk1MTE2Mjk0ODM_3b93a7bc-b87f-46de-8e7b-1659412bf9f8">2,643,000</ix:nonFraction>, respectively. At December 31, 2020 and 2019, respectively, the Company owed this supplier approximately $<ix:nonFraction unitRef="usd" contextRef="ie2101546a5f04f93a9393b9ac203e960_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzMvZnJhZzozNzkyMTk1YzY4ZDQ0OTdjYmFkYzZkNWRkNWM5NjBjYi90ZXh0cmVnaW9uOjM3OTIxOTVjNjhkNDQ5N2NiYWRjNmQ1ZGQ1Yzk2MGNiXzEwOTk1MTE2Mjk0NjU_ccfc1d86-48c6-46e2-8264-c796e93446c7">38,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i324ce5f416944371b0b0f1514f0a8c83_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzMvZnJhZzozNzkyMTk1YzY4ZDQ0OTdjYmFkYzZkNWRkNWM5NjBjYi90ZXh0cmVnaW9uOjM3OTIxOTVjNjhkNDQ5N2NiYWRjNmQ1ZGQ1Yzk2MGNiXzEwOTk1MTE2Mjk0NzQ_8eaf31a9-c78c-445d-96ff-0601f5f46a19">29,000</ix:nonFraction>, respective</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ly.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="idb46c8b71d7d4a27b277b6db52f68e8e_136"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 18. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzYvZnJhZzoxZDA2ZDA3NjQ1MGI0NDE4ODI5MTgzYTBhYTI5ZmNlNC90ZXh0cmVnaW9uOjFkMDZkMDc2NDUwYjQ0MTg4MjkxODNhMGFhMjlmY2U0XzcwMTI_5ad9b86c-543d-4187-b296-caeb0e0163d0" continuedAt="ideb78499fee9452581b199c7f1a0ad4c" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ideb78499fee9452581b199c7f1a0ad4c" continuedAt="i37af3d0ae622475ba6681d407c18a609"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The medical device industry is characterized by frequent claims and litigation, and the Company may become subject to various claims, lawsuits and proceedings in the ordinary course of our business. Such claims may include claims by current or former employees, distributors and competitors, claims concerning the marketing and promotion of our products and product liability claims.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is involved in a number of legal actions relating to the use of our Helium Plasma technology. The outcomes of these legal actions are not within the Company&#8217;s complete control and may not be known for prolonged periods of time. It believes that such claims are adequately covered by insurance; however, in the case of one of the Company&#8217;s carriers, the Company is in a dispute regarding the total level of coverage available. Notwithstanding the foregoing, in the opinion of management, the Company has meritorious defenses, and such claims are not expected, individually or in the aggregate, to result in a material, adverse effect on its financial condition, results of operations and cash flows. However, in the event that damages exceed the aggregate coverage limits of the Company&#8217;s policies or if its insurance carriers disclaim coverage, management believes it is possible that costs associated with these claims could have a material adverse impact on the consolidated financial condition, results of operations and cash flows.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 17, 2019, a complaint (the &#8220;Complaint&#8221;) was filed in the United States District Court for the Middle District of Florida, against the Company and Charles D. Goodwin, the Company&#8217;s President and Chief Executive Officer and a member of the Company&#8217;s Board of Directors, alleging certain violations of the Securities Exchange Act of 1934, as amended.  On July 16, 2019, the Court appointed lead plaintiff for the putative class and approved the lead plaintiff&#8217;s selection of counsel. On September 3, 2019, lead plaintiff filed an amended complaint (the &#8220;Amended Complaint&#8221;) with the Court. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i37af3d0ae622475ba6681d407c18a609" continuedAt="iee927d87f71f4af0881c7a432906f520"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Complaint seeks class action status on behalf of all persons and entities that acquired the Company&#8217;s securities between December 21, 2018 and April 1, 2019, and alleges violations by the Company and Goodwin of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended and Rule 10b-5 thereunder, primarily related to certain public statements concerning the Premarket Notification 510(k) submission made to the US Food and Drug Administration for a new indication for the Company&#8217;s J-Plasma&#174; technology for use in dermal resurfacing procedures.  On October 3, 2019, defendants filed a motion to dismiss the Amended Complaint, and on March 11, 2020, the Court denied that motion.  On July 10, 2020, the parties executed a settlement agreement, which was subject to Court approval. The Court preliminarily approved the settlement on July 21, 2020. The settlement agreement provides for the dismissal of the action with prejudice. On November 6, 2020, the Court issued its final order approving the settlement and dismissing the action and all claims contained in the Amended Complaint with prejudice. At December 31, 2020, the Company has settled and fully paid all obligations related to this matter. Included in selling, general and administrative expenses for the year ended December 31, 2019 is $<ix:nonFraction unitRef="usd" contextRef="i33ad88dc3b434353b50eb3acfab694d4_I20191231" decimals="-6" format="ixt:numdotdecimal" name="apyx:LossContingencyAccrualTotalAccruedToDate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzYvZnJhZzoxZDA2ZDA3NjQ1MGI0NDE4ODI5MTgzYTBhYTI5ZmNlNC90ZXh0cmVnaW9uOjFkMDZkMDc2NDUwYjQ0MTg4MjkxODNhMGFhMjlmY2U0XzEwOTk1MTE2NTE1MTI_9ee52496-ab1b-4a0c-a3ab-a9a0fdcfd7a7">1,000,000</ix:nonFraction> for the matter. At December 31, 2019, the Company had accrued $<ix:nonFraction unitRef="usd" contextRef="i33ad88dc3b434353b50eb3acfab694d4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzYvZnJhZzoxZDA2ZDA3NjQ1MGI0NDE4ODI5MTgzYTBhYTI5ZmNlNC90ZXh0cmVnaW9uOjFkMDZkMDc2NDUwYjQ0MTg4MjkxODNhMGFhMjlmY2U0XzEwOTk1MTE2NTE1MDI_93d805f9-9c27-4345-be55-b1d71c241a2d">820,000</ix:nonFraction> for the matter.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accrues a liability in our consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is recorded. If a loss is reasonably possible, but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the consolidated financial statements. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded, actual results may differ from these estimates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchase Commitments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, the Company has purchase commitments for inventories totaling approximately $<ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PurchaseObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzYvZnJhZzoxZDA2ZDA3NjQ1MGI0NDE4ODI5MTgzYTBhYTI5ZmNlNC90ZXh0cmVnaW9uOjFkMDZkMDc2NDUwYjQ0MTg4MjkxODNhMGFhMjlmY2U0XzEwOTk1MTE2NTA2Nzk_048c3282-bfa0-4a06-b5ba-b5b92847a258">1.9</ix:nonFraction>&#160;million, substantially all of which is expected to be purchased by the end of 2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">China Joint Venture</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Company's agreement in the China joint venture requires it to make a capital contribution into the newly formed entity of $<ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" format="ixt:numdotdecimal" name="apyx:NoncontrollingInterestRequiredCapitalContribution" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzYvZnJhZzoxZDA2ZDA3NjQ1MGI0NDE4ODI5MTgzYTBhYTI5ZmNlNC90ZXh0cmVnaW9uOjFkMDZkMDc2NDUwYjQ0MTg4MjkxODNhMGFhMjlmY2U0XzEwOTk1MTE2NTA2OTM_d43e19b8-8e5b-4882-933a-403de3657d43">357,000</ix:nonFraction>. As of the date of these consolidated financial statements, approximately $<ix:nonFraction unitRef="usd" contextRef="i24f804d243d24666a8bc91f19e0bc3dc_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="apyx:PaymentsToAcquireInterestInJointVentureRemaining" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzYvZnJhZzoxZDA2ZDA3NjQ1MGI0NDE4ODI5MTgzYTBhYTI5ZmNlNC90ZXh0cmVnaW9uOjFkMDZkMDc2NDUwYjQ0MTg4MjkxODNhMGFhMjlmY2U0XzEwOTk1MTE2NTA3MDg_6cb6e084-0d0c-4c11-b919-9b58c430fee1">203,000</ix:nonFraction> of its capital commitment remains to be funded.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations</span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iee927d87f71f4af0881c7a432906f520">Sales to one customer within the OEM segment represented <ix:nonFraction unitRef="number" contextRef="i0a42214a67b14472a2d145b68faf883b_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzYvZnJhZzoxZDA2ZDA3NjQ1MGI0NDE4ODI5MTgzYTBhYTI5ZmNlNC90ZXh0cmVnaW9uOjFkMDZkMDc2NDUwYjQ0MTg4MjkxODNhMGFhMjlmY2U0XzEwOTk1MTE2NTA3MDM_0f957672-7d79-438c-8a4c-3cbfeee999b6">10</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i1a14786bb32f4b7fbd8311532b5e461e_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzYvZnJhZzoxZDA2ZDA3NjQ1MGI0NDE4ODI5MTgzYTBhYTI5ZmNlNC90ZXh0cmVnaW9uOjFkMDZkMDc2NDUwYjQ0MTg4MjkxODNhMGFhMjlmY2U0XzY4NDc_53887b0a-c0db-4c06-9415-46b6be496607">11</ix:nonFraction>% of total sales for the year ended December 31, 2020 and 2019, respectively.</ix:continuation> </span></div><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><div id="idb46c8b71d7d4a27b277b6db52f68e8e_139"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 19. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzY2MTI_026e854d-d6a4-42aa-8925-bdd42b2553bc" continuedAt="i676b61cf448e463cb6725766a03e9742" escape="true">STOCK OPTIONS&#160;</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i676b61cf448e463cb6725766a03e9742" continuedAt="i142125817431496791f71f31e1d1a073"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 30, 2007, the Company's stockholders approved, and the Board of Directors adopted an amendment to the 2003 Executive and Employee Stock Option Plan (the &#8220;Plan&#8221;) to increase the maximum aggregate number of shares of common stock reserved for issuance under the Plan from <ix:nonFraction unitRef="shares" contextRef="i6ccc3072ced640849dd9bbd33abe34e5_I20011231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzMwMQ_3b30e80a-0642-4ba2-bdc8-ef20a07fbbff">1.2</ix:nonFraction> million shares (already reserved against outstanding options) to <ix:nonFraction unitRef="shares" contextRef="id2069ea94eb1477bb94891296fd7ccf0_I20071030" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzM2MQ_4b3f8304-b45e-451e-933b-086534d7d9a2">1.7</ix:nonFraction> million shares. Except for the increase in the number of shares covered by the Plan, the Plan remained otherwise unchanged. In 2001, the Board of Directors adopted the 2001 Executive and Employee Stock Option Plan which reserved for issuance <ix:nonFraction unitRef="shares" contextRef="i6ccc3072ced640849dd9bbd33abe34e5_I20011231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzU5OA_3b30e80a-0642-4ba2-bdc8-ef20a07fbbff">1.2</ix:nonFraction> million stock options. Stock options to employees typically have a <ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzEwOTk1MTE2MzcxMDE_401b01c7-9b18-4af9-8e20-bb1062014f92">ten-year</ix:nonNumeric> life and currently vest over periods between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzEwOTk1MTE2MzcxMDk_cf9a545e-25f8-4790-a167-4803e9a50ffa">one</span> and <ix:nonNumeric contextRef="i7ec1168e4e6e457abbce2a3267321f39_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzcyMQ_e154b7dc-d1ea-474b-ba54-63b9f9a55010">seven years</ix:nonNumeric>. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2012, the Company's stockholders approved the 2012 Share Incentive Plan covering a total of <ix:nonFraction unitRef="shares" contextRef="i1c9befc04c0e430b8f6bffceacc59a9d_I20120731" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzgyMA_30a8a42e-5a49-46da-998c-a08f2434769e">750,000</ix:nonFraction> shares of common stock issuable upon exercise of options to be granted under the plan. At December&#160;31, 2020 approximately <ix:nonFraction unitRef="shares" contextRef="i8f01e109bd104360a674e88733aec92b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzcxNDY4MjU1ODk1NDg_73ee8d16-1e67-42a7-b882-b48e5ff52b8f">60,000</ix:nonFraction> are available to be issued in this plan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2015, the Company's stockholders approved the 2015 Executive and Employee Stock Option Plan covering a total of <ix:nonFraction unitRef="shares" contextRef="ief0094005e77442fa9d4b4c6c22a8df0_I20150731" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzEwODg_4b356ec3-c660-4a0e-a4ff-27f360e703a6">2,000,000</ix:nonFraction> shares of common stock issuable upon exercise of options to be granted under the plan. At December&#160;31, 2020 approximately <ix:nonFraction unitRef="shares" contextRef="ib4bc94f07ff84f97b245be704259861e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzcxNDY4MjU1ODk1NTY_3c7acb19-3289-4bc6-9a97-9583af76ff96">230,000</ix:nonFraction> are available to be issued in this plan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2017, the Company's stockholders approved the 2017 Executive and Employee Stock Option Plan covering a total of <ix:nonFraction unitRef="shares" contextRef="i74bbca955e6f4c6e8758ac942298fe99_I20170831" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzEzNTg_0459598c-f67b-45cf-8c3c-98bc7bf076ef">3,000,000</ix:nonFraction> shares of common stock issuable upon exercise of options to be granted under the plan. At December&#160;31, 2020 approximately <ix:nonFraction unitRef="shares" contextRef="i04da05110f984d449da3c74c6a62b472_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzEwOTk1MTE2MzY1MTM_ddde27af-f9dd-42d1-a555-53b6436187dd">70,000</ix:nonFraction> are available to be issued in this plan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Company's stockholders approved the 2019 Share Incentive Plan covering a total of <ix:nonFraction unitRef="shares" contextRef="i865b7f7fe4ac4cfba2d0d6c0001de126_I20190831" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzE2MDg_6f17ccb9-57cc-4e71-941f-8621a24a8515">2,000,000</ix:nonFraction> shares of common stock issuable upon exercise of options to be granted under the plan. At December&#160;31, 2020, all <ix:nonFraction unitRef="shares" contextRef="i8dcd8a8a5fd54b70a6dd5754aceae3b0_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzE3MDk_e19f0e5d-7d69-4696-ad38-32b2acef23fc">2,000,000</ix:nonFraction> are available to be issued in this plan.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 29, 2021, the Company granted employees appro</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ximately <ix:nonFraction unitRef="shares" contextRef="ib625f4dfee414563bb1127dd3c30d6a0_D20200129-20200129" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzcxNDY4MjU1ODk1NjU_a117964c-6738-4725-9293-ea58a79c530b">700,000</ix:nonFraction> options to purchase common shares of the Company's stock. All options granted were pursuant to the plans noted above. The options ves</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t over a period of <ix:nonNumeric contextRef="ib625f4dfee414563bb1127dd3c30d6a0_D20200129-20200129" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzE5NzQ_df56b11f-8cc0-4c02-8c28-cbb18705cd2a">three years</ix:nonNumeric>. </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzY2MTk_66bad38f-31aa-41dd-862d-d7dac4cfc49b" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The status of the Company's stock options is summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of options </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i00df6877cb2d4b75a1a4abee0d94d57f_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTo5N2QzNWVmOGUwYjU0YTIzYjIzYzFlYzJkM2Q3ZmMyNy90YWJsZXJhbmdlOjk3ZDM1ZWY4ZTBiNTRhMjNiMjNjMWVjMmQzZDdmYzI3XzEzLTEtMS0xLTA_9d5c6b8d-1c79-46de-b43f-983348bac51e">3,254,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i00df6877cb2d4b75a1a4abee0d94d57f_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTo5N2QzNWVmOGUwYjU0YTIzYjIzYzFlYzJkM2Q3ZmMyNy90YWJsZXJhbmdlOjk3ZDM1ZWY4ZTBiNTRhMjNiMjNjMWVjMmQzZDdmYzI3XzEzLTMtMS0xLTA_9df9bf4b-828a-43b4-b539-b660babf782a">3.18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTo5N2QzNWVmOGUwYjU0YTIzYjIzYzFlYzJkM2Q3ZmMyNy90YWJsZXJhbmdlOjk3ZDM1ZWY4ZTBiNTRhMjNiMjNjMWVjMmQzZDdmYzI3XzE0LTEtMS0xLTA_4726e49b-3a1f-4741-bb29-c90bf57721b4">1,379,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTo5N2QzNWVmOGUwYjU0YTIzYjIzYzFlYzJkM2Q3ZmMyNy90YWJsZXJhbmdlOjk3ZDM1ZWY4ZTBiNTRhMjNiMjNjMWVjMmQzZDdmYzI3XzE0LTMtMS0xLTA_f1edce44-f2bc-4db9-ae01-e82c4033cab2">7.70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTo5N2QzNWVmOGUwYjU0YTIzYjIzYzFlYzJkM2Q3ZmMyNy90YWJsZXJhbmdlOjk3ZDM1ZWY4ZTBiNTRhMjNiMjNjMWVjMmQzZDdmYzI3XzE1LTEtMS0xLTA_59443ff0-e8cd-49e8-b5f5-170fa3c4de6a">410,635</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTo5N2QzNWVmOGUwYjU0YTIzYjIzYzFlYzJkM2Q3ZmMyNy90YWJsZXJhbmdlOjk3ZDM1ZWY4ZTBiNTRhMjNiMjNjMWVjMmQzZDdmYzI3XzE1LTMtMS0xLTA_279131cc-161a-4642-ae11-ecca24eea09a">2.99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTo5N2QzNWVmOGUwYjU0YTIzYjIzYzFlYzJkM2Q3ZmMyNy90YWJsZXJhbmdlOjk3ZDM1ZWY4ZTBiNTRhMjNiMjNjMWVjMmQzZDdmYzI3XzE2LTEtMS0xLTA_8c98c665-d653-41dc-a7ff-3d8dcf367dee">256,785</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTo5N2QzNWVmOGUwYjU0YTIzYjIzYzFlYzJkM2Q3ZmMyNy90YWJsZXJhbmdlOjk3ZDM1ZWY4ZTBiNTRhMjNiMjNjMWVjMmQzZDdmYzI3XzE2LTMtMS0xLTA_06165120-a5f2-495c-a0e0-9f34abde1b35">4.76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTo5N2QzNWVmOGUwYjU0YTIzYjIzYzFlYzJkM2Q3ZmMyNy90YWJsZXJhbmdlOjk3ZDM1ZWY4ZTBiNTRhMjNiMjNjMWVjMmQzZDdmYzI3XzE3LTEtMS0xLTA_7dfe439a-de2e-425a-93a1-188d4c2e7586">3,966,858</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTo5N2QzNWVmOGUwYjU0YTIzYjIzYzFlYzJkM2Q3ZmMyNy90YWJsZXJhbmdlOjk3ZDM1ZWY4ZTBiNTRhMjNiMjNjMWVjMmQzZDdmYzI3XzE3LTMtMS0xLTA_6b116e71-2915-4777-9f3a-63a8940ee31e">4.67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTo5N2QzNWVmOGUwYjU0YTIzYjIzYzFlYzJkM2Q3ZmMyNy90YWJsZXJhbmdlOjk3ZDM1ZWY4ZTBiNTRhMjNiMjNjMWVjMmQzZDdmYzI3XzE4LTEtMS0xLTQwMzg_c3d7bb8c-a8f1-4aa6-8296-981cffaa43fc">1,376,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTo5N2QzNWVmOGUwYjU0YTIzYjIzYzFlYzJkM2Q3ZmMyNy90YWJsZXJhbmdlOjk3ZDM1ZWY4ZTBiNTRhMjNiMjNjMWVjMmQzZDdmYzI3XzE4LTMtMS0xLTQwMzg_fd5e4110-e3b9-457b-bfde-c96c6d3a7ca9">7.94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTo5N2QzNWVmOGUwYjU0YTIzYjIzYzFlYzJkM2Q3ZmMyNy90YWJsZXJhbmdlOjk3ZDM1ZWY4ZTBiNTRhMjNiMjNjMWVjMmQzZDdmYzI3XzE5LTEtMS0xLTQwMzg_7e18ae41-7c7d-4441-84e8-1d98474fb3fd">112,965</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTo5N2QzNWVmOGUwYjU0YTIzYjIzYzFlYzJkM2Q3ZmMyNy90YWJsZXJhbmdlOjk3ZDM1ZWY4ZTBiNTRhMjNiMjNjMWVjMmQzZDdmYzI3XzE5LTMtMS0xLTQwMzg_4ec7bef9-b29c-44dd-8459-4a21aa3cd19c">3.37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTo5N2QzNWVmOGUwYjU0YTIzYjIzYzFlYzJkM2Q3ZmMyNy90YWJsZXJhbmdlOjk3ZDM1ZWY4ZTBiNTRhMjNiMjNjMWVjMmQzZDdmYzI3XzIwLTEtMS0xLTQwMzg_9d64c211-70ff-455c-9988-a59d57f1596d">291,850</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTo5N2QzNWVmOGUwYjU0YTIzYjIzYzFlYzJkM2Q3ZmMyNy90YWJsZXJhbmdlOjk3ZDM1ZWY4ZTBiNTRhMjNiMjNjMWVjMmQzZDdmYzI3XzIwLTMtMS0xLTQwMzg_86e6aa62-0ec0-45ff-824e-98bde3192a19">7.19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTo5N2QzNWVmOGUwYjU0YTIzYjIzYzFlYzJkM2Q3ZmMyNy90YWJsZXJhbmdlOjk3ZDM1ZWY4ZTBiNTRhMjNiMjNjMWVjMmQzZDdmYzI3XzIxLTEtMS0xLTQwMzg_c659a264-f880-4caf-a6fb-9a6d485e57c3">4,938,943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTo5N2QzNWVmOGUwYjU0YTIzYjIzYzFlYzJkM2Q3ZmMyNy90YWJsZXJhbmdlOjk3ZDM1ZWY4ZTBiNTRhMjNiMjNjMWVjMmQzZDdmYzI3XzIxLTMtMS0xLTQwMzg_f5c53839-fc19-4cc8-ab19-7bd981a19c10">5.46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzY2MDM_6e8b07b9-c211-49b7-bace-01b6f96113f9" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average grant date fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTo5YjFlMDQyZjNhYTA0MTY1YWI5ZWExNDI3ZGE3MzdlZS90YWJsZXJhbmdlOjliMWUwNDJmM2FhMDQxNjVhYjllYTE0MjdkYTczN2VlXzEtMS0xLTEtMA_9ff8d066-29c1-413f-8229-483997718f85">1,484,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTo5YjFlMDQyZjNhYTA0MTY1YWI5ZWExNDI3ZGE3MzdlZS90YWJsZXJhbmdlOjliMWUwNDJmM2FhMDQxNjVhYjllYTE0MjdkYTczN2VlXzEtMy0xLTEtMA_46d9eda4-8f39-451c-97a4-a1412226169b">4.11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTo5YjFlMDQyZjNhYTA0MTY1YWI5ZWExNDI3ZGE3MzdlZS90YWJsZXJhbmdlOjliMWUwNDJmM2FhMDQxNjVhYjllYTE0MjdkYTczN2VlXzItMS0xLTEtMA_a9e6656d-7647-4f3e-b6a9-93a16b239eec">1,376,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTo5YjFlMDQyZjNhYTA0MTY1YWI5ZWExNDI3ZGE3MzdlZS90YWJsZXJhbmdlOjliMWUwNDJmM2FhMDQxNjVhYjllYTE0MjdkYTczN2VlXzItMy0xLTEtMA_11a5cc08-1549-4572-a0ff-a03e319a6aca">4.78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTo5YjFlMDQyZjNhYTA0MTY1YWI5ZWExNDI3ZGE3MzdlZS90YWJsZXJhbmdlOjliMWUwNDJmM2FhMDQxNjVhYjllYTE0MjdkYTczN2VlXzMtMS0xLTEtMA_05c4aa5a-a07e-49b6-8543-9d5fcc25f082">665,510</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTo5YjFlMDQyZjNhYTA0MTY1YWI5ZWExNDI3ZGE3MzdlZS90YWJsZXJhbmdlOjliMWUwNDJmM2FhMDQxNjVhYjllYTE0MjdkYTczN2VlXzMtMy0xLTEtMA_281305f2-8d26-4078-8ff9-706133b01051">3.77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTo5YjFlMDQyZjNhYTA0MTY1YWI5ZWExNDI3ZGE3MzdlZS90YWJsZXJhbmdlOjliMWUwNDJmM2FhMDQxNjVhYjllYTE0MjdkYTczN2VlXzQtMS0xLTEtMA_341bc8a8-bc79-4667-a035-7e4f77768cef">151,850</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTo5YjFlMDQyZjNhYTA0MTY1YWI5ZWExNDI3ZGE3MzdlZS90YWJsZXJhbmdlOjliMWUwNDJmM2FhMDQxNjVhYjllYTE0MjdkYTczN2VlXzQtMy0xLTEtMA_bb007caf-7b0b-4256-83a4-17ecc324d293">4.53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTo5YjFlMDQyZjNhYTA0MTY1YWI5ZWExNDI3ZGE3MzdlZS90YWJsZXJhbmdlOjliMWUwNDJmM2FhMDQxNjVhYjllYTE0MjdkYTczN2VlXzUtMS0xLTEtMA_ee91d0d2-a90f-49ab-a831-5414165a452d">2,044,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTo5YjFlMDQyZjNhYTA0MTY1YWI5ZWExNDI3ZGE3MzdlZS90YWJsZXJhbmdlOjliMWUwNDJmM2FhMDQxNjVhYjllYTE0MjdkYTczN2VlXzUtMy0xLTEtMA_3e11cd9a-dcf1-4e83-a2a3-acf34d440376">4.61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div></div><div><span><br/></span></div><ix:continuation id="i142125817431496791f71f31e1d1a073" continuedAt="iddf6591370504093a891c17d31854cdb"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common shares required to be issued upon the exercise of stock options would be issued from authorized and unissued shares. Options are valued using the Black-Scholes model. For employee grants, the Company calculates expected life via the simplified method as it does not have sufficient history to determine actual expected life. For non-employee grants, the Company calculates expected life using a combination of past exercise behavior, the contractual term and expected remaining exercise behavior. <ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzY2MTY_9a973f6f-36cd-4a8d-a346-ba5201e0d746" continuedAt="i1de573e5f77a42d8a15f37e3bcabc8df" escape="true">Inputs used in the valuation models are as follows:</ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><ix:continuation id="i1de573e5f77a42d8a15f37e3bcabc8df"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:83.625%"><tr><td style="width:1.0%"></td><td style="width:60.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.116%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.116%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.674%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.116%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.121%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 Grants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019 Grants</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option value</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i79cf41051ed34d12a5fa5d78feeeef12_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTplZTI0ZDQ2Mjk4ZmM0ZTViODY4Mzg4ZjI3Njc4NTkxMy90YWJsZXJhbmdlOmVlMjRkNDYyOThmYzRlNWI4NjgzODhmMjc2Nzg1OTEzXzEtMS0xLTEtMA_179b21d1-6562-4dfd-b1fb-90099f6cdfd1">4.98</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i7ec1168e4e6e457abbce2a3267321f39_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTplZTI0ZDQ2Mjk4ZmM0ZTViODY4Mzg4ZjI3Njc4NTkxMy90YWJsZXJhbmdlOmVlMjRkNDYyOThmYzRlNWI4NjgzODhmMjc2Nzg1OTEzXzEtMy0xLTEtMA_61e476b0-b5a8-48af-ab72-e2523c20a1dc">8.18</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i7505016b032b4f8aaffab34edef82f38_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTplZTI0ZDQ2Mjk4ZmM0ZTViODY4Mzg4ZjI3Njc4NTkxMy90YWJsZXJhbmdlOmVlMjRkNDYyOThmYzRlNWI4NjgzODhmMjc2Nzg1OTEzXzEtNS0xLTEtMA_761fb2f1-b2f8-4795-abba-9a20d37cde78">7.15</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="iffb306c7379244eab19d37d41fd043d9_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTplZTI0ZDQ2Mjk4ZmM0ZTViODY4Mzg4ZjI3Njc4NTkxMy90YWJsZXJhbmdlOmVlMjRkNDYyOThmYzRlNWI4NjgzODhmMjc2Nzg1OTEzXzEtNy0xLTEtMA_60dfabe3-fdaa-401f-aab8-45ea22b90406">7.91</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i79cf41051ed34d12a5fa5d78feeeef12_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTplZTI0ZDQ2Mjk4ZmM0ZTViODY4Mzg4ZjI3Njc4NTkxMy90YWJsZXJhbmdlOmVlMjRkNDYyOThmYzRlNWI4NjgzODhmMjc2Nzg1OTEzXzItMS0xLTEtMA_3ee13c8c-d539-4ca0-a8de-9d21f231c200">0.3</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7ec1168e4e6e457abbce2a3267321f39_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTplZTI0ZDQ2Mjk4ZmM0ZTViODY4Mzg4ZjI3Njc4NTkxMy90YWJsZXJhbmdlOmVlMjRkNDYyOThmYzRlNWI4NjgzODhmMjc2Nzg1OTEzXzItMy0xLTEtMA_3dc97125-81f3-4a1d-9553-2a7e5a7a1cbd">1.7</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7505016b032b4f8aaffab34edef82f38_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTplZTI0ZDQ2Mjk4ZmM0ZTViODY4Mzg4ZjI3Njc4NTkxMy90YWJsZXJhbmdlOmVlMjRkNDYyOThmYzRlNWI4NjgzODhmMjc2Nzg1OTEzXzItNS0xLTEtMA_f3897f39-deb7-4439-b2f1-7eed276b04bb">1.7</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iffb306c7379244eab19d37d41fd043d9_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTplZTI0ZDQ2Mjk4ZmM0ZTViODY4Mzg4ZjI3Njc4NTkxMy90YWJsZXJhbmdlOmVlMjRkNDYyOThmYzRlNWI4NjgzODhmMjc2Nzg1OTEzXzItNy0xLTEtMA_e110c8ab-ecfd-4c10-8372-506bc1e4a573">2.6</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTplZTI0ZDQ2Mjk4ZmM0ZTViODY4Mzg4ZjI3Njc4NTkxMy90YWJsZXJhbmdlOmVlMjRkNDYyOThmYzRlNWI4NjgzODhmMjc2Nzg1OTEzXzMtMS0xLTEtMA_8d43910b-928d-4a63-b9fe-6ea5c17f66b8">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTplZTI0ZDQ2Mjk4ZmM0ZTViODY4Mzg4ZjI3Njc4NTkxMy90YWJsZXJhbmdlOmVlMjRkNDYyOThmYzRlNWI4NjgzODhmMjc2Nzg1OTEzXzMtNS0xLTEtMA_83bfc096-a0f2-4659-9300-23676be17d35">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTplZTI0ZDQ2Mjk4ZmM0ZTViODY4Mzg4ZjI3Njc4NTkxMy90YWJsZXJhbmdlOmVlMjRkNDYyOThmYzRlNWI4NjgzODhmMjc2Nzg1OTEzXzQtMS0xLTEtMA_f7961bc6-3114-4f6f-983a-d897c50c799f">65.9</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTplZTI0ZDQ2Mjk4ZmM0ZTViODY4Mzg4ZjI3Njc4NTkxMy90YWJsZXJhbmdlOmVlMjRkNDYyOThmYzRlNWI4NjgzODhmMjc2Nzg1OTEzXzQtMy0xLTEtMA_8b599fd9-4925-4a0c-8b8c-50ad9ce8d2fc">70.1</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTplZTI0ZDQ2Mjk4ZmM0ZTViODY4Mzg4ZjI3Njc4NTkxMy90YWJsZXJhbmdlOmVlMjRkNDYyOThmYzRlNWI4NjgzODhmMjc2Nzg1OTEzXzQtNS0xLTEtMA_61336c39-2cc7-42a5-89c8-c4fb12bb7d64">64.9</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTplZTI0ZDQ2Mjk4ZmM0ZTViODY4Mzg4ZjI3Njc4NTkxMy90YWJsZXJhbmdlOmVlMjRkNDYyOThmYzRlNWI4NjgzODhmMjc2Nzg1OTEzXzQtNy0xLTEtMA_df728e78-6365-4cf8-b1b6-9928489bd17d">66.4</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTplZTI0ZDQ2Mjk4ZmM0ZTViODY4Mzg4ZjI3Njc4NTkxMy90YWJsZXJhbmdlOmVlMjRkNDYyOThmYzRlNWI4NjgzODhmMjc2Nzg1OTEzXzUtMS0xLTEtMA_145925ab-69c0-4073-907b-cdf004883bfa">6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7505016b032b4f8aaffab34edef82f38_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTplZTI0ZDQ2Mjk4ZmM0ZTViODY4Mzg4ZjI3Njc4NTkxMy90YWJsZXJhbmdlOmVlMjRkNDYyOThmYzRlNWI4NjgzODhmMjc2Nzg1OTEzXzUtNS0xLTEtMA_73bba24d-5f93-49ba-ad9d-35f32ea1e773">4.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iffb306c7379244eab19d37d41fd043d9_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTplZTI0ZDQ2Mjk4ZmM0ZTViODY4Mzg4ZjI3Njc4NTkxMy90YWJsZXJhbmdlOmVlMjRkNDYyOThmYzRlNWI4NjgzODhmMjc2Nzg1OTEzXzUtNy0xLTEtNDA0Mg_1a119525-e860-4aa3-8227-20ba996ce7c2">6</ix:nonNumeric></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized approximately $<ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzcxNDY4MjU1ODk1NzQ_779bc2cb-53cb-4485-8c34-94fc04b55711">4,210,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzcxNDY4MjU1ODk1ODY_afa4d552-1be4-445d-b94a-26fee5f5739d">3,581,000</ix:nonFraction> in stock-based compensation expense during the years ended December 31, 2020 and 2019, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intrinsic value of each option share is the difference between the fair value of our common stock and the exercise price of such option share to the extent it is &#8220;in-the-money&#8221;. Aggregate intrinsic value represents the value that would have been received by the holders of in-the-money options had they exercised their options on the last trading day of the year and sold the underlying shares at the closing stock price on such day. The intrinsic value calculation at December 31, 2020 is based on the $<ix:nonFraction unitRef="usdPerShare" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="2" name="apyx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueClosingStockPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzcxNDY4MjU1ODk1OTg_1127b5d6-b038-4bd1-85ce-2c53ad871306">7.20</ix:nonFraction> closing stock price of the Company's common stock on December&#160;31, 2020, the last trading day of 2020. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, there were <ix:nonFraction unitRef="shares" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzcxNDY4MjU1ODk2MDU_cb455611-10c0-4913-b174-77df8fabc8a3">4,530,049</ix:nonFraction> stock options outstanding and expected to vest with an aggregate intrinsic value of approximately $<ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzcxNDY4MjU1ODk2MTY_2ee04b44-8338-4661-a86f-7005c67e729f">10,250,000</ix:nonFraction>. These options have a weighted average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzcxNDY4MjU1ODk2Mjk_0c2e67d9-ea0d-47b3-8ca5-2f684c0d56c7">5.26</ix:nonFraction> and a weighted average remaining contractual term of approximately <ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzcxNDY4MjU1ODk4NDE_60d20782-be36-487d-a13e-4b892e8fdbf7">7</ix:nonNumeric> years. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, there were <ix:nonFraction unitRef="shares" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzcxNDY4MjU1ODk2MzY_06725718-d8e7-4d79-b2a3-bade934ffc43">2,894,474</ix:nonFraction> stock options outstanding and exercisable with an aggregate intrinsic value of approximately $<ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzcxNDY4MjU1ODk2NDc_47cfd6ae-d418-4c63-966b-ef707c91d3d4">9,800,000</ix:nonFraction>. These options have a weighted average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzcxNDY4MjU1ODk2NTk_6ee35647-ef62-4a1e-b5bf-a8bb4984c387">3.89</ix:nonFraction> and a weighted average remaining contractual term of approximately <ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzcxNDY4MjU1ODk4Mjk_3220beb8-94de-438b-bdc6-fbf6629c1412">6</ix:nonNumeric> years. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of in the money options exercised during the years ended December 31, 2020 and 2019, was approximately $<ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzcxNDY4MjU1ODk2NjY_895b0109-2880-4e3c-bea1-431add61a15f">200,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzcxNDY4MjU1ODk2NzY_ab57f547-1e41-4de8-81b1-6dd282b7fe96">1,420,000</ix:nonFraction>, respectively. Intrinsic value of exercised shares is the total value of such shares on the date of exercise less the cash received from the option holder to exercise the options or other consideration paid. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of options granted during the years ended December 31, 2020 and 2019, was approximately $<ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="apyx:ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzcxNDY4MjU1ODk2ODg_676903a7-7621-49b2-ad45-28464f4fdfd6">6,580,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="apyx:ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzcxNDY4MjU1ODk3MDA_b9d0239d-3043-4597-8156-27c396ca79dd">6,300,000</ix:nonFraction>, respectively. The weighted average fair value of options granted during the years ended December 31, 2020 and 2019, was $<ix:nonFraction unitRef="usdPerShare" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzcxNDY4MjU1ODk3MTI_b205fe79-7f7b-46c8-b500-708a9fac5a79">4.78</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzcxNDY4MjU1ODk3MTk_b2b587e2-fb7a-4e5b-bcdd-6200ac0209d9">4.57</ix:nonFraction>, respectively. The total fair value of option shares vested during the years ended December 31, 2020 and 2019, was approximately $<ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzcxNDY4MjU1ODk3MjY_6e264374-d7c2-44f6-9dbc-698e261415a6">2,510,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzcxNDY4MjU1ODk3Mzg_5f108e8a-36b8-4663-ab6b-6d6b3e5b1ac5">2,130,000</ix:nonFraction>, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allows employees to exercise stock-based awards by surrendering stock-based awards with an intrinsic value equal to the cumulative exercise price of the stock-based awards being exercised, referred to as net settlements. These surrenders are included in stock options exercised in the options rollforward above. During the years ended December 31, 2020 and 2019, the Company received <ix:nonFraction unitRef="shares" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzcxNDY4MjU1ODk3NTA_d94d2f97-289c-44a4-9670-29833f55724d">39,448</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzcxNDY4MjU1ODk3NTg_4cf68c8c-5abc-43a6-b6c7-2e7a563851cc">125,948</ix:nonFraction> options as payment in the exercise of <ix:nonFraction unitRef="shares" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="apyx:StockIssuedDuringPeriodSharesStockSwaps" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzcxNDY4MjU1ODk3Njc_ff9487a2-daf7-47e8-8609-250ba94ccd5a">47,088</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="apyx:StockIssuedDuringPeriodSharesStockSwaps" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzcxNDY4MjU1ODk3NzU_1e1e1303-1433-4ecc-b304-2f4c4dece3e4">222,601</ix:nonFraction> options, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, there was approximately $<ix:nonFraction unitRef="usd" contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzcxNDY4MjU1ODk3ODQ_d9a02ecc-f3d3-4cb7-b69a-ab4c7f10de15">5,910,000</ix:nonFraction> of total unrecognized stock-based compensation expense, related to unvested stock options granted under the plans above. This expense is expected to be recognized over a weighted-average period of approximately <ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzYyNDI_c0c246e0-f10d-4dac-b836-67f5f0da1d1b">1</ix:nonNumeric> year.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iddf6591370504093a891c17d31854cdb">During October 2015, the Company granted <ix:nonFraction unitRef="shares" contextRef="i938276f948f8476088fcafef6b8fa346_I20151031" decimals="INF" format="ixt:numdotdecimal" name="apyx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedToDate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzYyODg_f8de7a14-5f44-40eb-bc36-4f1b5997a3d4">225,922</ix:nonFraction> restricted stock units that vest ratably over a period of <ix:nonNumeric contextRef="ic7261616081a40bbad79158817e1fdf0_D20151001-20151031" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzYzNTA_e90496b0-0278-4eb6-a6c5-e070589daa07">5</ix:nonNumeric> years. As of December 31, 2020, all of the restricted stock units had vested.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><div id="idb46c8b71d7d4a27b277b6db52f68e8e_145"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 20. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90ZXh0cmVnaW9uOjRjYmQ3MGIwNzQ2NDQ5MDNhZmJiZDY2NDllMTQxODM0XzE1OTE_00a08c18-54ca-44fe-bc21-b7931f5e797b" continuedAt="i4bdff6238eca4cfbb6dc0f16c264e2db" escape="true">GEOGRAPHIC AND SEGMENT INFORMATION</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4bdff6238eca4cfbb6dc0f16c264e2db" continuedAt="i9d8fe2c9e71548fb94a63ea15e56b200">&#160;</ix:continuation></span></div><div><span><br/></span></div><ix:continuation id="i9d8fe2c9e71548fb94a63ea15e56b200"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are aggregated into reportable segments only if they exhibit similar economic characteristics. In addition to similar economic characteristics, the Company also considers the following factors in determining the reportable segments: the nature of business activities, the management structure directly accountable to its chief operating decision maker for operating and administrative activities, availability of discrete financial information and information presented to the Board of Directors and investors. Asset information is not reviewed by the chief operating decision maker by segment and is not available by segment, accordingly, the Company has not presented a measure of assets by segment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's reportable segments are disclosed as principally organized and managed as</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="segment" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90ZXh0cmVnaW9uOjRjYmQ3MGIwNzQ2NDQ5MDNhZmJiZDY2NDllMTQxODM0XzgzNA_17238bc4-be7c-482e-9690-d046eced7381">two</ix:nonFraction> operating segments: Advanced Energy and OEM. "Corporate &amp; Other" includes certain unallocated corporate and administrative costs which were not specifically attributed to any reportable segment. The OEM segment is primarily development and manufacturing contract and product driven, all related expenses are recorded as cost of sales, therefore no segment specific operating expenses are incurred.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90ZXh0cmVnaW9uOjRjYmQ3MGIwNzQ2NDQ5MDNhZmJiZDY2NDllMTQxODM0XzE1ODY_1ad90d60-41b5-4cb3-96e5-af4f2b7c2db1" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information with respect to reportable segments is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate (Other)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i594539d6cfd54e88904eebbf46eef99a_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTphMWYxOWY3NmNiOTY0ZDQwOTc5ODFlYTlhODZlMTZkZS90YWJsZXJhbmdlOmExZjE5Zjc2Y2I5NjRkNDA5Nzk4MWVhOWE4NmUxNmRlXzItMS0xLTEtMA_a1229e14-b5dc-4b71-81ec-f9c0cff4b942">22,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a77d1947a3942e4b0d3b8009af417c4_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTphMWYxOWY3NmNiOTY0ZDQwOTc5ODFlYTlhODZlMTZkZS90YWJsZXJhbmdlOmExZjE5Zjc2Y2I5NjRkNDA5Nzk4MWVhOWE4NmUxNmRlXzItMy0xLTEtMA_f21c2ca9-135f-456a-9abb-593f51ac722c">5,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a90fc59d66d4c82b190fa272723dc6d_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTphMWYxOWY3NmNiOTY0ZDQwOTc5ODFlYTlhODZlMTZkZS90YWJsZXJhbmdlOmExZjE5Zjc2Y2I5NjRkNDA5Nzk4MWVhOWE4NmUxNmRlXzItNS0xLTEtMA_ce1e9150-d88d-4b12-96a3-f7083a9cc543">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTphMWYxOWY3NmNiOTY0ZDQwOTc5ODFlYTlhODZlMTZkZS90YWJsZXJhbmdlOmExZjE5Zjc2Y2I5NjRkNDA5Nzk4MWVhOWE4NmUxNmRlXzItNy0xLTEtMA_251e7e63-e5f1-40b2-a5a9-d8b56c6e79fb">27,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i594539d6cfd54e88904eebbf46eef99a_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTphMWYxOWY3NmNiOTY0ZDQwOTc5ODFlYTlhODZlMTZkZS90YWJsZXJhbmdlOmExZjE5Zjc2Y2I5NjRkNDA5Nzk4MWVhOWE4NmUxNmRlXzE1LTEtMS0xLTA_b7d9e4fa-1b5a-40a6-b577-f726bb9d492c">7,128</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a77d1947a3942e4b0d3b8009af417c4_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTphMWYxOWY3NmNiOTY0ZDQwOTc5ODFlYTlhODZlMTZkZS90YWJsZXJhbmdlOmExZjE5Zjc2Y2I5NjRkNDA5Nzk4MWVhOWE4NmUxNmRlXzE1LTMtMS0xLTA_59719d3a-9d5a-44d8-b5fe-612e963eb4d2">1,838</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a90fc59d66d4c82b190fa272723dc6d_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTphMWYxOWY3NmNiOTY0ZDQwOTc5ODFlYTlhODZlMTZkZS90YWJsZXJhbmdlOmExZjE5Zjc2Y2I5NjRkNDA5Nzk4MWVhOWE4NmUxNmRlXzE1LTUtMS0xLTA_f0f5ec7d-0f18-4e81-87db-c1a23587dceb">14,793</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTphMWYxOWY3NmNiOTY0ZDQwOTc5ODFlYTlhODZlMTZkZS90YWJsZXJhbmdlOmExZjE5Zjc2Y2I5NjRkNDA5Nzk4MWVhOWE4NmUxNmRlXzE1LTctMS0xLTA_3a230f04-31f9-45d8-a7ca-09327aa096ff"><ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTphMWYxOWY3NmNiOTY0ZDQwOTc5ODFlYTlhODZlMTZkZS90YWJsZXJhbmdlOmExZjE5Zjc2Y2I5NjRkNDA5Nzk4MWVhOWE4NmUxNmRlXzE1LTctMS0xLTA_da81baf8-76ae-40ec-9b58-9738333a2341">20,083</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i594539d6cfd54e88904eebbf46eef99a_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTphMWYxOWY3NmNiOTY0ZDQwOTc5ODFlYTlhODZlMTZkZS90YWJsZXJhbmdlOmExZjE5Zjc2Y2I5NjRkNDA5Nzk4MWVhOWE4NmUxNmRlXzE4LTEtMS0xLTA_2d6ecef8-0543-4ab1-92c5-28ace258f7d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a77d1947a3942e4b0d3b8009af417c4_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTphMWYxOWY3NmNiOTY0ZDQwOTc5ODFlYTlhODZlMTZkZS90YWJsZXJhbmdlOmExZjE5Zjc2Y2I5NjRkNDA5Nzk4MWVhOWE4NmUxNmRlXzE4LTMtMS0xLTA_f89ee430-89ea-49bf-9345-08fcf7ea3d3a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTphMWYxOWY3NmNiOTY0ZDQwOTc5ODFlYTlhODZlMTZkZS90YWJsZXJhbmdlOmExZjE5Zjc2Y2I5NjRkNDA5Nzk4MWVhOWE4NmUxNmRlXzE4LTUtMS0xLTA_c7657e66-8386-4e7e-824d-a561df032472">241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTphMWYxOWY3NmNiOTY0ZDQwOTc5ODFlYTlhODZlMTZkZS90YWJsZXJhbmdlOmExZjE5Zjc2Y2I5NjRkNDA5Nzk4MWVhOWE4NmUxNmRlXzE4LTctMS0xLTA_fa61c3b4-a22e-473a-b7db-ae73ac46c69d">241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i594539d6cfd54e88904eebbf46eef99a_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTphMWYxOWY3NmNiOTY0ZDQwOTc5ODFlYTlhODZlMTZkZS90YWJsZXJhbmdlOmExZjE5Zjc2Y2I5NjRkNDA5Nzk4MWVhOWE4NmUxNmRlXzE5LTEtMS0xLTA_3bc434ee-bd92-4621-a48c-6747f60db05a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a77d1947a3942e4b0d3b8009af417c4_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTphMWYxOWY3NmNiOTY0ZDQwOTc5ODFlYTlhODZlMTZkZS90YWJsZXJhbmdlOmExZjE5Zjc2Y2I5NjRkNDA5Nzk4MWVhOWE4NmUxNmRlXzE5LTMtMS0xLTA_5f4b2ae7-3163-41c1-9fb6-2be133eff3df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a90fc59d66d4c82b190fa272723dc6d_D20200101-20201231" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTphMWYxOWY3NmNiOTY0ZDQwOTc5ODFlYTlhODZlMTZkZS90YWJsZXJhbmdlOmExZjE5Zjc2Y2I5NjRkNDA5Nzk4MWVhOWE4NmUxNmRlXzE5LTUtMS0xLTA_bfabd677-0a23-4b3c-97ad-f4d916bae130">46</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTphMWYxOWY3NmNiOTY0ZDQwOTc5ODFlYTlhODZlMTZkZS90YWJsZXJhbmdlOmExZjE5Zjc2Y2I5NjRkNDA5Nzk4MWVhOWE4NmUxNmRlXzE5LTctMS0xLTA_02a9075c-042d-43f2-9055-ab37b3f42478">46</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i594539d6cfd54e88904eebbf46eef99a_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTphMWYxOWY3NmNiOTY0ZDQwOTc5ODFlYTlhODZlMTZkZS90YWJsZXJhbmdlOmExZjE5Zjc2Y2I5NjRkNDA5Nzk4MWVhOWE4NmUxNmRlXzIwLTEtMS0xLTA_e3ede33c-e886-4962-afe3-fec4f1f550a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a77d1947a3942e4b0d3b8009af417c4_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTphMWYxOWY3NmNiOTY0ZDQwOTc5ODFlYTlhODZlMTZkZS90YWJsZXJhbmdlOmExZjE5Zjc2Y2I5NjRkNDA5Nzk4MWVhOWE4NmUxNmRlXzIwLTMtMS0xLTA_2a5de15f-8663-423a-bec3-cc5fe2807f3d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a90fc59d66d4c82b190fa272723dc6d_D20200101-20201231" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTphMWYxOWY3NmNiOTY0ZDQwOTc5ODFlYTlhODZlMTZkZS90YWJsZXJhbmdlOmExZjE5Zjc2Y2I5NjRkNDA5Nzk4MWVhOWE4NmUxNmRlXzIwLTUtMS0xLTA_8dc32d98-f7da-4aa1-9159-93b384c7533e">479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTphMWYxOWY3NmNiOTY0ZDQwOTc5ODFlYTlhODZlMTZkZS90YWJsZXJhbmdlOmExZjE5Zjc2Y2I5NjRkNDA5Nzk4MWVhOWE4NmUxNmRlXzIwLTctMS0xLTA_6563f329-231d-48c4-bbd1-1cd2d686f44a">479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i594539d6cfd54e88904eebbf46eef99a_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTphMWYxOWY3NmNiOTY0ZDQwOTc5ODFlYTlhODZlMTZkZS90YWJsZXJhbmdlOmExZjE5Zjc2Y2I5NjRkNDA5Nzk4MWVhOWE4NmUxNmRlXzI1LTEtMS0xLTA_466066f8-ce12-435f-9f9a-b023a30919c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a77d1947a3942e4b0d3b8009af417c4_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTphMWYxOWY3NmNiOTY0ZDQwOTc5ODFlYTlhODZlMTZkZS90YWJsZXJhbmdlOmExZjE5Zjc2Y2I5NjRkNDA5Nzk4MWVhOWE4NmUxNmRlXzI1LTMtMS0xLTA_ff084000-854e-4820-b34f-95b783045885">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a90fc59d66d4c82b190fa272723dc6d_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTphMWYxOWY3NmNiOTY0ZDQwOTc5ODFlYTlhODZlMTZkZS90YWJsZXJhbmdlOmExZjE5Zjc2Y2I5NjRkNDA5Nzk4MWVhOWE4NmUxNmRlXzI1LTUtMS0xLTA_69726d54-e84e-4aeb-ae6f-994004a1653f">7,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTphMWYxOWY3NmNiOTY0ZDQwOTc5ODFlYTlhODZlMTZkZS90YWJsZXJhbmdlOmExZjE5Zjc2Y2I5NjRkNDA5Nzk4MWVhOWE4NmUxNmRlXzI1LTctMS0xLTA_99315a5c-5cd5-4383-95e3-61b64312278f">7,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate (Other)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d507772bdc84e94aa1f1e2764c3a5b4_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiYzcwZmI0OWU3M2Q0NjYzYTA0MjI5NmIyOTFjYmRhYy90YWJsZXJhbmdlOmJjNzBmYjQ5ZTczZDQ2NjNhMDQyMjk2YjI5MWNiZGFjXzItMS0xLTEtMA_bf43f2fc-1872-435f-a030-436e487663e0">22,676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacc05ae73fc84dee92f50cd7192ca9e1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiYzcwZmI0OWU3M2Q0NjYzYTA0MjI5NmIyOTFjYmRhYy90YWJsZXJhbmdlOmJjNzBmYjQ5ZTczZDQ2NjNhMDQyMjk2YjI5MWNiZGFjXzItMy0xLTEtMA_c6cfd732-27eb-4884-9a79-b6cb40cd646d">5,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief62b70f9e3643ea9918e4763977575f_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiYzcwZmI0OWU3M2Q0NjYzYTA0MjI5NmIyOTFjYmRhYy90YWJsZXJhbmdlOmJjNzBmYjQ5ZTczZDQ2NjNhMDQyMjk2YjI5MWNiZGFjXzItNS0xLTEtMA_7beb252d-6317-45a8-877d-002fae361510">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiYzcwZmI0OWU3M2Q0NjYzYTA0MjI5NmIyOTFjYmRhYy90YWJsZXJhbmdlOmJjNzBmYjQ5ZTczZDQ2NjNhMDQyMjk2YjI5MWNiZGFjXzItNy0xLTEtMA_e46fab52-816a-4334-aa9b-09b1626dca9a">28,235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0d507772bdc84e94aa1f1e2764c3a5b4_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiYzcwZmI0OWU3M2Q0NjYzYTA0MjI5NmIyOTFjYmRhYy90YWJsZXJhbmdlOmJjNzBmYjQ5ZTczZDQ2NjNhMDQyMjk2YjI5MWNiZGFjXzE0LTEtMS0xLTA_fb070948-e315-44fc-97f1-1dd87885d986">8,045</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacc05ae73fc84dee92f50cd7192ca9e1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiYzcwZmI0OWU3M2Q0NjYzYTA0MjI5NmIyOTFjYmRhYy90YWJsZXJhbmdlOmJjNzBmYjQ5ZTczZDQ2NjNhMDQyMjk2YjI5MWNiZGFjXzE0LTMtMS0xLTA_6e0b71ca-1897-48ef-a0a5-2a73648e26e3">2,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief62b70f9e3643ea9918e4763977575f_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiYzcwZmI0OWU3M2Q0NjYzYTA0MjI5NmIyOTFjYmRhYy90YWJsZXJhbmdlOmJjNzBmYjQ5ZTczZDQ2NjNhMDQyMjk2YjI5MWNiZGFjXzE0LTUtMS0xLTA_836238b4-6e77-4f60-a4d0-91b79c00a717">14,960</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiYzcwZmI0OWU3M2Q0NjYzYTA0MjI5NmIyOTFjYmRhYy90YWJsZXJhbmdlOmJjNzBmYjQ5ZTczZDQ2NjNhMDQyMjk2YjI5MWNiZGFjXzE0LTctMS0xLTA_f73228c6-30b2-4c16-920d-6c052219dc8a">20,869</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d507772bdc84e94aa1f1e2764c3a5b4_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiYzcwZmI0OWU3M2Q0NjYzYTA0MjI5NmIyOTFjYmRhYy90YWJsZXJhbmdlOmJjNzBmYjQ5ZTczZDQ2NjNhMDQyMjk2YjI5MWNiZGFjXzE3LTEtMS0xLTA_9c62f480-b103-4c9a-b1d1-2d1b23d1b07c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacc05ae73fc84dee92f50cd7192ca9e1_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiYzcwZmI0OWU3M2Q0NjYzYTA0MjI5NmIyOTFjYmRhYy90YWJsZXJhbmdlOmJjNzBmYjQ5ZTczZDQ2NjNhMDQyMjk2YjI5MWNiZGFjXzE3LTMtMS0xLTA_64a39da5-4e90-4e5b-a685-c26b07462b31">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief62b70f9e3643ea9918e4763977575f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiYzcwZmI0OWU3M2Q0NjYzYTA0MjI5NmIyOTFjYmRhYy90YWJsZXJhbmdlOmJjNzBmYjQ5ZTczZDQ2NjNhMDQyMjk2YjI5MWNiZGFjXzE3LTUtMS0xLTA_7ac238fc-7811-4916-8208-3242df98da94">1,392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiYzcwZmI0OWU3M2Q0NjYzYTA0MjI5NmIyOTFjYmRhYy90YWJsZXJhbmdlOmJjNzBmYjQ5ZTczZDQ2NjNhMDQyMjk2YjI5MWNiZGFjXzE3LTctMS0xLTA_bde7e918-744a-401e-84e1-d47b3b62e215">1,392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d507772bdc84e94aa1f1e2764c3a5b4_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiYzcwZmI0OWU3M2Q0NjYzYTA0MjI5NmIyOTFjYmRhYy90YWJsZXJhbmdlOmJjNzBmYjQ5ZTczZDQ2NjNhMDQyMjk2YjI5MWNiZGFjXzE4LTEtMS0xLTA_958dfd29-764d-4d5d-a4ac-c9940c03ff7e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacc05ae73fc84dee92f50cd7192ca9e1_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiYzcwZmI0OWU3M2Q0NjYzYTA0MjI5NmIyOTFjYmRhYy90YWJsZXJhbmdlOmJjNzBmYjQ5ZTczZDQ2NjNhMDQyMjk2YjI5MWNiZGFjXzE4LTMtMS0xLTA_9ce6dc2c-a519-42c1-8de0-b7194f1e554e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief62b70f9e3643ea9918e4763977575f_D20190101-20191231" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiYzcwZmI0OWU3M2Q0NjYzYTA0MjI5NmIyOTFjYmRhYy90YWJsZXJhbmdlOmJjNzBmYjQ5ZTczZDQ2NjNhMDQyMjk2YjI5MWNiZGFjXzE4LTUtMS0xLTA_7af29c3a-1aec-4010-b27b-7c707c86cf17">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiYzcwZmI0OWU3M2Q0NjYzYTA0MjI5NmIyOTFjYmRhYy90YWJsZXJhbmdlOmJjNzBmYjQ5ZTczZDQ2NjNhMDQyMjk2YjI5MWNiZGFjXzE4LTctMS0xLTA_e9887aa2-758b-446c-9122-26f3f211473d">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other losses, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d507772bdc84e94aa1f1e2764c3a5b4_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiYzcwZmI0OWU3M2Q0NjYzYTA0MjI5NmIyOTFjYmRhYy90YWJsZXJhbmdlOmJjNzBmYjQ5ZTczZDQ2NjNhMDQyMjk2YjI5MWNiZGFjXzE5LTEtMS0xLTA_86b1af30-80bf-4cf8-8aaa-4453c53c5958">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacc05ae73fc84dee92f50cd7192ca9e1_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiYzcwZmI0OWU3M2Q0NjYzYTA0MjI5NmIyOTFjYmRhYy90YWJsZXJhbmdlOmJjNzBmYjQ5ZTczZDQ2NjNhMDQyMjk2YjI5MWNiZGFjXzE5LTMtMS0xLTA_9fd85b7a-5845-482d-9cb4-b8e4bd6ee046">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief62b70f9e3643ea9918e4763977575f_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiYzcwZmI0OWU3M2Q0NjYzYTA0MjI5NmIyOTFjYmRhYy90YWJsZXJhbmdlOmJjNzBmYjQ5ZTczZDQ2NjNhMDQyMjk2YjI5MWNiZGFjXzE5LTUtMS0xLTA_41b154e5-90d0-4160-88d0-08f51fd5d165">351</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiYzcwZmI0OWU3M2Q0NjYzYTA0MjI5NmIyOTFjYmRhYy90YWJsZXJhbmdlOmJjNzBmYjQ5ZTczZDQ2NjNhMDQyMjk2YjI5MWNiZGFjXzE5LTctMS0xLTA_2ddf3f4a-5495-4468-82d1-d270c7625b9d">351</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d507772bdc84e94aa1f1e2764c3a5b4_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiYzcwZmI0OWU3M2Q0NjYzYTA0MjI5NmIyOTFjYmRhYy90YWJsZXJhbmdlOmJjNzBmYjQ5ZTczZDQ2NjNhMDQyMjk2YjI5MWNiZGFjXzIzLTEtMS0xLTA_d72479d3-d03b-4ddc-8172-807866ea2e93">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacc05ae73fc84dee92f50cd7192ca9e1_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiYzcwZmI0OWU3M2Q0NjYzYTA0MjI5NmIyOTFjYmRhYy90YWJsZXJhbmdlOmJjNzBmYjQ5ZTczZDQ2NjNhMDQyMjk2YjI5MWNiZGFjXzIzLTMtMS0xLTA_76babc4d-6e3b-4cdd-bbc9-d33b44173612">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief62b70f9e3643ea9918e4763977575f_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiYzcwZmI0OWU3M2Q0NjYzYTA0MjI5NmIyOTFjYmRhYy90YWJsZXJhbmdlOmJjNzBmYjQ5ZTczZDQ2NjNhMDQyMjk2YjI5MWNiZGFjXzIzLTUtMS0xLTA_0e0ec093-37e0-4ac0-800e-2f67e06aa26d">130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiYzcwZmI0OWU3M2Q0NjYzYTA0MjI5NmIyOTFjYmRhYy90YWJsZXJhbmdlOmJjNzBmYjQ5ZTczZDQ2NjNhMDQyMjk2YjI5MWNiZGFjXzIzLTctMS0xLTA_6bef245b-c8be-4d54-961b-798903398762">130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">International sales in 2020 and 2019, were <ix:nonFraction unitRef="number" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="3" name="apyx:TotalRevenuePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90ZXh0cmVnaW9uOjRjYmQ3MGIwNzQ2NDQ5MDNhZmJiZDY2NDllMTQxODM0XzEzNzY_c45c08bf-5000-439e-ab7c-50412641938f">32.1</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="3" name="apyx:TotalRevenuePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90ZXh0cmVnaW9uOjRjYmQ3MGIwNzQ2NDQ5MDNhZmJiZDY2NDllMTQxODM0XzEzODA_7c4436b1-97c8-4ff4-81cd-a2584a35078c">30.6</ix:nonFraction>% of sales, respectively. Substantially all of these sales are denominated in U.S. dollars. <ix:nonNumeric contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" name="us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90ZXh0cmVnaW9uOjRjYmQ3MGIwNzQ2NDQ5MDNhZmJiZDY2NDllMTQxODM0XzE1ODk_e8b35215-7654-45ed-ae0d-992029b78e01" continuedAt="ia95dbe9cc50641e8a2bc01c0d33b555c" escape="true">Revenue by geographic region, based on the "ship to" location on the invoice are as follows:</ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:5pt"><ix:continuation id="ia95dbe9cc50641e8a2bc01c0d33b555c"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales by Domestic and International</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i661eca8a002a4cb2af895f3f5c9a5ec2_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiNDgzYmFiZGQ2ZDQ0ODgxOThmYzU0MmY4Y2Q1NDBmMS90YWJsZXJhbmdlOmI0ODNiYWJkZDZkNDQ4ODE5OGZjNTQyZjhjZDU0MGYxXzMtMS0xLTEtMA_e6405a64-5e7b-4d2b-b2a5-8f0057c63d45">18,812</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd1b12aeda3f4c229577e1cc6e8722a7_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiNDgzYmFiZGQ2ZDQ0ODgxOThmYzU0MmY4Y2Q1NDBmMS90YWJsZXJhbmdlOmI0ODNiYWJkZDZkNDQ4ODE5OGZjNTQyZjhjZDU0MGYxXzMtMy0xLTEtMA_3c76059a-0c26-4257-957a-6c080150adac">19,584</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7e4bbf7a2034449bae0430f14b14d54_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiNDgzYmFiZGQ2ZDQ0ODgxOThmYzU0MmY4Y2Q1NDBmMS90YWJsZXJhbmdlOmI0ODNiYWJkZDZkNDQ4ODE5OGZjNTQyZjhjZDU0MGYxXzQtMS0xLTEtMA_a048a9c8-a6a7-4277-952f-0ae4d8ab364e">8,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i515759e8c6ae472bb639c3e78b1b52f8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiNDgzYmFiZGQ2ZDQ0ODgxOThmYzU0MmY4Y2Q1NDBmMS90YWJsZXJhbmdlOmI0ODNiYWJkZDZkNDQ4ODE5OGZjNTQyZjhjZDU0MGYxXzQtMy0xLTEtMA_f2d27b51-9cff-4739-a958-cdf809fb68eb">8,651</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiNDgzYmFiZGQ2ZDQ0ODgxOThmYzU0MmY4Y2Q1NDBmMS90YWJsZXJhbmdlOmI0ODNiYWJkZDZkNDQ4ODE5OGZjNTQyZjhjZDU0MGYxXzUtMS0xLTEtMA_5a7fe1d4-cd29-4ce0-ac62-fb28c289faab">27,711</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiNDgzYmFiZGQ2ZDQ0ODgxOThmYzU0MmY4Y2Q1NDBmMS90YWJsZXJhbmdlOmI0ODNiYWJkZDZkNDQ4ODE5OGZjNTQyZjhjZDU0MGYxXzUtMy0xLTEtMA_e46fab52-816a-4334-aa9b-09b1626dca9a">28,235</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div></ix:continuation><div><span><br/></span></div><div id="idb46c8b71d7d4a27b277b6db52f68e8e_154"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-align:justify"><span><br/></span></div><div id="idb46c8b71d7d4a27b277b6db52f68e8e_157"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9A. Controls and Procedures</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management has established and maintains disclosure controls and procedures that are designed to ensure that the information required to be disclosed by us in reports that we file or submit under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms, and that such information is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Management carried out an evaluation, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this report. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that as of December 31, 2020, the Company's disclosure controls and procedures were effective.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Report on Internal Control Over Financial Reporting</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as such term is defined in Exchange Act Rule 13a-15(f) and 15d-15(f) under the Exchange Act). The Company's internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, management carried out an evaluation of the effectiveness of the Company's internal control over financial reporting as of December 31, 2020, based on the framework set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control&#8212;Integrated Framework (2013). Based on that evaluation, management concluded that the Company's internal control over financial reporting was effective as of December 31, 2020. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remediation of Previously Reported Material Weaknesses in Internal Control over Financial Reporting</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have remediated the material weaknesses previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2019 and improved our internal control over financial reporting specifically in the areas of the overall control environment and documentation of control activities through the completion of remediation steps described below.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Control Environment</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have remediated the material weakness associated with the lack of sufficient qualified accounting personnel with an appropriate level of knowledge and experience with generally accepted accounting principle by (i) hiring a new Chief Financial Officer and a new Corporate Controller in 2019 with experience in internal controls and financial reporting that have been actively engaged in remediation efforts to address the material weaknesses (ii) enhancing our policies, procedures, and controls for all key business processes and (iii) training personnel to ensure consistent application of accounting principles and adherence to the Company&#8217;s policies, procedures, and controls.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Control Activities</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have remediated the material weakness associated with the ineffective control activities due to the lack of documentation and timeliness in executing certain business process controls specifically related to procure to pay and inventory processes and footnote reporting disclosures related to income tax accounts, primarily related to our United States operations by (i) enhancing our processes and review controls associated with the processes noted above (ii) ensuring the appropriate criteria for controls, including evidence of review, timeliness and variance thresholds are documented, (iii) engaging third-party specialists for </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">income tax calculations and disclosures .and (iv) increasing management oversight of performance of such procedures and controls.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have remediated the material weakness associated with the ineffective control over financial reporting in our Bulgarian subsidiary related to the purchasing of goods and services, including the processing and payment of vendor invoices by (i) enhancing controls over purchasing and disbursements in our Bulgarian subsidiary (ii) approving and validating vendor invoices received by verifying the related purchase authorization and the receipt of the goods or services and (iii) ensuring that documentation of approval was retained and performed timely.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as noted above, there were no changes in our internal control over financial reporting that occurred during the quarter ended December 31, 2020, that materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div><span><br/></span></div><div id="idb46c8b71d7d4a27b277b6db52f68e8e_160"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9B. Other Information</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><div id="idb46c8b71d7d4a27b277b6db52f68e8e_163"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part III</span></div><div style="text-align:justify"><span><br/></span></div><div id="idb46c8b71d7d4a27b277b6db52f68e8e_166"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 10. Directors, Executive Officers and Corporate Governance</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BACKGROUND AND EXPERIENCE OF DIRECTORS </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When considering whether directors and nominees have the experience, qualifications, attributes or skills, taken as a whole, to enable the Board of Directors (&#8220;Board&#8221;) to satisfy its oversight responsibilities effectively in light of the Company&#8217;s business and structure, the Governance and Nominating Committee focused primarily on each person&#8217;s background and experience as reflected in the information discussed in each of the directors&#8217; individual biographies set forth immediately below. We believe that our directors provide an appropriate mix of experience and skills relevant to the size and nature of our business. As more specifically described in such person&#8217;s individual biographies set forth below, our directors possess relevant and industry-specific experience and knowledge in the medical, engineering and business fields, as the case may be, which we believe enhances the Board&#8217;s ability to oversee, evaluate and direct our overall corporate strategy. The Governance and Nominating Committee annually reviews and makes recommendations to the Board regarding the composition and size of the Board so that the Board consists of members with the proper expertise, skills, attributes and personal and professional backgrounds needed by the Board, consistent with applicable regulatory requirements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Governance and Nominating Committee believes that all directors, including nominees, should possess the highest personal and professional ethics, integrity and values and be committed to representing the long-term interests of our stockholders. The Governance and Nominating Committee will consider criteria including the nominee&#8217;s current or recent experience as a senior executive officer, whether the nominee is independent, as that term is defined in existing independence requirements of The NASDAQ Stock Market LLC, the business, scientific or engineering experience currently desired on the Board, geography, the nominee&#8217;s industry experience and the nominee&#8217;s general ability to enhance the overall composition of the Board.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Governance and Nominating Committee does not have a formal policy on diversity; however, in recommending directors, the Board and the Committee consider the specific background and experience of the Board members and other personal attributes in an effort to provide a diverse mix of capabilities, contributions and viewpoints which the Board believes enables it to function effectively as the Board of Directors of a company with our size and nature of business..  Moreover, our corporate governance guidelines commit the Company to maintaining a Board with a strong and diverse membership.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Directors serve for one-year terms and are elected at the annual stockholders&#8217; meeting. Set forth below is information regarding the executive officers, directors and key employees of Apyx Medical Corporation as of March&#160;29, 2021.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:23.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.731%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.851%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.472%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Age</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Position</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Director Since</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charles D. Goodwin</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and Director</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2017</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tara Semb</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer, Treasurer and Secretary</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Todd Hornsby</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moshe Citronowicz</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Andrew Makrides</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 1982</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lawrence J. Waldman</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2011</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael Geraghty</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2011</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Andres</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice-Chairman of the Board</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2014</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Craig Swandal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minnie Baylor-Henry</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2019</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Andrew Makrides</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Esq. age 79, Chairman of the Board of Directors since December 1982, received a Bachelor of Arts degree in Psychology from Hofstra University and a Juris Doctor Degree from Brooklyn Law School. He is a member of the Bar of the State of New York and practiced law from 1968 until joining Apyx Medical Corporation as a co-founder and Executive Vice President and director, in 1982. Mr. Makrides became President of the Company in 1985 and the CEO in December 1998 and served as such until March 18, 2011 at which point he relinquished his position as President, but remained CEO until December 2013. Mr. Makrides employment contract expired December 31, 2016. Mr. Makrides has over 30 years of executive experience in the medical industry. The Company believes Mr. Makrides is qualified to serve as Chairman because of his over 30 years of experience in the medical device industry as well as with his previous tenure with the Company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Charles D. Goodwin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, age 55, Chief Executive Officer and a Director of Apyx Medical since December 2017, is an accomplished senior executive with over 25 years of experience in the healthcare industry. Before joining Apyx Medical in December 2017, Mr. Goodwin was the Chief Executive Officer of MIS Implants Technologies, Inc., a privately held company specializing in dental implants. Prior to this position, Mr. Goodwin spent more than 11 years with Olympus/Gyrus ACMI in a variety of commercial and leadership roles of increasing responsibility. Mr. Goodwin began as a regional sales director for Gyrus in 2002 and was later promoted to Vice President of Sales, overseeing the Company&#8217;s strong commercial ramp and assisting Gyrus&#8217; executive leadership team in the successful acquisition of American Cytoscope Makers, or &#8220;ACMI&#8221;, for $500 million in 2005. As President of Gyrus ACMI&#8217;s surgical division, Mr. Goodwin developed the company&#8217;s global distribution network and achieved average annual sales growth of 35% for three consecutive years, resulting in a promotion to President of Worldwide Sales in 2007. As President of Worldwide Sales for Gyrus ACMI, Mr. Goodwin was responsible for a global business with approximately 700 employees and was a key contributor to the successful sale of Gyrus ACMI to Olympus for $2.2 billion in 2008. Mr. Goodwin served as Group Vice President of Olympus Corporation&#8217;s global surgical energy group, where he was responsible for commercial strategy, R&amp;D and operations for a business with more than 500 employees worldwide. Mr. Goodwin held this position for five years before joining MIS Implants Technologies, Inc. in 2014. Mr. Goodwin holds a B.A. Finance and Economics from Eastern Washington University. The Company believes Mr. Goodwin is qualified to serve as a Director given his over 25 years of experience in the medical device industry.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tara Semb</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, age 51, Chief Financial Officer, Treasurer and Secretary since January 2019. Prior to joining Apyx Medical, Ms. Semb was the Chief Financial Officer for AVAIL Vapor LLC, a manufacturer and retailer of e-liquid for use in electronic vapor devices, from 2015 until 2018. Ms. Semb previously worked for Amsted Industries, a diversified global manufacturer of industrial components, in multiple positions of increasing responsibility from 2006 until 2015, culminating in her promotion to Director of Finance for the company&#8217;s rail bearings division in 2013. Before joining Amsted Industries as Director of Internal Audit in 2006, she held financial and operational roles at Blyth Industries, a manufacturer and seller of candles and home fragrance products, and Anixter International, a global distributor of network &amp; security solutions. She began her career in 1991 as an auditor at Price Waterhouse. Ms. Semb holds a Bachelor of Science degree in Accounting from the University of Illinois, as well as an MBA from Washington University in St. Louis. She is a Certified Public Accountant (CPA).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Todd Hornsby</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, age 45, Executive Vice President since January 2019, has responsibility for global Commercial operations. He is an accomplished Senior Executive with more than 19 years of success in the medical device and biotech industries. Throughout his career, Todd has held various leadership positions and has extensive experience in sales, sales management, and with building strong teams and launching new technologies. Since joining Apyx&#8482; Medical in August 2014, Todd has focused primarily on the commercialization of Apyx&#8217;s Renuvion / J-Plasma advanced energy system. Prior to joining Apyx, Todd held roles of increasing seniority and responsibility at CryoLife, Inc. During his tenure, Todd directed the US Sales team, with a diversified product portfolio of biological heart valves and vascular grafts, surgical adhesives and hemostatic agents, dialysis access and CHF chronic heart failure products. Todd also directed successful integrations of three acquisitions into the US sales channel. Early in his medical device career, Todd held positions with Ethicon - Endo Surgery and Medex Medical. Todd holds a BA in Psychology from Hope College. He is also the recipient of many awards for sales achievement and growth.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Moshe Citronowicz</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, age 68, Senior Vice President since 2012, came to the United States in 1978 and has worked in a variety of manufacturing and high technology industries. In October 1993, Mr. Citronowicz joined the Company as Vice President of Operations and served as our Chief Operating Officer until November 2011. Currently, he is serving as the Senior Vice President. Mr. Citronowicz&#8217;s employment contract extends to December 31, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Lawrence J. Waldman, CPA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, age 74, Director, Audit Committee Chair, and Lead Independent Director since March 2011. Mr. Waldman has over thirty-five years of experience in public accounting. Mr. Waldman currently serves as a senior advisor to First Long Island Investors, LLC, an investment and wealth management firm since May 2016. Prior to that Mr. Waldman served as an advisor to the accounting firm of EisnerAmper LLP, where he was previously the Partner-in-Charge of Commercial Audit Practice Development for Long Island since September 2011. Prior to joining EisnerAmper LLP, Mr. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Waldman was the Partner-in-Charge of Commercial Audit Practice Development for Holtz Rubenstein Reminick, LLP from July 2006 to August 2011. Mr. Waldman was the Managing Partner of the Long Island office of KPMG LLP from 1994 through 2006, the accounting firm where he began his career in 1972. Mr. Waldman was elected to the Board of Directors of Comtech Telecommunications Corp. in August of 2015 and since December 2015, serves as Chair of its audit committee. In October 2016, Mr. Waldman was appointed and subsequently in December 2016 elected to the Board of Directors of CVD Equipment Corporation, and serves as the Chair of the audit committee and as Lead Independent Director. In January 2021, Mr. Waldman was appointed to serve as non-Executive Chairman of the Board of CVD Equipment Corporation. Mr. Waldman served through October 2018 as a member of the Board of Directors of Northstar/ RXR Metro Income Fund, a non-traded Real Estate Investment Trust and has served as a member of its audit committee since 2014. Mr. Waldman is also the Chair of the Supervisory Committee of Bethpage Federal Credit Union. Mr. Waldman also served as a member of the State University of New York&#8217;s Board of Trustees and as chair of its audit committee. He previously served as the Chairman of the Board of Trustees of the Long Island Power Authority and as Chair and a member of the finance and audit committee of its Board of Trustees. Mr. Waldman meets the definition of a financial expert as defined by the SEC and The NASDAQ Stock Market LLC. The Company believes Mr. Waldman is qualified to serve as Director, Audit Committee Chair and Lead Independent Director because of his over 35 years experience in public accounting and his positions on various boards.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Michael Geraghty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, age 73, has served as a director since March 2010 and was previously employed as the President of Global Sales at Optos, Inc., a developer and manufacturer of retinal imaging devices for screening, detection and diagnosis of eye related conditions. From 2005 through 2008, he was the President of International Sales at Gyrus Acmi where he first started in 2000 as Senior Vice President of Sales for Gyrus Medical. Prior to this, Mr. Geraghty was the Vice President of Sales and Marketing for Everest Medical, Inc. and before that was the Director of Marketing for Advanced Products at Arthrocare Corporation. Mr. Geraghty specializes in building independent direct sales teams in the medical device industry and has extensive domestic and international sales and marketing experience. He received his bachelor&#8217;s degree from St. Mary&#8217;s University and graduate degree in Executive Sales Management from the University of Minnesota. The Company believes Mr. Geraghty is qualified to serve as Director and Compensation Committee Chair because of his extensive domestic and international sales, marketing, and management experience.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Craig Swandal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, age 60, Director since March 2018. Mr. Swandal has over 30 years of experience at public and privately-held medical technology and electronics manufacturing companies. He began his career in 1981 at Unisys Corporation, a manufacturer of main frame computer systems, where he held a variety of manufacturing positions of increasing responsibility. In 1995 he joined Silent Knight, a manufacturer of industrial fire and security systems, as a Manufacturing Manager and was promoted to Vice President of Operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2001, Mr. Swandal joined Gyrus, a manufacturer of surgical devices, where he was responsible for the company&#8217;s manufacturing operations as Director of Operations and later Vice President of Operations. Following Gyrus&#8217;s acquisition of ACMI in 2005, Mr. Swandal was promoted to Senior Vice President and was responsible for the global operations of the combined company. He developed and executed Gyrus ACMI&#8217;s strategy to consolidate its manufacturing, distribution, customer service and service and repair operations and was a member of the leadership team that successfully sold the company to Olympus Corporation for $2.2 billion in 2008. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the acquisition of Gyrus ACMI, Mr. Swandal served on the executive leadership teams of several companies, including ATS Medical, ACELL and Tendyne, where he was focused on operational development and currently holds a position. He is currently the Principal of Lead 2 Change Consulting, where he assists companies in identifying and implementing new manufacturing initiatives. Mr. Swandal serves as a member of the Board of Managers for Tiumed LLC a nontraded Medical Device start up. Mr. Swandal holds a Bachelor&#8217;s degree in Organizational Management and Communications from Concordia University, as well as a mini Master of Business Administration in Medical Technology from the University of St Thomas. The Company believes Mr. Swandal is qualified to serve as Director because of his extensive experience in manufacturing operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">John Andres</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, age 63, Vice Chairman of the Board of Directors and Nominating Chair since July 2014, has over thirty years of experience in the medical device industry. Since April, 2004, Mr. Andres has been a private consultant, doing business through John C. Andres, LLC, specializing in patent/business strategy development and execution. He also is a partner of Hawk Healthcare, LLC, which provides strategic transaction management to private individuals and companies. Since 2011, Mr. Andres has served as the Legal Compliance Officer of Electrocore, Inc., a medical device company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, Mr. Andres joined the Longeviti Neuro Solutions, LLC Board of Directors which is developing cranial implant products for cranial reconstruction. In 2004, Mr. Andres helped found K2M, Inc. (KTWO) and from 2004 until 2010 served as </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a member of the Board of Directors of K2M, Inc. Prior to 2004, Mr. Andres held various legal and strategic business development positions at the Surgical Division of Tyco Healthcare Group, LLP, now Medtronic (NYSE: MDT) and its predecessor, United States Surgical Corporation. Before joining U.S. Surgical, Mr. Andres worked at the New York law firm of Morgan &amp; Finnegan. He received his Associate of Applied Science degree from Rochester Institute of Technology, his Bachelor of Arts degree from Lehigh University and his Juris Doctor from Pace University School of Law. The Company believes Mr. Andres is qualified to serve as a director because of his extensive experience in patent and business strategy development and execution in the medical device industry.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Minnie Baylor-Henry</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, age 73, Director and Regulator Compliance Committee Chair since August 2019. Ms. Baylor-Henry has over 25 years of regulatory affairs experience. She is the President of B-Henry &amp; Associates, LLC, a consulting firm that she founded to provide regulatory strategic support to life sciences companies. Prior to starting her consulting company, she held various executive level positions over a 15-year period at Johnson &amp; Johnson (J&amp;J). Before retiring from J&amp;J in 2015, she was the Worldwide Vice President of Regulatory Affairs-Medical Devices. During her time at J&amp;J, she also had served as the Vice President-Medical &amp; Regulatory Affairs in the Over-the Counter Group, as well as Senior Director, Regulatory Affairs- Pharmaceuticals. Ms. Baylor-Henry also worked for Deloitte &amp; Touche (2008-2010) as the National Director Regulatory Affairs- Life Sciences. Prior to joining the private sector, she worked for the US Food &amp; Drug Administration (1991-1999) in many roles, including serving as the Director of the Division of Drug, Marketing, Advertising &amp; Communications and the FDA&#8217;s National Health Fraud Coordinator.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, Ms. Baylor-Henry joined the Board of Directors of scPharmaceuticals, a publicly-held company focused on developing technologies that enable subcutaneous administration of therapies and in 2019 the Board of Directors of PolarityTE, a publicly- held regenerative medicine company. Ms. Baylor-Henry received her pharmacy degree from Howard University&#8217;s College of Pharmacy and a law degree from Catholic University&#8217;s Columbus School of Law. The Company believes Ms. Baylor-Henry is qualified to serve as Director and Regulatory and Compliance Committee Chair because of her extensive experience in global and regulatory management and compliance.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Involvement in Certain Legal Proceedings</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Independent Board Members</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board currently has six independent members, Andrew Makrides, John Andres, Michael Geraghty, Lawrence J. Waldman, Craig Swandal and Minnie Baylor-Henry who meet the existing independence requirements of The NASDAQ Stock Market LLC and the Securities and Exchange Commission.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Board Leadership</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The independent directors appointed Lawrence J. Waldman as the Lead Independent Director. The Lead Independent Director is appointed by the Board and is responsible for coordinating the activities of the independent directors and coordinating with the Chief Executive Officer of the Company to set agendas for Board meetings and chair executive sessions of the independent directors. The Lead Independent Director is also responsible for meeting, from time to time, with the Company&#8217;s Compensation Committee to discuss the Chief Executive Officer&#8217;s performance.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Corporate Governance Policies also contain several features which the Company believes will ensure that the Board maintains effective and independent oversight of management, including the following:</span></div><div><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Executive sessions without management and non-independent directors present are a standing Board agenda item. Executive sessions of the independent directors are held at any time requested by an independent director and, in any event, are held in connection with all regularly scheduled Board meetings.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">The Board regularly meets in executive session with the CEO without other members of management present.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">All Board committee members are independent directors. The committee chairs have authority to hold executive sessions without management and non-independent directors present.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board has no formal policy with respect to separation of the positions of Chairman and CEO or with respect to whether the Chairman should be a member of management or an independent director, and believes that these are matters that should be </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">discussed and determined by the Board from time to time. The Chief Executive Officer of the Company, Charles D. Goodwin, is tasked with the responsibility of implementing our corporate strategy. We believe Mr. Goodwin is best suited for leading discussions, at the Board level, regarding performance relative to our corporate strategy and this discussion accounts for a significant portion of the time devoted at our Board meetings.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Board Evaluations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board has adopted a policy to evaluate its performance and effectiveness as well as that of the four standing committees on an annual basis. The purpose of the evaluation is to track progress in certain areas targeted for improvement from year to year and to identify ways to enhance the Board&#8217;s effectiveness. As part of the evaluation, each Director may complete a written questionnaire developed by the Governance and Nominating Committee to provide feedback on the effectiveness of the Board, the Committees, as well as each individual Director&#8217;s own contributions. The collective ratings and comments of the Directors are compiled and then presented to the Governance and Nominating Committee and to the full Board for discussion and action as necessary.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Management</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board believes that risk management is an important component of the Company&#8217;s corporate strategy. While we assess specific risks at our committee levels, the Board, as a whole, oversees our risk management process, and discusses and reviews with management major policies with respect to risk assessment and risk management. The Board is regularly informed through its interactions with management and committee reports about risks we face in the course of our business.&#160;Our Audit Committee also takes an active role in risk assessment and risk management.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Audit Committee</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Audit Committee assists the Board in its general oversight of our financial reporting, internal controls, and audit functions, and is directly responsible for the appointment, compensation and oversight of the work of our independent registered public accounting firm. The Audit Committee reviews and discusses with management and our independent accountants the annual audited and quarterly financial statements (including the disclosures under &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and matters required to be discussed by the applicable requirements of the PCAOB), reviews the integrity of the financial reporting processes, both internal and external, reviews the qualifications, performance and independence of our independent accountants, and prepares the Audit Committee Report included in its Annual Report in accordance with rules and regulations of the Securities and Exchange Commission. The Audit Committee has the power to investigate any matter brought to its attention within the scope of its duties. It also has the authority to retain counsel and advisors to fulfill its responsibilities and duties. The Audit Committee also acts as a qualified legal compliance committee.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The meetings of the Committee are designed to facilitate and encourage communication among the Committee, the Company and the Company&#8217;s independent auditor. The Committee discussed with the Company&#8217;s Independent Auditor the overall scope and plans for their respective audits. The Committee meets with the independent auditor, with and without management present, to discuss the results of their examinations; their evaluations of the Company&#8217;s internal controls; and the overall quality of the Company&#8217;s financial reporting.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, our Audit Committee consisted of four independent members of the Board of Directors, Lawrence J. Waldman, John Andres, Michael Geraghty and Craig Swandal. As a smaller reporting company, we are required to have at least two independent members comprising our Audit Committee in accordance with Rule 10A-3 of the Securities Exchange Act of 1934 and the rules of The NASDAQ Stock Market LLC. During 2020, Mr. Waldman served as the Audit Committee Chairman and financial expert. The Audit Committee meets as often as it determines necessary but not less frequently than once every fiscal quarter.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Governance and Nominating Committee</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Governance and Nominating Committee is responsible for matters relating to the corporate governance of our company and the nomination of members of the board and committees thereof. During 2020, our Governance and Nominating Committee consisted of three independent members of the Board of Directors, John Andres who serves as Chairman, Lawrence J. Waldman and Michael Geraghty. The Governance and Nominating Committee meets as often as it determines necessary, but not less than once a year. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compensation Committee</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee is responsible for overseeing our compensation and employee benefit plans (including those involving the issuance of our equity securities) and practices, including formulating, evaluating and approving the compensation of our executive officers and reviewing and recommending to the full Board of Directors the compensation of our Chief Executive Officer. During 2020, our Compensation Committee consisted of three independent members of the Board of Directors, Michael Geraghty who served as Chairman, John Andres and Lawrence J. Waldman. The Compensation Committee meets as often as it determines necessary, but not less than once a year. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Regulatory Compliance Committee</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Regulatory Compliance Committee, formed in the third quarter of 2019, is responsible for matters relating to the Company&#8217;s overall non-financial regulatory and compliance strategies and systems. Specifically, the Committee provides oversight of management&#8217;s efforts to comply with the requirements for a medical device company operating in a highly regulated environment with respect to healthcare compliance, product quality and safety, and other areas as directed by the Board. During 2020, our Regulatory Compliance Committee consisted of three independent members of the Board of Directors, Minnie Baylor-Henry who serves as Chairperson, John Andres and Craig Swandal. The Regulatory Compliance Committee meets as often as it determines necessary, but not less than once a year.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Code of Ethics</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company made revisions to the Code of Ethics in the fourth quarter of 2019.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A copy of the code of ethics, which expressly includes the fiduciary responsibilities of the CEO and CFO, along with a summary of the changes made in 2019, is available on our website at </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">https://apyxmedical.com/code-of-ethics-and-conduct/</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">.</span></div><div style="text-align:justify"><span><br/></span></div><div id="idb46c8b71d7d4a27b277b6db52f68e8e_169"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 11. Executive Compensation Discussion and Analysis</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Compensation Philosophy</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary objective of our compensation program for employees, including our compensation program for executive officers, is to attract, retain and motivate qualified individuals and reward them in a manner that is fair to all stockholders. We strive to provide incentives for every employee that rewards them for their contribution to the Company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our compensation program is designed to be competitive with other employment opportunities and to align the interests of all employees, including executive officers, with the long-term interests of our stockholders. Historically, for our executive officers, we link a much higher percentage of total compensation to incentive compensation such as stock-based compensation than we do for other employees.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With these objectives in mind, our Board has built executive and non-executive compensation programs that consist of three principal elements - base salary, performance bonuses and grants of stock options and/or shares of restricted stock.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To understand the competitiveness of compensation arrangements provided to our executive officers, in 2014 the Compensation Committee engaged Pearl Meyer &amp; Partners to perform a competitive assessment of base salaries, bonuses for on-target performance and grants of equity incentives. In 2018 and again in 2019, Pearl Meyer &amp; Partners updated the competitive frame of reference for the study to consist of the following group of pre-selected companies that were of comparable size and operated in our industry category.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corindus Vascular Robotics, Inc.</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IRIDEX Corporation</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restoration Robotics, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cutera, Inc.</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Misonix, Inc.</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sensus Healthcare, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ekso Bionics Holdings, Inc.</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuronetics, Inc.</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Utah Medical Products Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">iCAD, Inc.</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nuvectra Corporation</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Viveve Medical, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IRadimed Corporation</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OrthoPediatrics Corp.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the peer group, Pearl Meyer referenced industry-specific, size-adjusted market survey data where appropriate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of the survey confirmed that, consistent with our desired philosophy, our compensation arrangements were competitive with the marketplace, with some variation by individual.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compensation Program</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Base Salary</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We pay base salaries to our Executive Officers in order to provide a consistent, minimum level of pay that sustained individual performance warrants. We also believe that a competitive annual base salary is important to attract and retain an appropriate caliber of talent for each position over time.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The annual base salaries of our Executive Officers are determined by our Compensation Committee and approved by the Board of Directors. All salary decisions are based on each Executive Officer&#8217;s level of responsibility, experience and recent and past performance, as determined by the Compensation Committee. The Compensation Committee benchmarks base salaries using a major independent consulting firm and using their recommendations and other information the Committee evaluates and establishes the base compensation for our executives.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Bonus</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The second component of executive compensation is performance bonuses which are earned when defined metrics are achieved.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2020, the Company established a combination of financial, operational and personal objectives as the broad criteria that would determine annual performance bonus amounts for the year. As a result of COVID-19, the Compensation Committee, in consultation with Pearl Meyer, revised the financial portion of these objectives to non-financial objectives that correlate with the long-term growth of the Company. Based on the achievement of the non-financial objectives, the Compensation Committee approved payout of the 2020 bonuses at 50% of the levels paid in 2019. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After careful review and consideration of the revised measures that comprise the 2020 bonus, the Compensation Committee approved the following performance bonuses for the named executive officers:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Bonus</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charles D. Goodwin</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,750&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moshe Citronowicz</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Todd Hornsby</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tara Semb</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374,150&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The third component of executive compensation is equity grants which have mainly come in the form of stock options. We believe that equity ownership in our Company is important to provide our Executive Officers and key employees with long-term incentives to better align interests of executives with the interests of stockholders and build value for our stockholders. In addition, the equity compensation is designed to attract and retain the executive management team. Stock options have value only if the stock price increases over time and, therefore, provide executives with an incentive to build Apyx&#8217;s value. This characteristic ensures that the Executive Officers and key employees have a meaningful portion of their compensation tied to future stock price increases and rewards management for long-term strategic planning through the resulting enhancement of the stock price.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option awards to Executive Officers and key employees are entirely discretionary. The CEO recommends to the Compensation Committee awards for individuals other than himself. The Compensation Committee considers this recommendation along with the prior contribution of these individuals and their expected future contributions to our growth. The Committee formulates and presents its recommended allocation of stock option awards to the Board of Directors for approval. The Compensation Committee then would make an independent determination on CEO stock option awards, again formulating and presenting its recommendation for the allocation of stock option awards to the Board of Directors for approval. The Board of Directors approves, rejects, or, if necessary, modifies the Committee&#8217;s recommendations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Perquisites and Other Benefits</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Executive Officers are eligible for the same health and welfare programs and benefits as the rest of our employees in their respective locations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Executive Officers are entitled to participate in and receive employer contributions to Apyx's 401(k) Savings Plan. For more information on employer contributions to the 401(k) Savings Plan see the Summary Compensation Table and its footnotes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax and Accounting Considerations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 162(m) of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), places a limit of $1.0 million on the amount of compensation that we may deduct as a business expense in any year with respect to each of our most highly paid executives unless, among other things, such compensation is performance-based and has been approved by stockholders. The non-performance-based compensation paid to our executive officers for the 2020 fiscal year did not exceed the $1.0 million limit per executive officer. Accounting considerations also play an important role in the design of our executive compensation program. Accounting rules, such as FASB ASC Topic 718-10-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Payment,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> require us to expense the cost of our stock option grants which reduces the amount of our reported profits. Because of option expensing and the impact of dilution on our stockholders, we pay close attention to the number and value of the shares underlying stock options we grant.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compensation of Executive Officers</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the compensation paid to each of our Executive Officers for the three years ended December&#160;31, 2020 and 2019 for services to our Company in all capacities:</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:13.017%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.605%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.547%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.711%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.370%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.123%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.143%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="57" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name and Principal Position</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Salary</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Bonus<br/>($)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Awards<br/>($)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Option Awards<br/>($) (1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-Equity Incentive Plan Compensation Earnings<br/>($)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change in Pension Value and Nonqualified Deferred Compensation Earnings<br/>($)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">All Other Compensation<br/>($) (2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>($)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Charles D. Goodwin</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">450,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">168,750&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,195,074&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,056&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,832,880&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CEO and Director</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">450,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">344,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,135,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,945,258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Moshe Citronowicz</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">299,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">354,096&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,402&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">720,348&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Senior Vice President</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">270,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82,620&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">346,320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">721,355&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Todd Hornsby</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">347,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">491,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,722&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">954,272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Executive Vice President(*)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">330,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">168,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">365,560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">892,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tara Semb(**)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">472,128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">883,185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CFO, Treasurer and Secretary</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">271,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110,265&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">312,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">699,187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*Assumed role as Executive Vice President on January 2, 2019.  **Assumed role as CFO, Treasurer and Secretary on January 2, 2019. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">These columns represent the grant date fair value of the awards as calculated in accordance with FASB ASC 718 (Stock Compensation). </span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The amounts for 2020 include compensation under the following plans and programs:</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:77.339%"><tr><td style="width:1.0%"></td><td style="width:34.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.745%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.022%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.745%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.022%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.745%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.022%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.745%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.027%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">C.D.<br/>Goodwin</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">M.<br/>Citronowicz</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">T.<br/>Hornsby</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">T.<br/>Semb</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term disability premiums</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health insurance premiums</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,931&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,925&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employer 401(k) contribution</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,611&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,071&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,056&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,402&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,722&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,257&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts in the table above are pro-rated where applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employment Agreements and Potential Payments Upon Termination or Change in Control</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, we were obligated under four employment agreements.</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:68.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.226%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contract Expiration Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charles D. Goodwin</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tara Semb</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Todd Hornsby</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moshe Citronowicz</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.52pt">Employment contracts provide for the Executives to remain employed by the Company until such time as their employment is terminated pursuant to the terms of their Employment Agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Charles D. Goodwin Employment Agreement</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On September 17, 2020, the Company entered into an Amended and Restated Employment Agreement, effective as of September 17, 2020, with Charles D. Goodwin II, the Company&#8217;s President and Chief Executive Officer (the &#8220;Goodwin Agreement&#8221;). The Goodwin Agreement amends and restates Mr. Goodwin&#8217;s original employment agreement, dated as of December 15, 2017, in its entirety. The term of Mr. Goodwin&#8217;s employment under the Goodwin Agreement commenced as of the effective date thereof and shall continue until terminated in accordance with the terms of the Goodwin Agreement. Under the Goodwin Agreement, Mr. Goodwin will receive an initial annual base salary of $450,000, which shall be reviewed from time to time and may be increased, but not decreased, by the Compensation Committee of the Board of Directors (the &#8220;Committee&#8221;) in its sole and exclusive discretion. Mr. Goodwin shall be entitled to participate in (i) any bonus or incentive plan available to the Company&#8217;s executives generally, on such terms as the Committee may determine in its discretion, and (ii) the equity-based incentive plans of the Company, pursuant to which he may receive awards thereunder, as determined by the Company&#8217;s Board of Directors in its sole discretion from time to time and subject to the terms and conditions of such plans and any applicable award agreement.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the event Mr. Goodwin&#8217;s employment is terminated as a result of death or disability, Mr. Goodwin or his estate shall be entitled to receive (i) any unpaid base salary earned and accrued prior to the date of termination, (ii) reimbursement for expenses incurred prior to the date of termination, (iii) a pro rata bonus for the year of termination, and, (iv) if Mr. Goodwin is eligible for and elects continuation benefits under COBRA, the Company will pay the employer portion of the COBRA coverage premium for the shorter of (x) the 12-month period following the date of termination, or (y) the time at which Mr. Goodwin becomes eligible for medical and dental benefits through another employer. In addition, Mr. Goodwin&#8217;s outstanding option grants shall continue to be treated in accordance with the terms of the applicable plan and award agreement, provided that the portion of Mr. Goodwin&#8217;s options (i) that were exercisable as of the effective date of the Goodwin Agreement and (ii) that would have become exercisable on the next anniversary of the effective date following the date of termination shall become and remain exercisable for a period of 12 months following the date of termination.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the event Mr. Goodwin&#8217;s employment is terminated by the Company for cause or by Mr. Goodwin without good reason, Mr. Goodwin shall be entitled to receive any unpaid base salary earned and accrued prior to the date of termination, and reimbursement for expenses incurred prior to the date of termination. In addition, in the event Mr. Goodwin&#8217;s employment is terminated by Mr. Goodwin without good reason, Mr. Goodwin&#8217;s stock option grants shall continue to be treated in accordance with the terms of the applicable plan and award agreement, provided that the portion of Mr. Goodwin&#8217;s options which were exercisable as of the date of termination shall remain exercisable for a period of 3 months following the date of termination.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the event Mr. Goodwin&#8217;s employment is terminated by Mr. Goodwin for good reason, by the Company without cause, or in connection with a change of control (as defined in the Goodwin Agreement), Mr. Goodwin shall be entitled to receive (i) any unpaid base salary and other benefits earned and accrued prior to the date of termination, (ii) reimbursement for expenses incurred prior to the date of termination, (iii) a pro rata bonus for the year of termination, (iv) continued payment of his base salary for the twelve (12) month period following the date of termination, and (v) if Mr. Goodwin is eligible for and elects continuation benefits under COBRA, the Company will pay the employer portion of the COBRA coverage premium for the shorter of (x) the 12-month period following the date of termination, or (y) the time at which Mr. Goodwin becomes eligible for medical and dental benefits through another employer. In addition, Mr. Goodwin&#8217;s outstanding option grants shall continue to be treated in accordance with the terms of the applicable plan and award agreement, provided that the portion of Mr. Goodwin&#8217;s options that (i) were exercisable as of the date of termination and (ii) would have become exercisable on the next anniversary of the effective date following the date of termination, shall become and remain exercisable for a period of 12 months following the date of termination.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Goodwin Agreement contains customary non-competition, non-solicitation, and confidentiality provisions in favor of the Company. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tara Semb Employment Agreement</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On September 16, 2020, the Company entered into an Amended and Restated Employment Agreement, effective as of September 16, 2020, with Tara Harris Semb, the Company&#8217;s Chief Financial Officer, Secretary and Treasurer (the &#8220;Semb Agreement&#8221;). The Semb Agreement amends and restates Ms. Semb&#8217;s original employment agreement, dated as of January 2, 2019, in its entirety. The term of Ms. Semb&#8217;s employment under the Semb Agreement commenced as of the effective date thereof and shall continue until terminated in accordance with the terms of the Semb Agreement. Under the Semb Agreement, Ms. Semb will receive an initial annual base salary of $328,000, which shall be reviewed from time to time and may be increased, but not decreased, by the Committee in its sole and exclusive discretion. Ms. Semb shall be entitled to participate in any bonus or incentive plan available to the Company&#8217;s executives generally, on such terms as the Committee may determine in its discretion.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the event Ms. Semb&#8217;s employment is terminated as a result of death or disability, Ms. Semb or her estate shall be entitled to receive (i) any unpaid base salary earned and accrued prior to the date of termination, (ii) reimbursement for expenses incurred prior to the date of termination, (iii) a pro rata bonus for the year of termination, and, (iv) if Ms. Semb is eligible for and elects continuation benefits under COBRA, the Company will pay the employer portion of the COBRA coverage premium for the shorter of (x) the 12-month period following the date of termination, or (y) the time at which Ms. Semb becomes eligible for medical and dental benefits through another employer. In addition, Ms. Semb&#8217;s outstanding option grants shall continue to be treated in accordance with the terms of the applicable plan and award agreement, provided that the portion of Ms. Semb&#8217;s options (i) that were exercisable as of the effective date of the Semb Agreement and (ii) that would have become exercisable on the next anniversary of the effective date following the date of termination shall become and remain exercisable for a period of 12 months following the date of termination.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the event Ms. Semb&#8217;s employment is terminated for by the Company for cause or by Ms. Semb without good reason, Ms. Semb shall be entitled to receive any unpaid base salary earned and accrued prior to the date of termination, and reimbursement for expenses incurred prior to the date of termination. In addition, in the event Ms. Semb&#8217;s employment is terminated by Ms. Semb without good reason, Ms. Semb&#8217;s stock option grants shall continue to be treated in accordance with the terms of the applicable plan and award agreement, provided that the portion of Ms. Semb&#8217;s options which were exercisable as of the date of termination shall remain exercisable for a period of 3 months following the date of termination.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the event Ms. Semb&#8217;s employment is terminated by Ms. Semb for good reason, by the Company without cause, or in connection with a change of control (as defined in the Semb Agreement), Ms. Semb shall be entitled to receive (i) any unpaid base salary and other benefits earned and accrued prior to the date of termination, (ii) reimbursement for expenses incurred prior to the date of termination, (iii) a pro rata bonus for the year of termination, (iv) continued payment of her base salary for the twelve (12) month period following the date of termination, and (v) if Ms. Semb is eligible for and elects continuation benefits under COBRA, the Company will pay the employer portion of the COBRA coverage premium for the shorter of (x) the 12-month period following the date of termination, or (y) the time at which Ms. Semb becomes eligible for medical and dental benefits through another employer. In addition, Ms. Semb&#8217;s outstanding option grants shall continue to be treated in accordance with the terms of the applicable plan and award agreement, provided that the portion of Ms. Semb&#8217;s options that (i) were exercisable as of the date of termination and (ii) would have become exercisable on the next anniversary of the effective date following the date of termination, shall become and remain exercisable for a period of 12 months following the date of termination.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Semb Agreement contains customary non-competition, non-solicitation, and confidentiality provisions in favor of the Company.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Todd Hornsby Employment Agreement</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On September 17, 2020, the Company entered into an Amended and Restated Employment Agreement, effective as of September 17, 2020, with Todd Hornsby, the Company&#8217;s Executive Vice President (the &#8220;Hornsby Agreement&#8221;). The Hornsby Agreement amends and restates Mr. Hornsby&#8217;s original employment agreement, dated as of January 1, 2018, in its entirety. The term of Mr. Hornsby&#8217;s employment under the Hornsby Agreement commenced as of the effective date thereof and shall continue until terminated in accordance with the terms of the Hornsby Agreement. Under the Hornsby Agreement, Mr. Hornsby will receive an initial annual base salary of $347,000, which shall be reviewed from time to time and may be increased, but not decreased, by the Committee in its sole and exclusive discretion. Mr. Hornsby shall be entitled to participate in (i) any bonus or incentive plan available to the Company&#8217;s executives generally, on such terms as the Committee may determine in its discretion, and (ii) the equity-based incentive plans of the Company, pursuant to which he may receive awards thereunder, as determined by the Company&#8217;s Board of Directors in its sole discretion from time to time and subject to the terms and conditions of such plans and any applicable award agreement.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the event Mr. Hornsby&#8217;s employment is terminated as a result of death or disability, Mr. Hornsby or his estate shall be entitled to receive (i) any unpaid base salary earned and accrued prior to the date of termination, (ii) reimbursement for expenses incurred prior to the date of termination, (iii) a pro rata bonus for the year of termination, and, (iv) if Mr. Hornsby is eligible for and elects continuation benefits under COBRA, the Company will pay the employer portion of the COBRA coverage premium for the shorter of (x) the 12-month period following the date of termination, or (y) the time at which Mr. Hornsby becomes eligible for medical and dental benefits through another employer. In addition, Mr. Hornsby&#8217;s outstanding option grants shall continue to be treated in accordance with the terms of the applicable plan and award agreement, provided that the portion of Mr. Hornsby&#8217;s options (i) that were exercisable as of the effective date of the Hornsby Agreement and (ii) that would have become exercisable on the next anniversary of the effective date following the date of termination shall become and remain exercisable for a period of 12 months following the date of termination.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the event Mr. Hornsby&#8217;s employment is terminated by the Company for cause or by Mr. Hornsby without good reason, Mr. Hornsby shall be entitled to receive any unpaid base salary earned and accrued prior to the date of termination, and reimbursement for expenses incurred prior to the date of termination. In addition, in the event Mr. Hornsby&#8217;s employment is terminated by Mr. Hornsby without good reason, Mr. Hornsby&#8217;s stock option grants shall continue to be treated in accordance with the terms of the applicable plan and award agreement, provided that the portion of Mr. Hornsby&#8217;s options which were exercisable as of the date of termination shall remain exercisable for a period of 3 months following the date of termination.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the event Mr. Hornsby&#8217;s employment is terminated by Mr. Hornsby for good reason, by the Company without cause, or in connection with a change of control (as defined in the Hornsby Agreement), Mr. Hornsby shall be entitled to receive (i) any unpaid base salary and other benefits earned and accrued prior to the date of termination, (ii) reimbursement for expenses incurred prior to the date of termination, (iii) a pro rata bonus for the year of termination, (iv) continued payment of his base salary for the twelve (12) month period following the date of termination, and (v) if Mr. Hornsby is eligible for and elects continuation benefits under COBRA, the Company will pay the employer portion of the COBRA coverage premium for the shorter of (x) the 12-month period following the date of termination, or (y) the time at which Mr. Hornsby becomes eligible for medical and dental benefits through another employer. In addition, Mr. Hornsby&#8217;s outstanding option grants shall continue to be treated in accordance with the terms of the applicable plan and award agreement, provided that the portion of Mr. Hornsby&#8217;s options that (i) were exercisable as of the date of termination and (ii) would have become exercisable on the next anniversary of the effective date following the date of termination, shall become and remain exercisable for a period of 12 months following the date of termination.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Hornsby Agreement contains customary non-competition, non-solicitation, and confidentiality provisions in favor of the Company.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Moshe Citronowicz Employment Agreement</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Citronowicz employment agreement contains an automatic extension for a period of one year after the initial term unless we provide Mr. Citronowicz with appropriate 60 days written notice pursuant to the his contract. Mr. Citronowicz&#8217;s employment agreement provides, among other things, that the Mr. Citronowicz may be terminated as follows: </span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Upon the death of the Mr. Citronowicz, in which case Mr. Citronowicz&#8217;sestate shall be paid the basic annual compensation due to Mr. Citronowicz pro-rated through the date of death.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">By the resignation of Mr. Citronowicz at any time upon at least thirty (30) days prior written notice to Apyx in which case Apyx shall be obligated to pay Mr. Citronowicz the basic annual compensation due him pro-rated to the effective date of termination.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">By Apyx, &#8220;for cause&#8221; if during the term of the employment agreement Mr. Citronowicz violates the non-competition provisions of his employment agreement, or is found guilty in a court of law of any crime of moral turpitude in which case the contract would be terminated and provisions for future compensation forfeited.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">By Apyx, without cause, with the majority approval of the Board of Directors, for Mr. Citronowicz at any time upon at least thirty (30) days prior written notice to Mr. Citronowicz. In this case Apyx shall be obligated to pay Mr. Citronowicz compensation in effect at such time, including all bonuses, accrued or prorated and expenses up to the date of termination. Thereafter, Apyx shall pay Mr. Citronowicz three times the salary in effect at the time of termination payable in one lump sum.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">If Apyx fails to meet its obligations to Mr. Citronowicz on a timely basis, or if there is a change in the control of Apyx, the executive may elect to terminate Mr. Citronowicz&#8217;s employment agreement. Upon any such termination or breach of any of its obligations under the employment agreement, Apyx shall pay Mr. Citronowicz a lump sum severance equal to three times the annual salary and bonus in effect the month preceding such termination or breach as well as any other sums which may be due under the terms of the employment agreement up to the date of termination. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no other employment contracts that have non-cancelable terms in excess of one year.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Outstanding Equity Awards</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information with respect to each unexercised stock option held by our Executive Officers as of December&#160;31, 2020:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"># of Securities<br/>Underlying<br/>Unexercised<br/>Options<br/>(# Exercisable)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"># of Securities Underlying Unexercised Options <br/>(# Unexercisable)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Option<br/>Exercise Price<br/>($/Sh)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Option Expiration<br/>Range After Grant Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charles D. Goodwin</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,078,667&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,333&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.63&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/15/2027</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/15/2030</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moshe Citronowicz</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/12/2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/15/2030</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Todd Hornsby</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,583&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/27/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/15/2030</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tara Semb</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.07&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/9/2029</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/15/2030</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">*** </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:174%">These columns represent the grant date fair value of the awards as calculated in accordance with FASB ASC 718 (Stock Compensation).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2003, the Board of Directors adopted, and our stockholders approved Apyx's 2003 Executive and Employee Stock Option Plan covering a total of 1,200,000 shares of common stock issuable upon exercise of options to be granted under the Plan.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 30, 2007, our stockholders approved, and the Board of Directors adopted an amendment to the 2003 Executive and Employee Stock Option Plan to increase the maximum aggregate number of shares of common stock reserved for issuance under the 2003 Plan from 1.2 million shares (already reserved against outstanding options) to 1.7 million shares, or an increase of 500,000 shares of common stock for future issuance pursuant to the terms of the plan. Except for the increase in the number of shares covered by the plan, the plan remains otherwise unchanged from its present status. In 2011, the Board of Directors granted 25,000 options to purchase a like number of shares of common stock.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2012, our stockholders approved the 2012 Share Incentive Plan covering a total of 750,000 shares of common stock issuable upon exercise of options to be granted under the plan. At December&#160;31, 2020 approximately 60,000 are available to be issued in this plan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2015, our stockholders approved the 2015 Executive and Employee Stock Option Plan covering a total of 2,000,000 shares of common stock issuable upon exercise of options to be granted under the plan. At December&#160;31, 2020 approximately 230,000 are available to be issued in this plan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2017, our stockholders approved the 2017 Executive and Employee Stock Option Plan covering a total of 3,000,000 shares of common stock issuable upon exercise of options to be granted under the plan. At December&#160;31, 2020 approximately 70,000 are available to be issued in this plan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, our stockholders approved the 2019 Share Incentive Plan covering a total of 2,000,000 shares of common stock issuable upon exercise of options to be granted under the plan. At December&#160;31, 2020, all 2,000,000 are available to be issued in this plan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in the pricing of any options previously or currently awarded.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Compensation Committee Interlocks and Insider Participation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee of the Board of Directors is responsible for determining the compensation of executive officers of the Company, as well as compensation awarded pursuant to the Company&#8217;s equity incentive plans.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, our Compensation Committee consisted of three independent members of the Board of Directors, Michael Geraghty (Chairman), John Andres and Lawrence J. Waldman.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No member of the Compensation Committee is or has been an officer or employee of the Company or any of its subsidiaries. In addition, no member of the Compensation Committee had any relationships with the Company or any other entity that require disclosure under the proxy rules and regulations promulgated by the SEC.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">COMPENSATION COMMITTEE REPORT</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Compensation Committee has reviewed and discussed the Compensation Discussion and Analysis contained in this Annual Report on Form 10-K with management. Based on our Compensation Committee&#8217;s review of and the discussions with management with respect to the Compensation Discussion and Analysis, our Compensation Committee recommended to the Board of Directors that the Compensation Discussion and Analysis be included in our Proxy Statement and in this Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2020 for filing with the SEC. During 2020, our Compensation Committee consisted of three independent members of the Board of Directors, Michael Geraghty, who served as Chairman, John Andres and Lawrence J. Waldman.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><div id="idb46c8b71d7d4a27b277b6db52f68e8e_172"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity Compensation Plan Information&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;ITEM 5. Market for Registrant&#8217;s Common Equity and Related Stockholder Matters&#8221;.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Security Ownership of Certain Beneficial Owners </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth certain information as of March&#160;29, 2021, with respect to the beneficial ownership of the Company&#8217;s common stock by its executive officers, directors, all persons known by the Company to be the beneficial owners of more than 5% of its outstanding shares and by all officers and directors as a group. </span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:36.491%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.560%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name and Address</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Owned (i)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nature of Ownership</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percentage of Ownership (i)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RTW Investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,391,279&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beneficial</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">250 West 55th St. 16th Floor</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New York, NY 10019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">William Weeks Vanderfelt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,158,414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beneficial</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Coralis 44, Azzuri Village 44</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Roches Noires, 31201 Mauritius</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Archon Capital Management, LLC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,502,077&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beneficial</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1100 19th Avenue E</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Seattle, WA 98122</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BlackRock, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,328,764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beneficial</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4400 Computer Drive</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Westborough, MA 01581</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Andrew Makrides</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">692,712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(ii)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beneficial</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5115 Ulmerton Rd.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clearwater, FL 33760</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Charles D. Goodwin II</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,266,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(iii)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beneficial</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5115 Ulmerton Rd.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clearwater, FL 33760</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Moshe Citronowicz</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">635,504&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(iv)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beneficial</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5115 Ulmerton Rd.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clearwater, FL 33760</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:36.491%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.560%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lawrence Waldman</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">177,817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(v)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beneficial</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5115 Ulmerton Rd.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clearwater, FL 33760</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Todd Hornsby</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">239,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(vi)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beneficial</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5115 Ulmerton Rd.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clearwater, FL 33760</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Michael E. Geraghty</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128,740&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(vii)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beneficial</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5115 Ulmerton Rd.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clearwater, FL 33760</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Craig Swandal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,740&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(viii)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beneficial</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5115 Ulmerton Rd.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clearwater, FL 33760</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">John Andres</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101,240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(ix)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beneficial</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5115 Ulmerton Rd.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clearwater, FL 33760</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tara Semb</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(x)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beneficial</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5115 Ulmerton Rd.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clearwater, FL 33760</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minnie Baylor-Henry</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,740&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(xi)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beneficial</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5115 Ulmerton Rd.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clearwater, FL 33760</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Officers and Directors as a group (10 people)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,414,409&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:36pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(i) Based on 34,317,863 outstanding shares of Common Stock as of March 29, 2021, of which officers and directors owned a total of 2,285,606 shares at March 29, 2021. We have calculated the percentage on the basis of the number of outstanding securities plus, for each person or group, any securities that person or group has current or future right to acquire pursuant to options, warrants, conversion privileges or other rights based on the 13G and 13D SEC filings at March 29, 2021 (and exercisable within 60 days thereafter).</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(ii) Includes 607,972 shares and 84,740 vested options (and exercisable within 60 days thereafter).</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(iii) Includes 28,250 shares and 1,238,333 vested options (and exercisable within 60 days thereafter).</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(iv) Includes 426,504 shares and 209,000 vested options (and exercisable within 60 days thereafter).</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(v) Includes 5,577 shares and 172,240 vested options (and exercisable within 60 days thereafter).</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(vi) Includes 0 shares and 239,000 vested options (and exercisable within 60 days thereafter).</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(vii) Includes 7,500 shares and 121,240 vested options (and exercisable within 60 days thereafter).</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(viii) Includes 53,000 shares and 13,740 vested options (and exercisable within 60 days thereafter).</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(ix) Includes 0 shares and 101,240 vested options (and exercisable within 60 days thereafter).</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(x) Includes 0 shares and 75,333 vested options (and exercisable within 60 days thereafter).</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(xi) Includes 0 shares and 30,740 vested options (and exercisable within 60 days thereafter).</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="padding-left:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 16(a) Beneficial Ownership Reporting Compliance</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 16(a) of the Securities Exchange Act of 1934 requires our officers and directors and persons who own more than ten percent of a registered class of our equity securities, to file reports of ownership and changes in ownership with the Securities and Exchange Co</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mmission. Officers, directors and greater than ten-percent shareholders (the &#8220;Reporting Persons&#8221;) are required by SEC regulation to furnish us with copies of all Section 16(a) forms they file.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Company&#8217;s knowledge, based solely on its review of the copies of such reports received or written representations from certain Reporting Persons that no other reports were required, the Company believes that during its fiscal year ended December&#160;31, 2020 all filing requirements applicable to the Reporting Persons were timely met, with the exception of Craig A. Swandal who did not timely file his Form 4s for 2 separate transactions and Lawrence J. Waldman who did not timely file his Form 4 for 1 transaction.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><div id="idb46c8b71d7d4a27b277b6db52f68e8e_175"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 13. Certain Relationships and Related Transactions and Director Independence</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Certain Relationships and Related Transactions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several relatives of Nikolay Shilev, Apyx Bulgaria&#8217;s Managing Director, are considered related parties. Teodora Shileva, Mr. Shilev&#8217;s spouse, is an employee of the Company working in the accounting department. Antoaneta Dimitrova Shileva-Toromanova, Mr. Shilev&#8217;s sister, is t</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he manager of human resources. Svetoslav Shilev, Mr. Shilev&#8217;s son, is a quality manager in the quality assurance department.  In addition, as part of the purchase of the Bulgaria manufacturing facility, Mr. Shilev was issued a note payable for $0.1 million to be paid 5 years</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> after the original purchase date, which is in October 2020. The note was paid in full on October 20, 2020. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Independent Board Members</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board currently has six independent members, Andrew Makrides, John Andres, Michael Geraghty, Lawrence J. Waldman, Craig Swandal, and Minnie Baylor-Henry, who meet the existing independence requirements of The NASDAQ Stock Market LLC and the Securities and Exchange Commission.</span></div><div style="text-align:justify"><span><br/></span></div><div id="idb46c8b71d7d4a27b277b6db52f68e8e_178"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 14. Principal Accountant Fees and Services </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the aggregate fees billed to us and expected to be billed to us by RSM US, LLP, our principal accountant for 2020 and 2019:</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Audit fees </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Audit related fees </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax fees </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other fees </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fees billed</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In 2019, we reported BDO USA, LLP as our principal accountant. The 2019 year was subsequently reaudited by RSM US, LLP, and we have included them as our principal accountant in the table above. Fees paid to BDO USA, LLP in conjunction with their 2019 audit work was $0.8 million.</span></td></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.52pt">Audit fees consist of billed and unbilled fees for professional services rendered for the audit of Apyx's annual financial statements and reviews of its interim consolidated financial statements included in quarterly reports and other services related to statutory and regulatory filings or engagements.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.52pt">Audit related fees consist of billed and unbilled fees for assurance and related services that are reasonably related to the performance of the audit or reviews of Apyx's consolidated financial statements and are not reported under &#8220;Audit Fees&#8221;.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.52pt">Tax fees consist of billed and unbilled fees for professional services rendered for tax compliance and tax advice (domestic and international). These services include assistance regarding federal, state and international tax compliance, acquisitions and international tax planning.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.52pt">All other fees consist of fees for products and services other than the services reported above.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><div id="idb46c8b71d7d4a27b277b6db52f68e8e_181"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div style="text-align:justify"><span><br/></span></div><div id="idb46c8b71d7d4a27b277b6db52f68e8e_184"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 15. Exhibits and Financial Statement Schedules</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.759%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(a)(1)</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LISTING OF FINANCIAL STATEMENTS</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following consolidated financial statements of the Company are included in Item 8 of this Report:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_55">Consolidated Balance Sheets at December 31, 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_55">20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_55"> and 201</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_55">31</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_61">Consolidated Statements of Operations for the years ended December 31, 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_61">20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_61"> and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_61">201</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_61">9</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_61">32</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_64">Consolidated Statement of Changes in</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_64"> Equity for the years ended December 31, 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_64">20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_64"> a</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_64">nd</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_64"> 201</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_64">9</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_64">33</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_67">Consolidated Statements of Cash Flows for the years ended December 31, 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_67">20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_67"> and</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_67"> 201</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_67">9</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_67">34</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_70">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idb46c8b71d7d4a27b277b6db52f68e8e_70">35</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(a)(2)</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FINANCIAL STATEMENT SCHEDULES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All financial statement schedules have been omitted, since the required information is not applicable or is not present in amounts sufficient to require submission of the schedule, or because the information required is included in the consolidated financial statements and notes thereto included in this Report.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div id="idb46c8b71d7d4a27b277b6db52f68e8e_187"></div><div style="-sec-extract:summary;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)(3) EXHIBITS</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:10.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/719135/000100944811000015/exhibit31.htm">Articles of Incorporation of the Registrant (Incorporated by reference to the Registrant&#8217;s report on Form 10-K/A filed on March 31, 2011)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/719135/000100944811000015/exhibit32.htm">By laws of the Registrant (Incorporated by reference to the Registrant&#8217;s report on Form 10-K/A filed on March 31, 2011)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/719135/000071913517000064/a2017q310-q.htm">Certificate of Amendment of the Certificate of Incorporation of the Registrant</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Incorporated by reference to the Registrant's Quarterly Report on Form 10-Q filed on November 3, 2017)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/719135/000071913518000021/bvx201805038-k.htm">Certificate of Elimination of the Series A 6% Convertible Preferred Stock and Series B Convertible Preferred Stock</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Incorporated by reference to the Registrant's Current Report on Form 8-K filed on May 3, 2018)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/719135/000071913518000086/bvx_20181228x8-k.htm">Certificate of Amendment of the Certificate of Incorporation of the Registrant</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Incorporated by reference to the Registrant's Current Report on Form 8-K filed on December 28, 2018)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/719135/000071913518000024/bvx_s-3x201805.htm">Indenture </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Incorporated by reference to the Registrant's Registration Statement on Form S-3 filed on May 4, 2018)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000719135/000071913520000029/apyxdescriptionofsecurit.htm">Description of the Registrant&#8217;s Securities</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Incorporated by the reference to the Registrant's Annual Report on Form 10-K filed on March 31, 2020)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/719135/000071913518000015/a2017bvx10-kexhibit1017.htm">Charles D. Goodwin II Employment Agreement, dated December 15, 2017</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Incorporated by the reference to the Registrant's Annual Report on Form 10-K filed on March 13, 2018)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2**</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/719135/000162828019002892/a2018q4apyx10-kexhibit1010.htm">Separation Agreement and General Release, dated November 12, 2018, by and between the Company and Jay D. Ewers</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Incorporated by the reference to the Registrant's Annual Report on Form 10-K filed on March 14, 2019)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3**</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/719135/000162828019002892/a2018q4apyx10-kexhibit1011.htm">Tara Semb Employment Agreement, dated January 2, 2019</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Incorporated by the reference to the Registrant's Annual Report on Form 10-K filed on March 14, 2019)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.4**</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000719135/000071913520000070/sembemploymentagreement.htm">Tara Semb Amended and Restated Employment Agreement, dated September 16, 2020 </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Incorporated by reference to the Registrant's Current Report on Form 8-K filed on September 18, 2020)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.5**</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000719135/000071913520000070/amendedrestatedgoodwinem.htm">Charles D. Goodwin II Amended and Restated Employment Agreement, dated September 17, 2020 </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Incorporated by reference to the Registrant's Current Report on Form 8-K filed on September 18, 2020)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.6**</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000719135/000071913520000070/toddhornsbyagreement.htm">Todd Hornsby Amended and Restated Employment Agreement, dated September 17, 2020</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Incorporated by reference to the Registrant's Current Report on Form 8-K filed on September 18, 2020)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000719135/000071913520000029/apyxmedicalcodeofbusines.htm">Code of Ethics</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (Incorporated by the reference to the Registrant's Annual Report on Form 10-K filed on March 31, 2020)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000719135/000071913520000067/bdoletter.htm">Letter from </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000719135/000071913520000067/bdoletter.htm">B</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000719135/000071913520000067/bdoletter.htm">DO USA, LLP</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Incorporated by the reference to the Registrant's Current Report on Form 8-K filed on August 20, 2020)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000719135/000071913520000029/a2019q410-kexhibit211.htm">List of Subsidiaries</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (Incorporated by the reference to the Registrant's Annual Report on Form 10-K filed on March 31, 2020)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="rsmconsent.htm">Consent of RSM US, LLP</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="a2020q410-qexhibit311.htm">Certification pursuant to Section 302 of Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="a2020q410-qexhibit312.htm">Certification pursuant to Section 302 of Sarbanes-Oxley Act of 20</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="a2020q410-qexhibit312.htm">0</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="a2020q410-qexhibit312.htm">2</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="a2020q410-qexhibit321.htm">Certification pursuant to Section 906 of Sarbanes-Oxley Act of 2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="a2020q410-qexhibit321.htm">0</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="a2020q410-qexhibit321.htm">02</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="a2020q410-qexhibit322.htm">Certification pursuant to Section 906 of Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS***</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH***</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL***</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF***</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB***</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE***</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Presentation Document</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Filed herewith.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">** Management contract or compensatory arrangement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*** XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of registration&#160;statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended and otherwise is not subject to liability under these sections.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><div id="idb46c8b71d7d4a27b277b6db52f68e8e_190"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb46c8b71d7d4a27b277b6db52f68e8e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in Clearwater, Florida on&#160;March&#160;31, 2021.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:46.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.758%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Apyx Medical Corporation</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ Charles D. Goodwin II</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charles D. Goodwin II</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Director</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ Tara Semb</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tara Semb</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasurer and Secretary</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:31.744%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.744%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.746%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Directors:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ ANDREW MAKRIDES</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Andrew Makrides</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ CHARLES D. GOODWIN II</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charles D. Goodwin II</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ TARA SEMB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer, Treasurer and Secretary</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tara Semb</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ JOHN ANDRES</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice Chairman of the Board</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Andres</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ LAWRENCE J. WALDMAN</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lawrence J. Waldman</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ MICHAEL GERAGHTY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael Geraghty</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ CRAIG SWANDAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Craig Swandal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ MINNIE BAYLOR-HENRY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minnie Baylor-Henry</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>rsmconsent.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ic6856097ae8f469f8a8a35787b9d7886_33"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Consent of Independent Registered Public Accounting Firm</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">Apyx Medical Corporation</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">Clearwater, Florida</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We consent to the incorporation by reference in Registration Statements (No. 333-233994, No. 333-222657, No. 333-207206 and No. 333-195624) on Form S-8 of Apyx Medical Corporation of our report dated March 31, 2021, relating to the consolidated financial statements of Apyx Medical Corporation, appearing in this Annual Report on Form 10-K of Apyx Medical Corporation for the year ended December 31, 2020. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#47;s&#47; RSM US LLP</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Orlando, Florida</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March 31, 2021</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>a2020q410-qexhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ice7feb5767f24694aeabc58565f259ff_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right;text-indent:42.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.1</font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certificate Pursuant to Section&#160;302</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">of Sarbanes &#8211; Oxley Act of 2002</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CEO</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Charles D Goodwin II, the Registrant's Chief Executive Officer, certify that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this annual report on Form 10-K of Apyx Medical Corporation&#59;</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements and other financial information included in this report fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected or is reasonably likely to materially affect the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal controls over financial reporting.</font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:46.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.064%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.951%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March 31, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Charles D. Goodwin II</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charles D. Goodwin II</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>a2020q410-qexhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i16d8a46e064c443b87ba75cdce59d3f3_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right;text-indent:42.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.2</font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certificate Pursuant to Section&#160;302</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">of Sarbanes &#8211; Oxley Act of 2002</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CFO</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Tara Semb, the Registrant's Chief Financial Officer, certify that&#58;</font></div><div><font><br></font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this annual report on Form 10-K of Apyx Medical Corporation&#59;</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements and other financial information included in this report fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected or is reasonably likely to materially affect the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal controls over financial reporting.</font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:46.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.621%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.294%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March 31, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Tara Semb</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tara Semb</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer, Treasurer and Secretary</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify;text-indent:42.75pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>a2020q410-qexhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="id2250c5c38c14e7e8e104d019ef3aff1_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right;text-indent:42.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certificate Pursuant to 18 U.S.C Section 1350, as adopted pursuant to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;906 of Sarbanes &#8211; Oxley Act of 2002</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CEO</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the annual report on Form 10-K of Apyx Medical Corporation (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#34;Company&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) for the year ended December&#160;31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#34;Report&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), the undersigned Chief Executive Officer certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes - Oxley Act of 2002, that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:46.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.064%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.951%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March 31, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Charles D. Goodwin II</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charles D. Goodwin II</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>a2020q410-qexhibit322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i52cc9297171f433ca07aa8375d42ac64_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certificate Pursuant to 18 U.S.C Section 1350, as adopted pursuant to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;906 of Sarbanes &#8211; Oxley Act of 2002</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CFO</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the annual report on Form 10-K of Apyx Medical Corporation (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#34;Company&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) for the year ended December&#160;31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#34;Report&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), the undersigned Chief Financial Officer certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes - Oxley Act of 2002, that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:46.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.981%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March 31, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Tara Semb</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tara Semb</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer, Treasurer and Secretary</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>apyx-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:3619fb04-76d2-4e32-a22c-67723657dfe5,g:73c9cb31-492e-4d91-a8e4-50624d0c0cae-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:apyx="http://apyxmedical.com/20201231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://apyxmedical.com/20201231">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="apyx-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="apyx-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="apyx-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="apyx-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://apyxmedical.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" roleURI="http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY">
        <link:definition>1004005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DESCRIPTIONOFBUSINESS" roleURI="http://apyxmedical.com/role/DESCRIPTIONOFBUSINESS">
        <link:definition>2101101 - Disclosure - DESCRIPTION OF BUSINESS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>2102102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>2203201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" roleURI="http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails">
        <link:definition>2404401 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CHANGEINACCOUNTINGPOLICY" roleURI="http://apyxmedical.com/role/CHANGEINACCOUNTINGPOLICY">
        <link:definition>2105103 - Disclosure - CHANGE IN ACCOUNTING POLICY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RECENTACCOUNTINGPRONOUNCEMENTS" roleURI="http://apyxmedical.com/role/RECENTACCOUNTINGPRONOUNCEMENTS">
        <link:definition>2106104 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DISPOSITIONOFTHECOREBUSINESS" roleURI="http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESS">
        <link:definition>2107105 - Disclosure - DISPOSITION OF THE CORE BUSINESS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DISPOSITIONOFTHECOREBUSINESSDetails" roleURI="http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESSDetails">
        <link:definition>2408402 - Disclosure - DISPOSITION OF THE CORE BUSINESS - (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTERESTINJOINTVENTUREINVESTMENT" roleURI="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENT">
        <link:definition>2109106 - Disclosure - INTEREST IN JOINT VENTURE INVESTMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTERESTINJOINTVENTUREINVESTMENTTables" roleURI="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTTables">
        <link:definition>2310301 - Disclosure - INTEREST IN JOINT VENTURE INVESTMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails" roleURI="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails">
        <link:definition>2411403 - Disclosure - INTEREST IN JOINT VENTURE INVESTMENT - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTERESTINJOINTVENTUREINVESTMENTChangesinOwnershipInterestDetails" roleURI="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTChangesinOwnershipInterestDetails">
        <link:definition>2412404 - Disclosure - INTEREST IN JOINT VENTURE INVESTMENT - Changes in Ownership Interest (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORIES" roleURI="http://apyxmedical.com/role/INVENTORIES">
        <link:definition>2113107 - Disclosure - INVENTORIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORIESTables" roleURI="http://apyxmedical.com/role/INVENTORIESTables">
        <link:definition>2314302 - Disclosure - INVENTORIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORIESDetails" roleURI="http://apyxmedical.com/role/INVENTORIESDetails">
        <link:definition>2415405 - Disclosure - INVENTORIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENT" roleURI="http://apyxmedical.com/role/PROPERTYANDEQUIPMENT">
        <link:definition>2116108 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTTables" roleURI="http://apyxmedical.com/role/PROPERTYANDEQUIPMENTTables">
        <link:definition>2317303 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" roleURI="http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails">
        <link:definition>2418406 - Disclosure - PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASES" roleURI="http://apyxmedical.com/role/LEASES">
        <link:definition>2119109 - Disclosure - LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESTables" roleURI="http://apyxmedical.com/role/LEASESTables">
        <link:definition>2320304 - Disclosure - LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESNarrativeDetails" roleURI="http://apyxmedical.com/role/LEASESNarrativeDetails">
        <link:definition>2421407 - Disclosure - LEASES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESLeaseCostDetails" roleURI="http://apyxmedical.com/role/LEASESLeaseCostDetails">
        <link:definition>2422408 - Disclosure - LEASES - Lease Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESCashandNonCashInformationDetails" roleURI="http://apyxmedical.com/role/LEASESCashandNonCashInformationDetails">
        <link:definition>2423409 - Disclosure - LEASES - Cash and Non-Cash Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESLeaseTermsandDiscountRatesDetails" roleURI="http://apyxmedical.com/role/LEASESLeaseTermsandDiscountRatesDetails">
        <link:definition>2424410 - Disclosure - LEASES - Lease Terms and Discount Rates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESMaturitiesofLeaseLiabilitiesDetails" roleURI="http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails">
        <link:definition>2425411 - Disclosure - LEASES - Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES" roleURI="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES">
        <link:definition>2126110 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables" roleURI="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables">
        <link:definition>2327305 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" roleURI="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails">
        <link:definition>2428412 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PRODUCTWARRANTIES" roleURI="http://apyxmedical.com/role/PRODUCTWARRANTIES">
        <link:definition>2129111 - Disclosure - PRODUCT WARRANTIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PRODUCTWARRANTIESTables" roleURI="http://apyxmedical.com/role/PRODUCTWARRANTIESTables">
        <link:definition>2330306 - Disclosure - PRODUCT WARRANTIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PRODUCTWARRANTIESDetails" roleURI="http://apyxmedical.com/role/PRODUCTWARRANTIESDetails">
        <link:definition>2431413 - Disclosure - PRODUCT WARRANTIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="JOINTANDSEVERALPAYROLLLIABILITY" roleURI="http://apyxmedical.com/role/JOINTANDSEVERALPAYROLLLIABILITY">
        <link:definition>2132112 - Disclosure - JOINT AND SEVERAL PAYROLL LIABILITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="JOINTANDSEVERALPAYROLLLIABILITYDetails" roleURI="http://apyxmedical.com/role/JOINTANDSEVERALPAYROLLLIABILITYDetails">
        <link:definition>2433414 - Disclosure - JOINT AND SEVERAL PAYROLL LIABILITY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSLOSSPERSHARE" roleURI="http://apyxmedical.com/role/EARNINGSLOSSPERSHARE">
        <link:definition>2134113 - Disclosure - EARNINGS (LOSS) PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSLOSSPERSHARETables" roleURI="http://apyxmedical.com/role/EARNINGSLOSSPERSHARETables">
        <link:definition>2335307 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSLOSSPERSHAREDetails" roleURI="http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails">
        <link:definition>2436415 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTS" roleURI="http://apyxmedical.com/role/FINANCIALINSTRUMENTS">
        <link:definition>2137114 - Disclosure - FINANCIAL INSTRUMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSDetails" roleURI="http://apyxmedical.com/role/FINANCIALINSTRUMENTSDetails">
        <link:definition>2438416 - Disclosure - FINANCIAL INSTRUMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXES" roleURI="http://apyxmedical.com/role/INCOMETAXES">
        <link:definition>2139115 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESTables" roleURI="http://apyxmedical.com/role/INCOMETAXESTables">
        <link:definition>2340308 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESComponentsofProvisionForIncomeTaxesDetails" roleURI="http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails">
        <link:definition>2441417 - Disclosure - INCOME TAXES - Components of Provision For Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails" roleURI="http://apyxmedical.com/role/INCOMETAXESReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails">
        <link:definition>2442418 - Disclosure - INCOME TAXES - Reconciliation of Statutory Federal Income Tax Rate to Effective Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESDeferredTaxAssetsLiabilitiesDetails" roleURI="http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails">
        <link:definition>2443419 - Disclosure - INCOME TAXES - Deferred Tax Assets (Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESNarrativeDetails" roleURI="http://apyxmedical.com/role/INCOMETAXESNarrativeDetails">
        <link:definition>2444420 - Disclosure - INCOME TAXES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESUnrecognizedTaxBenefitsRollForwardDetails" roleURI="http://apyxmedical.com/role/INCOMETAXESUnrecognizedTaxBenefitsRollForwardDetails">
        <link:definition>2445421 - Disclosure - INCOME TAXES - Unrecognized Tax Benefits Roll-Forward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RETIREMENTPLAN" roleURI="http://apyxmedical.com/role/RETIREMENTPLAN">
        <link:definition>2146116 - Disclosure - RETIREMENT PLAN</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RETIREMENTPLANNarrativeDetails" roleURI="http://apyxmedical.com/role/RETIREMENTPLANNarrativeDetails">
        <link:definition>2447422 - Disclosure - RETIREMENT PLAN - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONS" roleURI="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONS">
        <link:definition>2148117 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONSNarrativeDetails" roleURI="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails">
        <link:definition>2449423 - Disclosure - RELATED PARTY TRANSACTIONS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>2150118 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESDetails" roleURI="http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails">
        <link:definition>2451424 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKOPTIONS" roleURI="http://apyxmedical.com/role/STOCKOPTIONS">
        <link:definition>2152119 - Disclosure - STOCK OPTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKOPTIONSTables" roleURI="http://apyxmedical.com/role/STOCKOPTIONSTables">
        <link:definition>2353309 - Disclosure - STOCK OPTIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKOPTIONSNarrativeDetails" roleURI="http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails">
        <link:definition>2454425 - Disclosure - STOCK OPTIONS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKOPTIONSSummaryofStockOptionsDetails" roleURI="http://apyxmedical.com/role/STOCKOPTIONSSummaryofStockOptionsDetails">
        <link:definition>2455426 - Disclosure - STOCK OPTIONS - Summary of Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKOPTIONSSummaryofNonvestedStockOptionsDetails" roleURI="http://apyxmedical.com/role/STOCKOPTIONSSummaryofNonvestedStockOptionsDetails">
        <link:definition>2456427 - Disclosure - STOCK OPTIONS - Summary of Nonvested Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKOPTIONSSTOCKOPTIONSFairValueAssumptionsDetails" roleURI="http://apyxmedical.com/role/STOCKOPTIONSSTOCKOPTIONSFairValueAssumptionsDetails">
        <link:definition>2457428 - Disclosure - STOCK OPTIONS STOCK OPTIONS - Fair Value Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GEOGRAPHICANDSEGMENTINFORMATION" roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATION">
        <link:definition>2158120 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GEOGRAPHICANDSEGMENTINFORMATIONTables" roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONTables">
        <link:definition>2359310 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails" roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails">
        <link:definition>2460429 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails">
        <link:definition>2461430 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Reportable Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails" roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails">
        <link:definition>2462431 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Geographic (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="apyx_A2003ExecutiveandEmployeeStockOptionPlanMember" abstract="true" name="A2003ExecutiveandEmployeeStockOptionPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="apyx_A2001ExecutiveandEmployeeStockOptionPlanMember" abstract="true" name="A2001ExecutiveandEmployeeStockOptionPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="apyx_A2017ExecutiveandEmployeeStockOptionPlanMember" abstract="true" name="A2017ExecutiveandEmployeeStockOptionPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="apyx_AccessoriesMember" abstract="true" name="AccessoriesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="apyx_AdvancedEnergyMember" abstract="true" name="AdvancedEnergyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="apyx_SalesDiscountBillingTermsUpperLimit" abstract="false" name="SalesDiscountBillingTermsUpperLimit" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="apyx_NoncontrollingInterestRequiredCapitalContribution" abstract="false" name="NoncontrollingInterestRequiredCapitalContribution" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_ApyxSYMedicalDevicesNingboCoLtdMember" abstract="true" name="ApyxSYMedicalDevicesNingboCoLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="apyx_DefinedContributionPlanEmployersMatchingContributionVestingPeriod" abstract="false" name="DefinedContributionPlanEmployersMatchingContributionVestingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="apyx_NoncontrollingInterestTableTextBlock" abstract="false" name="NoncontrollingInterestTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="apyx_SalesDiscountBillingTermsLowerLimit" abstract="false" name="SalesDiscountBillingTermsLowerLimit" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="apyx_OperatingLeaseCostsAbstract" abstract="true" name="OperatingLeaseCostsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="apyx_OtherAccruedExpensesAndLiabilitiesCurrent" abstract="false" name="OtherAccruedExpensesAndLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations" abstract="false" name="Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_IncomeTaxExpenseBenefitValuationAllowance" abstract="false" name="IncomeTaxExpenseBenefitValuationAllowance" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_RepaymentofFinanceLeaseLiabilities" abstract="false" name="RepaymentofFinanceLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_MountingFixturesMember" abstract="true" name="MountingFixturesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="apyx_ProvisionForInventoryObsolescence" abstract="false" name="ProvisionForInventoryObsolescence" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_ProductWarranty" abstract="false" name="ProductWarranty" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="apyx_NonCashTransferOfOtherAssetsToFixedAssets" abstract="false" name="NonCashTransferOfOtherAssetsToFixedAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_OEMMember" abstract="false" name="OEMMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="apyx_JointAndSeveralPayrollLiability" abstract="false" name="JointAndSeveralPayrollLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_LargestCustomerMember" abstract="true" name="LargestCustomerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="apyx_TwoThousandTwelveShareIncentivePlanMember" abstract="false" name="TwoThousandTwelveShareIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="apyx_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue" abstract="false" name="ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_LeaseExecutionMember" abstract="true" name="LeaseExecutionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="apyx_StockIssuedDuringPeriodSharesStockSwaps" abstract="false" name="StockIssuedDuringPeriodSharesStockSwaps" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="apyx_StockSwapToAcquireOptionsShares" abstract="false" name="StockSwapToAcquireOptionsShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="apyx_JointAndSeveralPayrollExpense" abstract="false" name="JointAndSeveralPayrollExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards" abstract="false" name="CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_FinanceLeasePayments" abstract="false" name="FinanceLeasePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_CurrentIncomeTaxExpenseBenefitAfterValuationAllowance" abstract="false" name="CurrentIncomeTaxExpenseBenefitAfterValuationAllowance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" abstract="false" name="StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="apyx_FinanceLeaseCostsAbstract" abstract="true" name="FinanceLeaseCostsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="apyx_ProvisionForObsolescenceInventory" abstract="false" name="ProvisionForObsolescenceInventory" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" abstract="false" name="AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="apyx_LeaseArrangementsDomain" abstract="true" name="LeaseArrangementsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="apyx_DefinedContributionPlanEmployersMatchingContributionVestingPercentageAfterThreeYears" abstract="false" name="DefinedContributionPlanEmployersMatchingContributionVestingPercentageAfterThreeYears" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="apyx_RenuvionJPlasmaGeneratorsMember" abstract="true" name="RenuvionJPlasmaGeneratorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="apyx_UncertainTaxPositionsLiability" abstract="false" name="UncertainTaxPositionsLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedToDate" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedToDate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="apyx_PaymentsToAcquireInterestInJointVentureRemaining" abstract="false" name="PaymentsToAcquireInterestInJointVentureRemaining" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_TotalRevenuePercent" abstract="false" name="TotalRevenuePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="apyx_LeaseRemeasurementMember" abstract="true" name="LeaseRemeasurementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="apyx_EffectiveIncomeTaxRateReconciliationCARESActNetOperatingLossCarryforwardsPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationCARESActNetOperatingLossCarryforwardsPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="apyx_SophiaBulgariaMember" abstract="true" name="SophiaBulgariaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="apyx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueClosingStockPrice" abstract="false" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueClosingStockPrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="apyx_NonCashTransfersOfInventoryToFromFixedAssets" abstract="false" name="NonCashTransfersOfInventoryToFromFixedAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_LossContingencyAccrualTotalAccruedToDate" abstract="false" name="LossContingencyAccrualTotalAccruedToDate" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_SymmetrySurgicalInc.Member" abstract="true" name="SymmetrySurgicalInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="apyx_LeaseArrangementsAxis" abstract="true" name="LeaseArrangementsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="apyx_JointandSeveralPayrollLiabilityTextBlock" abstract="false" name="JointandSeveralPayrollLiabilityTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="apyx_LesseeDiscountRateIncrementalBorrowingRate" abstract="false" name="LesseeDiscountRateIncrementalBorrowingRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="apyx_ComputerEquipmentandSoftwareMember" abstract="true" name="ComputerEquipmentandSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="apyx_CARESActEffectiveIncomeTaxRateReconciliationFederalNetOperatingLossCarryforwardsAmount" abstract="false" name="CARESActEffectiveIncomeTaxRateReconciliationFederalNetOperatingLossCarryforwardsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_TwoThousandFifteenExecutiveAndEmployeeStockOptionPlanMember" abstract="false" name="TwoThousandFifteenExecutiveAndEmployeeStockOptionPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="apyx_CARESActIncomeTaxExpenseBenefitValuationAllowance" abstract="false" name="CARESActIncomeTaxExpenseBenefitValuationAllowance" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_ChineseSupplierMember" abstract="true" name="ChineseSupplierMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="apyx_AssetPurchaseAgreementTerm" abstract="false" name="AssetPurchaseAgreementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="apyx_InventoryWriteDownReversals" abstract="false" name="InventoryWriteDownReversals" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised" abstract="false" name="ProceedsFromStockOptionsExercisedAndWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember" abstract="true" name="ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="apyx_A2019ShareIncentivePlanMember" abstract="true" name="A2019ShareIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>apyx-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:3619fb04-76d2-4e32-a22c-67723657dfe5,g:73c9cb31-492e-4d91-a8e4-50624d0c0cae-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://apyxmedical.com/role/Cover" xlink:type="simple" xlink:href="apyx-20201231.xsd#Cover"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/Cover" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="apyx-20201231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_316b745a-2619-4eb5-8a76-f780cee65beb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_9ceafc10-a820-4658-889e-c20d96c2803a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_316b745a-2619-4eb5-8a76-f780cee65beb" xlink:to="loc_us-gaap_MinorityInterest_9ceafc10-a820-4658-889e-c20d96c2803a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_aca6a3f8-7510-485c-b075-c627005f98b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_316b745a-2619-4eb5-8a76-f780cee65beb" xlink:to="loc_us-gaap_StockholdersEquity_aca6a3f8-7510-485c-b075-c627005f98b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_aa03485f-02ef-4e27-9519-987a3a793df1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_56e8a754-f6a0-488d-b08d-e2a687537d6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_aa03485f-02ef-4e27-9519-987a3a793df1" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_56e8a754-f6a0-488d-b08d-e2a687537d6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_070a1294-95c0-46b7-a5a8-88eae1f8957e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_aa03485f-02ef-4e27-9519-987a3a793df1" xlink:to="loc_us-gaap_LiabilitiesCurrent_070a1294-95c0-46b7-a5a8-88eae1f8957e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_6434ab03-8db9-4cf5-a7e6-99e58b583d55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_aa03485f-02ef-4e27-9519-987a3a793df1" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_6434ab03-8db9-4cf5-a7e6-99e58b583d55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_19d31e63-0ae9-48c5-8341-aecf64ee5d96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_aa03485f-02ef-4e27-9519-987a3a793df1" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_19d31e63-0ae9-48c5-8341-aecf64ee5d96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9235d4a7-e4d7-4523-97f7-92a5a305ba05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_aa03485f-02ef-4e27-9519-987a3a793df1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9235d4a7-e4d7-4523-97f7-92a5a305ba05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2017a5f4-e58e-4508-9e42-b90b6b9aaf9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_9415fba1-9e37-497d-8e94-880e4ef59f13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2017a5f4-e58e-4508-9e42-b90b6b9aaf9a" xlink:to="loc_us-gaap_AccountsPayableCurrent_9415fba1-9e37-497d-8e94-880e4ef59f13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_9dcf9bfd-9356-4f51-af5a-e1bd76c0a0d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2017a5f4-e58e-4508-9e42-b90b6b9aaf9a" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_9dcf9bfd-9356-4f51-af5a-e1bd76c0a0d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_200f7c85-6bee-4742-9086-ddead1ffe704" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2017a5f4-e58e-4508-9e42-b90b6b9aaf9a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_200f7c85-6bee-4742-9086-ddead1ffe704" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_80524e0f-91f1-4eb1-8506-3dcd6e5e9b2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2017a5f4-e58e-4508-9e42-b90b6b9aaf9a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_80524e0f-91f1-4eb1-8506-3dcd6e5e9b2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_ead642b5-c174-4975-8ca6-d188a65d6a3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2017a5f4-e58e-4508-9e42-b90b6b9aaf9a" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_ead642b5-c174-4975-8ca6-d188a65d6a3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1f7110bc-87f3-410e-9f6e-a46f7dc79d7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_dd21b9e0-c01b-4ecd-a043-a477619c847b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1f7110bc-87f3-410e-9f6e-a46f7dc79d7b" xlink:to="loc_us-gaap_CommonStockValue_dd21b9e0-c01b-4ecd-a043-a477619c847b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_d2d54674-c228-4b92-97d7-1f1825e99bf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1f7110bc-87f3-410e-9f6e-a46f7dc79d7b" xlink:to="loc_us-gaap_AdditionalPaidInCapital_d2d54674-c228-4b92-97d7-1f1825e99bf4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_81dc9877-915d-45ae-a8f5-7bea34e403ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1f7110bc-87f3-410e-9f6e-a46f7dc79d7b" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_81dc9877-915d-45ae-a8f5-7bea34e403ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_cf07e312-f99c-4127-9284-849861d3464a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_04bb90d2-73f6-44e1-846f-8ad069ead6bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_cf07e312-f99c-4127-9284-849861d3464a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_04bb90d2-73f6-44e1-846f-8ad069ead6bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4cbc8585-83c4-4308-affd-32efc9e1363a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_cf07e312-f99c-4127-9284-849861d3464a" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4cbc8585-83c4-4308-affd-32efc9e1363a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_bb3dda6e-e657-4d42-af26-5bef3f5c15c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_cf07e312-f99c-4127-9284-849861d3464a" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_bb3dda6e-e657-4d42-af26-5bef3f5c15c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_91f75d38-1724-4c3c-bc26-0e1cf1eaed60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_cf07e312-f99c-4127-9284-849861d3464a" xlink:to="loc_us-gaap_InventoryNet_91f75d38-1724-4c3c-bc26-0e1cf1eaed60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d47d4cb3-4c47-4ba7-b92f-23dac0dd5a2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_cf07e312-f99c-4127-9284-849861d3464a" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d47d4cb3-4c47-4ba7-b92f-23dac0dd5a2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_211cebbb-3660-493a-9c53-91066869ae96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_cf07e312-f99c-4127-9284-849861d3464a" xlink:to="loc_us-gaap_IncomeTaxesReceivable_211cebbb-3660-493a-9c53-91066869ae96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_71d1e341-b6b4-4091-afef-356edf720fd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d3ce3cc1-59a3-4922-90c2-8d8462a94c64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_71d1e341-b6b4-4091-afef-356edf720fd4" xlink:to="loc_us-gaap_Liabilities_d3ce3cc1-59a3-4922-90c2-8d8462a94c64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_52d2b0b2-947e-4a95-acf8-c38f53ff7be2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_71d1e341-b6b4-4091-afef-356edf720fd4" xlink:to="loc_us-gaap_CommitmentsAndContingencies_52d2b0b2-947e-4a95-acf8-c38f53ff7be2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d9652ac6-14b4-47cc-b7a1-e4106db2c203" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_71d1e341-b6b4-4091-afef-356edf720fd4" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d9652ac6-14b4-47cc-b7a1-e4106db2c203" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_66ea00bc-f61a-4cb5-a7e5-4c1f7910cf95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_39b462a2-1225-4509-9585-23d49cf9ebcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_66ea00bc-f61a-4cb5-a7e5-4c1f7910cf95" xlink:to="loc_us-gaap_AssetsCurrent_39b462a2-1225-4509-9585-23d49cf9ebcd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d1607cbe-2206-4289-81d1-ec7ba4bec230" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_66ea00bc-f61a-4cb5-a7e5-4c1f7910cf95" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_d1607cbe-2206-4289-81d1-ec7ba4bec230" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_b165e411-c5bd-4aeb-9cb5-723d73b9376e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_66ea00bc-f61a-4cb5-a7e5-4c1f7910cf95" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_b165e411-c5bd-4aeb-9cb5-723d73b9376e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_812a7d9a-02d8-4fc5-869e-7b649aeb683c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_66ea00bc-f61a-4cb5-a7e5-4c1f7910cf95" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_812a7d9a-02d8-4fc5-869e-7b649aeb683c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b28c9b7c-2790-47b5-8694-4e605ab1ef60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_66ea00bc-f61a-4cb5-a7e5-4c1f7910cf95" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b28c9b7c-2790-47b5-8694-4e605ab1ef60" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="apyx-20201231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="apyx-20201231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_35fb9348-7e3b-4af8-a3d0-f5c1c60c7b00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_86b30ba2-f05c-48a2-bd32-f954b70b77e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_35fb9348-7e3b-4af8-a3d0-f5c1c60c7b00" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_86b30ba2-f05c-48a2-bd32-f954b70b77e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees_bcfb5cf2-1df8-46ef-b966-8e5208fbcaae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfessionalFees"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_35fb9348-7e3b-4af8-a3d0-f5c1c60c7b00" xlink:to="loc_us-gaap_ProfessionalFees_bcfb5cf2-1df8-46ef-b966-8e5208fbcaae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalariesAndWages_c6677026-5c7f-4b9a-ae7b-c268a9d8310e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalariesAndWages"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_35fb9348-7e3b-4af8-a3d0-f5c1c60c7b00" xlink:to="loc_us-gaap_SalariesAndWages_c6677026-5c7f-4b9a-ae7b-c268a9d8310e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_972fc9f5-1661-40e2-9794-31443ec54003" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_35fb9348-7e3b-4af8-a3d0-f5c1c60c7b00" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_972fc9f5-1661-40e2-9794-31443ec54003" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_fdc888e2-ccb1-4c8e-9694-d3df7f88ecfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_41a5052d-c3e3-4673-a4d7-ce6f4aff093b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_fdc888e2-ccb1-4c8e-9694-d3df7f88ecfc" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_41a5052d-c3e3-4673-a4d7-ce6f4aff093b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_cad75221-643a-4834-a0fe-6299ee13dc03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_fdc888e2-ccb1-4c8e-9694-d3df7f88ecfc" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_cad75221-643a-4834-a0fe-6299ee13dc03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c2171038-18a8-405a-b9fd-da901be0c12b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_1e391407-e225-4225-8502-2a7c86cd0411" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_c2171038-18a8-405a-b9fd-da901be0c12b" xlink:to="loc_us-gaap_OperatingExpenses_1e391407-e225-4225-8502-2a7c86cd0411" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_7631a8ca-4619-4fd1-a2c0-f192fa3c9455" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_c2171038-18a8-405a-b9fd-da901be0c12b" xlink:to="loc_us-gaap_GrossProfit_7631a8ca-4619-4fd1-a2c0-f192fa3c9455" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ede43401-dbf1-45d5-8f09-866fd76bd325" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_22b8a14d-229f-4c1b-b123-b723cf86a587" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ede43401-dbf1-45d5-8f09-866fd76bd325" xlink:to="loc_us-gaap_OperatingIncomeLoss_22b8a14d-229f-4c1b-b123-b723cf86a587" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_a5520480-6fb6-404b-98e8-4389e237b1f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ede43401-dbf1-45d5-8f09-866fd76bd325" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_a5520480-6fb6-404b-98e8-4389e237b1f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_eb13934b-fa77-446d-9790-0e18d52103ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_76d94c7f-0114-457b-b49f-1d59e4e3364b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_eb13934b-fa77-446d-9790-0e18d52103ad" xlink:to="loc_us-gaap_ProfitLoss_76d94c7f-0114-457b-b49f-1d59e4e3364b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0d9d2318-9e6e-4c2a-ba50-2653d982bed3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_eb13934b-fa77-446d-9790-0e18d52103ad" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0d9d2318-9e6e-4c2a-ba50-2653d982bed3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_9cb49483-9f26-40f4-b5da-008024c22736" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_26489981-83dd-4441-b5ff-4899a0c2a4ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOperating"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_9cb49483-9f26-40f4-b5da-008024c22736" xlink:to="loc_us-gaap_InterestIncomeOperating_26489981-83dd-4441-b5ff-4899a0c2a4ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_186f092c-79b2-432e-8188-0d92db2cd4a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_9cb49483-9f26-40f4-b5da-008024c22736" xlink:to="loc_us-gaap_InterestExpense_186f092c-79b2-432e-8188-0d92db2cd4a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_fcc9fdb1-c501-4823-8fb5-a81f034aa466" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_9cb49483-9f26-40f4-b5da-008024c22736" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_fcc9fdb1-c501-4823-8fb5-a81f034aa466" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_9e816cfb-7131-482a-8dd4-65aadeb8aea3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fd9ed0fe-932a-4699-a0db-bcbfd3de1053" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_9e816cfb-7131-482a-8dd4-65aadeb8aea3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fd9ed0fe-932a-4699-a0db-bcbfd3de1053" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_8524eaf1-c627-4f9e-b270-ad08f48ca1b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_9e816cfb-7131-482a-8dd4-65aadeb8aea3" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_8524eaf1-c627-4f9e-b270-ad08f48ca1b5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" xlink:type="simple" xlink:href="apyx-20201231.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="apyx-20201231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_92711f21-8da8-40d7-9bab-580ff95eb5dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_27b2a846-1751-4b52-825b-3619c1e5835f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_92711f21-8da8-40d7-9bab-580ff95eb5dc" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_27b2a846-1751-4b52-825b-3619c1e5835f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_5218042d-be11-45f9-8d0c-079c5e556881" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_92711f21-8da8-40d7-9bab-580ff95eb5dc" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_5218042d-be11-45f9-8d0c-079c5e556881" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_ee13967e-ae45-4223-b93c-2617b43146f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_92711f21-8da8-40d7-9bab-580ff95eb5dc" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_ee13967e-ae45-4223-b93c-2617b43146f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ebe5d5af-aa43-4b1e-ad64-92ebdc24f0bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1c4c2d8f-09c9-43a5-8232-f7b3d50ea245" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ebe5d5af-aa43-4b1e-ad64-92ebdc24f0bf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1c4c2d8f-09c9-43a5-8232-f7b3d50ea245" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b9ec563d-0bea-4384-8ab5-9508a765279d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ebe5d5af-aa43-4b1e-ad64-92ebdc24f0bf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b9ec563d-0bea-4384-8ab5-9508a765279d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_25bcff5f-ff80-42e8-83af-45436edb6d7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ebe5d5af-aa43-4b1e-ad64-92ebdc24f0bf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_25bcff5f-ff80-42e8-83af-45436edb6d7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_43dd77c2-669c-443f-85c9-2b51723348c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ebe5d5af-aa43-4b1e-ad64-92ebdc24f0bf" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_43dd77c2-669c-443f-85c9-2b51723348c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_28ae88ae-4ddf-4cfb-9767-caeddf82d001" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_19d4373c-45dc-4de4-ad6b-b231a7a2c760" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_28ae88ae-4ddf-4cfb-9767-caeddf82d001" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_19d4373c-45dc-4de4-ad6b-b231a7a2c760" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ProvisionForInventoryObsolescence_3e74a4c7-f344-4342-aa4f-60c4c32a9f27" xlink:href="apyx-20201231.xsd#apyx_ProvisionForInventoryObsolescence"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_28ae88ae-4ddf-4cfb-9767-caeddf82d001" xlink:to="loc_apyx_ProvisionForInventoryObsolescence_3e74a4c7-f344-4342-aa4f-60c4c32a9f27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyExpense_0e5acae7-1f80-4563-b5ff-f0167948e3fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductWarrantyExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_28ae88ae-4ddf-4cfb-9767-caeddf82d001" xlink:to="loc_us-gaap_ProductWarrantyExpense_0e5acae7-1f80-4563-b5ff-f0167948e3fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_cd2ab288-d763-419a-b7bf-1cb05f1feba5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_28ae88ae-4ddf-4cfb-9767-caeddf82d001" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_cd2ab288-d763-419a-b7bf-1cb05f1feba5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_15702323-7661-4a8c-9fc6-38cb329cc4a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_28ae88ae-4ddf-4cfb-9767-caeddf82d001" xlink:to="loc_us-gaap_ShareBasedCompensation_15702323-7661-4a8c-9fc6-38cb329cc4a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_9ffb8522-c870-4709-bbd4-ddfd0a901bfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_28ae88ae-4ddf-4cfb-9767-caeddf82d001" xlink:to="loc_us-gaap_GainLossOnInvestments_9ffb8522-c870-4709-bbd4-ddfd0a901bfc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_9de1ff71-a14d-4997-9f4a-929b1385047f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_28ae88ae-4ddf-4cfb-9767-caeddf82d001" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_9de1ff71-a14d-4997-9f4a-929b1385047f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_3b4f9b82-e00b-4a81-8fbc-7b4abbb21b75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_28ae88ae-4ddf-4cfb-9767-caeddf82d001" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_3b4f9b82-e00b-4a81-8fbc-7b4abbb21b75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_8a227d16-997b-4ef7-933d-793230d8d51c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_28ae88ae-4ddf-4cfb-9767-caeddf82d001" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_8a227d16-997b-4ef7-933d-793230d8d51c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_e8504efb-929a-479e-9c41-1086274969e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_28ae88ae-4ddf-4cfb-9767-caeddf82d001" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_e8504efb-929a-479e-9c41-1086274969e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_2ebf5fd5-9e47-42c7-90fe-c99e80c41d75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_28ae88ae-4ddf-4cfb-9767-caeddf82d001" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_2ebf5fd5-9e47-42c7-90fe-c99e80c41d75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_270c1fa8-bc07-4e65-92ad-07d178e72552" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_28ae88ae-4ddf-4cfb-9767-caeddf82d001" xlink:to="loc_us-gaap_ProfitLoss_270c1fa8-bc07-4e65-92ad-07d178e72552" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b74b295c-f65b-46fe-b432-1f3f55d112e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_28ae88ae-4ddf-4cfb-9767-caeddf82d001" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b74b295c-f65b-46fe-b432-1f3f55d112e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_2625f430-d697-4787-819c-2d513665964d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_28ae88ae-4ddf-4cfb-9767-caeddf82d001" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_2625f430-d697-4787-819c-2d513665964d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5d6fb5fa-d907-4bb9-8b3f-7a663ba0eccd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised_67bbfa77-9f70-48c0-bd12-d27fee2e2124" xlink:href="apyx-20201231.xsd#apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5d6fb5fa-d907-4bb9-8b3f-7a663ba0eccd" xlink:to="loc_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised_67bbfa77-9f70-48c0-bd12-d27fee2e2124" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_RepaymentofFinanceLeaseLiabilities_9dd6e44f-f2e7-4f51-bd9d-e2dd81c38482" xlink:href="apyx-20201231.xsd#apyx_RepaymentofFinanceLeaseLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5d6fb5fa-d907-4bb9-8b3f-7a663ba0eccd" xlink:to="loc_apyx_RepaymentofFinanceLeaseLiabilities_9dd6e44f-f2e7-4f51-bd9d-e2dd81c38482" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_83450175-0f99-42aa-8330-a5619ce1861c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5d6fb5fa-d907-4bb9-8b3f-7a663ba0eccd" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_83450175-0f99-42aa-8330-a5619ce1861c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_15663845-e658-4c12-8e4e-cb2a4f622e8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5d6fb5fa-d907-4bb9-8b3f-7a663ba0eccd" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_15663845-e658-4c12-8e4e-cb2a4f622e8b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/DESCRIPTIONOFBUSINESS" xlink:type="simple" xlink:href="apyx-20201231.xsd#DESCRIPTIONOFBUSINESS"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/DESCRIPTIONOFBUSINESS" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="apyx-20201231.xsd#SIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="apyx-20201231.xsd#SIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/CHANGEINACCOUNTINGPOLICY" xlink:type="simple" xlink:href="apyx-20201231.xsd#CHANGEINACCOUNTINGPOLICY"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/CHANGEINACCOUNTINGPOLICY" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/RECENTACCOUNTINGPRONOUNCEMENTS" xlink:type="simple" xlink:href="apyx-20201231.xsd#RECENTACCOUNTINGPRONOUNCEMENTS"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/RECENTACCOUNTINGPRONOUNCEMENTS" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESS" xlink:type="simple" xlink:href="apyx-20201231.xsd#DISPOSITIONOFTHECOREBUSINESS"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESS" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESSDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#DISPOSITIONOFTHECOREBUSINESSDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESSDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENT" xlink:type="simple" xlink:href="apyx-20201231.xsd#INTERESTINJOINTVENTUREINVESTMENT"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENT" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTTables" xlink:type="simple" xlink:href="apyx-20201231.xsd#INTERESTINJOINTVENTUREINVESTMENTTables"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTChangesinOwnershipInterestDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#INTERESTINJOINTVENTUREINVESTMENTChangesinOwnershipInterestDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTChangesinOwnershipInterestDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/INVENTORIES" xlink:type="simple" xlink:href="apyx-20201231.xsd#INVENTORIES"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/INVENTORIES" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/INVENTORIESTables" xlink:type="simple" xlink:href="apyx-20201231.xsd#INVENTORIESTables"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/INVENTORIESTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/INVENTORIESDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#INVENTORIESDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/INVENTORIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_c3f6c4e5-6203-4665-872e-06517fa467c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_4d3041ed-0934-4564-859a-ccfc9c6fe56a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_c3f6c4e5-6203-4665-872e-06517fa467c3" xlink:to="loc_us-gaap_InventoryRawMaterials_4d3041ed-0934-4564-859a-ccfc9c6fe56a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_c5a6f269-1b51-4a01-a3a9-953fcef59a7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_c3f6c4e5-6203-4665-872e-06517fa467c3" xlink:to="loc_us-gaap_InventoryWorkInProcess_c5a6f269-1b51-4a01-a3a9-953fcef59a7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_08d8da20-e93f-44df-b2eb-eace28ba3762" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_c3f6c4e5-6203-4665-872e-06517fa467c3" xlink:to="loc_us-gaap_InventoryFinishedGoods_08d8da20-e93f-44df-b2eb-eace28ba3762" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_b6eadca3-7414-4185-9f07-3a93557e56b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_38b77fdb-86ec-4dbc-a274-586b9df97fc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_b6eadca3-7414-4185-9f07-3a93557e56b5" xlink:to="loc_us-gaap_InventoryGross_38b77fdb-86ec-4dbc-a274-586b9df97fc1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_ad7d6658-f794-4ecf-b69f-9a989ef0c7ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_b6eadca3-7414-4185-9f07-3a93557e56b5" xlink:to="loc_us-gaap_InventoryValuationReserves_ad7d6658-f794-4ecf-b69f-9a989ef0c7ca" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/PROPERTYANDEQUIPMENT" xlink:type="simple" xlink:href="apyx-20201231.xsd#PROPERTYANDEQUIPMENT"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/PROPERTYANDEQUIPMENT" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/PROPERTYANDEQUIPMENTTables" xlink:type="simple" xlink:href="apyx-20201231.xsd#PROPERTYANDEQUIPMENTTables"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/PROPERTYANDEQUIPMENTTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_612274b3-fd6a-471d-842d-8d032a73d998" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations_12088855-710a-424d-bc92-ffce66500164" xlink:href="apyx-20201231.xsd#apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_612274b3-fd6a-471d-842d-8d032a73d998" xlink:to="loc_apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations_12088855-710a-424d-bc92-ffce66500164" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_51688286-264a-40fa-aa68-64f2a74ed57a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_612274b3-fd6a-471d-842d-8d032a73d998" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_51688286-264a-40fa-aa68-64f2a74ed57a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations_d4c86b94-288e-4a9e-a1ab-c8954476cb45" xlink:href="apyx-20201231.xsd#apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_96357465-55ee-4d58-a7fd-5bab55dd935b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations_d4c86b94-288e-4a9e-a1ab-c8954476cb45" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_96357465-55ee-4d58-a7fd-5bab55dd935b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_04016c53-e4eb-48d5-b93b-83c575ba487b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations_d4c86b94-288e-4a9e-a1ab-c8954476cb45" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_04016c53-e4eb-48d5-b93b-83c575ba487b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/LEASES" xlink:type="simple" xlink:href="apyx-20201231.xsd#LEASES"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/LEASES" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/LEASESTables" xlink:type="simple" xlink:href="apyx-20201231.xsd#LEASESTables"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/LEASESTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/LEASESNarrativeDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#LEASESNarrativeDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/LEASESNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/LEASESLeaseCostDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#LEASESLeaseCostDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/LEASESLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_10baf471-32f5-4afc-a692-2b820951a9d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_0f72cf30-f43f-4d27-be74-1bfa1da017de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_10baf471-32f5-4afc-a692-2b820951a9d7" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_0f72cf30-f43f-4d27-be74-1bfa1da017de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_3a1780a9-2c38-409e-a19a-7fa2ed9df4c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_10baf471-32f5-4afc-a692-2b820951a9d7" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_3a1780a9-2c38-409e-a19a-7fa2ed9df4c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_9c243330-77ce-42f5-9368-25b1b42b0f97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_10baf471-32f5-4afc-a692-2b820951a9d7" xlink:to="loc_us-gaap_VariableLeaseCost_9c243330-77ce-42f5-9368-25b1b42b0f97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_42ac48f2-bbbb-4ab4-b6f6-7b1c7cc740f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_10baf471-32f5-4afc-a692-2b820951a9d7" xlink:to="loc_us-gaap_OperatingLeaseCost_42ac48f2-bbbb-4ab4-b6f6-7b1c7cc740f6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/LEASESCashandNonCashInformationDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#LEASESCashandNonCashInformationDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/LEASESCashandNonCashInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/LEASESLeaseTermsandDiscountRatesDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#LEASESLeaseTermsandDiscountRatesDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/LEASESLeaseTermsandDiscountRatesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#LEASESMaturitiesofLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_d11e5305-1b05-4b49-a3f5-a463d971a30c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ade9de80-5a8f-4353-b73a-266ba5be84a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_d11e5305-1b05-4b49-a3f5-a463d971a30c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ade9de80-5a8f-4353-b73a-266ba5be84a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e703a6fb-13cc-496f-b6a1-3652b78cff76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_d11e5305-1b05-4b49-a3f5-a463d971a30c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e703a6fb-13cc-496f-b6a1-3652b78cff76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_0fbe9e38-af8e-4c07-89e0-ac3397561cd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_f1540d2f-66fe-4609-8010-c0c84cb48419" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_0fbe9e38-af8e-4c07-89e0-ac3397561cd2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_f1540d2f-66fe-4609-8010-c0c84cb48419" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_ac8cecb6-43b8-438a-be15-339a5b88f869" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_0fbe9e38-af8e-4c07-89e0-ac3397561cd2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_ac8cecb6-43b8-438a-be15-339a5b88f869" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_ef0b28ec-cd03-4a20-9518-46a355657df2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_0fbe9e38-af8e-4c07-89e0-ac3397561cd2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_ef0b28ec-cd03-4a20-9518-46a355657df2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_641a3ecc-f409-4c90-9b0e-e0e3d247b44b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_6165143b-94fe-41f6-8000-4dad7453873f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_641a3ecc-f409-4c90-9b0e-e0e3d247b44b" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_6165143b-94fe-41f6-8000-4dad7453873f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_4abecea5-3028-4db4-ae6a-24c3f35d4617" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_641a3ecc-f409-4c90-9b0e-e0e3d247b44b" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_4abecea5-3028-4db4-ae6a-24c3f35d4617" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6be9ea13-e160-47f5-a0ef-c8fbcc614017" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_68ed613a-b534-49cd-9e5d-4cf59cf4f4c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6be9ea13-e160-47f5-a0ef-c8fbcc614017" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_68ed613a-b534-49cd-9e5d-4cf59cf4f4c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8b08bd54-407b-4f87-a7c4-2262259bc301" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6be9ea13-e160-47f5-a0ef-c8fbcc614017" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8b08bd54-407b-4f87-a7c4-2262259bc301" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_abc6d0e4-ef45-4141-8a34-5969ff87be38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6be9ea13-e160-47f5-a0ef-c8fbcc614017" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_abc6d0e4-ef45-4141-8a34-5969ff87be38" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES" xlink:type="simple" xlink:href="apyx-20201231.xsd#ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables" xlink:type="simple" xlink:href="apyx-20201231.xsd#ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_9b7f97d8-aff6-4373-a9c0-cee59fd17771" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_c4f5e84f-c23c-4767-9a6a-06b5feedd60c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_9b7f97d8-aff6-4373-a9c0-cee59fd17771" xlink:to="loc_us-gaap_AccruedSalariesCurrent_c4f5e84f-c23c-4767-9a6a-06b5feedd60c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedBonusesCurrent_e1cb405d-7b04-44f3-a949-8e58883d44ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedBonusesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_9b7f97d8-aff6-4373-a9c0-cee59fd17771" xlink:to="loc_us-gaap_AccruedBonusesCurrent_e1cb405d-7b04-44f3-a949-8e58883d44ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalesCommissionCurrent_d9c60f1f-b9ed-495d-a023-8e75010a236c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalesCommissionCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_9b7f97d8-aff6-4373-a9c0-cee59fd17771" xlink:to="loc_us-gaap_AccruedSalesCommissionCurrent_d9c60f1f-b9ed-495d-a023-8e75010a236c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_a054ab7a-f286-4f8a-b7c5-4644d1309094" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_9b7f97d8-aff6-4373-a9c0-cee59fd17771" xlink:to="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_a054ab7a-f286-4f8a-b7c5-4644d1309094" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedInsuranceCurrent_8fc998c6-4a80-4789-b4ec-430a8dc03032" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedInsuranceCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_9b7f97d8-aff6-4373-a9c0-cee59fd17771" xlink:to="loc_us-gaap_AccruedInsuranceCurrent_8fc998c6-4a80-4789-b4ec-430a8dc03032" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_2771da62-c264-4701-9ff5-826a16b94cf8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_9b7f97d8-aff6-4373-a9c0-cee59fd17771" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_2771da62-c264-4701-9ff5-826a16b94cf8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_JointAndSeveralPayrollLiability_7de300df-481d-42a7-8595-065ebcb7d1f9" xlink:href="apyx-20201231.xsd#apyx_JointAndSeveralPayrollLiability"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_9b7f97d8-aff6-4373-a9c0-cee59fd17771" xlink:to="loc_apyx_JointAndSeveralPayrollLiability_7de300df-481d-42a7-8595-065ebcb7d1f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_UncertainTaxPositionsLiability_8d78f3d2-1edf-49a4-b91b-28a8f3e5f626" xlink:href="apyx-20201231.xsd#apyx_UncertainTaxPositionsLiability"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_9b7f97d8-aff6-4373-a9c0-cee59fd17771" xlink:to="loc_apyx_UncertainTaxPositionsLiability_8d78f3d2-1edf-49a4-b91b-28a8f3e5f626" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_OtherAccruedExpensesAndLiabilitiesCurrent_913f822c-2834-40af-bc49-ac441238c2c2" xlink:href="apyx-20201231.xsd#apyx_OtherAccruedExpensesAndLiabilitiesCurrent"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_9b7f97d8-aff6-4373-a9c0-cee59fd17771" xlink:to="loc_apyx_OtherAccruedExpensesAndLiabilitiesCurrent_913f822c-2834-40af-bc49-ac441238c2c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent_1ec2557f-f76c-486b-acca-188f388a9fe4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesAndExciseTaxPayableCurrent"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_9b7f97d8-aff6-4373-a9c0-cee59fd17771" xlink:to="loc_us-gaap_SalesAndExciseTaxPayableCurrent_1ec2557f-f76c-486b-acca-188f388a9fe4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/PRODUCTWARRANTIES" xlink:type="simple" xlink:href="apyx-20201231.xsd#PRODUCTWARRANTIES"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/PRODUCTWARRANTIES" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/PRODUCTWARRANTIESTables" xlink:type="simple" xlink:href="apyx-20201231.xsd#PRODUCTWARRANTIESTables"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/PRODUCTWARRANTIESTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/PRODUCTWARRANTIESDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#PRODUCTWARRANTIESDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/PRODUCTWARRANTIESDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/JOINTANDSEVERALPAYROLLLIABILITY" xlink:type="simple" xlink:href="apyx-20201231.xsd#JOINTANDSEVERALPAYROLLLIABILITY"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/JOINTANDSEVERALPAYROLLLIABILITY" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/JOINTANDSEVERALPAYROLLLIABILITYDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#JOINTANDSEVERALPAYROLLLIABILITYDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/JOINTANDSEVERALPAYROLLLIABILITYDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/EARNINGSLOSSPERSHARE" xlink:type="simple" xlink:href="apyx-20201231.xsd#EARNINGSLOSSPERSHARE"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/EARNINGSLOSSPERSHARE" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/EARNINGSLOSSPERSHARETables" xlink:type="simple" xlink:href="apyx-20201231.xsd#EARNINGSLOSSPERSHARETables"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/EARNINGSLOSSPERSHARETables" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#EARNINGSLOSSPERSHAREDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/FINANCIALINSTRUMENTS" xlink:type="simple" xlink:href="apyx-20201231.xsd#FINANCIALINSTRUMENTS"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/FINANCIALINSTRUMENTS" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/FINANCIALINSTRUMENTSDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#FINANCIALINSTRUMENTSDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/FINANCIALINSTRUMENTSDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/INCOMETAXES" xlink:type="simple" xlink:href="apyx-20201231.xsd#INCOMETAXES"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/INCOMETAXES" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/INCOMETAXESTables" xlink:type="simple" xlink:href="apyx-20201231.xsd#INCOMETAXESTables"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/INCOMETAXESTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#INCOMETAXESComponentsofProvisionForIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_cb42e47d-1730-40a9-9baa-1a7ede5164e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_06ce1f0a-d76f-4c7b-a2de-4582ef754f7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_cb42e47d-1730-40a9-9baa-1a7ede5164e7" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_06ce1f0a-d76f-4c7b-a2de-4582ef754f7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_5bffa1cd-2498-47a6-8f47-8655f0c00ae1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_cb42e47d-1730-40a9-9baa-1a7ede5164e7" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_5bffa1cd-2498-47a6-8f47-8655f0c00ae1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_33eae332-f30e-486d-a128-badb4981b3e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_cb42e47d-1730-40a9-9baa-1a7ede5164e7" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_33eae332-f30e-486d-a128-badb4981b3e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ae00a62e-e8a5-42b1-ae51-c03eb5ff662d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_IncomeTaxExpenseBenefitValuationAllowance_d1961c5a-070c-4b12-8884-618adcfbdfb4" xlink:href="apyx-20201231.xsd#apyx_IncomeTaxExpenseBenefitValuationAllowance"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_ae00a62e-e8a5-42b1-ae51-c03eb5ff662d" xlink:to="loc_apyx_IncomeTaxExpenseBenefitValuationAllowance_d1961c5a-070c-4b12-8884-618adcfbdfb4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_87a6e9e2-8af8-4124-9750-30fd9eb72cd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_ae00a62e-e8a5-42b1-ae51-c03eb5ff662d" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_87a6e9e2-8af8-4124-9750-30fd9eb72cd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_CurrentIncomeTaxExpenseBenefitAfterValuationAllowance_a472acc1-fdff-4998-8a71-40776de4c956" xlink:href="apyx-20201231.xsd#apyx_CurrentIncomeTaxExpenseBenefitAfterValuationAllowance"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_ae00a62e-e8a5-42b1-ae51-c03eb5ff662d" xlink:to="loc_apyx_CurrentIncomeTaxExpenseBenefitAfterValuationAllowance_a472acc1-fdff-4998-8a71-40776de4c956" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_CurrentIncomeTaxExpenseBenefitAfterValuationAllowance_b863b029-bbe4-4b87-9584-b82240d96c39" xlink:href="apyx-20201231.xsd#apyx_CurrentIncomeTaxExpenseBenefitAfterValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_456a1119-e083-4c9d-945c-51da961ce27d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_apyx_CurrentIncomeTaxExpenseBenefitAfterValuationAllowance_b863b029-bbe4-4b87-9584-b82240d96c39" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_456a1119-e083-4c9d-945c-51da961ce27d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_CARESActIncomeTaxExpenseBenefitValuationAllowance_0b7160de-9eb1-41d3-a6db-8b15d3f19a63" xlink:href="apyx-20201231.xsd#apyx_CARESActIncomeTaxExpenseBenefitValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_apyx_CurrentIncomeTaxExpenseBenefitAfterValuationAllowance_b863b029-bbe4-4b87-9584-b82240d96c39" xlink:to="loc_apyx_CARESActIncomeTaxExpenseBenefitValuationAllowance_0b7160de-9eb1-41d3-a6db-8b15d3f19a63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_0c5a8292-d0c3-4590-b4fe-d1161020c0d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_34d49ca5-3139-4d99-8fb2-564bd2349680" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_0c5a8292-d0c3-4590-b4fe-d1161020c0d5" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_34d49ca5-3139-4d99-8fb2-564bd2349680" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_5b7cd231-8d3d-439b-9932-a02e3c1e3c84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_0c5a8292-d0c3-4590-b4fe-d1161020c0d5" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_5b7cd231-8d3d-439b-9932-a02e3c1e3c84" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INCOMETAXESReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#INCOMETAXESReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/INCOMETAXESReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_e5661602-d9b2-48cb-a99e-986dc7ca497a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductions"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_6dc52751-2709-435f-81b2-6272a0b6dac2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_e5661602-d9b2-48cb-a99e-986dc7ca497a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_6dc52751-2709-435f-81b2-6272a0b6dac2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_98be60d8-ecaa-4cdc-b6ea-aca2068a0160" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_e5661602-d9b2-48cb-a99e-986dc7ca497a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_98be60d8-ecaa-4cdc-b6ea-aca2068a0160" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_64fbf47c-da39-4587-98da-d2a9ba5340b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_e5661602-d9b2-48cb-a99e-986dc7ca497a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_64fbf47c-da39-4587-98da-d2a9ba5340b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_EffectiveIncomeTaxRateReconciliationCARESActNetOperatingLossCarryforwardsPercent_18117de7-bc87-4653-9bb3-8689a01791a7" xlink:href="apyx-20201231.xsd#apyx_EffectiveIncomeTaxRateReconciliationCARESActNetOperatingLossCarryforwardsPercent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_e5661602-d9b2-48cb-a99e-986dc7ca497a" xlink:to="loc_apyx_EffectiveIncomeTaxRateReconciliationCARESActNetOperatingLossCarryforwardsPercent_18117de7-bc87-4653-9bb3-8689a01791a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_76b01c2b-8df4-48df-9e79-ae072d7700da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_e5661602-d9b2-48cb-a99e-986dc7ca497a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_76b01c2b-8df4-48df-9e79-ae072d7700da" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#INCOMETAXESDeferredTaxAssetsLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_8f29a485-e181-49ad-b2b7-7d6ee9a0ec7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_6074bb72-b5c7-45eb-9d35-4825663d8d83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8f29a485-e181-49ad-b2b7-7d6ee9a0ec7a" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_6074bb72-b5c7-45eb-9d35-4825663d8d83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_af720f63-e2cd-42a4-ad71-35b00b5747d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8f29a485-e181-49ad-b2b7-7d6ee9a0ec7a" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_af720f63-e2cd-42a4-ad71-35b00b5747d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_22bd7be1-3a04-4b92-8182-6e6048159677" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8f29a485-e181-49ad-b2b7-7d6ee9a0ec7a" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_22bd7be1-3a04-4b92-8182-6e6048159677" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_2b7ec805-aa24-4e8a-a9d4-0f931a8e2b00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_1649ab7f-7eee-4efb-86ca-f368ebe21b55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_2b7ec805-aa24-4e8a-a9d4-0f931a8e2b00" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_1649ab7f-7eee-4efb-86ca-f368ebe21b55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_ca7686cb-1b97-4602-bfd8-da325c266001" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_2b7ec805-aa24-4e8a-a9d4-0f931a8e2b00" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_ca7686cb-1b97-4602-bfd8-da325c266001" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_c4f40ddd-9511-4620-a591-9b05f75f1706" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_a772b957-f29b-4b50-a25f-a94e26648b9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_c4f40ddd-9511-4620-a591-9b05f75f1706" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_a772b957-f29b-4b50-a25f-a94e26648b9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_597fe66d-a229-4cdb-9925-4fbb4db17312" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_c4f40ddd-9511-4620-a591-9b05f75f1706" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_597fe66d-a229-4cdb-9925-4fbb4db17312" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_a3649cee-55a7-4b69-a859-d03d50cf2ff6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_cb51ac5a-f24f-4858-aa6d-6c3fb665c9a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_a3649cee-55a7-4b69-a859-d03d50cf2ff6" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_cb51ac5a-f24f-4858-aa6d-6c3fb665c9a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_73b34a22-ce1b-4712-a97e-bdb0a2f18ebe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_a3649cee-55a7-4b69-a859-d03d50cf2ff6" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_73b34a22-ce1b-4712-a97e-bdb0a2f18ebe" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INCOMETAXESNarrativeDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#INCOMETAXESNarrativeDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/INCOMETAXESNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/INCOMETAXESUnrecognizedTaxBenefitsRollForwardDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#INCOMETAXESUnrecognizedTaxBenefitsRollForwardDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/INCOMETAXESUnrecognizedTaxBenefitsRollForwardDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/RETIREMENTPLAN" xlink:type="simple" xlink:href="apyx-20201231.xsd#RETIREMENTPLAN"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/RETIREMENTPLAN" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/RETIREMENTPLANNarrativeDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#RETIREMENTPLANNarrativeDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/RETIREMENTPLANNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="simple" xlink:href="apyx-20201231.xsd#RELATEDPARTYTRANSACTIONS"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#RELATEDPARTYTRANSACTIONSNarrativeDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="apyx-20201231.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/STOCKOPTIONS" xlink:type="simple" xlink:href="apyx-20201231.xsd#STOCKOPTIONS"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/STOCKOPTIONS" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/STOCKOPTIONSTables" xlink:type="simple" xlink:href="apyx-20201231.xsd#STOCKOPTIONSTables"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/STOCKOPTIONSTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#STOCKOPTIONSNarrativeDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/STOCKOPTIONSSummaryofStockOptionsDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#STOCKOPTIONSSummaryofStockOptionsDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/STOCKOPTIONSSummaryofStockOptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/STOCKOPTIONSSummaryofNonvestedStockOptionsDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#STOCKOPTIONSSummaryofNonvestedStockOptionsDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/STOCKOPTIONSSummaryofNonvestedStockOptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/STOCKOPTIONSSTOCKOPTIONSFairValueAssumptionsDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#STOCKOPTIONSSTOCKOPTIONSFairValueAssumptionsDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/STOCKOPTIONSSTOCKOPTIONSFairValueAssumptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATION" xlink:type="simple" xlink:href="apyx-20201231.xsd#GEOGRAPHICANDSEGMENTINFORMATION"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATION" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONTables" xlink:type="simple" xlink:href="apyx-20201231.xsd#GEOGRAPHICANDSEGMENTINFORMATIONTables"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>apyx-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:3619fb04-76d2-4e32-a22c-67723657dfe5,g:73c9cb31-492e-4d91-a8e4-50624d0c0cae-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/Cover" xlink:type="simple" xlink:href="apyx-20201231.xsd#Cover"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/Cover" xlink:type="extended" id="i42f07eefad48465ea7afeb2ae524c9a7_Cover"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="apyx-20201231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended" id="i8b8932baac3e4068a5d08ed9cb5bb6a6_CONSOLIDATEDBALANCESHEETS"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="apyx-20201231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended" id="ifa8c67b0b62d41ca9f8c002852078782_CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="apyx-20201231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended" id="i9084fd000e194edaa0c838e601264c37_CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" xlink:type="simple" xlink:href="apyx-20201231.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" xlink:type="extended" id="iae27e68cc6ee46e0b0871ad0e1e7e382_CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b898370b-f0b3-498b-9a44-7ea6354a262b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_287aa085-3472-4897-8b15-0535b06a6a21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b898370b-f0b3-498b-9a44-7ea6354a262b" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_287aa085-3472-4897-8b15-0535b06a6a21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_66ebaf87-676f-41e5-8972-16510c392512" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_287aa085-3472-4897-8b15-0535b06a6a21" xlink:to="loc_us-gaap_SharesIssued_66ebaf87-676f-41e5-8972-16510c392512" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_78fc85da-03ac-4c91-8f82-e0b98a268d89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_287aa085-3472-4897-8b15-0535b06a6a21" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_78fc85da-03ac-4c91-8f82-e0b98a268d89" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_28425d4a-bec0-499a-a81a-829556a89ed7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_287aa085-3472-4897-8b15-0535b06a6a21" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_28425d4a-bec0-499a-a81a-829556a89ed7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1c0184ed-3b97-4af0-85af-3384791806fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_287aa085-3472-4897-8b15-0535b06a6a21" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1c0184ed-3b97-4af0-85af-3384791806fd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0be28cdb-a7ea-413c-b99d-5c40e0455066" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_287aa085-3472-4897-8b15-0535b06a6a21" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0be28cdb-a7ea-413c-b99d-5c40e0455066" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3ec08fb7-3343-4275-91f4-aa548b4f73ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_287aa085-3472-4897-8b15-0535b06a6a21" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3ec08fb7-3343-4275-91f4-aa548b4f73ac" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_StockSwapToAcquireOptionsShares_19e1b98f-5a3c-4704-88d1-4377cafb16a0" xlink:href="apyx-20201231.xsd#apyx_StockSwapToAcquireOptionsShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_287aa085-3472-4897-8b15-0535b06a6a21" xlink:to="loc_apyx_StockSwapToAcquireOptionsShares_19e1b98f-5a3c-4704-88d1-4377cafb16a0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_5ba03586-2f7b-46bb-a93c-f92b0a8d4ea4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_287aa085-3472-4897-8b15-0535b06a6a21" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_5ba03586-2f7b-46bb-a93c-f92b0a8d4ea4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c253c71a-e316-4005-b949-7e7beb549baa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_287aa085-3472-4897-8b15-0535b06a6a21" xlink:to="loc_us-gaap_ProfitLoss_c253c71a-e316-4005-b949-7e7beb549baa" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_f1ba1306-6d26-482c-8e3e-5d0dc32cdd17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7c6ce073-0946-433f-a83f-9ec846dd3b61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_843c1b34-d44e-47b7-bc64-5d2930dc49d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_b898370b-f0b3-498b-9a44-7ea6354a262b" xlink:to="loc_us-gaap_StatementTable_843c1b34-d44e-47b7-bc64-5d2930dc49d6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_31a7c839-1adc-49cc-88ba-2fe6c3976f0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_843c1b34-d44e-47b7-bc64-5d2930dc49d6" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_31a7c839-1adc-49cc-88ba-2fe6c3976f0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_31a7c839-1adc-49cc-88ba-2fe6c3976f0d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_31a7c839-1adc-49cc-88ba-2fe6c3976f0d" xlink:to="loc_us-gaap_EquityComponentDomain_31a7c839-1adc-49cc-88ba-2fe6c3976f0d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b2d3570e-1daf-4de2-ac25-5158bcd3f271" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_31a7c839-1adc-49cc-88ba-2fe6c3976f0d" xlink:to="loc_us-gaap_EquityComponentDomain_b2d3570e-1daf-4de2-ac25-5158bcd3f271" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_263eefeb-9ee0-4371-8dd0-a31b35c8c6a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b2d3570e-1daf-4de2-ac25-5158bcd3f271" xlink:to="loc_us-gaap_CommonStockMember_263eefeb-9ee0-4371-8dd0-a31b35c8c6a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_20e271ff-1895-45c8-b64a-b458ade3cfa4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b2d3570e-1daf-4de2-ac25-5158bcd3f271" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_20e271ff-1895-45c8-b64a-b458ade3cfa4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_1af67008-b370-4c1d-96ef-604f2c20b864" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b2d3570e-1daf-4de2-ac25-5158bcd3f271" xlink:to="loc_us-gaap_RetainedEarningsMember_1af67008-b370-4c1d-96ef-604f2c20b864" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_a043d3e6-2467-4134-9fe5-eb2d701d738d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b2d3570e-1daf-4de2-ac25-5158bcd3f271" xlink:to="loc_us-gaap_NoncontrollingInterestMember_a043d3e6-2467-4134-9fe5-eb2d701d738d" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="apyx-20201231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended" id="ic5e409f5e4e84b32911724ad5a2e5328_CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/DESCRIPTIONOFBUSINESS" xlink:type="simple" xlink:href="apyx-20201231.xsd#DESCRIPTIONOFBUSINESS"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/DESCRIPTIONOFBUSINESS" xlink:type="extended" id="iec31420d41484bde87ba7fa58c206281_DESCRIPTIONOFBUSINESS"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="apyx-20201231.xsd#SIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended" id="i10b42be0457f402a82dc2a6aac6c9f53_SIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="apyx-20201231.xsd#SIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended" id="idaae253a259e4481948142d601669423_SIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="extended" id="iec23d043a11a4b4d9a0ff6b53ed5416f_SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_18c9f329-b312-4738-8958-9fb83cc3e47d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_4f3d0b19-2524-46d4-ad09-ec7bb485ab28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_18c9f329-b312-4738-8958-9fb83cc3e47d" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_4f3d0b19-2524-46d4-ad09-ec7bb485ab28" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SalesDiscountBillingTermsLowerLimit_30782c30-508f-4cd1-ba61-5075106fcd8f" xlink:href="apyx-20201231.xsd#apyx_SalesDiscountBillingTermsLowerLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_18c9f329-b312-4738-8958-9fb83cc3e47d" xlink:to="loc_apyx_SalesDiscountBillingTermsLowerLimit_30782c30-508f-4cd1-ba61-5075106fcd8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SalesDiscountBillingTermsUpperLimit_80a1bf05-de49-45ce-aa58-6087586c03a1" xlink:href="apyx-20201231.xsd#apyx_SalesDiscountBillingTermsUpperLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_18c9f329-b312-4738-8958-9fb83cc3e47d" xlink:to="loc_apyx_SalesDiscountBillingTermsUpperLimit_80a1bf05-de49-45ce-aa58-6087586c03a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_542b6965-45ab-4851-a37d-d7d9a0e16d52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_18c9f329-b312-4738-8958-9fb83cc3e47d" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_542b6965-45ab-4851-a37d-d7d9a0e16d52" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_522504d1-8371-436c-ad4c-a7927b60c7fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_18c9f329-b312-4738-8958-9fb83cc3e47d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_522504d1-8371-436c-ad4c-a7927b60c7fc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ProductWarranty_136e4841-d7c5-4bcb-b9fe-937a0c2c6e6f" xlink:href="apyx-20201231.xsd#apyx_ProductWarranty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_18c9f329-b312-4738-8958-9fb83cc3e47d" xlink:to="loc_apyx_ProductWarranty_136e4841-d7c5-4bcb-b9fe-937a0c2c6e6f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_617fe436-5906-49b0-91c0-0c70a7ae5da3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_18c9f329-b312-4738-8958-9fb83cc3e47d" xlink:to="loc_us-gaap_ContractWithCustomerLiability_617fe436-5906-49b0-91c0-0c70a7ae5da3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_dff6c0cf-117c-4251-8348-2f0ab508f739" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_18c9f329-b312-4738-8958-9fb83cc3e47d" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_dff6c0cf-117c-4251-8348-2f0ab508f739" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_2edd0a64-9ac9-43a3-8634-d387dafc513a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_18c9f329-b312-4738-8958-9fb83cc3e47d" xlink:to="loc_us-gaap_AdvertisingExpense_2edd0a64-9ac9-43a3-8634-d387dafc513a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1d6d23a1-d1a9-4996-9fb1-0d13ee99b351" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_18c9f329-b312-4738-8958-9fb83cc3e47d" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1d6d23a1-d1a9-4996-9fb1-0d13ee99b351" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_78339cd9-0ca8-4d2d-9065-f81d264e28c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1d6d23a1-d1a9-4996-9fb1-0d13ee99b351" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_78339cd9-0ca8-4d2d-9065-f81d264e28c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_78339cd9-0ca8-4d2d-9065-f81d264e28c3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_78339cd9-0ca8-4d2d-9065-f81d264e28c3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_78339cd9-0ca8-4d2d-9065-f81d264e28c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_16bd3d24-ad63-47ca-a4d2-9cf64efd859d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_78339cd9-0ca8-4d2d-9065-f81d264e28c3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_16bd3d24-ad63-47ca-a4d2-9cf64efd859d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_480076df-ca59-4540-82a7-4b4692a604f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_16bd3d24-ad63-47ca-a4d2-9cf64efd859d" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_480076df-ca59-4540-82a7-4b4692a604f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_8c644420-02cc-4479-b51d-a341d63f2814" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_16bd3d24-ad63-47ca-a4d2-9cf64efd859d" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_8c644420-02cc-4479-b51d-a341d63f2814" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_bad36573-244e-443e-80ae-3aa749933b0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_16bd3d24-ad63-47ca-a4d2-9cf64efd859d" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_bad36573-244e-443e-80ae-3aa749933b0f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ComputerEquipmentandSoftwareMember_771dc03d-716e-4a16-8392-827b87246dc7" xlink:href="apyx-20201231.xsd#apyx_ComputerEquipmentandSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_16bd3d24-ad63-47ca-a4d2-9cf64efd859d" xlink:to="loc_apyx_ComputerEquipmentandSoftwareMember_771dc03d-716e-4a16-8392-827b87246dc7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ToolsDiesAndMoldsMember_151aa83f-5718-4a62-a07e-9ddad4e94e77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ToolsDiesAndMoldsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_16bd3d24-ad63-47ca-a4d2-9cf64efd859d" xlink:to="loc_us-gaap_ToolsDiesAndMoldsMember_151aa83f-5718-4a62-a07e-9ddad4e94e77" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_RenuvionJPlasmaGeneratorsMember_c2a3fe47-aeb2-4d8e-99ef-1d2a1ed0c25e" xlink:href="apyx-20201231.xsd#apyx_RenuvionJPlasmaGeneratorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_16bd3d24-ad63-47ca-a4d2-9cf64efd859d" xlink:to="loc_apyx_RenuvionJPlasmaGeneratorsMember_c2a3fe47-aeb2-4d8e-99ef-1d2a1ed0c25e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_MountingFixturesMember_dad04932-cbcf-45f5-80c0-e69c33e926cd" xlink:href="apyx-20201231.xsd#apyx_MountingFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_16bd3d24-ad63-47ca-a4d2-9cf64efd859d" xlink:to="loc_apyx_MountingFixturesMember_dad04932-cbcf-45f5-80c0-e69c33e926cd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AccessoriesMember_64b564b3-4856-4236-852a-2f8822c32998" xlink:href="apyx-20201231.xsd#apyx_AccessoriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_16bd3d24-ad63-47ca-a4d2-9cf64efd859d" xlink:to="loc_apyx_AccessoriesMember_64b564b3-4856-4236-852a-2f8822c32998" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1d31b973-88af-44c5-aa7b-fa0934000ec1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1d6d23a1-d1a9-4996-9fb1-0d13ee99b351" xlink:to="loc_srt_RangeAxis_1d31b973-88af-44c5-aa7b-fa0934000ec1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1d31b973-88af-44c5-aa7b-fa0934000ec1_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1d31b973-88af-44c5-aa7b-fa0934000ec1" xlink:to="loc_srt_RangeMember_1d31b973-88af-44c5-aa7b-fa0934000ec1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a9f2b596-c4a6-4d6f-9cef-7dd6702435b7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1d31b973-88af-44c5-aa7b-fa0934000ec1" xlink:to="loc_srt_RangeMember_a9f2b596-c4a6-4d6f-9cef-7dd6702435b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_47e20b77-d907-46d0-ba59-a5b59875a0bf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a9f2b596-c4a6-4d6f-9cef-7dd6702435b7" xlink:to="loc_srt_MinimumMember_47e20b77-d907-46d0-ba59-a5b59875a0bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bd3d9a31-a2b0-4c05-b66f-8a099564faec" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a9f2b596-c4a6-4d6f-9cef-7dd6702435b7" xlink:to="loc_srt_MaximumMember_bd3d9a31-a2b0-4c05-b66f-8a099564faec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_b7f8a004-b340-4cca-8e27-35372a084042" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1d6d23a1-d1a9-4996-9fb1-0d13ee99b351" xlink:to="loc_srt_OwnershipAxis_b7f8a004-b340-4cca-8e27-35372a084042" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_b7f8a004-b340-4cca-8e27-35372a084042_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_b7f8a004-b340-4cca-8e27-35372a084042" xlink:to="loc_srt_OwnershipDomain_b7f8a004-b340-4cca-8e27-35372a084042_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_542ad6b9-a28f-4bbb-98cb-ec77ccf50d3c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_b7f8a004-b340-4cca-8e27-35372a084042" xlink:to="loc_srt_OwnershipDomain_542ad6b9-a28f-4bbb-98cb-ec77ccf50d3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ApyxSYMedicalDevicesNingboCoLtdMember_43b7d5c9-6b24-4145-82d3-51bfbe528e76" xlink:href="apyx-20201231.xsd#apyx_ApyxSYMedicalDevicesNingboCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_542ad6b9-a28f-4bbb-98cb-ec77ccf50d3c" xlink:to="loc_apyx_ApyxSYMedicalDevicesNingboCoLtdMember_43b7d5c9-6b24-4145-82d3-51bfbe528e76" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CHANGEINACCOUNTINGPOLICY" xlink:type="simple" xlink:href="apyx-20201231.xsd#CHANGEINACCOUNTINGPOLICY"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/CHANGEINACCOUNTINGPOLICY" xlink:type="extended" id="i4dfc442f0d394bc2bbd399ddaff88d10_CHANGEINACCOUNTINGPOLICY"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/RECENTACCOUNTINGPRONOUNCEMENTS" xlink:type="simple" xlink:href="apyx-20201231.xsd#RECENTACCOUNTINGPRONOUNCEMENTS"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/RECENTACCOUNTINGPRONOUNCEMENTS" xlink:type="extended" id="ie8c63a6256c14f12aa1241fbf0f34ed8_RECENTACCOUNTINGPRONOUNCEMENTS"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESS" xlink:type="simple" xlink:href="apyx-20201231.xsd#DISPOSITIONOFTHECOREBUSINESS"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESS" xlink:type="extended" id="ibe099713eccc4e4f809fc4945fd54330_DISPOSITIONOFTHECOREBUSINESS"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESSDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#DISPOSITIONOFTHECOREBUSINESSDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESSDetails" xlink:type="extended" id="i015ae03a27304ea9a87f503c6cf2f447_DISPOSITIONOFTHECOREBUSINESSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_abc68fcb-1516-4206-ae06-2e1ef9252a40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_608d2d17-ffc0-4fa1-882f-32430b889fb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_abc68fcb-1516-4206-ae06-2e1ef9252a40" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_608d2d17-ffc0-4fa1-882f-32430b889fb3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AssetPurchaseAgreementTerm_b5dab036-19be-4a47-a900-a5ddc0252b80" xlink:href="apyx-20201231.xsd#apyx_AssetPurchaseAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_abc68fcb-1516-4206-ae06-2e1ef9252a40" xlink:to="loc_apyx_AssetPurchaseAgreementTerm_b5dab036-19be-4a47-a900-a5ddc0252b80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_4b407956-8511-4159-ba77-6d82f4f8acc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_abc68fcb-1516-4206-ae06-2e1ef9252a40" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_4b407956-8511-4159-ba77-6d82f4f8acc9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_d9104fc3-b6b1-4e06-b7f0-a476e1714098" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_abc68fcb-1516-4206-ae06-2e1ef9252a40" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_d9104fc3-b6b1-4e06-b7f0-a476e1714098" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_eafd8e82-a828-4395-b36f-bab468fa9df5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_abc68fcb-1516-4206-ae06-2e1ef9252a40" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_eafd8e82-a828-4395-b36f-bab468fa9df5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_826afb7b-21e8-4453-8e81-d3447ecfb04f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_abc68fcb-1516-4206-ae06-2e1ef9252a40" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_826afb7b-21e8-4453-8e81-d3447ecfb04f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1325d896-646b-4636-848c-909a3aaf77e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_abc68fcb-1516-4206-ae06-2e1ef9252a40" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1325d896-646b-4636-848c-909a3aaf77e9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_66da8bed-1b7b-4b61-87ac-73b2cb09b8c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1325d896-646b-4636-848c-909a3aaf77e9" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_66da8bed-1b7b-4b61-87ac-73b2cb09b8c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_66da8bed-1b7b-4b61-87ac-73b2cb09b8c9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_66da8bed-1b7b-4b61-87ac-73b2cb09b8c9" xlink:to="loc_us-gaap_RelatedPartyDomain_66da8bed-1b7b-4b61-87ac-73b2cb09b8c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_bec64f32-6f07-435b-a438-2c542ca01636" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_66da8bed-1b7b-4b61-87ac-73b2cb09b8c9" xlink:to="loc_us-gaap_RelatedPartyDomain_bec64f32-6f07-435b-a438-2c542ca01636" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SymmetrySurgicalInc.Member_7c1bbc69-9164-4439-840e-584095b7e1eb" xlink:href="apyx-20201231.xsd#apyx_SymmetrySurgicalInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_bec64f32-6f07-435b-a438-2c542ca01636" xlink:to="loc_apyx_SymmetrySurgicalInc.Member_7c1bbc69-9164-4439-840e-584095b7e1eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_c9c52644-a21d-4679-93fe-131de6c2dfc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1325d896-646b-4636-848c-909a3aaf77e9" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_c9c52644-a21d-4679-93fe-131de6c2dfc9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_c9c52644-a21d-4679-93fe-131de6c2dfc9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_c9c52644-a21d-4679-93fe-131de6c2dfc9" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_c9c52644-a21d-4679-93fe-131de6c2dfc9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_fb8312a0-82f4-4832-a019-6f0ac6884c6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_c9c52644-a21d-4679-93fe-131de6c2dfc9" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_fb8312a0-82f4-4832-a019-6f0ac6884c6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember_6eb68329-fb89-4b8f-8bfb-cf507efb10f0" xlink:href="apyx-20201231.xsd#apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_fb8312a0-82f4-4832-a019-6f0ac6884c6e" xlink:to="loc_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember_6eb68329-fb89-4b8f-8bfb-cf507efb10f0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENT" xlink:type="simple" xlink:href="apyx-20201231.xsd#INTERESTINJOINTVENTUREINVESTMENT"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENT" xlink:type="extended" id="i922803be7e4443aaaa54ecf978b0b1a4_INTERESTINJOINTVENTUREINVESTMENT"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTTables" xlink:type="simple" xlink:href="apyx-20201231.xsd#INTERESTINJOINTVENTUREINVESTMENTTables"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTTables" xlink:type="extended" id="i9ab1902aea0d4af8a646305a8f552f7a_INTERESTINJOINTVENTUREINVESTMENTTables"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails" xlink:type="extended" id="ib8b247037e2c4ee992163a6e8f46b540_INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_35826f1b-8580-4843-84d3-5610de771499" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_NoncontrollingInterestRequiredCapitalContribution_8922d276-760f-4869-8f96-4b9bb29f131f" xlink:href="apyx-20201231.xsd#apyx_NoncontrollingInterestRequiredCapitalContribution"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_35826f1b-8580-4843-84d3-5610de771499" xlink:to="loc_apyx_NoncontrollingInterestRequiredCapitalContribution_8922d276-760f-4869-8f96-4b9bb29f131f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_b67d3d34-404d-4d68-a471-e04612944ca6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_35826f1b-8580-4843-84d3-5610de771499" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_b67d3d34-404d-4d68-a471-e04612944ca6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_c829f1ba-88f2-44ea-9f01-6adcd351e6e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_35826f1b-8580-4843-84d3-5610de771499" xlink:to="loc_us-gaap_MinorityInterestTable_c829f1ba-88f2-44ea-9f01-6adcd351e6e1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3ab149cd-6af3-4793-9d5e-06739f6b6238" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_c829f1ba-88f2-44ea-9f01-6adcd351e6e1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3ab149cd-6af3-4793-9d5e-06739f6b6238" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_3ab149cd-6af3-4793-9d5e-06739f6b6238_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3ab149cd-6af3-4793-9d5e-06739f6b6238" xlink:to="loc_us-gaap_RelatedPartyDomain_3ab149cd-6af3-4793-9d5e-06739f6b6238_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_45d5af24-d5aa-4608-9dc5-5dfacd330aed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3ab149cd-6af3-4793-9d5e-06739f6b6238" xlink:to="loc_us-gaap_RelatedPartyDomain_45d5af24-d5aa-4608-9dc5-5dfacd330aed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember_cb931c4a-d8a2-457d-9fe9-f995141acc06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_45d5af24-d5aa-4608-9dc5-5dfacd330aed" xlink:to="loc_us-gaap_CorporateJointVentureMember_cb931c4a-d8a2-457d-9fe9-f995141acc06" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTChangesinOwnershipInterestDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#INTERESTINJOINTVENTUREINVESTMENTChangesinOwnershipInterestDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTChangesinOwnershipInterestDetails" xlink:type="extended" id="i31a6f254d8ef451ab26fa6a0082a05d9_INTERESTINJOINTVENTUREINVESTMENTChangesinOwnershipInterestDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_6eb1b7a1-b702-48b9-8a31-5a066b538f1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_10f60e5a-eac6-4220-ad8a-13e99157de15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_6eb1b7a1-b702-48b9-8a31-5a066b538f1c" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_10f60e5a-eac6-4220-ad8a-13e99157de15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward_c8f668b1-e7f7-4ab9-9af2-2240e061f54b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_6eb1b7a1-b702-48b9-8a31-5a066b538f1c" xlink:to="loc_us-gaap_MovementInMinorityInterestRollForward_c8f668b1-e7f7-4ab9-9af2-2240e061f54b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_62a0eef4-93b4-477f-ae61-dc742052b40b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_c8f668b1-e7f7-4ab9-9af2-2240e061f54b" xlink:to="loc_us-gaap_MinorityInterest_62a0eef4-93b4-477f-ae61-dc742052b40b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_4e7a6f8a-4b36-42f4-ba9d-586377dd5afc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_c8f668b1-e7f7-4ab9-9af2-2240e061f54b" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_4e7a6f8a-4b36-42f4-ba9d-586377dd5afc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_200c6f29-be71-419f-b348-8876110622ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_c8f668b1-e7f7-4ab9-9af2-2240e061f54b" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_200c6f29-be71-419f-b348-8876110622ef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_0829463a-59ce-4272-88e3-b33df649e2b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_ebf3e965-1bde-47af-b8c3-20be3b29e165" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_6eb1b7a1-b702-48b9-8a31-5a066b538f1c" xlink:to="loc_us-gaap_MinorityInterestTable_ebf3e965-1bde-47af-b8c3-20be3b29e165" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_8af760e2-9e3d-453e-aa18-3e6b8537cfd3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_ebf3e965-1bde-47af-b8c3-20be3b29e165" xlink:to="loc_srt_OwnershipAxis_8af760e2-9e3d-453e-aa18-3e6b8537cfd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_8af760e2-9e3d-453e-aa18-3e6b8537cfd3_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_8af760e2-9e3d-453e-aa18-3e6b8537cfd3" xlink:to="loc_srt_OwnershipDomain_8af760e2-9e3d-453e-aa18-3e6b8537cfd3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_f3436348-39fe-4aff-ab85-6412bb778d0b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_8af760e2-9e3d-453e-aa18-3e6b8537cfd3" xlink:to="loc_srt_OwnershipDomain_f3436348-39fe-4aff-ab85-6412bb778d0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ChineseSupplierMember_937fb031-2727-4543-9e2c-d9ddcf366fce" xlink:href="apyx-20201231.xsd#apyx_ChineseSupplierMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_f3436348-39fe-4aff-ab85-6412bb778d0b" xlink:to="loc_apyx_ChineseSupplierMember_937fb031-2727-4543-9e2c-d9ddcf366fce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6b150267-504b-421c-b6ed-3bc62ae6d997" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_ebf3e965-1bde-47af-b8c3-20be3b29e165" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6b150267-504b-421c-b6ed-3bc62ae6d997" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_6b150267-504b-421c-b6ed-3bc62ae6d997_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6b150267-504b-421c-b6ed-3bc62ae6d997" xlink:to="loc_us-gaap_RelatedPartyDomain_6b150267-504b-421c-b6ed-3bc62ae6d997_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_23c098f6-c6cb-42ee-aa3c-c5ecc0a178ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6b150267-504b-421c-b6ed-3bc62ae6d997" xlink:to="loc_us-gaap_RelatedPartyDomain_23c098f6-c6cb-42ee-aa3c-c5ecc0a178ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember_b9a9582c-b779-4e6f-865b-8559bc85e446" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_23c098f6-c6cb-42ee-aa3c-c5ecc0a178ff" xlink:to="loc_us-gaap_CorporateJointVentureMember_b9a9582c-b779-4e6f-865b-8559bc85e446" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INVENTORIES" xlink:type="simple" xlink:href="apyx-20201231.xsd#INVENTORIES"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/INVENTORIES" xlink:type="extended" id="i4ca7ff85e5154e7fb5154f964ce2f175_INVENTORIES"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/INVENTORIESTables" xlink:type="simple" xlink:href="apyx-20201231.xsd#INVENTORIESTables"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/INVENTORIESTables" xlink:type="extended" id="id6276579bd83477da5b98eee213d97de_INVENTORIESTables"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/INVENTORIESDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#INVENTORIESDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/INVENTORIESDetails" xlink:type="extended" id="i3a34f6ceca5b4647aea2aeeb40edc3db_INVENTORIESDetails"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/PROPERTYANDEQUIPMENT" xlink:type="simple" xlink:href="apyx-20201231.xsd#PROPERTYANDEQUIPMENT"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/PROPERTYANDEQUIPMENT" xlink:type="extended" id="i629ac98e6ac44e4ca0ff8f7a68e71322_PROPERTYANDEQUIPMENT"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/PROPERTYANDEQUIPMENTTables" xlink:type="simple" xlink:href="apyx-20201231.xsd#PROPERTYANDEQUIPMENTTables"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/PROPERTYANDEQUIPMENTTables" xlink:type="extended" id="i4b8be61873b44e5fa0f7e9b56fc7824d_PROPERTYANDEQUIPMENTTables"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" xlink:type="extended" id="ic1580879e91e46988b0106aeb1bd4e5e_PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6ab78af3-568b-4a55-965d-7e5edc21009b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_a946ca07-6b22-485b-b843-7ac3ee016899" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6ab78af3-568b-4a55-965d-7e5edc21009b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_a946ca07-6b22-485b-b843-7ac3ee016899" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_94ca4318-a091-4fe9-94f9-f255e3bc57ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6ab78af3-568b-4a55-965d-7e5edc21009b" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_94ca4318-a091-4fe9-94f9-f255e3bc57ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations_72b86947-0e70-4aff-b682-3f5e25ed0966" xlink:href="apyx-20201231.xsd#apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6ab78af3-568b-4a55-965d-7e5edc21009b" xlink:to="loc_apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations_72b86947-0e70-4aff-b682-3f5e25ed0966" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_4c6a8212-b206-4322-9644-c373163b8355" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6ab78af3-568b-4a55-965d-7e5edc21009b" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_4c6a8212-b206-4322-9644-c373163b8355" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_540310ab-d87d-492a-9287-657df72e0435" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6ab78af3-568b-4a55-965d-7e5edc21009b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_540310ab-d87d-492a-9287-657df72e0435" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_49472756-75af-48b9-bd10-6b2985b05501" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6ab78af3-568b-4a55-965d-7e5edc21009b" xlink:to="loc_us-gaap_Depreciation_49472756-75af-48b9-bd10-6b2985b05501" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_34f8b5cf-955f-44f3-b13b-e197bfbafb00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6ab78af3-568b-4a55-965d-7e5edc21009b" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_34f8b5cf-955f-44f3-b13b-e197bfbafb00" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_72de166a-0ea1-47c0-8f2b-a443bd7dea51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_34f8b5cf-955f-44f3-b13b-e197bfbafb00" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_72de166a-0ea1-47c0-8f2b-a443bd7dea51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_72de166a-0ea1-47c0-8f2b-a443bd7dea51_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_72de166a-0ea1-47c0-8f2b-a443bd7dea51" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_72de166a-0ea1-47c0-8f2b-a443bd7dea51_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ef916bc8-0136-413a-8abd-73524e5c36b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_72de166a-0ea1-47c0-8f2b-a443bd7dea51" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ef916bc8-0136-413a-8abd-73524e5c36b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_f2fc782a-1675-480c-a23c-65c75f868fe7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ef916bc8-0136-413a-8abd-73524e5c36b9" xlink:to="loc_us-gaap_LandMember_f2fc782a-1675-480c-a23c-65c75f868fe7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_0712e80d-3436-477f-a32d-c36c031803f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ef916bc8-0136-413a-8abd-73524e5c36b9" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_0712e80d-3436-477f-a32d-c36c031803f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_4c18f5f6-31d6-439b-87a3-8caac5cafb29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ef916bc8-0136-413a-8abd-73524e5c36b9" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_4c18f5f6-31d6-439b-87a3-8caac5cafb29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_54e69f98-2c96-4cef-9fb9-6db19ae2e05c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ef916bc8-0136-413a-8abd-73524e5c36b9" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_54e69f98-2c96-4cef-9fb9-6db19ae2e05c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ComputerEquipmentandSoftwareMember_4ff4c7bb-f7d7-4d89-8955-682a5632ca04" xlink:href="apyx-20201231.xsd#apyx_ComputerEquipmentandSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ef916bc8-0136-413a-8abd-73524e5c36b9" xlink:to="loc_apyx_ComputerEquipmentandSoftwareMember_4ff4c7bb-f7d7-4d89-8955-682a5632ca04" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_8851606a-46b3-4233-af00-fd0abfca3b33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ef916bc8-0136-413a-8abd-73524e5c36b9" xlink:to="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_8851606a-46b3-4233-af00-fd0abfca3b33" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ToolsDiesAndMoldsMember_d5603058-f968-446d-9185-2ea085b352b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ToolsDiesAndMoldsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ef916bc8-0136-413a-8abd-73524e5c36b9" xlink:to="loc_us-gaap_ToolsDiesAndMoldsMember_d5603058-f968-446d-9185-2ea085b352b5" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/LEASES" xlink:type="simple" xlink:href="apyx-20201231.xsd#LEASES"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/LEASES" xlink:type="extended" id="idd7abf9f6c064f05932f1cfbd3b05a54_LEASES"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/LEASESTables" xlink:type="simple" xlink:href="apyx-20201231.xsd#LEASESTables"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/LEASESTables" xlink:type="extended" id="i2a4a5cdf8dd74f5f89cd98e485ed0a80_LEASESTables"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/LEASESNarrativeDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#LEASESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/LEASESNarrativeDetails" xlink:type="extended" id="i08e34a5cc79f41c0b090c806c280e348_LEASESNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_b4f02465-ff00-42c1-bec4-d3b8d37bcc95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_LesseeDiscountRateIncrementalBorrowingRate_3f7e8f82-807c-4a7d-b904-3d1de4b82d40" xlink:href="apyx-20201231.xsd#apyx_LesseeDiscountRateIncrementalBorrowingRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b4f02465-ff00-42c1-bec4-d3b8d37bcc95" xlink:to="loc_apyx_LesseeDiscountRateIncrementalBorrowingRate_3f7e8f82-807c-4a7d-b904-3d1de4b82d40" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_fc950064-305b-46ae-9ee1-3f87b4ee5d25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b4f02465-ff00-42c1-bec4-d3b8d37bcc95" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_fc950064-305b-46ae-9ee1-3f87b4ee5d25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_d1ee9217-2bdd-4669-a083-ee73d22d198b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b4f02465-ff00-42c1-bec4-d3b8d37bcc95" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_d1ee9217-2bdd-4669-a083-ee73d22d198b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_49d0226c-2149-4c82-82ef-881404bba401" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_d1ee9217-2bdd-4669-a083-ee73d22d198b" xlink:to="loc_srt_StatementGeographicalAxis_49d0226c-2149-4c82-82ef-881404bba401" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_49d0226c-2149-4c82-82ef-881404bba401_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_49d0226c-2149-4c82-82ef-881404bba401" xlink:to="loc_srt_SegmentGeographicalDomain_49d0226c-2149-4c82-82ef-881404bba401_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_5a2a4a05-2e80-451a-9f8d-0137d8afbf9d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_49d0226c-2149-4c82-82ef-881404bba401" xlink:to="loc_srt_SegmentGeographicalDomain_5a2a4a05-2e80-451a-9f8d-0137d8afbf9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SophiaBulgariaMember_b2643a52-10a5-44d6-9cbe-c730586a0a85" xlink:href="apyx-20201231.xsd#apyx_SophiaBulgariaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_5a2a4a05-2e80-451a-9f8d-0137d8afbf9d" xlink:to="loc_apyx_SophiaBulgariaMember_b2643a52-10a5-44d6-9cbe-c730586a0a85" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/LEASESLeaseCostDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#LEASESLeaseCostDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/LEASESLeaseCostDetails" xlink:type="extended" id="i32c983893c18424eb4a200f492a6121a_LEASESLeaseCostDetails"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/LEASESCashandNonCashInformationDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#LEASESCashandNonCashInformationDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/LEASESCashandNonCashInformationDetails" xlink:type="extended" id="i8ee18820ff7f4602a0376d2e49da27df_LEASESCashandNonCashInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_0d98b902-efbb-423e-86e2-dc062bc92006" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_OperatingLeaseCostsAbstract_4a964de5-978e-4fba-b87a-3a5f1ad2a8dc" xlink:href="apyx-20201231.xsd#apyx_OperatingLeaseCostsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0d98b902-efbb-423e-86e2-dc062bc92006" xlink:to="loc_apyx_OperatingLeaseCostsAbstract_4a964de5-978e-4fba-b87a-3a5f1ad2a8dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_e4d21dbb-8722-4a63-b855-14f5ad4f22d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_apyx_OperatingLeaseCostsAbstract_4a964de5-978e-4fba-b87a-3a5f1ad2a8dc" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_e4d21dbb-8722-4a63-b855-14f5ad4f22d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_8a892966-37d9-470a-b1bb-c2d86e19b611" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_apyx_OperatingLeaseCostsAbstract_4a964de5-978e-4fba-b87a-3a5f1ad2a8dc" xlink:to="loc_us-gaap_OperatingLeasePayments_8a892966-37d9-470a-b1bb-c2d86e19b611" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_FinanceLeaseCostsAbstract_51ce3d41-926f-4b81-b63d-c169c16fe231" xlink:href="apyx-20201231.xsd#apyx_FinanceLeaseCostsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0d98b902-efbb-423e-86e2-dc062bc92006" xlink:to="loc_apyx_FinanceLeaseCostsAbstract_51ce3d41-926f-4b81-b63d-c169c16fe231" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_c98713f3-22e2-4efe-b22b-5c15ae46e0cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_apyx_FinanceLeaseCostsAbstract_51ce3d41-926f-4b81-b63d-c169c16fe231" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_c98713f3-22e2-4efe-b22b-5c15ae46e0cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_FinanceLeasePayments_7af357cb-72ec-4936-ba90-9953e174721d" xlink:href="apyx-20201231.xsd#apyx_FinanceLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_apyx_FinanceLeaseCostsAbstract_51ce3d41-926f-4b81-b63d-c169c16fe231" xlink:to="loc_apyx_FinanceLeasePayments_7af357cb-72ec-4936-ba90-9953e174721d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_2625360e-46ef-47f6-974b-4a153ed8605d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0d98b902-efbb-423e-86e2-dc062bc92006" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_2625360e-46ef-47f6-974b-4a153ed8605d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_94fb578b-d252-4971-a638-ce7a03ee4365" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_2625360e-46ef-47f6-974b-4a153ed8605d" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_94fb578b-d252-4971-a638-ce7a03ee4365" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_94fb578b-d252-4971-a638-ce7a03ee4365_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_94fb578b-d252-4971-a638-ce7a03ee4365" xlink:to="loc_us-gaap_TypeOfAdoptionMember_94fb578b-d252-4971-a638-ce7a03ee4365_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_3a224196-0bc5-49da-b11b-d632c6684218" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_94fb578b-d252-4971-a638-ce7a03ee4365" xlink:to="loc_us-gaap_TypeOfAdoptionMember_3a224196-0bc5-49da-b11b-d632c6684218" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_d14d3dc2-5ba5-4d3b-97eb-8ffd6530c43a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_3a224196-0bc5-49da-b11b-d632c6684218" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_d14d3dc2-5ba5-4d3b-97eb-8ffd6530c43a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_LeaseArrangementsAxis_a505e7f8-e567-45f5-95fe-6520058ab7d9" xlink:href="apyx-20201231.xsd#apyx_LeaseArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_2625360e-46ef-47f6-974b-4a153ed8605d" xlink:to="loc_apyx_LeaseArrangementsAxis_a505e7f8-e567-45f5-95fe-6520058ab7d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_LeaseArrangementsDomain_a505e7f8-e567-45f5-95fe-6520058ab7d9_default" xlink:href="apyx-20201231.xsd#apyx_LeaseArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_apyx_LeaseArrangementsAxis_a505e7f8-e567-45f5-95fe-6520058ab7d9" xlink:to="loc_apyx_LeaseArrangementsDomain_a505e7f8-e567-45f5-95fe-6520058ab7d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_LeaseArrangementsDomain_b897b434-390f-4181-9137-204c03d98937" xlink:href="apyx-20201231.xsd#apyx_LeaseArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_apyx_LeaseArrangementsAxis_a505e7f8-e567-45f5-95fe-6520058ab7d9" xlink:to="loc_apyx_LeaseArrangementsDomain_b897b434-390f-4181-9137-204c03d98937" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_LeaseRemeasurementMember_888836b4-5d3e-41c3-8664-0466bb5609bc" xlink:href="apyx-20201231.xsd#apyx_LeaseRemeasurementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_apyx_LeaseArrangementsDomain_b897b434-390f-4181-9137-204c03d98937" xlink:to="loc_apyx_LeaseRemeasurementMember_888836b4-5d3e-41c3-8664-0466bb5609bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_LeaseExecutionMember_064fb036-2fac-492a-b5a8-82bba54e49b7" xlink:href="apyx-20201231.xsd#apyx_LeaseExecutionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_apyx_LeaseArrangementsDomain_b897b434-390f-4181-9137-204c03d98937" xlink:to="loc_apyx_LeaseExecutionMember_064fb036-2fac-492a-b5a8-82bba54e49b7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/LEASESLeaseTermsandDiscountRatesDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#LEASESLeaseTermsandDiscountRatesDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/LEASESLeaseTermsandDiscountRatesDetails" xlink:type="extended" id="i3e738be10d9b4614ad9089a3c97c2051_LEASESLeaseTermsandDiscountRatesDetails"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#LEASESMaturitiesofLeaseLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended" id="ib9ef3b6522cc48cbb1bf559d130a831f_LEASESMaturitiesofLeaseLiabilitiesDetails"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES" xlink:type="simple" xlink:href="apyx-20201231.xsd#ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES" xlink:type="extended" id="i51026ec741894b29aa98e6ceceed61eb_ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables" xlink:type="simple" xlink:href="apyx-20201231.xsd#ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables" xlink:type="extended" id="i184584c8d95d45dca55f5842ca0282c7_ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" xlink:type="extended" id="i75583951252b4ddfb419ec324bee0cc4_ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/PRODUCTWARRANTIES" xlink:type="simple" xlink:href="apyx-20201231.xsd#PRODUCTWARRANTIES"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/PRODUCTWARRANTIES" xlink:type="extended" id="ie03e7b337b0e4461b1569b36f1c9c5f1_PRODUCTWARRANTIES"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/PRODUCTWARRANTIESTables" xlink:type="simple" xlink:href="apyx-20201231.xsd#PRODUCTWARRANTIESTables"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/PRODUCTWARRANTIESTables" xlink:type="extended" id="ia03acb03ead448d7a9b3c4537bcef254_PRODUCTWARRANTIESTables"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/PRODUCTWARRANTIESDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#PRODUCTWARRANTIESDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/PRODUCTWARRANTIESDetails" xlink:type="extended" id="ifc41210c1617463eabccf0bef581e58e_PRODUCTWARRANTIESDetails"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/JOINTANDSEVERALPAYROLLLIABILITY" xlink:type="simple" xlink:href="apyx-20201231.xsd#JOINTANDSEVERALPAYROLLLIABILITY"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/JOINTANDSEVERALPAYROLLLIABILITY" xlink:type="extended" id="i1e3560f34d9147f28a0317e6990587ad_JOINTANDSEVERALPAYROLLLIABILITY"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/JOINTANDSEVERALPAYROLLLIABILITYDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#JOINTANDSEVERALPAYROLLLIABILITYDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/JOINTANDSEVERALPAYROLLLIABILITYDetails" xlink:type="extended" id="i64fcdcaa34da4eb98001f81fd5571513_JOINTANDSEVERALPAYROLLLIABILITYDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_3a30e58f-6a60-456e-b954-8e354efa6daf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_JointAndSeveralPayrollLiability_cbdb3ef8-f193-467e-89c9-d97e5da73599" xlink:href="apyx-20201231.xsd#apyx_JointAndSeveralPayrollLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_3a30e58f-6a60-456e-b954-8e354efa6daf" xlink:to="loc_apyx_JointAndSeveralPayrollLiability_cbdb3ef8-f193-467e-89c9-d97e5da73599" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_JointAndSeveralPayrollExpense_15975d32-9587-450f-aaf0-72ea2eb07b8c" xlink:href="apyx-20201231.xsd#apyx_JointAndSeveralPayrollExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_3a30e58f-6a60-456e-b954-8e354efa6daf" xlink:to="loc_apyx_JointAndSeveralPayrollExpense_15975d32-9587-450f-aaf0-72ea2eb07b8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_55f7eda0-4fcd-4b1c-8c38-300472fc07f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_3a30e58f-6a60-456e-b954-8e354efa6daf" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_55f7eda0-4fcd-4b1c-8c38-300472fc07f6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_7a8fb87c-8e88-45f7-9327-1fe5991dd3bf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_55f7eda0-4fcd-4b1c-8c38-300472fc07f6" xlink:to="loc_srt_RestatementAxis_7a8fb87c-8e88-45f7-9327-1fe5991dd3bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_7a8fb87c-8e88-45f7-9327-1fe5991dd3bf_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_7a8fb87c-8e88-45f7-9327-1fe5991dd3bf" xlink:to="loc_srt_RestatementDomain_7a8fb87c-8e88-45f7-9327-1fe5991dd3bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_63834cf5-e10b-46f9-91f4-0f0110590fdc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_7a8fb87c-8e88-45f7-9327-1fe5991dd3bf" xlink:to="loc_srt_RestatementDomain_63834cf5-e10b-46f9-91f4-0f0110590fdc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAdjustmentMember_7d1acd85-4417-4862-8033-870574915186" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_63834cf5-e10b-46f9-91f4-0f0110590fdc" xlink:to="loc_srt_RestatementAdjustmentMember_7d1acd85-4417-4862-8033-870574915186" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/EARNINGSLOSSPERSHARE" xlink:type="simple" xlink:href="apyx-20201231.xsd#EARNINGSLOSSPERSHARE"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/EARNINGSLOSSPERSHARE" xlink:type="extended" id="ia3b7e7c225114eb5b0e0e43a1522d089_EARNINGSLOSSPERSHARE"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/EARNINGSLOSSPERSHARETables" xlink:type="simple" xlink:href="apyx-20201231.xsd#EARNINGSLOSSPERSHARETables"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/EARNINGSLOSSPERSHARETables" xlink:type="extended" id="i75cad2c8a83d401fa89d20f769517b20_EARNINGSLOSSPERSHARETables"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#EARNINGSLOSSPERSHAREDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" xlink:type="extended" id="ic985499f59f34ac1917448a01933621d_EARNINGSLOSSPERSHAREDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_00d2c348-9bc5-4be2-bd86-a2a229899460" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_961006a1-1f1a-4232-8081-23d6c5fac0df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_00d2c348-9bc5-4be2-bd86-a2a229899460" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_961006a1-1f1a-4232-8081-23d6c5fac0df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_14f156af-1783-4cde-ba76-e269115f5901" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_961006a1-1f1a-4232-8081-23d6c5fac0df" xlink:to="loc_us-gaap_NetIncomeLoss_14f156af-1783-4cde-ba76-e269115f5901" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_6c63b440-bc81-415f-89be-431d90447a0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_00d2c348-9bc5-4be2-bd86-a2a229899460" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_6c63b440-bc81-415f-89be-431d90447a0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_e7aa1b96-1d43-4095-9f5c-c660bed446f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_00d2c348-9bc5-4be2-bd86-a2a229899460" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_e7aa1b96-1d43-4095-9f5c-c660bed446f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_5bf9796a-df88-4d87-b43f-36402f1be939" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_00d2c348-9bc5-4be2-bd86-a2a229899460" xlink:to="loc_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_5bf9796a-df88-4d87-b43f-36402f1be939" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d1142c8f-0580-4b33-bb7e-f4b387d08f4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_5bf9796a-df88-4d87-b43f-36402f1be939" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d1142c8f-0580-4b33-bb7e-f4b387d08f4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_762fca61-e494-46f1-a63e-fcc192f6b602" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_00d2c348-9bc5-4be2-bd86-a2a229899460" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_762fca61-e494-46f1-a63e-fcc192f6b602" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_149c8358-0802-4ae0-a12a-b9d8595c7261" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_762fca61-e494-46f1-a63e-fcc192f6b602" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_149c8358-0802-4ae0-a12a-b9d8595c7261" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_149c8358-0802-4ae0-a12a-b9d8595c7261_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_149c8358-0802-4ae0-a12a-b9d8595c7261" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_149c8358-0802-4ae0-a12a-b9d8595c7261_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_266f710c-a64e-413f-a242-ee7d34166093" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_149c8358-0802-4ae0-a12a-b9d8595c7261" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_266f710c-a64e-413f-a242-ee7d34166093" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionOnSecuritiesMember_8c38085f-c87e-4115-b7f0-2493c80dce93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionOnSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_266f710c-a64e-413f-a242-ee7d34166093" xlink:to="loc_us-gaap_OptionOnSecuritiesMember_8c38085f-c87e-4115-b7f0-2493c80dce93" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/FINANCIALINSTRUMENTS" xlink:type="simple" xlink:href="apyx-20201231.xsd#FINANCIALINSTRUMENTS"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/FINANCIALINSTRUMENTS" xlink:type="extended" id="id93b5888d90b440ab04260b89d583d3b_FINANCIALINSTRUMENTS"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/FINANCIALINSTRUMENTSDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#FINANCIALINSTRUMENTSDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/FINANCIALINSTRUMENTSDetails" xlink:type="extended" id="iafea5a3902f9417cb9f9df2cee6732e4_FINANCIALINSTRUMENTSDetails"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/INCOMETAXES" xlink:type="simple" xlink:href="apyx-20201231.xsd#INCOMETAXES"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/INCOMETAXES" xlink:type="extended" id="i3cd4fc50a9084f5999927e4082173128_INCOMETAXES"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/INCOMETAXESTables" xlink:type="simple" xlink:href="apyx-20201231.xsd#INCOMETAXESTables"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/INCOMETAXESTables" xlink:type="extended" id="ia8c99f8a77884fa3b5c13e814da70094_INCOMETAXESTables"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#INCOMETAXESComponentsofProvisionForIncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails" xlink:type="extended" id="if338ac18239c42aa91c0cd16bfd9805c_INCOMETAXESComponentsofProvisionForIncomeTaxesDetails"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/INCOMETAXESReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#INCOMETAXESReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/INCOMETAXESReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails" xlink:type="extended" id="id9525c7143914de7834f38e12dfe76d2_INCOMETAXESReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#INCOMETAXESDeferredTaxAssetsLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails" xlink:type="extended" id="ia7fefd652a644581a954d023634dcb97_INCOMETAXESDeferredTaxAssetsLiabilitiesDetails"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/INCOMETAXESNarrativeDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#INCOMETAXESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/INCOMETAXESNarrativeDetails" xlink:type="extended" id="i7c79dd7ca7fd4dff8f0441f8a674eae7_INCOMETAXESNarrativeDetails"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/INCOMETAXESUnrecognizedTaxBenefitsRollForwardDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#INCOMETAXESUnrecognizedTaxBenefitsRollForwardDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/INCOMETAXESUnrecognizedTaxBenefitsRollForwardDetails" xlink:type="extended" id="i241733a72e4543c1895bd665566acba0_INCOMETAXESUnrecognizedTaxBenefitsRollForwardDetails"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/RETIREMENTPLAN" xlink:type="simple" xlink:href="apyx-20201231.xsd#RETIREMENTPLAN"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/RETIREMENTPLAN" xlink:type="extended" id="ie339646f93814669bd541bd12877ee37_RETIREMENTPLAN"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/RETIREMENTPLANNarrativeDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#RETIREMENTPLANNarrativeDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/RETIREMENTPLANNarrativeDetails" xlink:type="extended" id="i4d6d2dc391de4c24bd6e1bda7a774baa_RETIREMENTPLANNarrativeDetails"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="simple" xlink:href="apyx-20201231.xsd#RELATEDPARTYTRANSACTIONS"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="extended" id="ib459deaa31264f0e85fc8acd4b681b20_RELATEDPARTYTRANSACTIONS"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#RELATEDPARTYTRANSACTIONSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails" xlink:type="extended" id="i5d1e75c57406459b958e3fae11af6d3f_RELATEDPARTYTRANSACTIONSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_0a3c1263-1f92-4f63-b11d-03de8adcd48f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesNoncurrent_39d0645c-9354-4c4a-bab4-29935833516c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableRelatedPartiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0a3c1263-1f92-4f63-b11d-03de8adcd48f" xlink:to="loc_us-gaap_NotesPayableRelatedPartiesNoncurrent_39d0645c-9354-4c4a-bab4-29935833516c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_4617ad08-4b49-46a4-8f69-5142c7009207" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0a3c1263-1f92-4f63-b11d-03de8adcd48f" xlink:to="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_4617ad08-4b49-46a4-8f69-5142c7009207" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_6e82e9a8-3461-4c81-b424-def53d87f08b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0a3c1263-1f92-4f63-b11d-03de8adcd48f" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_6e82e9a8-3461-4c81-b424-def53d87f08b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_54574c64-7804-4a16-b43a-9b0e8f6b74c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0a3c1263-1f92-4f63-b11d-03de8adcd48f" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_54574c64-7804-4a16-b43a-9b0e8f6b74c0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_869dd833-6b97-4943-9d1b-625866859297" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_54574c64-7804-4a16-b43a-9b0e8f6b74c0" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_869dd833-6b97-4943-9d1b-625866859297" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_869dd833-6b97-4943-9d1b-625866859297_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_869dd833-6b97-4943-9d1b-625866859297" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_869dd833-6b97-4943-9d1b-625866859297_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_abe526e2-ec35-4896-b873-695838ef607a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_869dd833-6b97-4943-9d1b-625866859297" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_abe526e2-ec35-4896-b873-695838ef607a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CoVenturerMember_ebae31e4-1603-4eac-9e68-383dd98b7ce8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CoVenturerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_abe526e2-ec35-4896-b873-695838ef607a" xlink:to="loc_us-gaap_CoVenturerMember_ebae31e4-1603-4eac-9e68-383dd98b7ce8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="apyx-20201231.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended" id="i1f3e9353f6804619bfc964dcc39f2d93_COMMITMENTSANDCONTINGENCIES"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended" id="i5f7903a842184a2f9dcd88f2b5a767b6_COMMITMENTSANDCONTINGENCIESDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_ace4890d-c34a-46a0-8e9f-aaeaf3fe8f48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_LossContingencyAccrualTotalAccruedToDate_f4147eea-9b77-4aa9-8a84-c5ec7e83033d" xlink:href="apyx-20201231.xsd#apyx_LossContingencyAccrualTotalAccruedToDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_ace4890d-c34a-46a0-8e9f-aaeaf3fe8f48" xlink:to="loc_apyx_LossContingencyAccrualTotalAccruedToDate_f4147eea-9b77-4aa9-8a84-c5ec7e83033d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_e0870cae-36f6-4e63-a43e-6985d75461e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_ace4890d-c34a-46a0-8e9f-aaeaf3fe8f48" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_e0870cae-36f6-4e63-a43e-6985d75461e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_6af1efb2-5178-4514-a5a5-7bc33ee06a86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_ace4890d-c34a-46a0-8e9f-aaeaf3fe8f48" xlink:to="loc_us-gaap_PurchaseObligation_6af1efb2-5178-4514-a5a5-7bc33ee06a86" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_NoncontrollingInterestRequiredCapitalContribution_0cdf488a-b47e-49eb-a8db-e0897f1ad714" xlink:href="apyx-20201231.xsd#apyx_NoncontrollingInterestRequiredCapitalContribution"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_ace4890d-c34a-46a0-8e9f-aaeaf3fe8f48" xlink:to="loc_apyx_NoncontrollingInterestRequiredCapitalContribution_0cdf488a-b47e-49eb-a8db-e0897f1ad714" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_PaymentsToAcquireInterestInJointVentureRemaining_0aeed514-22c3-4174-89a3-3848333a4328" xlink:href="apyx-20201231.xsd#apyx_PaymentsToAcquireInterestInJointVentureRemaining"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_ace4890d-c34a-46a0-8e9f-aaeaf3fe8f48" xlink:to="loc_apyx_PaymentsToAcquireInterestInJointVentureRemaining_0aeed514-22c3-4174-89a3-3848333a4328" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_aefebdea-306b-42d8-addd-9636d5ac9538" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_ace4890d-c34a-46a0-8e9f-aaeaf3fe8f48" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_aefebdea-306b-42d8-addd-9636d5ac9538" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_3ac973c8-6053-4770-b0d1-7c6f094e07af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_ace4890d-c34a-46a0-8e9f-aaeaf3fe8f48" xlink:to="loc_us-gaap_OtherCommitmentsTable_3ac973c8-6053-4770-b0d1-7c6f094e07af" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_a629dd50-49b4-475b-9d1f-9276773ca2b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_3ac973c8-6053-4770-b0d1-7c6f094e07af" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_a629dd50-49b4-475b-9d1f-9276773ca2b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_a629dd50-49b4-475b-9d1f-9276773ca2b2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_a629dd50-49b4-475b-9d1f-9276773ca2b2" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_a629dd50-49b4-475b-9d1f-9276773ca2b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_4d4a85b6-f393-439f-a229-523b53ed0f8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_a629dd50-49b4-475b-9d1f-9276773ca2b2" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_4d4a85b6-f393-439f-a229-523b53ed0f8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember_3dd1a0df-5900-4dbb-ab6e-b10b28278262" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_4d4a85b6-f393-439f-a229-523b53ed0f8b" xlink:to="loc_us-gaap_CorporateJointVentureMember_3dd1a0df-5900-4dbb-ab6e-b10b28278262" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_c449edff-3af3-451e-b9b2-d1258f063e70" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_3ac973c8-6053-4770-b0d1-7c6f094e07af" xlink:to="loc_srt_MajorCustomersAxis_c449edff-3af3-451e-b9b2-d1258f063e70" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_c449edff-3af3-451e-b9b2-d1258f063e70_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_c449edff-3af3-451e-b9b2-d1258f063e70" xlink:to="loc_srt_NameOfMajorCustomerDomain_c449edff-3af3-451e-b9b2-d1258f063e70_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_78dec2e4-f84b-4d64-aea8-fb0dbda8a81c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_c449edff-3af3-451e-b9b2-d1258f063e70" xlink:to="loc_srt_NameOfMajorCustomerDomain_78dec2e4-f84b-4d64-aea8-fb0dbda8a81c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_LargestCustomerMember_27473be8-7133-47a9-81e2-2fb6a10a806e" xlink:href="apyx-20201231.xsd#apyx_LargestCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_78dec2e4-f84b-4d64-aea8-fb0dbda8a81c" xlink:to="loc_apyx_LargestCustomerMember_27473be8-7133-47a9-81e2-2fb6a10a806e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_151e42fb-215a-4e48-97f3-9651d765b410" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_3ac973c8-6053-4770-b0d1-7c6f094e07af" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_151e42fb-215a-4e48-97f3-9651d765b410" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_151e42fb-215a-4e48-97f3-9651d765b410_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_151e42fb-215a-4e48-97f3-9651d765b410" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_151e42fb-215a-4e48-97f3-9651d765b410_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b222d16d-967e-4fdb-83f0-a27700420509" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_151e42fb-215a-4e48-97f3-9651d765b410" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b222d16d-967e-4fdb-83f0-a27700420509" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_5dde907a-45da-4ea7-a49a-f6007d32f7f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b222d16d-967e-4fdb-83f0-a27700420509" xlink:to="loc_us-gaap_SalesRevenueNetMember_5dde907a-45da-4ea7-a49a-f6007d32f7f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_14571b5c-791d-46a3-823e-45c6f47d59a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_3ac973c8-6053-4770-b0d1-7c6f094e07af" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_14571b5c-791d-46a3-823e-45c6f47d59a7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_14571b5c-791d-46a3-823e-45c6f47d59a7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_14571b5c-791d-46a3-823e-45c6f47d59a7" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_14571b5c-791d-46a3-823e-45c6f47d59a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_284f85b7-be15-40b3-bd2a-91d9c3092048" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_14571b5c-791d-46a3-823e-45c6f47d59a7" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_284f85b7-be15-40b3-bd2a-91d9c3092048" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_53f9597f-5f95-41db-a10a-5b694aff47a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_284f85b7-be15-40b3-bd2a-91d9c3092048" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_53f9597f-5f95-41db-a10a-5b694aff47a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_896052f6-a0dc-47c5-8956-a3e5c21422f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_3ac973c8-6053-4770-b0d1-7c6f094e07af" xlink:to="loc_us-gaap_LitigationStatusAxis_896052f6-a0dc-47c5-8956-a3e5c21422f5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_896052f6-a0dc-47c5-8956-a3e5c21422f5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_896052f6-a0dc-47c5-8956-a3e5c21422f5" xlink:to="loc_us-gaap_LitigationStatusDomain_896052f6-a0dc-47c5-8956-a3e5c21422f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_6b65df89-ebcb-4c2e-85a4-782e94b61eec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_896052f6-a0dc-47c5-8956-a3e5c21422f5" xlink:to="loc_us-gaap_LitigationStatusDomain_6b65df89-ebcb-4c2e-85a4-782e94b61eec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_45cc7125-ae26-43ce-978c-8a2005c5f50b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_6b65df89-ebcb-4c2e-85a4-782e94b61eec" xlink:to="loc_us-gaap_PendingLitigationMember_45cc7125-ae26-43ce-978c-8a2005c5f50b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/STOCKOPTIONS" xlink:type="simple" xlink:href="apyx-20201231.xsd#STOCKOPTIONS"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/STOCKOPTIONS" xlink:type="extended" id="i1626bda1c98642118d5c387ea1674e07_STOCKOPTIONS"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/STOCKOPTIONSTables" xlink:type="simple" xlink:href="apyx-20201231.xsd#STOCKOPTIONSTables"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/STOCKOPTIONSTables" xlink:type="extended" id="i2a08e15655814e3f835da9defcdb7f0b_STOCKOPTIONSTables"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#STOCKOPTIONSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails" xlink:type="extended" id="ie8152be838be4a4d9d54b6ca018b6d98_STOCKOPTIONSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630ce5ec-e193-4e5a-9d29-18024529b22d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_165a37b6-0b58-420c-a25a-13d469d7204b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630ce5ec-e193-4e5a-9d29-18024529b22d" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_165a37b6-0b58-420c-a25a-13d469d7204b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_d8d33522-b377-45cc-8b2e-914763510196" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630ce5ec-e193-4e5a-9d29-18024529b22d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_d8d33522-b377-45cc-8b2e-914763510196" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_443c51b3-b73e-44c4-9578-563fbe317b39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630ce5ec-e193-4e5a-9d29-18024529b22d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_443c51b3-b73e-44c4-9578-563fbe317b39" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1af94df5-3bb3-49bc-b4d5-e0299f3d7656" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630ce5ec-e193-4e5a-9d29-18024529b22d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1af94df5-3bb3-49bc-b4d5-e0299f3d7656" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b1487552-0d37-4711-91d8-d0082081581f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630ce5ec-e193-4e5a-9d29-18024529b22d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b1487552-0d37-4711-91d8-d0082081581f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_31c195b2-57a1-4513-a941-9605f46b8d5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630ce5ec-e193-4e5a-9d29-18024529b22d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_31c195b2-57a1-4513-a941-9605f46b8d5f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueClosingStockPrice_7433e856-397e-4498-8446-554d5d53b810" xlink:href="apyx-20201231.xsd#apyx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueClosingStockPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630ce5ec-e193-4e5a-9d29-18024529b22d" xlink:to="loc_apyx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueClosingStockPrice_7433e856-397e-4498-8446-554d5d53b810" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_57529e85-76fa-41fe-a14e-cb767a101c3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630ce5ec-e193-4e5a-9d29-18024529b22d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_57529e85-76fa-41fe-a14e-cb767a101c3b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_7fc8c298-7e08-464a-8f31-8c1eb428ca06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630ce5ec-e193-4e5a-9d29-18024529b22d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_7fc8c298-7e08-464a-8f31-8c1eb428ca06" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_a430bf01-3cb7-40d5-8f50-5841796c04b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630ce5ec-e193-4e5a-9d29-18024529b22d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_a430bf01-3cb7-40d5-8f50-5841796c04b0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_0a959447-37f7-46e7-9c42-80501f14ac57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630ce5ec-e193-4e5a-9d29-18024529b22d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_0a959447-37f7-46e7-9c42-80501f14ac57" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_709ad281-5527-4719-a8d1-75a93af7a379" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630ce5ec-e193-4e5a-9d29-18024529b22d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_709ad281-5527-4719-a8d1-75a93af7a379" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_b88e796b-7851-49d6-9b79-55634b998740" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630ce5ec-e193-4e5a-9d29-18024529b22d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_b88e796b-7851-49d6-9b79-55634b998740" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_8f4f6625-ccaa-41f2-8a65-3e14963a0575" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630ce5ec-e193-4e5a-9d29-18024529b22d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_8f4f6625-ccaa-41f2-8a65-3e14963a0575" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_c15fbe75-19ec-4875-9e52-488717bc4db7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630ce5ec-e193-4e5a-9d29-18024529b22d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_c15fbe75-19ec-4875-9e52-488717bc4db7" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_bbec4766-5d08-4c1a-8623-d39588a36ce4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630ce5ec-e193-4e5a-9d29-18024529b22d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_bbec4766-5d08-4c1a-8623-d39588a36ce4" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue_4d179fbd-a4c8-4794-8806-ccdca921e163" xlink:href="apyx-20201231.xsd#apyx_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630ce5ec-e193-4e5a-9d29-18024529b22d" xlink:to="loc_apyx_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue_4d179fbd-a4c8-4794-8806-ccdca921e163" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fd5ff121-0daa-4ad5-8fde-c56d2f13f0b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630ce5ec-e193-4e5a-9d29-18024529b22d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fd5ff121-0daa-4ad5-8fde-c56d2f13f0b1" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_7c4d8488-156b-45a3-a469-b2599c1e16ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630ce5ec-e193-4e5a-9d29-18024529b22d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_7c4d8488-156b-45a3-a469-b2599c1e16ac" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived_cfad74c8-696d-4005-bffe-a58e0d807c88" xlink:href="apyx-20201231.xsd#apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630ce5ec-e193-4e5a-9d29-18024529b22d" xlink:to="loc_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived_cfad74c8-696d-4005-bffe-a58e0d807c88" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_StockIssuedDuringPeriodSharesStockSwaps_74fc99aa-28a4-4287-b007-32ce79788d74" xlink:href="apyx-20201231.xsd#apyx_StockIssuedDuringPeriodSharesStockSwaps"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630ce5ec-e193-4e5a-9d29-18024529b22d" xlink:to="loc_apyx_StockIssuedDuringPeriodSharesStockSwaps_74fc99aa-28a4-4287-b007-32ce79788d74" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_e82f30e1-d557-4e9d-a496-05b9f7219527" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630ce5ec-e193-4e5a-9d29-18024529b22d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_e82f30e1-d557-4e9d-a496-05b9f7219527" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e04f9ade-52a1-4b41-9759-15f4e54c5690" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630ce5ec-e193-4e5a-9d29-18024529b22d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e04f9ade-52a1-4b41-9759-15f4e54c5690" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedToDate_95dff702-b697-4965-a21d-2833870d5901" xlink:href="apyx-20201231.xsd#apyx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedToDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630ce5ec-e193-4e5a-9d29-18024529b22d" xlink:to="loc_apyx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedToDate_95dff702-b697-4965-a21d-2833870d5901" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_850ae2c5-da0c-427a-8c3d-47ae07aa6b65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630ce5ec-e193-4e5a-9d29-18024529b22d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_850ae2c5-da0c-427a-8c3d-47ae07aa6b65" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_cfbf98e2-0c10-44ed-b620-d48525686520" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_850ae2c5-da0c-427a-8c3d-47ae07aa6b65" xlink:to="loc_us-gaap_PlanNameAxis_cfbf98e2-0c10-44ed-b620-d48525686520" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_cfbf98e2-0c10-44ed-b620-d48525686520_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_cfbf98e2-0c10-44ed-b620-d48525686520" xlink:to="loc_us-gaap_PlanNameDomain_cfbf98e2-0c10-44ed-b620-d48525686520_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_dc32cf63-f72b-40f7-b822-a29447ddd78c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_cfbf98e2-0c10-44ed-b620-d48525686520" xlink:to="loc_us-gaap_PlanNameDomain_dc32cf63-f72b-40f7-b822-a29447ddd78c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_A2001ExecutiveandEmployeeStockOptionPlanMember_a23310d8-f41b-49e1-b82c-fa6dae19b87d" xlink:href="apyx-20201231.xsd#apyx_A2001ExecutiveandEmployeeStockOptionPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_dc32cf63-f72b-40f7-b822-a29447ddd78c" xlink:to="loc_apyx_A2001ExecutiveandEmployeeStockOptionPlanMember_a23310d8-f41b-49e1-b82c-fa6dae19b87d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_A2003ExecutiveandEmployeeStockOptionPlanMember_d8258206-0121-414b-9932-30295351d31f" xlink:href="apyx-20201231.xsd#apyx_A2003ExecutiveandEmployeeStockOptionPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_dc32cf63-f72b-40f7-b822-a29447ddd78c" xlink:to="loc_apyx_A2003ExecutiveandEmployeeStockOptionPlanMember_d8258206-0121-414b-9932-30295351d31f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_TwoThousandTwelveShareIncentivePlanMember_9563afa9-1400-46c3-bd47-c3ceb5075aac" xlink:href="apyx-20201231.xsd#apyx_TwoThousandTwelveShareIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_dc32cf63-f72b-40f7-b822-a29447ddd78c" xlink:to="loc_apyx_TwoThousandTwelveShareIncentivePlanMember_9563afa9-1400-46c3-bd47-c3ceb5075aac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_TwoThousandFifteenExecutiveAndEmployeeStockOptionPlanMember_aa1f669e-a049-43ff-ae5d-257e521cc152" xlink:href="apyx-20201231.xsd#apyx_TwoThousandFifteenExecutiveAndEmployeeStockOptionPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_dc32cf63-f72b-40f7-b822-a29447ddd78c" xlink:to="loc_apyx_TwoThousandFifteenExecutiveAndEmployeeStockOptionPlanMember_aa1f669e-a049-43ff-ae5d-257e521cc152" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_A2017ExecutiveandEmployeeStockOptionPlanMember_7b265885-82ae-43c5-b27d-4f1c4b72e19f" xlink:href="apyx-20201231.xsd#apyx_A2017ExecutiveandEmployeeStockOptionPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_dc32cf63-f72b-40f7-b822-a29447ddd78c" xlink:to="loc_apyx_A2017ExecutiveandEmployeeStockOptionPlanMember_7b265885-82ae-43c5-b27d-4f1c4b72e19f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_A2019ShareIncentivePlanMember_9db586d4-ecaf-4361-88bd-0619a8e1c621" xlink:href="apyx-20201231.xsd#apyx_A2019ShareIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_dc32cf63-f72b-40f7-b822-a29447ddd78c" xlink:to="loc_apyx_A2019ShareIncentivePlanMember_9db586d4-ecaf-4361-88bd-0619a8e1c621" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_99b86729-ec38-4521-99fd-6d31f816756c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_850ae2c5-da0c-427a-8c3d-47ae07aa6b65" xlink:to="loc_us-gaap_AwardTypeAxis_99b86729-ec38-4521-99fd-6d31f816756c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99b86729-ec38-4521-99fd-6d31f816756c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_99b86729-ec38-4521-99fd-6d31f816756c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99b86729-ec38-4521-99fd-6d31f816756c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7bcccd1b-c0e3-4ddf-84b5-402e9a4b00a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_99b86729-ec38-4521-99fd-6d31f816756c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7bcccd1b-c0e3-4ddf-84b5-402e9a4b00a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_c65d037a-d975-4797-b588-a0e0b5d51dc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7bcccd1b-c0e3-4ddf-84b5-402e9a4b00a7" xlink:to="loc_us-gaap_RestrictedStockMember_c65d037a-d975-4797-b588-a0e0b5d51dc3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f714f038-2a90-4b21-ba65-f7cd296348d7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_850ae2c5-da0c-427a-8c3d-47ae07aa6b65" xlink:to="loc_srt_RangeAxis_f714f038-2a90-4b21-ba65-f7cd296348d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f714f038-2a90-4b21-ba65-f7cd296348d7_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f714f038-2a90-4b21-ba65-f7cd296348d7" xlink:to="loc_srt_RangeMember_f714f038-2a90-4b21-ba65-f7cd296348d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d9a0f2fd-25b1-4830-8dc9-6285cc18ef11" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f714f038-2a90-4b21-ba65-f7cd296348d7" xlink:to="loc_srt_RangeMember_d9a0f2fd-25b1-4830-8dc9-6285cc18ef11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0f4c8e64-0fe7-404b-8632-3f1e6e9d6360" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d9a0f2fd-25b1-4830-8dc9-6285cc18ef11" xlink:to="loc_srt_MinimumMember_0f4c8e64-0fe7-404b-8632-3f1e6e9d6360" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_05bba58f-9dfd-4be1-9105-1c35621e44bf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d9a0f2fd-25b1-4830-8dc9-6285cc18ef11" xlink:to="loc_srt_MaximumMember_05bba58f-9dfd-4be1-9105-1c35621e44bf" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/STOCKOPTIONSSummaryofStockOptionsDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#STOCKOPTIONSSummaryofStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/STOCKOPTIONSSummaryofStockOptionsDetails" xlink:type="extended" id="i3e7ebcafd4814d9fbf6ff24ecea7503e_STOCKOPTIONSSummaryofStockOptionsDetails"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/STOCKOPTIONSSummaryofNonvestedStockOptionsDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#STOCKOPTIONSSummaryofNonvestedStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/STOCKOPTIONSSummaryofNonvestedStockOptionsDetails" xlink:type="extended" id="idfb4348f7ffa4ae3ad03c7a3fbf45482_STOCKOPTIONSSummaryofNonvestedStockOptionsDetails"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/STOCKOPTIONSSTOCKOPTIONSFairValueAssumptionsDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#STOCKOPTIONSSTOCKOPTIONSFairValueAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/STOCKOPTIONSSTOCKOPTIONSFairValueAssumptionsDetails" xlink:type="extended" id="i40acae400e7c4b7ca3982b2f02441623_STOCKOPTIONSSTOCKOPTIONSFairValueAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c41af633-d47c-4d4d-8996-07612d772a1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_31aa8bf6-c8de-4525-a413-75f8aa092289" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c41af633-d47c-4d4d-8996-07612d772a1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_31aa8bf6-c8de-4525-a413-75f8aa092289" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_cc0d9075-7672-408b-a09c-e7433c4475ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c41af633-d47c-4d4d-8996-07612d772a1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_cc0d9075-7672-408b-a09c-e7433c4475ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b89ceb14-b3c6-4728-8bbf-b17d6fe78f75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c41af633-d47c-4d4d-8996-07612d772a1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b89ceb14-b3c6-4728-8bbf-b17d6fe78f75" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_fde8d117-6773-456e-b549-7adf9178b654" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c41af633-d47c-4d4d-8996-07612d772a1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_fde8d117-6773-456e-b549-7adf9178b654" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_b5c0ce8c-7fa3-4ff1-905c-400d5b8feed7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c41af633-d47c-4d4d-8996-07612d772a1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_b5c0ce8c-7fa3-4ff1-905c-400d5b8feed7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9c1253d0-589e-43c5-b0a6-007cff4e162f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c41af633-d47c-4d4d-8996-07612d772a1e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9c1253d0-589e-43c5-b0a6-007cff4e162f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bc70845b-5640-464f-a1b2-df2bba2841bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c41af633-d47c-4d4d-8996-07612d772a1e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bc70845b-5640-464f-a1b2-df2bba2841bf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_aed6dd10-b466-4ed4-bd8b-f271275ca464" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bc70845b-5640-464f-a1b2-df2bba2841bf" xlink:to="loc_srt_RangeAxis_aed6dd10-b466-4ed4-bd8b-f271275ca464" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_aed6dd10-b466-4ed4-bd8b-f271275ca464_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_aed6dd10-b466-4ed4-bd8b-f271275ca464" xlink:to="loc_srt_RangeMember_aed6dd10-b466-4ed4-bd8b-f271275ca464_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e6267868-0c08-4048-86c1-bc15aeebfdaa" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_aed6dd10-b466-4ed4-bd8b-f271275ca464" xlink:to="loc_srt_RangeMember_e6267868-0c08-4048-86c1-bc15aeebfdaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_303cf225-0104-43e7-8cc1-0848775b8c4c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e6267868-0c08-4048-86c1-bc15aeebfdaa" xlink:to="loc_srt_MinimumMember_303cf225-0104-43e7-8cc1-0848775b8c4c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b671a38e-81bf-4e15-9b26-5a609f007fa9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e6267868-0c08-4048-86c1-bc15aeebfdaa" xlink:to="loc_srt_MaximumMember_b671a38e-81bf-4e15-9b26-5a609f007fa9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATION" xlink:type="simple" xlink:href="apyx-20201231.xsd#GEOGRAPHICANDSEGMENTINFORMATION"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATION" xlink:type="extended" id="i6025f031a1544c2694c10fe9dd342704_GEOGRAPHICANDSEGMENTINFORMATION"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONTables" xlink:type="simple" xlink:href="apyx-20201231.xsd#GEOGRAPHICANDSEGMENTINFORMATIONTables"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONTables" xlink:type="extended" id="i9074c9105f3542cb848de03e831d8df2_GEOGRAPHICANDSEGMENTINFORMATIONTables"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails" xlink:type="extended" id="i5e0413f906b04142b8132cc61a1fa9eb_GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" xlink:type="extended" id="i3527c26988ce406a879adfe7c43a42c8_GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_3abf380f-ca25-4aa9-a507-695e0b483940" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4542b333-3f55-4008-9926-8746027a1800" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3abf380f-ca25-4aa9-a507-695e0b483940" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4542b333-3f55-4008-9926-8746027a1800" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e0f00381-f572-4416-9642-14285f1799cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3abf380f-ca25-4aa9-a507-695e0b483940" xlink:to="loc_us-gaap_OperatingIncomeLoss_e0f00381-f572-4416-9642-14285f1799cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_b7637cdf-d5b6-404c-8ecb-9dc580c67774" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3abf380f-ca25-4aa9-a507-695e0b483940" xlink:to="loc_us-gaap_InterestIncomeOperating_b7637cdf-d5b6-404c-8ecb-9dc580c67774" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_0dd7c7e1-5d8b-4098-9dab-e7a857f40add" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3abf380f-ca25-4aa9-a507-695e0b483940" xlink:to="loc_us-gaap_InterestExpense_0dd7c7e1-5d8b-4098-9dab-e7a857f40add" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_887d35f8-60ca-44d1-9e7e-362ad55b503f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3abf380f-ca25-4aa9-a507-695e0b483940" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_887d35f8-60ca-44d1-9e7e-362ad55b503f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a5d34af2-50f9-4402-8976-83eac6df7f49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3abf380f-ca25-4aa9-a507-695e0b483940" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a5d34af2-50f9-4402-8976-83eac6df7f49" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a992265b-bb00-47be-8d7b-6e938f2d52ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3abf380f-ca25-4aa9-a507-695e0b483940" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a992265b-bb00-47be-8d7b-6e938f2d52ba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_858b4b9b-1c1d-41c1-9aca-bca1066a56df" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a992265b-bb00-47be-8d7b-6e938f2d52ba" xlink:to="loc_srt_ConsolidationItemsAxis_858b4b9b-1c1d-41c1-9aca-bca1066a56df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_858b4b9b-1c1d-41c1-9aca-bca1066a56df_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_858b4b9b-1c1d-41c1-9aca-bca1066a56df" xlink:to="loc_srt_ConsolidationItemsDomain_858b4b9b-1c1d-41c1-9aca-bca1066a56df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_1f83c943-af50-4812-ac63-bbde7abcd4c3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_858b4b9b-1c1d-41c1-9aca-bca1066a56df" xlink:to="loc_srt_ConsolidationItemsDomain_1f83c943-af50-4812-ac63-bbde7abcd4c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_6a225c51-af57-4cbe-9d7e-1d55fc4ab48e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_1f83c943-af50-4812-ac63-bbde7abcd4c3" xlink:to="loc_us-gaap_OperatingSegmentsMember_6a225c51-af57-4cbe-9d7e-1d55fc4ab48e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_f9ba0a42-10ae-455b-ae51-89fe6bdd11b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_1f83c943-af50-4812-ac63-bbde7abcd4c3" xlink:to="loc_us-gaap_CorporateNonSegmentMember_f9ba0a42-10ae-455b-ae51-89fe6bdd11b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_61e4885d-ee53-4df1-877c-507d38c02a23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a992265b-bb00-47be-8d7b-6e938f2d52ba" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_61e4885d-ee53-4df1-877c-507d38c02a23" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_61e4885d-ee53-4df1-877c-507d38c02a23_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_61e4885d-ee53-4df1-877c-507d38c02a23" xlink:to="loc_us-gaap_SegmentDomain_61e4885d-ee53-4df1-877c-507d38c02a23_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f97a607c-8125-4453-b10f-e657b7a8bf01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_61e4885d-ee53-4df1-877c-507d38c02a23" xlink:to="loc_us-gaap_SegmentDomain_f97a607c-8125-4453-b10f-e657b7a8bf01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AdvancedEnergyMember_b7ad31b1-2689-419b-805f-a9c2353be291" xlink:href="apyx-20201231.xsd#apyx_AdvancedEnergyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_f97a607c-8125-4453-b10f-e657b7a8bf01" xlink:to="loc_apyx_AdvancedEnergyMember_b7ad31b1-2689-419b-805f-a9c2353be291" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_OEMMember_ba86684e-17e1-4f41-9af0-ce375c8379c1" xlink:href="apyx-20201231.xsd#apyx_OEMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_f97a607c-8125-4453-b10f-e657b7a8bf01" xlink:to="loc_apyx_OEMMember_ba86684e-17e1-4f41-9af0-ce375c8379c1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails" xlink:type="extended" id="i0c12b7f66aa74cce8b7961c614e84e98_GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_99811c6f-4188-44ab-abb9-cdf2e8dac3e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_52dd18e7-fe91-43b2-a8c3-50414fa7a1ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_99811c6f-4188-44ab-abb9-cdf2e8dac3e9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_52dd18e7-fe91-43b2-a8c3-50414fa7a1ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_356d8964-48ce-4a1d-b1e4-e93d960ae413" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_99811c6f-4188-44ab-abb9-cdf2e8dac3e9" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_356d8964-48ce-4a1d-b1e4-e93d960ae413" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_4689a3c9-5d83-4768-b754-48d7abbde323" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_356d8964-48ce-4a1d-b1e4-e93d960ae413" xlink:to="loc_srt_StatementGeographicalAxis_4689a3c9-5d83-4768-b754-48d7abbde323" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4689a3c9-5d83-4768-b754-48d7abbde323_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_4689a3c9-5d83-4768-b754-48d7abbde323" xlink:to="loc_srt_SegmentGeographicalDomain_4689a3c9-5d83-4768-b754-48d7abbde323_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d9407b25-753e-445d-9d56-cd2d9a19c3d6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_4689a3c9-5d83-4768-b754-48d7abbde323" xlink:to="loc_srt_SegmentGeographicalDomain_d9407b25-753e-445d-9d56-cd2d9a19c3d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_00c8eb73-9f7b-462e-b50c-0280c1b51859" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_d9407b25-753e-445d-9d56-cd2d9a19c3d6" xlink:to="loc_country_US_00c8eb73-9f7b-462e-b50c-0280c1b51859" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_e901086f-8e67-4287-9ed3-c75587a0ed3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_d9407b25-753e-445d-9d56-cd2d9a19c3d6" xlink:to="loc_us-gaap_NonUsMember_e901086f-8e67-4287-9ed3-c75587a0ed3a" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>apyx-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:3619fb04-76d2-4e32-a22c-67723657dfe5,g:73c9cb31-492e-4d91-a8e4-50624d0c0cae-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_srt_RestatementAxis_f93aae5a-2573-4d4d-81d6-83f72cb8d8f5_terseLabel_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:label id="lab_srt_RestatementAxis_label_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAxis" xlink:to="lab_srt_RestatementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_84ad9cc0-8ec5-4241-9be5-013d1b2d2011_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_9c74ae9a-b78d-415a-9840-1ea86a92983d_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_87bbc857-d24c-439b-99d1-297e504750a8_totalLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock_4ae5de9b-846f-4493-add8-ec03f40f33ba_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Product Warranty Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Product Warranty Liability [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7629d1bb-e8b2-4757-bc4a-c2a6b670c23b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_307a589c-2c84-47e5-bf7d-de33167c5cbc_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options Non-vested, Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_02e349d2-7b0a-4f03-b05a-cafb0de44f8a_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8bb4415b-7b70-4d0b-9962-6fd1a9592cfe_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_8d2da513-b733-4fa7-ba12-fc3d1dcf502a_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations_47ef590b-56e5-43fe-8143-5db610b2c89a_totalLabel_en-US" xlink:label="lab_apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment in service</link:label>
    <link:label id="lab_apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations_label_en-US" xlink:label="lab_apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net property, plant and equipment of continuing and discontinued operations</link:label>
    <link:label id="lab_apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations_documentation_en-US" xlink:label="lab_apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net property, plant and equipment of continuing and discontinued operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations" xlink:href="apyx-20201231.xsd#apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations" xlink:to="lab_apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_0d64fbe3-c454-4bde-b4be-9d16c505faef_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FINANCIAL INSTRUMENTS</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestTable_41c8a354-b035-483a-82be-bcf1dd7c0f73_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestTable_label_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestTable" xlink:to="lab_us-gaap_MinorityInterestTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_3e8a1c65-3d7a-4dc2-a88c-1f80303e6311_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_35e0db1e-7bba-480e-84a4-a5485ff7d872_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RETIREMENT PLAN</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_SophiaBulgariaMember_659842c3-3158-43f9-be24-60ec1725f018_terseLabel_en-US" xlink:label="lab_apyx_SophiaBulgariaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sophia, Bulgaria</link:label>
    <link:label id="lab_apyx_SophiaBulgariaMember_label_en-US" xlink:label="lab_apyx_SophiaBulgariaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sophia, Bulgaria [Member]</link:label>
    <link:label id="lab_apyx_SophiaBulgariaMember_documentation_en-US" xlink:label="lab_apyx_SophiaBulgariaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sophia, Bulgaria [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SophiaBulgariaMember" xlink:href="apyx-20201231.xsd#apyx_SophiaBulgariaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_SophiaBulgariaMember" xlink:to="lab_apyx_SophiaBulgariaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_27b439a4-d6d6-422d-bcbe-f19c0ade0453_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory write-down</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueClosingStockPrice_01cb56cc-e298-4c9f-8ff5-e95961bdeeb7_terseLabel_en-US" xlink:label="lab_apyx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueClosingStockPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Closing stock price for computation of intrinsic value (in dollars per share)</link:label>
    <link:label id="lab_apyx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueClosingStockPrice_label_en-US" xlink:label="lab_apyx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueClosingStockPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Options, Intrinsic Value, Closing Stock Price</link:label>
    <link:label id="lab_apyx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueClosingStockPrice_documentation_en-US" xlink:label="lab_apyx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueClosingStockPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Options, Intrinsic Value, Closing Stock Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueClosingStockPrice" xlink:href="apyx-20201231.xsd#apyx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueClosingStockPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueClosingStockPrice" xlink:to="lab_apyx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueClosingStockPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_868ef02b-9b09-40ce-ade3-485bf86c759d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards_a111f072-18b4-48ae-928d-9112c587a234_negatedTerseLabel_en-US" xlink:label="lab_apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards_label_en-US" xlink:label="lab_apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act, Income Tax Expense (Benefit), Release Of Valuation Allowance, Federal Net Operating Loss Carryforwards</link:label>
    <link:label id="lab_apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards_documentation_en-US" xlink:label="lab_apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act, Income Tax Expense (Benefit), Release Of Valuation Allowance, Federal Net Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards" xlink:href="apyx-20201231.xsd#apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards" xlink:to="lab_apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductWarrantyDisclosureTextBlock_36040515-2cd3-4697-af2b-348b69d513d5_terseLabel_en-US" xlink:label="lab_us-gaap_ProductWarrantyDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PRODUCT WARRANTIES</link:label>
    <link:label id="lab_us-gaap_ProductWarrantyDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_ProductWarrantyDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Warranty Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductWarrantyDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductWarrantyDisclosureTextBlock" xlink:to="lab_us-gaap_ProductWarrantyDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_503b2563-e0de-4f7c-85e8-42578922efed_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_55309586-ff12-462b-bf96-b1a17a45cdfd_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bdb70de4-021a-4f9b-924e-ed7cd5395598_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_StockIssuedDuringPeriodSharesStockSwaps_e1bc56a6-0c5c-4dea-98aa-176e210f459a_terseLabel_en-US" xlink:label="lab_apyx_StockIssuedDuringPeriodSharesStockSwaps" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued in stock swaps (in shares)</link:label>
    <link:label id="lab_apyx_StockIssuedDuringPeriodSharesStockSwaps_label_en-US" xlink:label="lab_apyx_StockIssuedDuringPeriodSharesStockSwaps" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Stock Swaps</link:label>
    <link:label id="lab_apyx_StockIssuedDuringPeriodSharesStockSwaps_documentation_en-US" xlink:label="lab_apyx_StockIssuedDuringPeriodSharesStockSwaps" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Stock Swaps</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_StockIssuedDuringPeriodSharesStockSwaps" xlink:href="apyx-20201231.xsd#apyx_StockIssuedDuringPeriodSharesStockSwaps"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_StockIssuedDuringPeriodSharesStockSwaps" xlink:to="lab_apyx_StockIssuedDuringPeriodSharesStockSwaps" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_baa6e033-d6e9-40e6-9a1d-44156c050a00_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of right-of-use assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_LesseeDiscountRateIncrementalBorrowingRate_e3820d37-972a-4ffc-9a98-a571244e3a3a_terseLabel_en-US" xlink:label="lab_apyx_LesseeDiscountRateIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_apyx_LesseeDiscountRateIncrementalBorrowingRate_label_en-US" xlink:label="lab_apyx_LesseeDiscountRateIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Discount Rate, Incremental Borrowing Rate</link:label>
    <link:label id="lab_apyx_LesseeDiscountRateIncrementalBorrowingRate_documentation_en-US" xlink:label="lab_apyx_LesseeDiscountRateIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Discount Rate, Incremental Borrowing Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_LesseeDiscountRateIncrementalBorrowingRate" xlink:href="apyx-20201231.xsd#apyx_LesseeDiscountRateIncrementalBorrowingRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_LesseeDiscountRateIncrementalBorrowingRate" xlink:to="lab_apyx_LesseeDiscountRateIncrementalBorrowingRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent_e3c3b8f7-8799-4c34-a0d0-6e9532883d5e_terseLabel_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued product warranties</link:label>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent_label_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Warranty Accrual, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:to="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_4f91a246-0879-45d5-9e3d-d8f4bd88f3d1_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DefinedContributionPlanEmployersMatchingContributionVestingPeriod_fc692cdf-9481-4dd8-b396-6275c3078bcc_terseLabel_en-US" xlink:label="lab_apyx_DefinedContributionPlanEmployersMatchingContributionVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan, vesting period</link:label>
    <link:label id="lab_apyx_DefinedContributionPlanEmployersMatchingContributionVestingPeriod_label_en-US" xlink:label="lab_apyx_DefinedContributionPlanEmployersMatchingContributionVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employers Matching Contribution, Vesting Period</link:label>
    <link:label id="lab_apyx_DefinedContributionPlanEmployersMatchingContributionVestingPeriod_documentation_en-US" xlink:label="lab_apyx_DefinedContributionPlanEmployersMatchingContributionVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employers Matching Contribution, Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DefinedContributionPlanEmployersMatchingContributionVestingPeriod" xlink:href="apyx-20201231.xsd#apyx_DefinedContributionPlanEmployersMatchingContributionVestingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DefinedContributionPlanEmployersMatchingContributionVestingPeriod" xlink:to="lab_apyx_DefinedContributionPlanEmployersMatchingContributionVestingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_3a9c7128-5600-4b79-8329-06f51a3c77b2_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value, Non-vested Options, Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_16c99d64-7de0-4fdb-bb47-134b707b77f4_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_0a8032e3-928d-4bc2-9c0f-fbf0e8b7f212_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_cc5639e6-5026-49c1-a59b-7b039098f263_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_f70d37c1-afb6-4854-92b9-2b65d6bfd66f_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Accounts Receivable and Allowance for Doubtful Accounts</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDisclosureTextBlock_5483cfeb-f0f6-45ef-ae54-9f1f4e6944bd_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INTEREST IN JOINT VENTURE INVESTMENT</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDisclosureTextBlock" xlink:to="lab_us-gaap_MinorityInterestDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_JointandSeveralPayrollLiabilityTextBlock_4b0ecd60-9972-4702-822a-a2e53c79ea46_terseLabel_en-US" xlink:label="lab_apyx_JointandSeveralPayrollLiabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JOINT AND SEVERAL PAYROLL LIABILITY</link:label>
    <link:label id="lab_apyx_JointandSeveralPayrollLiabilityTextBlock_label_en-US" xlink:label="lab_apyx_JointandSeveralPayrollLiabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint and Several Payroll Liability [Text Block]</link:label>
    <link:label id="lab_apyx_JointandSeveralPayrollLiabilityTextBlock_documentation_en-US" xlink:label="lab_apyx_JointandSeveralPayrollLiabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint and Several Payroll Liability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_JointandSeveralPayrollLiabilityTextBlock" xlink:href="apyx-20201231.xsd#apyx_JointandSeveralPayrollLiabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_JointandSeveralPayrollLiabilityTextBlock" xlink:to="lab_apyx_JointandSeveralPayrollLiabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_6129e995-70b7-465c-a483-f74aaf0c7c74_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Weighted Average Grant-Date Fair Values of Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_23bee7e7-b8ae-421a-8556-4695a658e3a5_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_916a37fb-c653-4439-97b7-6b5c77d9eb58_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_8aacc246-8713-40d0-ab5c-992915321fe0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:to="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_OEMMember_5e0aae0c-fab6-40a2-8a9e-64ef64700ec5_terseLabel_en-US" xlink:label="lab_apyx_OEMMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OEM</link:label>
    <link:label id="lab_apyx_OEMMember_label_en-US" xlink:label="lab_apyx_OEMMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OEM [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_OEMMember" xlink:href="apyx-20201231.xsd#apyx_OEMMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_OEMMember" xlink:to="lab_apyx_OEMMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_0310a73e-7340-469b-9de6-f36dcc005e99_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES (NOTE 18)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_730c466c-4fdc-427a-91ec-bd5dd07665b5_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_824b8bd2-6c71-470b-af00-3eb11e6aa576_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payment, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_66f266e6-4410-40ae-8c3c-f3b592eee0cd_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2fe4a350-0fe6-491a-a627-61c16078ed7d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_75411280-f14d-42ae-be51-d3d40241e59c_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_63387b08-6a0d-4f7d-bfd7-a01af46c6cf1_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_LossContingencyAccrualTotalAccruedToDate_dcec1647-88ed-4777-9fc9-2734f1a77948_terseLabel_en-US" xlink:label="lab_apyx_LossContingencyAccrualTotalAccruedToDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total loss contingency accrued</link:label>
    <link:label id="lab_apyx_LossContingencyAccrualTotalAccruedToDate_label_en-US" xlink:label="lab_apyx_LossContingencyAccrualTotalAccruedToDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual, Total Accrued To Date</link:label>
    <link:label id="lab_apyx_LossContingencyAccrualTotalAccruedToDate_documentation_en-US" xlink:label="lab_apyx_LossContingencyAccrualTotalAccruedToDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual, Total Accrued To Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_LossContingencyAccrualTotalAccruedToDate" xlink:href="apyx-20201231.xsd#apyx_LossContingencyAccrualTotalAccruedToDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_LossContingencyAccrualTotalAccruedToDate" xlink:to="lab_apyx_LossContingencyAccrualTotalAccruedToDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_5aac9862-5765-42b2-99a9-22c143a56173_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_c51e2770-c83b-4ca7-b978-6115c851aa32_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party note payable</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_28cfbbf7-de36-47bd-a088-822a898b3ee9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_d19a4182-e777-4d78-8b7e-c11dd5b68089_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_65c9b233-ea9c-44d7-a9c1-2b3164dc0043_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerators:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised_c85a51c0-3c7b-4833-be49-9f4a8e726483_terseLabel_en-US" xlink:label="lab_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock option exercises</link:label>
    <link:label id="lab_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised_label_en-US" xlink:label="lab_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Stock Options Exercised And Warrants Exercised</link:label>
    <link:label id="lab_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised_documentation_en-US" xlink:label="lab_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Stock Options Exercised And Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised" xlink:href="apyx-20201231.xsd#apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised" xlink:to="lab_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_d3d7405b-325c-4f6f-bf04-d4d182feb8f7_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_1dd6bf03-3a90-489b-9e48-228521fbe1f1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_14c1bb69-998b-49e7-80fb-6482397acd92_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_0b7fe104-34fc-49c5-9b89-4438279bbc53_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedSalesCommissionCurrent_73611fa9-c358-4b33-bc88-0f9d9074c1ea_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedSalesCommissionCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued commissions</link:label>
    <link:label id="lab_us-gaap_AccruedSalesCommissionCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedSalesCommissionCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Sales Commission, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalesCommissionCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalesCommissionCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalesCommissionCurrent" xlink:to="lab_us-gaap_AccruedSalesCommissionCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_203af7a6-305c-4e67-8d63-b353631dc7d6_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_AssetPurchaseAgreementTerm_cb30d309-f4df-4ee4-a141-0904025c7ded_terseLabel_en-US" xlink:label="lab_apyx_AssetPurchaseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset purchase agreement, term</link:label>
    <link:label id="lab_apyx_AssetPurchaseAgreementTerm_label_en-US" xlink:label="lab_apyx_AssetPurchaseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Purchase Agreement, Term</link:label>
    <link:label id="lab_apyx_AssetPurchaseAgreementTerm_documentation_en-US" xlink:label="lab_apyx_AssetPurchaseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Purchase Agreement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AssetPurchaseAgreementTerm" xlink:href="apyx-20201231.xsd#apyx_AssetPurchaseAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_AssetPurchaseAgreementTerm" xlink:to="lab_apyx_AssetPurchaseAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_da905a90-01e0-451b-85ad-03f481ef71cb_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_0e22abdf-a308-4e7e-a32a-fd21073de190_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_19b567cd-0bf9-4b53-916e-195c7ffbc2e2_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8672adda-e15f-4e42-8ee8-48ce41e0c4db_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_16682f34-53a2-4877-b75f-185205cc8834_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_fc95897c-1c0e-48ea-a010-7b536d0e7d02_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases from supplier</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Purchases from Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_1aee28b7-ce1b-4a8e-809b-52260f1b4da8_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_4a4a7ba0-1668-4e7b-a2d1-ffb07479d09f_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_9be7310f-6b98-4aa4-a189-494ab4b8ec75_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss and credit carryforwards</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_683e4eec-d31d-492c-9bde-9aba641c3e87_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_8a9b246f-c7ac-41fe-8e41-5c64975c989b_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease costs</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_8120d4b5-392b-4bab-8088-df5c5bb410e9_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other costs and expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_741cde93-0b64-441a-83b3-b88472a86e40_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_7cd15570-93f5-43d4-899e-a9d535cc915a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_a06f4076-1a69-4d2d-b004-20bd85700101_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled and forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_91c336c4-1f58-453f-b0ff-1465dc537bf6_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_293467d1-2ef8-401e-a852-3582b9f080f6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of option shares vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_e248bd75-6f35-41b9-bc97-f5573a0f7dd7_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8c18c311-0703-406c-be66-42ed0702c22d_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rates on cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_6605d3a5-0c8e-42c2-a065-46388f72dc3b_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled and forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_e63ee523-9b56-472e-83b3-aebfb2535d3e_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net of provision for obsolescence of $388 and $392</link:label>
    <link:label id="lab_us-gaap_InventoryNet_5d013176-2efe-4b2a-ba61-44b6d26cbeb0_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0b1a58a1-14ec-422b-8bc1-bf043e7921d9_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_InventoryWriteDownReversals_655dadad-ca81-481a-bb8d-68aa4856e949_terseLabel_en-US" xlink:label="lab_apyx_InventoryWriteDownReversals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory write down reversals</link:label>
    <link:label id="lab_apyx_InventoryWriteDownReversals_label_en-US" xlink:label="lab_apyx_InventoryWriteDownReversals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write Down Reversals</link:label>
    <link:label id="lab_apyx_InventoryWriteDownReversals_documentation_en-US" xlink:label="lab_apyx_InventoryWriteDownReversals" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write Down Reversals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_InventoryWriteDownReversals" xlink:href="apyx-20201231.xsd#apyx_InventoryWriteDownReversals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_InventoryWriteDownReversals" xlink:to="lab_apyx_InventoryWriteDownReversals" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_50486333-3100-4a92-8f27-48f30cbca52b_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising expense</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_27926378-9fb0-4478-bcc4-886111d24e2d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration receivable risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_4d64d368-6c5d-42b5-a37c-90e1d41a7449_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_d40f5d3f-09f7-4f67-9934-9a935c4839f0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_b7ae71c5-5bb5-41b1-8ea8-8dfbae46ad21_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_LeaseArrangementsAxis_40558cba-aeda-4250-96f0-87299f7145c0_terseLabel_en-US" xlink:label="lab_apyx_LeaseArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Axis]</link:label>
    <link:label id="lab_apyx_LeaseArrangementsAxis_label_en-US" xlink:label="lab_apyx_LeaseArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Axis]</link:label>
    <link:label id="lab_apyx_LeaseArrangementsAxis_documentation_en-US" xlink:label="lab_apyx_LeaseArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_LeaseArrangementsAxis" xlink:href="apyx-20201231.xsd#apyx_LeaseArrangementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_LeaseArrangementsAxis" xlink:to="lab_apyx_LeaseArrangementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_a69855d5-2d15-43ac-8513-45edca8757b4_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_ea93aa13-b1a2-41a7-b248-1c9bb809c583_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options Non-vested, Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_c5f4cce2-6d96-4ee8-9d6a-af2d200b0632_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StandardProductWarrantyPolicy_f50af900-1db1-4b81-8bc4-bab807329a9d_terseLabel_en-US" xlink:label="lab_us-gaap_StandardProductWarrantyPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Warranties</link:label>
    <link:label id="lab_us-gaap_StandardProductWarrantyPolicy_label_en-US" xlink:label="lab_us-gaap_StandardProductWarrantyPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standard Product Warranty, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandardProductWarrantyPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StandardProductWarrantyPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StandardProductWarrantyPolicy" xlink:to="lab_us-gaap_StandardProductWarrantyPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_2fec2f5c-9d3a-481b-b76c-fbd08111c8a8_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_c023f274-53d2-4df1-847b-af074f630076_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility - minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_d5257743-904f-4a0a-b6af-eccbc555af5d_netLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_00f403ad-c42e-432c-91a5-ae1f33a40789_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per share - basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_c48ae735-5975-4ad1-bbd9-7f068ab4f9b7_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_9fdab7fe-a38d-4939-bfe7-d3932540fcf1_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Financial Statements</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_733f5018-81b0-4b6b-9f41-68039f903115_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (loss), net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_5df97874-c97e-4574-89ed-1e826690163b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b522e723-724b-48af-98d0-1b3ff2d83ede_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0e37d350-9828-447a-b68a-480bdbe3555d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_9b84ff6d-9334-42f3-8d27-99df6986121e_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_MountingFixturesMember_2bc94ef0-028b-4a02-a629-3b1e13e1faa6_terseLabel_en-US" xlink:label="lab_apyx_MountingFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mounting Fixtures</link:label>
    <link:label id="lab_apyx_MountingFixturesMember_label_en-US" xlink:label="lab_apyx_MountingFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mounting Fixtures [Member]</link:label>
    <link:label id="lab_apyx_MountingFixturesMember_documentation_en-US" xlink:label="lab_apyx_MountingFixturesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mounting Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_MountingFixturesMember" xlink:href="apyx-20201231.xsd#apyx_MountingFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_MountingFixturesMember" xlink:to="lab_apyx_MountingFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_70e55000-0e60-4758-8155-cc68f4768370_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_a5b6512e-9055-47e7-a25b-8bcb615156c1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and Diluted Earnings (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_96361865-b5e9-4b6d-912c-f32824027607_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest and penalties</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_fa5a00d5-30d5-4e31-9c7a-28a117d83e88_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_886dedf4-381b-4707-85d5-f47be4b11fd0_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Costs of Goods Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_ae8e25e0-44b5-479a-8584-a9190b748e9a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_024cf57b-9cfc-4884-804b-9cce7f088c02_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate (Other)</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_9c1759b2-f089-4cf7-aca8-fb997beeb2b7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining shares for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfRelatedPartyDebt_3665b85a-5bba-4601-935e-13eee5af91ed_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfRelatedPartyDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of related party note payable</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfRelatedPartyDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfRelatedPartyDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Related Party Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="lab_us-gaap_RepaymentsOfRelatedPartyDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_A2001ExecutiveandEmployeeStockOptionPlanMember_ef776d33-5b0f-4739-93f9-2b8314fcd570_terseLabel_en-US" xlink:label="lab_apyx_A2001ExecutiveandEmployeeStockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2001 Executive and Employee Stock Option Plan</link:label>
    <link:label id="lab_apyx_A2001ExecutiveandEmployeeStockOptionPlanMember_label_en-US" xlink:label="lab_apyx_A2001ExecutiveandEmployeeStockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2001 Executive and Employee Stock Option Plan [Member]</link:label>
    <link:label id="lab_apyx_A2001ExecutiveandEmployeeStockOptionPlanMember_documentation_en-US" xlink:label="lab_apyx_A2001ExecutiveandEmployeeStockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2001 Executive and Employee Stock Option Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_A2001ExecutiveandEmployeeStockOptionPlanMember" xlink:href="apyx-20201231.xsd#apyx_A2001ExecutiveandEmployeeStockOptionPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_A2001ExecutiveandEmployeeStockOptionPlanMember" xlink:to="lab_apyx_A2001ExecutiveandEmployeeStockOptionPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_cc61612d-3ca7-4908-9a64-7e5fb5b261dd_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_f0e7753d-241e-4db0-8e7c-1cb5e403f18f_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_b2323855-1181-4091-9e19-3d3115ff631e_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_AccessoriesMember_5d6e55da-6ca1-4d0e-8fa6-bf03cfaa099a_terseLabel_en-US" xlink:label="lab_apyx_AccessoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accessories</link:label>
    <link:label id="lab_apyx_AccessoriesMember_label_en-US" xlink:label="lab_apyx_AccessoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accessories [Member]</link:label>
    <link:label id="lab_apyx_AccessoriesMember_documentation_en-US" xlink:label="lab_apyx_AccessoriesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accessories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AccessoriesMember" xlink:href="apyx-20201231.xsd#apyx_AccessoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_AccessoriesMember" xlink:to="lab_apyx_AccessoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_0dafeb00-a494-4e99-8d5b-ef87cc2dec8b_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember_cb9f8643-5b5e-4442-9806-373f1b290a04_terseLabel_en-US" xlink:label="lab_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Electro Surgical Disposables and Accessories, Cauteries and Other Products Supply Agreement</link:label>
    <link:label id="lab_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember_label_en-US" xlink:label="lab_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Electro Surgical Disposables And Accessories, Cauteries And Other Products Supply Agreement [Member]</link:label>
    <link:label id="lab_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember_documentation_en-US" xlink:label="lab_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Electro Surgical Disposables And Accessories, Cauteries And Other Products Supply Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember" xlink:href="apyx-20201231.xsd#apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember" xlink:to="lab_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_29bf92c4-a848-4350-ba3a-0f10fe63e0da_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax receivables</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesReceivable" xlink:to="lab_us-gaap_IncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_28e6ecc5-9e33-48cb-a64a-9f8b50a93651_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_86856b3f-f806-48a4-a272-255787547143_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_b3347163-46d5-4b24-93f1-7b118202c088_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deduction, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_9dfa0503-4b8b-4efc-a7e4-b21ce2a58b9e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock-based compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_3bf7f63d-4443-4650-b109-4760c61aa183_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_1bd15dab-b2f8-481f-9815-742d7abee210_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_551f5c22-5b01-42a9-bf6f-b9b0beecb776_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1e816bfc-99de-4607-94d3-0c6202da7c61_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_bf817069-b86e-44a3-9036-c653dbe42a1a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive instruments excluded from diluted loss per common share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted, Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_d109b5f5-c629-4bc2-a1e1-3c04ebe98ccd_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_67538afd-0b76-4cf6-96cf-695ac3cfaf75_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_111d2df8-51bd-41ab-a761-74a594ae00cc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_79816a6b-9d83-45a6-8188-f2563d79fa9d_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_f5a92f78-f5d7-4b38-bb28-51d79b99f324_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_5f2f7425-1919-4ba5-96b3-e8d8226da0a1_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedBonusesCurrent_27f7b822-07a1-43d6-aa0d-3370e632dd9b_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedBonusesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued bonus</link:label>
    <link:label id="lab_us-gaap_AccruedBonusesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedBonusesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Bonuses, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedBonusesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedBonusesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedBonusesCurrent" xlink:to="lab_us-gaap_AccruedBonusesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_02fd8a90-b713-43e9-b84b-c6749e0ec1ae_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Geographic Area</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_UncertainTaxPositionsLiability_3f8a94d7-a1e7-42cb-8ec7-2f983751811a_terseLabel_en-US" xlink:label="lab_apyx_UncertainTaxPositionsLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncertain tax positions</link:label>
    <link:label id="lab_apyx_UncertainTaxPositionsLiability_label_en-US" xlink:label="lab_apyx_UncertainTaxPositionsLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncertain Tax Positions Liability</link:label>
    <link:label id="lab_apyx_UncertainTaxPositionsLiability_documentation_en-US" xlink:label="lab_apyx_UncertainTaxPositionsLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncertain Tax Positions Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_UncertainTaxPositionsLiability" xlink:href="apyx-20201231.xsd#apyx_UncertainTaxPositionsLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_UncertainTaxPositionsLiability" xlink:to="lab_apyx_UncertainTaxPositionsLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_0afce766-2371-4f22-bb94-828a627dda10_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Costs</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_NonCashTransferOfOtherAssetsToFixedAssets_f3dc746e-dcd6-490e-93a4-80b20631e17e_terseLabel_en-US" xlink:label="lab_apyx_NonCashTransferOfOtherAssetsToFixedAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer of other assets to fixed assets</link:label>
    <link:label id="lab_apyx_NonCashTransferOfOtherAssetsToFixedAssets_label_en-US" xlink:label="lab_apyx_NonCashTransferOfOtherAssetsToFixedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash, Transfer Of Other Assets To Fixed Assets</link:label>
    <link:label id="lab_apyx_NonCashTransferOfOtherAssetsToFixedAssets_documentation_en-US" xlink:label="lab_apyx_NonCashTransferOfOtherAssetsToFixedAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash, Transfer Of Other Assets To Fixed Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_NonCashTransferOfOtherAssetsToFixedAssets" xlink:href="apyx-20201231.xsd#apyx_NonCashTransferOfOtherAssetsToFixedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_NonCashTransferOfOtherAssetsToFixedAssets" xlink:to="lab_apyx_NonCashTransferOfOtherAssetsToFixedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f1c8a152-6362-45a9-9da7-8302bbaec67b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalCostsPolicyTextBlock_85dd06da-d749-4e0d-865d-6082b187814b_terseLabel_en-US" xlink:label="lab_us-gaap_LegalCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Contingencies</link:label>
    <link:label id="lab_us-gaap_LegalCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalCostsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalCostsPolicyTextBlock" xlink:to="lab_us-gaap_LegalCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_b4a40500-f3ef-433f-b5d9-225134661dc0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_e8df14cf-9f74-4605-b539-45ef9a9d3a88_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_FinanceLeasePayments_55ad25bd-78c6-47eb-81f3-f802222ba5ab_terseLabel_en-US" xlink:label="lab_apyx_FinanceLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for lease liabilities</link:label>
    <link:label id="lab_apyx_FinanceLeasePayments_label_en-US" xlink:label="lab_apyx_FinanceLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Payments</link:label>
    <link:label id="lab_apyx_FinanceLeasePayments_documentation_en-US" xlink:label="lab_apyx_FinanceLeasePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_FinanceLeasePayments" xlink:href="apyx-20201231.xsd#apyx_FinanceLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_FinanceLeasePayments" xlink:to="lab_apyx_FinanceLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_4780cd60-ba4d-48e7-8a8a-7f06240f9846_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GEOGRAPHIC AND SEGMENT INFORMATION</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_0ee76e27-4e3d-4c45-96c8-c2a1097c99bd_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested restricted stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_1347675b-c9bf-4b2e-9fd2-cdd70d5daa4e_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_add18403-e4e6-4fef-a1aa-00256e5ac2eb_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_StockSwapToAcquireOptionsShares_bf1ace4f-779c-4c05-b16a-d9243c667f21_terseLabel_en-US" xlink:label="lab_apyx_StockSwapToAcquireOptionsShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued on net settlement of stock options (in shares)</link:label>
    <link:label id="lab_apyx_StockSwapToAcquireOptionsShares_label_en-US" xlink:label="lab_apyx_StockSwapToAcquireOptionsShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock swap to acquire options, Shares</link:label>
    <link:label id="lab_apyx_StockSwapToAcquireOptionsShares_documentation_en-US" xlink:label="lab_apyx_StockSwapToAcquireOptionsShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock swap to acquire options shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_StockSwapToAcquireOptionsShares" xlink:href="apyx-20201231.xsd#apyx_StockSwapToAcquireOptionsShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_StockSwapToAcquireOptionsShares" xlink:to="lab_apyx_StockSwapToAcquireOptionsShares" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_TwoThousandTwelveShareIncentivePlanMember_e75234e6-04a9-4536-b7a4-04f4549468af_terseLabel_en-US" xlink:label="lab_apyx_TwoThousandTwelveShareIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2012 Share Incentive Plan</link:label>
    <link:label id="lab_apyx_TwoThousandTwelveShareIncentivePlanMember_label_en-US" xlink:label="lab_apyx_TwoThousandTwelveShareIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2012 Share Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_TwoThousandTwelveShareIncentivePlanMember" xlink:href="apyx-20201231.xsd#apyx_TwoThousandTwelveShareIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_TwoThousandTwelveShareIncentivePlanMember" xlink:to="lab_apyx_TwoThousandTwelveShareIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_469ceb5c-c3ce-408d-83ab-cfd0f74e2ce3_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_OtherAccruedExpensesAndLiabilitiesCurrent_1595c1de-2969-43a6-b509-1cadc01670aa_terseLabel_en-US" xlink:label="lab_apyx_OtherAccruedExpensesAndLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued expenses and current liabilities</link:label>
    <link:label id="lab_apyx_OtherAccruedExpensesAndLiabilitiesCurrent_label_en-US" xlink:label="lab_apyx_OtherAccruedExpensesAndLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Expenses And Liabilities, Current</link:label>
    <link:label id="lab_apyx_OtherAccruedExpensesAndLiabilitiesCurrent_documentation_en-US" xlink:label="lab_apyx_OtherAccruedExpensesAndLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Expenses And Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_OtherAccruedExpensesAndLiabilitiesCurrent" xlink:href="apyx-20201231.xsd#apyx_OtherAccruedExpensesAndLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_OtherAccruedExpensesAndLiabilitiesCurrent" xlink:to="lab_apyx_OtherAccruedExpensesAndLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_50bc6423-b359-4079-ae86-e6d9ab1e1675_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_efabdfb7-854d-4a43-ad5a-2b506070ca9d_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value of options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ce0c79ce-5e25-4602-80ba-98d38a950ba0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value, Non-vested Options, Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_03e4da69-28c7-49c3-8356-8d6bb7340c8f_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_RenuvionJPlasmaGeneratorsMember_32e4be21-7f29-419a-83d4-77e0f8268176_terseLabel_en-US" xlink:label="lab_apyx_RenuvionJPlasmaGeneratorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renuvion/J-Plasma generators</link:label>
    <link:label id="lab_apyx_RenuvionJPlasmaGeneratorsMember_label_en-US" xlink:label="lab_apyx_RenuvionJPlasmaGeneratorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renuvion/J-Plasma Generators [Member]</link:label>
    <link:label id="lab_apyx_RenuvionJPlasmaGeneratorsMember_documentation_en-US" xlink:label="lab_apyx_RenuvionJPlasmaGeneratorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renuvion/J-Plasma Generators [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_RenuvionJPlasmaGeneratorsMember" xlink:href="apyx-20201231.xsd#apyx_RenuvionJPlasmaGeneratorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_RenuvionJPlasmaGeneratorsMember" xlink:to="lab_apyx_RenuvionJPlasmaGeneratorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1710cfdf-2968-45d4-890b-fb11062400e4_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_d08ed8a0-f070-452f-b071-be45c5066291_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DESCRIPTION OF BUSINESS</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_59a915f3-7661-4dcf-aa29-5454f4314b5d_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity of Finance Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_5c3e92f8-7ce0-4ec9-83e8-44691c990824_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_06cc1288-c628-4727-a8b7-0b00a49a163e_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_363e65d4-3675-4454-a121-dfbdbd635ae1_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_502bc289-57eb-4de6-9786-a312e5e00aa2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components Of Provision For Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_a6318328-9fb6-4661-9ba2-651588e767f0_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalariesAndWages_a5a1f242-5930-423e-bfc7-74bdb1191f55_terseLabel_en-US" xlink:label="lab_us-gaap_SalariesAndWages" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salaries and related costs</link:label>
    <link:label id="lab_us-gaap_SalariesAndWages_label_en-US" xlink:label="lab_us-gaap_SalariesAndWages" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalariesAndWages" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalariesAndWages"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalariesAndWages" xlink:to="lab_us-gaap_SalariesAndWages" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_525112f6-e684-48dd-a17e-eb2af205eb1c_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_be146837-18f4-4599-bac9-07a20779efb6_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock-based compensation cost, recognition period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_926fa808-7c36-4ee1-a261-1b349fb810e9_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_786824bb-46eb-4ff4-b966-2fafff4ffe40_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_A2019ShareIncentivePlanMember_f62888d8-0039-4c93-85e0-cf899b964086_terseLabel_en-US" xlink:label="lab_apyx_A2019ShareIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Share Incentive Plan</link:label>
    <link:label id="lab_apyx_A2019ShareIncentivePlanMember_label_en-US" xlink:label="lab_apyx_A2019ShareIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Share Incentive Plan [Member]</link:label>
    <link:label id="lab_apyx_A2019ShareIncentivePlanMember_documentation_en-US" xlink:label="lab_apyx_A2019ShareIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Share Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_A2019ShareIncentivePlanMember" xlink:href="apyx-20201231.xsd#apyx_A2019ShareIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_A2019ShareIncentivePlanMember" xlink:to="lab_apyx_A2019ShareIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_TwoThousandFifteenExecutiveAndEmployeeStockOptionPlanMember_c6b1770d-861e-4104-bc61-48e5ff212873_terseLabel_en-US" xlink:label="lab_apyx_TwoThousandFifteenExecutiveAndEmployeeStockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015 Executive and Employee Stock Option Plan</link:label>
    <link:label id="lab_apyx_TwoThousandFifteenExecutiveAndEmployeeStockOptionPlanMember_label_en-US" xlink:label="lab_apyx_TwoThousandFifteenExecutiveAndEmployeeStockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015 Executive and Employee Stock Option Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_TwoThousandFifteenExecutiveAndEmployeeStockOptionPlanMember" xlink:href="apyx-20201231.xsd#apyx_TwoThousandFifteenExecutiveAndEmployeeStockOptionPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_TwoThousandFifteenExecutiveAndEmployeeStockOptionPlanMember" xlink:to="lab_apyx_TwoThousandFifteenExecutiveAndEmployeeStockOptionPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fbf5d018-18e9-43aa-85fb-b3e8281309bb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_53641b9b-b838-4486-b16b-0c34d5fbb074_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_c2727df7-8a49-4d5c-bf72-eb93194ddae1_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options outstanding and exercisable, weighted average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_c4f8fda9-bd2e-4bd6-a1f5-b532edd6d675_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableRelatedPartiesNoncurrent_d1729fde-602a-4705-95f3-b0481abb1ec1_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableRelatedPartiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note payable issued</link:label>
    <link:label id="lab_us-gaap_NotesPayableRelatedPartiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_NotesPayableRelatedPartiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Related Parties, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableRelatedPartiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableRelatedPartiesNoncurrent" xlink:to="lab_us-gaap_NotesPayableRelatedPartiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_CARESActEffectiveIncomeTaxRateReconciliationFederalNetOperatingLossCarryforwardsAmount_3559a660-071f-41b1-9b73-fe6ff1b74745_terseLabel_en-US" xlink:label="lab_apyx_CARESActEffectiveIncomeTaxRateReconciliationFederalNetOperatingLossCarryforwardsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryback</link:label>
    <link:label id="lab_apyx_CARESActEffectiveIncomeTaxRateReconciliationFederalNetOperatingLossCarryforwardsAmount_label_en-US" xlink:label="lab_apyx_CARESActEffectiveIncomeTaxRateReconciliationFederalNetOperatingLossCarryforwardsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act, Effective Income Tax Rate Reconciliation, Federal Net Operating Loss Carryforwards, Amount</link:label>
    <link:label id="lab_apyx_CARESActEffectiveIncomeTaxRateReconciliationFederalNetOperatingLossCarryforwardsAmount_documentation_en-US" xlink:label="lab_apyx_CARESActEffectiveIncomeTaxRateReconciliationFederalNetOperatingLossCarryforwardsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act, Effective Income Tax Rate Reconciliation, Federal Net Operating Loss Carryforwards, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_CARESActEffectiveIncomeTaxRateReconciliationFederalNetOperatingLossCarryforwardsAmount" xlink:href="apyx-20201231.xsd#apyx_CARESActEffectiveIncomeTaxRateReconciliationFederalNetOperatingLossCarryforwardsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_CARESActEffectiveIncomeTaxRateReconciliationFederalNetOperatingLossCarryforwardsAmount" xlink:to="lab_apyx_CARESActEffectiveIncomeTaxRateReconciliationFederalNetOperatingLossCarryforwardsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_7b188dbc-4d0b-461e-9a64-4a7a65d844bb_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c0ccb171-225e-4ef0-8c39-13fad8af0fb4_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value, Non-vested Options, Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_70c638e9-6b70-493a-879a-487d4d1567b4_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_10ffe078-c46b-4223-9a6a-66d8f4ec5a4f_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross inventories</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_48cd35db-2a55-43c2-948e-8b1f3efbdb58_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_d888cf59-2e01-46ad-a4c7-03d2da390f02_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_2ac3cb2d-233a-4598-9ba9-15c0ce04baf4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_AdvancedEnergyMember_ac802777-bfb8-4fec-bfae-bd00583bc72a_terseLabel_en-US" xlink:label="lab_apyx_AdvancedEnergyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advanced Energy</link:label>
    <link:label id="lab_apyx_AdvancedEnergyMember_label_en-US" xlink:label="lab_apyx_AdvancedEnergyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advanced Energy [Member]</link:label>
    <link:label id="lab_apyx_AdvancedEnergyMember_documentation_en-US" xlink:label="lab_apyx_AdvancedEnergyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advanced Energy [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AdvancedEnergyMember" xlink:href="apyx-20201231.xsd#apyx_AdvancedEnergyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_AdvancedEnergyMember" xlink:to="lab_apyx_AdvancedEnergyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f1319ed4-b150-4e81-9046-675845289c23_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_8f330da9-f6ce-47b7-b057-116ace64fcf3_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_f987d4e3-d47b-44f5-aca4-eb0efb85ec52_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_92856fb3-a337-4dc2-8219-3b966cc2cccb_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_5024e777-92e6-4cf7-ae17-ee836c820700_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_us-gaap_MachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_3bede9c1-694f-4f49-bcfd-ee43068f8db5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_1bebee1f-a541-43d2-a615-d8e5ff7590b0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_bbe0d7ff-ee28-4842-b3ba-4cef0974b0d5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_27013e79-3d97-4105-82af-5f6910b113e5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_edcc6343-7d95-4622-a7ee-1e1221bd3bdb_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease costs</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DefinedContributionPlanEmployersMatchingContributionVestingPercentageAfterThreeYears_08d4c634-e954-47e5-a743-372210dbb57f_terseLabel_en-US" xlink:label="lab_apyx_DefinedContributionPlanEmployersMatchingContributionVestingPercentageAfterThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan, vesting percentage after 3 years</link:label>
    <link:label id="lab_apyx_DefinedContributionPlanEmployersMatchingContributionVestingPercentageAfterThreeYears_label_en-US" xlink:label="lab_apyx_DefinedContributionPlanEmployersMatchingContributionVestingPercentageAfterThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employers Matching Contribution, Vesting Percentage After Three Years</link:label>
    <link:label id="lab_apyx_DefinedContributionPlanEmployersMatchingContributionVestingPercentageAfterThreeYears_documentation_en-US" xlink:label="lab_apyx_DefinedContributionPlanEmployersMatchingContributionVestingPercentageAfterThreeYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employers Matching Contribution, Vesting Percentage After Three Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DefinedContributionPlanEmployersMatchingContributionVestingPercentageAfterThreeYears" xlink:href="apyx-20201231.xsd#apyx_DefinedContributionPlanEmployersMatchingContributionVestingPercentageAfterThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DefinedContributionPlanEmployersMatchingContributionVestingPercentageAfterThreeYears" xlink:to="lab_apyx_DefinedContributionPlanEmployersMatchingContributionVestingPercentageAfterThreeYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0bb6fb0d-a176-46d1-a1f9-0f3151a72172_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_4a81fad6-eb8a-4b6b-911c-076f0bab2272_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_ced19e64-b0a5-4f01-bf8c-fef562187a87_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_63e9c52a-314d-49ee-b88b-ad0c4e3652af_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_600a2358-9906-4497-ad38-e75089feaaee_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6f71d854-bd43-4525-b18f-dec451d8d886_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_a0d48b6b-4616-4f87-bcfc-a38e8145aed1_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_158d9fd8-d9ba-4341-9a0b-fd1f0eef0a5c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Changes and Error Corrections [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Changes and Error Corrections [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_8cf0bab6-30f6-46a3-a2a3-21b964aefebd_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_7a494ed9-87cd-4d47-a450-27c9738d4329_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_dbd3fd89-e346-43bf-ba9b-d6540bffea5a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_c615ed1c-c819-497f-8338-9e33a1b194d6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_EffectiveIncomeTaxRateReconciliationCARESActNetOperatingLossCarryforwardsPercent_78b18908-02d2-4b66-bdad-82b951303964_terseLabel_en-US" xlink:label="lab_apyx_EffectiveIncomeTaxRateReconciliationCARESActNetOperatingLossCarryforwardsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NOL carryback from CARES Act</link:label>
    <link:label id="lab_apyx_EffectiveIncomeTaxRateReconciliationCARESActNetOperatingLossCarryforwardsPercent_label_en-US" xlink:label="lab_apyx_EffectiveIncomeTaxRateReconciliationCARESActNetOperatingLossCarryforwardsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, CARES Act, Net Operating Loss Carryforwards, Percent</link:label>
    <link:label id="lab_apyx_EffectiveIncomeTaxRateReconciliationCARESActNetOperatingLossCarryforwardsPercent_documentation_en-US" xlink:label="lab_apyx_EffectiveIncomeTaxRateReconciliationCARESActNetOperatingLossCarryforwardsPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, CARES Act, Net Operating Loss Carryforwards, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_EffectiveIncomeTaxRateReconciliationCARESActNetOperatingLossCarryforwardsPercent" xlink:href="apyx-20201231.xsd#apyx_EffectiveIncomeTaxRateReconciliationCARESActNetOperatingLossCarryforwardsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_EffectiveIncomeTaxRateReconciliationCARESActNetOperatingLossCarryforwardsPercent" xlink:to="lab_apyx_EffectiveIncomeTaxRateReconciliationCARESActNetOperatingLossCarryforwardsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_FinanceLeaseCostsAbstract_60e02f3b-d429-49fa-a7ea-c5987e5b25b5_terseLabel_en-US" xlink:label="lab_apyx_FinanceLeaseCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance</link:label>
    <link:label id="lab_apyx_FinanceLeaseCostsAbstract_label_en-US" xlink:label="lab_apyx_FinanceLeaseCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Costs [Abstract]</link:label>
    <link:label id="lab_apyx_FinanceLeaseCostsAbstract_documentation_en-US" xlink:label="lab_apyx_FinanceLeaseCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Costs [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_FinanceLeaseCostsAbstract" xlink:href="apyx-20201231.xsd#apyx_FinanceLeaseCostsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_FinanceLeaseCostsAbstract" xlink:to="lab_apyx_FinanceLeaseCostsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StandardProductWarrantyAccrual_1d5aa295-fffb-4fa6-bf1a-036a8cf3d529_periodStartLabel_en-US" xlink:label="lab_us-gaap_StandardProductWarrantyAccrual" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StandardProductWarrantyAccrual_96cffc26-d8fd-488c-8dbf-c48fc764a88d_periodEndLabel_en-US" xlink:label="lab_us-gaap_StandardProductWarrantyAccrual" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued product warranties</link:label>
    <link:label id="lab_us-gaap_StandardProductWarrantyAccrual_label_en-US" xlink:label="lab_us-gaap_StandardProductWarrantyAccrual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standard Product Warranty Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandardProductWarrantyAccrual" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StandardProductWarrantyAccrual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StandardProductWarrantyAccrual" xlink:to="lab_us-gaap_StandardProductWarrantyAccrual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_7cfe16ee-4bde-4f83-b256-80c91fc67075_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reporting Information by Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeOperating_2e64ee7d-eb4f-48be-bcb2-f894d1ddf8da_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOperating_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income, Operating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOperating" xlink:to="lab_us-gaap_InterestIncomeOperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_fb4856fc-ce37-4258-94cd-8a43f0154076_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Operations</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_7df73c46-fb4e-4641-bdf0-5949d84b6768_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedInsuranceCurrent_a84d1f4a-a841-4db2-9833-db0fe1c503f6_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedInsuranceCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued product liability claim insurance deductibles</link:label>
    <link:label id="lab_us-gaap_AccruedInsuranceCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedInsuranceCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Insurance, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedInsuranceCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedInsuranceCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedInsuranceCurrent" xlink:to="lab_us-gaap_AccruedInsuranceCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a720fbad-b53e-4221-b880-db482e2cd943_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StandardProductWarrantyAccrualWarrantiesIssued_996dd477-be28-441d-949e-48eaf7733fda_terseLabel_en-US" xlink:label="lab_us-gaap_StandardProductWarrantyAccrualWarrantiesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for product warranties</link:label>
    <link:label id="lab_us-gaap_StandardProductWarrantyAccrualWarrantiesIssued_label_en-US" xlink:label="lab_us-gaap_StandardProductWarrantyAccrualWarrantiesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standard Product Warranty Accrual, Increase for Warranties Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandardProductWarrantyAccrualWarrantiesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StandardProductWarrantyAccrualWarrantiesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StandardProductWarrantyAccrualWarrantiesIssued" xlink:to="lab_us-gaap_StandardProductWarrantyAccrualWarrantiesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductWarrantyExpense_7ad72ba1-8ea8-459d-b40c-897d58bbab38_terseLabel_en-US" xlink:label="lab_us-gaap_ProductWarrantyExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for product warranties</link:label>
    <link:label id="lab_us-gaap_ProductWarrantyExpense_label_en-US" xlink:label="lab_us-gaap_ProductWarrantyExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Warranty Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductWarrantyExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductWarrantyExpense" xlink:to="lab_us-gaap_ProductWarrantyExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_49a99fee-0794-423f-a717-982298f24177_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6ef8eeea-c2ea-4c4d-ac67-bd0980b71d46_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_cc4d3365-c6c9-4481-a8fa-c083464a4deb_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates in the Preparation of Financial Statements</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_CurrentIncomeTaxExpenseBenefitAfterValuationAllowance_0d77a9c7-0c38-4a33-91e1-3b9b8c3c28c2_totalLabel_en-US" xlink:label="lab_apyx_CurrentIncomeTaxExpenseBenefitAfterValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current income tax expense (benefit), after valuation allowance</link:label>
    <link:label id="lab_apyx_CurrentIncomeTaxExpenseBenefitAfterValuationAllowance_label_en-US" xlink:label="lab_apyx_CurrentIncomeTaxExpenseBenefitAfterValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), After Valuation Allowance</link:label>
    <link:label id="lab_apyx_CurrentIncomeTaxExpenseBenefitAfterValuationAllowance_documentation_en-US" xlink:label="lab_apyx_CurrentIncomeTaxExpenseBenefitAfterValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), After Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_CurrentIncomeTaxExpenseBenefitAfterValuationAllowance" xlink:href="apyx-20201231.xsd#apyx_CurrentIncomeTaxExpenseBenefitAfterValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_CurrentIncomeTaxExpenseBenefitAfterValuationAllowance" xlink:to="lab_apyx_CurrentIncomeTaxExpenseBenefitAfterValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_3551a7eb-dcba-4081-9a84-2a238208feb7_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_SalesDiscountBillingTermsLowerLimit_58a8580b-498d-48a6-99ac-caf0f385bee6_terseLabel_en-US" xlink:label="lab_apyx_SalesDiscountBillingTermsLowerLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit terms, billing term, lower limit</link:label>
    <link:label id="lab_apyx_SalesDiscountBillingTermsLowerLimit_label_en-US" xlink:label="lab_apyx_SalesDiscountBillingTermsLowerLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Discount, Billing Terms, Lower Limit</link:label>
    <link:label id="lab_apyx_SalesDiscountBillingTermsLowerLimit_documentation_en-US" xlink:label="lab_apyx_SalesDiscountBillingTermsLowerLimit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Discount, Billing Terms, Lower Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SalesDiscountBillingTermsLowerLimit" xlink:href="apyx-20201231.xsd#apyx_SalesDiscountBillingTermsLowerLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_SalesDiscountBillingTermsLowerLimit" xlink:to="lab_apyx_SalesDiscountBillingTermsLowerLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_ChineseSupplierMember_d39e4a92-e66c-4de0-8420-6e627de590f1_terseLabel_en-US" xlink:label="lab_apyx_ChineseSupplierMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chinese Supplier</link:label>
    <link:label id="lab_apyx_ChineseSupplierMember_label_en-US" xlink:label="lab_apyx_ChineseSupplierMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chinese Supplier [Member]</link:label>
    <link:label id="lab_apyx_ChineseSupplierMember_documentation_en-US" xlink:label="lab_apyx_ChineseSupplierMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chinese Supplier</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ChineseSupplierMember" xlink:href="apyx-20201231.xsd#apyx_ChineseSupplierMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_ChineseSupplierMember" xlink:to="lab_apyx_ChineseSupplierMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_20affffe-096e-4a05-9a44-a22c65beaf0b_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2189195c-a1c2-4c9a-94bf-880faa9dacb1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_80fbf1b9-b425-4cd3-9b90-b4f4cf7fff35_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory Federal Income Tax Rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_ComputerEquipmentandSoftwareMember_29757021-c676-4c70-bd94-26d0e612d373_terseLabel_en-US" xlink:label="lab_apyx_ComputerEquipmentandSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_apyx_ComputerEquipmentandSoftwareMember_label_en-US" xlink:label="lab_apyx_ComputerEquipmentandSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment and Software [Member]</link:label>
    <link:label id="lab_apyx_ComputerEquipmentandSoftwareMember_documentation_en-US" xlink:label="lab_apyx_ComputerEquipmentandSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment and Software [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ComputerEquipmentandSoftwareMember" xlink:href="apyx-20201231.xsd#apyx_ComputerEquipmentandSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_ComputerEquipmentandSoftwareMember" xlink:to="lab_apyx_ComputerEquipmentandSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e17360fe-264f-4152-94e0-c00227fdc50d_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_06fb40ad-ea58-4f3d-b1de-d6a11ca5de61_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_cc801b56-505b-4f0f-865d-6d05c2b3dc14_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementAdjustmentMember_2d2b43e3-e482-46ed-98d7-60002a5f0a60_verboseLabel_en-US" xlink:label="lab_srt_RestatementAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments</link:label>
    <link:label id="lab_srt_RestatementAdjustmentMember_label_en-US" xlink:label="lab_srt_RestatementAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAdjustmentMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAdjustmentMember" xlink:to="lab_srt_RestatementAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_ff0cf30e-1fc6-40e8-9fb9-1baa5f4227c9_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock_e84f91b6-e308-4bbb-aed4-48612e9714be_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CHANGE IN ACCOUNTING POLICY</link:label>
    <link:label id="lab_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Changes and Error Corrections [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock" xlink:to="lab_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_c5e796d2-2d4e-4f10-ac7a-06ea3393b806_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_A2003ExecutiveandEmployeeStockOptionPlanMember_133ff4b7-f49d-4395-a0e4-6e7e0af0b28d_terseLabel_en-US" xlink:label="lab_apyx_A2003ExecutiveandEmployeeStockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2003 Executive and Employee Stock Option Plan</link:label>
    <link:label id="lab_apyx_A2003ExecutiveandEmployeeStockOptionPlanMember_label_en-US" xlink:label="lab_apyx_A2003ExecutiveandEmployeeStockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2003 Executive and Employee Stock Option Plan [Member]</link:label>
    <link:label id="lab_apyx_A2003ExecutiveandEmployeeStockOptionPlanMember_documentation_en-US" xlink:label="lab_apyx_A2003ExecutiveandEmployeeStockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2003 Executive and Employee Stock Option Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_A2003ExecutiveandEmployeeStockOptionPlanMember" xlink:href="apyx-20201231.xsd#apyx_A2003ExecutiveandEmployeeStockOptionPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_A2003ExecutiveandEmployeeStockOptionPlanMember" xlink:to="lab_apyx_A2003ExecutiveandEmployeeStockOptionPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_e882718f-0aa8-476f-a508-aca352bd06d8_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost accrued</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesAndExciseTaxPayableCurrent_c5c34eb9-1668-42bf-8e59-2382a0adaf2f_terseLabel_en-US" xlink:label="lab_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales tax payable</link:label>
    <link:label id="lab_us-gaap_SalesAndExciseTaxPayableCurrent_label_en-US" xlink:label="lab_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and Excise Tax Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesAndExciseTaxPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:to="lab_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_8d1a99a8-551a-4744-a721-d448c3b67a9b_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value, Non-vested Options at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_216f756d-dc45-4608-9622-38cc0411cf66_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value, Non-vested Options at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_f799bafe-ef96-4927-9d59-1e6655e2bdf4_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_dfe36790-ebfd-44e4-a87d-70d3d4013da8_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_LeaseExecutionMember_7a6b1673-0a9e-4842-a750-2c4f803f400e_terseLabel_en-US" xlink:label="lab_apyx_LeaseExecutionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Execution</link:label>
    <link:label id="lab_apyx_LeaseExecutionMember_label_en-US" xlink:label="lab_apyx_LeaseExecutionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Execution [Member]</link:label>
    <link:label id="lab_apyx_LeaseExecutionMember_documentation_en-US" xlink:label="lab_apyx_LeaseExecutionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Execution [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_LeaseExecutionMember" xlink:href="apyx-20201231.xsd#apyx_LeaseExecutionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_LeaseExecutionMember" xlink:to="lab_apyx_LeaseExecutionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_ProductWarranty_b08ff19a-65d0-4352-aad4-bc021153fa78_terseLabel_en-US" xlink:label="lab_apyx_ProductWarranty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product warranty</link:label>
    <link:label id="lab_apyx_ProductWarranty_label_en-US" xlink:label="lab_apyx_ProductWarranty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Warranty</link:label>
    <link:label id="lab_apyx_ProductWarranty_documentation_en-US" xlink:label="lab_apyx_ProductWarranty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Warranty</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ProductWarranty" xlink:href="apyx-20201231.xsd#apyx_ProductWarranty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_ProductWarranty" xlink:to="lab_apyx_ProductWarranty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_fb9ad854-2230-461c-a60c-59029bbab37a_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInStandardProductWarrantyAccrualRollForward_ce0b1e51-c91e-4625-9c37-b9a9469fde69_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInStandardProductWarrantyAccrualRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Movement in Standard Product Warranty Accrual [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInStandardProductWarrantyAccrualRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInStandardProductWarrantyAccrualRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Movement in Standard Product Warranty Accrual [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInStandardProductWarrantyAccrualRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MovementInStandardProductWarrantyAccrualRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInStandardProductWarrantyAccrualRollForward" xlink:to="lab_us-gaap_MovementInStandardProductWarrantyAccrualRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_029aa8ec-0c94-4e59-accc-92f5d0b95250_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductWarrantiesDisclosuresAbstract_f2a24357-5106-492e-a003-11beba026b02_terseLabel_en-US" xlink:label="lab_us-gaap_ProductWarrantiesDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Warranties Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ProductWarrantiesDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ProductWarrantiesDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Warranties Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantiesDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductWarrantiesDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductWarrantiesDisclosuresAbstract" xlink:to="lab_us-gaap_ProductWarrantiesDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_b3e03e71-0be8-4edb-9245-7864abbda03e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_756594d0-b9c7-4088-91c1-a197a3b68f71_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_5f9a13d7-c60b-4b32-9cf3-553ef7440f6c_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan, percent of employees' gross pay</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_16d9fb2e-7c6e-4553-9a35-35e697616909_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_b7a7801d-0ef7-4dd2-bdc0-e711aede946a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_2a015214-bed4-4bbb-9940-c92332d9f366_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_5b277751-3020-4ade-8540-1c54b50c8284_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_b4a03876-3d85-4b99-9023-52bfa64f1ce6_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_c7e1a1b6-ac0e-41ab-bcf8-eac21a0c37e4_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_JointAndSeveralPayrollExpense_8d500c16-51f8-44bd-9ba6-b2ef9b4e5474_terseLabel_en-US" xlink:label="lab_apyx_JointAndSeveralPayrollExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint and several payroll expense</link:label>
    <link:label id="lab_apyx_JointAndSeveralPayrollExpense_label_en-US" xlink:label="lab_apyx_JointAndSeveralPayrollExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint And Several Payroll Expense</link:label>
    <link:label id="lab_apyx_JointAndSeveralPayrollExpense_documentation_en-US" xlink:label="lab_apyx_JointAndSeveralPayrollExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint And Several Payroll Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_JointAndSeveralPayrollExpense" xlink:href="apyx-20201231.xsd#apyx_JointAndSeveralPayrollExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_JointAndSeveralPayrollExpense" xlink:to="lab_apyx_JointAndSeveralPayrollExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_f5516e8e-64c9-4879-a78d-803aae800629_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_6b31a294-4941-40cd-98d9-94a8fc930910_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_868b02fa-e1e6-4edd-b945-a89cae8b5821_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_8ad782ce-d929-46e8-a587-5b03d2e00990_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_fe7c60aa-f2ca-48b3-869b-17cf5d420211_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandMember_a43e7ecd-6359-4850-ad24-865a9ed73401_terseLabel_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_LandMember_label_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandMember" xlink:to="lab_us-gaap_LandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_66e464c3-282d-4701-bbe1-0d5b8b7843a8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_98cc0e87-f16e-4bab-87cd-42263851f198_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less current portion of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_TotalRevenuePercent_827914e2-c34f-418a-91fb-7ceac1b6bf82_terseLabel_en-US" xlink:label="lab_apyx_TotalRevenuePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International sales</link:label>
    <link:label id="lab_apyx_TotalRevenuePercent_label_en-US" xlink:label="lab_apyx_TotalRevenuePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Revenue, Percent</link:label>
    <link:label id="lab_apyx_TotalRevenuePercent_documentation_en-US" xlink:label="lab_apyx_TotalRevenuePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Revenue, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_TotalRevenuePercent" xlink:href="apyx-20201231.xsd#apyx_TotalRevenuePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_TotalRevenuePercent" xlink:to="lab_apyx_TotalRevenuePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_b320e95a-1ec5-4061-9be6-113b06a54236_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options Non-vested, Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_96dc174d-cd24-426d-a85c-d571cef7ebb2_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets capitalized and lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_b5df8a8a-4da5-4657-ae53-17c716b19ed9_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to non-controlling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_24506d1b-5c6e-4d8e-a3a0-b44f4e8200fd_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Apyx</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_cee4870d-9c86-47d4-9ead-5c1ed53ecc6a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Option Fair Value Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_2bf776b4-92fb-421c-ae9a-2e3d58aca9f9_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan, employer matching contribution</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_9a74835d-ffe4-4db2-9c05-4a11b5a74c3b_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll</link:label>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Salaries, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrent" xlink:to="lab_us-gaap_AccruedSalariesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_cf08234d-3326-4038-b39c-125e876a64b8_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_22f5654f-305c-40b5-973d-2f29f12ebd82_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_59bb589b-eb2b-4bab-9b9f-73b23f29285f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_89b9e3a4-564c-4fc9-805b-0f725b9cc0f2_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_35f3db46-aa6f-44f8-8493-385797f28ed8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Options And Stock Awards</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligation_fa3d43a0-20e2-4cb3-a9a1-b676a20f79b5_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase commitments</link:label>
    <link:label id="lab_us-gaap_PurchaseObligation_label_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligation" xlink:to="lab_us-gaap_PurchaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_d3a378a0-26c2-4674-8d3e-dcc04dd0d414_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_d67454a6-ee82-4ef1-a9c3-617a4965599b_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_e68e4c0b-7276-47ea-b59c-d193f0a5e014_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OptionOnSecuritiesMember_e1685261-5be2-4d4a-afdb-37600c65387a_terseLabel_en-US" xlink:label="lab_us-gaap_OptionOnSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_OptionOnSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_OptionOnSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option on Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionOnSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionOnSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionOnSecuritiesMember" xlink:to="lab_us-gaap_OptionOnSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_650a5aa6-e802-4a37-952b-db94abd825c6_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_ddd07fca-83d6-4b91-9179-cedfebe66fa2_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options Non-vested at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_ab4cb060-7416-4bb6-b1e2-cd4953e982d8_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options Non-vested at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_4fedf44b-8ca7-41bd-a994-8310cfadf062_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_37689dfc-352e-49cc-acba-8896ae6bfa7f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue_4ec1466f-4994-45a0-b375-766193da94db_terseLabel_en-US" xlink:label="lab_apyx_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options granted</link:label>
    <link:label id="lab_apyx_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue_label_en-US" xlink:label="lab_apyx_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Options, Grants In Period, Fair Value</link:label>
    <link:label id="lab_apyx_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue_documentation_en-US" xlink:label="lab_apyx_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Options, Grants In Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:href="apyx-20201231.xsd#apyx_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:to="lab_apyx_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_7b320c08-871d-4443-badf-8154995e8a96_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_02c2800b-1eba-43e6-9aef-3e7ca08ece5d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options outstanding and exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_364bff77-6d19-4e79-b8ed-f485a31e729c_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_12626a55-8bf2-4588-8fbe-045bfc7250d8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_83f66901-86b8-48a5-bdc9-2d338f741166_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_028c811b-7660-4223-a89b-42e186631255_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_OperatingLeaseCostsAbstract_6aed7ff6-991a-4b6a-8f06-281d7221f777_terseLabel_en-US" xlink:label="lab_apyx_OperatingLeaseCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating</link:label>
    <link:label id="lab_apyx_OperatingLeaseCostsAbstract_label_en-US" xlink:label="lab_apyx_OperatingLeaseCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Costs [Abstract]</link:label>
    <link:label id="lab_apyx_OperatingLeaseCostsAbstract_documentation_en-US" xlink:label="lab_apyx_OperatingLeaseCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Costs [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_OperatingLeaseCostsAbstract" xlink:href="apyx-20201231.xsd#apyx_OperatingLeaseCostsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_OperatingLeaseCostsAbstract" xlink:to="lab_apyx_OperatingLeaseCostsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_b9dfe8e4-5be3-4625-a373-d0f2226d78a8_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_02bc6352-ce27-4b69-a566-6ffdc366c5b4_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade accounts receivable, net of allowance of $300 and $273</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_553bb78c-0562-4338-97f6-c42a7516ee1e_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b321a841-3d26-4418-bd73-4e3ccea751f2_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_07427897-68e2-4124-a514-62909b3d2758_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_df0751f4-569c-431f-b7d9-43107a8038a4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract" xlink:to="lab_us-gaap_NoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_NonCashTransfersOfInventoryToFromFixedAssets_b6eb258e-034b-405d-9cc4-83f90f9cb79e_terseLabel_en-US" xlink:label="lab_apyx_NonCashTransfersOfInventoryToFromFixedAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer of inventory to fixed assets</link:label>
    <link:label id="lab_apyx_NonCashTransfersOfInventoryToFromFixedAssets_label_en-US" xlink:label="lab_apyx_NonCashTransfersOfInventoryToFromFixedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash, Transfers Of Inventory To (From) Fixed Assets</link:label>
    <link:label id="lab_apyx_NonCashTransfersOfInventoryToFromFixedAssets_documentation_en-US" xlink:label="lab_apyx_NonCashTransfersOfInventoryToFromFixedAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash, Transfers Of Inventory To (From) Fixed Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_NonCashTransfersOfInventoryToFromFixedAssets" xlink:href="apyx-20201231.xsd#apyx_NonCashTransfersOfInventoryToFromFixedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_NonCashTransfersOfInventoryToFromFixedAssets" xlink:to="lab_apyx_NonCashTransfersOfInventoryToFromFixedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_67bf8654-9926-4514-840b-f1caa177dc0d_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_f34568bf-5b2b-436f-bc9b-49aeea0cab68_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_901db565-34dc-4948-b419-e96332c869be_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_ca3032cd-aca2-439a-8cc7-f552341e4f1a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Topic 842</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_a55fa423-11dc-49de-923f-4ed3db5787d3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_0145c6ab-ccf0-4b84-b024-05215afef870_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of shares outstanding - basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_9e556f86-6c70-468e-9d05-fe9c597f5df0_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets, net of valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Cash_ad893248-eff5-431f-80ca-1c544a3d602d_terseLabel_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_Cash_label_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash" xlink:to="lab_us-gaap_Cash" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_0d3178cb-fd73-4b12-9119-1c0bb2361150_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_204a643b-9a17-4165-b37d-56ea42fd1ac5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_RepaymentofFinanceLeaseLiabilities_6fc6a1b5-78e8-4bef-b189-18d660253259_negatedTerseLabel_en-US" xlink:label="lab_apyx_RepaymentofFinanceLeaseLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of finance lease liabilities</link:label>
    <link:label id="lab_apyx_RepaymentofFinanceLeaseLiabilities_label_en-US" xlink:label="lab_apyx_RepaymentofFinanceLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of Finance Lease Liabilities</link:label>
    <link:label id="lab_apyx_RepaymentofFinanceLeaseLiabilities_documentation_en-US" xlink:label="lab_apyx_RepaymentofFinanceLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of Finance Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_RepaymentofFinanceLeaseLiabilities" xlink:href="apyx-20201231.xsd#apyx_RepaymentofFinanceLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_RepaymentofFinanceLeaseLiabilities" xlink:to="lab_apyx_RepaymentofFinanceLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_1cc2cfb4-74b0-4840-9c5d-4d69e00d92f3_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and improvements</link:label>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_label_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and Building Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:to="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_55f2197e-47cb-4b37-935e-36dd23329288_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d3810161-d18c-48a6-b0d3-b700a1a5190d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_731bb61b-0975-496e-856e-c61a507be9c5_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DISPOSITION OF THE CORE BUSINESS</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_72a077ab-54ad-42af-b545-186351e1fd75_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non cash operating and investing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ce7df284-75cc-426f-8d76-204a2ea67be9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d34decca-7a8e-4d47-824d-f2c7e2ba0947_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_5014e879-8712-436e-a692-54cd59e2537d_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_6e21067b-fe08-4510-a008-7d5aedb6cf6c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options outstanding and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_ProvisionForObsolescenceInventory_bb86cd07-ce30-45fa-87d8-4c6e8455ac9a_terseLabel_en-US" xlink:label="lab_apyx_ProvisionForObsolescenceInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for obsolescence</link:label>
    <link:label id="lab_apyx_ProvisionForObsolescenceInventory_label_en-US" xlink:label="lab_apyx_ProvisionForObsolescenceInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision For Obsolescence, Inventory</link:label>
    <link:label id="lab_apyx_ProvisionForObsolescenceInventory_documentation_en-US" xlink:label="lab_apyx_ProvisionForObsolescenceInventory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision For Obsolescence, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ProvisionForObsolescenceInventory" xlink:href="apyx-20201231.xsd#apyx_ProvisionForObsolescenceInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_ProvisionForObsolescenceInventory" xlink:to="lab_apyx_ProvisionForObsolescenceInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_5a238665-ac00-4286-85ae-aff0f88f7906_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_cad07a8d-de78-4968-8f95-c5225d16c036_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_5f6b9c7e-ddd9-4a83-bf3a-f36dbb3299c7_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_0174b2d3-04c7-40dc-8222-12b157b64fda_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_aa811bf8-7e34-4f29-bc4a-64d76523695f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMinorityShareholders_5b83c87c-922b-4793-9dc3-32a62d13f1d5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions from non-controlling interests</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMinorityShareholders" xlink:to="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryValuationReserves_e839c228-15c7-4907-a97b-b036f6115949_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: provision for obsolescence</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Valuation Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserves" xlink:to="lab_us-gaap_InventoryValuationReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_68969a19-2b30-4c5e-8a75-d2629cd2002f_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Abstract]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_573b10e7-51eb-46ad-8199-f914dcc232bc_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_3e146464-39e0-450e-8b23-5227787503ee_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leaseholds and Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_a859791a-98b1-49aa-9b47-effbc02d7798_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_eefb9b91-1dce-4516-8582-b0119809e4e8_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning of year balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_be45e4bb-e9ed-4d2b-9b31-1ba79a8eb895_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">End of year balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_a1561b33-089d-49a3-a8bb-25d4b91d92fc_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 75,000,000 shares authorized; 34,289,222 issued and outstanding as of December 31, 2020, and 34,312,527 issued and 34,169,952 outstanding as of December 31, 2019</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_021cf31c-6d62-4737-ab4b-d577877b66c5_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_8bcaadf8-c62a-40c1-bbd2-47ecb40697b8_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ToolsDiesAndMoldsMember_b265eeed-5ce6-479f-a6c0-495822a5c88a_terseLabel_en-US" xlink:label="lab_us-gaap_ToolsDiesAndMoldsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molds</link:label>
    <link:label id="lab_us-gaap_ToolsDiesAndMoldsMember_label_en-US" xlink:label="lab_us-gaap_ToolsDiesAndMoldsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tools, Dies and Molds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ToolsDiesAndMoldsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ToolsDiesAndMoldsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ToolsDiesAndMoldsMember" xlink:to="lab_us-gaap_ToolsDiesAndMoldsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_524fcff3-2e22-4525-80bd-2b35ebb215c1_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of currently exercisable stock options</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_LeaseArrangementsDomain_84a8f117-2a08-4cc5-be66-4234feece70b_terseLabel_en-US" xlink:label="lab_apyx_LeaseArrangementsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Domain]</link:label>
    <link:label id="lab_apyx_LeaseArrangementsDomain_label_en-US" xlink:label="lab_apyx_LeaseArrangementsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Domain]</link:label>
    <link:label id="lab_apyx_LeaseArrangementsDomain_documentation_en-US" xlink:label="lab_apyx_LeaseArrangementsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Lease Arrangements [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_LeaseArrangementsDomain" xlink:href="apyx-20201231.xsd#apyx_LeaseArrangementsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_LeaseArrangementsDomain" xlink:to="lab_apyx_LeaseArrangementsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_22a1dc91-62e3-4bdf-a619-5e5465d67e32_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_6901bbfa-bb99-468c-91d4-82c1875c9137_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfessionalFees_587c82bb-3a3b-40f0-826c-62fef46f5117_terseLabel_en-US" xlink:label="lab_us-gaap_ProfessionalFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional services</link:label>
    <link:label id="lab_us-gaap_ProfessionalFees_label_en-US" xlink:label="lab_us-gaap_ProfessionalFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfessionalFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfessionalFees" xlink:to="lab_us-gaap_ProfessionalFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_fd1dc745-26ad-4f7b-a580-5778912bb790_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_a944c26d-e143-4f85-9e91-67da95c43391_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_c5f732fc-1494-45b4-98f2-9fdc65b5bb14_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued on stock options exercised for cash (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_1ad41ff8-4328-4ac8-9e71-a457bcac600c_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_c99ff72e-7ae3-4d85-805f-deca7055fe8d_periodStartLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning interest in China JV</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_435c2ee6-f9ab-46df-bea6-256649d66677_periodEndLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending interest in China JV</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_d3a3e3de-1a5d-48df-9ca6-b99e25fe0a3a_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_438ac1f1-f16d-4190-b743-800b9d2b4da4_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_53d014cb-3cd9-4c07-a91e-7f40b49afb59_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_792dfcab-1876-4e03-8d37-c25849841e52_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_73c704f2-d3d8-4972-bc5f-4f51784f747c_terseLabel_en-US" xlink:label="lab_apyx_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_apyx_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_apyx_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses And Other Current Liabilities [Table Text Block]</link:label>
    <link:label id="lab_apyx_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_documentation_en-US" xlink:label="lab_apyx_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses And Other Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:href="apyx-20201231.xsd#apyx_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:to="lab_apyx_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_5a2e4aa3-29de-453f-9dc9-71e8bd2e3971_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized under common stock option plans (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_9d9d56fc-87e7-40e2-a0f9-ca8fce09819c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_96432ac4-c780-4aec-b409-3e61d4c9b5af_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_6e4242b9-3bca-40b9-8b9c-122bf90b77eb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusAxis_e3e34f22-e4b7-4d95-a4d3-2aef6d76fd10_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis" xlink:to="lab_us-gaap_LitigationStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedToDate_dc4a631d-c416-4545-b747-7a6ff2a25394_terseLabel_en-US" xlink:label="lab_apyx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedToDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants to date (in shares)</link:label>
    <link:label id="lab_apyx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedToDate_label_en-US" xlink:label="lab_apyx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedToDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Non-Option Equity Instruments, Granted To Date</link:label>
    <link:label id="lab_apyx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedToDate_documentation_en-US" xlink:label="lab_apyx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedToDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Non-Option Equity Instruments, Granted To Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedToDate" xlink:href="apyx-20201231.xsd#apyx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedToDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedToDate" xlink:to="lab_apyx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedToDate" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_LeaseRemeasurementMember_d4b6dc69-35c5-41d5-b3bd-cf92b4cddfd9_terseLabel_en-US" xlink:label="lab_apyx_LeaseRemeasurementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Remeasurement</link:label>
    <link:label id="lab_apyx_LeaseRemeasurementMember_label_en-US" xlink:label="lab_apyx_LeaseRemeasurementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Remeasurement [Member]</link:label>
    <link:label id="lab_apyx_LeaseRemeasurementMember_documentation_en-US" xlink:label="lab_apyx_LeaseRemeasurementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Remeasurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_LeaseRemeasurementMember" xlink:href="apyx-20201231.xsd#apyx_LeaseRemeasurementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_LeaseRemeasurementMember" xlink:to="lab_apyx_LeaseRemeasurementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_cdf4c9e0-3fa8-48ec-ab11-f1921fc3499b_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_18f66bcf-5eff-4494-a4ab-954d82244a20_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_1499b05e-5ce3-4f15-ab68-2b974f1e9e64_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_1c6a498f-5317-4f7c-b86e-ff88f5120328_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_60c3b8b4-f849-4ca7-8835-66621155bbdd_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_868fa925-53cf-4625-bf95-8ffaaf43908c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_e8c8354f-976e-4cd1-b69e-998a7a5eb2a4_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_363a8515-2d35-468e-86c5-886583092845_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_7130d335-7dde-4dc2-ba9e-d402e4646f1e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease costs</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_acb47765-81f7-4bde-b6c6-f5d4cc858be9_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for Change in Accounting Principle [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2f643a3a-9d98-4cb7-b688-a0fcc4a13fe9_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_82f979b1-62b9-4b57-92a2-af8fd0662001_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_092d5abb-e36c-4e79-a939-9c5c0a36196a_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_1ff11bd0-4ed9-4cf2-9e5f-32a302eda0ee_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions of tax positions related to the prior year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_00ad9c8b-e5db-4fad-a637-9bce33df6202_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions of tax positions related to the current year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_4daa60b9-9112-43f8-b00c-2db0182fea79_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_e451f521-7f10-4077-b6a0-50c35331985d_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_SalesDiscountBillingTermsUpperLimit_7b0240bb-bf14-4f4a-8c80-e68a8010eea7_terseLabel_en-US" xlink:label="lab_apyx_SalesDiscountBillingTermsUpperLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit terms, billing term, upper limit</link:label>
    <link:label id="lab_apyx_SalesDiscountBillingTermsUpperLimit_label_en-US" xlink:label="lab_apyx_SalesDiscountBillingTermsUpperLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Discount, Billing Terms, Upper Limit</link:label>
    <link:label id="lab_apyx_SalesDiscountBillingTermsUpperLimit_documentation_en-US" xlink:label="lab_apyx_SalesDiscountBillingTermsUpperLimit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Discount, Billing Terms, Upper Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SalesDiscountBillingTermsUpperLimit" xlink:href="apyx-20201231.xsd#apyx_SalesDiscountBillingTermsUpperLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_SalesDiscountBillingTermsUpperLimit" xlink:to="lab_apyx_SalesDiscountBillingTermsUpperLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_9d8a5eed-fb6a-41d3-a5ef-dde710ce4121_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInMinorityInterestRollForward_a80f407d-27a0-478d-8cdf-46c7d659355d_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:label id="lab_us-gaap_MovementInMinorityInterestRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward" xlink:to="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_3390fe5d-f734-46c7-bea2-469b52ff7bcb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_f4229440-7bfe-4872-b3ed-3f4d93bea962_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_e541b397-8058-498e-bdf8-cc5c703bf232_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_4be7a8ff-5a1c-473b-94b0-fcab850feb81_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_adebff35-4796-45f4-acd0-e595ebf7c411_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_718f5f66-d755-4e4c-a642-82b347e16da7_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCK OPTIONS</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_cd077140-302d-4a77-adff-beb4bdddb26a_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_cbd8c9bb-4d71-4dd9-9fa4-40218a9a3a76_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_75ddc73e-c636-48fd-a3a8-1699414f3827_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_565759ed-b78f-4d5c-81f8-659b6ff769e6_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in current assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_bf309817-bf2f-4872-9129-6ae4e5ef5566_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVENTORIES</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_c897a502-ecc2-4f6d-9e12-5c163ad3da86_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_70d4f15f-288f-4acd-90db-5afddf56b7d9_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_CARESActIncomeTaxExpenseBenefitValuationAllowance_cbe329fc-9376-4097-a7b1-693fc5a49ed4_negatedTerseLabel_en-US" xlink:label="lab_apyx_CARESActIncomeTaxExpenseBenefitValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Release of valuation allowance due to CARES Act</link:label>
    <link:label id="lab_apyx_CARESActIncomeTaxExpenseBenefitValuationAllowance_label_en-US" xlink:label="lab_apyx_CARESActIncomeTaxExpenseBenefitValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act, Income Tax Expense (Benefit), Valuation Allowance</link:label>
    <link:label id="lab_apyx_CARESActIncomeTaxExpenseBenefitValuationAllowance_documentation_en-US" xlink:label="lab_apyx_CARESActIncomeTaxExpenseBenefitValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act, Income Tax Expense (Benefit), Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_CARESActIncomeTaxExpenseBenefitValuationAllowance" xlink:href="apyx-20201231.xsd#apyx_CARESActIncomeTaxExpenseBenefitValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_CARESActIncomeTaxExpenseBenefitValuationAllowance" xlink:to="lab_apyx_CARESActIncomeTaxExpenseBenefitValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_abc31588-7f8c-4558-af78-ecf29bce73ae_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_3024881a-0910-4080-bdf1-99a23bc34691_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_497797d7-881b-4c57-b8ae-1844a0096699_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_026e0a11-5d15-437e-a185-c70348084679_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets (Liabilities)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_d81c8953-9381-48fb-a9a9-c0a1254c981e_verboseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_58125c5b-a109-4588-b6e4-a9c2b32afa69_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_cee00dee-ceb1-44ee-9d73-0649442f4215_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_e4cab87b-a8a6-4540-86d7-556db9e84ab0_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State taxes (net of federal benefit)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_abc29108-2e42-454e-94ed-df86787ae502_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_6d6536f2-a76d-4236-818e-6f122313a717_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions from non-controlling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_fa82cc8f-c635-499c-9bff-453712d8f337_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase from Subsidiary Equity Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_3385dec2-092c-48c5-b26f-4eb46115a21e_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_67c1e402-e4e3-4bc8-93a2-a031795f4d90_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_ebf39e80-b7b4-4e05-88ba-c68c659cf043_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_JointAndSeveralPayrollLiability_9e6f959d-7c8c-4726-bf96-ecaa8939e651_terseLabel_en-US" xlink:label="lab_apyx_JointAndSeveralPayrollLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint and several payroll liability</link:label>
    <link:label id="lab_apyx_JointAndSeveralPayrollLiability_label_en-US" xlink:label="lab_apyx_JointAndSeveralPayrollLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint And Several Payroll Liability</link:label>
    <link:label id="lab_apyx_JointAndSeveralPayrollLiability_documentation_en-US" xlink:label="lab_apyx_JointAndSeveralPayrollLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint And Several Payroll Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_JointAndSeveralPayrollLiability" xlink:href="apyx-20201231.xsd#apyx_JointAndSeveralPayrollLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_JointAndSeveralPayrollLiability" xlink:to="lab_apyx_JointAndSeveralPayrollLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_68b3f410-3fe7-422b-a2de-468a8b008265_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_cfab00ff-de29-4916-8045-4e0a1ae73947_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_ae72f10d-f07b-4305-b0b5-4676bbb79706_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_9ecb6859-6192-485d-a901-bc618bfd2ce8_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of the statutory federal income tax rate to our effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateJointVentureMember_cd2e9941-3e0e-43b6-bda7-401a04ea3ae4_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">China joint venture</link:label>
    <link:label id="lab_us-gaap_CorporateJointVentureMember_label_en-US" xlink:label="lab_us-gaap_CorporateJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Joint Venture [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateJointVentureMember" xlink:to="lab_us-gaap_CorporateJointVentureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_41b4576a-fa51-4795-8d66-6c4f33343f1c_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_f4f59ece-ede0-4a53-bbef-273c80bbc517_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_534a6b2c-afb7-496e-ac80-935f8f0b48a8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_ba78ba6e-38e3-4477-a1c1-470a9e1d0ffb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_ApyxSYMedicalDevicesNingboCoLtdMember_fd0b5f46-b21b-46fe-a349-ec1f1f393dc9_terseLabel_en-US" xlink:label="lab_apyx_ApyxSYMedicalDevicesNingboCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apyx SY Medical Devices (Ningbo) Co., Ltd</link:label>
    <link:label id="lab_apyx_ApyxSYMedicalDevicesNingboCoLtdMember_label_en-US" xlink:label="lab_apyx_ApyxSYMedicalDevicesNingboCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apyx SY Medical Devices (Ningbo) Co., Ltd [Member]</link:label>
    <link:label id="lab_apyx_ApyxSYMedicalDevicesNingboCoLtdMember_documentation_en-US" xlink:label="lab_apyx_ApyxSYMedicalDevicesNingboCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apyx SY Medical Devices (Ningbo) Co., Ltd</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ApyxSYMedicalDevicesNingboCoLtdMember" xlink:href="apyx-20201231.xsd#apyx_ApyxSYMedicalDevicesNingboCoLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_ApyxSYMedicalDevicesNingboCoLtdMember" xlink:to="lab_apyx_ApyxSYMedicalDevicesNingboCoLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_82770182-5502-4199-bb85-74fd0606feeb_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_5067bbc0-d794-4645-a521-29c19987cc1e_verboseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to supplier</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_4d937553-89e5-4710-8832-2978370aaec5_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_e7ba0094-2da8-44ee-82f8-63e97435c4ad_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_acc695e7-4e10-49e6-978e-091d68818ac1_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementDomain_42073f3b-a3d4-4251-81d3-680ae70635a5_terseLabel_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:label id="lab_srt_RestatementDomain_label_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementDomain" xlink:to="lab_srt_RestatementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_9cc5c3cb-aa8e-4206-ae49-7c082a97bb1c_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision (benefit) for allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_NoncontrollingInterestTableTextBlock_706db1eb-d8af-42bb-b731-ee76d1953911_terseLabel_en-US" xlink:label="lab_apyx_NoncontrollingInterestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Noncontrolling Interest</link:label>
    <link:label id="lab_apyx_NoncontrollingInterestTableTextBlock_label_en-US" xlink:label="lab_apyx_NoncontrollingInterestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Table Text Block]</link:label>
    <link:label id="lab_apyx_NoncontrollingInterestTableTextBlock_documentation_en-US" xlink:label="lab_apyx_NoncontrollingInterestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest Table Text Block</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_NoncontrollingInterestTableTextBlock" xlink:href="apyx-20201231.xsd#apyx_NoncontrollingInterestTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_NoncontrollingInterestTableTextBlock" xlink:to="lab_apyx_NoncontrollingInterestTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9e8a113d-c74a-423c-b45b-207ad2f9ede1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_3d88c6a6-3ddd-4c02-9241-f4622c558064_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of all stock options outstanding and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5136c1f8-ebdc-4a4f-a62f-a70501003739_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_209a65fb-53e7-4800-8636-832604899bb4_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6d79abca-2b7d-4c2d-9042-1aa38cc9088a_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_9cdd8ecd-7557-41f8-9c66-5102b4cf9b56_terseLabel_en-US" xlink:label="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Error Corrections and Prior Period Adjustments Restatement [Line Items]</link:label>
    <link:label id="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_label_en-US" xlink:label="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Error Corrections and Prior Period Adjustments Restatement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_a39ef887-52a7-4146-8b30-3c6461973ea4_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_d5230e8b-640e-42b2-8ed0-d2501a7efbc8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_c3f3cd1c-58d4-449c-aff8-8ed168dfb81e_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_93c2e82d-222a-453a-a081-82b9770a7ccd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_NoncontrollingInterestRequiredCapitalContribution_c9a216b9-7831-4735-99a7-0732872a00f8_terseLabel_en-US" xlink:label="lab_apyx_NoncontrollingInterestRequiredCapitalContribution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Required capital contribution</link:label>
    <link:label id="lab_apyx_NoncontrollingInterestRequiredCapitalContribution_label_en-US" xlink:label="lab_apyx_NoncontrollingInterestRequiredCapitalContribution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Required Capital Contribution</link:label>
    <link:label id="lab_apyx_NoncontrollingInterestRequiredCapitalContribution_documentation_en-US" xlink:label="lab_apyx_NoncontrollingInterestRequiredCapitalContribution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Required Capital Contribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_NoncontrollingInterestRequiredCapitalContribution" xlink:href="apyx-20201231.xsd#apyx_NoncontrollingInterestRequiredCapitalContribution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_NoncontrollingInterestRequiredCapitalContribution" xlink:to="lab_apyx_NoncontrollingInterestRequiredCapitalContribution" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_403291a9-e18e-49ae-ac7f-adf120d9ebb2_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_9b58a203-328b-4f9d-ae59-3c3091d592ef_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_ba3b252a-362e-4bfe-860b-23199739a115_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_6832da18-d2bf-4f24-a00d-95de0995eaa2_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_IncomeTaxExpenseBenefitValuationAllowance_4b939f86-ae71-4656-97d6-6e93262a1d48_negatedTerseLabel_en-US" xlink:label="lab_apyx_IncomeTaxExpenseBenefitValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_apyx_IncomeTaxExpenseBenefitValuationAllowance_label_en-US" xlink:label="lab_apyx_IncomeTaxExpenseBenefitValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit), Valuation Allowance</link:label>
    <link:label id="lab_apyx_IncomeTaxExpenseBenefitValuationAllowance_documentation_en-US" xlink:label="lab_apyx_IncomeTaxExpenseBenefitValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit), Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_IncomeTaxExpenseBenefitValuationAllowance" xlink:href="apyx-20201231.xsd#apyx_IncomeTaxExpenseBenefitValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_IncomeTaxExpenseBenefitValuationAllowance" xlink:to="lab_apyx_IncomeTaxExpenseBenefitValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_1f24eb4e-6cb0-45a2-bc6c-aadc3c57d50e_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_ce73466b-644c-41e5-88c3-251d82707f2a_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_dcfd4465-c844-4012-923f-48db84455a90_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility - maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7b733602-9270-4640-924e-355d41fa3c28_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_79b07cc3-42c0-4785-bc22-dcb8f404fc37_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b6d6d433-423f-4ae3-9014-f877a4e549eb_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_3d73ab01-0d30-4917-ad8d-bf57de6e7ecb_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets capitalized and lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_c1a6291c-2708-409f-9d13-6525b702c844_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_f6af0a24-ae0d-4eae-8173-dd1414ae38db_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_b845ce36-f033-4912-bbaa-b78e8a6a5b23_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_920b8c21-bbaa-44f7-985e-74466f0534d6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_67d65cf5-1e7d-422d-8c82-1fb8e174b54f_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total provision for income tax</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_57a3dbea-eabf-4207-88a7-20a754c6771e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_8df0206c-f459-4140-aa24-0f12e8f9c388_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the disposition of Core business</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1fb7087b-86c4-4b9c-900b-a902fb42e50a_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_328b0e30-cb1a-49d9-b5c7-98b72ab39351_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_ccded4be-940f-406b-ae04-4440b7a1ca97_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company matching contributions</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_92299251-acb9-4c29-9908-b441f151ef51_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_94fa1560-ec7a-4bcc-b6a6-709046e97c9d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_0f7f1f7f-b10c-4a32-9346-680abb984f91_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_e58f2260-cd27-4f1d-8b8e-83894fbb64d1_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_52cc1d30-e463-47be-91de-35d50041b67a_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_ad3f2fce-3ef0-49ca-b138-ff8bd7b20431_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less current portion of lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_dea968b7-74f0-4200-b196-4015e86ecd30_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived_22e29b49-5662-4265-97c9-89416ad15bc8_terseLabel_en-US" xlink:label="lab_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares received in stock swaps (in shares)</link:label>
    <link:label id="lab_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived_label_en-US" xlink:label="lab_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Stock Swaps Equity Instruments Received</link:label>
    <link:label id="lab_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived_documentation_en-US" xlink:label="lab_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Stock Swaps Equity Instruments Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" xlink:href="apyx-20201231.xsd#apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" xlink:to="lab_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_9fe87a04-a9ce-438c-b928-5c77681cb3a5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits Roll-Forward</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_921159ae-849f-43e9-8c13-1d6a070fe10a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_651a0900-4312-4594-b624-789eb1c931c9_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net other income</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0e149b57-52f6-400f-a3cc-6d34e702d59a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_2f9abeb1-8210-4f0a-b79e-00a83794f937_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_label_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestLineItems" xlink:to="lab_us-gaap_MinorityInterestLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_8866a75c-fb79-45b1-be79-4fa28470d0ac_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_b9a308d9-b992-4a6e-8b20-f1b60de2036b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_037bbcd3-50e2-4d2f-909d-338fb91a629c_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decreases for tax positions related to prior year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_af3cc2ff-ee64-4fa1-8437-798ef21ca3f7_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_8ff88349-1025-43ce-ad6e-ab42c5f88d7e_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_9ae8d48f-331c-49c6-9e88-1736c982cc75_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_793171ad-53b1-498b-80a5-9d92cbf5b248_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued on stock options exercised for cash</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_9fd19ff9-2e5c-4e04-92a0-e7843663ca81_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_A2017ExecutiveandEmployeeStockOptionPlanMember_b6a44f5b-4166-4dd2-863f-4736feadd334_terseLabel_en-US" xlink:label="lab_apyx_A2017ExecutiveandEmployeeStockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Executive and Employee Stock Option Plan</link:label>
    <link:label id="lab_apyx_A2017ExecutiveandEmployeeStockOptionPlanMember_label_en-US" xlink:label="lab_apyx_A2017ExecutiveandEmployeeStockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Executive and Employee Stock Option Plan [Member]</link:label>
    <link:label id="lab_apyx_A2017ExecutiveandEmployeeStockOptionPlanMember_documentation_en-US" xlink:label="lab_apyx_A2017ExecutiveandEmployeeStockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Executive and Employee Stock Option Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_A2017ExecutiveandEmployeeStockOptionPlanMember" xlink:href="apyx-20201231.xsd#apyx_A2017ExecutiveandEmployeeStockOptionPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_A2017ExecutiveandEmployeeStockOptionPlanMember" xlink:to="lab_apyx_A2017ExecutiveandEmployeeStockOptionPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_61f9527a-14f6-4b72-a0c5-9ac68342de0e_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CoVenturerMember_6d27c435-8383-4eb9-a432-17a5c453da0c_terseLabel_en-US" xlink:label="lab_us-gaap_CoVenturerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Co-venturer</link:label>
    <link:label id="lab_us-gaap_CoVenturerMember_label_en-US" xlink:label="lab_us-gaap_CoVenturerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Co-venturer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CoVenturerMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CoVenturerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CoVenturerMember" xlink:to="lab_us-gaap_CoVenturerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_5d9dc59e-e187-4ab3-9521-ebbe46b8f2e7_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_abd5ba13-6904-499e-99f0-90ab345d1091_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interest equity</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_e18a94d4-f22b-4ac1-b5d3-ad65d812e7ca_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestments_efe22c36-767a-4afa-87f9-16b08b610929_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized and unrealized gains on short term investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestments" xlink:to="lab_us-gaap_GainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_695bd54b-2def-4dfa-b1dc-dfacde78ba22_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_91658688-a02b-4c60-9b41-fea26cceb01a_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_4bbde786-7d14-4e44-800d-a4bddef33a01_verboseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RECENT ACCOUNTING PRONOUNCEMENTS</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1aedf238-6854-4ca2-81e9-ea3690e5adbc_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_64311057-79ad-44b3-bf25-b4860da0c4e1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PendingLitigationMember_70fba8c1-63f8-48ae-8fbd-17d5aa9819a0_terseLabel_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation</link:label>
    <link:label id="lab_us-gaap_PendingLitigationMember_label_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PendingLitigationMember" xlink:to="lab_us-gaap_PendingLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_43fd32e9-e627-4d25-888d-d007a0b25351_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_8504dd31-169b-4f64-b7a0-aa423b9bcd11_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowances for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_16a0b306-2813-4a87-8406-b418dee4e7b8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_SymmetrySurgicalInc.Member_1a21f6ed-a730-47f1-8a47-78f7e5099fa9_terseLabel_en-US" xlink:label="lab_apyx_SymmetrySurgicalInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Symmetry Surgical Inc.</link:label>
    <link:label id="lab_apyx_SymmetrySurgicalInc.Member_label_en-US" xlink:label="lab_apyx_SymmetrySurgicalInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Symmetry Surgical Inc. [Member]</link:label>
    <link:label id="lab_apyx_SymmetrySurgicalInc.Member_documentation_en-US" xlink:label="lab_apyx_SymmetrySurgicalInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Symmetry Surgical Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SymmetrySurgicalInc.Member" xlink:href="apyx-20201231.xsd#apyx_SymmetrySurgicalInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_SymmetrySurgicalInc.Member" xlink:to="lab_apyx_SymmetrySurgicalInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_cfe29bb2-0801-4816-a7fc-7fa8c40e3f2b_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_LargestCustomerMember_3d097186-4cb5-47d3-9aea-a82692da4ba8_terseLabel_en-US" xlink:label="lab_apyx_LargestCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Largest Customer</link:label>
    <link:label id="lab_apyx_LargestCustomerMember_label_en-US" xlink:label="lab_apyx_LargestCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Largest Customer [Member]</link:label>
    <link:label id="lab_apyx_LargestCustomerMember_documentation_en-US" xlink:label="lab_apyx_LargestCustomerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Largest Customer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_LargestCustomerMember" xlink:href="apyx-20201231.xsd#apyx_LargestCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_LargestCustomerMember" xlink:to="lab_apyx_LargestCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_efb86394-4ee9-490a-b5d0-7ee448b62fc8_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_763cf0c5-a16c-4fa9-9dc0-ff12410d68dd_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PROPERTY AND EQUIPMENT</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusDomain_220c8405-03d3-4f74-a2c1-bb4dcedb83bc_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain" xlink:to="lab_us-gaap_LitigationStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StandardProductWarrantyAccrualPayments_0fe4f597-1c91-4d49-86c8-badf868ecdb6_negatedLabel_en-US" xlink:label="lab_us-gaap_StandardProductWarrantyAccrualPayments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product warranty expenses incurred</link:label>
    <link:label id="lab_us-gaap_StandardProductWarrantyAccrualPayments_label_en-US" xlink:label="lab_us-gaap_StandardProductWarrantyAccrualPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standard Product Warranty Accrual, Decrease for Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandardProductWarrantyAccrualPayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StandardProductWarrantyAccrualPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StandardProductWarrantyAccrualPayments" xlink:to="lab_us-gaap_StandardProductWarrantyAccrualPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_ProvisionForInventoryObsolescence_c2350722-76f9-4c3d-aa23-a06dd3b9c17d_terseLabel_en-US" xlink:label="lab_apyx_ProvisionForInventoryObsolescence" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for inventory obsolescence</link:label>
    <link:label id="lab_apyx_ProvisionForInventoryObsolescence_label_en-US" xlink:label="lab_apyx_ProvisionForInventoryObsolescence" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision For Inventory Obsolescence</link:label>
    <link:label id="lab_apyx_ProvisionForInventoryObsolescence_documentation_en-US" xlink:label="lab_apyx_ProvisionForInventoryObsolescence" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision For Inventory Obsolescence</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ProvisionForInventoryObsolescence" xlink:href="apyx-20201231.xsd#apyx_ProvisionForInventoryObsolescence"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_ProvisionForInventoryObsolescence" xlink:to="lab_apyx_ProvisionForInventoryObsolescence" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_bb6011b8-a4bd-4698-b99d-e79584044a74_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_PaymentsToAcquireInterestInJointVentureRemaining_06e1a90a-6843-455d-bce6-900074b2e627_terseLabel_en-US" xlink:label="lab_apyx_PaymentsToAcquireInterestInJointVentureRemaining" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining payments to acquire interest in joint venture</link:label>
    <link:label id="lab_apyx_PaymentsToAcquireInterestInJointVentureRemaining_label_en-US" xlink:label="lab_apyx_PaymentsToAcquireInterestInJointVentureRemaining" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Interest In Joint Venture, Remaining</link:label>
    <link:label id="lab_apyx_PaymentsToAcquireInterestInJointVentureRemaining_documentation_en-US" xlink:label="lab_apyx_PaymentsToAcquireInterestInJointVentureRemaining" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Interest In Joint Venture, Remaining</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_PaymentsToAcquireInterestInJointVentureRemaining" xlink:href="apyx-20201231.xsd#apyx_PaymentsToAcquireInterestInJointVentureRemaining"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_PaymentsToAcquireInterestInJointVentureRemaining" xlink:to="lab_apyx_PaymentsToAcquireInterestInJointVentureRemaining" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_8ef1c433-f467-44e7-9b71-25a07d1a1216_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EARNINGS (LOSS) PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1d8530a6-9461-4ade-996a-2763a6174ee3_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_e42c8e28-cb36-4591-ae4c-b8cbf07b93a1_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_ef996c4d-df80-4c35-8676-81c2c319954c_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal tax provision</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_5efede2c-19c2-4750-87b5-97d6de78e33c_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_68cb9ee3-6681-4b42-a020-d9188e12a04a_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_dd4d9630-57fc-4040-9304-303c932a7f02_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options outstanding and expected to vest, weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_c8872b90-e57c-4747-934f-219d6c461db1_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8da1e49b-2bf1-4613-8b68-cb2cf907cb69_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_bb94bef2-1e8c-41c8-99a2-3c4399a16e8b_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_39c38fcb-e34f-4d3c-8aa7-0a9b3240269a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>apyx-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:3619fb04-76d2-4e32-a22c-67723657dfe5,g:73c9cb31-492e-4d91-a8e4-50624d0c0cae-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://apyxmedical.com/role/Cover" xlink:type="simple" xlink:href="apyx-20201231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_4bbf96f5-26cf-4677-bc5c-e1cc7bf2a3ee" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_d51dfa78-10cb-4609-a5d5-19fa0d3093e8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bbf96f5-26cf-4677-bc5c-e1cc7bf2a3ee" xlink:to="loc_dei_DocumentType_d51dfa78-10cb-4609-a5d5-19fa0d3093e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_853f65d2-b028-48d3-b874-a06b5d350393" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bbf96f5-26cf-4677-bc5c-e1cc7bf2a3ee" xlink:to="loc_dei_DocumentAnnualReport_853f65d2-b028-48d3-b874-a06b5d350393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_e924813d-7a3c-4aad-8183-9ea9f23b057a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bbf96f5-26cf-4677-bc5c-e1cc7bf2a3ee" xlink:to="loc_dei_CurrentFiscalYearEndDate_e924813d-7a3c-4aad-8183-9ea9f23b057a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_66f1c4cd-ae1e-4ab0-bb0f-f828229a3f5c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bbf96f5-26cf-4677-bc5c-e1cc7bf2a3ee" xlink:to="loc_dei_DocumentPeriodEndDate_66f1c4cd-ae1e-4ab0-bb0f-f828229a3f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_0637eed7-f15a-4125-80b0-929acf4c1890" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bbf96f5-26cf-4677-bc5c-e1cc7bf2a3ee" xlink:to="loc_dei_DocumentTransitionReport_0637eed7-f15a-4125-80b0-929acf4c1890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_993c9cfd-241c-4b6a-9679-006f0e5c98f2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bbf96f5-26cf-4677-bc5c-e1cc7bf2a3ee" xlink:to="loc_dei_EntityFileNumber_993c9cfd-241c-4b6a-9679-006f0e5c98f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_8c580a0d-501b-44b7-99dd-bd2afff03eeb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bbf96f5-26cf-4677-bc5c-e1cc7bf2a3ee" xlink:to="loc_dei_EntityRegistrantName_8c580a0d-501b-44b7-99dd-bd2afff03eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_3e1093bb-a03c-4736-95b4-f0b7f2009296" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bbf96f5-26cf-4677-bc5c-e1cc7bf2a3ee" xlink:to="loc_dei_EntityIncorporationStateCountryCode_3e1093bb-a03c-4736-95b4-f0b7f2009296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_ca544033-f17f-4eab-9e77-13abc1e4fffc" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bbf96f5-26cf-4677-bc5c-e1cc7bf2a3ee" xlink:to="loc_dei_EntityTaxIdentificationNumber_ca544033-f17f-4eab-9e77-13abc1e4fffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_e63c51f6-dbf5-4b0e-8ccd-0abb61588b69" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bbf96f5-26cf-4677-bc5c-e1cc7bf2a3ee" xlink:to="loc_dei_EntityAddressAddressLine1_e63c51f6-dbf5-4b0e-8ccd-0abb61588b69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_117235ca-3eb5-48f8-912e-af33e928143c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bbf96f5-26cf-4677-bc5c-e1cc7bf2a3ee" xlink:to="loc_dei_EntityAddressCityOrTown_117235ca-3eb5-48f8-912e-af33e928143c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_fdb81b33-43c7-476e-aaf6-69d9fcaa6cbd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bbf96f5-26cf-4677-bc5c-e1cc7bf2a3ee" xlink:to="loc_dei_EntityAddressStateOrProvince_fdb81b33-43c7-476e-aaf6-69d9fcaa6cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_9c193d23-cf77-4720-b164-0e028cf0730b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bbf96f5-26cf-4677-bc5c-e1cc7bf2a3ee" xlink:to="loc_dei_EntityAddressPostalZipCode_9c193d23-cf77-4720-b164-0e028cf0730b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_bcb81740-8b04-4db1-8e03-547c39d1b529" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bbf96f5-26cf-4677-bc5c-e1cc7bf2a3ee" xlink:to="loc_dei_CityAreaCode_bcb81740-8b04-4db1-8e03-547c39d1b529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_d285f8cd-4bdc-45fc-b3f8-861a90b56ae5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bbf96f5-26cf-4677-bc5c-e1cc7bf2a3ee" xlink:to="loc_dei_LocalPhoneNumber_d285f8cd-4bdc-45fc-b3f8-861a90b56ae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_79cadaaf-6839-41b6-a903-7c765278395e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bbf96f5-26cf-4677-bc5c-e1cc7bf2a3ee" xlink:to="loc_dei_Security12bTitle_79cadaaf-6839-41b6-a903-7c765278395e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_4e2c2aee-5b98-4d49-beb2-29b81ad7509b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bbf96f5-26cf-4677-bc5c-e1cc7bf2a3ee" xlink:to="loc_dei_TradingSymbol_4e2c2aee-5b98-4d49-beb2-29b81ad7509b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_d7790092-4461-48a6-888a-083ccc39faad" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bbf96f5-26cf-4677-bc5c-e1cc7bf2a3ee" xlink:to="loc_dei_SecurityExchangeName_d7790092-4461-48a6-888a-083ccc39faad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_190166cc-c51c-4c8b-8514-f4b14625af54" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bbf96f5-26cf-4677-bc5c-e1cc7bf2a3ee" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_190166cc-c51c-4c8b-8514-f4b14625af54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_0abd0f49-58a3-4b0b-9213-3c34abba36b8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bbf96f5-26cf-4677-bc5c-e1cc7bf2a3ee" xlink:to="loc_dei_EntityVoluntaryFilers_0abd0f49-58a3-4b0b-9213-3c34abba36b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_20dce98c-0a83-4912-bda1-436c3b4b5ea9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bbf96f5-26cf-4677-bc5c-e1cc7bf2a3ee" xlink:to="loc_dei_EntityCurrentReportingStatus_20dce98c-0a83-4912-bda1-436c3b4b5ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_b1c92a98-acbb-452a-a0df-6e50077cb939" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bbf96f5-26cf-4677-bc5c-e1cc7bf2a3ee" xlink:to="loc_dei_EntityInteractiveDataCurrent_b1c92a98-acbb-452a-a0df-6e50077cb939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_d6df3779-b111-44dd-b310-9c1493e4fb6e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bbf96f5-26cf-4677-bc5c-e1cc7bf2a3ee" xlink:to="loc_dei_EntityFilerCategory_d6df3779-b111-44dd-b310-9c1493e4fb6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_9ec5a6e2-afb1-42f8-9234-5a82be0fb029" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bbf96f5-26cf-4677-bc5c-e1cc7bf2a3ee" xlink:to="loc_dei_EntitySmallBusiness_9ec5a6e2-afb1-42f8-9234-5a82be0fb029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_66eed756-224e-40e8-abbd-dbb7bc9114e7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bbf96f5-26cf-4677-bc5c-e1cc7bf2a3ee" xlink:to="loc_dei_EntityEmergingGrowthCompany_66eed756-224e-40e8-abbd-dbb7bc9114e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_1be69a30-0bbb-4a7b-941f-6e63a76f8d4a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bbf96f5-26cf-4677-bc5c-e1cc7bf2a3ee" xlink:to="loc_dei_IcfrAuditorAttestationFlag_1be69a30-0bbb-4a7b-941f-6e63a76f8d4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_87b4a880-5eea-4563-9932-ffeca6e091eb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bbf96f5-26cf-4677-bc5c-e1cc7bf2a3ee" xlink:to="loc_dei_EntityShellCompany_87b4a880-5eea-4563-9932-ffeca6e091eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_811ff6c8-b89a-4c06-949b-47e71bf390f4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bbf96f5-26cf-4677-bc5c-e1cc7bf2a3ee" xlink:to="loc_dei_EntityPublicFloat_811ff6c8-b89a-4c06-949b-47e71bf390f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_6c2a7106-41f1-4492-a20d-f0882212e26c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bbf96f5-26cf-4677-bc5c-e1cc7bf2a3ee" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_6c2a7106-41f1-4492-a20d-f0882212e26c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_fda1bc6b-04e7-4960-93fb-a6a2f1752f00" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bbf96f5-26cf-4677-bc5c-e1cc7bf2a3ee" xlink:to="loc_dei_EntityCentralIndexKey_fda1bc6b-04e7-4960-93fb-a6a2f1752f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_e88d980e-4cf9-42e1-b3c2-49850386443e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bbf96f5-26cf-4677-bc5c-e1cc7bf2a3ee" xlink:to="loc_dei_AmendmentFlag_e88d980e-4cf9-42e1-b3c2-49850386443e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_02b611ef-3bb4-4c09-ab6e-f372e0abe695" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bbf96f5-26cf-4677-bc5c-e1cc7bf2a3ee" xlink:to="loc_dei_DocumentFiscalPeriodFocus_02b611ef-3bb4-4c09-ab6e-f372e0abe695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_5f6682c2-0fb0-4920-8e8b-188f76a11dcd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bbf96f5-26cf-4677-bc5c-e1cc7bf2a3ee" xlink:to="loc_dei_DocumentFiscalYearFocus_5f6682c2-0fb0-4920-8e8b-188f76a11dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="apyx-20201231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_c3f0d7a9-7649-4436-95ad-062cdfdde68e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_4fcaf7df-115c-4073-ab48-8436d1102f8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c3f0d7a9-7649-4436-95ad-062cdfdde68e" xlink:to="loc_us-gaap_AssetsAbstract_4fcaf7df-115c-4073-ab48-8436d1102f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_39f7ba2a-952c-48dd-b92e-6a0626206497" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4fcaf7df-115c-4073-ab48-8436d1102f8d" xlink:to="loc_us-gaap_AssetsCurrentAbstract_39f7ba2a-952c-48dd-b92e-6a0626206497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c16b7ba3-0e73-4d32-b1a6-43720f55c554" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_39f7ba2a-952c-48dd-b92e-6a0626206497" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c16b7ba3-0e73-4d32-b1a6-43720f55c554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_9cc1240f-8677-4036-bfe2-c66d020ff159" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_39f7ba2a-952c-48dd-b92e-6a0626206497" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_9cc1240f-8677-4036-bfe2-c66d020ff159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_34dad7d7-8cd3-44b6-a327-509fa020217b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_39f7ba2a-952c-48dd-b92e-6a0626206497" xlink:to="loc_us-gaap_IncomeTaxesReceivable_34dad7d7-8cd3-44b6-a327-509fa020217b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_4ea3b05e-c647-4c2c-82a9-8bbba467e0b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_39f7ba2a-952c-48dd-b92e-6a0626206497" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_4ea3b05e-c647-4c2c-82a9-8bbba467e0b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_a36e4767-bb00-4629-ade7-347c096a1afc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_39f7ba2a-952c-48dd-b92e-6a0626206497" xlink:to="loc_us-gaap_InventoryNet_a36e4767-bb00-4629-ade7-347c096a1afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6a11f335-3ece-4b20-865c-e5b2674d7fa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_39f7ba2a-952c-48dd-b92e-6a0626206497" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6a11f335-3ece-4b20-865c-e5b2674d7fa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_034b2559-4f55-46a3-9ee7-52fcce3e3db2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_39f7ba2a-952c-48dd-b92e-6a0626206497" xlink:to="loc_us-gaap_AssetsCurrent_034b2559-4f55-46a3-9ee7-52fcce3e3db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_061b4277-ffb5-4f2b-b2ca-04f7740c88b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4fcaf7df-115c-4073-ab48-8436d1102f8d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_061b4277-ffb5-4f2b-b2ca-04f7740c88b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_97e13757-6e80-4c3d-8ce8-5cfb2a00d988" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4fcaf7df-115c-4073-ab48-8436d1102f8d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_97e13757-6e80-4c3d-8ce8-5cfb2a00d988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_cb8d8595-14c9-428d-9706-c43adaed79f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4fcaf7df-115c-4073-ab48-8436d1102f8d" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_cb8d8595-14c9-428d-9706-c43adaed79f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_7476ff43-cf25-428e-9831-970d1f030d23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4fcaf7df-115c-4073-ab48-8436d1102f8d" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_7476ff43-cf25-428e-9831-970d1f030d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_eb4ee690-b62f-4cb9-94db-073206552e90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4fcaf7df-115c-4073-ab48-8436d1102f8d" xlink:to="loc_us-gaap_Assets_eb4ee690-b62f-4cb9-94db-073206552e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_385afbf3-c7e7-460c-8350-5e249870a380" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c3f0d7a9-7649-4436-95ad-062cdfdde68e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_385afbf3-c7e7-460c-8350-5e249870a380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_28454b80-9a2b-4e1b-a3b5-4fc55332b492" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_385afbf3-c7e7-460c-8350-5e249870a380" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_28454b80-9a2b-4e1b-a3b5-4fc55332b492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_36fffa23-509b-4d97-97af-882979b12039" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_28454b80-9a2b-4e1b-a3b5-4fc55332b492" xlink:to="loc_us-gaap_AccountsPayableCurrent_36fffa23-509b-4d97-97af-882979b12039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_7bc694a5-c398-4ee6-b285-d6c5e6d62b0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_28454b80-9a2b-4e1b-a3b5-4fc55332b492" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_7bc694a5-c398-4ee6-b285-d6c5e6d62b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_5cbd68ac-57ae-4265-95a0-7590d6e2afdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_28454b80-9a2b-4e1b-a3b5-4fc55332b492" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_5cbd68ac-57ae-4265-95a0-7590d6e2afdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_c54a8c57-a850-47a9-b857-f84db647c7b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_28454b80-9a2b-4e1b-a3b5-4fc55332b492" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_c54a8c57-a850-47a9-b857-f84db647c7b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_09ea8f88-4c0e-46cd-8cbe-31c275301d99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_28454b80-9a2b-4e1b-a3b5-4fc55332b492" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_09ea8f88-4c0e-46cd-8cbe-31c275301d99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_8e1dad29-ef48-4018-87db-fe5ec76980a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_28454b80-9a2b-4e1b-a3b5-4fc55332b492" xlink:to="loc_us-gaap_LiabilitiesCurrent_8e1dad29-ef48-4018-87db-fe5ec76980a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4e874785-b70e-43a4-be49-f0adc433a66f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_385afbf3-c7e7-460c-8350-5e249870a380" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4e874785-b70e-43a4-be49-f0adc433a66f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_022aa083-ee9f-4eff-b422-2aadb982cf06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_385afbf3-c7e7-460c-8350-5e249870a380" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_022aa083-ee9f-4eff-b422-2aadb982cf06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_3fe1bdf9-ea40-46d6-b8cd-5af7b30f535c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_385afbf3-c7e7-460c-8350-5e249870a380" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_3fe1bdf9-ea40-46d6-b8cd-5af7b30f535c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_c37086a9-3109-473f-86d9-6268cc5051fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_385afbf3-c7e7-460c-8350-5e249870a380" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_c37086a9-3109-473f-86d9-6268cc5051fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_251c1b10-0dcf-4584-a188-2e3e87185345" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_385afbf3-c7e7-460c-8350-5e249870a380" xlink:to="loc_us-gaap_Liabilities_251c1b10-0dcf-4584-a188-2e3e87185345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_ec6d2fa8-fbe8-4aeb-91af-130930450a72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_385afbf3-c7e7-460c-8350-5e249870a380" xlink:to="loc_us-gaap_CommitmentsAndContingencies_ec6d2fa8-fbe8-4aeb-91af-130930450a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_805d3685-aac4-4d8f-ae59-b33199faa4e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_385afbf3-c7e7-460c-8350-5e249870a380" xlink:to="loc_us-gaap_StockholdersEquityAbstract_805d3685-aac4-4d8f-ae59-b33199faa4e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_1dfd6090-4091-41e7-bed8-d03c971419f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_805d3685-aac4-4d8f-ae59-b33199faa4e0" xlink:to="loc_us-gaap_CommonStockValue_1dfd6090-4091-41e7-bed8-d03c971419f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_9ab7a2a2-5609-4e8e-a63c-f16b4fe931b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_805d3685-aac4-4d8f-ae59-b33199faa4e0" xlink:to="loc_us-gaap_AdditionalPaidInCapital_9ab7a2a2-5609-4e8e-a63c-f16b4fe931b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ac0ec81a-90bf-4ccd-b297-bd8fd3d24ace" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_805d3685-aac4-4d8f-ae59-b33199faa4e0" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ac0ec81a-90bf-4ccd-b297-bd8fd3d24ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a1d724dc-3030-44e8-bb8f-97c880f4f2ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_805d3685-aac4-4d8f-ae59-b33199faa4e0" xlink:to="loc_us-gaap_StockholdersEquity_a1d724dc-3030-44e8-bb8f-97c880f4f2ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_98c9384c-6f3f-40fd-a54d-edd5c4427830" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_805d3685-aac4-4d8f-ae59-b33199faa4e0" xlink:to="loc_us-gaap_MinorityInterest_98c9384c-6f3f-40fd-a54d-edd5c4427830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_399c798c-1604-4819-bb02-92e510e2ef1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_805d3685-aac4-4d8f-ae59-b33199faa4e0" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_399c798c-1604-4819-bb02-92e510e2ef1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_5f608d6a-e68d-42ab-94df-631ad6f9b31f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_385afbf3-c7e7-460c-8350-5e249870a380" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_5f608d6a-e68d-42ab-94df-631ad6f9b31f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="apyx-20201231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_cbbd741c-b4c2-4113-a59f-b8f22473020f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_435e61ec-c4ae-4425-ba20-87145c86d842" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cbbd741c-b4c2-4113-a59f-b8f22473020f" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_435e61ec-c4ae-4425-ba20-87145c86d842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ProvisionForObsolescenceInventory_90ee196b-8563-4f18-99a9-2aa391b0baa6" xlink:href="apyx-20201231.xsd#apyx_ProvisionForObsolescenceInventory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cbbd741c-b4c2-4113-a59f-b8f22473020f" xlink:to="loc_apyx_ProvisionForObsolescenceInventory_90ee196b-8563-4f18-99a9-2aa391b0baa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_c3a9adb6-04b3-4f12-b7f4-c747886ee5a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cbbd741c-b4c2-4113-a59f-b8f22473020f" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_c3a9adb6-04b3-4f12-b7f4-c747886ee5a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_39a6e20a-bba8-4700-be3f-4e8af4e6c2db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cbbd741c-b4c2-4113-a59f-b8f22473020f" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_39a6e20a-bba8-4700-be3f-4e8af4e6c2db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_970b1496-ce13-4456-8027-d7235c697c09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cbbd741c-b4c2-4113-a59f-b8f22473020f" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_970b1496-ce13-4456-8027-d7235c697c09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_97218536-0832-4d7b-8951-5ce6dccd6587" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cbbd741c-b4c2-4113-a59f-b8f22473020f" xlink:to="loc_us-gaap_CommonStockSharesIssued_97218536-0832-4d7b-8951-5ce6dccd6587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="apyx-20201231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_579b64db-2f01-4eb1-8501-02ccc19efc7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_45e1c522-f9ff-4a21-bd73-f533183bc742" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_579b64db-2f01-4eb1-8501-02ccc19efc7e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_45e1c522-f9ff-4a21-bd73-f533183bc742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_235d4800-050d-455a-8363-4521c6583aff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_579b64db-2f01-4eb1-8501-02ccc19efc7e" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_235d4800-050d-455a-8363-4521c6583aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_b0908503-142f-45a5-ad2c-73e4c602a78e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_579b64db-2f01-4eb1-8501-02ccc19efc7e" xlink:to="loc_us-gaap_GrossProfit_b0908503-142f-45a5-ad2c-73e4c602a78e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_5dbb7c73-4ec4-400c-8ffb-d6e38fa1bfc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_579b64db-2f01-4eb1-8501-02ccc19efc7e" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_5dbb7c73-4ec4-400c-8ffb-d6e38fa1bfc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_16e12f37-b56c-4d16-a1b0-78bc47537283" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_5dbb7c73-4ec4-400c-8ffb-d6e38fa1bfc4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_16e12f37-b56c-4d16-a1b0-78bc47537283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees_de8fbdcd-3250-4c41-be2a-badf78bd7bcf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfessionalFees"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_5dbb7c73-4ec4-400c-8ffb-d6e38fa1bfc4" xlink:to="loc_us-gaap_ProfessionalFees_de8fbdcd-3250-4c41-be2a-badf78bd7bcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalariesAndWages_2f387c0f-4343-4d39-87d7-945550a08c51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalariesAndWages"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_5dbb7c73-4ec4-400c-8ffb-d6e38fa1bfc4" xlink:to="loc_us-gaap_SalariesAndWages_2f387c0f-4343-4d39-87d7-945550a08c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_46643955-dba8-45e9-b326-f50d21d53374" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_5dbb7c73-4ec4-400c-8ffb-d6e38fa1bfc4" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_46643955-dba8-45e9-b326-f50d21d53374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_bc01453e-edcf-4644-bdcc-75da010d15e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_5dbb7c73-4ec4-400c-8ffb-d6e38fa1bfc4" xlink:to="loc_us-gaap_OperatingExpenses_bc01453e-edcf-4644-bdcc-75da010d15e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d69e2102-0a9e-42ac-aae6-4f6bbf43fa6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_579b64db-2f01-4eb1-8501-02ccc19efc7e" xlink:to="loc_us-gaap_OperatingIncomeLoss_d69e2102-0a9e-42ac-aae6-4f6bbf43fa6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_4c00e362-5836-4044-b216-f81845efe54d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOperating"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_579b64db-2f01-4eb1-8501-02ccc19efc7e" xlink:to="loc_us-gaap_InterestIncomeOperating_4c00e362-5836-4044-b216-f81845efe54d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_4868627f-0c54-47cb-8297-5c0a05a9c8a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_579b64db-2f01-4eb1-8501-02ccc19efc7e" xlink:to="loc_us-gaap_InterestExpense_4868627f-0c54-47cb-8297-5c0a05a9c8a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_9f48190c-99a6-4925-b5d3-e38f119a0fe1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_579b64db-2f01-4eb1-8501-02ccc19efc7e" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_9f48190c-99a6-4925-b5d3-e38f119a0fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_99b6425c-35aa-4947-a230-1f556d40cbe4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_579b64db-2f01-4eb1-8501-02ccc19efc7e" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_99b6425c-35aa-4947-a230-1f556d40cbe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d2e4f13e-a291-4305-8db7-e2cdafecef18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_579b64db-2f01-4eb1-8501-02ccc19efc7e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d2e4f13e-a291-4305-8db7-e2cdafecef18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6995edd3-2bbd-4c06-9add-6334d78c1e80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_579b64db-2f01-4eb1-8501-02ccc19efc7e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_6995edd3-2bbd-4c06-9add-6334d78c1e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_33517b41-b452-4c62-982d-dfa00f3c6688" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_579b64db-2f01-4eb1-8501-02ccc19efc7e" xlink:to="loc_us-gaap_ProfitLoss_33517b41-b452-4c62-982d-dfa00f3c6688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_89f6a3af-ea83-4c8d-aa56-018d50e5e35e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_579b64db-2f01-4eb1-8501-02ccc19efc7e" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_89f6a3af-ea83-4c8d-aa56-018d50e5e35e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_91292330-895d-47dd-ad80-1ee07e09a97d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_579b64db-2f01-4eb1-8501-02ccc19efc7e" xlink:to="loc_us-gaap_NetIncomeLoss_91292330-895d-47dd-ad80-1ee07e09a97d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_72deb4b9-9c88-43cc-852a-5b60b3eb0ad3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_579b64db-2f01-4eb1-8501-02ccc19efc7e" xlink:to="loc_us-gaap_EarningsPerShareAbstract_72deb4b9-9c88-43cc-852a-5b60b3eb0ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_9517b06b-25c3-43e7-99dd-ef12f4151349" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_72deb4b9-9c88-43cc-852a-5b60b3eb0ad3" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_9517b06b-25c3-43e7-99dd-ef12f4151349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_eb9adb5e-52bb-4c5c-9b19-168c1c77abb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_579b64db-2f01-4eb1-8501-02ccc19efc7e" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_eb9adb5e-52bb-4c5c-9b19-168c1c77abb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" xlink:type="simple" xlink:href="apyx-20201231.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_9a281c19-ee6d-4fde-b614-3050b9928a80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_843c1b34-d44e-47b7-bc64-5d2930dc49d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_9a281c19-ee6d-4fde-b614-3050b9928a80" xlink:to="loc_us-gaap_StatementTable_843c1b34-d44e-47b7-bc64-5d2930dc49d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_31a7c839-1adc-49cc-88ba-2fe6c3976f0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_843c1b34-d44e-47b7-bc64-5d2930dc49d6" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_31a7c839-1adc-49cc-88ba-2fe6c3976f0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b2d3570e-1daf-4de2-ac25-5158bcd3f271" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_31a7c839-1adc-49cc-88ba-2fe6c3976f0d" xlink:to="loc_us-gaap_EquityComponentDomain_b2d3570e-1daf-4de2-ac25-5158bcd3f271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_263eefeb-9ee0-4371-8dd0-a31b35c8c6a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b2d3570e-1daf-4de2-ac25-5158bcd3f271" xlink:to="loc_us-gaap_CommonStockMember_263eefeb-9ee0-4371-8dd0-a31b35c8c6a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_20e271ff-1895-45c8-b64a-b458ade3cfa4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b2d3570e-1daf-4de2-ac25-5158bcd3f271" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_20e271ff-1895-45c8-b64a-b458ade3cfa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_1af67008-b370-4c1d-96ef-604f2c20b864" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b2d3570e-1daf-4de2-ac25-5158bcd3f271" xlink:to="loc_us-gaap_RetainedEarningsMember_1af67008-b370-4c1d-96ef-604f2c20b864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_a043d3e6-2467-4134-9fe5-eb2d701d738d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b2d3570e-1daf-4de2-ac25-5158bcd3f271" xlink:to="loc_us-gaap_NoncontrollingInterestMember_a043d3e6-2467-4134-9fe5-eb2d701d738d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b898370b-f0b3-498b-9a44-7ea6354a262b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_843c1b34-d44e-47b7-bc64-5d2930dc49d6" xlink:to="loc_us-gaap_StatementLineItems_b898370b-f0b3-498b-9a44-7ea6354a262b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_287aa085-3472-4897-8b15-0535b06a6a21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b898370b-f0b3-498b-9a44-7ea6354a262b" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_287aa085-3472-4897-8b15-0535b06a6a21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_66ebaf87-676f-41e5-8972-16510c392512" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_287aa085-3472-4897-8b15-0535b06a6a21" xlink:to="loc_us-gaap_SharesIssued_66ebaf87-676f-41e5-8972-16510c392512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_78fc85da-03ac-4c91-8f82-e0b98a268d89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_287aa085-3472-4897-8b15-0535b06a6a21" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_78fc85da-03ac-4c91-8f82-e0b98a268d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_28425d4a-bec0-499a-a81a-829556a89ed7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_287aa085-3472-4897-8b15-0535b06a6a21" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_28425d4a-bec0-499a-a81a-829556a89ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1c0184ed-3b97-4af0-85af-3384791806fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_287aa085-3472-4897-8b15-0535b06a6a21" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1c0184ed-3b97-4af0-85af-3384791806fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0be28cdb-a7ea-413c-b99d-5c40e0455066" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_287aa085-3472-4897-8b15-0535b06a6a21" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0be28cdb-a7ea-413c-b99d-5c40e0455066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3ec08fb7-3343-4275-91f4-aa548b4f73ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_287aa085-3472-4897-8b15-0535b06a6a21" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3ec08fb7-3343-4275-91f4-aa548b4f73ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_StockSwapToAcquireOptionsShares_19e1b98f-5a3c-4704-88d1-4377cafb16a0" xlink:href="apyx-20201231.xsd#apyx_StockSwapToAcquireOptionsShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_287aa085-3472-4897-8b15-0535b06a6a21" xlink:to="loc_apyx_StockSwapToAcquireOptionsShares_19e1b98f-5a3c-4704-88d1-4377cafb16a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_5ba03586-2f7b-46bb-a93c-f92b0a8d4ea4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_287aa085-3472-4897-8b15-0535b06a6a21" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_5ba03586-2f7b-46bb-a93c-f92b0a8d4ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c253c71a-e316-4005-b949-7e7beb549baa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_287aa085-3472-4897-8b15-0535b06a6a21" xlink:to="loc_us-gaap_ProfitLoss_c253c71a-e316-4005-b949-7e7beb549baa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_f1ba1306-6d26-482c-8e3e-5d0dc32cdd17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_287aa085-3472-4897-8b15-0535b06a6a21" xlink:to="loc_us-gaap_SharesIssued_f1ba1306-6d26-482c-8e3e-5d0dc32cdd17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7c6ce073-0946-433f-a83f-9ec846dd3b61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_287aa085-3472-4897-8b15-0535b06a6a21" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7c6ce073-0946-433f-a83f-9ec846dd3b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="apyx-20201231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_2fc0ba09-b42b-4dd1-8640-91c5901aa75c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a23e47ef-073f-4f67-9224-267c85224f7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2fc0ba09-b42b-4dd1-8640-91c5901aa75c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a23e47ef-073f-4f67-9224-267c85224f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_2ac9cbce-2bd3-444a-9703-3ed284155d6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a23e47ef-073f-4f67-9224-267c85224f7f" xlink:to="loc_us-gaap_ProfitLoss_2ac9cbce-2bd3-444a-9703-3ed284155d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2b69f25b-9b7f-46ff-aece-181743dc1b6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a23e47ef-073f-4f67-9224-267c85224f7f" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2b69f25b-9b7f-46ff-aece-181743dc1b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_ad27c0b2-a260-40ce-8de1-a1f05ead542e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2b69f25b-9b7f-46ff-aece-181743dc1b6e" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_ad27c0b2-a260-40ce-8de1-a1f05ead542e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ProvisionForInventoryObsolescence_0c1c251d-0594-43a3-a6e3-0ef762ca3fdc" xlink:href="apyx-20201231.xsd#apyx_ProvisionForInventoryObsolescence"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2b69f25b-9b7f-46ff-aece-181743dc1b6e" xlink:to="loc_apyx_ProvisionForInventoryObsolescence_0c1c251d-0594-43a3-a6e3-0ef762ca3fdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyExpense_2453d8b6-5275-4fe6-9faf-3da1b7611fb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductWarrantyExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2b69f25b-9b7f-46ff-aece-181743dc1b6e" xlink:to="loc_us-gaap_ProductWarrantyExpense_2453d8b6-5275-4fe6-9faf-3da1b7611fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_d9c93d9d-1599-4e47-9b5a-71e8efbf7b40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2b69f25b-9b7f-46ff-aece-181743dc1b6e" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_d9c93d9d-1599-4e47-9b5a-71e8efbf7b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_f37890f5-1f09-4cc3-8cb5-696ae5ad17c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2b69f25b-9b7f-46ff-aece-181743dc1b6e" xlink:to="loc_us-gaap_ShareBasedCompensation_f37890f5-1f09-4cc3-8cb5-696ae5ad17c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_4e5c73a9-af79-4e08-9ee9-f1f9009a0bd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2b69f25b-9b7f-46ff-aece-181743dc1b6e" xlink:to="loc_us-gaap_GainLossOnInvestments_4e5c73a9-af79-4e08-9ee9-f1f9009a0bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_56889911-8b54-48e8-95c4-8291676350cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2b69f25b-9b7f-46ff-aece-181743dc1b6e" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_56889911-8b54-48e8-95c4-8291676350cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7d17fb03-35ac-4572-92c9-92d479a42a58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2b69f25b-9b7f-46ff-aece-181743dc1b6e" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7d17fb03-35ac-4572-92c9-92d479a42a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_235c3b68-bb1d-4900-95e3-3309de7b7f0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7d17fb03-35ac-4572-92c9-92d479a42a58" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_235c3b68-bb1d-4900-95e3-3309de7b7f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_f498bbcd-c3cd-467e-91ec-024fc24352d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7d17fb03-35ac-4572-92c9-92d479a42a58" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_f498bbcd-c3cd-467e-91ec-024fc24352d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d313a6b6-7449-4712-89b3-ca38edd3d0e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7d17fb03-35ac-4572-92c9-92d479a42a58" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d313a6b6-7449-4712-89b3-ca38edd3d0e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_a99c707c-638e-4f31-8e1d-8501f424a818" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7d17fb03-35ac-4572-92c9-92d479a42a58" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_a99c707c-638e-4f31-8e1d-8501f424a818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_78e3af4a-f5b3-4f94-b426-16dc20b9ad93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7d17fb03-35ac-4572-92c9-92d479a42a58" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_78e3af4a-f5b3-4f94-b426-16dc20b9ad93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_56f216f2-3110-4c01-8642-4deb8e0d72b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7d17fb03-35ac-4572-92c9-92d479a42a58" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_56f216f2-3110-4c01-8642-4deb8e0d72b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e5292aa9-1263-456b-8cdd-21038174f23b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a23e47ef-073f-4f67-9224-267c85224f7f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e5292aa9-1263-456b-8cdd-21038174f23b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_da66c105-b601-483a-95fe-d96469ea58d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2fc0ba09-b42b-4dd1-8640-91c5901aa75c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_da66c105-b601-483a-95fe-d96469ea58d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_74fc7032-8304-487a-b2e2-26ebf9bb0fd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_da66c105-b601-483a-95fe-d96469ea58d5" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_74fc7032-8304-487a-b2e2-26ebf9bb0fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_72cdc26f-2435-43fb-9093-f45d1d72084c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_da66c105-b601-483a-95fe-d96469ea58d5" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_72cdc26f-2435-43fb-9093-f45d1d72084c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_9054ef7b-b5e1-4334-903d-f4cf0847d7d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_da66c105-b601-483a-95fe-d96469ea58d5" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_9054ef7b-b5e1-4334-903d-f4cf0847d7d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_214e7a61-6313-4d4b-a4e0-3b8d0db646fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_da66c105-b601-483a-95fe-d96469ea58d5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_214e7a61-6313-4d4b-a4e0-3b8d0db646fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0d3322a1-8d09-4539-be0b-6418ca955f36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2fc0ba09-b42b-4dd1-8640-91c5901aa75c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0d3322a1-8d09-4539-be0b-6418ca955f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised_f104f281-d1fd-4a61-ba35-332f21206b46" xlink:href="apyx-20201231.xsd#apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0d3322a1-8d09-4539-be0b-6418ca955f36" xlink:to="loc_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised_f104f281-d1fd-4a61-ba35-332f21206b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_8b2de22c-400a-4c8a-ad0f-7f06c8c18d29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0d3322a1-8d09-4539-be0b-6418ca955f36" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_8b2de22c-400a-4c8a-ad0f-7f06c8c18d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_RepaymentofFinanceLeaseLiabilities_a5a0654e-4d5d-40dd-8e24-8a93dd782f0d" xlink:href="apyx-20201231.xsd#apyx_RepaymentofFinanceLeaseLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0d3322a1-8d09-4539-be0b-6418ca955f36" xlink:to="loc_apyx_RepaymentofFinanceLeaseLiabilities_a5a0654e-4d5d-40dd-8e24-8a93dd782f0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_e57fb411-7fee-41bd-9235-a59bdafdc8bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0d3322a1-8d09-4539-be0b-6418ca955f36" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_e57fb411-7fee-41bd-9235-a59bdafdc8bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cccc63cd-93db-49f4-90e9-251599ba82b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0d3322a1-8d09-4539-be0b-6418ca955f36" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cccc63cd-93db-49f4-90e9-251599ba82b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9d1a3897-3eb6-490c-ba71-70ecc987023a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2fc0ba09-b42b-4dd1-8640-91c5901aa75c" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9d1a3897-3eb6-490c-ba71-70ecc987023a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ff68b861-c8ac-41ab-aefe-d5f88fe087e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2fc0ba09-b42b-4dd1-8640-91c5901aa75c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ff68b861-c8ac-41ab-aefe-d5f88fe087e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_db1d0b68-5f8d-4a67-b355-271fd707c4c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2fc0ba09-b42b-4dd1-8640-91c5901aa75c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_db1d0b68-5f8d-4a67-b355-271fd707c4c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d6fb7b05-ba5d-4610-b120-3623674bb6be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2fc0ba09-b42b-4dd1-8640-91c5901aa75c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d6fb7b05-ba5d-4610-b120-3623674bb6be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_b7f0de31-c553-40da-aafa-7132a1241524" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2fc0ba09-b42b-4dd1-8640-91c5901aa75c" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_b7f0de31-c553-40da-aafa-7132a1241524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_54787ea4-37ee-4503-85bc-930284222ccc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_b7f0de31-c553-40da-aafa-7132a1241524" xlink:to="loc_us-gaap_InterestPaidNet_54787ea4-37ee-4503-85bc-930284222ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_354f0582-2fea-4f1d-b5da-311b259d02dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_b7f0de31-c553-40da-aafa-7132a1241524" xlink:to="loc_us-gaap_IncomeTaxesPaid_354f0582-2fea-4f1d-b5da-311b259d02dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_ab382393-9e83-43f7-972d-a046cb1a528c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2fc0ba09-b42b-4dd1-8640-91c5901aa75c" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_ab382393-9e83-43f7-972d-a046cb1a528c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_NonCashTransferOfOtherAssetsToFixedAssets_bfdc98f0-4cd1-4b17-8d24-8183c6618227" xlink:href="apyx-20201231.xsd#apyx_NonCashTransferOfOtherAssetsToFixedAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_ab382393-9e83-43f7-972d-a046cb1a528c" xlink:to="loc_apyx_NonCashTransferOfOtherAssetsToFixedAssets_bfdc98f0-4cd1-4b17-8d24-8183c6618227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_NonCashTransfersOfInventoryToFromFixedAssets_d92ba5ff-e1aa-43c7-9aea-ef9448135a5f" xlink:href="apyx-20201231.xsd#apyx_NonCashTransfersOfInventoryToFromFixedAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_ab382393-9e83-43f7-972d-a046cb1a528c" xlink:to="loc_apyx_NonCashTransfersOfInventoryToFromFixedAssets_d92ba5ff-e1aa-43c7-9aea-ef9448135a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/DESCRIPTIONOFBUSINESS" xlink:type="simple" xlink:href="apyx-20201231.xsd#DESCRIPTIONOFBUSINESS"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/DESCRIPTIONOFBUSINESS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_701517a6-63c5-4884-b775-21d01fe1405f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_41630728-c61a-46e0-b08c-5ba60034540d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_701517a6-63c5-4884-b775-21d01fe1405f" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_41630728-c61a-46e0-b08c-5ba60034540d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="apyx-20201231.xsd#SIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3f475833-d8bd-439e-a063-6ca30a1df76d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_075b8954-3d74-4401-90e2-22f751722761" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3f475833-d8bd-439e-a063-6ca30a1df76d" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_075b8954-3d74-4401-90e2-22f751722761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="apyx-20201231.xsd#SIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e10defac-a194-4990-80e5-f96ec9ba02da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_dc868eb6-8968-4d30-8074-271566aa44e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e10defac-a194-4990-80e5-f96ec9ba02da" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_dc868eb6-8968-4d30-8074-271566aa44e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_f9ea6443-0b91-42d5-8126-609b2a5569ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e10defac-a194-4990-80e5-f96ec9ba02da" xlink:to="loc_us-gaap_UseOfEstimates_f9ea6443-0b91-42d5-8126-609b2a5569ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1c9a61ce-2c3e-4167-877b-4d51cb4c8364" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e10defac-a194-4990-80e5-f96ec9ba02da" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1c9a61ce-2c3e-4167-877b-4d51cb4c8364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_2de4c44b-b491-431d-8d80-a63cc56dd223" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e10defac-a194-4990-80e5-f96ec9ba02da" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_2de4c44b-b491-431d-8d80-a63cc56dd223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_ceb1364c-b724-4212-90b7-1eccb2123c94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e10defac-a194-4990-80e5-f96ec9ba02da" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_ceb1364c-b724-4212-90b7-1eccb2123c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_9cde6925-4947-485d-a44f-9879e3de28c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e10defac-a194-4990-80e5-f96ec9ba02da" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_9cde6925-4947-485d-a44f-9879e3de28c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_129457ae-31f9-430f-bb7e-cb057315eb2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e10defac-a194-4990-80e5-f96ec9ba02da" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_129457ae-31f9-430f-bb7e-cb057315eb2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_f425572c-1bc1-4f8b-865e-72d1e12aafd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e10defac-a194-4990-80e5-f96ec9ba02da" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_f425572c-1bc1-4f8b-865e-72d1e12aafd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandardProductWarrantyPolicy_8e60be11-45e6-44f6-9e8e-8ad5934df526" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StandardProductWarrantyPolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e10defac-a194-4990-80e5-f96ec9ba02da" xlink:to="loc_us-gaap_StandardProductWarrantyPolicy_8e60be11-45e6-44f6-9e8e-8ad5934df526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_99f7e0d7-4a9c-42aa-8a43-8ef941e034b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e10defac-a194-4990-80e5-f96ec9ba02da" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_99f7e0d7-4a9c-42aa-8a43-8ef941e034b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_c840182e-6f42-42bb-b1fc-de78fa2c34fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e10defac-a194-4990-80e5-f96ec9ba02da" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_c840182e-6f42-42bb-b1fc-de78fa2c34fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_5c3c3cd3-5047-4471-9104-8e69f58b1a3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e10defac-a194-4990-80e5-f96ec9ba02da" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_5c3c3cd3-5047-4471-9104-8e69f58b1a3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalCostsPolicyTextBlock_12513eac-b861-4618-874b-83bcd626e999" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalCostsPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e10defac-a194-4990-80e5-f96ec9ba02da" xlink:to="loc_us-gaap_LegalCostsPolicyTextBlock_12513eac-b861-4618-874b-83bcd626e999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_b0f4b28d-bd0c-4e8c-951a-0910d4afb108" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e10defac-a194-4990-80e5-f96ec9ba02da" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_b0f4b28d-bd0c-4e8c-951a-0910d4afb108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_9f882a68-c880-4750-9041-98ad561e9909" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e10defac-a194-4990-80e5-f96ec9ba02da" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_9f882a68-c880-4750-9041-98ad561e9909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_41566f17-5517-4f4c-a9f8-b7b46d910877" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e10defac-a194-4990-80e5-f96ec9ba02da" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_41566f17-5517-4f4c-a9f8-b7b46d910877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_e3a41618-04ad-4317-844a-998a46858403" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e10defac-a194-4990-80e5-f96ec9ba02da" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_e3a41618-04ad-4317-844a-998a46858403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_b8cf9430-f79c-4b9b-9a18-a07f08a8baf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e10defac-a194-4990-80e5-f96ec9ba02da" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_b8cf9430-f79c-4b9b-9a18-a07f08a8baf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c0ff1ee1-cd90-43c5-9e99-b9d1d814f665" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1d6d23a1-d1a9-4996-9fb1-0d13ee99b351" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c0ff1ee1-cd90-43c5-9e99-b9d1d814f665" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1d6d23a1-d1a9-4996-9fb1-0d13ee99b351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_78339cd9-0ca8-4d2d-9065-f81d264e28c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1d6d23a1-d1a9-4996-9fb1-0d13ee99b351" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_78339cd9-0ca8-4d2d-9065-f81d264e28c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_16bd3d24-ad63-47ca-a4d2-9cf64efd859d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_78339cd9-0ca8-4d2d-9065-f81d264e28c3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_16bd3d24-ad63-47ca-a4d2-9cf64efd859d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_480076df-ca59-4540-82a7-4b4692a604f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_16bd3d24-ad63-47ca-a4d2-9cf64efd859d" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_480076df-ca59-4540-82a7-4b4692a604f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_8c644420-02cc-4479-b51d-a341d63f2814" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_16bd3d24-ad63-47ca-a4d2-9cf64efd859d" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_8c644420-02cc-4479-b51d-a341d63f2814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_bad36573-244e-443e-80ae-3aa749933b0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_16bd3d24-ad63-47ca-a4d2-9cf64efd859d" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_bad36573-244e-443e-80ae-3aa749933b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ComputerEquipmentandSoftwareMember_771dc03d-716e-4a16-8392-827b87246dc7" xlink:href="apyx-20201231.xsd#apyx_ComputerEquipmentandSoftwareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_16bd3d24-ad63-47ca-a4d2-9cf64efd859d" xlink:to="loc_apyx_ComputerEquipmentandSoftwareMember_771dc03d-716e-4a16-8392-827b87246dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ToolsDiesAndMoldsMember_151aa83f-5718-4a62-a07e-9ddad4e94e77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ToolsDiesAndMoldsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_16bd3d24-ad63-47ca-a4d2-9cf64efd859d" xlink:to="loc_us-gaap_ToolsDiesAndMoldsMember_151aa83f-5718-4a62-a07e-9ddad4e94e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_RenuvionJPlasmaGeneratorsMember_c2a3fe47-aeb2-4d8e-99ef-1d2a1ed0c25e" xlink:href="apyx-20201231.xsd#apyx_RenuvionJPlasmaGeneratorsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_16bd3d24-ad63-47ca-a4d2-9cf64efd859d" xlink:to="loc_apyx_RenuvionJPlasmaGeneratorsMember_c2a3fe47-aeb2-4d8e-99ef-1d2a1ed0c25e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_MountingFixturesMember_dad04932-cbcf-45f5-80c0-e69c33e926cd" xlink:href="apyx-20201231.xsd#apyx_MountingFixturesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_16bd3d24-ad63-47ca-a4d2-9cf64efd859d" xlink:to="loc_apyx_MountingFixturesMember_dad04932-cbcf-45f5-80c0-e69c33e926cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AccessoriesMember_64b564b3-4856-4236-852a-2f8822c32998" xlink:href="apyx-20201231.xsd#apyx_AccessoriesMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_16bd3d24-ad63-47ca-a4d2-9cf64efd859d" xlink:to="loc_apyx_AccessoriesMember_64b564b3-4856-4236-852a-2f8822c32998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1d31b973-88af-44c5-aa7b-fa0934000ec1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1d6d23a1-d1a9-4996-9fb1-0d13ee99b351" xlink:to="loc_srt_RangeAxis_1d31b973-88af-44c5-aa7b-fa0934000ec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a9f2b596-c4a6-4d6f-9cef-7dd6702435b7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1d31b973-88af-44c5-aa7b-fa0934000ec1" xlink:to="loc_srt_RangeMember_a9f2b596-c4a6-4d6f-9cef-7dd6702435b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_47e20b77-d907-46d0-ba59-a5b59875a0bf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a9f2b596-c4a6-4d6f-9cef-7dd6702435b7" xlink:to="loc_srt_MinimumMember_47e20b77-d907-46d0-ba59-a5b59875a0bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bd3d9a31-a2b0-4c05-b66f-8a099564faec" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a9f2b596-c4a6-4d6f-9cef-7dd6702435b7" xlink:to="loc_srt_MaximumMember_bd3d9a31-a2b0-4c05-b66f-8a099564faec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_b7f8a004-b340-4cca-8e27-35372a084042" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1d6d23a1-d1a9-4996-9fb1-0d13ee99b351" xlink:to="loc_srt_OwnershipAxis_b7f8a004-b340-4cca-8e27-35372a084042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_542ad6b9-a28f-4bbb-98cb-ec77ccf50d3c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_b7f8a004-b340-4cca-8e27-35372a084042" xlink:to="loc_srt_OwnershipDomain_542ad6b9-a28f-4bbb-98cb-ec77ccf50d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ApyxSYMedicalDevicesNingboCoLtdMember_43b7d5c9-6b24-4145-82d3-51bfbe528e76" xlink:href="apyx-20201231.xsd#apyx_ApyxSYMedicalDevicesNingboCoLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_542ad6b9-a28f-4bbb-98cb-ec77ccf50d3c" xlink:to="loc_apyx_ApyxSYMedicalDevicesNingboCoLtdMember_43b7d5c9-6b24-4145-82d3-51bfbe528e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_18c9f329-b312-4738-8958-9fb83cc3e47d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1d6d23a1-d1a9-4996-9fb1-0d13ee99b351" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_18c9f329-b312-4738-8958-9fb83cc3e47d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_4f3d0b19-2524-46d4-ad09-ec7bb485ab28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_18c9f329-b312-4738-8958-9fb83cc3e47d" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_4f3d0b19-2524-46d4-ad09-ec7bb485ab28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SalesDiscountBillingTermsLowerLimit_30782c30-508f-4cd1-ba61-5075106fcd8f" xlink:href="apyx-20201231.xsd#apyx_SalesDiscountBillingTermsLowerLimit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_18c9f329-b312-4738-8958-9fb83cc3e47d" xlink:to="loc_apyx_SalesDiscountBillingTermsLowerLimit_30782c30-508f-4cd1-ba61-5075106fcd8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SalesDiscountBillingTermsUpperLimit_80a1bf05-de49-45ce-aa58-6087586c03a1" xlink:href="apyx-20201231.xsd#apyx_SalesDiscountBillingTermsUpperLimit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_18c9f329-b312-4738-8958-9fb83cc3e47d" xlink:to="loc_apyx_SalesDiscountBillingTermsUpperLimit_80a1bf05-de49-45ce-aa58-6087586c03a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_542b6965-45ab-4851-a37d-d7d9a0e16d52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_18c9f329-b312-4738-8958-9fb83cc3e47d" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_542b6965-45ab-4851-a37d-d7d9a0e16d52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_522504d1-8371-436c-ad4c-a7927b60c7fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_18c9f329-b312-4738-8958-9fb83cc3e47d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_522504d1-8371-436c-ad4c-a7927b60c7fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ProductWarranty_136e4841-d7c5-4bcb-b9fe-937a0c2c6e6f" xlink:href="apyx-20201231.xsd#apyx_ProductWarranty"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_18c9f329-b312-4738-8958-9fb83cc3e47d" xlink:to="loc_apyx_ProductWarranty_136e4841-d7c5-4bcb-b9fe-937a0c2c6e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_617fe436-5906-49b0-91c0-0c70a7ae5da3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_18c9f329-b312-4738-8958-9fb83cc3e47d" xlink:to="loc_us-gaap_ContractWithCustomerLiability_617fe436-5906-49b0-91c0-0c70a7ae5da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_dff6c0cf-117c-4251-8348-2f0ab508f739" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_18c9f329-b312-4738-8958-9fb83cc3e47d" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_dff6c0cf-117c-4251-8348-2f0ab508f739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_2edd0a64-9ac9-43a3-8634-d387dafc513a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_18c9f329-b312-4738-8958-9fb83cc3e47d" xlink:to="loc_us-gaap_AdvertisingExpense_2edd0a64-9ac9-43a3-8634-d387dafc513a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CHANGEINACCOUNTINGPOLICY" xlink:type="simple" xlink:href="apyx-20201231.xsd#CHANGEINACCOUNTINGPOLICY"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/CHANGEINACCOUNTINGPOLICY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_1003b13d-4033-4c98-8d03-a72e381dbd03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock_9e5682fc-231d-4c03-a7c8-5c32069aae25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_1003b13d-4033-4c98-8d03-a72e381dbd03" xlink:to="loc_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock_9e5682fc-231d-4c03-a7c8-5c32069aae25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/RECENTACCOUNTINGPRONOUNCEMENTS" xlink:type="simple" xlink:href="apyx-20201231.xsd#RECENTACCOUNTINGPRONOUNCEMENTS"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/RECENTACCOUNTINGPRONOUNCEMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_65d63e21-04d0-42da-a0f2-bf6e1e9a24f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_8f07f445-e620-409e-a216-aed5ebc01e54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_65d63e21-04d0-42da-a0f2-bf6e1e9a24f7" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_8f07f445-e620-409e-a216-aed5ebc01e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESS" xlink:type="simple" xlink:href="apyx-20201231.xsd#DISPOSITIONOFTHECOREBUSINESS"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_4e11c311-1cba-4a09-8ae6-ccc997368036" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_58fa43cd-92b2-4211-871c-ecdbbbec8373" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_4e11c311-1cba-4a09-8ae6-ccc997368036" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_58fa43cd-92b2-4211-871c-ecdbbbec8373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESSDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#DISPOSITIONOFTHECOREBUSINESSDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_74700ca3-0561-4931-84f9-20e7d8d8103c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1325d896-646b-4636-848c-909a3aaf77e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_74700ca3-0561-4931-84f9-20e7d8d8103c" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1325d896-646b-4636-848c-909a3aaf77e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_66da8bed-1b7b-4b61-87ac-73b2cb09b8c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1325d896-646b-4636-848c-909a3aaf77e9" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_66da8bed-1b7b-4b61-87ac-73b2cb09b8c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_bec64f32-6f07-435b-a438-2c542ca01636" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_66da8bed-1b7b-4b61-87ac-73b2cb09b8c9" xlink:to="loc_us-gaap_RelatedPartyDomain_bec64f32-6f07-435b-a438-2c542ca01636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SymmetrySurgicalInc.Member_7c1bbc69-9164-4439-840e-584095b7e1eb" xlink:href="apyx-20201231.xsd#apyx_SymmetrySurgicalInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_bec64f32-6f07-435b-a438-2c542ca01636" xlink:to="loc_apyx_SymmetrySurgicalInc.Member_7c1bbc69-9164-4439-840e-584095b7e1eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_c9c52644-a21d-4679-93fe-131de6c2dfc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1325d896-646b-4636-848c-909a3aaf77e9" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_c9c52644-a21d-4679-93fe-131de6c2dfc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_fb8312a0-82f4-4832-a019-6f0ac6884c6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_c9c52644-a21d-4679-93fe-131de6c2dfc9" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_fb8312a0-82f4-4832-a019-6f0ac6884c6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember_6eb68329-fb89-4b8f-8bfb-cf507efb10f0" xlink:href="apyx-20201231.xsd#apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_fb8312a0-82f4-4832-a019-6f0ac6884c6e" xlink:to="loc_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember_6eb68329-fb89-4b8f-8bfb-cf507efb10f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_abc68fcb-1516-4206-ae06-2e1ef9252a40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1325d896-646b-4636-848c-909a3aaf77e9" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_abc68fcb-1516-4206-ae06-2e1ef9252a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_608d2d17-ffc0-4fa1-882f-32430b889fb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_abc68fcb-1516-4206-ae06-2e1ef9252a40" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_608d2d17-ffc0-4fa1-882f-32430b889fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AssetPurchaseAgreementTerm_b5dab036-19be-4a47-a900-a5ddc0252b80" xlink:href="apyx-20201231.xsd#apyx_AssetPurchaseAgreementTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_abc68fcb-1516-4206-ae06-2e1ef9252a40" xlink:to="loc_apyx_AssetPurchaseAgreementTerm_b5dab036-19be-4a47-a900-a5ddc0252b80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_4b407956-8511-4159-ba77-6d82f4f8acc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_abc68fcb-1516-4206-ae06-2e1ef9252a40" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_4b407956-8511-4159-ba77-6d82f4f8acc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_d9104fc3-b6b1-4e06-b7f0-a476e1714098" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_abc68fcb-1516-4206-ae06-2e1ef9252a40" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_d9104fc3-b6b1-4e06-b7f0-a476e1714098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_eafd8e82-a828-4395-b36f-bab468fa9df5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_abc68fcb-1516-4206-ae06-2e1ef9252a40" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_eafd8e82-a828-4395-b36f-bab468fa9df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_826afb7b-21e8-4453-8e81-d3447ecfb04f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_abc68fcb-1516-4206-ae06-2e1ef9252a40" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_826afb7b-21e8-4453-8e81-d3447ecfb04f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENT" xlink:type="simple" xlink:href="apyx-20201231.xsd#INTERESTINJOINTVENTUREINVESTMENT"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_cbc89ff1-42ce-4f45-85e6-f194228c0394" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDisclosureTextBlock_5dc47c9e-89d5-4734-8b0a-e86c1982758c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_cbc89ff1-42ce-4f45-85e6-f194228c0394" xlink:to="loc_us-gaap_MinorityInterestDisclosureTextBlock_5dc47c9e-89d5-4734-8b0a-e86c1982758c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTTables" xlink:type="simple" xlink:href="apyx-20201231.xsd#INTERESTINJOINTVENTUREINVESTMENTTables"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_cc4df612-49d9-4de2-b9e3-4c6e0981d875" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_NoncontrollingInterestTableTextBlock_9a3053e3-8496-4810-9ba4-971716f73b2e" xlink:href="apyx-20201231.xsd#apyx_NoncontrollingInterestTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_cc4df612-49d9-4de2-b9e3-4c6e0981d875" xlink:to="loc_apyx_NoncontrollingInterestTableTextBlock_9a3053e3-8496-4810-9ba4-971716f73b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_70d01b7d-2289-4412-be10-4f7cf090bdba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_c829f1ba-88f2-44ea-9f01-6adcd351e6e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_70d01b7d-2289-4412-be10-4f7cf090bdba" xlink:to="loc_us-gaap_MinorityInterestTable_c829f1ba-88f2-44ea-9f01-6adcd351e6e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3ab149cd-6af3-4793-9d5e-06739f6b6238" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_c829f1ba-88f2-44ea-9f01-6adcd351e6e1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3ab149cd-6af3-4793-9d5e-06739f6b6238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_45d5af24-d5aa-4608-9dc5-5dfacd330aed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3ab149cd-6af3-4793-9d5e-06739f6b6238" xlink:to="loc_us-gaap_RelatedPartyDomain_45d5af24-d5aa-4608-9dc5-5dfacd330aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember_cb931c4a-d8a2-457d-9fe9-f995141acc06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_45d5af24-d5aa-4608-9dc5-5dfacd330aed" xlink:to="loc_us-gaap_CorporateJointVentureMember_cb931c4a-d8a2-457d-9fe9-f995141acc06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_35826f1b-8580-4843-84d3-5610de771499" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_c829f1ba-88f2-44ea-9f01-6adcd351e6e1" xlink:to="loc_us-gaap_MinorityInterestLineItems_35826f1b-8580-4843-84d3-5610de771499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_NoncontrollingInterestRequiredCapitalContribution_8922d276-760f-4869-8f96-4b9bb29f131f" xlink:href="apyx-20201231.xsd#apyx_NoncontrollingInterestRequiredCapitalContribution"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_35826f1b-8580-4843-84d3-5610de771499" xlink:to="loc_apyx_NoncontrollingInterestRequiredCapitalContribution_8922d276-760f-4869-8f96-4b9bb29f131f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_b67d3d34-404d-4d68-a471-e04612944ca6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_35826f1b-8580-4843-84d3-5610de771499" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_b67d3d34-404d-4d68-a471-e04612944ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTChangesinOwnershipInterestDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#INTERESTINJOINTVENTUREINVESTMENTChangesinOwnershipInterestDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTChangesinOwnershipInterestDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_74a2a6b5-c089-4c67-a413-007363fdba70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_ebf3e965-1bde-47af-b8c3-20be3b29e165" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_74a2a6b5-c089-4c67-a413-007363fdba70" xlink:to="loc_us-gaap_MinorityInterestTable_ebf3e965-1bde-47af-b8c3-20be3b29e165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_8af760e2-9e3d-453e-aa18-3e6b8537cfd3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_ebf3e965-1bde-47af-b8c3-20be3b29e165" xlink:to="loc_srt_OwnershipAxis_8af760e2-9e3d-453e-aa18-3e6b8537cfd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_f3436348-39fe-4aff-ab85-6412bb778d0b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_8af760e2-9e3d-453e-aa18-3e6b8537cfd3" xlink:to="loc_srt_OwnershipDomain_f3436348-39fe-4aff-ab85-6412bb778d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ChineseSupplierMember_937fb031-2727-4543-9e2c-d9ddcf366fce" xlink:href="apyx-20201231.xsd#apyx_ChineseSupplierMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_f3436348-39fe-4aff-ab85-6412bb778d0b" xlink:to="loc_apyx_ChineseSupplierMember_937fb031-2727-4543-9e2c-d9ddcf366fce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6b150267-504b-421c-b6ed-3bc62ae6d997" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_ebf3e965-1bde-47af-b8c3-20be3b29e165" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6b150267-504b-421c-b6ed-3bc62ae6d997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_23c098f6-c6cb-42ee-aa3c-c5ecc0a178ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6b150267-504b-421c-b6ed-3bc62ae6d997" xlink:to="loc_us-gaap_RelatedPartyDomain_23c098f6-c6cb-42ee-aa3c-c5ecc0a178ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember_b9a9582c-b779-4e6f-865b-8559bc85e446" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_23c098f6-c6cb-42ee-aa3c-c5ecc0a178ff" xlink:to="loc_us-gaap_CorporateJointVentureMember_b9a9582c-b779-4e6f-865b-8559bc85e446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_6eb1b7a1-b702-48b9-8a31-5a066b538f1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_ebf3e965-1bde-47af-b8c3-20be3b29e165" xlink:to="loc_us-gaap_MinorityInterestLineItems_6eb1b7a1-b702-48b9-8a31-5a066b538f1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_10f60e5a-eac6-4220-ad8a-13e99157de15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_6eb1b7a1-b702-48b9-8a31-5a066b538f1c" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_10f60e5a-eac6-4220-ad8a-13e99157de15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward_c8f668b1-e7f7-4ab9-9af2-2240e061f54b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_6eb1b7a1-b702-48b9-8a31-5a066b538f1c" xlink:to="loc_us-gaap_MovementInMinorityInterestRollForward_c8f668b1-e7f7-4ab9-9af2-2240e061f54b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_62a0eef4-93b4-477f-ae61-dc742052b40b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_c8f668b1-e7f7-4ab9-9af2-2240e061f54b" xlink:to="loc_us-gaap_MinorityInterest_62a0eef4-93b4-477f-ae61-dc742052b40b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_4e7a6f8a-4b36-42f4-ba9d-586377dd5afc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_c8f668b1-e7f7-4ab9-9af2-2240e061f54b" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_4e7a6f8a-4b36-42f4-ba9d-586377dd5afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_200c6f29-be71-419f-b348-8876110622ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_c8f668b1-e7f7-4ab9-9af2-2240e061f54b" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_200c6f29-be71-419f-b348-8876110622ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_0829463a-59ce-4272-88e3-b33df649e2b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_c8f668b1-e7f7-4ab9-9af2-2240e061f54b" xlink:to="loc_us-gaap_MinorityInterest_0829463a-59ce-4272-88e3-b33df649e2b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INVENTORIES" xlink:type="simple" xlink:href="apyx-20201231.xsd#INVENTORIES"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/INVENTORIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_3690e945-575e-4424-b01c-3354a56103a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_5f1f611d-c416-4671-ac4c-a29b6c686e12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3690e945-575e-4424-b01c-3354a56103a2" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_5f1f611d-c416-4671-ac4c-a29b6c686e12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INVENTORIESTables" xlink:type="simple" xlink:href="apyx-20201231.xsd#INVENTORIESTables"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/INVENTORIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_e346bda5-3697-4cc4-94b1-cc9a18754341" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_8ec63dbf-618a-4d70-91c5-484482553a4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_e346bda5-3697-4cc4-94b1-cc9a18754341" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_8ec63dbf-618a-4d70-91c5-484482553a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INVENTORIESDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#INVENTORIESDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/INVENTORIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_3644d32f-5f6a-4711-8555-921742c0568f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_bb4ce15d-3e45-481f-8c68-aa19cbb78312" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3644d32f-5f6a-4711-8555-921742c0568f" xlink:to="loc_us-gaap_InventoryRawMaterials_bb4ce15d-3e45-481f-8c68-aa19cbb78312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_16c2bd24-483f-4d8b-bfbe-f905f776be52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3644d32f-5f6a-4711-8555-921742c0568f" xlink:to="loc_us-gaap_InventoryWorkInProcess_16c2bd24-483f-4d8b-bfbe-f905f776be52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_5ea38e52-8bb0-4250-a65c-5851b5c1de32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3644d32f-5f6a-4711-8555-921742c0568f" xlink:to="loc_us-gaap_InventoryFinishedGoods_5ea38e52-8bb0-4250-a65c-5851b5c1de32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_e516609a-0515-4cd5-8f03-4f753230b459" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3644d32f-5f6a-4711-8555-921742c0568f" xlink:to="loc_us-gaap_InventoryGross_e516609a-0515-4cd5-8f03-4f753230b459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_8214517a-4c0e-46ab-903d-cae1193c5f4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3644d32f-5f6a-4711-8555-921742c0568f" xlink:to="loc_us-gaap_InventoryValuationReserves_8214517a-4c0e-46ab-903d-cae1193c5f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_92ac3e26-37ba-4b08-bd06-36795b3971f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3644d32f-5f6a-4711-8555-921742c0568f" xlink:to="loc_us-gaap_InventoryNet_92ac3e26-37ba-4b08-bd06-36795b3971f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_06dfd257-dfbb-4d18-9883-e7d7bb469cf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3644d32f-5f6a-4711-8555-921742c0568f" xlink:to="loc_us-gaap_InventoryWriteDown_06dfd257-dfbb-4d18-9883-e7d7bb469cf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_InventoryWriteDownReversals_a518070b-33bc-48f6-99ea-59a6eb577cb8" xlink:href="apyx-20201231.xsd#apyx_InventoryWriteDownReversals"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3644d32f-5f6a-4711-8555-921742c0568f" xlink:to="loc_apyx_InventoryWriteDownReversals_a518070b-33bc-48f6-99ea-59a6eb577cb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/PROPERTYANDEQUIPMENT" xlink:type="simple" xlink:href="apyx-20201231.xsd#PROPERTYANDEQUIPMENT"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/PROPERTYANDEQUIPMENT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0a6d7134-110a-4ffb-b290-216c81a6bc7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_ac5ed494-f2d1-4fad-bc8a-08e25a7e741b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0a6d7134-110a-4ffb-b290-216c81a6bc7d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_ac5ed494-f2d1-4fad-bc8a-08e25a7e741b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/PROPERTYANDEQUIPMENTTables" xlink:type="simple" xlink:href="apyx-20201231.xsd#PROPERTYANDEQUIPMENTTables"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/PROPERTYANDEQUIPMENTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0876e735-4a7f-4fe8-9dab-1fdff8e912b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_2e61078d-b338-489e-b637-1d97774e0ded" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0876e735-4a7f-4fe8-9dab-1fdff8e912b7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_2e61078d-b338-489e-b637-1d97774e0ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_49ef968a-bdb3-4650-bc56-6c02c6af9d48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_34f8b5cf-955f-44f3-b13b-e197bfbafb00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_49ef968a-bdb3-4650-bc56-6c02c6af9d48" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_34f8b5cf-955f-44f3-b13b-e197bfbafb00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_72de166a-0ea1-47c0-8f2b-a443bd7dea51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_34f8b5cf-955f-44f3-b13b-e197bfbafb00" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_72de166a-0ea1-47c0-8f2b-a443bd7dea51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ef916bc8-0136-413a-8abd-73524e5c36b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_72de166a-0ea1-47c0-8f2b-a443bd7dea51" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ef916bc8-0136-413a-8abd-73524e5c36b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_f2fc782a-1675-480c-a23c-65c75f868fe7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LandMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ef916bc8-0136-413a-8abd-73524e5c36b9" xlink:to="loc_us-gaap_LandMember_f2fc782a-1675-480c-a23c-65c75f868fe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_0712e80d-3436-477f-a32d-c36c031803f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ef916bc8-0136-413a-8abd-73524e5c36b9" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_0712e80d-3436-477f-a32d-c36c031803f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_4c18f5f6-31d6-439b-87a3-8caac5cafb29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ef916bc8-0136-413a-8abd-73524e5c36b9" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_4c18f5f6-31d6-439b-87a3-8caac5cafb29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_54e69f98-2c96-4cef-9fb9-6db19ae2e05c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ef916bc8-0136-413a-8abd-73524e5c36b9" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_54e69f98-2c96-4cef-9fb9-6db19ae2e05c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ComputerEquipmentandSoftwareMember_4ff4c7bb-f7d7-4d89-8955-682a5632ca04" xlink:href="apyx-20201231.xsd#apyx_ComputerEquipmentandSoftwareMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ef916bc8-0136-413a-8abd-73524e5c36b9" xlink:to="loc_apyx_ComputerEquipmentandSoftwareMember_4ff4c7bb-f7d7-4d89-8955-682a5632ca04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_8851606a-46b3-4233-af00-fd0abfca3b33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ef916bc8-0136-413a-8abd-73524e5c36b9" xlink:to="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_8851606a-46b3-4233-af00-fd0abfca3b33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ToolsDiesAndMoldsMember_d5603058-f968-446d-9185-2ea085b352b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ToolsDiesAndMoldsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ef916bc8-0136-413a-8abd-73524e5c36b9" xlink:to="loc_us-gaap_ToolsDiesAndMoldsMember_d5603058-f968-446d-9185-2ea085b352b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6ab78af3-568b-4a55-965d-7e5edc21009b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_34f8b5cf-955f-44f3-b13b-e197bfbafb00" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6ab78af3-568b-4a55-965d-7e5edc21009b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_a946ca07-6b22-485b-b843-7ac3ee016899" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6ab78af3-568b-4a55-965d-7e5edc21009b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_a946ca07-6b22-485b-b843-7ac3ee016899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_94ca4318-a091-4fe9-94f9-f255e3bc57ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6ab78af3-568b-4a55-965d-7e5edc21009b" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_94ca4318-a091-4fe9-94f9-f255e3bc57ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations_72b86947-0e70-4aff-b682-3f5e25ed0966" xlink:href="apyx-20201231.xsd#apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6ab78af3-568b-4a55-965d-7e5edc21009b" xlink:to="loc_apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations_72b86947-0e70-4aff-b682-3f5e25ed0966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_4c6a8212-b206-4322-9644-c373163b8355" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6ab78af3-568b-4a55-965d-7e5edc21009b" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_4c6a8212-b206-4322-9644-c373163b8355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_540310ab-d87d-492a-9287-657df72e0435" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6ab78af3-568b-4a55-965d-7e5edc21009b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_540310ab-d87d-492a-9287-657df72e0435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_49472756-75af-48b9-bd10-6b2985b05501" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6ab78af3-568b-4a55-965d-7e5edc21009b" xlink:to="loc_us-gaap_Depreciation_49472756-75af-48b9-bd10-6b2985b05501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/LEASES" xlink:type="simple" xlink:href="apyx-20201231.xsd#LEASES"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/LEASES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a9d9cf97-033f-4198-a53f-2a5699251bee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_820fdb39-7125-45e6-9c63-6a06e652b4c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a9d9cf97-033f-4198-a53f-2a5699251bee" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_820fdb39-7125-45e6-9c63-6a06e652b4c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_3618730d-3699-4fa9-bccd-8a00fc0e78fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a9d9cf97-033f-4198-a53f-2a5699251bee" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_3618730d-3699-4fa9-bccd-8a00fc0e78fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/LEASESTables" xlink:type="simple" xlink:href="apyx-20201231.xsd#LEASESTables"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/LEASESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_cefb1c74-7cec-412b-9338-b194f3bc7fc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_3e8d884d-abe5-458f-8939-f845f2b0f5bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cefb1c74-7cec-412b-9338-b194f3bc7fc5" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_3e8d884d-abe5-458f-8939-f845f2b0f5bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_4b6eb12e-0ee8-4315-8b8b-119de700c301" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cefb1c74-7cec-412b-9338-b194f3bc7fc5" xlink:to="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_4b6eb12e-0ee8-4315-8b8b-119de700c301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_2845aa0e-8b43-475c-91b6-5153ebd85f73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cefb1c74-7cec-412b-9338-b194f3bc7fc5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_2845aa0e-8b43-475c-91b6-5153ebd85f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/LEASESNarrativeDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#LEASESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/LEASESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_5a39d84a-236b-4ea7-9f70-f9d0ce5990da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_d1ee9217-2bdd-4669-a083-ee73d22d198b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5a39d84a-236b-4ea7-9f70-f9d0ce5990da" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_d1ee9217-2bdd-4669-a083-ee73d22d198b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_49d0226c-2149-4c82-82ef-881404bba401" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_d1ee9217-2bdd-4669-a083-ee73d22d198b" xlink:to="loc_srt_StatementGeographicalAxis_49d0226c-2149-4c82-82ef-881404bba401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_5a2a4a05-2e80-451a-9f8d-0137d8afbf9d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_49d0226c-2149-4c82-82ef-881404bba401" xlink:to="loc_srt_SegmentGeographicalDomain_5a2a4a05-2e80-451a-9f8d-0137d8afbf9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SophiaBulgariaMember_b2643a52-10a5-44d6-9cbe-c730586a0a85" xlink:href="apyx-20201231.xsd#apyx_SophiaBulgariaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_5a2a4a05-2e80-451a-9f8d-0137d8afbf9d" xlink:to="loc_apyx_SophiaBulgariaMember_b2643a52-10a5-44d6-9cbe-c730586a0a85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_b4f02465-ff00-42c1-bec4-d3b8d37bcc95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_d1ee9217-2bdd-4669-a083-ee73d22d198b" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_b4f02465-ff00-42c1-bec4-d3b8d37bcc95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_LesseeDiscountRateIncrementalBorrowingRate_3f7e8f82-807c-4a7d-b904-3d1de4b82d40" xlink:href="apyx-20201231.xsd#apyx_LesseeDiscountRateIncrementalBorrowingRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b4f02465-ff00-42c1-bec4-d3b8d37bcc95" xlink:to="loc_apyx_LesseeDiscountRateIncrementalBorrowingRate_3f7e8f82-807c-4a7d-b904-3d1de4b82d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_fc950064-305b-46ae-9ee1-3f87b4ee5d25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b4f02465-ff00-42c1-bec4-d3b8d37bcc95" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_fc950064-305b-46ae-9ee1-3f87b4ee5d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/LEASESLeaseCostDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#LEASESLeaseCostDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/LEASESLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_275b184a-51ff-4c64-a00e-9fc3026e4151" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_6d92c57e-a8fd-40a4-9ccd-3eaa778e74db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_275b184a-51ff-4c64-a00e-9fc3026e4151" xlink:to="loc_us-gaap_OperatingLeaseCost_6d92c57e-a8fd-40a4-9ccd-3eaa778e74db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_8c0ee15a-8af7-4558-abc6-f7082d996df4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_275b184a-51ff-4c64-a00e-9fc3026e4151" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_8c0ee15a-8af7-4558-abc6-f7082d996df4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_77f5e47a-9cbc-465b-ad42-41ab88ece15f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_275b184a-51ff-4c64-a00e-9fc3026e4151" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_77f5e47a-9cbc-465b-ad42-41ab88ece15f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_401f8b67-a645-4b28-a7bb-96797580b00b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_275b184a-51ff-4c64-a00e-9fc3026e4151" xlink:to="loc_us-gaap_VariableLeaseCost_401f8b67-a645-4b28-a7bb-96797580b00b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_8e3b8345-e5b0-440d-9eae-7512a4a2d0ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_275b184a-51ff-4c64-a00e-9fc3026e4151" xlink:to="loc_us-gaap_LeaseCost_8e3b8345-e5b0-440d-9eae-7512a4a2d0ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/LEASESCashandNonCashInformationDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#LEASESCashandNonCashInformationDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/LEASESCashandNonCashInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_f8b505ae-1d3f-4d99-98e1-9df9b68afb36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_2625360e-46ef-47f6-974b-4a153ed8605d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f8b505ae-1d3f-4d99-98e1-9df9b68afb36" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_2625360e-46ef-47f6-974b-4a153ed8605d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_94fb578b-d252-4971-a638-ce7a03ee4365" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_2625360e-46ef-47f6-974b-4a153ed8605d" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_94fb578b-d252-4971-a638-ce7a03ee4365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_3a224196-0bc5-49da-b11b-d632c6684218" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_94fb578b-d252-4971-a638-ce7a03ee4365" xlink:to="loc_us-gaap_TypeOfAdoptionMember_3a224196-0bc5-49da-b11b-d632c6684218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_d14d3dc2-5ba5-4d3b-97eb-8ffd6530c43a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_3a224196-0bc5-49da-b11b-d632c6684218" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_d14d3dc2-5ba5-4d3b-97eb-8ffd6530c43a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_LeaseArrangementsAxis_a505e7f8-e567-45f5-95fe-6520058ab7d9" xlink:href="apyx-20201231.xsd#apyx_LeaseArrangementsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_2625360e-46ef-47f6-974b-4a153ed8605d" xlink:to="loc_apyx_LeaseArrangementsAxis_a505e7f8-e567-45f5-95fe-6520058ab7d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_LeaseArrangementsDomain_b897b434-390f-4181-9137-204c03d98937" xlink:href="apyx-20201231.xsd#apyx_LeaseArrangementsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_apyx_LeaseArrangementsAxis_a505e7f8-e567-45f5-95fe-6520058ab7d9" xlink:to="loc_apyx_LeaseArrangementsDomain_b897b434-390f-4181-9137-204c03d98937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_LeaseRemeasurementMember_888836b4-5d3e-41c3-8664-0466bb5609bc" xlink:href="apyx-20201231.xsd#apyx_LeaseRemeasurementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_apyx_LeaseArrangementsDomain_b897b434-390f-4181-9137-204c03d98937" xlink:to="loc_apyx_LeaseRemeasurementMember_888836b4-5d3e-41c3-8664-0466bb5609bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_LeaseExecutionMember_064fb036-2fac-492a-b5a8-82bba54e49b7" xlink:href="apyx-20201231.xsd#apyx_LeaseExecutionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_apyx_LeaseArrangementsDomain_b897b434-390f-4181-9137-204c03d98937" xlink:to="loc_apyx_LeaseExecutionMember_064fb036-2fac-492a-b5a8-82bba54e49b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_0d98b902-efbb-423e-86e2-dc062bc92006" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_2625360e-46ef-47f6-974b-4a153ed8605d" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_0d98b902-efbb-423e-86e2-dc062bc92006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_OperatingLeaseCostsAbstract_4a964de5-978e-4fba-b87a-3a5f1ad2a8dc" xlink:href="apyx-20201231.xsd#apyx_OperatingLeaseCostsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0d98b902-efbb-423e-86e2-dc062bc92006" xlink:to="loc_apyx_OperatingLeaseCostsAbstract_4a964de5-978e-4fba-b87a-3a5f1ad2a8dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_e4d21dbb-8722-4a63-b855-14f5ad4f22d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_apyx_OperatingLeaseCostsAbstract_4a964de5-978e-4fba-b87a-3a5f1ad2a8dc" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_e4d21dbb-8722-4a63-b855-14f5ad4f22d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_8a892966-37d9-470a-b1bb-c2d86e19b611" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_apyx_OperatingLeaseCostsAbstract_4a964de5-978e-4fba-b87a-3a5f1ad2a8dc" xlink:to="loc_us-gaap_OperatingLeasePayments_8a892966-37d9-470a-b1bb-c2d86e19b611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_FinanceLeaseCostsAbstract_51ce3d41-926f-4b81-b63d-c169c16fe231" xlink:href="apyx-20201231.xsd#apyx_FinanceLeaseCostsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0d98b902-efbb-423e-86e2-dc062bc92006" xlink:to="loc_apyx_FinanceLeaseCostsAbstract_51ce3d41-926f-4b81-b63d-c169c16fe231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_c98713f3-22e2-4efe-b22b-5c15ae46e0cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_apyx_FinanceLeaseCostsAbstract_51ce3d41-926f-4b81-b63d-c169c16fe231" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_c98713f3-22e2-4efe-b22b-5c15ae46e0cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_FinanceLeasePayments_7af357cb-72ec-4936-ba90-9953e174721d" xlink:href="apyx-20201231.xsd#apyx_FinanceLeasePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_apyx_FinanceLeaseCostsAbstract_51ce3d41-926f-4b81-b63d-c169c16fe231" xlink:to="loc_apyx_FinanceLeasePayments_7af357cb-72ec-4936-ba90-9953e174721d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/LEASESLeaseTermsandDiscountRatesDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#LEASESLeaseTermsandDiscountRatesDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/LEASESLeaseTermsandDiscountRatesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_0dd0eee6-3636-48ca-bf86-a98f4129fa48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_OperatingLeaseCostsAbstract_ed60a411-f6a4-44f8-914e-b1d766940421" xlink:href="apyx-20201231.xsd#apyx_OperatingLeaseCostsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0dd0eee6-3636-48ca-bf86-a98f4129fa48" xlink:to="loc_apyx_OperatingLeaseCostsAbstract_ed60a411-f6a4-44f8-914e-b1d766940421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1704b0c3-03db-468a-8d05-66b1c91be758" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_apyx_OperatingLeaseCostsAbstract_ed60a411-f6a4-44f8-914e-b1d766940421" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1704b0c3-03db-468a-8d05-66b1c91be758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_8cf2ff88-8b63-4627-aa82-965d4501812f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_apyx_OperatingLeaseCostsAbstract_ed60a411-f6a4-44f8-914e-b1d766940421" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_8cf2ff88-8b63-4627-aa82-965d4501812f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_FinanceLeaseCostsAbstract_e81cb4cc-e7bd-4121-aa59-251d2ecccd8f" xlink:href="apyx-20201231.xsd#apyx_FinanceLeaseCostsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0dd0eee6-3636-48ca-bf86-a98f4129fa48" xlink:to="loc_apyx_FinanceLeaseCostsAbstract_e81cb4cc-e7bd-4121-aa59-251d2ecccd8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_7e322b94-86c2-4730-aa62-567187ee4d5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_apyx_FinanceLeaseCostsAbstract_e81cb4cc-e7bd-4121-aa59-251d2ecccd8f" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_7e322b94-86c2-4730-aa62-567187ee4d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_f1bd6205-584d-4d33-b024-c5fe13acb547" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_apyx_FinanceLeaseCostsAbstract_e81cb4cc-e7bd-4121-aa59-251d2ecccd8f" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_f1bd6205-584d-4d33-b024-c5fe13acb547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#LEASESMaturitiesofLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9cffea3e-b8cd-4d00-9644-efe339a3ee4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ef4a2fec-bfa1-4b1b-8c89-6a7da2a680fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9cffea3e-b8cd-4d00-9644-efe339a3ee4d" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ef4a2fec-bfa1-4b1b-8c89-6a7da2a680fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_137b335a-758a-4009-b866-f6093ade7593" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ef4a2fec-bfa1-4b1b-8c89-6a7da2a680fc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_137b335a-758a-4009-b866-f6093ade7593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_46066e6b-545c-4fdc-9e21-9e755214c5a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ef4a2fec-bfa1-4b1b-8c89-6a7da2a680fc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_46066e6b-545c-4fdc-9e21-9e755214c5a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7847523f-d11a-4db2-8cd5-01b9b6a795ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ef4a2fec-bfa1-4b1b-8c89-6a7da2a680fc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7847523f-d11a-4db2-8cd5-01b9b6a795ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c326cf78-bdd5-4ede-a83a-64c7704761e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ef4a2fec-bfa1-4b1b-8c89-6a7da2a680fc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c326cf78-bdd5-4ede-a83a-64c7704761e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_783161e4-1f7a-4ed8-9e66-bd4a4344c5eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ef4a2fec-bfa1-4b1b-8c89-6a7da2a680fc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_783161e4-1f7a-4ed8-9e66-bd4a4344c5eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_05e60276-a0dd-4bf8-b4ba-5bdf0ffd4e25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ef4a2fec-bfa1-4b1b-8c89-6a7da2a680fc" xlink:to="loc_us-gaap_OperatingLeaseLiability_05e60276-a0dd-4bf8-b4ba-5bdf0ffd4e25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_5d677133-72c8-43f5-b89a-94571b4ea1cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ef4a2fec-bfa1-4b1b-8c89-6a7da2a680fc" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_5d677133-72c8-43f5-b89a-94571b4ea1cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_19dc4a8f-d2ea-40a1-9798-30e0e0dbf08b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ef4a2fec-bfa1-4b1b-8c89-6a7da2a680fc" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_19dc4a8f-d2ea-40a1-9798-30e0e0dbf08b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_d6d08621-bf6e-4874-b7a2-029fb529de1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9cffea3e-b8cd-4d00-9644-efe339a3ee4d" xlink:to="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_d6d08621-bf6e-4874-b7a2-029fb529de1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_c54617c4-6513-4eed-a758-ba38a6392aa0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_d6d08621-bf6e-4874-b7a2-029fb529de1e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_c54617c4-6513-4eed-a758-ba38a6392aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_cb436c1f-de29-4b0e-aeac-f65c98357be2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_d6d08621-bf6e-4874-b7a2-029fb529de1e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_cb436c1f-de29-4b0e-aeac-f65c98357be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_323356ee-63a8-4336-b601-59a804f43c84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_d6d08621-bf6e-4874-b7a2-029fb529de1e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_323356ee-63a8-4336-b601-59a804f43c84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_c064db34-ab12-47ef-bb73-20df4f88b2f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_d6d08621-bf6e-4874-b7a2-029fb529de1e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_c064db34-ab12-47ef-bb73-20df4f88b2f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_9f2bcfb9-e191-4503-9152-a54b01560eeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_d6d08621-bf6e-4874-b7a2-029fb529de1e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_9f2bcfb9-e191-4503-9152-a54b01560eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_5e9c6019-6321-489d-bb68-d46792a1e95f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_d6d08621-bf6e-4874-b7a2-029fb529de1e" xlink:to="loc_us-gaap_FinanceLeaseLiability_5e9c6019-6321-489d-bb68-d46792a1e95f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_cd34b1e3-7030-4735-859a-f8b947dcb94f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_d6d08621-bf6e-4874-b7a2-029fb529de1e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_cd34b1e3-7030-4735-859a-f8b947dcb94f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_65609d5b-3ee2-494f-ac04-d1d135ca5609" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_d6d08621-bf6e-4874-b7a2-029fb529de1e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_65609d5b-3ee2-494f-ac04-d1d135ca5609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES" xlink:type="simple" xlink:href="apyx-20201231.xsd#ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_25466c2a-bc37-461c-b737-75c3f61be048" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_9734e53e-fd77-4903-9f96-d686d7a430d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_25466c2a-bc37-461c-b737-75c3f61be048" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_9734e53e-fd77-4903-9f96-d686d7a430d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables" xlink:type="simple" xlink:href="apyx-20201231.xsd#ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_4ae2b4b7-d38e-49d6-9b68-f35d5c717c52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_1292dcf4-81d9-4f7c-8e98-df71d0883d60" xlink:href="apyx-20201231.xsd#apyx_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_4ae2b4b7-d38e-49d6-9b68-f35d5c717c52" xlink:to="loc_apyx_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_1292dcf4-81d9-4f7c-8e98-df71d0883d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_07082eeb-fa20-496b-9ddc-60575c476860" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_773df50f-1712-4f13-abe3-3fd9b900776d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_07082eeb-fa20-496b-9ddc-60575c476860" xlink:to="loc_us-gaap_AccruedSalariesCurrent_773df50f-1712-4f13-abe3-3fd9b900776d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedBonusesCurrent_1b4f738e-67f8-49ff-a919-0c04cfba9291" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedBonusesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_07082eeb-fa20-496b-9ddc-60575c476860" xlink:to="loc_us-gaap_AccruedBonusesCurrent_1b4f738e-67f8-49ff-a919-0c04cfba9291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalesCommissionCurrent_1141b95d-7dbc-45cf-8eb8-cd2108a81681" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalesCommissionCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_07082eeb-fa20-496b-9ddc-60575c476860" xlink:to="loc_us-gaap_AccruedSalesCommissionCurrent_1141b95d-7dbc-45cf-8eb8-cd2108a81681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_1f7b9006-b393-43e1-b870-4135498e2eab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_07082eeb-fa20-496b-9ddc-60575c476860" xlink:to="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_1f7b9006-b393-43e1-b870-4135498e2eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedInsuranceCurrent_8fd83f98-d29a-49ac-ba87-d9bf43b9b188" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedInsuranceCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_07082eeb-fa20-496b-9ddc-60575c476860" xlink:to="loc_us-gaap_AccruedInsuranceCurrent_8fd83f98-d29a-49ac-ba87-d9bf43b9b188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_eaa85340-c78f-4242-b711-0f1045fc15af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_07082eeb-fa20-496b-9ddc-60575c476860" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_eaa85340-c78f-4242-b711-0f1045fc15af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_JointAndSeveralPayrollLiability_12f9a5f3-d026-44ad-9c59-a11316d891ee" xlink:href="apyx-20201231.xsd#apyx_JointAndSeveralPayrollLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_07082eeb-fa20-496b-9ddc-60575c476860" xlink:to="loc_apyx_JointAndSeveralPayrollLiability_12f9a5f3-d026-44ad-9c59-a11316d891ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_UncertainTaxPositionsLiability_8f93e53c-1f5b-48de-9681-02520956085e" xlink:href="apyx-20201231.xsd#apyx_UncertainTaxPositionsLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_07082eeb-fa20-496b-9ddc-60575c476860" xlink:to="loc_apyx_UncertainTaxPositionsLiability_8f93e53c-1f5b-48de-9681-02520956085e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent_a1e5d1aa-7004-4972-b185-3d763f4cd2fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesAndExciseTaxPayableCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_07082eeb-fa20-496b-9ddc-60575c476860" xlink:to="loc_us-gaap_SalesAndExciseTaxPayableCurrent_a1e5d1aa-7004-4972-b185-3d763f4cd2fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_OtherAccruedExpensesAndLiabilitiesCurrent_98f9b589-42d2-481a-9d39-29017ad56092" xlink:href="apyx-20201231.xsd#apyx_OtherAccruedExpensesAndLiabilitiesCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_07082eeb-fa20-496b-9ddc-60575c476860" xlink:to="loc_apyx_OtherAccruedExpensesAndLiabilitiesCurrent_98f9b589-42d2-481a-9d39-29017ad56092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_a2b673ef-a074-4b3d-9501-9cdb8dc52112" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_07082eeb-fa20-496b-9ddc-60575c476860" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_a2b673ef-a074-4b3d-9501-9cdb8dc52112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/PRODUCTWARRANTIES" xlink:type="simple" xlink:href="apyx-20201231.xsd#PRODUCTWARRANTIES"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/PRODUCTWARRANTIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantiesDisclosuresAbstract_8d33bbab-9f46-4742-936b-dcc87ddeb43e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductWarrantiesDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyDisclosureTextBlock_449dedfa-d827-4381-bc1c-93d84d3ff866" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductWarrantyDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductWarrantiesDisclosuresAbstract_8d33bbab-9f46-4742-936b-dcc87ddeb43e" xlink:to="loc_us-gaap_ProductWarrantyDisclosureTextBlock_449dedfa-d827-4381-bc1c-93d84d3ff866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/PRODUCTWARRANTIESTables" xlink:type="simple" xlink:href="apyx-20201231.xsd#PRODUCTWARRANTIESTables"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/PRODUCTWARRANTIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantiesDisclosuresAbstract_c45ca4fb-afb7-448b-9917-bc1e9069c7d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductWarrantiesDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock_7ba37f19-115d-47ab-935f-39977f67daab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductWarrantiesDisclosuresAbstract_c45ca4fb-afb7-448b-9917-bc1e9069c7d6" xlink:to="loc_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock_7ba37f19-115d-47ab-935f-39977f67daab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/PRODUCTWARRANTIESDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#PRODUCTWARRANTIESDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/PRODUCTWARRANTIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantiesDisclosuresAbstract_208f871a-7dcd-46f2-a34d-642521f623b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductWarrantiesDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInStandardProductWarrantyAccrualRollForward_03ccc701-9efd-42b5-a4a0-8d91a67d9286" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MovementInStandardProductWarrantyAccrualRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductWarrantiesDisclosuresAbstract_208f871a-7dcd-46f2-a34d-642521f623b4" xlink:to="loc_us-gaap_MovementInStandardProductWarrantyAccrualRollForward_03ccc701-9efd-42b5-a4a0-8d91a67d9286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandardProductWarrantyAccrual_85e07356-c6d1-4f1d-a7ed-49c1c45619f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StandardProductWarrantyAccrual"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInStandardProductWarrantyAccrualRollForward_03ccc701-9efd-42b5-a4a0-8d91a67d9286" xlink:to="loc_us-gaap_StandardProductWarrantyAccrual_85e07356-c6d1-4f1d-a7ed-49c1c45619f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandardProductWarrantyAccrualWarrantiesIssued_30a71d22-bdee-40e1-aa36-b3895a26ec28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StandardProductWarrantyAccrualWarrantiesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInStandardProductWarrantyAccrualRollForward_03ccc701-9efd-42b5-a4a0-8d91a67d9286" xlink:to="loc_us-gaap_StandardProductWarrantyAccrualWarrantiesIssued_30a71d22-bdee-40e1-aa36-b3895a26ec28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandardProductWarrantyAccrualPayments_d6f4580c-29b4-44de-90ed-83acdd6d7f28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StandardProductWarrantyAccrualPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInStandardProductWarrantyAccrualRollForward_03ccc701-9efd-42b5-a4a0-8d91a67d9286" xlink:to="loc_us-gaap_StandardProductWarrantyAccrualPayments_d6f4580c-29b4-44de-90ed-83acdd6d7f28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandardProductWarrantyAccrual_d4d81184-7f12-4f64-9742-b93cbf289a6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StandardProductWarrantyAccrual"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInStandardProductWarrantyAccrualRollForward_03ccc701-9efd-42b5-a4a0-8d91a67d9286" xlink:to="loc_us-gaap_StandardProductWarrantyAccrual_d4d81184-7f12-4f64-9742-b93cbf289a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/JOINTANDSEVERALPAYROLLLIABILITY" xlink:type="simple" xlink:href="apyx-20201231.xsd#JOINTANDSEVERALPAYROLLLIABILITY"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/JOINTANDSEVERALPAYROLLLIABILITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_bfeeba2e-08f9-47ad-89ce-ecc64f264f24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_JointandSeveralPayrollLiabilityTextBlock_89e930ec-877f-4766-a5a7-19f42b6d26e1" xlink:href="apyx-20201231.xsd#apyx_JointandSeveralPayrollLiabilityTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_bfeeba2e-08f9-47ad-89ce-ecc64f264f24" xlink:to="loc_apyx_JointandSeveralPayrollLiabilityTextBlock_89e930ec-877f-4766-a5a7-19f42b6d26e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/JOINTANDSEVERALPAYROLLLIABILITYDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#JOINTANDSEVERALPAYROLLLIABILITYDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/JOINTANDSEVERALPAYROLLLIABILITYDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_8f485435-a3bf-4fa5-8f5c-210478428fca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_55f7eda0-4fcd-4b1c-8c38-300472fc07f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_8f485435-a3bf-4fa5-8f5c-210478428fca" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_55f7eda0-4fcd-4b1c-8c38-300472fc07f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_7a8fb87c-8e88-45f7-9327-1fe5991dd3bf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_55f7eda0-4fcd-4b1c-8c38-300472fc07f6" xlink:to="loc_srt_RestatementAxis_7a8fb87c-8e88-45f7-9327-1fe5991dd3bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_63834cf5-e10b-46f9-91f4-0f0110590fdc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_7a8fb87c-8e88-45f7-9327-1fe5991dd3bf" xlink:to="loc_srt_RestatementDomain_63834cf5-e10b-46f9-91f4-0f0110590fdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAdjustmentMember_7d1acd85-4417-4862-8033-870574915186" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_63834cf5-e10b-46f9-91f4-0f0110590fdc" xlink:to="loc_srt_RestatementAdjustmentMember_7d1acd85-4417-4862-8033-870574915186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_3a30e58f-6a60-456e-b954-8e354efa6daf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_55f7eda0-4fcd-4b1c-8c38-300472fc07f6" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_3a30e58f-6a60-456e-b954-8e354efa6daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_JointAndSeveralPayrollLiability_cbdb3ef8-f193-467e-89c9-d97e5da73599" xlink:href="apyx-20201231.xsd#apyx_JointAndSeveralPayrollLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_3a30e58f-6a60-456e-b954-8e354efa6daf" xlink:to="loc_apyx_JointAndSeveralPayrollLiability_cbdb3ef8-f193-467e-89c9-d97e5da73599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_JointAndSeveralPayrollExpense_15975d32-9587-450f-aaf0-72ea2eb07b8c" xlink:href="apyx-20201231.xsd#apyx_JointAndSeveralPayrollExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_3a30e58f-6a60-456e-b954-8e354efa6daf" xlink:to="loc_apyx_JointAndSeveralPayrollExpense_15975d32-9587-450f-aaf0-72ea2eb07b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/EARNINGSLOSSPERSHARE" xlink:type="simple" xlink:href="apyx-20201231.xsd#EARNINGSLOSSPERSHARE"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/EARNINGSLOSSPERSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_7593dadf-824e-470f-b9e5-72afbc5c22ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_82420a40-475a-4827-9eb5-31f6f24a2a7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7593dadf-824e-470f-b9e5-72afbc5c22ff" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_82420a40-475a-4827-9eb5-31f6f24a2a7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/EARNINGSLOSSPERSHARETables" xlink:type="simple" xlink:href="apyx-20201231.xsd#EARNINGSLOSSPERSHARETables"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/EARNINGSLOSSPERSHARETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_7968dc82-f6a7-4387-8a84-1ae059931b7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_5e4d60f7-ac51-40d1-9951-8c0f2318d094" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7968dc82-f6a7-4387-8a84-1ae059931b7d" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_5e4d60f7-ac51-40d1-9951-8c0f2318d094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#EARNINGSLOSSPERSHAREDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_6a98e2f1-74fb-4996-87dd-77c16e3ce125" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_762fca61-e494-46f1-a63e-fcc192f6b602" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6a98e2f1-74fb-4996-87dd-77c16e3ce125" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_762fca61-e494-46f1-a63e-fcc192f6b602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_149c8358-0802-4ae0-a12a-b9d8595c7261" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_762fca61-e494-46f1-a63e-fcc192f6b602" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_149c8358-0802-4ae0-a12a-b9d8595c7261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_266f710c-a64e-413f-a242-ee7d34166093" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_149c8358-0802-4ae0-a12a-b9d8595c7261" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_266f710c-a64e-413f-a242-ee7d34166093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionOnSecuritiesMember_8c38085f-c87e-4115-b7f0-2493c80dce93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionOnSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_266f710c-a64e-413f-a242-ee7d34166093" xlink:to="loc_us-gaap_OptionOnSecuritiesMember_8c38085f-c87e-4115-b7f0-2493c80dce93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_00d2c348-9bc5-4be2-bd86-a2a229899460" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_762fca61-e494-46f1-a63e-fcc192f6b602" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_00d2c348-9bc5-4be2-bd86-a2a229899460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_961006a1-1f1a-4232-8081-23d6c5fac0df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_00d2c348-9bc5-4be2-bd86-a2a229899460" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_961006a1-1f1a-4232-8081-23d6c5fac0df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_14f156af-1783-4cde-ba76-e269115f5901" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_961006a1-1f1a-4232-8081-23d6c5fac0df" xlink:to="loc_us-gaap_NetIncomeLoss_14f156af-1783-4cde-ba76-e269115f5901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_6c63b440-bc81-415f-89be-431d90447a0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_00d2c348-9bc5-4be2-bd86-a2a229899460" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_6c63b440-bc81-415f-89be-431d90447a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_e7aa1b96-1d43-4095-9f5c-c660bed446f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_00d2c348-9bc5-4be2-bd86-a2a229899460" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_e7aa1b96-1d43-4095-9f5c-c660bed446f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_5bf9796a-df88-4d87-b43f-36402f1be939" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_00d2c348-9bc5-4be2-bd86-a2a229899460" xlink:to="loc_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_5bf9796a-df88-4d87-b43f-36402f1be939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d1142c8f-0580-4b33-bb7e-f4b387d08f4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_5bf9796a-df88-4d87-b43f-36402f1be939" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d1142c8f-0580-4b33-bb7e-f4b387d08f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/FINANCIALINSTRUMENTS" xlink:type="simple" xlink:href="apyx-20201231.xsd#FINANCIALINSTRUMENTS"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/FINANCIALINSTRUMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_31b3ab0c-0613-4569-8580-1b30954501ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_c5d9d596-9204-4b50-9767-2e371aca9f41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_31b3ab0c-0613-4569-8580-1b30954501ae" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_c5d9d596-9204-4b50-9767-2e371aca9f41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/FINANCIALINSTRUMENTSDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#FINANCIALINSTRUMENTSDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/FINANCIALINSTRUMENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a1b0a164-c7a7-4ef9-9a1a-23aeb7d3c7b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_69073e32-fc03-4323-bc34-541e7de9ada0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a1b0a164-c7a7-4ef9-9a1a-23aeb7d3c7b2" xlink:to="loc_us-gaap_Cash_69073e32-fc03-4323-bc34-541e7de9ada0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_b7c51e5d-94af-4f3a-b7c8-218781abc40c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a1b0a164-c7a7-4ef9-9a1a-23aeb7d3c7b2" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_b7c51e5d-94af-4f3a-b7c8-218781abc40c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INCOMETAXES" xlink:type="simple" xlink:href="apyx-20201231.xsd#INCOMETAXES"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/INCOMETAXES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_342a390f-31a9-4233-a681-c40b75a6897a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_151a26d8-f981-4458-bcb3-be50842ae6af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_342a390f-31a9-4233-a681-c40b75a6897a" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_151a26d8-f981-4458-bcb3-be50842ae6af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INCOMETAXESTables" xlink:type="simple" xlink:href="apyx-20201231.xsd#INCOMETAXESTables"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/INCOMETAXESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_259a714f-d8d1-4e59-8a05-c738bf9e8a0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_773c8459-a263-4410-bd04-a82f5377c81d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_259a714f-d8d1-4e59-8a05-c738bf9e8a0d" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_773c8459-a263-4410-bd04-a82f5377c81d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_8c2872c9-9718-4ea3-8871-ac234c8e393d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_259a714f-d8d1-4e59-8a05-c738bf9e8a0d" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_8c2872c9-9718-4ea3-8871-ac234c8e393d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_563d5c24-9177-4a42-9eed-9760a45aa9ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_259a714f-d8d1-4e59-8a05-c738bf9e8a0d" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_563d5c24-9177-4a42-9eed-9760a45aa9ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_244a6779-5769-4f80-a035-ae346384200a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_259a714f-d8d1-4e59-8a05-c738bf9e8a0d" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_244a6779-5769-4f80-a035-ae346384200a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#INCOMETAXESComponentsofProvisionForIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_64ffeada-505f-4b88-999a-395b4668a4aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_11dc45b9-6f6d-4a52-aed0-0671359750eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_64ffeada-505f-4b88-999a-395b4668a4aa" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_11dc45b9-6f6d-4a52-aed0-0671359750eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_1081b865-8f64-4d6a-90b8-8ec25cb57317" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_11dc45b9-6f6d-4a52-aed0-0671359750eb" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_1081b865-8f64-4d6a-90b8-8ec25cb57317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_9fa59b67-8a96-4105-973d-931a22d36965" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_11dc45b9-6f6d-4a52-aed0-0671359750eb" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_9fa59b67-8a96-4105-973d-931a22d36965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_5ffc633d-4eb6-4f0c-bd4e-608b2d3effc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_11dc45b9-6f6d-4a52-aed0-0671359750eb" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_5ffc633d-4eb6-4f0c-bd4e-608b2d3effc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_11c91cd3-a99a-4279-a853-e39644018e3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_11dc45b9-6f6d-4a52-aed0-0671359750eb" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_11c91cd3-a99a-4279-a853-e39644018e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_CARESActIncomeTaxExpenseBenefitValuationAllowance_3733568e-92e6-4e36-8566-f8a339cf2a9f" xlink:href="apyx-20201231.xsd#apyx_CARESActIncomeTaxExpenseBenefitValuationAllowance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_64ffeada-505f-4b88-999a-395b4668a4aa" xlink:to="loc_apyx_CARESActIncomeTaxExpenseBenefitValuationAllowance_3733568e-92e6-4e36-8566-f8a339cf2a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_CurrentIncomeTaxExpenseBenefitAfterValuationAllowance_9cce3c95-8a5d-4486-98b0-100b68175c78" xlink:href="apyx-20201231.xsd#apyx_CurrentIncomeTaxExpenseBenefitAfterValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_64ffeada-505f-4b88-999a-395b4668a4aa" xlink:to="loc_apyx_CurrentIncomeTaxExpenseBenefitAfterValuationAllowance_9cce3c95-8a5d-4486-98b0-100b68175c78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_a576c9f6-4d31-4ac3-9ec4-4a8c2b5d67f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_64ffeada-505f-4b88-999a-395b4668a4aa" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_a576c9f6-4d31-4ac3-9ec4-4a8c2b5d67f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_5f4ee39f-1885-413c-be3d-b5c0eb812e86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_a576c9f6-4d31-4ac3-9ec4-4a8c2b5d67f7" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_5f4ee39f-1885-413c-be3d-b5c0eb812e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_63a3b085-285d-4b4c-815e-5c0c303d9d87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_a576c9f6-4d31-4ac3-9ec4-4a8c2b5d67f7" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_63a3b085-285d-4b4c-815e-5c0c303d9d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_c0d9866e-6f61-45f8-b858-31ae4d662c3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_a576c9f6-4d31-4ac3-9ec4-4a8c2b5d67f7" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_c0d9866e-6f61-45f8-b858-31ae4d662c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_IncomeTaxExpenseBenefitValuationAllowance_57d23f7a-5f97-4c72-a619-31ba495ae3ff" xlink:href="apyx-20201231.xsd#apyx_IncomeTaxExpenseBenefitValuationAllowance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_64ffeada-505f-4b88-999a-395b4668a4aa" xlink:to="loc_apyx_IncomeTaxExpenseBenefitValuationAllowance_57d23f7a-5f97-4c72-a619-31ba495ae3ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_beb83403-f8bb-4788-bb2f-5853d2ed95ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_64ffeada-505f-4b88-999a-395b4668a4aa" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_beb83403-f8bb-4788-bb2f-5853d2ed95ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INCOMETAXESReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#INCOMETAXESReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/INCOMETAXESReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3227eafc-19a5-4b84-af73-f2fb3dd24d60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_f154daee-0592-426e-8b81-68f7bc95519a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3227eafc-19a5-4b84-af73-f2fb3dd24d60" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_f154daee-0592-426e-8b81-68f7bc95519a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_be8e83a7-727f-47cb-abd0-b75abb4b084c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_f154daee-0592-426e-8b81-68f7bc95519a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_be8e83a7-727f-47cb-abd0-b75abb4b084c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_411b89bb-fdc2-4412-b213-b73555e037f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_f154daee-0592-426e-8b81-68f7bc95519a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_411b89bb-fdc2-4412-b213-b73555e037f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_07134fec-a1d1-4335-be2e-e6aae66cfbac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_f154daee-0592-426e-8b81-68f7bc95519a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_07134fec-a1d1-4335-be2e-e6aae66cfbac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_EffectiveIncomeTaxRateReconciliationCARESActNetOperatingLossCarryforwardsPercent_38b2806c-9357-47c5-be52-bb2d40f8eee4" xlink:href="apyx-20201231.xsd#apyx_EffectiveIncomeTaxRateReconciliationCARESActNetOperatingLossCarryforwardsPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_f154daee-0592-426e-8b81-68f7bc95519a" xlink:to="loc_apyx_EffectiveIncomeTaxRateReconciliationCARESActNetOperatingLossCarryforwardsPercent_38b2806c-9357-47c5-be52-bb2d40f8eee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_b10ce736-2143-4aea-948a-5e4c05f462e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_f154daee-0592-426e-8b81-68f7bc95519a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_b10ce736-2143-4aea-948a-5e4c05f462e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_4fab4e23-5fde-495d-bc0b-9b97e860d464" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_f154daee-0592-426e-8b81-68f7bc95519a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_4fab4e23-5fde-495d-bc0b-9b97e860d464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#INCOMETAXESDeferredTaxAssetsLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0d412f91-47c3-4bc4-805c-f2183f50da3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_ae67adc9-7ee5-4215-8166-47509e413cbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0d412f91-47c3-4bc4-805c-f2183f50da3d" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_ae67adc9-7ee5-4215-8166-47509e413cbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_7209c404-b890-4c33-92d5-51fe514756ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_ae67adc9-7ee5-4215-8166-47509e413cbc" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_7209c404-b890-4c33-92d5-51fe514756ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_e30fac5d-ce6a-43a9-ac96-b3cadf15b8ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_ae67adc9-7ee5-4215-8166-47509e413cbc" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_e30fac5d-ce6a-43a9-ac96-b3cadf15b8ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_ffe18621-911a-4162-abeb-f8d633f9db7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_ae67adc9-7ee5-4215-8166-47509e413cbc" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_ffe18621-911a-4162-abeb-f8d633f9db7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_e3099f49-b41c-4bcc-b9ae-3f3266cdcfcf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_ae67adc9-7ee5-4215-8166-47509e413cbc" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_e3099f49-b41c-4bcc-b9ae-3f3266cdcfcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_12f80384-18b1-435d-8c85-2a47d970d91a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_ae67adc9-7ee5-4215-8166-47509e413cbc" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_12f80384-18b1-435d-8c85-2a47d970d91a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_5c401e75-34f8-4f32-9e07-f6ea98a38028" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_ae67adc9-7ee5-4215-8166-47509e413cbc" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_5c401e75-34f8-4f32-9e07-f6ea98a38028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_b8d3ef3b-314c-4e36-bde9-de1fc9dd875e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0d412f91-47c3-4bc4-805c-f2183f50da3d" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_b8d3ef3b-314c-4e36-bde9-de1fc9dd875e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_8b50637e-d490-4eff-b008-a35fcb384132" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_b8d3ef3b-314c-4e36-bde9-de1fc9dd875e" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_8b50637e-d490-4eff-b008-a35fcb384132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_d1300d3c-6a60-4d56-b992-1520aa35e86a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_b8d3ef3b-314c-4e36-bde9-de1fc9dd875e" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_d1300d3c-6a60-4d56-b992-1520aa35e86a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_90e8ab2f-bfe5-4b49-a972-b180770e5a92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_b8d3ef3b-314c-4e36-bde9-de1fc9dd875e" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_90e8ab2f-bfe5-4b49-a972-b180770e5a92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_3929a0f8-d703-434c-b49b-3c0af5320f92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0d412f91-47c3-4bc4-805c-f2183f50da3d" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_3929a0f8-d703-434c-b49b-3c0af5320f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INCOMETAXESNarrativeDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#INCOMETAXESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/INCOMETAXESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_5ea8af97-d0c9-4fba-98f8-37219b5fc58e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards_6505d08e-d0ab-40ce-abf0-b1a47e9d6022" xlink:href="apyx-20201231.xsd#apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5ea8af97-d0c9-4fba-98f8-37219b5fc58e" xlink:to="loc_apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards_6505d08e-d0ab-40ce-abf0-b1a47e9d6022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_CARESActEffectiveIncomeTaxRateReconciliationFederalNetOperatingLossCarryforwardsAmount_a78d9e96-3135-4d85-831f-7c74e620db10" xlink:href="apyx-20201231.xsd#apyx_CARESActEffectiveIncomeTaxRateReconciliationFederalNetOperatingLossCarryforwardsAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5ea8af97-d0c9-4fba-98f8-37219b5fc58e" xlink:to="loc_apyx_CARESActEffectiveIncomeTaxRateReconciliationFederalNetOperatingLossCarryforwardsAmount_a78d9e96-3135-4d85-831f-7c74e620db10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_a0f35089-f80e-4b10-aafb-2ab1ea14c854" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5ea8af97-d0c9-4fba-98f8-37219b5fc58e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_a0f35089-f80e-4b10-aafb-2ab1ea14c854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_cc7f6f2c-13ab-4ab0-a8fe-a9f4482dfbbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5ea8af97-d0c9-4fba-98f8-37219b5fc58e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_cc7f6f2c-13ab-4ab0-a8fe-a9f4482dfbbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INCOMETAXESUnrecognizedTaxBenefitsRollForwardDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#INCOMETAXESUnrecognizedTaxBenefitsRollForwardDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/INCOMETAXESUnrecognizedTaxBenefitsRollForwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b6e61a6e-67ab-40c4-b49a-514d9a4a304a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_a90eb576-5a28-453e-8755-cea101313a2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b6e61a6e-67ab-40c4-b49a-514d9a4a304a" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_a90eb576-5a28-453e-8755-cea101313a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_ba7e062f-80b4-4429-b23e-4546a502c307" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_a90eb576-5a28-453e-8755-cea101313a2d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_ba7e062f-80b4-4429-b23e-4546a502c307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_4e83810b-43e2-4535-b5f1-7e19b7f0c856" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_a90eb576-5a28-453e-8755-cea101313a2d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_4e83810b-43e2-4535-b5f1-7e19b7f0c856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_ded716b6-4ea6-4ebd-84af-cea9fab5847e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_a90eb576-5a28-453e-8755-cea101313a2d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_ded716b6-4ea6-4ebd-84af-cea9fab5847e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_1ed37a05-0419-4f21-a3b9-d4cde55fa380" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_a90eb576-5a28-453e-8755-cea101313a2d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_1ed37a05-0419-4f21-a3b9-d4cde55fa380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_288accdb-5737-468d-bcf0-d698f048ab2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_a90eb576-5a28-453e-8755-cea101313a2d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_288accdb-5737-468d-bcf0-d698f048ab2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/RETIREMENTPLAN" xlink:type="simple" xlink:href="apyx-20201231.xsd#RETIREMENTPLAN"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/RETIREMENTPLAN" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_6a0a235a-72e8-4afb-8941-f5adb870be89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_63cc2fb6-8b70-4e58-b4a2-12f60b00ffdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_6a0a235a-72e8-4afb-8941-f5adb870be89" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_63cc2fb6-8b70-4e58-b4a2-12f60b00ffdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/RETIREMENTPLANNarrativeDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#RETIREMENTPLANNarrativeDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/RETIREMENTPLANNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_bb0caa33-2c48-4d72-9c3f-6739497bfc7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DefinedContributionPlanEmployersMatchingContributionVestingPeriod_c6c633ba-e4f8-4293-8485-33bcab135d6a" xlink:href="apyx-20201231.xsd#apyx_DefinedContributionPlanEmployersMatchingContributionVestingPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_bb0caa33-2c48-4d72-9c3f-6739497bfc7c" xlink:to="loc_apyx_DefinedContributionPlanEmployersMatchingContributionVestingPeriod_c6c633ba-e4f8-4293-8485-33bcab135d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DefinedContributionPlanEmployersMatchingContributionVestingPercentageAfterThreeYears_4689df2f-5049-4d81-9c61-59af60f46860" xlink:href="apyx-20201231.xsd#apyx_DefinedContributionPlanEmployersMatchingContributionVestingPercentageAfterThreeYears"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_bb0caa33-2c48-4d72-9c3f-6739497bfc7c" xlink:to="loc_apyx_DefinedContributionPlanEmployersMatchingContributionVestingPercentageAfterThreeYears_4689df2f-5049-4d81-9c61-59af60f46860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_0f9c3295-0df6-4128-bb25-4aff656f7722" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_bb0caa33-2c48-4d72-9c3f-6739497bfc7c" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_0f9c3295-0df6-4128-bb25-4aff656f7722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_5907b3a7-fca4-459d-8f31-2a2c30cc21d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_bb0caa33-2c48-4d72-9c3f-6739497bfc7c" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_5907b3a7-fca4-459d-8f31-2a2c30cc21d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_60b1cbbb-997d-4065-87c0-281693512864" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_bb0caa33-2c48-4d72-9c3f-6739497bfc7c" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_60b1cbbb-997d-4065-87c0-281693512864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="simple" xlink:href="apyx-20201231.xsd#RELATEDPARTYTRANSACTIONS"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_069c25c3-0568-4a6a-9f14-5024debb5cfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_a530a4bc-5776-490e-a1c6-87c1441c184c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_069c25c3-0568-4a6a-9f14-5024debb5cfc" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_a530a4bc-5776-490e-a1c6-87c1441c184c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#RELATEDPARTYTRANSACTIONSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_23c88a40-b609-48b8-8df2-82480d68b853" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_54574c64-7804-4a16-b43a-9b0e8f6b74c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_23c88a40-b609-48b8-8df2-82480d68b853" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_54574c64-7804-4a16-b43a-9b0e8f6b74c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_869dd833-6b97-4943-9d1b-625866859297" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_54574c64-7804-4a16-b43a-9b0e8f6b74c0" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_869dd833-6b97-4943-9d1b-625866859297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_abe526e2-ec35-4896-b873-695838ef607a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_869dd833-6b97-4943-9d1b-625866859297" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_abe526e2-ec35-4896-b873-695838ef607a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CoVenturerMember_ebae31e4-1603-4eac-9e68-383dd98b7ce8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CoVenturerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_abe526e2-ec35-4896-b873-695838ef607a" xlink:to="loc_us-gaap_CoVenturerMember_ebae31e4-1603-4eac-9e68-383dd98b7ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_0a3c1263-1f92-4f63-b11d-03de8adcd48f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_54574c64-7804-4a16-b43a-9b0e8f6b74c0" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_0a3c1263-1f92-4f63-b11d-03de8adcd48f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesNoncurrent_39d0645c-9354-4c4a-bab4-29935833516c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableRelatedPartiesNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0a3c1263-1f92-4f63-b11d-03de8adcd48f" xlink:to="loc_us-gaap_NotesPayableRelatedPartiesNoncurrent_39d0645c-9354-4c4a-bab4-29935833516c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_4617ad08-4b49-46a4-8f69-5142c7009207" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0a3c1263-1f92-4f63-b11d-03de8adcd48f" xlink:to="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_4617ad08-4b49-46a4-8f69-5142c7009207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_6e82e9a8-3461-4c81-b424-def53d87f08b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0a3c1263-1f92-4f63-b11d-03de8adcd48f" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_6e82e9a8-3461-4c81-b424-def53d87f08b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="apyx-20201231.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_860c7a24-2f0a-4d5e-af00-a4d49c8b6cb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a6deb625-2141-49b2-9413-c485fefdb5d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_860c7a24-2f0a-4d5e-af00-a4d49c8b6cb0" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a6deb625-2141-49b2-9413-c485fefdb5d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_06d645f2-14d2-4763-9925-90bea94063a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_3ac973c8-6053-4770-b0d1-7c6f094e07af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_06d645f2-14d2-4763-9925-90bea94063a5" xlink:to="loc_us-gaap_OtherCommitmentsTable_3ac973c8-6053-4770-b0d1-7c6f094e07af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_a629dd50-49b4-475b-9d1f-9276773ca2b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_3ac973c8-6053-4770-b0d1-7c6f094e07af" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_a629dd50-49b4-475b-9d1f-9276773ca2b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_4d4a85b6-f393-439f-a229-523b53ed0f8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_a629dd50-49b4-475b-9d1f-9276773ca2b2" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_4d4a85b6-f393-439f-a229-523b53ed0f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember_3dd1a0df-5900-4dbb-ab6e-b10b28278262" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_4d4a85b6-f393-439f-a229-523b53ed0f8b" xlink:to="loc_us-gaap_CorporateJointVentureMember_3dd1a0df-5900-4dbb-ab6e-b10b28278262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_c449edff-3af3-451e-b9b2-d1258f063e70" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_3ac973c8-6053-4770-b0d1-7c6f094e07af" xlink:to="loc_srt_MajorCustomersAxis_c449edff-3af3-451e-b9b2-d1258f063e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_78dec2e4-f84b-4d64-aea8-fb0dbda8a81c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_c449edff-3af3-451e-b9b2-d1258f063e70" xlink:to="loc_srt_NameOfMajorCustomerDomain_78dec2e4-f84b-4d64-aea8-fb0dbda8a81c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_LargestCustomerMember_27473be8-7133-47a9-81e2-2fb6a10a806e" xlink:href="apyx-20201231.xsd#apyx_LargestCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_78dec2e4-f84b-4d64-aea8-fb0dbda8a81c" xlink:to="loc_apyx_LargestCustomerMember_27473be8-7133-47a9-81e2-2fb6a10a806e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_151e42fb-215a-4e48-97f3-9651d765b410" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_3ac973c8-6053-4770-b0d1-7c6f094e07af" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_151e42fb-215a-4e48-97f3-9651d765b410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b222d16d-967e-4fdb-83f0-a27700420509" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_151e42fb-215a-4e48-97f3-9651d765b410" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b222d16d-967e-4fdb-83f0-a27700420509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_5dde907a-45da-4ea7-a49a-f6007d32f7f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b222d16d-967e-4fdb-83f0-a27700420509" xlink:to="loc_us-gaap_SalesRevenueNetMember_5dde907a-45da-4ea7-a49a-f6007d32f7f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_14571b5c-791d-46a3-823e-45c6f47d59a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_3ac973c8-6053-4770-b0d1-7c6f094e07af" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_14571b5c-791d-46a3-823e-45c6f47d59a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_284f85b7-be15-40b3-bd2a-91d9c3092048" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_14571b5c-791d-46a3-823e-45c6f47d59a7" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_284f85b7-be15-40b3-bd2a-91d9c3092048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_53f9597f-5f95-41db-a10a-5b694aff47a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_284f85b7-be15-40b3-bd2a-91d9c3092048" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_53f9597f-5f95-41db-a10a-5b694aff47a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_896052f6-a0dc-47c5-8956-a3e5c21422f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_3ac973c8-6053-4770-b0d1-7c6f094e07af" xlink:to="loc_us-gaap_LitigationStatusAxis_896052f6-a0dc-47c5-8956-a3e5c21422f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_6b65df89-ebcb-4c2e-85a4-782e94b61eec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_896052f6-a0dc-47c5-8956-a3e5c21422f5" xlink:to="loc_us-gaap_LitigationStatusDomain_6b65df89-ebcb-4c2e-85a4-782e94b61eec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_45cc7125-ae26-43ce-978c-8a2005c5f50b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_6b65df89-ebcb-4c2e-85a4-782e94b61eec" xlink:to="loc_us-gaap_PendingLitigationMember_45cc7125-ae26-43ce-978c-8a2005c5f50b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_ace4890d-c34a-46a0-8e9f-aaeaf3fe8f48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_3ac973c8-6053-4770-b0d1-7c6f094e07af" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_ace4890d-c34a-46a0-8e9f-aaeaf3fe8f48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_LossContingencyAccrualTotalAccruedToDate_f4147eea-9b77-4aa9-8a84-c5ec7e83033d" xlink:href="apyx-20201231.xsd#apyx_LossContingencyAccrualTotalAccruedToDate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_ace4890d-c34a-46a0-8e9f-aaeaf3fe8f48" xlink:to="loc_apyx_LossContingencyAccrualTotalAccruedToDate_f4147eea-9b77-4aa9-8a84-c5ec7e83033d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_e0870cae-36f6-4e63-a43e-6985d75461e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_ace4890d-c34a-46a0-8e9f-aaeaf3fe8f48" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_e0870cae-36f6-4e63-a43e-6985d75461e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_6af1efb2-5178-4514-a5a5-7bc33ee06a86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_ace4890d-c34a-46a0-8e9f-aaeaf3fe8f48" xlink:to="loc_us-gaap_PurchaseObligation_6af1efb2-5178-4514-a5a5-7bc33ee06a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_NoncontrollingInterestRequiredCapitalContribution_0cdf488a-b47e-49eb-a8db-e0897f1ad714" xlink:href="apyx-20201231.xsd#apyx_NoncontrollingInterestRequiredCapitalContribution"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_ace4890d-c34a-46a0-8e9f-aaeaf3fe8f48" xlink:to="loc_apyx_NoncontrollingInterestRequiredCapitalContribution_0cdf488a-b47e-49eb-a8db-e0897f1ad714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_PaymentsToAcquireInterestInJointVentureRemaining_0aeed514-22c3-4174-89a3-3848333a4328" xlink:href="apyx-20201231.xsd#apyx_PaymentsToAcquireInterestInJointVentureRemaining"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_ace4890d-c34a-46a0-8e9f-aaeaf3fe8f48" xlink:to="loc_apyx_PaymentsToAcquireInterestInJointVentureRemaining_0aeed514-22c3-4174-89a3-3848333a4328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_aefebdea-306b-42d8-addd-9636d5ac9538" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_ace4890d-c34a-46a0-8e9f-aaeaf3fe8f48" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_aefebdea-306b-42d8-addd-9636d5ac9538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/STOCKOPTIONS" xlink:type="simple" xlink:href="apyx-20201231.xsd#STOCKOPTIONS"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/STOCKOPTIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7e1feb96-8d5e-4fb6-b450-15d6e2f0973a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9740fb1b-dd1d-453e-ad7c-203019aed262" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7e1feb96-8d5e-4fb6-b450-15d6e2f0973a" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9740fb1b-dd1d-453e-ad7c-203019aed262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/STOCKOPTIONSTables" xlink:type="simple" xlink:href="apyx-20201231.xsd#STOCKOPTIONSTables"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/STOCKOPTIONSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e3b26c7e-55b9-4a82-92bf-f6c7e8035b83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8f8b4b07-41c3-46d7-b2cf-9232baded4dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e3b26c7e-55b9-4a82-92bf-f6c7e8035b83" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8f8b4b07-41c3-46d7-b2cf-9232baded4dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_b5f108c4-4f62-4f59-afc0-e9d2bafb0d76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e3b26c7e-55b9-4a82-92bf-f6c7e8035b83" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_b5f108c4-4f62-4f59-afc0-e9d2bafb0d76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_34120f58-0736-40b9-9e77-b244d969bc39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e3b26c7e-55b9-4a82-92bf-f6c7e8035b83" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_34120f58-0736-40b9-9e77-b244d969bc39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#STOCKOPTIONSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_622b71b3-3f37-49ea-a571-ecfc0464caca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_850ae2c5-da0c-427a-8c3d-47ae07aa6b65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_622b71b3-3f37-49ea-a571-ecfc0464caca" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_850ae2c5-da0c-427a-8c3d-47ae07aa6b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_cfbf98e2-0c10-44ed-b620-d48525686520" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_850ae2c5-da0c-427a-8c3d-47ae07aa6b65" xlink:to="loc_us-gaap_PlanNameAxis_cfbf98e2-0c10-44ed-b620-d48525686520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_dc32cf63-f72b-40f7-b822-a29447ddd78c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_cfbf98e2-0c10-44ed-b620-d48525686520" xlink:to="loc_us-gaap_PlanNameDomain_dc32cf63-f72b-40f7-b822-a29447ddd78c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_A2001ExecutiveandEmployeeStockOptionPlanMember_a23310d8-f41b-49e1-b82c-fa6dae19b87d" xlink:href="apyx-20201231.xsd#apyx_A2001ExecutiveandEmployeeStockOptionPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_dc32cf63-f72b-40f7-b822-a29447ddd78c" xlink:to="loc_apyx_A2001ExecutiveandEmployeeStockOptionPlanMember_a23310d8-f41b-49e1-b82c-fa6dae19b87d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_A2003ExecutiveandEmployeeStockOptionPlanMember_d8258206-0121-414b-9932-30295351d31f" xlink:href="apyx-20201231.xsd#apyx_A2003ExecutiveandEmployeeStockOptionPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_dc32cf63-f72b-40f7-b822-a29447ddd78c" xlink:to="loc_apyx_A2003ExecutiveandEmployeeStockOptionPlanMember_d8258206-0121-414b-9932-30295351d31f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_TwoThousandTwelveShareIncentivePlanMember_9563afa9-1400-46c3-bd47-c3ceb5075aac" xlink:href="apyx-20201231.xsd#apyx_TwoThousandTwelveShareIncentivePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_dc32cf63-f72b-40f7-b822-a29447ddd78c" xlink:to="loc_apyx_TwoThousandTwelveShareIncentivePlanMember_9563afa9-1400-46c3-bd47-c3ceb5075aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_TwoThousandFifteenExecutiveAndEmployeeStockOptionPlanMember_aa1f669e-a049-43ff-ae5d-257e521cc152" xlink:href="apyx-20201231.xsd#apyx_TwoThousandFifteenExecutiveAndEmployeeStockOptionPlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_dc32cf63-f72b-40f7-b822-a29447ddd78c" xlink:to="loc_apyx_TwoThousandFifteenExecutiveAndEmployeeStockOptionPlanMember_aa1f669e-a049-43ff-ae5d-257e521cc152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_A2017ExecutiveandEmployeeStockOptionPlanMember_7b265885-82ae-43c5-b27d-4f1c4b72e19f" xlink:href="apyx-20201231.xsd#apyx_A2017ExecutiveandEmployeeStockOptionPlanMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_dc32cf63-f72b-40f7-b822-a29447ddd78c" xlink:to="loc_apyx_A2017ExecutiveandEmployeeStockOptionPlanMember_7b265885-82ae-43c5-b27d-4f1c4b72e19f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_A2019ShareIncentivePlanMember_9db586d4-ecaf-4361-88bd-0619a8e1c621" xlink:href="apyx-20201231.xsd#apyx_A2019ShareIncentivePlanMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_dc32cf63-f72b-40f7-b822-a29447ddd78c" xlink:to="loc_apyx_A2019ShareIncentivePlanMember_9db586d4-ecaf-4361-88bd-0619a8e1c621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_99b86729-ec38-4521-99fd-6d31f816756c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_850ae2c5-da0c-427a-8c3d-47ae07aa6b65" xlink:to="loc_us-gaap_AwardTypeAxis_99b86729-ec38-4521-99fd-6d31f816756c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7bcccd1b-c0e3-4ddf-84b5-402e9a4b00a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_99b86729-ec38-4521-99fd-6d31f816756c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7bcccd1b-c0e3-4ddf-84b5-402e9a4b00a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_c65d037a-d975-4797-b588-a0e0b5d51dc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7bcccd1b-c0e3-4ddf-84b5-402e9a4b00a7" xlink:to="loc_us-gaap_RestrictedStockMember_c65d037a-d975-4797-b588-a0e0b5d51dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f714f038-2a90-4b21-ba65-f7cd296348d7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_850ae2c5-da0c-427a-8c3d-47ae07aa6b65" xlink:to="loc_srt_RangeAxis_f714f038-2a90-4b21-ba65-f7cd296348d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d9a0f2fd-25b1-4830-8dc9-6285cc18ef11" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f714f038-2a90-4b21-ba65-f7cd296348d7" xlink:to="loc_srt_RangeMember_d9a0f2fd-25b1-4830-8dc9-6285cc18ef11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0f4c8e64-0fe7-404b-8632-3f1e6e9d6360" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d9a0f2fd-25b1-4830-8dc9-6285cc18ef11" xlink:to="loc_srt_MinimumMember_0f4c8e64-0fe7-404b-8632-3f1e6e9d6360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_05bba58f-9dfd-4be1-9105-1c35621e44bf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d9a0f2fd-25b1-4830-8dc9-6285cc18ef11" xlink:to="loc_srt_MaximumMember_05bba58f-9dfd-4be1-9105-1c35621e44bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630ce5ec-e193-4e5a-9d29-18024529b22d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_850ae2c5-da0c-427a-8c3d-47ae07aa6b65" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630ce5ec-e193-4e5a-9d29-18024529b22d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_165a37b6-0b58-420c-a25a-13d469d7204b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630ce5ec-e193-4e5a-9d29-18024529b22d" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_165a37b6-0b58-420c-a25a-13d469d7204b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_d8d33522-b377-45cc-8b2e-914763510196" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630ce5ec-e193-4e5a-9d29-18024529b22d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_d8d33522-b377-45cc-8b2e-914763510196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_443c51b3-b73e-44c4-9578-563fbe317b39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630ce5ec-e193-4e5a-9d29-18024529b22d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_443c51b3-b73e-44c4-9578-563fbe317b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1af94df5-3bb3-49bc-b4d5-e0299f3d7656" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630ce5ec-e193-4e5a-9d29-18024529b22d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1af94df5-3bb3-49bc-b4d5-e0299f3d7656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b1487552-0d37-4711-91d8-d0082081581f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630ce5ec-e193-4e5a-9d29-18024529b22d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b1487552-0d37-4711-91d8-d0082081581f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_31c195b2-57a1-4513-a941-9605f46b8d5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630ce5ec-e193-4e5a-9d29-18024529b22d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_31c195b2-57a1-4513-a941-9605f46b8d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueClosingStockPrice_7433e856-397e-4498-8446-554d5d53b810" xlink:href="apyx-20201231.xsd#apyx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueClosingStockPrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630ce5ec-e193-4e5a-9d29-18024529b22d" xlink:to="loc_apyx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueClosingStockPrice_7433e856-397e-4498-8446-554d5d53b810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_57529e85-76fa-41fe-a14e-cb767a101c3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630ce5ec-e193-4e5a-9d29-18024529b22d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_57529e85-76fa-41fe-a14e-cb767a101c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_7fc8c298-7e08-464a-8f31-8c1eb428ca06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630ce5ec-e193-4e5a-9d29-18024529b22d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_7fc8c298-7e08-464a-8f31-8c1eb428ca06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_a430bf01-3cb7-40d5-8f50-5841796c04b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630ce5ec-e193-4e5a-9d29-18024529b22d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_a430bf01-3cb7-40d5-8f50-5841796c04b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_0a959447-37f7-46e7-9c42-80501f14ac57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630ce5ec-e193-4e5a-9d29-18024529b22d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_0a959447-37f7-46e7-9c42-80501f14ac57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_709ad281-5527-4719-a8d1-75a93af7a379" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630ce5ec-e193-4e5a-9d29-18024529b22d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_709ad281-5527-4719-a8d1-75a93af7a379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_b88e796b-7851-49d6-9b79-55634b998740" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630ce5ec-e193-4e5a-9d29-18024529b22d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_b88e796b-7851-49d6-9b79-55634b998740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_8f4f6625-ccaa-41f2-8a65-3e14963a0575" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630ce5ec-e193-4e5a-9d29-18024529b22d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_8f4f6625-ccaa-41f2-8a65-3e14963a0575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_c15fbe75-19ec-4875-9e52-488717bc4db7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630ce5ec-e193-4e5a-9d29-18024529b22d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_c15fbe75-19ec-4875-9e52-488717bc4db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_bbec4766-5d08-4c1a-8623-d39588a36ce4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630ce5ec-e193-4e5a-9d29-18024529b22d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_bbec4766-5d08-4c1a-8623-d39588a36ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue_4d179fbd-a4c8-4794-8806-ccdca921e163" xlink:href="apyx-20201231.xsd#apyx_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630ce5ec-e193-4e5a-9d29-18024529b22d" xlink:to="loc_apyx_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue_4d179fbd-a4c8-4794-8806-ccdca921e163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fd5ff121-0daa-4ad5-8fde-c56d2f13f0b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630ce5ec-e193-4e5a-9d29-18024529b22d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fd5ff121-0daa-4ad5-8fde-c56d2f13f0b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_7c4d8488-156b-45a3-a469-b2599c1e16ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630ce5ec-e193-4e5a-9d29-18024529b22d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_7c4d8488-156b-45a3-a469-b2599c1e16ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived_cfad74c8-696d-4005-bffe-a58e0d807c88" xlink:href="apyx-20201231.xsd#apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630ce5ec-e193-4e5a-9d29-18024529b22d" xlink:to="loc_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived_cfad74c8-696d-4005-bffe-a58e0d807c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_StockIssuedDuringPeriodSharesStockSwaps_74fc99aa-28a4-4287-b007-32ce79788d74" xlink:href="apyx-20201231.xsd#apyx_StockIssuedDuringPeriodSharesStockSwaps"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630ce5ec-e193-4e5a-9d29-18024529b22d" xlink:to="loc_apyx_StockIssuedDuringPeriodSharesStockSwaps_74fc99aa-28a4-4287-b007-32ce79788d74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_e82f30e1-d557-4e9d-a496-05b9f7219527" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630ce5ec-e193-4e5a-9d29-18024529b22d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_e82f30e1-d557-4e9d-a496-05b9f7219527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e04f9ade-52a1-4b41-9759-15f4e54c5690" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630ce5ec-e193-4e5a-9d29-18024529b22d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e04f9ade-52a1-4b41-9759-15f4e54c5690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedToDate_95dff702-b697-4965-a21d-2833870d5901" xlink:href="apyx-20201231.xsd#apyx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedToDate"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630ce5ec-e193-4e5a-9d29-18024529b22d" xlink:to="loc_apyx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedToDate_95dff702-b697-4965-a21d-2833870d5901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/STOCKOPTIONSSummaryofStockOptionsDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#STOCKOPTIONSSummaryofStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/STOCKOPTIONSSummaryofStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e70b56b8-bcfb-42d0-ab12-37754f2c2d9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_aae21a63-550f-44f1-b87a-0e0b2236f506" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e70b56b8-bcfb-42d0-ab12-37754f2c2d9e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_aae21a63-550f-44f1-b87a-0e0b2236f506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_25426e85-ac5d-4969-a67b-f488ef1fdc7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_aae21a63-550f-44f1-b87a-0e0b2236f506" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_25426e85-ac5d-4969-a67b-f488ef1fdc7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4d36162e-06e0-4781-8a5c-ef419356ab8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_aae21a63-550f-44f1-b87a-0e0b2236f506" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4d36162e-06e0-4781-8a5c-ef419356ab8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b8fe20ed-cfa1-44f7-b056-7ff01fbb6bdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_aae21a63-550f-44f1-b87a-0e0b2236f506" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b8fe20ed-cfa1-44f7-b056-7ff01fbb6bdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_602c7cad-3b8e-4b73-9625-df2276f31424" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_aae21a63-550f-44f1-b87a-0e0b2236f506" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_602c7cad-3b8e-4b73-9625-df2276f31424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_065a9b4b-c348-4944-a98e-8dc83637deed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_aae21a63-550f-44f1-b87a-0e0b2236f506" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_065a9b4b-c348-4944-a98e-8dc83637deed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0eb5167f-9505-475c-9f34-f8fe118b637a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e70b56b8-bcfb-42d0-ab12-37754f2c2d9e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0eb5167f-9505-475c-9f34-f8fe118b637a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5119aaea-3ef9-4ddb-8ffc-b297ffe81870" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0eb5167f-9505-475c-9f34-f8fe118b637a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5119aaea-3ef9-4ddb-8ffc-b297ffe81870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1bd37ce6-d76a-49c0-a633-7a335456d67e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0eb5167f-9505-475c-9f34-f8fe118b637a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1bd37ce6-d76a-49c0-a633-7a335456d67e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_e49f0d8f-cd8d-4fe2-ba5d-5bcea8bc668d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0eb5167f-9505-475c-9f34-f8fe118b637a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_e49f0d8f-cd8d-4fe2-ba5d-5bcea8bc668d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_92f4e697-81b4-4975-87e1-d083eb22ab27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0eb5167f-9505-475c-9f34-f8fe118b637a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_92f4e697-81b4-4975-87e1-d083eb22ab27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_21f99495-e69e-4c28-b96d-2472d5b2840e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0eb5167f-9505-475c-9f34-f8fe118b637a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_21f99495-e69e-4c28-b96d-2472d5b2840e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/STOCKOPTIONSSummaryofNonvestedStockOptionsDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#STOCKOPTIONSSummaryofNonvestedStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/STOCKOPTIONSSummaryofNonvestedStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6bbe51aa-ed6d-45e1-b266-6cfd3014e6bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_ed0989b7-faef-48e2-af58-abb65b5bf3e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6bbe51aa-ed6d-45e1-b266-6cfd3014e6bf" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_ed0989b7-faef-48e2-af58-abb65b5bf3e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_ac9453be-b888-4b90-9ba3-7f50db7944a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_ed0989b7-faef-48e2-af58-abb65b5bf3e0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_ac9453be-b888-4b90-9ba3-7f50db7944a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6e93e647-1766-4c42-851d-98d715ed1ca7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_ed0989b7-faef-48e2-af58-abb65b5bf3e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6e93e647-1766-4c42-851d-98d715ed1ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_4b420b86-085b-449e-9ea9-d56d5c55f6dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_ed0989b7-faef-48e2-af58-abb65b5bf3e0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_4b420b86-085b-449e-9ea9-d56d5c55f6dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_884b7686-dedb-4295-9247-e193b1f88fbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_ed0989b7-faef-48e2-af58-abb65b5bf3e0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_884b7686-dedb-4295-9247-e193b1f88fbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_de301765-f670-4b0f-8125-4a94ced1c5c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_ed0989b7-faef-48e2-af58-abb65b5bf3e0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_de301765-f670-4b0f-8125-4a94ced1c5c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_9d60e30c-e158-40a4-a26d-51e8e255126e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6bbe51aa-ed6d-45e1-b266-6cfd3014e6bf" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_9d60e30c-e158-40a4-a26d-51e8e255126e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2e7e89ab-8e05-41e1-8826-c5c12fc918e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_9d60e30c-e158-40a4-a26d-51e8e255126e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2e7e89ab-8e05-41e1-8826-c5c12fc918e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a6c46f72-c0c3-44ad-a8e6-ab2f9c2757b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_9d60e30c-e158-40a4-a26d-51e8e255126e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a6c46f72-c0c3-44ad-a8e6-ab2f9c2757b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_bce07415-1e4e-4ce8-bdc5-7186e98c452b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_9d60e30c-e158-40a4-a26d-51e8e255126e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_bce07415-1e4e-4ce8-bdc5-7186e98c452b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_49863892-df10-4b1b-b0b4-ea28885e5c45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_9d60e30c-e158-40a4-a26d-51e8e255126e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_49863892-df10-4b1b-b0b4-ea28885e5c45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_0d2a6408-7047-48b6-9408-bce33d6267b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_9d60e30c-e158-40a4-a26d-51e8e255126e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_0d2a6408-7047-48b6-9408-bce33d6267b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/STOCKOPTIONSSTOCKOPTIONSFairValueAssumptionsDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#STOCKOPTIONSSTOCKOPTIONSFairValueAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/STOCKOPTIONSSTOCKOPTIONSFairValueAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2a48adaf-c1ae-4730-8cb9-888a5882b616" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bc70845b-5640-464f-a1b2-df2bba2841bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2a48adaf-c1ae-4730-8cb9-888a5882b616" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bc70845b-5640-464f-a1b2-df2bba2841bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_aed6dd10-b466-4ed4-bd8b-f271275ca464" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bc70845b-5640-464f-a1b2-df2bba2841bf" xlink:to="loc_srt_RangeAxis_aed6dd10-b466-4ed4-bd8b-f271275ca464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e6267868-0c08-4048-86c1-bc15aeebfdaa" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_aed6dd10-b466-4ed4-bd8b-f271275ca464" xlink:to="loc_srt_RangeMember_e6267868-0c08-4048-86c1-bc15aeebfdaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_303cf225-0104-43e7-8cc1-0848775b8c4c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e6267868-0c08-4048-86c1-bc15aeebfdaa" xlink:to="loc_srt_MinimumMember_303cf225-0104-43e7-8cc1-0848775b8c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b671a38e-81bf-4e15-9b26-5a609f007fa9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e6267868-0c08-4048-86c1-bc15aeebfdaa" xlink:to="loc_srt_MaximumMember_b671a38e-81bf-4e15-9b26-5a609f007fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c41af633-d47c-4d4d-8996-07612d772a1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bc70845b-5640-464f-a1b2-df2bba2841bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c41af633-d47c-4d4d-8996-07612d772a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_31aa8bf6-c8de-4525-a413-75f8aa092289" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c41af633-d47c-4d4d-8996-07612d772a1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_31aa8bf6-c8de-4525-a413-75f8aa092289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_cc0d9075-7672-408b-a09c-e7433c4475ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c41af633-d47c-4d4d-8996-07612d772a1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_cc0d9075-7672-408b-a09c-e7433c4475ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b89ceb14-b3c6-4728-8bbf-b17d6fe78f75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c41af633-d47c-4d4d-8996-07612d772a1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b89ceb14-b3c6-4728-8bbf-b17d6fe78f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_fde8d117-6773-456e-b549-7adf9178b654" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c41af633-d47c-4d4d-8996-07612d772a1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_fde8d117-6773-456e-b549-7adf9178b654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_b5c0ce8c-7fa3-4ff1-905c-400d5b8feed7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c41af633-d47c-4d4d-8996-07612d772a1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_b5c0ce8c-7fa3-4ff1-905c-400d5b8feed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9c1253d0-589e-43c5-b0a6-007cff4e162f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c41af633-d47c-4d4d-8996-07612d772a1e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9c1253d0-589e-43c5-b0a6-007cff4e162f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATION" xlink:type="simple" xlink:href="apyx-20201231.xsd#GEOGRAPHICANDSEGMENTINFORMATION"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_424436d4-ebf5-45f9-a9da-85982cc74af0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_f7bb79b7-fa56-484f-a237-5f2c9b1b9d01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_424436d4-ebf5-45f9-a9da-85982cc74af0" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_f7bb79b7-fa56-484f-a237-5f2c9b1b9d01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONTables" xlink:type="simple" xlink:href="apyx-20201231.xsd#GEOGRAPHICANDSEGMENTINFORMATIONTables"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_8c737e32-bf80-4c58-a6eb-01a2a4544ff0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_52c0a1e0-3ea4-4116-be49-f0c840faec23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_8c737e32-bf80-4c58-a6eb-01a2a4544ff0" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_52c0a1e0-3ea4-4116-be49-f0c840faec23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_028a6afa-f0d7-41d4-815e-68a0b66d3429" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_8c737e32-bf80-4c58-a6eb-01a2a4544ff0" xlink:to="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_028a6afa-f0d7-41d4-815e-68a0b66d3429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_4d1fa3f7-2aed-49f6-ac06-76a019aaf762" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_4718e044-2b09-4147-938e-41b5fdc19e5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_4d1fa3f7-2aed-49f6-ac06-76a019aaf762" xlink:to="loc_us-gaap_NumberOfOperatingSegments_4718e044-2b09-4147-938e-41b5fdc19e5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_TotalRevenuePercent_76e06002-8c26-441b-ad81-84f03042a9fa" xlink:href="apyx-20201231.xsd#apyx_TotalRevenuePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_4d1fa3f7-2aed-49f6-ac06-76a019aaf762" xlink:to="loc_apyx_TotalRevenuePercent_76e06002-8c26-441b-ad81-84f03042a9fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_c2c3eff1-eb2c-4063-8ec6-cb305408d410" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a992265b-bb00-47be-8d7b-6e938f2d52ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c2c3eff1-eb2c-4063-8ec6-cb305408d410" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a992265b-bb00-47be-8d7b-6e938f2d52ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_858b4b9b-1c1d-41c1-9aca-bca1066a56df" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a992265b-bb00-47be-8d7b-6e938f2d52ba" xlink:to="loc_srt_ConsolidationItemsAxis_858b4b9b-1c1d-41c1-9aca-bca1066a56df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_1f83c943-af50-4812-ac63-bbde7abcd4c3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_858b4b9b-1c1d-41c1-9aca-bca1066a56df" xlink:to="loc_srt_ConsolidationItemsDomain_1f83c943-af50-4812-ac63-bbde7abcd4c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_6a225c51-af57-4cbe-9d7e-1d55fc4ab48e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_1f83c943-af50-4812-ac63-bbde7abcd4c3" xlink:to="loc_us-gaap_OperatingSegmentsMember_6a225c51-af57-4cbe-9d7e-1d55fc4ab48e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_f9ba0a42-10ae-455b-ae51-89fe6bdd11b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_1f83c943-af50-4812-ac63-bbde7abcd4c3" xlink:to="loc_us-gaap_CorporateNonSegmentMember_f9ba0a42-10ae-455b-ae51-89fe6bdd11b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_61e4885d-ee53-4df1-877c-507d38c02a23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a992265b-bb00-47be-8d7b-6e938f2d52ba" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_61e4885d-ee53-4df1-877c-507d38c02a23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f97a607c-8125-4453-b10f-e657b7a8bf01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_61e4885d-ee53-4df1-877c-507d38c02a23" xlink:to="loc_us-gaap_SegmentDomain_f97a607c-8125-4453-b10f-e657b7a8bf01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AdvancedEnergyMember_b7ad31b1-2689-419b-805f-a9c2353be291" xlink:href="apyx-20201231.xsd#apyx_AdvancedEnergyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_f97a607c-8125-4453-b10f-e657b7a8bf01" xlink:to="loc_apyx_AdvancedEnergyMember_b7ad31b1-2689-419b-805f-a9c2353be291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_OEMMember_ba86684e-17e1-4f41-9af0-ce375c8379c1" xlink:href="apyx-20201231.xsd#apyx_OEMMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_f97a607c-8125-4453-b10f-e657b7a8bf01" xlink:to="loc_apyx_OEMMember_ba86684e-17e1-4f41-9af0-ce375c8379c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_3abf380f-ca25-4aa9-a507-695e0b483940" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a992265b-bb00-47be-8d7b-6e938f2d52ba" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_3abf380f-ca25-4aa9-a507-695e0b483940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4542b333-3f55-4008-9926-8746027a1800" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3abf380f-ca25-4aa9-a507-695e0b483940" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4542b333-3f55-4008-9926-8746027a1800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e0f00381-f572-4416-9642-14285f1799cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3abf380f-ca25-4aa9-a507-695e0b483940" xlink:to="loc_us-gaap_OperatingIncomeLoss_e0f00381-f572-4416-9642-14285f1799cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_b7637cdf-d5b6-404c-8ecb-9dc580c67774" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOperating"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3abf380f-ca25-4aa9-a507-695e0b483940" xlink:to="loc_us-gaap_InterestIncomeOperating_b7637cdf-d5b6-404c-8ecb-9dc580c67774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_0dd7c7e1-5d8b-4098-9dab-e7a857f40add" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3abf380f-ca25-4aa9-a507-695e0b483940" xlink:to="loc_us-gaap_InterestExpense_0dd7c7e1-5d8b-4098-9dab-e7a857f40add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_887d35f8-60ca-44d1-9e7e-362ad55b503f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3abf380f-ca25-4aa9-a507-695e0b483940" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_887d35f8-60ca-44d1-9e7e-362ad55b503f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a5d34af2-50f9-4402-8976-83eac6df7f49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3abf380f-ca25-4aa9-a507-695e0b483940" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a5d34af2-50f9-4402-8976-83eac6df7f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails" xlink:type="simple" xlink:href="apyx-20201231.xsd#GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_1f0889d8-af87-4554-8578-f142252dde14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_356d8964-48ce-4a1d-b1e4-e93d960ae413" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1f0889d8-af87-4554-8578-f142252dde14" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_356d8964-48ce-4a1d-b1e4-e93d960ae413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_4689a3c9-5d83-4768-b754-48d7abbde323" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_356d8964-48ce-4a1d-b1e4-e93d960ae413" xlink:to="loc_srt_StatementGeographicalAxis_4689a3c9-5d83-4768-b754-48d7abbde323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d9407b25-753e-445d-9d56-cd2d9a19c3d6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_4689a3c9-5d83-4768-b754-48d7abbde323" xlink:to="loc_srt_SegmentGeographicalDomain_d9407b25-753e-445d-9d56-cd2d9a19c3d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_00c8eb73-9f7b-462e-b50c-0280c1b51859" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_d9407b25-753e-445d-9d56-cd2d9a19c3d6" xlink:to="loc_country_US_00c8eb73-9f7b-462e-b50c-0280c1b51859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_e901086f-8e67-4287-9ed3-c75587a0ed3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_d9407b25-753e-445d-9d56-cd2d9a19c3d6" xlink:to="loc_us-gaap_NonUsMember_e901086f-8e67-4287-9ed3-c75587a0ed3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_99811c6f-4188-44ab-abb9-cdf2e8dac3e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_356d8964-48ce-4a1d-b1e4-e93d960ae413" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_99811c6f-4188-44ab-abb9-cdf2e8dac3e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_52dd18e7-fe91-43b2-a8c3-50414fa7a1ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_99811c6f-4188-44ab-abb9-cdf2e8dac3e9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_52dd18e7-fe91-43b2-a8c3-50414fa7a1ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>apyx-20201231_g1.jpg
<TEXT>
begin 644 apyx-20201231_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" *0 _(# 2(  A$! Q$!_\0
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MG[CPEF'UO ^PD_>IZ?+I_E\AE%%%?&'VX5]*?LA^.-LFI^%+F3 ;_3;3<>_
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MVX9RCZ]6^LUE^[A^+[?+=_<?#<49S]0H?5J+_>3_  7?U>R^;->BBBOV<_$
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JKJFI6^CZ;=7
M]W((K6UB::60_P *J"2?R%6J\(_:P\<?V+X1MO#UO)BZU5]TV#R($()_[Z;:
M/H&KS\PQD<#A9XB7V5^/1?>>EEV#EF&+IX:/VG]RZO[CY?\ &7B>X\9^*M3U
MNZXEO)FDVYSL7HJ_0* /PK&HHK^=:DY5)N<W=O5G])TX1IP5."LEHOD%%%%0
M6/AA>XF2*)#))(P5549)). !^-?H%\,/!L?@'P/I6C!5$\,6^X9?XIFY<Y[\
MG ]@*^6/V8_ _P#PE?Q"CU">/?8:,!=-NZ&7.(A]<@M_P"OM*OU;@_ <E.>-
MFM9:+T6_WO\ (_).-,PYZL,#!Z1]Y^KV^Y:_,****_1S\R"BBB@ KXM_:<\#
M?\(I\0I-0@CV6.L@W2X' ESB4?F0W_ Z^TJ\R_:$\#_\)M\-[WR8]]_IW^FV
M^.IV@[U_%<\>H%?-<08'Z]@)**]Z/O+Y;KYK\3ZCAS,/[/S"#D_=G[K^>S^3
MM\KGPY1117X.?T %%%% 'US^R?XX_MKPC<^'KB3-UI3[H<GDP.21_P!\MN'T
M*U[O7P+\&_&Y^'_Q"TS4W?99.WV:[]/)? )/^Z<-_P !%??"L& (.0>AK]MX
M7Q_UO JG)^]3T^73\-/D?A7%67_4\>ZL5[M37Y]?QU^8ZBBBOL#XP**** "B
MBB@ HHHH **** /DO]K[Q ;SQAI&CJV8K&T,S#_;D;G_ ,=1?SKP.O0_V@=2
M.I?&#Q')G*QRI /;9&JG]0:\\K^>\YK/$9A6F_YFONT7Y']'9+06'RVA37\J
M?S>K_%A1117C'M!7M7[-OPCC\;ZT^NZK")-%TZ0!8G&5N)^"%/JJ@@D=\J.0
M37C$,+W$J11J7D=@JJO4D\ 5^A?P^\(P^!?!NEZ)"%S;0@2LO\<IY=OQ8G\,
M5]CPQEL<=BG4JJ\*>OJ^B_7Y'Q?%6:2R_"*E2=IU-/1=7^GS.AZ<#@4M%%?M
MA^%A1110 4444 %%%% !1110 4444 %%%% '+_$3X?Z=\2/#-QI.H(%9ANM[
MD*"\$G9A_4=QD5\%>)O#M[X3UZ]TC48_*O+20QN.Q]&'J",$'T(K]':^:OVO
M/!*&'3/%5O'B0-]BNB/X@06C8_3##/NHKX+BK*XU\/\ 7*:]^&_FO^!^5S]"
MX1S66'Q/U*H_<GMY2_X/YV/F2BBBOQ\_9@HHHH _0'X2>)#XN^&^@:F[;YI+
M81RL>\B$HY_%E)_&NOKPS]D75C>?#V_LG.6L[]MOLCHK#_Q[?7N=?T1E6(>*
MP-&J]W%7]=G^)_-N;8=87'UJ*V4G;T>J_ Q_%WANW\7^&=3T:ZXAO8&B+8SM
M)'RL/<'!_"OSPU33;C1]2NK"[C,5U:RM#*A_A9201^8K])Z^/OVKO!/]A>-H
M-<MX]MKJ\>7(Z"=,!OS78?<[J^2XOP/M:$<7%:PT?H_\G^9]CP9C_98B>#F]
M)ZKU7^:_(\0HHHK\D/V$*T?#FN7/AG7M/U:T.+BSG2=/0E3G!]CT/UK.HJHR
M<)*479HF48SBXR5TS](=#UBV\1:+8ZI9MOM;R%)XSWVL 0#[C/-7Z\%_9+\;
M?VMX3O/#UQ)FXTN3S(0>\+DG ^C[O^^A7O5?T3EV,6.PE/$+[2U]>OXG\V9E
M@Y9?BZF&?V7IZ=/P"BBBO2/,"BBB@ HHHH **** "O/OCIXT_P"$'^&^IW44
MGEWUT/L=J1U\QP02/<*&;\*]!KY!_:P\:_VUXTMM!@?-MI,?[S!X,S@$_DNT
M>Q+5\]GV.^H8"<T_>EHO5_Y*[/H^'\!_:&84Z<E[L?>?HO\ -V1X;1117X&?
MT*%%%% 'JW[-?@O_ (2SXD6MS,A:RTD?;9#C@N#^[7_OKGZ*:^VJ\@_9B\%_
M\(O\.8K^:/;>ZPWVIB>OE=(A],9;_@=>OU^Z\-X'ZE@(\R]Z?O/Y[?@?@7$V
M/^O9C-1?NP]U?+?\?PL%%%%?4'R@4444 %%%% !1110!\J_M1_"7^RKT^,-*
M@Q9W+A=0CC7B.4G E]@W0_[7^]7SS7Z2ZIIEKK.G7-A>PK<6ES&T4L3=&4C!
M%?!WQ:^&]U\,?%T^FR;I;&3][9W##_61$]_]H=#],]"*_(.*,H^K5?KE%>Y+
M?R?^3_/U1^S<*9S]:I?4:[]^&WG'_-?EZ,XNBBBO@3]""MOP9XNO_ _B2RUG
M3GVW%N^2A/RR*?O(WL1Q^M8E%73J2I352#LUJB*E.-6#IS5T]&C]%/!OBZP\
M<>'++6=.?=;W*9VG[T;#AD;W!XK<KXJ_9Y^+7_"O?$G]GZA+C0=2<+,6/$$G
M19?IT#>W/;%?::L& (.0>AK][R7-(YIAE4^VM)+S[^C_ .!T/Y[SS*9Y3BG3
M^P]8OR[>J_X/4=116%XT\76'@7PU>ZUJ+[8+=,A ?FD<\*B^Y/'Z]!7MU*D:
M4'.;LEJSPJ=.=6:ITU=O1(\\_:*^+7_" ^'?[+TZ;;KVI(51E/-O%T:3V)Y"
M^^3_  U\7]:V?&'BR_\ &_B.]UG47WW-R^[:/NQKT5%]@, ?2L:OP3.LTEFF
M)=3["TBO+_-_\#H?T)DF50RG"JGO-ZR?GV]%T^_J%%%%>"?0!2JK2,%4%F8X
M  R2:2OH+]E_X2_VSJ"^+]4AS8VCXL8W'^MF'63Z+V_VO]VO1R_ U,QQ$</2
MZ[OLNK/-S''TLMPTL35V6R[OHCUKX ?"@?#GPN+F]B U[4%#W)/6%>JQ#Z=3
M[GV%>J445_0.%PM/!T8T*2M&/]?B?SKB\55QM>6(K.\I/^EZ(****ZSC"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &LP4$DX ZFO@?XR>
M-S\0/B%J>IH^^R1OLUIZ>2F0"/\ >.6_X$:^J?VBO'!\%_#F[2"39?ZF?L4&
M#@@,/G;\%R,]BPKX@K\MXPQ_-*&"@]O>?Z+]?FC]8X+R_EC/'36_NQ_5_DOD
MPHHHK\T/U ***[GX+>!_^$^^(6FZ?(F^QB;[5=^GE(02I_WCM7_@5;X>C/$U
M8T:>\G9'/B*\,-1G7J/W8IM_(^JOV>_ _P#PA/PWLO.CV7^H_P"FW&>HW ;%
M_!<<>I->FTG3@<"EK^C,+AX82A"A3VBK'\U8O$SQE>>(J;R=_P"O0****ZCD
M"BBB@ I.O!Y%+10!\$?&GP/_ ,(#\0M2T^--EC*WVJT]/*<DA1_NG<O_  &N
M&KZ^_:M\#?V]X,@UZWCW7>D/^\V]3 Y ;ZX;:?8;J^0:_ L]P/\ 9^.G3BO=
M>J]'_D]#^AL@S#^T<!"I)^\M'ZK_ #5F%%%%?/GT05]O_LZ^.#XT^'-HD\F^
M_P!,/V*?)R2%'R-^*X&>Y4U\05ZW^S/XX_X1/XB0V4S[;'6 +23)X$F<Q-]=
MV5_X&:^IX;QWU+'Q4G[L_=?SV?W_ (7/E.)LO^OY?)Q7O0]Y?+=?=^-C[5HH
MHK]T/P(**** "BBB@ HHHH **** /SY^*TQG^)OBQB #_:MRO'M*P_I7*UTW
MQ/\ ^2E>+?\ L+W?_HYZYFOYLQ;OB*C_ +S_ #/Z>PFF&IK^ZOR"BBBN4ZCL
M_@UIBZO\4_#%NXW+]M24@]]GS_\ LM??M?"/[/W_ "6+PU_UVD_]%/7W=7Z]
MP;%?4ZDNO-^B_P S\;XVD_KM*/11_5_Y!1117WY^=A1110 4444 %%%% !11
M10 4444 %%%% !7"_&_25UKX3^)H&&?+M&N1[&(B3_V2NZK ^($:S> _$B.,
MHVFW((]08FKDQD%4PU2#V<6OP.S!3=/$TIK=23_$_.ZBBBOYM/Z<"BBB@#Z8
M_8SN?^1LMR?^?611C_KJ#_2OIBOEW]C7_D)>*?\ KC;_ /H4E?45?NG#+;RJ
ME?\ O?\ I3/P/BE)9O6M_=_])05YW\>/!/\ PG'PWU*WBCWWUH/MMKZ[T!RH
M_P!Y2R_4BO1**^@Q-"&*HSH5-I)H^<PN(GA:\*]/>+3^X_,^BN[^-O@G_A _
MB-J=C%'LLIF^UVH[>4Y)P/93N7_@-<)7\YXBA/#594:F\6U]Q_2^'KPQ5&%>
MGM))KYA1117.=!W7P4\:_P#"!_$;2[^1]EE,WV6ZYP/*<@$GV4[6_P" U][5
M^9]?=GP%\:#QM\-=,N)'WWMF/L5SZ[T  8_52I^I-?IO!V.UJ8*3_O+\G^C^
M\_+>-,!=4\=!?W7^:_5?<>B4445^H'Y2%%%% !1110 4444 9/BKQ%;^$_#>
MI:Q=G]Q9P-,PSRQ X4>Y. /K7YX:MJEQKFJ7FHW;^9=74S3RMZLQ)/ZFOI[]
MKKQK]AT73?#$#CS;UOM5RH/(B0X0'V+Y/_;.OE:OQ[B['>WQ4<-%Z0W]7_DK
M?B?M'!V ^KX26*DM:CT]%_F[_@%%%%?!GZ %=%\/?"<GCCQII.B1AMMU.!*R
M]5C'S.WX*#7.U],_L@^"]J:KXIN(^6_T&U+#MPTC#_QP9]F%>QE&"_M#&TZ'
M2]WZ+?\ R/%SC'?V=@:E=;VLO5Z+_/Y'TE;V\=G;Q00H(HHU"(BC 50, #\*
MEHHK^A-M$?SEOJPHHHIB"BBB@ HHHH **** "N&^,'PTMOB=X1FL"$CU&',M
ME<-_!)C[I/\ =;H?P/85W-%85Z%/$TI4:JO&2LSHP^(J86K&M2=I1=T?FOJ&
MGW.E7T]G>0O;W5O(T4L4@PR,#@@_C5>OJ/\ :D^$OVVV;QCI4/\ I$*A=1BC
M'WT P)OJO /M@]C7RY7\_P":9?4RS$RH3VZ/NOZW\S^B<JS*GFF%CB(;[-=G
MU7^7D%%%%>2>N%?6?[,/Q;_X2#3%\*:I-G4K&/-G(YYFA'\'NR#\U^A-?)E7
M-&UB[\/ZK:ZE83-;WEK()8I%ZAA_3V[U[.4YE/*\2JT=5LUW7^?8\7-\LIYK
MA94):2WB^S_R[GZ1,P4$DX ZFOBS]H;XL'X@^)O[/L)=V@Z:[+$5;Y;B3HTO
MTZA?;)_BQ79?%#]I2+Q%\-K*PT<M;:OJ<1340N1]F4<.BG_;['^Z3W-?.5?6
M<2YY#$PCA,+*\79R??JE^K\].C/C^%\AGA9RQF+C:2NHKMT;_1>6O5!1117Y
MT?I0445-96<^HWD%I:Q-/<SNL442#+.Q.  /4DTTFW9!HE=G5_"KX<W?Q,\7
M6^EP[HK1/WMY< ?ZJ('G'^T>@]SZ U]YZ3I5IH>FVNGV,*V]G;1K%%&G15 P
M*X[X.?#*#X8>$H[([9-4N,37TZ_Q28X4'^ZHX'XGO7>U^Y</Y2LMP_-47[R6
M_EV7^?F?@G$></-,3RTW^[AMY]W_ )>04445]4?)!1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !117(_%3QJG@#P+JFL9'VB./R[93_%,W
M"?D>3[ UC6JPH4Y5:CLHJ[^1M1HSQ%6-&FKRDTE\SY8_:8\<?\)9\1)K*%]U
MCHX-I'@\&3.96^N["_\  !7DE.DD::1I'8N[$LS,<DD]33:_G3&8J>,Q$\1/
M>3O_ ,#Y+0_I;!X6&"PU/#0VBK?YOYO4****XSL"OK[]E+P-_8/@R?7KB/;=
MZN_[O=U$"$A?IEMQ]QMKY=\$>%Y_&WBS2]$MLA[R8(S*/N)U=_P4$_A7Z%Z;
MI\&DZ?:V-I&(;6VC6&*,=%10 !^0K]"X0P'M:\L9):0T7J_\E^9^<<9YA[*A
M#!0>L]7Z+;[W^19HHHK];/QX**** "BBB@ HHHH K:EI\&K:?=6-W&)K6YC:
M&6,]&1@01^1K\]/&_A>?P3XLU31+G)>SF**S#[Z=4?\ %2#^-?HI7S/^UYX%
M^73?%=M'S_QY7>!]3&Q_\>4G_=%?#\68'ZQA%B(+WJ?Y/?[M']Y][PAF'U;&
M/#3?NU/_ $I;??JON/F>BBBOQH_:PIT<C0R+(C%'4AE93@@CH:;10!^@7PK\
M:IX_\"Z7K&1]HDC\NY4?PS+P_P"9Y'L1775\G_LD^./[-\17WABX?%OJ*FXM
M@>@F0?,!_O(/_'!ZU]85_0&2X[^T,#"JW[RT?JO\]_F?SMGF7_V;CYT4O=>L
M?1_Y;?(****]T\ **** "BBB@ HHHH _/7XG_P#)2O%O_87N_P#T<]<S73?$
M_P#Y*5XM_P"PO=_^CGKF:_FO%?[Q4]7^9_3V%_W>G_A7Y(****YCJ/0OV?O^
M2Q>&O^NTG_HIZ^[J^$?V?O\ DL7AK_KM)_Z*>ONZOV#@W_<:G^-_DC\9XV_W
M^G_@7YL****^]/ST**** "BBB@ HHHH **** "BBB@ HHHH *PO'G_(C^(?^
MP=<_^BFK=K"\>?\ (C^(?^P=<_\ HIJPQ'\&?H_R.C#_ ,:'JOS/SLHHHK^:
M3^H HHHH ^COV-?^0EXI_P"N-O\ ^A25]15\N_L:_P#(2\4_]<;?_P!"DKZB
MK]SX8_Y%5+_M[_TIGX)Q5_R-ZO\ V[_Z2@HHHKZH^2/!_P!K+P3_ &QX1M/$
M%O'FYTN39,0.3"Y _':VW_OIC7R/7Z1:UI-OKVDWNFW:;[6\A>"5?]E@0?QY
MK\\/$WA^Y\*^(-1TB['^D64[0L<8#8/##V(P1[&OR+B_ ^RQ$<7%:3T?JO\
M-?D?LG!N/]MAI8.;UAJO1_Y/\S,HHHK\_/T0*]P_91\:_P!A^-I]#GD"VNKQ
MX3)X$Z E?S7>/<[:\/JUI>I7&BZG::A:/Y=U:RK-$_HRD$'\Q7H9?BY8'%4\
M1'[+_#K^!Y^88../PE3#2^TOQZ/[S])J*R/"?B.W\7>&=-UFU_U%[ LP7/W2
M1\RGW!R#]*UZ_HJ$XU(J<7=/4_FJ<)4Y.$U9K1A1115D!1110 4UF6-69B%5
M1DDG  IU>7_M%>-?^$.^&MZD,FR^U,_8H<'D!@?,;\$R,]BPKEQ6(AA*$Z\]
MHJ_]>IUX3#3QF(AAZ>\FE_7H?)OQ7\9MX]\?:MJX8M;/+Y5L/2%/E3CMD#<?
M=C7(T45_.5:M.O4E5GO)MOYG]+T:,,/2C1IJRBDE\@HHHK$V);2UFOKJ&VMX
MS+<3.L<<:]68G  ^I-?H7X!\*Q>"?!VDZ)%C_1(%61E_BD/+M^+%C^-?*'[+
M_@K_ (2;XAKJ4T>ZRT9/M!ST,IR(Q^!RW_ *^SZ_6.#\#R49XR2UEHO1;_>_
MR/R+C3'^TK0P47I'5^KV^Y?F%%%%?HI^:!1110 4444 %%%% !1110 4444
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M^G*+BY Z&9Q\H/\ NH?_ !\^E?3GB;Q!;>%?#^H:O>'%M9PM,PZ%L#A1[DX
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M\[****_FD_J **** /H[]C7_ )"7BG_KC;_^A25]15\N_L:_\A+Q3_UQM_\
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M6C7I.THO^OO.7%86GC*$\/65XR5OZ]#]+E99%5E(96&00<@BG5X+^R[\5/\
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MYJZ:L_F:4ZDJ,XU(.S3NO5'YJ7=K-8W4UM<1F*XA=HY(VZJP."#]"*BKV/\
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M<![#"O%36L]O1?YO]#\8XQS#ZQBHX2#]VGO_ (G_ )*WXA1117WI^?!1110
MUF"*68@*!DD]!7XE?M6_&)OCC\<?$/B**4R:3')]@TL9.!:Q$A&&>F\[I,=C
M(:_27]OCXR_\*F^ FI6EI/Y6N>)2=)M-K89(V7]_(._$>5R.C2(:_'ZOJ\EP
M]E*O+T7ZG@9E6NU27JPHHHKZ@\,**** "OV(_80^,O\ PMWX":7'>3^;KGAX
MC2;W<V6=44>3(<\G='M!)ZLCU^.]?3?_  3Y^,P^%GQVM=*O9_*T3Q0JZ9<;
MCA4GSFW<_P# R4]A*3VKR<SP_M\.[;QU._!5O95E?9Z'Z\4445\$?6!1110
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MC"/#3?O4_P GM]SO^!^+<89?]7Q:Q4%[M3?_ !+?[U9_>7****^Z/@ HHHH
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M/X/HG_H6?05X'7XYQ1FWUNO]4I/W(;^<O^!M]Y^U<*91]3H?6ZR]^:T\H_\
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M*^8/J0KW#]F/XJ?\(KX@_P"$<U&;;I.IR#R6<\0W!P ?8-PI]]OO7A]'2N_
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M,_9.#<O]CAI8R:UGHO1?YO\ )!1117Y^?H@5);V\EW<100HTLTC!$11DLQ.
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MK[B/[/H=F?EG_P .LOBO_P!#!X-_\#;O_P"1:/\ AUE\5_\ H8/!O_@;=_\
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M:<8'EN2=H]E;<O\ P&OO.O$?VJO W_"0>"8M;MTW7FCN6; Y:!\!_P CM;V
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MWK#[DW#!6!"0GYG<WN"M>WU7L;&#3;*WL[:,16]O&L44:]%50 !^ %6*_HK
M82.!PT,/'[*_'J_FS^:\PQDL?BJF)G]I_AT7R04445WGGA1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !5>^L8-2LKBSN8Q+;W$;12QMT96
M!!'X@U8HI-)JS&FXNZ/SM\>>%)_!'B_5=$GR3:3%$<_QQGE&_%2#^-8-?3G[
M7G@?S(--\5VZ?-'_ *%=D?W228V/T.X?BM?,=?SWF^!>7XV=#INO1[?Y']'9
M/CUF6!IXCKL_5;_Y_,****\<]D<CM&ZNC%74Y#*<$&OOWX2^-E^('@/2]6+
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M/#1J_"M?=EOUZ=SY>HKZA_X8UL_^AIG_ / )?_BZ/^&-;/\ Z&F?_P  E_\
MBZ\[_5C-?^?7_DT?\ST_]:LH_P"?O_DLO\CY>KZI_93^&,^CV=QXLU& Q37D
M?DV*.,,(<Y:3'^T0,>P)Z$5T_@O]F'PCX5NH[N[$VNW2'*_;<>2I]?+ P?\
M@1(KU_IP.!7UV1<-5,'66*Q;5ULEKKW?Z?>?&Y_Q/3QE!X3!IV>[>FG9?K?T
ML+1117Z*?FH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% &/XN\-6WC#PSJ6BW?\ J+R%HBV,E#U5A[A@"/I7Y^^*O"^H>#=>
MN](U2 P7=NVUA_"P[,I[J1R#7Z-5R_CCX;>'_B)9I;ZW8K.T8(BN$.R:+/\
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MX'Z]CX1DO=C[S^7^;LCYKB+'_P!GY?.47[TO=7J_\E=GME%%%?O1_/@4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MHK[H^ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 ?GK\3_^2E>+?^PO=_\ HYZY
MFNF^)_\ R4KQ;_V%[O\ ]'/7,U_->*_WBIZO\S^GL+_N]/\ PK\D%%%%<QU'
MH7[/W_)8O#7_ %VD_P#13U]W5\(_L_?\EB\-?]=I/_13U]W5^P<&_P"XU/\
M&_R1^,\;?[_3_P "_-A1117WI^>A1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 5\-_M)?\EJ\1?\ ;M_Z315]R5\-_M)?\EJ\1?\
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MBBOK#Y **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[QJ7(N "Q"C)  SV%<O_ ,/3?BO_ -"_X-_\ KO_ .2:^>?VBO\ DX+XG?\
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MO':^]HX'#2I1;@KV1\I4Q593DE+J?8__  ]-^*__ $+_ (-_\ KO_P"2:/\
MAZ;\5_\ H7_!O_@%=_\ R37QQ16WU#"_\^T9?6Z_\[/L?_AZ;\5_^A?\&_\
M@%=__)-3V?\ P50^)L<V;OPSX3GC_NPV]U&?S,[?RKXQHH_L_"_\^T'UNO\
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MB5%,L3'WRC(/^NAKLS/#JM0<K:QU_P SGP-9TJJ71Z'ZVT445\&?5A7YZ_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 ?A;^T5_R<%\3O\ L9]4_P#2N6O/J]!_:*_Y."^)
MW_8SZI_Z5RUY]7Z;1_AQ]$?$5/CEZA0K%&#*2K Y!'45[S\1/@BMK^RK\*OB
MAID&%NC>Z7J^Q?XQ?7)@F/U4&,D_W8QWKP:G3J1JIN/1M?<*<'!I/R?WG[4_
MLA_&@?'+X':)K5S/Y^N6:_V=JN?O&XC !<_[ZE'^KD=J]JK\G?\ @G+\;/\
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MN<8RQ4$U=K.\._\ (OZ7_P!>L7_H K1K\Y>Y]DM@HHHI#/Q._;&_Y.<^(O\
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M_>:GJSZS"_P8>@4445Q'2?B=^V-_R<Y\1?\ L*-_Z"M>.U[%^V-_R<Y\1?\
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M97/B?(_?BQM%L;&WMD8LD,:QJS=2 ,<_E5BBBORT^Z"OSU_X*T_\TJ_[BO\
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M_!AZ+\CXJM_$EZL_6S_@FQ_R;#8_]A2[_P#0A7U/7RQ_P38_Y-AL?^PI=_\
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M*7D89X!VJ0,]R.O2OT>4HTH-O1(^,BG.5ENSSNBOTZ_X=4_#[_H;O$WYV_\
M\:H_X=4_#[_H;O$WYV__ ,:KRO[6PO=_<>A_9]?M^)^8M%?IU_PZI^'W_0W>
M)OSM_P#XU1_PZI^'W_0W>)OSM_\ XU1_:V%[O[@_L^OV_$_,6BOTZ_X=4_#[
M_H;O$WYV_P#\:KX]_;"_9M@_9K^(&G:5IM[=:GHFI6(NK:ZO OF;PQ62,[0
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MJ]!_:*_Y."^)W_8SZI_Z5RUY]7Z;1_AQ]$?$5/CEZG[&_P#!/_\ Y-&\!_\
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M,E9:16W^9]/A,*L/&[^)A1117E'>%?GK_P %:?\ FE7_ '%?_;.OT*K\]?\
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MOP-:I.LHRDVC[9HHHKXT^D"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6*W\[^]A[&G_ "K[CQO_ (8[^"W_ $3K1O\ OVW_ ,51_P ,=_!;_HG6C?\
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M?C-XLC\-^%=9N+[5I(7G6*2PFA&Q!ECN90.]>T5^2/\ P39_Y.>L?^P7=_\
MH(K];JK,,/#"UO9PVL3A*TJ]/GEO<****\T[0HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBOG+]LC]J/5/V9=-\+W.F:)9ZTVL37$<BW<KH(_
M+6,@C;USO/Y5K2I3K35.&[,ZE2-*+G+9'T;17P7\$/\ @HUXC^*WQ8\,>$;O
MPAI=C;:M=BV>YAN)&>,$$Y /!/%?>E:5\/4PTE&HK-D4:T*ZO!A7E?QQ_:3\
M%_L]?V)_PF$]Y#_;'G_9?LEL9L^5Y>_.#Q_K4_6O5*_/7_@K3_S2K_N*_P#M
MG6F"HQQ%>-*>SO\ D1B:DJ-)SCNO\SWWP7^WQ\)_'WBW2/#FDWFJOJ>J7,=I
M;++I[(ID<X7+9X&3UKZ-K\/OV5_^3C_AM_V'K3_T:*_<&NK,<+3PLXQI]488
M+$3Q$&Y] HHHKR#T0HHHH **** "BBB@ HHHH **** "BBB@ HHHH H:]K5I
MX;T/4-6OW,5C86\EU/(JEBL:*68X')X!X%?/'_#Q+X&_]#+>?^"JY_\ B*]D
M^-'_ "1WQW_V ;__ -)WK\'J]W+<#2Q<9.HWIV/*QF*GAW%0MJ?O;\-_B)H?
MQ8\%Z?XJ\-7+W>BZAYGV>:2)HF;9(T;95@"/F1ASZ5TU?//_  3_ /\ DT;P
M'_V__P#I?<U]#5Y->"IU9P6R;7XGH4I.=.,GU2"BBBL#4*XKXN?%SP]\$_!T
MGB?Q/)<1:5'-' S6T)E?<YPORCMQ7:U\L?\ !2?_ )-AOO\ L*6G_H1KIP]-
M5:T*<MFS&M-TZ<IK=(/^'D_P6_Y_M9_\%K?XU]0VETE[:PW$63',BR)D8.",
MBOY\J_H"\._\B_I?_7K%_P"@"O3S+!4L(H>SOK?]#AP6)GB.;GZ&C1117AGJ
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% '\]E?JY_P3%_Y-ONO^P]=?\ HN&ORCK]7/\ @F+_ ,FWW7_8>NO_ $7#
M7W&<?[M\T?,9=_'^1];T445\.?3A1110 45B>-KZ?2_!NOWEK(8;FWL+B6*0
M $JZQL0>?0BOQ[_X;B^./_10;S_P%MO_ (W7HX3 U,8FX-*W<X\1BH8=I26Y
M^S]%?FAK_P#P4L\0:/\ "WPUHOA](]6\9&P4ZOXAU*(;(YB22L<0 #,!C+'Y
M<C&UNM?..O\ [5_QB\2737%W\2/$4,C')&GWSV:?@D.Q1^5=E/)Z\[\S2.:>
M8TH[*Y^WM%?C;\/?V[OC'X!U"*63Q3+XDL@P,ECKJBY609_YZ']XO?HP_&OT
MJ_9E_:>\/?M*>%9;RPC.EZ_8A5U+1Y7W-"3G#HV!OC;!PV 1C! XSRXK+ZV%
M7-+5=T;T,93KOE6C/:***0D*"2< =Z\P[A:*^"?VD/\ @I1%X=U2[\/?"RWM
M=3F@8Q3>(;M2\&X<$0)D;\?WV^4XX##!KX[\0_M:?&/Q-<-/>?$?Q!"[')&G
MWC62_@L&P#\!7M4<IKU8\TO=7GN>95S"E3?*M3]NJ*_%?PC^VA\:/!MQ');>
M/=3U!%(W0ZNPO5<#L3*&;\00?>OO+]E/]O;2/C=J%OX6\5VMOX<\82#;;O$Y
M^QW[?W8]QRC^B$G/9B>*C$977P\>?=>15''4JSY=F?6U%%<O\4M6NM!^&?B[
M4K"8V]]9Z1>7-O,H!*2)"[*P!X." >:\F*YFD>@W97.HHK\8/^&XOCC_ -%!
MO/\ P%MO_C=>^?$+_@I7K.E_#_POH?@Y(K[Q-_8UG_;/B34(@P%X8$,PBBP%
M+!RP+,-N00%(P:]J>48B+25G?\#S(YC1DFW=6/TCHK\0-<_:K^,/B&Z:XNOB
M3XDBD8Y(L=0DM$_!(2JC\J[CX8_M\_%WX>:I#)>Z^_B[2PV9M/UH"4NN>=LV
M/,4XSCD@=U/2M99+64;J2;,XYG2;LT['[#T5SGPZ\72^/? ^B>(9M'OM DU*
MV6X;3=14+/!GLP'YCH<$9 .0/B#]J+_@HW>Z!X@U#PK\+5M6:SD:"Y\1W"+.
MID'#"W0_*0#QO8,#@X&,,?*H86KB*CIP6JW\CT*N(IT8<\GN?H%17X>ZQ^U-
M\7]<N#/<_$KQ-$Y).+/4I;9>?]F(J/TKM_AK^WM\8/A_J4,EUXCD\5:<&S+8
M:VHF\P=\2X\Q3SQAL=,@]*]:62UDKJ2;//CF=-NS3/V+HK\JOCY_P4 \9>)O
M%6EZC\.?$E]X:T>;2X3=:6\$+FWNP\@D7<R'<,;"&'!!' .0/7?^">O[0WQ$
M^,'Q,\1Z9XQ\37&N6-KI!N(8988D"2>=&N[*(#T8C\:Y:F65J=%UI-:=.IT0
MQU.=14XGWQ17D7[5EUXOTOX%>)=7\#ZM/I'B#28AJ"201HYDAC.9DPX(_P!7
MN;IG*BOR]_X;B^./_10;S_P%MO\ XW487+ZF+@YPDM"J^+AAY*,DS]GZ*XKX
M+_$*'XK?"GPKXMB*DZI81S3*G1)@-LJ#_=D5U_"NUKS91<9.+W1VQ:DDT%%>
M%?MH?&.]^"?P'U;6=(NOL6OWD\6GZ;-M#%)7)9F (()$:2$9'4"OS8M_VV_C
MM=3QPP^/;Z6:1@B1I:6Y+,3@ #RNN:]+"Y=5Q4/:1:2\SAKXRG0ER23;/V<H
MKF_ASIVM:3X"\/VGB34'U7Q!%91#4+QPH,EQM!D.% &-Q(&!T KI*\QJS:.Y
M.ZN%%%%(9^0'_!1/_DZOQ+_UZV7_ *31UV?_  2R_P"3@O$'_8KW'_I7:5QG
M_!1/_DZOQ+_UZV7_ *31UV?_  2R_P"3@O$'_8KW'_I7:5]O4_Y%O_;J/EX_
M[[\V?J91117Q!]0%%%% !7YA?\%5O^2Q>$O^P"/_ $HEK]/:_,+_ (*K?\EB
M\)?]@$?^E$M>QE/^]+T9YN8?P'\CCO\ @FS_ ,G/6/\ V"[O_P!!%?K=7Y(_
M\$V?^3GK'_L%W?\ Z"*_6ZM,X_WGY+]2<M_@_,***\S^/7[0'A;]GGP>=;\1
MSM)/,3'8Z9;D&XO) .B@]%&1N8\ $=20#XT(2J24(*[9Z4I*"<I/0],HK\A_
MBA_P4.^+7CZ\F72=3C\&:4Q/EV>DH#*!VW3L"Y;W7:#Z5Y?#^TY\7(+PW*_$
MOQ49#_"^KSLG_?!;;^E>[#):TE>4DCRI9G23LDV?N117Y3_![_@I/\1?!=]!
M;^,O)\:Z+D+(9(T@O(U]4D0!6/LX.<?>'6OTI^%OQ3\.?&3P;9^)_"U^+[3+
M@E""-LD$@QNBD7^%QD9'H01D$$^=BL%6PNLUIW1V4,53Q'PO7L=?17DG[5$_
MB[3O@7XFU7P/JL^D>(M)A&H1RP(CF2*,[ID(=6!_=[R,#.5%?EW_ ,-Q?''_
M **#>?\ @+;?_&ZTPN7U,7!SA):$5\7##R49)G[/T5Q7P7^(4/Q6^%/A7Q;$
M5)U2PCFF5.B3 ;94'^[(KK^%=K7G2BXR<7NCMBU))H**\-_;,^,5W\$O@/K&
MM:5=?8]?NI8M/TR7"DK-(<E@"""5C61AP>5%?FK;_MM_':ZGCAA\>WTLTC!$
MC2TMR68G  'E=<UZ6%R^KBH>TBTEYG#7QE/#RY))MG[.45SOP]TW6='\"Z#9
M^(M0;5=?ALHEU"\8*/-N-H\Q@%  &[.,=L5\C?M2?\%$K7X;ZU>>%/AY;6FN
M:U;$Q7>KW)+VEM(."D:J1YCCN<A01CYN0.6CAZF(J>SI*_Y'14K0HPYYZ'VW
M17XG^(OVQ/C/XGN));KXAZQ;;\C9ITHLU4'L!"%Q]>M9&G_M/?%W2Y/,A^)?
MBIVR#BXU:><<>SL1_C7L+):MM9K\3S?[3IWTBS]QZ*_*#X6_\%)OB?X.OK>/
MQ2UKXUTD$+(ES"EO=!?]B6-0,_[ZMGVZU^E/P@^+WAOXX>"+/Q1X8NOM%E,3
M'+#( LUM, "T4JY.UAD>Q!!!((->9B<#6PNLUIW1VT,53Q&D=SMJ^!?^"L7_
M "+_ ,./^OJ^_P#0(:^N/V@_$FI>#_@?XYUO2+IK'5=/TBXN+:Y10QCD5"58
M @@X/J*_&KXG?'CQY\9(+"'QGXBGUV*P9WMEFBB3RRX 8C8JYR%'7TKORG#2
MJ5573TC_ )'+F%:,8.DUJ_\ ,Z;]CG_DYSX=?]A1?_06K]L:_ 'PIXJU7P/X
MBL->T.\;3]6L)/.MKI%5C&^,9 8$'KW%>O\ _#<7QQ_Z*#>?^ MM_P#&Z]?,
M,OJ8NHIP:5EU//P>+AAX.,DS]GZK7>G6FH;/M5K#<[<[?.C#XSUQGZ#\JLU\
M=_\ !13XU>-?@WHW@>;P9KTVA2W]Q=I<M%%&_F!%B*@[U;IN/3UKY+#T98BJ
MJ<79L^@K5%1@YRV1]:PZ#IEO(LD>G6L<BG*ND"@@^H(%7Z_*W]F7]KCXN>./
MCUX)T'7/&EUJ&DW]^L-S:O;P*)$VL<$K&".G8U^J5:XK"SPLE&;O<SP^(CB(
MN4$%%?%W_!1KXX^.?@S_ ,*]_P"$+\03:%_:7]H_:_)BB?S?+^S;,[U.,>8_
M3UKYM^!?[>GCW1_BAI-[\1/&6H:GX/@CNGO;*.T@+SD6TOE(NU%.3+Y>.0,]
M2!FNFCEM:M1]O!JVNG70QJ8VG3J^RDC]8Z*_)/XN?\%%?BCX^U*=/#EXG@G1
M-Q$5OIZJ]RR]C).P)W?[@0>QZUY+:_M/_%VSO#<Q_$OQ2TA.=LNK32)US]QF
M*_I73#)J\HWE))F$LRI)VBFS]QJ*_,W]G_\ X*6>)=%U:UTKXH+'KNBRL(SK
M-M L5W;=MSH@"R*.,X ;J<L>#^D^EZI::YIMIJ.GW,5[87<2SV]S X>.6-@"
MKJPZ@@@@^]>9B<)5PLK5%\^AW4<13Q"O MT45\W_ +6W[8VE?LWV,&EV%K'K
MGC2^B\VWL)&(AMHR2!-,1S@D'" @M@\KUK"E2G6FH4U=LUJ5(THN4W9'TA17
MXL>,OVTOC/XUNI9KCQWJ6F1N3MM]'8621@]@8@&./4DGWJCX8_:[^,GA.\CN
M+3XB:Y=%&SY>IW1O4;V*S;N*]Q9+6M\2O\SR_P"TZ=_A9^VM%?F1XN_X*0>(
M_&'P3^S6,Q\)?$>UOX2UWI\2O;7EKM<.5$@;8P;9E3GU!Z@>>_"W]LSXSZ]\
M3/".FWWCJ[N+&]U>SM[B%K:W >-YD5E)$>>02.*PCE.(<7*5E8U>84DTE=W/
MUYHHHKQ3TPHHHH XWXT?\D=\=_\ 8!O_ /TG>OP>K]X?C1_R1WQW_P!@&_\
M_2=Z_!ZOK<D^"?JCY_-/BB?L;_P3_P#^31O ?_;_ /\ I?<U]#5\\_\ !/\
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MPG5]E9IGVS1117DGH!17Y'_&#]N[XHWWQ0\42>$_&5QIOAI;^6/3K>&W@91
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MW8[_ '>7]=3Y(_8Y_P"3G/AU_P!A1?\ T%J_;&OQ._8Y_P"3G/AU_P!A1?\
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MY;:?BSBI<F)Q#G5>G]61[5I_["OP.L=)-A_P@MO<(R@--<7=PTS>^_S,J?\
M=P*^-?VT/V%[7X-Z$_C?P-+<S^&(Y%2_TVY?S)+'<0JR*_5HRQ"D'YE)!R03
MM^T/^&XO@;_T4"S_ / 6Y_\ C5<O\4/VN/@5XY^&_BGP])XZL;@:IIEQ:",V
MMP,L\;*N#Y?!R00>Q&:\+#U<=2J*4E)KK=,]2M3PM2#2<4^FQ^:7[.OQFO\
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M*G_DL7BW_L G_P!*(J^8_CK\3I/C)\7/%'C)HF@35+LO!"_WD@11'"K>XC1
M<=P:^G/^"5/_ "6+Q;_V 3_Z415]MB(.GE[@]U%?H?+T9*IC.9;-L_3VO*/V
MI/A;_P +A^!/BSPY%%YNH-:F[L /O?:8CYD8'IN*[#[.:]7HKXFG-TY*<=T?
M42BIQ<7LS^>^&:6SN(Y8G:&:)@Z.IPRL#D$>A!K]6?CG^TE%>_L)Q^,[6X5-
M4\5Z=%I2>6P&VZE!CNE7'0H$N,8_NCI7P=^V5\+?^%2_M#>*-,AB$.F7TO\
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M&T"-;A&UO0;>/2M2M=PWHT:[8Y"/1T56SC&=X_A-?0%<-7-,52J2IR2T\O\
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MGZ5^.=FL+7<"W+,EN742,G4+GDCWQFNG)J,.259K6]C#,JLN94UMN>P_"?\
M8_\ BI\9M)35_#_AMH]'D_U>H:C,EM%+[IN.YQVW*",]Z] _X=L_&G_GQT;_
M ,&2_P"%?K!HEI8:?HUA:Z7'%%ID-O'':I!_JUB"@(%]MH&/:KU<<\YKN3Y4
MDCICEM*WO-MGX??'']FOQI^SS_8O_"806</]L>?]E^R7(FSY7E[\X''^M3]:
M[']@'_D[GP'_ -O_ /Z07->R_P#!5CQ9:ZAXZ\#>'H;A9;G2[&XNIXE(/E>>
M\84'T)$&<'M@]^?&OV ?^3N? ?\ V_\ _I!<U[JJSK8"52INXR_4\ITXTL6H
M0V37Z'[(5\"_\%8O^1?^''_7U??^@0U]]5\#?\%8E;_A'/AR^T[!=WH+8X!*
M0X'Z'\J^6RW_ 'N'S_)GO8[_ '>7]=3Y'_8Y_P"3G/AU_P!A1?\ T%J_;&OQ
M*_9!N(K7]IKX<O*ZQH=6C0%CQN8%5'XD@?C7[:UWYU_&CZ?J<F5_PY>OZ!7P
M+_P5B_Y%_P"''_7U??\ H$-??5? O_!6+_D7_AQ_U]7W_H$-<&6?[W#Y_DSK
MQW^[R_KJ?)'['/\ R<Y\.O\ L*+_ .@M7[8U^)W['/\ R<Y\.O\ L*+_ .@M
M7[8UWYU_&CZ?J<N6?PI>OZ'YZ_\ !6G_ )I5_P!Q7_VSKYJ_8=_Y.J^'W_7U
M-_Z32U]*_P#!6G_FE7_<5_\ ;.OFK]AW_DZKX??]?4W_ *32UZ>%_P"19\I?
MJ<.(_P!]^:_0_9^BBBOBCZ8_&_\ ;^_Y.Y\>?]N'_I!;5[M_P2=_Y&#XC_\
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M^\T_5?F<V)_@S]&?D%7]"=?SV5_0G7NYY_R[^?Z'EY7]OY?J%?C1^W)\*_\
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ML1/$=TO^#^AX$J[J48T>W](_2_\ X)?_  L/AOX6ZUXVNX=EUXBNO(MF8?\
M+K 2N1_O2F0'_KFM?8^M6[W6C:A#$N^62WD1%'<E2 *ROASX)LOAOX#T#POI
MX M-)LHK1&QC?L4 N?=CEC[DUT=?#XFLZ]:57NSZFC3]E24#^>RO?OAK^P[\
M3_BQX(TOQ9X>M]*GT?45=H'EOU1_DD:-@5QP0R,/PKSKX[>!I?AK\8_&/AN6
M+R5T_4YDA7UA9B\+?C&R'\:_0#_@F-\9+'7?AO>?#JZN5CUG0YY;NS@8\RVD
MK;F*COME9L_]=%K[7&XBI2PZK4==ON9\SAJ,*E;V=7^F?-?_  [9^-/_ #XZ
M-_X,E_PH_P"';/QI_P"?'1O_  9+_A7ZW4A(4$DX [U\Y_;&)\ON_P"">S_9
MM'S/R2_X=L_&G_GQT;_P9+_A7Z._LR?#_5_A7\"O"?A77DACU;38)([A8)/,
M0%II'&&'7AA72^"?BIX1^)-QJ\'ACQ!9:U-I-RUI>I:R;C%(/YKZ.,J<'!.#
M765S8K&U\1%4ZJM;78VP^%I47STW>YG>(/#^G>*M#OM&U>SBU#2[Z%K>YM9A
ME)(V&"#_ )XK\]OC#_P2WU2/4KJ^^&VO6L^GNQ=-(UIFCEB!/W$F4$.!VW!3
MCJ2>3^AVK:M9:#I=UJ6I7<-CI]I$TT]S<.$CB11EF9CP !67X%\?>'_B9X;M
MM?\ "^JV^LZ1<9$=S;DXR.JL" 58=U8 CN*QP^)KX:\Z>WX&M:C2K^[/?\3\
MC-6_8)^.FDLV?!#W<8Z26FH6L@;C/ $N[\Q7G_C#]GOXE^ +"2_\0>!]<TRP
MC&Z2\DLG:",>K2*"J_B:_=.FR1K*C(ZAT88*L,@CTKU(YU67Q13^_P#X)Y\L
MLI_9DS\#O ?Q \0_#'Q-:>(/#&JW&D:K;-E)H&QN&>4=>CJ>ZL"#Z5^T7[-G
MQI@^/OPAT;Q8L4=M?R;K;4+6(DK#<H<.!G^$\. 23M=<G-?CI\<K71+/XS>-
MX/#?DC08]9NTLA;',0B$K!0G^R.W;&*_0G_@E;YW_"D_%.[=]G_X2%]F?N[O
MLT&['OC;G\*]#-J<*F'5:UFK?CT.3+YRA6=.^A]IT445\<?2!1110 4444 %
M%%% '\]E>@>!?V@?B+\,M$;1_"WBW4-$TQIFG-M:L AD8 %N1U(4?E7WU_PZ
MI^'W_0W>)OSM_P#XU1_PZI^'W_0W>)OSM_\ XU7W$LSP<U:6J]#Y=8'$Q=XZ
M?,^)_P#AL;XT?]%%UG_OXO\ \31_PV-\:/\ HHNL_P#?Q?\ XFOMC_AU3\/O
M^AN\3?G;_P#QJC_AU3\/O^AN\3?G;_\ QJLOKV7_ ,J_\!-/JN,[_B?$_P#P
MV-\:/^BBZS_W\7_XFOKW_@G+\;_'?Q6\:>+[3Q=XGOM>MK33XI8([M@1&QDP
M2, <XK;_ .'5/P^_Z&[Q-^=O_P#&J]>_9R_8_P##7[->M:QJ6AZUJNJ2ZG;I
M;R)J!BVJJMN!&Q!SFN/%XO!5*,HTE[S\CHP^'Q,*JE-Z>IZS\1O^2>^)_P#L
M%W7_ **:OP.K^@37-)CUW1=0TV9VCBO+>2W=TQN574J2/?!KXU_X=4_#[_H;
MO$WYV_\ \:KGRO&4L*IJJ][&V.P]2NXN"V/=?V.O^38OAU_V"U_]":O9*Y7X
M7_#^S^%?P_T/PEI]S/=V6DVXMXIKK;YCJ"3EMH SSV%=57BUI*=24ELVSTJ<
M7&$8OHCY8_X*3_\ )L-]_P!A2T_]"-?E'X=_Y&#3/^OJ+_T,5^WWQX^"NE_'
M[X?S>$]8OKS3K*2XBN#/8[/,#(20/F!&.?2OG*Q_X):^ +&^M[E/%GB1GAD6
M0*QM\$@Y_P">?M7T&7XZAAZ#A4>MV>1C,+5K55."T/M*O)OVG/@/9_M#?"G4
M/#4DD=KJD;"[TN\D!Q#<J#MW8YVL"R-UX;."0*]9HKYVG.5.2G'='LRBIQ<9
M;,_ ;QIX)USX=^)KWP_XBTV?2M7LWV36UPN"/0@]"I&"&'!!R*]F^%O[=7Q;
M^%.CVVD6>M6^MZ3;*$@M-<@^T>4HZ*L@*R;0, +NP!P *_57XK_ OP-\;--6
MS\8>'[;5#&NV&[YCN8._R2J0RC/.,X/<&OEWQ'_P2J\$WMP[Z)XQUS2HV.1%
M>11707V! C./KG\:^KCF>%Q$%'$QU]+H^?E@:]&5Z,OT/G/Q7_P4F^,GB6SD
MM[2?1?#GF+M,NDV!\P9]#,\F#[CD=L5\WMJ.O>+O%27GVC4-8\1WMRK),KO-
M=SSDC:0>69\XQCGI7Z):/_P2C\*PW"G5?'>L7L.[)2SM(K=B/3<QDY]\5](?
M!O\ 9:^&_P "S]H\,:!&-5*[6U:^;[1=D8P0';[@(ZA H/<4?VC@\-%_5XW?
MI8/J>)K->VEH6OV;H_B'#\(=$3XGF%O%*IARC;I?*X\OSR.#+C.XK[9YS6]\
M:/\ DCOCO_L W_\ Z3O795D^*O#\/BSPOK&AW$DD-OJ=G-92218WJLB%"5R,
M9 :OE^?FJ<[5M;Z'O<MH<JUT/P"K]O\ ]E?_ )-O^&O_ & ;3_T6*^>O^'5/
MP^_Z&[Q-^=O_ /&J^MOAWX)M?AQX%T'PM8SS75GH]G'9137&/,=44*"V !GC
ML*]S,\;1Q5.,:;V9Y>!PU2A-N:.CHHHKYT]@R/%GA?3O&WAG5= U>W%UI>IV
MTEI<PG^*-U*G!['G@]C@BOQ=_:+_ &;_ !/^SOXPGT_5;6:XT*:1O[,UI4_<
MW<?4#(X60#[R'D8R,@@G]N:H:UH>G>)--FT[5]/M=4T^<;9;2]@6:*0>C(P(
M(^HKTL%CI8.3TO%[HXL5A8XE+HT?@3HNOZIX;O1>:1J5WI=VHP+BRG:&0#TW
M*0:NZKXD\2^.KVUAU+5=5\0W981V\=U<2W,A8G 5 Q)R3V%?K_JW["_P+UJZ
M:XN/ %K'(3G;:7MU;)_WS%*J_I7:_#O]GOX;_"BX%UX4\'Z9I-X 5%X(S+<
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M/4_$;G6+C<,$(X A7Z>4J-]7-?2=06=G#I]G!:VT206\"+%%%&,*B@8"@=@
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MO4KGQ#K=S=ZE>:A.YEU&Z+.9I %+#<>I 9.!T!7H,5[=^P#_ ,G<^ _^W_\
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M=P=_D>-_9M5.RDK'Y$7?PC\3Z=\+8?B#>Z=)9>&KG48],M)[@%&NI'CED+1
MCYD41$%NF2 ,X;"?!?\ Y+%X$_[#UC_Z4)7Z&_\ !4[4;6S^"'A/25VQS3>(
M(YX8U  \N*VG5L#T!E3\Z_/WX!Z?)JWQS^'EG'G=-XAT]<@9VC[0F3CV&3^%
M>CA\0\3AY59*VYQUJ*HUE33OL?NQ1117Y^?7!1110!QOQH_Y([X[_P"P#?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<91P]#ZMAW=[>B_S'AL/4K5?;5EYG6T445\D?0A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>apyx-20201231_g2.jpg
<TEXT>
begin 644 apyx-20201231_g2.jpg
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M_P %3/\ I+M_Y4-<_P#CU?O]10!^ /\ Q";?\%3/^DNW_E0US_X]1_Q";?\
M!4S_ *2[?^5#7/\ X]7[_44 ?@#_ ,0FW_!4S_I+M_Y4-<_^/4?\0FW_  5,
M_P"DNW_E0US_ ./5^_U% 'X _P#$)M_P5,_Z2[?^5#7/_CU'_$)M_P %3/\
MI+M_Y4-<_P#CU?O]10!^ /\ Q";?\%3/^DNW_E0US_X]1_Q";?\ !4S_ *2[
M?^5#7/\ X]7[_44 ?@#_ ,0FW_!4S_I+M_Y4-<_^/4?\0FW_  5,_P"DNW_E
M0US_ ./5^_U% 'X _P#$)M_P5,_Z2[?^5#7/_CU'_$)M_P %3/\ I+M_Y4-<
M_P#CU?O]10!^ /\ Q";?\%3/^DNW_E0US_X]1_Q";?\ !4S_ *2[?^5#7/\
MX]7[_44 ?@#_ ,0FW_!4S_I+M_Y4-<_^/4?\0FW_  5,_P"DNW_E0US_ ./5
M^_U% 'X _P#$)M_P5,_Z2[?^5#7/_CU'_$)M_P %3/\ I+M_Y4-<_P#CU?O]
M10!^ /\ Q";?\%3/^DNW_E0US_X]1_Q";?\ !4S_ *2[?^5#7/\ X]7[_44
M?@#_ ,0FW_!4S_I+M_Y4-<_^/4?\0FW_  5,_P"DNW_E0US_ ./5^_U% 'X
M_P#$)M_P5,_Z2[?^5#7/_CU'_$)M_P %3/\ I+M_Y4-<_P#CU?O]10!^ /\
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M_P %3/\ I+M_Y4-<_P#CU?O]10!^ /\ Q";?\%3/^DNW_E0US_X]1_Q";?\
M!4S_ *2[?^5#7/\ X]7[_44 ?@#_ ,0FW_!4S_I+M_Y4-<_^/4?\0FW_  5,
M_P"DNW_E0US_ ./5^_U% 'X _P#$)M_P5,_Z2[?^5#7/_CU'_$)M_P %3/\
MI+M_Y4-<_P#CU?O]10!^ /\ Q";?\%3/^DNW_E0US_X]1_Q";?\ !4S_ *2[
M?^5#7/\ X]7[_44 ?@#_ ,0FW_!4S_I+M_Y4-<_^/4?\0FW_  5,_P"DNW_E
M0US_ ./5^_U% 'X _P#$)M_P5,_Z2[?^5#7/_CU'_$)M_P %3/\ I+M_Y4-<
M_P#CU?O]10!^ /\ Q";?\%3/^DNW_E0US_X]1_Q";?\ !4S_ *2[?^5#7/\
MX]7[_44 ?@#_ ,0FW_!4S_I+M_Y4-<_^/4?\0FW_  5,_P"DNW_E0US_ ./5
M^_U% 'X _P#$)M_P5,_Z2[?^5#7/_CU'_$)M_P %3/\ I+M_Y4-<_P#CU?O]
M10!^ /\ Q";?\%3/^DNW_E0US_X]1_Q";?\ !4S_ *2[?^5#7/\ X]7[_44
M?@#_ ,0FW_!4S_I+M_Y4-<_^/4?\0FW_  5,_P"DNW_E0US_ ./5^_U% 'X
M_P#$)M_P5,_Z2[?^5#7/_CU'_$)M_P %3/\ I+M_Y4-<_P#CU?O]10!^ /\
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M;LO_  &/^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\
MT&[+_P !C_C6Q10!C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^-;%% &/
M]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_ -!NR_\  8_X
MT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/
M^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_ -!N
MR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\ T&[+_P !C_C1]B\;_P#0
M;LO_  &/^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XUL44 8_V
M+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\ T&[+_P !C_C1
M]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_X
MUL44 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!SL5QXQFU:72%
MU>U#PQ+(S&VX(/XU:^Q>-_\ H-V7_@,?\:++_D=[W_KRB_F:V* ,?[%XW_Z#
M=E_X#'_&C[%XW_Z#=E_X#'_&MBB@#'^Q>-_^@W9?^ Q_QH^Q>-_^@W9?^ Q_
MQK8HH Q_L7C?_H-V7_@,?\:/L7C?_H-V7_@,?\:V** ,?[%XW_Z#=E_X#'_&
MC[%XW_Z#=E_X#'_&MBB@#'^Q>-_^@W9?^ Q_QH^Q>-_^@W9?^ Q_QK8HH Q_
ML7C?_H-V7_@,?\:/L7C?_H-V7_@,?\:V** ,?[%XW_Z#=E_X#'_&C[%XW_Z#
M=E_X#'_&MBB@#'^Q>-_^@W9?^ Q_QH^Q>-_^@W9?^ Q_QK8HH Q_L7C?_H-V
M7_@,?\:/L7C?_H-V7_@,?\:V** ,?[%XW_Z#=E_X#'_&C[%XW_Z#=E_X#'_&
MMBB@#'^Q>-_^@W9?^ Q_QH^Q>-_^@W9?^ Q_QK8HH Q_L7C?_H-V7_@,?\:/
ML7C?_H-V7_@,?\:V** ,?[%XW_Z#=E_X#'_&C[%XW_Z#=E_X#'_&MBB@#'^Q
M>-_^@W9?^ Q_QH^Q>-_^@W9?^ Q_QK8HH Q_L7C?_H-V7_@,?\:KZH_C+2M/
MEU&;6+1EA3<RK;')_6N@K-\8_P#(L7O_ %P- %:"W\:SPI.NM68#J& -L>X^
MM/\ L7C?_H-V7_@,?\:TM._Y!\'_ %Q7^0J:@#'^Q>-_^@W9?^ Q_P :/L7C
M?_H-V7_@,?\ &MBB@#'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &MBB@#'^
MQ>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &MBB@#'^Q>-_^@W9?^ Q_P :/L7C
M?_H-V7_@,?\ &MBB@#'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &MBB@#'^
MQ>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &MBB@#'^Q>-_^@W9?^ Q_P :/L7C
M?_H-V7_@,?\ &MBB@#'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &MBB@#'^
MQ>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &MBB@#'^Q>-_^@W9?^ Q_P :/L7C
M?_H-V7_@,?\ &MBB@#'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &MBB@#'^
MQ>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &MBB@#'^Q>-_^@W9?^ Q_P :/L7C
M?_H-V7_@,?\ &MBB@#'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &MBB@#'^
MQ>-_^@W9?^ Q_P :JZ1<>,=8MFNH-7M5"RM&0]MSE3CUKHJQ_ __ "")?^OV
M;_T*@ ^Q>-_^@W9?^ Q_QH^Q>-_^@W9?^ Q_QK8HH Q_L7C?_H-V7_@,?\:/
ML7C?_H-V7_@,?\:V** ,?[%XW_Z#=E_X#'_&C[%XW_Z#=E_X#'_&MBB@#'^Q
M>-_^@W9?^ Q_QH^Q>-_^@W9?^ Q_QK8HH Q_L7C?_H-V7_@,?\:/L7C?_H-V
M7_@,?\:V** ,?[%XW_Z#=E_X#'_&C[%XW_Z#=E_X#'_&MBB@#'^Q>-_^@W9?
M^ Q_QH^Q>-_^@W9?^ Q_QK8HH Q_L7C?_H-V7_@,?\:/L7C?_H-V7_@,?\:V
M** ,?[%XW_Z#=E_X#'_&C[%XW_Z#=E_X#'_&MBB@#'^Q>-_^@W9?^ Q_QH^Q
M>-_^@W9?^ Q_QK8HH Q_L7C?_H-V7_@,?\:/L7C?_H-V7_@,?\:V** ,?[%X
MW_Z#=E_X#'_&C[%XW_Z#=E_X#'_&MBB@#'^Q>-_^@W9?^ Q_QH^Q>-_^@W9?
M^ Q_QK8HH Q_L7C?_H-V7_@,?\:/L7C?_H-V7_@,?\:V** ,?[%XW_Z#=E_X
M#'_&C[%XW_Z#=E_X#'_&MBB@#G;^X\8Z?<VMK+J]JQNI?+0K;< XSSS5K[%X
MW_Z#=E_X#'_&CQ+_ ,A?1_\ K]/_ *":V* ,?[%XW_Z#=E_X#'_&C[%XW_Z#
M=E_X#'_&MBB@#'^Q>-_^@W9?^ Q_QH^Q>-_^@W9?^ Q_QK8HH Q_L7C?_H-V
M7_@,?\:/L7C?_H-V7_@,?\:V** ,?[%XW_Z#=E_X#'_&C[%XW_Z#=E_X#'_&
MMBB@#'^Q>-_^@W9?^ Q_QH^Q>-_^@W9?^ Q_QK8HH Q_L7C?_H-V7_@,?\:/
ML7C?_H-V7_@,?\:V** ,?[%XW_Z#=E_X#'_&C[%XW_Z#=E_X#'_&MBB@"CI4
M&OPR.=8OX)E*_((HMI!J]110!^(/_![S_P FL_ __LH&H_\ I"**/^#WG_DU
MGX'_ /90-1_](110!Y__ ,&FW_*4S]KO_MX_]/D]?O\ 5^ /_!IM_P I3/VN
M_P#MX_\ 3Y/7[_4 %%%% &=XA\(>$_%R01^*_"^G:FMK,);9=0LHYA#(.CKO
M!VM[CFM$  8 HHH I:CX<\/:Q?V>JZOH-E=76G2&33[FYM4>2V<C!:-F!*$C
MC(Q5VBB@ HHHH *\+_X)[_\ )$]6_P"Q[UG_ -*37NE>%_\ !/?_ )(GJW_8
M]ZS_ .E)H ]THHHH **** "BBB@ HHHH **** "BBB@ HHHH S?&/_(L7O\
MUP-7-._Y!\'_ %Q7^0JGXQ_Y%B]_ZX&KFG?\@^#_ *XK_(4 34444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!CV7_([WO_7E%_,UL5CV7_([WO\ UY1?S-;% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /Q!_X/>?^36?@?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M8_B7_D+Z/_U^G_T$UL5C^)?^0OH__7Z?_036Q0 4444 %%%% !1110 4444
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ML4_"\_$KXP:Q*9;N;[+X>\.Z;'YVHZ[>M@):VD(YDD8E03]U<@L0*^??@/\
ML;?&K]L;XI:7^VA_P4OT>*%M-F^T_##X&"7S=-\*H>4NKY3Q=:@1@G<,1GJ
M0L</N9/SX"O#,9OEA!Z=YOK&*]-&]HI][)^#G7L\PH3RV"YIS6O:"Z2D_76*
MWDUVNU_-]17]%/[;G_!OK^QE^UUXLOOB?X0N]2^&WBK496FU"\\-PQR6%[,Q
MRTTMF^ ')Y)B>+<268,Q)KYX^#__  :N?">35AJWQ5_:\U_6-+CNG5]/T+PI
M#ITSJK8QYTL]R!GG_EGWK]0H<<Y#4H<]23C+^5Q;?WI-?BC\LK\"9_2K\E.*
MG'^9227S3:?X/YGYL_\ !.S]D;]H3]JGX\VEY\!_@_%XQ_X0:>VU_6],O]16
MRM+J&"976S>X<;8WN"AC0'D_,W 1B/Z"/V7_ /@J!\"?C]XS/P-^(ND:M\*O
MBO;D)>_#7X@0_9+R1SGFTD;$=ZC8)4Q_,RC=L YKU#]F/]E/X!_L=_#&W^$?
M[//P\M/#^CQ/YLXB+23WDQ #33S.2\TAP!N8G  484 "K^U#^QO^S;^V3X,'
M@G]H;X6V&NPP@G3M093%?:<Y_P"6EM<QXDA;(!.UL-@!@PXKX/.^(<'GN*M6
MIN-..D6G[R[MJ_*[]M'_ 'C[_(N',;D&$O1J*526LHM>Z^R32YE;OJG_ "GI
MU%?#I\&_\%+O^"<G[[X::O?_ +3/PCM.OAO7+E8O&FAVX[6]QC;J:J/X&'F-
M\J(J %J]\_9-_;[_ &8_VS]-N%^#GCHIKVG977?!>NP&RUK29%.&2>TD.X;6
M^4NFY,\!B:^?KY=5IT_;4FJE/^:/3_$MXOU5NS9]#A\RI5:JHU4Z=3^677_"
M]I+T=UU2/9J***\\]$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH Q_$O\ R%]'_P"OT_\ H)K8K'\2_P#(7T?_ *_3
M_P"@FMB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /Q!_X/>?^
M36?@?_V4#4?_ $A%%'_![S_R:S\#_P#LH&H_^D(HH \__P"#3;_E*9^UW_V\
M?^GR>OW^K\ ?^#3;_E*9^UW_ -O'_I\GK]_J "BBB@ HHHH **** "BBB@ K
MPO\ X)[_ /)$]6_['O6?_2DU[I7A?_!/?_DB>K?]CWK/_I2: /=**** "BBB
M@ HHHH **** "BBB@ HHHH **** ,WQC_P BQ>_]<#5S3O\ D'P?]<5_D*I^
M,?\ D6+W_K@:N:=_R#X/^N*_R% $U%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8]E_R.][_P!>
M47\S6Q6/9?\ ([WO_7E%_,UL4 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 5F^,?\ D6+W_K@:TJS?
M&/\ R+%[_P!<#0!<T[_D'P?]<5_D*FJ'3O\ D'P?]<5_D*FH **** "BBB@
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M -BBL?\ X0?2/^?F]_\  MJ/^$'TC_GYO?\ P+:@";QC_P BQ>_]<#5S3O\
MD'P?]<5_D*Y_Q+X2TRQT&ZNX;BZ+1Q$@/<L1^(JS9>"]*ELXI6N;S+1*3BZ;
M'2@#=HK'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VH V**Q_^$'TC_GYO?\
MP+:C_A!](_Y^;W_P+:@#8HK'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VH V
M**Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:@#8HK'_P"$'TC_ )^;W_P+:C_A
M!](_Y^;W_P "VH V**Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:@#8HK'_P"$
M'TC_ )^;W_P+:C_A!](_Y^;W_P "VH V**Q_^$'TC_GYO?\ P+:C_A!](_Y^
M;W_P+:@#8HK'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VH V**Q_^$'TC_GY
MO?\ P+:C_A!](_Y^;W_P+:@#8HK'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "
MVH V**Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:@#8HK'_P"$'TC_ )^;W_P+
M:C_A!](_Y^;W_P "VH V**Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:@#8HK'
M_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VH ++_D=[W_KRB_F:V*Y2U\*Z=)X
MINK!I[G9';1LI%PV[))ZFM/_ (0?2/\ GYO?_ MJ -BBL?\ X0?2/^?F]_\
M MJ/^$'TC_GYO?\ P+:@#8HK'_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+:@#8
MHK'_ .$'TC_GYO?_  +:C_A!](_Y^;W_ ,"VH V**Q_^$'TC_GYO?_ MJ/\
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M;W_P+:C_ (0?2/\ GYO?_ MJ -BBL?\ X0?2/^?F]_\  MJ/^$'TC_GYO?\
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M16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U &Q16/_P@^D?\_-[_ .!;4?\
M"#Z1_P _-[_X%M0!L45C_P#"#Z1_S\WO_@6U,F\&Z';PO<7%]=1QHI9W>]8!
M0.223T% &W7QW^T[^W%\6OC%\6[_ /88_P"";<5GJWCVV_=^/OB3=)YNC> 8
M6)5B[8*W%]PP2 9VL#N!*NJ</\1OC?\ %K_@H_\ $;4OV9_^">?B_4- ^'6D
M79L_B7\?8YG:,D?ZS3M$.0)YR#AK@':@.Y2 4>3ZG_9O_8Q^ G[)WPMLOA#\
M$/#4^E:5:?//)]J+7%]<$ /<W$F 996P,L>@ 50JJJCV8T*.6153$1YJKU4'
MLNSG^D.N\K+1^+*O6S23IX:7+26DIK>7=0_6?3:-WJLW]B[]ASX2?L4>![O1
M_!DMYKGB?7[C[;XV\>Z])YVJ^(KYB6>:>5B2%W,Q6,':NXGYF9W;V>L?_A!]
M(_Y^;W_P+:C_ (0?2/\ GYO?_ MJ\NO7K8FJZE65Y/=L]6A0HX:DJ5*-HK9+
M^O\ AS8HK'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJR-38K'\#_\ ((E_Z_9O
M_0J/^$'TC_GYO?\ P+:LSPKX5T[4-.DFFGN01<R* EPRC :@#JZ*Q_\ A!](
M_P"?F]_\"VH_X0?2/^?F]_\  MJ -BBL?_A!](_Y^;W_ ,"VH_X0?2/^?F]_
M\"VH V**Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJ +^LZ-H_B+2;G0?$&
ME6U]8WD+0W=E>0++%/&PPR.C AE(X((P:^._&W_!+GQC\ ?%5[\9?^"67QF/
MPIUN[F-SJOPYU57N_!^NR>DEKRUDQZ>9#]U>$5,DU]:_\(/I'_/S>_\ @6U'
M_"#Z1_S\WO\ X%M77A<;B,&W[-Z/=/6+]4]'^G0Y,5@<-C$O:+5;-:27HUJO
MUZGRS\)_^"K&F>$?'-I\ ?\ @HI\*+OX&^/;AO*T_4-7G$WAG7F! WV6I#]V
MN>I24C9N"EV;BOKNWN(+J!+JUF22*1 \<D; JRD9!!'4$=ZXCXH_LW?!OXV^
M#+KX=_%WP9;^)-#O5Q<Z9K"B>)CV8!L[6&<AAAE/((-?)>K_ /!/W]KG]AN=
MO$W_  3<^+$OBKP5 QDN?@1\1]8D>!$ZE-*U$G?:MC[L<IV9)9V?A:Z_9Y?C
MOX;]E/LW[C]);Q])77]Y'%[3,<!_$7MH=TO?7K%:2]8V?]UGW=17RI^R_P#\
M%!OV<OC_ .,C\#OB'9>(OA7\5[;"7WPT\?RM:7KN<\VDC8CO8VP2K1G<RC=L
M KZ3_P"$'TC_ )^;W_P+:N#$87$82IR5HM/\UW3V:\UH>AAL5A\73YZ,E)?D
M^S6Z?D]38HK'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VK Z#8HK'_X0?2/^
M?F]_\"VH_P"$'TC_ )^;W_P+:@#8HK'_ .$'TC_GYO?_  +:C_A!](_Y^;W_
M ,"VH V**Q_^$'TC_GYO?_ MJ/\ A!](_P"?F]_\"VH V**Q_P#A!](_Y^;W
M_P "VH_X0?2/^?F]_P# MJ -BBL?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJ
M -BBL?\ X0?2/^?F]_\  MJ/^$'TC_GYO?\ P+:@#8HK'_X0?2/^?F]_\"VH
M_P"$'TC_ )^;W_P+:@#8HK'_ .$'TC_GYO?_  +:C_A!](_Y^;W_ ,"VH /$
MO_(7T?\ Z_3_ .@FMBN4USPKIUKJ.FPQSW)$]R5<M<,2!M[>E:?_  @^D?\
M/S>_^!;4 ;%%8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;4 ;%%8__"#Z1_S\
MWO\ X%M1_P (/I'_ #\WO_@6U &Q16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\
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M?_!/?_DB>K?]CWK/_I2: /=**** "BBB@ HHHH **** "BBB@ HHHH ****
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M44 %%%% !1110 4444 8_B7_ )"^C_\ 7Z?_ $$UL5C^)?\ D+Z/_P!?I_\
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MGC+XD^+)#;> OAKH'SZAK-P<@,0 ?)MU.2\S# "M@,1BML/AZV*JJE25Y/\
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MZ]HIL$\%U ES;3))'(@:.1&!5E(R"".H(IU>4>L%%%% !1110 4444 %%%%
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M#78H03IVHD&&^TYS_P M+:YC(DA;(!PK;6P P8<5ZGU^AC-,;&[_ )XVYO\
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MP!_X--O^4IG[7?\ V\?^GR>OW^H **** "BBB@ HHHH **** "O"_P#@GO\
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MK8K'\#_\@B7_ *_9O_0J -BBBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MB@#\0?\ @]Y_Y-9^!_\ V4#4?_2$44?\'O/_ ":S\#_^R@:C_P"D(HH \_\
M^#3;_E*9^UW_ -O'_I\GK]_J_ '_ (--O^4IG[7?_;Q_Z?)Z_?Z@ HHHH **
M** "BBB@ HHHH *\+_X)[_\ )$]6_P"Q[UG_ -*37NE>%_\ !/?_ )(GJW_8
M]ZS_ .E)H ]THHHH **** "BBB@ HHHH **** "BBB@ HHHH S?&/_(L7O\
MUP-7-._Y!\'_ %Q7^0JGXQ_Y%B]_ZX&KFG?\@^#_ *XK_(4 34444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!CV7_([WO_7E%_,UL5CV7_([WO\ UY1?S-;% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7O\ WTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\
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MH V**Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EH V**Q_P#A)=7_ .A0O?\
MOI:/^$EU?_H4+W_OI: -BBL?_A)=7_Z%"]_[Z6C_ (275_\ H4+W_OI: -BL
MWQC_ ,BQ>_\ 7 U#_P )+J__ $*%[_WTM4?$NO:G<Z#=03>&+J%6B(,KLN%]
MS0!T&G?\@^#_ *XK_(5-6%9>(]52SB1?"5XP$2@,&7!XZU+_ ,)+J_\ T*%[
M_P!]+0!L45C_ /"2ZO\ ]"A>_P#?2T?\)+J__0H7O_?2T ;%%8__  DNK_\
M0H7O_?2T?\)+J_\ T*%[_P!]+0!L45C_ /"2ZO\ ]"A>_P#?2T?\)+J__0H7
MO_?2T ;%%8__  DNK_\ 0H7O_?2T?\)+J_\ T*%[_P!]+0!L5X7^VU^WC\-_
MV-?#^G:3)HM[XN^(7BF7[+X"^&WA\>9J6NW1.%PH!,4 ;[\S A0#@,V%/%?M
MC_\ !1C5_A!XLM/V8?V:OA5-X\^./B.WW:'X0BF!@TF(C_D(:DZ'_1[= 0VU
MBK/P 5!WA/V)_P!B2^_9^\0ZE^T5\?KB_P#B-\;_ !5'_P 5/X\U!%VVD9'_
M !X:=&<"VM4'R@*%+@#(5=L:^K0PE'#TEB,7L_AALY^?E'SW>T>K7E5\76Q%
M9X;!_$OBGNH>7G/LMEO+HG1_9*_8/^)&O?%:']N3_@H7K5EXJ^+LT>?#7AVV
M._1O %LW(M;&,DJTXXWW')W [68YD?ZXK'_X275_^A0O?^^EH_X275_^A0O?
M^^EKCQ6+K8RISU.FB2T271)=%_P[U.O"82C@Z7)3ZZMO5M]6WU;_ . M#8HK
M'_X275_^A0O?^^EH_P"$EU?_ *%"]_[Z6N8ZC8HK'_X275_^A0O?^^EH_P"$
MEU?_ *%"]_[Z6@#8HK'_ .$EU?\ Z%"]_P"^EH_X275_^A0O?^^EH V**Q_^
M$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EH V**Q_P#A)=7_ .A0O?\ OI:/^$EU
M?_H4+W_OI: -BBL?_A)=7_Z%"]_[Z6C_ (275_\ H4+W_OI: -BBL?\ X275
M_P#H4+W_ +Z6C_A)=7_Z%"]_[Z6@#8HK'_X275_^A0O?^^EH_P"$EU?_ *%"
M]_[Z6@#8K'\#_P#((E_Z_9O_ $*C_A)=7_Z%"]_[Z6LSPKKFHVNG21P^&[F<
M&YD8NC+@$MT_"@#JZ*Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ (27
M5_\ H4+W_OI:/^$EU?\ Z%"]_P"^EH V**Q_^$EU?_H4+W_OI:/^$EU?_H4+
MW_OI: -BBL?_ (275_\ H4+W_OI:/^$EU?\ Z%"]_P"^EH V**Q_^$EU?_H4
M+W_OI:/^$EU?_H4+W_OI: -BBL?_ (275_\ H4+W_OI:/^$EU?\ Z%"]_P"^
MEH V**Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ (275_\ H4+W_OI:
M/^$EU?\ Z%"]_P"^EH V**Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_
M (275_\ H4+W_OI:/^$EU?\ Z%"]_P"^EH V**Q_^$EU?_H4+W_OI:/^$EU?
M_H4+W_OI: -BBL?_ (275_\ H4+W_OI:/^$EU?\ Z%"]_P"^EH V**Q_^$EU
M?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ (275_\ H4+W_OI:/^$EU?\ Z%"]
M_P"^EH XC]J+]C7]FW]LKP8/!7[0WPNL-=BA!.G:B08;[3G/_+2VN8R)(6R
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M_?2T?\)+J_\ T*%[_P!]+0!L451TK5;W4)'2ZT2>U"KD-*1AO;BKU 'X@_\
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M'_D6+W_K@:N:=_R#X/\ KBO\A5/QC_R+%[_UP-7-._Y!\'_7%?Y"@":BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** ,>R_Y'>]_Z\HOYFMBL>R_Y'>]_Z\HOYFMB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "LWQC_R+%[_UP-:59OC'_D6+W_K@: +FG?\ (/@_ZXK_ "%35#IW_(/@
M_P"N*_R%34 %%%% !1110 444CND2&21PJJ,LS'  ]: %KY!_:H_;J^*7Q!^
M+%W^PS_P3DTZS\0?$Y5">,O&]TOF:+\/[=B0TMR^"LUWUV6XW88?,&*F,\W\
M7?VKOCA_P4*^(NJ_LG?\$Y/$K:-X1TNY-E\3_P!H")"UO8#_ ):6&CD$"YNR
MIP9E.V,'*L,K)7TS^RM^R=\$OV-?A/:?!_X&^%A86$3&:_OIV\R\U2Z8?/=7
M4Q&9I6/4G@#"J%4!1[$:%'+(JIB5S5'K&#V79S_2&[WE9:/QIUZV9R=/#2Y:
M:TE-;ONH?K/9;1N]5S7[%/["OPN_8N\)7RZ)J%YXE\:>))_M?CKXAZ\WFZGK
M]X3N9Y'8DI&&)V1 D*#DEF+,?;J**\RO7K8FJZE65Y/K_7Y=#TZ%"CA:*I4H
MVBME_7XOJ%%%%9&P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6
M/X'_ .01+_U^S?\ H5;%8_@?_D$2_P#7[-_Z%0!L4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Y5?\
M%OO^"(/C/]I#QG>?M?\ [(&D07?BR[@3_A,?!WFI"VK-&@1;NV9R$$^Q0'C)
M'F;0RG?D2?JK17HY7FF+RC%K$8=Z[-/9KLSS<URK"9QA'A\0M-TUNGW1_(1\
M0/A+\4_A/XB?PC\4?AMKWAS58Y-CZ;KND36DX;TV2JK?I7T%^P]_P2&_;,_;
M@\6V,/AKX::EX8\)22J=1\<>)=.DM[*&'^)H0^UKM\=$BSR1N9%)8?TN^)?^
M0OH__7Z?_036Q7V=?Q#Q<Z'+2HJ,N[=U\E9?BV?$X?PXP=.NI5J[E#LE9_-W
M?X)?(\]_97_9H^&?[('P$\._L\_"2P>'1O#MGY233D&:[F9B\UQ*0!F221F<
MXX&[    'H5%%?GU2I4K5'4F[R;NWW;/T6E2IT:<:=-6BE9+LEL%%%%06%%%
M% !1110 4444 %%%% !1110 4444 ?B#_P 'O/\ R:S\#_\ LH&H_P#I"**/
M^#WG_DUGX'_]E U'_P!(110!Y_\ \&FW_*4S]KO_ +>/_3Y/7[_5^ /_  :;
M?\I3/VN_^WC_ -/D]?O]0 4444 %%%% !1110 4444 %>%_\$]_^2)ZM_P!C
MWK/_ *4FO=*\+_X)[_\ )$]6_P"Q[UG_ -*30![I1110 4444 %%%% !1110
M 4444 %%%% !1110!F^,?^18O?\ K@:N:=_R#X/^N*_R%4_&/_(L7O\ UP-7
M-._Y!\'_ %Q7^0H FHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@#'LO^1WO?^O*+^9K8K'LO^1W
MO?\ KRB_F:V* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *S?&/_(L7O\ UP-:59OC'_D6+W_K@: +
MFG?\@^#_ *XK_(5-4.G?\@^#_KBO\A4U !1110 445S'QD^,_P +OV?/AMJO
MQ>^,OC6R\/\ AW1K<S:AJ=_)M1!T"J!EG=CA51069B H)(%5"$ZDU&*NWLD3
M.<*<'*3LEJV^AM>)?$OAWP;X?O?%GBW7+33-+TVU>YU#4;^X6*"VA0%GD=V(
M"J "22<#%?"6N^//C=_P65U^[^'_ ,$M6UGP#^S'9W3VOB7Q]$C6VJ_$$HQ6
M2STX,,P61(*O,1E^5P?GC"^&_AS\;O\ @L=XCL_B=^T%H>K^ _V:+*Z2Z\)?
M#>:1K?4_'FQ@T5]J90YALS@-' #EAA@2-LK?=OA_P_H7A/0K/PQX7T6UT[3=
M/MDM[#3[&W6*&VA10J1QHH"HJ@     "O8_=91VE7^]4_P!'/\(^<MO&_>YQ
MWC0^Z53]5#\9>4?BQ_A#\'_AG\!/ASI7PE^#W@RQT#P[HML(-.TO3XMJ1KU)
M)ZN[$EF=B69B68DDFNDHHKQYSE.3E)W;W;/9A"-.*C%62V04445)04444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 5C^!_\ D$2_]?LW_H5;
M%8_@?_D$2_\ 7[-_Z%0!L4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!C^)?^0OH_\ U^G_ -!-
M;%8_B7_D+Z/_ -?I_P#036Q0 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% 'X@_\'O/_ ":S\#_^R@:C_P"D(HH_X/>?^36?@?\ ]E U'_TA%% '
MG_\ P:;?\I3/VN_^WC_T^3U^_P!7X _\&FW_ "E,_:[_ .WC_P!/D]?O]0 4
M444 %%%% !1110 4444 %>%_\$]_^2)ZM_V/>L_^E)KW2O"_^">__)$]6_['
MO6?_ $I- 'NE%%% !1110 4444 %%%% !1110 4444 %%%% &;XQ_P"18O?^
MN!JYIW_(/@_ZXK_(53\8_P#(L7O_ %P-7-._Y!\'_7%?Y"@":BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** ,>R_Y'>]_P"O*+^9K8K'LO\ D=[W_KRB_F:V* "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *S?&/\ R+%[_P!<#6E6;XQ_Y%B]_P"N!H N:=_R#X/^N*_R%35#IW_(/@_Z
MXK_(5-0 445X=^VQ^W;\,_V,O#.GVE_I-[XJ\>>)YOLG@/X<: /,U/7KLG:J
MHB@F.$,1OF((4< ,V%.U"A6Q-54J4;R?3^NG=[(QKXBCA:3JU96BNO\ 77LM
MV=+^U=^UO\$OV,?A/<_%WXX>)OL=FK^1IFFVJ>;>ZM=L/DM;6'(,LK'MP%&6
M8JH+#YL^#7[)7QP_;X^)&E?M=_\ !23PW_97A[3+@7GPO^ $CE[32%_Y9WVK
M*0!<WI4Y\IAMCR0RC)B7I/V4?V$OB;XO^*]M^W+_ ,%%-6LO$OQ69"WA3PE:
M'S-$^']NQW+;V<9)62Z'&^X)8[A\K,1YC?7=>E.O1RV#IX:7-4>DIKIW4/UE
MN]E9;^9"A6S.:JXJ/+36L8/KVE/](;+=W>B1555"JH  P !TI:**\<]D****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K'\#_
M /((E_Z_9O\ T*MBL?P/_P @B7_K]F_]"H V**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Q_$O
M_(7T?_K]/_H)K8K'\2_\A?1_^OT_^@FMB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** /Q!_P"#WG_DUGX'_P#90-1_](111_P>\_\ )K/P/_[*
M!J/_ *0BB@#S_P#X--O^4IG[7?\ V\?^GR>OW^K\ ?\ @TV_Y2F?M=_]O'_I
M\GK]_J "BBB@ HHHH **** "BBB@ KPO_@GO_P D3U;_ +'O6?\ TI->Z5X7
M_P $]_\ DB>K?]CWK/\ Z4F@#W2BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#-\8_\BQ>_P#7 U<T[_D'P?\ 7%?Y"J?C'_D6+W_K@:N:=_R#X/\ KBO\
MA0!-1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% &/9?\CO>_]>47\S6Q6/9?\CO>_P#7E%_,UL4
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M_7 U<T[_ )!\'_7%?Y"J?C'_ )%B]_ZX&KFG?\@^#_KBO\A0!-1110 4444
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M%% 'X@_\'O/_ ":S\#_^R@:C_P"D(HH_X/>?^36?@?\ ]E U'_TA%% 'G_\
MP:;?\I3/VN_^WC_T^3U^_P!7X _\&FW_ "E,_:[_ .WC_P!/D]?O]0 445^=
M?[)NI_%SP[_P<+?'?X0^,/VA?&WC+P_8? K0]3T;3?%&J(]OIDMQ=0^:+>W@
MCB@A#%224C5CNY)P* /T4HKYB_;G_P""?/CO]NWXB>'%UG]L[XK?"OP1X6TJ
M9XM-^"_B]]$U'6M3GDP[WMQY;AK>&**(11J,EYYBQ4*N[YP_8:_8NU/X$?\
M!83Q+X&^'O[;/[0WQ#\'_"OX26MSXOL?BI\6+G6+4^(M9GE%E (=L<9\JPMI
MYV#*Q#74# J0,@'Z645^-_[;'[;7[#?[8_\ P4F\2_LJ?M.?\%-_CY^S=;^
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBB@ HHHH **** "BBB@ K'\#_P#((E_Z_9O_ $*MBL?P/_R")?\ K]F_]"H
MV**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MYO?_  +:MBB@#'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJV** ,?_ (0?2/\
MGYO?_ MJ/^$'TC_GYO?_  +:MBB@#'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ M
MJV** .9\2^$M,L=!NKN&XNBT<1(#W+$?B*LV7@O2I;.*5KF\RT2DXNFQTJWX
MQ_Y%B]_ZX&KFG?\ (/@_ZXK_ "% &;_P@^D?\_-[_P"!;4?\(/I'_/S>_P#@
M6U;%% &/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U;%% &/\ \(/I'_/S>_\
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M #\WO_@6U'_"#Z1_S\WO_@6U;%% &/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\
MX%M6Q10!REKX5TZ3Q3=6#3W.R.VC92+AMV23U-:?_"#Z1_S\WO\ X%M19?\
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MS+1*3BZ;'2I?^$'TC_GYO?\ P+:M+3O^0?!_UQ7^0J:L38Q_^$'TC_GYO?\
MP+:C_A!](_Y^;W_P+:MBB@#'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VK8H
MH Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:MBB@#'_P"$'TC_ )^;W_P+:C_A
M!](_Y^;W_P "VK8HH Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:MBB@#'_P"$
M'TC_ )^;W_P+:C_A!](_Y^;W_P "VK8HH Q_^$'TC_GYO?\ P+:C_A!](_Y^
M;W_P+:MBB@#'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VK8HH Q_^$'TC_GY
MO?\ P+:C_A!](_Y^;W_P+:MBB@#'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "
MVK8HH Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:MBB@#'_P"$'TC_ )^;W_P+
M:C_A!](_Y^;W_P "VK8HH Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:MBB@#'
M_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VK8HH Q_^$'TC_GYO?\ P+:LSPKX
M5T[4-.DFFGN01<R* EPRC :NKK'\#_\ ((E_Z_9O_0J #_A!](_Y^;W_ ,"V
MH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJV** ,
M?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2
M/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](
M_P"?F]_\"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_
M\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y^;W_
M ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJV
M** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_
MX0?2/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\
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MUGX'_P#90-1_](111_P>\_\ )K/P/_[*!J/_ *0BB@#S_P#X--O^4IG[7?\
MV\?^GR>OW^K\ ?\ @TV_Y2F?M=_]O'_I\GK]_J "BBB@ HHHH **** "BBB@
M KPO_@GO_P D3U;_ +'O6?\ TI->Z5X7_P $]_\ DB>K?]CWK/\ Z4F@#W2B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#-\8_\BQ>_P#7 U<T[_D'P?\
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M@NT.GSD_>?ERI[!6;XQ_Y%B]_P"N!K2K-\8_\BQ>_P#7 UY)ZY<T[_D'P?\
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M+MW@3ROM.  =N,X&<X&.VH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M].K?G)W;];=#GR[#5*%)SK?Q)OFEZ]$O**LEZ7W;"BBBN ] *S?&/_(L7O\
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MMCP7X$AFUEF+S^(M7<WFH2N>KF:7)4GN$V@^E>ET44 %%%% !1110!C^)?\
MD+Z/_P!?I_\ 036Q6/XE_P"0OH__ %^G_P!!-;% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 ?B#_P>\_\FL_ _P#[*!J/_I"**/\ @]Y_Y-9^
M!_\ V4#4?_2$44 >?_\ !IM_RE,_:[_[>/\ T^3U^_U?@#_P:;?\I3/VN_\
MMX_]/D]?O]0 4444 %%%% !1110 4444 %>%_P#!/?\ Y(GJW_8]ZS_Z4FO=
M*\+_ .">_P#R1/5O^Q[UG_TI- 'NE%%% !1110 4444 %%%% !1110 4444
M%%%% &;XQ_Y%B]_ZX&KFG?\ (/@_ZXK_ "%4_&/_ "+%[_UP-7-._P"0?!_U
MQ7^0H FHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#'LO\ D=[W_KRB_F:V*Q[+_D=[W_KRB_F:
MV* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH K:SK&E>'M(NO$&O:C!9V-C;27%[=W,@2.")%+.[L>%55!))X %?%G_  3[
MT?5OVW?VEO%/_!5'XA:;/'H!2?PM\ ]+O8RIM-#BD9+G5-A^[+=R!P#]Y4\Q
M,LI4U<_X*:^-O%7[27Q)\)?\$J/@OK<]KJ7Q$B_M7XK:S8G+Z%X0AD G!/\
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M 4444 %%%% !1165XR\<^#/AWH<OB;QYXKT[1M/A_P!9>:G>)#&#Z;G(!)[
M<GM0!JT5\^WG[<>I?$VZDT+]D+X)ZWX^F5S&WB*ZC.G:+ V<$FXF ,A')**
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M /7Z?_036Q0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'X@_\
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M^$EU?_H4+W_OI:/^$EU?_H4+W_OI:V** ,?_ (275_\ H4+W_OI:/^$EU?\
MZ%"]_P"^EK8HH Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI:V** ,?_ (275_\
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M)=7_ .A0O?\ OI:V** ,?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6MBD9E12[L
M ,DD\ 4 ?.W_  4'_;3UW]D[]GVXU_PCX(N;[QWXHOHO#WPVT,[7?4=;NLI;
MJ$ZNJ',C#@$)MR"PJ;_@G]^S5<_L8_LW:9\,+W1+W5O%&HW$NL^/?$<D@:76
M-;N2'NKAF/+#=B-2>=D:YYR3X_\ LN(W_!1K]NO6?V[=95KGX6_"2>[\+?!&
M"3F#4]1SLU+7%!X8$@0Q/R"H!^5XC7W)7KXW_8<-'!KXG:4_7[,?^W4]?[S:
MZ(\C!?[=B98U_"KQI^GVI?\ ;S6G]U)]68__  DNK_\ 0H7O_?2T?\)+J_\
MT*%[_P!]+6Q17D'KF/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+6Q10!C_\
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M/@1\!(<?$[XBV-E>, 8-)A8SWLQ/W0L$89SDX ) 7GDBO-O^%X_M@?'K]Q\
M/@='X(T2;[OBWXD92=D/\4-A'ELXY5G)1L]J[_X-_LD_ 'X%3?VIX%\ V[:L
MY+3^(-48W=_*Y^\QGERRD]PFT'TKTB@#P30/V"O"'B'5X?&'[3?Q#USXHZU$
MV^-->F\G3+=O^F-E$?+4=<JQ93Z5[CHNAZ+X;TN'0_#NCVMA96R;+>SLK=8H
MHE]%10 H]@*M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !16/XT^(/@;X<Z6=:\>>+M.TBUYQ-J%VD08^B[CEC[#)KRJ;]L:7
MQU,VG?LV?!SQ!XWDW%1JSPG3],4].;B<#)'7&T9QP:]/!9/F6/@ZE&F^1;R=
MHP7K.345\V>7C<YRS+YJG6J+G>T%>4WZ0BG)_)'MM?BW7Z:_\*A_:J^+(\SX
MO_'&'PGITGWM!^'\)24KZ->2Y<-C@[05.37YE5^Y^$6"H8+Z[&->-23]G?EN
MU'^);WFDFWK\-UINS\'\8L;7QOU&4J$J<5[6SG9.7\._NIMQ2T^*SUV04445
M^S'XF?:7_!(+_FH?_<)_]O:^TJ^+?^"07_-0_P#N$_\ M[7VE7\G>)G_ "6^
M+_[A_P#IJ!_77A?_ ,D-A/\ N)_Z=F%%%%?"'WP4444 %%%% !1110 4444
M%%%% !1110!^(/\ P>\_\FL_ _\ [*!J/_I"**/^#WG_ )-9^!__ &4#4?\
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MN*_R% $U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MSI&?WDZ_[N#[4?\ #,_QA^)_[_\ :*_:%U*XM7YD\->#%_LZRQW1Y,>;,O\
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MM3M"_8DU+XCZO!XV_;)^)]UX_P!1AD$MMX<@W6NA6#>B6ZX,Q'3>^-P^\IH
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MK8K'\2_\A?1_^OT_^@FMB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M* "BBB@ HHHH *Q_ _\ R")?^OV;_P!"K8K'\#_\@B7_ *_9O_0J -BBBB@
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M5O&.JQ2[!J-W!:XATZQ23$ALK&SB$,2D;MB/*X#S/D _.+]MC]MK]AO]L?\
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M$\8=''H5/!% 'EO_  W/^R/_ -%ZT'_O\_\ \37&_P#!//QKX4F^!VISQ:Y
MR2>-M6DC8$_,CS[U/T*L#^->V?\ "KOAG_T3O0O_  40_P#Q->0_\$]M-TY?
M@EJJKI\  \<ZP !$. +@@#IV  _"@#VG_A,?#'_0:@_[ZH_X3'PQ_P!!J#_O
MJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@
M_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\
MA,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[Z
MH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[
MZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!
MJ#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A
M,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4
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M^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\
MWZ% %/\ X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^JN?V=I__/C#_P!^A1_9VG_\
M^,/_ 'Z% %/_ (3'PQ_T&H/^^J/^$Q\,?]!J#_OJKG]G:?\ \^,/_?H4?V=I
M_P#SXP_]^A0!3_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZJY_9VG_P#/C#_WZ%']
MG:?_ ,^,/_?H4 4_^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^,/\
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M8?\ OT*/[.T__GQA_P"_0KBKUJF)K2JU'>4G=_,[:%"EAJ,:5-6C%67R*?\
MPF/AC_H-0?\ ?5'_  F/AC_H-0?]]5<_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*
MR-2G_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]5<_L[3_P#GQA_[]"C^SM/_ .?&
M'_OT* *?_"8^&/\ H-0?]]4?\)CX8_Z#4'_?57/[.T__ )\8?^_0H_L[3_\
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M^SM/_P"?&'_OT*Q-RG_PF/AC_H-0?]]4?\)CX8_Z#4'_ 'U5S^SM/_Y\8?\
MOT*/[.T__GQA_P"_0H I_P#"8^&/^@U!_P!]4?\ "8^&/^@U!_WU5S^SM/\
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MH-SJ>F30:I$RPW1:5@?NC;U-:G_"8^&/^@U!_P!]54\1V5FFJZ2J6D0#7A#
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MQ$U"*W<FDOO>AV=-FFBMXFGGE5$12SN[8"@=22>@KQ'_ (7U^T5\6_W/P#^
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M0JGXQ_Y%B]_ZX&KFG?\ (/@_ZXK_ "% $U%%% !1110 4444 %%%% !1110
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M%% !1537-?T+PQIDNM^)-:M-/LX1F:[O;A8HT'NS$ 5Y'JW[:7A'6]0E\._
M/P-KGQ#U.-MC-HEJ8K&%O26ZD 11T^8!A[UZ&"RK,<QN\/3;BMY;17^*3M&/
MS:/.QV;9=EK2Q%11D]H[R?\ ABKRE\DSV>N4^)?QQ^$GP>L_MOQ)\?:=I65W
M);S3;IY!ZI$N7?\ !37G7_"NOVOOC%\_Q*^*=EX TF3KHO@I/-OF7^Z]X_\
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M>H7=@E)!61^WGHGASX]?M<_#[]@G]GCPGH^D^)+V5/%/Q7\9:7H]O]HT+PY
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M &AO!4FE7OAZ<V^CW#ZG;7/VFR(W(N8)7VF,[DP<?*$QG!P >Y4444 %%%%
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M-1_](110!Y__ ,&FW_*4S]KO_MX_]/D]?O\ 5^ /_!IM_P I3/VN_P#MX_\
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M]]+&G;:MJ H..QX'2O4_U<S*G_O#A2_QSC%_^ WY_NB>5_K+EE3_ '93K?\
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M,'Q@\6_-\6/VN_%MVK_ZRU\+6\.D1X_NYC#%AVYP37M=%'^L.*I?[M2ITO\
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M%+_M^4C6AP]ET*JK5TZU1;2J/F:?>*^&'_;D8@  , 4445XA[@4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5C^!_^01+_ -?LW_H5;%8_
M@?\ Y!$O_7[-_P"A4 ;%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 8_B7_ )"^C_\ 7Z?_ $$U
ML5C^)?\ D+Z/_P!?I_\ 036Q0 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% 'X@_\'O/_)K/P/\ ^R@:C_Z0BBC_ (/>?^36?@?_ -E U'_TA%%
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M16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XT ;%%8_V+QO\ ]!NR_P#
M8_XT?8O&_P#T&[+_ ,!C_C0!L45C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\
MP&/^- &Q16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XT ;%%8_V+QO\
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MX>0RC/U!K&_X90^(/A+Y_@]^U;XTT@+S'::ZT6KVR?[*I,%VC\37J?V+QO\
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M'V+QO_T&[+_P&/\ C0!L45C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (T
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M?R+_ ,0PXY_Z!/\ RI2_^3/C:OM+_@D%_P U#_[A/_M[3+?_ ()$?:+>.?\
MX:$QO0-C_A$^F1G_ )^Z]L_9!_9!_P"&4_\ A(?^+A_V]_;WV3_F$_9?(\CS
MO^FLF[=YWMC;WSQ\GQSQSPMG'"V(P>#Q'-4ER67)-7M.+>KBELF]6?7<!\!\
M5Y+Q7A\9C,/R4X<]WSTW:].45I&3>[2T1[31117\]']&!1110 4444 %%%%
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M 'G_ /P:;?\ *4S]KO\ [>/_ $^3U^_U?@#_ ,&FW_*4S]KO_MX_]/D]?O\
M4 %%%% !1110 4444 %%%% !7A?_  3W_P"2)ZM_V/>L_P#I2:]TKPO_ ()[
M_P#)$]6_['O6?_2DT >Z4444 %%%% !1110 4444 %%%% !1110 4444 9OC
M'_D6+W_K@:N:=_R#X/\ KBO\A5/QC_R+%[_UP-7-._Y!\'_7%?Y"@":BBB@
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MLZ\V=.=*;A---;IZ,].G4A5@IP::>S6J"BBBH+"BBB@ HHHH **** "BBB@
MHHHH **** ,>R_Y'>]_Z\HOYFMBL>R_Y'>]_Z\HOYFMB@ HHHH *^&OA4?\
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M&:5W!4\0E5BNDMUZ25I+TO;R9Y=3*J"FZF';I2?6.S]8N\7ZVOV:/#OV7/\
M@HS^R%^U].VA?"/XKV\?B6W+)?\ @KQ!$VG:S:2+]]'M)L.Y7HS1[T!_BKW&
MO&/VI/\ @GW^R/\ MC0+<?'/X/:?>:Q %^P>*M.+66KV;+]QH[N$K)\IP0C%
MDR.5->'GX!?\%4/V*?\ 2/V9/CM9_M >";;E/ 7Q;NEM?$$$0_Y9VVKH LS]
M!FX 11P%JOJV7XO_ '>IR2_EGM\IK3_P)1]63]9S'"?[Q3YX_P T-_G!Z_\
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MUO$.:5HK2*[16B7W;]W=]0P.%^IX=0;O)ZR?>3U;^_;LK+H%%%%<AV!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9OC'_D
M6+W_ *X&M*LWQC_R+%[_ -<#0!<T[_D'P?\ 7%?Y"IJAT[_D'P?]<5_D*FH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ K'\#_ /((E_Z_9O\ T*MBL?P/_P @B7_K]F_]"H V****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH Q_$O_(7T?_K]/_H)K8K'\2_\A?1_^OT_^@FMB@ HHHH
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M_@IWC#SEM.7_ +8O^WNC"BBBO(/8"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "LWQC_R+%[_UP-:59OC'_D6+W_K@
M: +FG?\ (/@_ZXK_ "%35#IW_(/@_P"N*_R%34 %%%% !1110 4444 %%%%
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M_H-0?]]4 :5%9O\ PF/AC_H-0?\ ?5'_  F/AC_H-0?]]4 :5%9O_"8^&/\
MH-0?]]4?\)CX8_Z#4'_?5 &E16;_ ,)CX8_Z#4'_ 'U1_P )CX8_Z#4'_?5
M&E16;_PF/AC_ *#4'_?5'_"8^&/^@U!_WU0!I45F_P#"8^&/^@U!_P!]4?\
M"8^&/^@U!_WU0!I45F_\)CX8_P"@U!_WU1_PF/AC_H-0?]]4 :5?/O[3?_!,
M/]D#]J;7!X^\4^ )O#7C:&3S;+XA>!;PZ3K=O-VE^T0C$KCL95DQVQ7N'_"8
M^&/^@U!_WU1_PF/AC_H-0?\ ?5;X?$XC"U.>C)Q?=.QAB,-A\53Y*T%)=FKG
MQU_8'_!77]B4[O"^OZ/^U#X#MO\ F'ZU(FC>+[2$=DN.8+TJ,DE\RR$  +FO
M0_V=_P#@JW^R3\>?%7_"J=?U_4OAM\08F6.[^'OQ.T]M'U-)3T2,3'RYR3G
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M#O@'PEI?@3PAI45CI.BZ=!8:790C"6]O#&L<<:^RHJ@?2@#S7]LG]EO]EO\
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M% 'G_P#P:;?\I3/VN_\ MX_]/D]?O]7X _\ !IM_RE,_:[_[>/\ T^3U^_U
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M_6[;^5['#E/"63Y/7]M23E-;.33MZ627SM<****^:/I@HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S?&/\
MR+%[_P!<#6E6;XQ_Y%B]_P"N!H N:=_R#X/^N*_R%35#IW_(/@_ZXK_(5-0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !6/X'_ .01+_U^S?\ H5;%8_@?_D$2_P#7[-_Z%0!L4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^18O?^N!H N:=_R#X/\ KBO\A4U0Z=_R#X/^N*_R%34 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MC^!_^01+_P!?LW_H5;%8_@?_ )!$O_7[-_Z%0!L4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!C
M^)?^0OH__7Z?_036Q6/XE_Y"^C_]?I_]!-;% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 ?B#_ ,'O/_)K/P/_ .R@:C_Z0BBC_@]Y_P"36?@?
M_P!E U'_ -(110!Y_P#\&FW_ "E,_:[_ .WC_P!/D]?O]7X _P#!IM_RE,_:
M[_[>/_3Y/7[_ % !1110 4444 %%%% !1110 5X7_P $]_\ DB>K?]CWK/\
MZ4FO=*\+_P"">_\ R1/5O^Q[UG_TI- 'NE%%% !1110 4444 %%%% !1110
M4444 %%%% &;XQ_Y%B]_ZX&KFG?\@^#_ *XK_(53\8_\BQ>_]<#5S3O^0?!_
MUQ7^0H FHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@#'LO^1WO?^O*+^9K8K'LO^1WO?^O*+^9K
M8H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ K-\8_\BQ>_]<#6E6;XQ_Y%B]_ZX&@"YIW_ "#X/^N*
M_P A4U0Z=_R#X/\ KBO\A4U !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %8_@?_D$2_P#7[-_Z%6Q6
M/X'_ .01+_U^S?\ H5 &Q1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% &/XE_P"0OH__ %^G_P!!
M-;%8_B7_ )"^C_\ 7Z?_ $$UL4 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!^(/_![S_R:S\#_ /LH&H_^D(HH_P"#WG_DUGX'_P#90-1_](11
M0!Y__P &FW_*4S]KO_MX_P#3Y/7[_5^ /_!IM_RE,_:[_P"WC_T^3U^_U !1
M110 4444 %%%% !1110 5X7_ ,$]_P#DB>K?]CWK/_I2:]TKPO\ X)[_ /)$
M]6_['O6?_2DT >Z4444 %%%% !1110 4444 %%%% !1110 4444 9OC'_D6+
MW_K@:N:=_P @^#_KBO\ (53\8_\ (L7O_7 U<T[_ )!\'_7%?Y"@":BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** ,>R_P"1WO?^O*+^9K8K'LO^1WO?^O*+^9K8H **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ K-\8_\ (L7O_7 UI5F^,?\ D6+W_K@: +FG?\@^#_KBO\A4U0Z=_P @
M^#_KBO\ (5-0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !6/X'_P"01+_U^S?^A5L5C^!_^01+_P!?
MLW_H5 &Q1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% &/XE_Y"^C_P#7Z?\ T$UL5C^)?^0OH_\
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M*L0"2* /I.LGQU9^,;_PC?V?P_UBTT_6I("-.O;ZW,L,,F1AG0?>&,\5K44
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M#RY9HW8N@YZ@&O7Z /!?^%??\%#_ /HX+P)_X2[T?\*^_P""A_\ T<%X$_\
M"7>O>J* /!?^%??\%#_^C@O G_A+O1_PK[_@H?\ ]'!>!/\ PEWKWJB@#P7_
M (5]_P %#_\ HX+P)_X2[T?\*^_X*'_]'!>!/_"7>O>J* /!?^%??\%#_P#H
MX+P)_P"$N]'_  K[_@H?_P!'!>!/_"7>O>J* /!?^%??\%#_ /HX+P)_X2[T
M?\*^_P""A_\ T<%X$_\ "7>O>J* /!?^%??\%#_^C@O G_A+O1_PK[_@H?\
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M_P!'!>!/_"7>O>J* /!?^%??\%#_ /HX+P)_X2[T?\*^_P""A_\ T<%X$_\
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M\"?^$N]>]44 >"_\*^_X*'_]'!>!/_"7>C_A7W_!0_\ Z."\"?\ A+O7O5%
M'@O_  K[_@H?_P!'!>!/_"7>C_A7W_!0_P#Z."\"?^$N]>]44 >"_P#"OO\
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M\)=Z]ZHH \%_X5]_P4/_ .C@O G_ (2[T?\ "OO^"A__ $<%X$_\)=Z]ZHH
M\%_X5]_P4/\ ^C@O G_A+O1_PK[_ (*'_P#1P7@3_P )=Z]ZHH \%_X5]_P4
M/_Z."\"?^$N]'_"OO^"A_P#T<%X$_P#"7>O>J* /.O@KX:_::T/5KV;X[?$K
MP]KEF]NHL8=&TAK9XI=W+,3U&.,5Z+110!^(/_![S_R:S\#_ /LH&H_^D(HH
M_P"#WG_DUGX'_P#90-1_](110!Y__P &FW_*4S]KO_MX_P#3Y/7[_5^ /_!I
MM_RE,_:[_P"WC_T^3U^_U !1110 4444 %%%% !1110 4444 %%%% !1110
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MX9\::=X;&DS:+XFMD25;&:)9I$DM;M'*P$?O8Y8BLC2APZ 'V!1110 4444
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M>!?@;\/-2^)_Q&U9K32]-C7?Y,+2SW$KN(X;:") 7GGEE9(HH4!>221$4%F
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M W_A+K?2_#MQX\T+4_'-M/:M(VKZ/87T=[-IR$$;//DMX8V8Y'EF08.:]EH
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M:NMGHW[(5M;>(I4'R&235[:2*-B/XB&C8 \XC/I7T?\ \%'=)UO]K7P9>_\
M!-;X4ZD\6I_$;3XX_B9KUN R>%/"4DNV[F<G(^U7B1RVEK$>69YIL&.VE-:W
MP"_87\4_!37?C!^T++\6M+U/XZ?&9H9-9\=W/A9FTS21:VOV;3;*UT[[4'-G
M;+ABC7(DG<N[R+N4)\[_  Y_X)5_\%A_A/#K*^!O^"\ME;3^(=:GU;7+^X_9
M5T6YNK^\EP#++--?N[[46.*-22L444<2!8XT4 '&?\%D/A]I/PS_ &Z_^":O
MAGPCHL>F>"?#/QEDT2SLX\_9[1Q%IL>GP#.>0D,BIGGY36M_P<00ZGK7Q<_8
M9\)>$U?^WKK]KWP[<Z<\0R\<<+@RR<<[5WHS'H N37TG\6_^";$/Q]_8A\*?
MLQ_&GX_ZYKOCSP=JUAXGT3XR2V$:ZA;>+K6X:[368K8NT<:&>24"T#;$@D,*
M,H566QH7[#_Q&^*G[5'@7]KS]L[XC^&_$FM_"K2;^U^''AKP=X>GL-+T^]OD
M2*\U:;[3<3R3W+Q1K'&F52W4OCS';S  ?2]%%% !1110 4444 %%%% !1110
M 4444 %%%% 'X@_\'O/_ ":S\#_^R@:C_P"D(HH_X/>?^36?@?\ ]E U'_TA
M%% 'G_\ P:;?\I3/VN_^WC_T^3U^_P!7X _\&FW_ "E,_:[_ .WC_P!/D]?O
M]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!^(/\ P>\_\FL_ _\ [*!J/_I"**/^
M#WG_ )-9^!__ &4#4?\ TA%% 'G_ /P:;?\ *4S]KO\ [>/_ $^3U^_U?@#_
M ,&FW_*4S]KO_MX_]/D]?O\ 4 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?B#_P>
M\_\ )K/P/_[*!J/_ *0BBC_@]Y_Y-9^!_P#V4#4?_2$44 >?_P#!IM_RE,_:
M[_[>/_3Y/7[_ %?@#_P:;?\ *4S]KO\ [>/_ $^3U^_U !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%>)_MX_MY?!#_@G
MS\$YOC#\8[V6>6>4VWA[P]8LOVO5[O;D11@\*H'+R'Y47U8JK?BY\;/^#E;_
M (*(?$'Q//??"B[\,> -)$A^QZ=I^A0W\RQYX\V:\602/V+(D8/]T5[^4<-9
MIG,'4H12A_-)V5_+1M_<?/9QQ/E62S5.O)N?\L5=V\]4E]]S^@^BOPY_8X_X
M.=_CWX6\76?AS]M'P5I7BGPW<3*EUXA\.V L]3LE)YE,2GR;A5_N!8VZG<>
M?VL^'/Q%\#_%WP'I/Q.^&OB:UUG0-=L([S2=4LGW1W$+C*L.X]"#@@@@@$$5
MAFV19CDLTL3'1[-:I_UV=CHRC/LMSN#>&EJMT]&OEV\U=&U1117CGLA1110
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M^^(<7P7U'P(_@7XKZMX'N-'U;5X;RXDFL([9I)I# /+C)>=DV(\JCR\B1@V
M ?1E%%% !1110 4444 %%%% !1110 4444 %%>/_ +<'[3$?[+7P(OO'.G&"
M37+R9;'P];3C<KW+Y)=ESRJ('<]B0H_BKMO@C\6?#WQS^%&A?%?PNX^R:U8+
M-Y6[)@E^[)"Q_O)(&0^ZT =51110 4444 %%%?(7QO\ ^"M5K\%?VX_#O_!/
MA/V+?BAXF^(/B[P]/KOA=-!U'P\EGJ&GPFX$DHGN]3@$946TI*2;6QMP#D4
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M!_\ V4#4?_2$44 >?_\ !IM_RE,_:[_[>/\ T^3U^_U?@#_P:;?\I3/VN_\
MMX_]/D]?O]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
MS7QB^*GAWX(?#'6OBQXML=3N=-T*S-S>0:/I[W5TZ @8CA3YI&YZ"OE[_A^!
M^R1_T3/XQ_\ AJK_ /\ B:^QJ*[,/5P4(M5J;D_*7+_[:SCQ-+&U)IT:BBO.
M/-_[<CXY_P"'X'[)'_1,_C'_ .&JO_\ XFC_ (?@?LD?]$S^,?\ X:J__P#B
M:^QJ*Z/K&4_\^)?^#/\ [0Y_J^;_ /01'_P7_P#;G\VG_!<G]N*#]MC]L*+4
M/"L&NV7A7PIX?MM/T+2_$&F26-Q')*HGN)GMY/FC9V=5R?O)#&>F*^,J_3__
M (.;OV/O%W@7]IS3?VQ-&TB:?PSXYTRVT_5[Z-"5L]5M8O*6.0]%$ELD13^\
M89?[O/Y@5^W<.U<+5R6@\.K1Y4K7O9]4_.]_7<_"N)*6+HYW76(=Y<S=[6NG
MLTM=+6ZNVP5^M?\ P0:_X*L^"/V:_P!FSQ%\ OC=HGCC6;71_$7VSPRWA?PM
M<:H+2WN4)E@?R@?*7SHWD4'[QFD/:OR4K^A+_@W*_8^\7?LV?L7WOQ/^(ND3
M:?K/Q/U6/5;>QN$*20Z7%%LM"ZGHS[YIA_L2Q]\UYO&=;!4LF:Q$>:\E97L[
M^3L]E?IY=3T^":.-JYVGAY<MHOF=KJWFKK=VZ^?0] _X?@?LD?\ 1,_C'_X:
MJ_\ _B:/^'X'[)'_ $3/XQ_^&JO_ /XFOL:BOR/ZQE/_ #XE_P"#/_M#]B^K
MYO\ ]!$?_!?_ -N?+WP=_P""MG[-7QN^)VB_"?PEX"^*%MJ6NW@MK.?6/AU>
M6MJCD$YDF<;8UXZFOJ&BBN/$3PTY)T8.*\Y<WZ([,-#$TX-5IJ3\H\OZL^5?
M^"L?Q?\ "6B_!OPY^RGK7Q0TSPE<_'CQ,GA.\UO4M9CL5T_0!&UQKER)I&4(
MW]GQ36\;;@1<7EOCDU\;?\$TOB7\#/V#O^"XWQ=_8$^"7Q$\*ZC\)/V@](3X
M@_"RU\*:Q;7-EI.MQ(XU#38Q;L4A+I%<2"/C;#:VR@8-?8'PA\%_'#XT_P#!
M0WQY\:?VF_V.=;T#PEH?@^R\+_"#4?$&KZ#?VYMGE>ZU:[D@M;^XE@FN;B.Q
MC4%/]38PDE&9U'C'_!=C]AS]HCXL:/\ !/XX?\$X?V8AK?QD^$/Q1MO$6@W^
MF:CH^E6D=B%S=6ET]Y=V[.DS16WRH'R(V4X#&N<Z#L?^"NW[7W[;G[*OQR_9
ML\+?LP>)O!ATGXK?%VS\*:MH>NZ#(+BX=P7 :_,LBPV[@;'\NU,RC+(Y.%KS
M77_VK/\ @I__ ,$[O^"E7P<^"/[;7[0GA+XO_"3]HK5KC0-$UC0/A_#X?N?"
M.O84PV\<:2S&:!GEB16FEE=E+L=K18ER?^"U_P 3/BIJ?BG]@[XFW7[.FNZ9
MXJ7]IO2KJ7X<7^M:8]\9UMV+VB7,%S)9LY^94<S*A.W<R DCV_XY? 7XG_\
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M=%?]+_#VIWNM:'::MJ7AV\TBXN;=9)M+U!X6GM6(R8Y#!))$6'0E'=?1B.:
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M?5M56SF8-(6AC22U@E?:3=(7:01.K^;?M._#CXU_#C_@X@_84L_B/^T-J7Q
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M , /C[X)\7>+_#$_CO1EO==N=,CN1>7MN$G,3Q332M))<7,Z3M)-N,;KOEH
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M[0?A33$AFVM&^LW5OY\XDO71F2(%MMM$[A07D=Z].^)/[/?[3W_!6S_@G/\
M%G]GK]O7]GG3O@=JGC9FL_!_A:W\56WB&;2/LOD7%GJ-S>6A\J5FO8]YAC"[
M88PA)9V- '#_ /!PSX%\+>'O^#?_ .*'A2V6.*T\.>&?#0T>6$G]P]MJVFK
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MB;K_  H_X>-? S_H3_'_ /X1-U_A7OE% '@?_#QKX&?]"?X__P#")NO\*/\
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M4=@9H-?LWOIX;?[8A+!U+@NS'_GXFD2?_@H)\-/VL;/]NS]ES_@IG\%/V/\
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M:>US+!&SPPQ;/,<X/RJ7(4$].2!SR0*^(O\ @@9^SM^TU^RC^R!KWP8_:D^
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M"-.U3QGX)T7Q7;6&J>%O$-M;"!YH7N !-#( S$A,-N"L8O+4R '>?LW?%?\
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MLDL2N]M.4+PDC)1BC,I(Z':Q&1P2.:EH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH _$'_@]Y_P"36?@?_P!E U'_ -(111_P>\_\FL_
M_P#[*!J/_I"** //_P#@TV_Y2F?M=_\ ;Q_Z?)Z_?ZOP!_X--O\ E*9^UW_V
M\?\ I\GK]_J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH _$'_@]Y_P"36?@?_P!E U'_ -(111_P>\_\FL_
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MWQ _\**Q_P */^(WG]EG_HQ[X@?^%%8_X4 ?M]17X@_\1O/[+/\ T8]\0/\
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MOB!_X45C_A0!^WU%?B#_ ,1O/[+/_1CWQ _\**Q_PH_XC>?V6?\ HQ[X@?\
MA16/^% '[?45^(/_ !&\_LL_]&/?$#_PHK'_  H_XC>?V6?^C'OB!_X45C_A
M0!^WU%?B#_Q&\_LL_P#1CWQ _P#"BL?\*/\ B-Y_99_Z,>^('_A16/\ A0!^
MWU%?B#_Q&\_LL_\ 1CWQ _\ "BL?\*/^(WG]EG_HQ[X@?^%%8_X4 ?M]17X@
M_P#$;S^RS_T8]\0/_"BL?\*/^(WG]EG_ *,>^('_ (45C_A0!^WU%?B#_P 1
MO/[+/_1CWQ _\**Q_P */^(WG]EG_HQ[X@?^%%8_X4 ?M]17X@_\1O/[+/\
MT8]\0/\ PHK'_"C_ (C>?V6?^C'OB!_X45C_ (4 ?M]17X@_\1O/[+/_ $8]
M\0/_  HK'_"C_B-Y_99_Z,>^('_A16/^% '[?45^(/\ Q&\_LL_]&/?$#_PH
MK'_"C_B-Y_99_P"C'OB!_P"%%8_X4 ?M]17X@_\ $;S^RS_T8]\0/_"BL?\
M"C_B-Y_99_Z,>^('_A16/^% '[?45^(/_$;S^RS_ -&/?$#_ ,**Q_PH_P"(
MWG]EG_HQ[X@?^%%8_P"% '[?45^(/_$;S^RS_P!&/?$#_P **Q_PH_XC>?V6
M?^C'OB!_X45C_A0!^WU%?B#_ ,1O/[+/_1CWQ _\**Q_PH_XC>?V6?\ HQ[X
M@?\ A16/^% '[?45^(/_ !&\_LL_]&/?$#_PHK'_  H_XC>?V6?^C'OB!_X4
M5C_A0!^WU%?B#_Q&\_LL_P#1CWQ _P#"BL?\*/\ B-Y_99_Z,>^('_A16/\
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M>?V6?^C'OB!_X45C_A0!^WU%?B#_ ,1O/[+/_1CWQ _\**Q_PH_XC>?V6?\
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5ZYJ=O.EPDMN(@BB(9!!&<FB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>apyx-20201231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:apyx="http://apyxmedical.com/20201231"
  xmlns:country="http://xbrl.sec.gov/country/2020-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="apyx-20201231.xsd" xlink:type="simple"/>
    <context id="id55f6de3007948b69061635a4640b62b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7ed1b671dc694c3ca5cd5bc47208993d_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ib31d35568ba546f9a9d4089583b98733_I20210329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <instant>2021-03-29</instant>
        </period>
    </context>
    <context id="i96df8138377f4df5b064ec7bcc292732_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9020d4fc4c274bc28ceac88534fe42fd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i96fdd56f4a934deb9be8b429dd443450_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i56b0b5fc07294eaa8b9b7c9c449eee1a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i67c608a0d0d84f82b2791e369dd406ef_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="idd03c7764245458ba14ccb5108168190_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i00df6877cb2d4b75a1a4abee0d94d57f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id992bd2f876c4b41b9cacd2ed36d028b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if1b9838e537a4797bfd3b3f72116ce4a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3251c9a7258d4e12930f0fe7a2b79ff9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib71a81c6cf874b9f8f5abe1afdc8701d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0cae677daf3a4680b30b757dd83c4a07_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3a3d8fad4cc642db8994868640f75384_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4bb3f044ef5d488f992a3c49afc08bf0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1e0b3ac3abbb4da6ba6ebb3596d95da5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8bd3c576836a42909e45df1e4cbe6038_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1386a67ac59644f3bcf3f6f4a0040e4f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i868214ceea314396813754fb0220fc1f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1b9e760795d04740980adf4105f44066_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7d4c03e853084e12b45168c562e7aeac_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i09376f8c140d4e28b47971c939c7a4fb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6a1a44a54fd4403d892b074c44ed1d4d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i45882c1ec2804d9e9753f1f3e2754339_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">apyx:ApyxSYMedicalDevicesNingboCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0bc128762b18423fb747675dee1c2b38_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1cbbd8dbe42a42989174fca0d2219d64_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ided82545571a4ee3959a92c88503da8a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id16feebf7b354586bb519173e63e4a13_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia212175fe18e4aa78e12bf752ae2656e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7f6eeb41de814d65b926757c9f6c1659_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">apyx:ComputerEquipmentandSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9461cea186574f9d99826a2a0dc1e166_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">apyx:ComputerEquipmentandSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i373f3e4cf9074d1eaadacf5820f14dc7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ToolsDiesAndMoldsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i37622543d9574bb98c9c743b9e441331_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ToolsDiesAndMoldsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0b779b72fb924855b2f72a574d145bd7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">apyx:RenuvionJPlasmaGeneratorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i981157b059a44725985cef208243fc13_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">apyx:MountingFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8df0935c0bc549ebafb864ba67aab0d3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">apyx:AccessoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i67552fb7889b46aebef782a87a2fa29c_D20180830-20180830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <startDate>2018-08-30</startDate>
            <endDate>2018-08-30</endDate>
        </period>
    </context>
    <context id="ice559c8f3fad43108151f29c47e8b650_D20180830-20180830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">apyx:ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apyx:SymmetrySurgicalInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-30</startDate>
            <endDate>2018-08-30</endDate>
        </period>
    </context>
    <context id="i1f29cae9fd29439fa7f042f1814f46aa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">apyx:ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apyx:SymmetrySurgicalInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibf67c4dec56341a2a59058b71b03ea9c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">apyx:ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apyx:SymmetrySurgicalInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8e0b17e778314c9c90e0d88fd0f6dd2b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i63baacc6f0574a6e8bf0b19a1687afb0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">apyx:ChineseSupplierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id0a28971628c45e3b9e9d97e753d9756_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie7edc49dacbe457c9d33e24e671deb98_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7a54987fec4e4d109be138c336d48d57_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iee3b318d7e9f4b0a847b69cbdeb233ce_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie3f4327a210e4a4da700fd1022432191_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i19401a17feaf403f899024675a2ec439_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4036b967bee44ae799da3bf97a2bdb7f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i22cf6c2b0fa640009153ca8537851d59_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4fb285bd8adc40a4b2a0c9d050a1f420_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0306c2a7b1164d41a4a0dca8f17a1e2a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i40e12307801b4ccb8c56cf5e4fd98ec4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">apyx:ComputerEquipmentandSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id798580ebbff4f89bc905e8051c3b2b2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">apyx:ComputerEquipmentandSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie6680d593e9440dbbfd54f5193fbf907_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i22cabb993e2b4682a7111b3d2814c1c0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1e903bdd325546128d4b5baaaa0369ec_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ToolsDiesAndMoldsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3f57e20923764c72859b130e5896e87f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ToolsDiesAndMoldsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i810adca1ebab41a5a9488ebb3154fda3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">apyx:SophiaBulgariaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0363bd7ae504408f83e9148242c28770_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i672dd521a5844f22a7fa22968f746eed_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2fc3ec19ac0e4ed4895cf47c5da6347f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="apyx:LeaseArrangementsAxis">apyx:LeaseRemeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6241803215ac41d1bca740510e6f9f94_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="apyx:LeaseArrangementsAxis">apyx:LeaseRemeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia07cd0c04ff44e70938ff407067b900c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="apyx:LeaseArrangementsAxis">apyx:LeaseExecutionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i796972f9750c4ee3b870255ed2cedf91_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="apyx:LeaseArrangementsAxis">apyx:LeaseExecutionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib92bbe0f312c4b5ba37e35fb5203b324_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i12dd582368554dba97b8aa9e153c5b2b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:OptionOnSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i47bce2e772fe46be81b0517aa210b5d9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:OptionOnSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8ae0b3b25b524ed89da35d0c86ded00e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:CoVenturerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i42b2e2edfea349f6bef6deafaa0b9c9f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:CoVenturerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie2101546a5f04f93a9393b9ac203e960_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:CoVenturerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i324ce5f416944371b0b0f1514f0a8c83_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:CoVenturerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i33ad88dc3b434353b50eb3acfab694d4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i24f804d243d24666a8bc91f19e0bc3dc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0a42214a67b14472a2d145b68faf883b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">apyx:LargestCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1a14786bb32f4b7fbd8311532b5e461e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">apyx:LargestCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6ccc3072ced640849dd9bbd33abe34e5_I20011231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apyx:A2001ExecutiveandEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2001-12-31</instant>
        </period>
    </context>
    <context id="id2069ea94eb1477bb94891296fd7ccf0_I20071030">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apyx:A2003ExecutiveandEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2007-10-30</instant>
        </period>
    </context>
    <context id="i79cf41051ed34d12a5fa5d78feeeef12_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7ec1168e4e6e457abbce2a3267321f39_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1c9befc04c0e430b8f6bffceacc59a9d_I20120731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apyx:TwoThousandTwelveShareIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-07-31</instant>
        </period>
    </context>
    <context id="i8f01e109bd104360a674e88733aec92b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apyx:TwoThousandTwelveShareIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ief0094005e77442fa9d4b4c6c22a8df0_I20150731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apyx:TwoThousandFifteenExecutiveAndEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-07-31</instant>
        </period>
    </context>
    <context id="ib4bc94f07ff84f97b245be704259861e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apyx:TwoThousandFifteenExecutiveAndEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i74bbca955e6f4c6e8758ac942298fe99_I20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apyx:A2017ExecutiveandEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="i04da05110f984d449da3c74c6a62b472_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apyx:A2017ExecutiveandEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i865b7f7fe4ac4cfba2d0d6c0001de126_I20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apyx:A2019ShareIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-31</instant>
        </period>
    </context>
    <context id="i8dcd8a8a5fd54b70a6dd5754aceae3b0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apyx:A2019ShareIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib625f4dfee414563bb1127dd3c30d6a0_D20200129-20200129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <startDate>2020-01-29</startDate>
            <endDate>2020-01-29</endDate>
        </period>
    </context>
    <context id="i7505016b032b4f8aaffab34edef82f38_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iffb306c7379244eab19d37d41fd043d9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i938276f948f8476088fcafef6b8fa346_I20151031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-10-31</instant>
        </period>
    </context>
    <context id="ic7261616081a40bbad79158817e1fdf0_D20151001-20151031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-10-01</startDate>
            <endDate>2015-10-31</endDate>
        </period>
    </context>
    <context id="i594539d6cfd54e88904eebbf46eef99a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:AdvancedEnergyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5a77d1947a3942e4b0d3b8009af417c4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:OEMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5a90fc59d66d4c82b190fa272723dc6d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0d507772bdc84e94aa1f1e2764c3a5b4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:AdvancedEnergyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iacc05ae73fc84dee92f50cd7192ca9e1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:OEMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ief62b70f9e3643ea9918e4763977575f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i661eca8a002a4cb2af895f3f5c9a5ec2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idd1b12aeda3f4c229577e1cc6e8722a7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie7e4bbf7a2034449bae0430f14b14d54_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i515759e8c6ae472bb639c3e78b1b52f8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>apyx:segment</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV80L2ZyYWc6YTcxNWU2Nzc0ZTRjNDA4NjgyZGMyZTQyMjNiOGM4NjgvdGFibGU6MWI1YjlmMjNiOTBkNGRiNjgwYTE3YzEwODVjNGQ4NjkvdGFibGVyYW5nZToxYjViOWYyM2I5MGQ0ZGI2ODBhMTdjMTA4NWM0ZDg2OV8yLTEtMS0xLTA_478ac2cb-7551-4575-8f41-52727e8d1acb">0000719135</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV80L2ZyYWc6YTcxNWU2Nzc0ZTRjNDA4NjgyZGMyZTQyMjNiOGM4NjgvdGFibGU6MWI1YjlmMjNiOTBkNGRiNjgwYTE3YzEwODVjNGQ4NjkvdGFibGVyYW5nZToxYjViOWYyM2I5MGQ0ZGI2ODBhMTdjMTA4NWM0ZDg2OV81LTEtMS0xLTA_7b680101-1e4f-417b-a1a7-88a3240ca088">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV80L2ZyYWc6YTcxNWU2Nzc0ZTRjNDA4NjgyZGMyZTQyMjNiOGM4NjgvdGFibGU6MWI1YjlmMjNiOTBkNGRiNjgwYTE3YzEwODVjNGQ4NjkvdGFibGVyYW5nZToxYjViOWYyM2I5MGQ0ZGI2ODBhMTdjMTA4NWM0ZDg2OV8xNi0xLTEtMS0w_36981a18-5556-43fb-887b-ffd807d0f3f0">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV80L2ZyYWc6YTcxNWU2Nzc0ZTRjNDA4NjgyZGMyZTQyMjNiOGM4NjgvdGFibGU6MWI1YjlmMjNiOTBkNGRiNjgwYTE3YzEwODVjNGQ4NjkvdGFibGVyYW5nZToxYjViOWYyM2I5MGQ0ZGI2ODBhMTdjMTA4NWM0ZDg2OV8xNy0xLTEtMS0w_d204c6c8-1a67-4a9c-9970-375e5adce881">2020</dei:DocumentFiscalYearFocus>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i79cf41051ed34d12a5fa5d78feeeef12_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzEwOTk1MTE2MzcxMDk_cf9a545e-25f8-4790-a167-4803e9a50ffa">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xL2ZyYWc6ZDFhY2YxMTYzNWZmNDZmZjk3NTNlM2EwOWI4YjI4MDYvdGV4dHJlZ2lvbjpkMWFjZjExNjM1ZmY0NmZmOTc1M2UzYTA5YjhiMjgwNl8yMzA0_7d34ea68-d3ee-4e63-a7b6-aa8d704c7f26">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xL2ZyYWc6ZDFhY2YxMTYzNWZmNDZmZjk3NTNlM2EwOWI4YjI4MDYvdGFibGU6MjRmMTczMzc1YThjNDI2ZThhMGVlZjFiMzIzOWVhZDMvdGFibGVyYW5nZToyNGYxNzMzNzVhOGM0MjZlOGEwZWVmMWIzMjM5ZWFkM18wLTAtMS0xLTUzNTM_b87a2e7a-b6da-417b-a81d-7120dee48679">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xL2ZyYWc6ZDFhY2YxMTYzNWZmNDZmZjk3NTNlM2EwOWI4YjI4MDYvdGFibGU6MjRmMTczMzc1YThjNDI2ZThhMGVlZjFiMzIzOWVhZDMvdGFibGVyYW5nZToyNGYxNzMzNzVhOGM0MjZlOGEwZWVmMWIzMjM5ZWFkM18xLTMtMS0xLTUzNDM_e73745f5-892d-4397-ac35-db76d24798ab">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xL2ZyYWc6ZDFhY2YxMTYzNWZmNDZmZjk3NTNlM2EwOWI4YjI4MDYvdGFibGU6MjRmMTczMzc1YThjNDI2ZThhMGVlZjFiMzIzOWVhZDMvdGFibGVyYW5nZToyNGYxNzMzNzVhOGM0MjZlOGEwZWVmMWIzMjM5ZWFkM18xLTMtMS0xLTUzNDM_f50335ad-d8ee-4a9a-a747-60cc3b333237">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xL2ZyYWc6ZDFhY2YxMTYzNWZmNDZmZjk3NTNlM2EwOWI4YjI4MDYvdGFibGU6MjRmMTczMzc1YThjNDI2ZThhMGVlZjFiMzIzOWVhZDMvdGFibGVyYW5nZToyNGYxNzMzNzVhOGM0MjZlOGEwZWVmMWIzMjM5ZWFkM181LTAtMS0xLTUzNTE_ee1f9495-8914-4ad2-a463-6027ea1e0bbf">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xL2ZyYWc6ZDFhY2YxMTYzNWZmNDZmZjk3NTNlM2EwOWI4YjI4MDYvdGFibGU6MjRmMTczMzc1YThjNDI2ZThhMGVlZjFiMzIzOWVhZDMvdGFibGVyYW5nZToyNGYxNzMzNzVhOGM0MjZlOGEwZWVmMWIzMjM5ZWFkM183LTMtMS0xLTUzNDY_878551e3-e96f-4aa0-a503-b190dff3ace8">0-12183</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xL2ZyYWc6ZDFhY2YxMTYzNWZmNDZmZjk3NTNlM2EwOWI4YjI4MDYvdGFibGU6MDM0OTAwOGYxZDU5NGVlZDk3MWU5MDcwN2YyMDhjZDgvdGFibGVyYW5nZTowMzQ5MDA4ZjFkNTk0ZWVkOTcxZTkwNzA3ZjIwOGNkOF8xLTAtMS0xLTUzNjA_8cd6747c-4543-4aaa-813d-cd8fe074c277">APYX MEDICAL CORPORATION</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xL2ZyYWc6ZDFhY2YxMTYzNWZmNDZmZjk3NTNlM2EwOWI4YjI4MDYvdGFibGU6ZWE3NWY4ZjIyMDFiNDMxMjgxYWI5MGNiYjUyNjkzYjEvdGFibGVyYW5nZTplYTc1ZjhmMjIwMWI0MzEyODFhYjkwY2JiNTI2OTNiMV8wLTAtMS0xLTM1NzE_da21b49b-7e89-4443-9d59-fd42f1033362">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xL2ZyYWc6ZDFhY2YxMTYzNWZmNDZmZjk3NTNlM2EwOWI4YjI4MDYvdGFibGU6ZWE3NWY4ZjIyMDFiNDMxMjgxYWI5MGNiYjUyNjkzYjEvdGFibGVyYW5nZTplYTc1ZjhmMjIwMWI0MzEyODFhYjkwY2JiNTI2OTNiMV8wLTItMS0xLTM1NzQ_97ad472e-1045-42bd-b209-48d708f3cd1b">11-2644611</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xL2ZyYWc6ZDFhY2YxMTYzNWZmNDZmZjk3NTNlM2EwOWI4YjI4MDYvdGV4dHJlZ2lvbjpkMWFjZjExNjM1ZmY0NmZmOTc1M2UzYTA5YjhiMjgwNl8xMDk5NTExNjMwMTYz_f06309c8-b2bf-4a72-a91d-a79362125f18">5115 Ulmerton Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xL2ZyYWc6ZDFhY2YxMTYzNWZmNDZmZjk3NTNlM2EwOWI4YjI4MDYvdGV4dHJlZ2lvbjpkMWFjZjExNjM1ZmY0NmZmOTc1M2UzYTA5YjhiMjgwNl8xMDk5NTExNjMwMTY0_9f0e038f-dd31-431c-a9f2-73ee5d80ed4e">Clearwater</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xL2ZyYWc6ZDFhY2YxMTYzNWZmNDZmZjk3NTNlM2EwOWI4YjI4MDYvdGV4dHJlZ2lvbjpkMWFjZjExNjM1ZmY0NmZmOTc1M2UzYTA5YjhiMjgwNl8xMDk5NTExNjMwMTY1_f7fb3ff6-26dc-460d-9a5f-a9896964ea6f">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xL2ZyYWc6ZDFhY2YxMTYzNWZmNDZmZjk3NTNlM2EwOWI4YjI4MDYvdGV4dHJlZ2lvbjpkMWFjZjExNjM1ZmY0NmZmOTc1M2UzYTA5YjhiMjgwNl8xMDk5NTExNjMwMTY3_61c479be-e785-43db-aa26-d8e03d796c72">33760</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xL2ZyYWc6ZDFhY2YxMTYzNWZmNDZmZjk3NTNlM2EwOWI4YjI4MDYvdGV4dHJlZ2lvbjpkMWFjZjExNjM1ZmY0NmZmOTc1M2UzYTA5YjhiMjgwNl8xMDk5NTExNjMwMTc0_5a13ec2b-6dc8-4c1b-918d-37f38ec11a82">727</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xL2ZyYWc6ZDFhY2YxMTYzNWZmNDZmZjk3NTNlM2EwOWI4YjI4MDYvdGV4dHJlZ2lvbjpkMWFjZjExNjM1ZmY0NmZmOTc1M2UzYTA5YjhiMjgwNl8xMDk5NTExNjMwMTc4_3e55319a-dc3c-4ade-bbc0-99178635dcb6">384-2323</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xL2ZyYWc6ZDFhY2YxMTYzNWZmNDZmZjk3NTNlM2EwOWI4YjI4MDYvdGFibGU6Y2Y5YTFhNGQ1M2Q3NDgzNmEwZWUyOWMyZTAzNmU0ZGEvdGFibGVyYW5nZTpjZjlhMWE0ZDUzZDc0ODM2YTBlZTI5YzJlMDM2ZTRkYV8xLTAtMS0xLTM1NjQ_e3545a24-b8fd-4949-97f9-a9da170c7972">Common Stock, $.001 Par Value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xL2ZyYWc6ZDFhY2YxMTYzNWZmNDZmZjk3NTNlM2EwOWI4YjI4MDYvdGFibGU6Y2Y5YTFhNGQ1M2Q3NDgzNmEwZWUyOWMyZTAzNmU0ZGEvdGFibGVyYW5nZTpjZjlhMWE0ZDUzZDc0ODM2YTBlZTI5YzJlMDM2ZTRkYV8xLTItMS0xLTM1Njc_60891eff-60f9-4b97-9259-c4d0d6d0ff39">APYX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xL2ZyYWc6ZDFhY2YxMTYzNWZmNDZmZjk3NTNlM2EwOWI4YjI4MDYvdGFibGU6Y2Y5YTFhNGQ1M2Q3NDgzNmEwZWUyOWMyZTAzNmU0ZGEvdGFibGVyYW5nZTpjZjlhMWE0ZDUzZDc0ODM2YTBlZTI5YzJlMDM2ZTRkYV8xLTQtMS0xLTM1Njk_8e2ffc62-471c-4f12-94fe-778b7d49f1f8">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xL2ZyYWc6ZDFhY2YxMTYzNWZmNDZmZjk3NTNlM2EwOWI4YjI4MDYvdGV4dHJlZ2lvbjpkMWFjZjExNjM1ZmY0NmZmOTc1M2UzYTA5YjhiMjgwNl80OTQ3ODAyMzI3MzQz_db619411-0287-470e-b983-1bf18f5e43e5">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xL2ZyYWc6ZDFhY2YxMTYzNWZmNDZmZjk3NTNlM2EwOWI4YjI4MDYvdGV4dHJlZ2lvbjpkMWFjZjExNjM1ZmY0NmZmOTc1M2UzYTA5YjhiMjgwNl80OTQ3ODAyMzI3MzQ0_b7e6b391-801c-46c5-9a15-7ce17fad559c">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xL2ZyYWc6ZDFhY2YxMTYzNWZmNDZmZjk3NTNlM2EwOWI4YjI4MDYvdGV4dHJlZ2lvbjpkMWFjZjExNjM1ZmY0NmZmOTc1M2UzYTA5YjhiMjgwNl80OTQ3ODAyMzI3MzQ1_3d895b85-2be9-41aa-8597-948da99ecb40">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xL2ZyYWc6ZDFhY2YxMTYzNWZmNDZmZjk3NTNlM2EwOWI4YjI4MDYvdGV4dHJlZ2lvbjpkMWFjZjExNjM1ZmY0NmZmOTc1M2UzYTA5YjhiMjgwNl80OTQ3ODAyMzI3MzQ3_427d3571-3e79-4889-bfb2-7e1d0aa6de61">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xL2ZyYWc6ZDFhY2YxMTYzNWZmNDZmZjk3NTNlM2EwOWI4YjI4MDYvdGFibGU6NzJhMzg0NWExNTMxNDI1ZmIyY2UzMzI0MjgyMjQ3ZDAvdGFibGVyYW5nZTo3MmEzODQ1YTE1MzE0MjVmYjJjZTMzMjQyODIyNDdkMF8xLTAtMS0xLTUxOTg_63c1562f-c7de-496b-b1a0-5f920203ce8e">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xL2ZyYWc6ZDFhY2YxMTYzNWZmNDZmZjk3NTNlM2EwOWI4YjI4MDYvdGFibGU6NzJhMzg0NWExNTMxNDI1ZmIyY2UzMzI0MjgyMjQ3ZDAvdGFibGVyYW5nZTo3MmEzODQ1YTE1MzE0MjVmYjJjZTMzMjQyODIyNDdkMF8xLTQtMS0xLTM1NDQ_702750e9-042e-42fa-818a-3ed5c3fcebba">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xL2ZyYWc6ZDFhY2YxMTYzNWZmNDZmZjk3NTNlM2EwOWI4YjI4MDYvdGFibGU6NzJhMzg0NWExNTMxNDI1ZmIyY2UzMzI0MjgyMjQ3ZDAvdGFibGVyYW5nZTo3MmEzODQ1YTE1MzE0MjVmYjJjZTMzMjQyODIyNDdkMF8yLTQtMS0xLTM1NDA_16252790-0b83-4b74-ae3e-cfbdf9fac90e">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xL2ZyYWc6ZDFhY2YxMTYzNWZmNDZmZjk3NTNlM2EwOWI4YjI4MDYvdGFibGU6NzJhMzg0NWExNTMxNDI1ZmIyY2UzMzI0MjgyMjQ3ZDAvdGFibGVyYW5nZTo3MmEzODQ1YTE1MzE0MjVmYjJjZTMzMjQyODIyNDdkMF80LTQtMS0xLTUzNTU_291faf13-e7c9-41e8-9e48-4ee01a3443a7">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xL2ZyYWc6ZDFhY2YxMTYzNWZmNDZmZjk3NTNlM2EwOWI4YjI4MDYvdGV4dHJlZ2lvbjpkMWFjZjExNjM1ZmY0NmZmOTc1M2UzYTA5YjhiMjgwNl80OTQ3ODAyMzI3MzQ2_81da8888-5c2f-4b68-854e-22782e1bb27d">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i7ed1b671dc694c3ca5cd5bc47208993d_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xL2ZyYWc6ZDFhY2YxMTYzNWZmNDZmZjk3NTNlM2EwOWI4YjI4MDYvdGV4dHJlZ2lvbjpkMWFjZjExNjM1ZmY0NmZmOTc1M2UzYTA5YjhiMjgwNl80OTQ3ODAyMzI3MzQ5_4ae6ba27-7d28-49c3-9e53-2fa83f3ab915"
      unitRef="usd">189800000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ib31d35568ba546f9a9d4089583b98733_I20210329"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xL2ZyYWc6ZDFhY2YxMTYzNWZmNDZmZjk3NTNlM2EwOWI4YjI4MDYvdGV4dHJlZ2lvbjpkMWFjZjExNjM1ZmY0NmZmOTc1M2UzYTA5YjhiMjgwNl85MzQ1ODQ4ODM4NTc5_1f22652d-c40e-4a59-9566-2d9d73230d86"
      unitRef="shares">34317863</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfMy0xLTEtMS0w_27307a98-2162-449d-b230-1c543ccce7d0"
      unitRef="usd">41915000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfMy0zLTEtMS0w_86be10df-52e4-48e5-994d-090d8389cbe3"
      unitRef="usd">58812000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNi0wLTEtMS0wL3RleHRyZWdpb246NTViYWNjN2VjMmExNGY0MmI3ZmY5YWI1MTY5NDllZjNfMTA5OTUxMTYyNzg0NA_ff0a8256-4df8-4806-a58b-64b07d45a582"
      unitRef="usd">300000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNi0wLTEtMS0wL3RleHRyZWdpb246NTViYWNjN2VjMmExNGY0MmI3ZmY5YWI1MTY5NDllZjNfMTA5OTUxMTYyNzg1MQ_5283322c-bc0f-42d4-9eca-7482fc68acb5"
      unitRef="usd">273000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNi0xLTEtMS0w_d93e2d5b-c25e-4c0c-bfcb-3ca68eab5049"
      unitRef="usd">8399000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNi0zLTEtMS0w_ee5e3a05-faad-40be-a499-882bae056e47"
      unitRef="usd">7987000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:IncomeTaxesReceivable
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNy0xLTEtMS0xMzI_0c603164-0ced-4ab7-b355-3dd62ddea1c9"
      unitRef="usd">7654000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNy0zLTEtMS0xMzI_58b18cae-28c1-413e-a0d1-906949b5996f"
      unitRef="usd">426000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNy0xLTEtMS0w_f206da9c-f99b-4b17-af39-5ec31cf19a89"
      unitRef="usd">1275000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNy0zLTEtMS0w_92fbbfcd-dcb8-41fc-8b3e-ae723781c155"
      unitRef="usd">1233000</us-gaap:OtherReceivablesNetCurrent>
    <apyx:ProvisionForObsolescenceInventory
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfOC0wLTEtMS0wL3RleHRyZWdpb246MGZhMGIwZjQwYjRiNDU3Njk0ZmZmOWFiNzNkYjAzM2FfMTA5OTUxMTYyNzg0Nw_329d841a-7bf1-4241-bfcc-9a17b233f0d9"
      unitRef="usd">388000</apyx:ProvisionForObsolescenceInventory>
    <apyx:ProvisionForObsolescenceInventory
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfOC0wLTEtMS0wL3RleHRyZWdpb246MGZhMGIwZjQwYjRiNDU3Njk0ZmZmOWFiNzNkYjAzM2FfMTA5OTUxMTYyNzg1NA_ab6b87a2-83c4-4acf-8f7c-00d0ec6819d7"
      unitRef="usd">392000</apyx:ProvisionForObsolescenceInventory>
    <us-gaap:InventoryNet
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfOC0xLTEtMS0w_4cca3aee-7d29-4124-894f-9247db909628"
      unitRef="usd">4051000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfOC0zLTEtMS0w_ff6e7fc7-4f50-4133-89cb-332a14b21604"
      unitRef="usd">5068000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfMTAtMS0xLTEtMA_83116c5e-4a2a-4327-8a1c-696db5d24cc8"
      unitRef="usd">2795000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfMTAtMy0xLTEtMA_2eab3fdc-bbe9-406f-966e-4712416f38e1"
      unitRef="usd">3207000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfMTItMS0xLTEtMA_bf9daa06-d018-481b-a1f2-d50990675378"
      unitRef="usd">66089000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfMTItMy0xLTEtMA_1ebdfc9e-6db4-4a81-87bf-4a38ebc9a1d9"
      unitRef="usd">76733000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfMTMtMS0xLTEtMA_d497df63-e174-4cea-915d-143509ba3381"
      unitRef="usd">6541000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfMTMtMy0xLTEtMA_4db7410f-3646-45bb-ac94-94aaade11d22"
      unitRef="usd">6618000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfMTQtMS0xLTEtMA_d734a495-e0fe-4d86-9a11-a56bda26f72e"
      unitRef="usd">237000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfMTQtMy0xLTEtMA_1d25f005-da66-4935-834b-a6fa368a85c7"
      unitRef="usd">350000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfMTgtMS0xLTEtMA_d4915c8f-87ed-4d24-a5e7-0ac4b95d0324"
      unitRef="usd">437000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfMTgtMy0xLTEtMA_8a36d548-7a44-43b0-8293-1cb8fe8c4d87"
      unitRef="usd">653000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfMTktMS0xLTEtMA_b0d22643-2b74-40a3-8f99-78e21e74e2fa"
      unitRef="usd">807000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfMTktMy0xLTEtMA_494107ae-1173-496c-aedc-3b00b323ea51"
      unitRef="usd">391000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfMjEtMS0xLTEtMA_a96c96ad-4de0-4130-a15b-fedcbb653cf7"
      unitRef="usd">74111000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfMjEtMy0xLTEtMA_74d257ec-7c3b-4c4f-8e88-e9da6066f5a4"
      unitRef="usd">84745000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfMjYtMS0xLTEtMA_c2cefb9e-40c9-4751-9aaa-799328e92941"
      unitRef="usd">1511000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfMjYtMy0xLTEtMA_830ec1de-aa4d-477f-8fdb-ecdf0f568565"
      unitRef="usd">2438000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfMjctMS0xLTEtMA_df72342b-87ed-41ee-bf54-75be41d6669c"
      unitRef="usd">7278000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfMjctMy0xLTEtMA_1b684e2b-627b-4ff2-a70b-907220b4a159"
      unitRef="usd">9396000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfMzEtMS0xLTEtMA_07c598a3-ae60-45ef-bc68-3fbfe2a3b21d"
      unitRef="usd">126000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfMzEtMy0xLTEtMA_a8b86100-477c-410f-b9e9-cb7ef19769b3"
      unitRef="usd">108000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfMzItMS0xLTEtMA_00566cd9-8be2-4c64-9bf2-fe1b3ba7403b"
      unitRef="usd">238000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfMzItMy0xLTEtMA_e4414655-df57-4d0e-8ba0-cbfa1f3d63a5"
      unitRef="usd">229000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfMzMtMS0xLTEtMA_3222110c-abbd-4c45-b6f4-1fb70db3d949"
      unitRef="usd">0</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfMzMtMy0xLTEtMA_ccc5b199-31a2-4405-b209-140226372943"
      unitRef="usd">140000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNDAtMS0xLTEtMA_c3b4f8bc-e5df-4f0b-8c3f-afd58ce9338c"
      unitRef="usd">9153000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNDAtMy0xLTEtMA_5c843e95-b52b-4d10-ae00-4573dc9f2f03"
      unitRef="usd">12311000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNDItMS0xLTEtMA_69881be3-3e30-40fb-9517-b73b0e48e7b6"
      unitRef="usd">129000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNDItMy0xLTEtMA_c749d053-9c8f-4f81-9adb-74cc6fd5f83d"
      unitRef="usd">235000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNDMtMS0xLTEtMA_593bd6bc-36b8-4edc-a82f-5e6321abdecf"
      unitRef="usd">183000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNDMtMy0xLTEtMA_166354ca-f18c-4dc0-9221-6037b68ede6a"
      unitRef="usd">421000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNDQtMS0xLTEtMA_1a495784-42f0-4b5a-ac30-31795daf4a84"
      unitRef="usd">621000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNDQtMy0xLTEtODI_e4550917-d979-408e-9858-d9330b502bf2"
      unitRef="usd">405000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNDUtMS0xLTEtMA_398d7667-deac-4ad4-bbd0-90c60e88f05e"
      unitRef="usd">166000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNDUtMy0xLTEtMA_527b05fd-d142-4157-9f13-fde39ae3965f"
      unitRef="usd">114000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNDctMS0xLTEtMA_94b12e4a-494a-4f5e-a6bd-a2697f02b48b"
      unitRef="usd">10252000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNDctMy0xLTEtMA_fa21e73f-713b-40a1-824d-635267a657a8"
      unitRef="usd">13486000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNDktMS0xLTEtMA_411378e8-15c4-4c8e-bddf-19523483d842"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNDktMy0xLTEtMA_9f2d9288-cb24-47da-904d-25ed265549e5"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNTEtMC0xLTEtMC90ZXh0cmVnaW9uOjRlOWQzMjk0NDE5ZjRlZjg5YzhhOTRkOWViOWMyMGIzXzEwOTk1MTE2Mjc5Nzk_7df126f3-3fce-41ed-b2f9-e8e741d6b3d6"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNTEtMC0xLTEtMC90ZXh0cmVnaW9uOjRlOWQzMjk0NDE5ZjRlZjg5YzhhOTRkOWViOWMyMGIzXzEwOTk1MTE2Mjc5Nzk_ad802057-8772-407e-9e8c-126c54b8bb28"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNTEtMC0xLTEtMC90ZXh0cmVnaW9uOjRlOWQzMjk0NDE5ZjRlZjg5YzhhOTRkOWViOWMyMGIzXzEwOTk1MTE2Mjc5OTI_126cebd6-cf09-4ee0-9205-96b19bdc8547"
      unitRef="shares">75000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNTEtMC0xLTEtMC90ZXh0cmVnaW9uOjRlOWQzMjk0NDE5ZjRlZjg5YzhhOTRkOWViOWMyMGIzXzEwOTk1MTE2Mjc5OTI_3ff0a23f-9a94-491b-aba8-332b822a32de"
      unitRef="shares">75000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNTEtMC0xLTEtMC90ZXh0cmVnaW9uOjRlOWQzMjk0NDE5ZjRlZjg5YzhhOTRkOWViOWMyMGIzXzEwOTk1MTE2MjgwMDU_8e500aa4-4daf-429b-9cfc-abe9f84c676d"
      unitRef="shares">34289222</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNTEtMC0xLTEtMC90ZXh0cmVnaW9uOjRlOWQzMjk0NDE5ZjRlZjg5YzhhOTRkOWViOWMyMGIzXzEwOTk1MTE2MjgwMDU_d96729ff-c38b-4b8e-8d0a-381fa5646079"
      unitRef="shares">34289222</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNTEtMC0xLTEtMC90ZXh0cmVnaW9uOjRlOWQzMjk0NDE5ZjRlZjg5YzhhOTRkOWViOWMyMGIzXzEwOTk1MTE2MjgwMTg_aea57991-f1a7-42aa-a817-c7a58822a749"
      unitRef="shares">34312527</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNTEtMC0xLTEtMC90ZXh0cmVnaW9uOjRlOWQzMjk0NDE5ZjRlZjg5YzhhOTRkOWViOWMyMGIzXzEwOTk1MTE2MjgwMzE_e06ff0c9-6e4d-431a-b4dc-e84f9f53ee49"
      unitRef="shares">34169952</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNTEtMS0xLTEtMA_ff912ace-7338-45ba-ae2b-e43dd010c80d"
      unitRef="usd">34000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNTEtMy0xLTEtMA_b7101feb-eba7-4c26-ade5-33b7f3a68300"
      unitRef="usd">34000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNTItMS0xLTEtMA_dc361b27-6f2f-42ae-8313-3994ff8c89ac"
      unitRef="usd">61066000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNTItMy0xLTEtMA_12b6048e-910e-4580-ad83-ee125414ee31"
      unitRef="usd">56708000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNTMtMS0xLTEtMA_0099245f-6357-4255-a742-45d96f2b9c96"
      unitRef="usd">2621000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNTMtMy0xLTEtMA_12b7348f-c60d-4345-a4e2-4646a7abaa45"
      unitRef="usd">14517000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNTQtMS0xLTEtMA_0ff4c242-71f7-45c1-b40d-1c3a10812695"
      unitRef="usd">63721000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNTQtMy0xLTEtMA_78a84f77-d7cc-4777-bff7-36b7c9eb5dbd"
      unitRef="usd">71259000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNTUtMS0xLTEtMTA0_aeb40917-cc49-4401-b57c-c25665de255a"
      unitRef="usd">138000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNTUtMy0xLTEtMTA0_b9d455a0-a343-4177-9689-76a41b6955b4"
      unitRef="usd">0</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNTctMS0xLTEtMzU4Mw_8858a148-a59e-4a66-a96c-862812ae8764"
      unitRef="usd">63859000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNTctMy0xLTEtMzU4Nw_d9d59025-a1af-47c1-9a0e-29cd6e85afe0"
      unitRef="usd">71259000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNTUtMS0xLTEtMA_b7c5c7ef-ed03-4881-90d5-f50b4af93004"
      unitRef="usd">74111000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV81NS9mcmFnOmFjYzg0NGYxOWQwMjQ3ZWY5OTRmNzQzNTcwOWMxZmVmL3RhYmxlOmIyZDE0OWZkOTEyOTQ0YjNiOTEzNGUxZjcwODJkNTM2L3RhYmxlcmFuZ2U6YjJkMTQ5ZmQ5MTI5NDRiM2I5MTM0ZTFmNzA4MmQ1MzZfNTUtMy0xLTEtMA_7b947b3d-d084-4303-9904-aeca407da9d1"
      unitRef="usd">84745000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfMi0xLTEtMS0w_5a7fe1d4-cd29-4ce0-ac62-fb28c289faab"
      unitRef="usd">27711000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfMi0zLTEtMS0w_e46fab52-816a-4334-aa9b-09b1626dca9a"
      unitRef="usd">28235000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfMy0xLTEtMS0w_43fe5483-43bf-40db-945b-d6c8f10b62ac"
      unitRef="usd">10207000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfMy0zLTEtMS0w_4939e319-1450-4cb8-8504-5e200c27be5e"
      unitRef="usd">9141000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfNC0xLTEtMS0w_4cb51c6c-5f95-4cd7-80b2-e6e84367bca6"
      unitRef="usd">17504000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfNC0zLTEtMS0w_3d2cbd80-6bd6-4a22-b405-28d7d0735f6a"
      unitRef="usd">19094000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfNi0xLTEtMS0w_13b94bdd-1b15-4e1c-8488-401816fcbf5b"
      unitRef="usd">3920000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfNi0zLTEtMS0w_3340eae1-8a08-433a-aede-9f133d7fda4f"
      unitRef="usd">3731000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ProfessionalFees
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfNy0xLTEtMS0w_7f02cc0e-fe63-473f-af2c-6b7830fae72e"
      unitRef="usd">7350000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfNy0zLTEtMS0w_e4688dd1-dbcf-4d7f-bffc-caa3206f98aa"
      unitRef="usd">8507000</us-gaap:ProfessionalFees>
    <us-gaap:SalariesAndWages
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfOC0xLTEtMS0w_169cb689-1672-4766-bef5-7b93dbfaf253"
      unitRef="usd">14630000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfOC0zLTEtMS0w_9c0a1d9e-53ef-4564-af1e-40bbaa026525"
      unitRef="usd">14025000</us-gaap:SalariesAndWages>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfOS0xLTEtMS0w_be1b3c1b-1f84-4f09-8795-27afd1e16c68"
      unitRef="usd">11687000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfOS0zLTEtMS0w_e577f7b6-963c-40f6-b0c9-abb0e9bfafe1"
      unitRef="usd">13700000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfMTEtMS0xLTEtMA_8b0b6a75-43a0-47ba-8e17-a1ae00cc8f4b"
      unitRef="usd">37587000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfMTEtMy0xLTEtMA_c8b88149-87af-4ef1-9d0b-52bd5c977941"
      unitRef="usd">39963000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfMTItMS0xLTEtMA_3a230f04-31f9-45d8-a7ca-09327aa096ff"
      unitRef="usd">-20083000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfMTItMS0xLTEtMA_da81baf8-76ae-40ec-9b58-9738333a2341"
      unitRef="usd">-20083000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfMTItMy0xLTEtMA_f73228c6-30b2-4c16-920d-6c052219dc8a"
      unitRef="usd">-20869000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOperating
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfMTQtMS0xLTEtMA_c7657e66-8386-4e7e-824d-a561df032472"
      unitRef="usd">241000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfMTQtMy0xLTEtMA_e68c09ac-f5d8-40aa-8ce7-95937e9a5486"
      unitRef="usd">1392000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestExpense
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfMTUtMS0xLTEtMA_1bd644f3-dcf3-469b-8f91-da7a0d5de2c7"
      unitRef="usd">46000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfMTUtMy0xLTEtMA_17d69843-1b2a-42cf-871d-6985806143bb"
      unitRef="usd">8000</us-gaap:InterestExpense>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfMTgtMS0xLTEtMA_199383b5-a389-4415-866c-7e2252c43233"
      unitRef="usd">479000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfMTgtMy0xLTEtMA_c7cacc41-63b5-4bb1-b8df-e6be788de916"
      unitRef="usd">-351000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfMjEtMS0xLTEtMA_3f6285d0-979e-4d84-a11c-3823111f4af6"
      unitRef="usd">674000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfMjEtMy0xLTEtMA_81ec758b-fb50-4017-abbb-9225046f4b5a"
      unitRef="usd">1033000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfMjItMS0xLTEtMA_2c25f35c-c171-47ec-b47c-3b75439ff59b"
      unitRef="usd">-19409000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfMjItMy0xLTEtMA_11227ec3-da8a-478b-9c6a-35b9ff3b30ca"
      unitRef="usd">-19836000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfMjMtMS0xLTEtMA_03a6a7dc-ab3a-4c7a-bdbb-a3d2b3b725e1"
      unitRef="usd">-7503000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfMjMtMy0xLTEtMA_aae979e1-15eb-4df6-93e5-a40dfd2e8ba2"
      unitRef="usd">-130000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfMjQtMS0xLTEtMA_b8aa7559-8a56-4d49-8318-262b9a47a925"
      unitRef="usd">-11906000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfMjQtMy0xLTEtMA_70d34d50-ce0e-40b6-91b2-8da3c4bf23ee"
      unitRef="usd">-19706000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfMjUtMS0xLTEtMA_3f5e0059-8aff-4207-bb33-d6d3f739f0ab"
      unitRef="usd">-10000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfMjUtMy0xLTEtMA_def018c7-2afa-41a5-b73f-fb9901d1475e"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfMjYtMS0xLTEtMA_bead852b-9fe2-4bb1-9624-d752b940aafa"
      unitRef="usd">-11896000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfMjYtMy0xLTEtMA_2c31e165-b1eb-416d-b730-af5e89196e4d"
      unitRef="usd">-19706000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfMzEtMS0xLTEtMA_b1a97deb-fb87-42c5-b9ad-248234c16d93"
      unitRef="usdPerShare">-0.35</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfMzEtMy0xLTEtMA_2a45bf55-dce6-4518-b6ac-91f28346304d"
      unitRef="usdPerShare">-0.58</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfNDItMS0xLTEtMA_bd47576c-9cf7-46c5-9e38-1ec3a7d8d020"
      unitRef="shares">34212000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82MS9mcmFnOmQ1ZGU2YjNmYTQzYTQ3ZTI4ZDZlYjU2MWQwY2EwYmQyL3RhYmxlOmRiODI1NjQwYTI5NjQ3ZjVhYWJlNDhiMTczYjA5ODM1L3RhYmxlcmFuZ2U6ZGI4MjU2NDBhMjk2NDdmNWFhYmU0OGIxNzNiMDk4MzVfNDItMy0xLTEtMA_377f7bed-86e1-4b85-b1cc-de38b8fdcf19"
      unitRef="shares">34069000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:SharesIssued
      contextRef="i96fdd56f4a934deb9be8b429dd443450_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMjItNS0xLTEtMA_7942230e-8684-497d-8844-99632625b730"
      unitRef="shares">33705000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i96fdd56f4a934deb9be8b429dd443450_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMjItNy0xLTEtMA_eaf8c387-1fc1-4239-8863-f172ae0e63e5"
      unitRef="usd">34000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i56b0b5fc07294eaa8b9b7c9c449eee1a_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMjItOS0xLTEtMA_53b05c0a-9c8e-44d2-a1b9-e10852c4a84f"
      unitRef="usd">52920000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i67c608a0d0d84f82b2791e369dd406ef_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMjItMTEtMS0xLTA_ab32d2bf-d031-496b-970c-2a7c8d65acd5"
      unitRef="usd">34223000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idd03c7764245458ba14ccb5108168190_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMjItMTMtMS0xLTA_a8ab873e-c5c1-493e-94d3-7ce213923abd"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i00df6877cb2d4b75a1a4abee0d94d57f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMjItMTUtMS0xLTA_62e80886-8517-4fc0-91fc-ada9719a7324"
      unitRef="usd">87177000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="id992bd2f876c4b41b9cacd2ed36d028b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMjMtNS0xLTEtMA_67a873dd-06ff-47dc-ba97-17877582141d"
      unitRef="shares">61000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="if1b9838e537a4797bfd3b3f72116ce4a_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMjMtOS0xLTEtMA_ae40eb6f-c85f-46c1-bfe1-9e30a9134d36"
      unitRef="usd">207000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMjMtMTUtMS0xLTA_23076b27-1b95-4676-9b8e-173a4d2a1123"
      unitRef="usd">207000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if1b9838e537a4797bfd3b3f72116ce4a_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMjgtOS0xLTEtMA_d6302fc9-7239-4828-a33b-a5730f3e95dc"
      unitRef="usd">3581000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMjgtMTUtMS0xLTA_d1c1d7fa-615f-444a-801c-a3514e6ce5d5"
      unitRef="usd">3581000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <apyx:StockSwapToAcquireOptionsShares
      contextRef="id992bd2f876c4b41b9cacd2ed36d028b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMjktNS0xLTEtMA_f8421414-31d4-4c55-9d9a-92c3ad9c124c"
      unitRef="shares">223000</apyx:StockSwapToAcquireOptionsShares>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="id992bd2f876c4b41b9cacd2ed36d028b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMzAtNS0xLTEtMA_b75a8e82-f685-46d2-99d6-091ae3888949"
      unitRef="shares">181000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:ProfitLoss
      contextRef="i3251c9a7258d4e12930f0fe7a2b79ff9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMzMtMTEtMS0xLTA_89f053db-b9aa-4e11-9451-0a1709ac15bf"
      unitRef="usd">-19706000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMzMtMTUtMS0xLTA_1bd3144a-4b42-4422-8c6f-58bfcab85d05"
      unitRef="usd">-19706000</us-gaap:ProfitLoss>
    <us-gaap:SharesIssued
      contextRef="ib71a81c6cf874b9f8f5abe1afdc8701d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMzQtNS0xLTEtMA_d0751714-403b-4f06-83fc-81333c56ca6f"
      unitRef="shares">34170000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib71a81c6cf874b9f8f5abe1afdc8701d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMzQtNy0xLTEtMA_32ae4276-3cea-479f-8ef2-dccf4093ec52"
      unitRef="usd">34000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0cae677daf3a4680b30b757dd83c4a07_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMzQtOS0xLTEtMA_800eca9b-1517-4899-b4f9-5144ec468b9c"
      unitRef="usd">56708000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3a3d8fad4cc642db8994868640f75384_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMzQtMTEtMS0xLTA_f0562a43-7a78-4d51-950d-83fce31721ba"
      unitRef="usd">14517000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4bb3f044ef5d488f992a3c49afc08bf0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMzQtMTMtMS0xLTA_b1c76dba-b97e-44e7-8b55-18c0f798422f"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMzQtMTUtMS0xLTA_ea7ad58c-bbbb-4b1a-93c5-957232212773"
      unitRef="usd">71259000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="i1e0b3ac3abbb4da6ba6ebb3596d95da5_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMzUtMTMtMS0xLTIyNw_4e99fa6d-35b6-4655-9175-8e07692507ac"
      unitRef="usd">148000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMzUtMTUtMS0xLTIyNw_b973a557-b4bc-404f-bede-779afbdb13c4"
      unitRef="usd">148000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i8bd3c576836a42909e45df1e4cbe6038_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMzYtNS0xLTEtMjI3_2120e36c-cc59-407d-b01d-c611cd636ded"
      unitRef="shares">27000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i1386a67ac59644f3bcf3f6f4a0040e4f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMzYtOS0xLTEtMjI3_085cf4a0-8e5a-45fd-b622-0a2e8b3263d9"
      unitRef="usd">148000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMzYtMTUtMS0xLTIyNw_406784b1-5138-4cdd-95e1-705e1c97c7f6"
      unitRef="usd">148000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1386a67ac59644f3bcf3f6f4a0040e4f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMzctOS0xLTEtMjI3_2d4608ea-42e6-4f2b-a006-ce77d4ffe291"
      unitRef="usd">4210000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMzctMTUtMS0xLTIyNw_b6ce3a61-0ef4-4f5d-9cd5-e614f48f3b6f"
      unitRef="usd">4210000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <apyx:StockSwapToAcquireOptionsShares
      contextRef="i8bd3c576836a42909e45df1e4cbe6038_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMzgtNS0xLTEtMjI3_b118002c-aee6-4fef-8981-02ff6d21fbfc"
      unitRef="shares">47000</apyx:StockSwapToAcquireOptionsShares>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i8bd3c576836a42909e45df1e4cbe6038_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfMzktNS0xLTEtMjI3_7d61d952-fded-4844-993b-49d8bd3ca51f"
      unitRef="shares">45000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:ProfitLoss
      contextRef="i868214ceea314396813754fb0220fc1f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfNDAtMTEtMS0xLTIyNw_fab8cf41-d846-4f44-aa9f-cbcc6f9b6f47"
      unitRef="usd">-11896000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i1e0b3ac3abbb4da6ba6ebb3596d95da5_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfNDAtMTMtMS0xLTIyNw_51e922f0-a69c-437a-806c-6aaeb30fc95f"
      unitRef="usd">-10000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfNDAtMTUtMS0xLTIyNw_bd098300-204c-4258-aff2-773fee773cf3"
      unitRef="usd">-11906000</us-gaap:ProfitLoss>
    <us-gaap:SharesIssued
      contextRef="i1b9e760795d04740980adf4105f44066_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfNDEtNS0xLTEtMjI3_9cca7727-d4cd-465f-995e-565fdf135d59"
      unitRef="shares">34289000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1b9e760795d04740980adf4105f44066_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfNDEtNy0xLTEtMjI3_a78e3c84-ffa1-48a0-90f8-8a1f9c734b9f"
      unitRef="usd">34000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7d4c03e853084e12b45168c562e7aeac_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfNDEtOS0xLTEtMjI3_2e424aa4-b378-45c3-8b09-a1b20c552ab3"
      unitRef="usd">61066000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i09376f8c140d4e28b47971c939c7a4fb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfNDEtMTEtMS0xLTIyNw_04a6d0fb-7258-42b1-9502-e3cde896eed5"
      unitRef="usd">2621000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6a1a44a54fd4403d892b074c44ed1d4d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfNDEtMTMtMS0xLTIyNw_e06681fb-f9e9-428b-86e3-84282beb549c"
      unitRef="usd">138000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82NC9mcmFnOmE2ZDRmMjE4OTY3NzQ3YWFiNmQ3M2U0YjkzYTA2YmQxL3RhYmxlOjY2OTMwNWZhYzM5MzQyNTk5YWZiMjM2ZjJjMjk4YThiL3RhYmxlcmFuZ2U6NjY5MzA1ZmFjMzkzNDI1OTlhZmIyMzZmMmMyOThhOGJfNDEtMTUtMS0xLTIyNw_af59ae5d-9f69-43d4-8010-d3115de5e163"
      unitRef="usd">63859000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMy0xLTEtMS0w_ffa866a1-9948-4de0-839d-ed2a55b82a49"
      unitRef="usd">-11906000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMy0zLTEtMS0w_e9480eab-25a7-4c15-9dae-b7aa4ddd5604"
      unitRef="usd">-19706000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfNy0xLTEtMS0w_3d5e71aa-9753-4569-91f1-168e56fe2860"
      unitRef="usd">887000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfNy0zLTEtMS0w_036eeae0-0277-4ccc-8739-c4e6c613a6a0"
      unitRef="usd">754000</us-gaap:DepreciationDepletionAndAmortization>
    <apyx:ProvisionForInventoryObsolescence
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfOC0xLTEtMS0w_b7ccee32-ee91-406b-9d43-3282e8840481"
      unitRef="usd">506000</apyx:ProvisionForInventoryObsolescence>
    <apyx:ProvisionForInventoryObsolescence
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfOC0zLTEtMS0w_edccfb6f-d4c9-46df-b0e6-b89c383d98d9"
      unitRef="usd">132000</apyx:ProvisionForInventoryObsolescence>
    <us-gaap:ProductWarrantyExpense
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfOS0xLTEtMS0w_093c03ac-69ee-4ce7-93e4-6d654149e0c5"
      unitRef="usd">215000</us-gaap:ProductWarrantyExpense>
    <us-gaap:ProductWarrantyExpense
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfOS0zLTEtMS0w_e4e905f6-c9dc-454d-a71d-d8dfbe3f0ba5"
      unitRef="usd">321000</us-gaap:ProductWarrantyExpense>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMTAtMS0xLTEtMA_1c3e0143-ee5e-4b03-8eae-691af6a0a6d3"
      unitRef="usd">-13000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMTAtMy0xLTEtMA_6edc0f9a-8f5e-4841-9337-275d9d56472c"
      unitRef="usd">-89000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:ShareBasedCompensation
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMTEtMS0xLTEtMA_2a554c68-b5c4-434c-a7ab-80b7d4151ff3"
      unitRef="usd">4210000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMTEtMy0xLTEtMA_4981fcb9-d509-4a1d-aad7-89edc5a8fbbe"
      unitRef="usd">3581000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnInvestments
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMTQtMS0xLTEtMA_30464bef-5429-4d3b-895b-648dec9a2f08"
      unitRef="usd">0</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMTQtMy0xLTEtMA_ef52ef74-6fc3-4744-b02e-f64c7181e247"
      unitRef="usd">164000</us-gaap:GainLossOnInvestments>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMTUtMS0xLTEtMA_f60ae142-e86c-491e-9a87-d20a92af3729"
      unitRef="usd">262000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMTUtMy0xLTEtMA_53bd53b7-474b-4872-8b64-56b16f877ed1"
      unitRef="usd">-163000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMTgtMS0xLTEtMA_6aa69be4-24f8-44e8-a0ea-cb8fc3a00b69"
      unitRef="usd">558000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMTgtMy0xLTEtMA_1e70e763-3925-4608-a1ba-7e9d5fc6cc44"
      unitRef="usd">3970000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMTktMS0xLTEtMA_11994be3-c5d8-4690-be02-517110ce6338"
      unitRef="usd">7228000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMTktMy0xLTEtMA_b02a78e1-dc04-47dc-872a-d2944df2d1e6"
      unitRef="usd">-180000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMjAtMS0xLTEtMA_0e8c6a2f-2fda-4690-8c27-8ef069a19a41"
      unitRef="usd">27000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMjAtMy0xLTEtMA_fc872d73-508f-4b22-92e3-502e2008c1bd"
      unitRef="usd">586000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMjEtMS0xLTEtMA_32daa676-827f-456e-b950-43d5da6444b5"
      unitRef="usd">-615000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMjEtMy0xLTEtMA_13c477c2-802d-49cb-937d-6e58a6faaa47"
      unitRef="usd">2367000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMjMtMS0xLTEtMA_8b3c4cd0-a152-4716-88d8-129cd943a627"
      unitRef="usd">-965000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMjMtMy0xLTEtMA_4a2b31bf-1658-4624-b040-3b5f02e49f5e"
      unitRef="usd">1054000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMjUtMS0xLTEtMA_01f1ae98-08ad-44fb-9575-3a5ca77af864"
      unitRef="usd">-2090000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMjUtMy0xLTEtMA_70bc26ca-13b7-43b4-b65d-307d76420264"
      unitRef="usd">2370000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMjgtMS0xLTEtMA_fff61d77-a87a-4a4a-b63a-b4b7d1fbef6e"
      unitRef="usd">-16066000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMjgtMy0xLTEtMA_1f34c740-c89d-470d-94a6-99277c700692"
      unitRef="usd">-18475000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMzAtMS0xLTEtMA_68e35276-1000-420b-b29e-9f966535811c"
      unitRef="usd">581000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMzAtMy0xLTEtMA_3b7d8669-71d8-4257-bffd-97da4fe8f729"
      unitRef="usd">1301000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMzItMS0xLTEtMA_a7f10575-97a0-497b-979f-5d6e080b9849"
      unitRef="usd">0</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMzItMy0xLTEtMA_8f3f16b8-2f64-4a5d-80df-9e67195547c9"
      unitRef="usd">18884000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMzMtMS0xLTEtMA_8428d5a4-ef4f-4b0c-a030-301a5b75c23f"
      unitRef="usd">0</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMzMtMy0xLTEtMA_0eca8896-c107-46b6-9a5c-55c855a5ef86"
      unitRef="usd">80726000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMzQtMS0xLTEtMA_43402628-8a5c-4439-a2a0-96a72ac18388"
      unitRef="usd">-581000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMzQtMy0xLTEtMA_afbe7c76-323b-44fa-b31e-599e44bd3939"
      unitRef="usd">60541000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <apyx:ProceedsFromStockOptionsExercisedAndWarrantsExercised
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMzctMS0xLTEtMA_bf9cf70c-02e3-4a63-acab-7c186a1016ab"
      unitRef="usd">148000</apyx:ProceedsFromStockOptionsExercisedAndWarrantsExercised>
    <apyx:ProceedsFromStockOptionsExercisedAndWarrantsExercised
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMzctMy0xLTEtMA_2f7f9095-98d3-45ad-a5b8-83a1f9c13993"
      unitRef="usd">207000</apyx:ProceedsFromStockOptionsExercisedAndWarrantsExercised>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMzgtMS0xLTEtMjkx_d4c534ec-4d80-4c89-b85c-c0b9de74480d"
      unitRef="usd">140000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMzgtMy0xLTEtMzYxNw_d5075f0e-1050-43c3-8a4b-c6ad08e09a6c"
      unitRef="usd">0</us-gaap:RepaymentsOfRelatedPartyDebt>
    <apyx:RepaymentofFinanceLeaseLiabilities
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMzgtMS0xLTEtMA_1c97e890-f5fd-4426-a1a4-1510fc8ae9ba"
      unitRef="usd">229000</apyx:RepaymentofFinanceLeaseLiabilities>
    <apyx:RepaymentofFinanceLeaseLiabilities
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMzgtMy0xLTEtMA_c8c47fc2-a1a3-47b1-a8b2-f38f4068820d"
      unitRef="usd">60000</apyx:RepaymentofFinanceLeaseLiabilities>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMzktMS0xLTEtMA_7778480f-93be-43b2-b63e-6e38176cddd6"
      unitRef="usd">148000</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfMzktMy0xLTEtMA_d8a504bc-a4db-4223-8cb5-38291ad5f184"
      unitRef="usd">0</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfNDMtMS0xLTEtMA_ff0bcae3-b200-41b5-b12f-349e249f7c76"
      unitRef="usd">-73000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfNDMtMy0xLTEtMA_da6d64ce-2694-418e-83f9-308979764561"
      unitRef="usd">147000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfNDQtMS0xLTEtMA_a1e28dd1-c1f7-4399-be99-8435155a6d93"
      unitRef="usd">-177000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfNDQtMy0xLTEtMA_d9d3054d-8c45-4950-967b-2ae758af3603"
      unitRef="usd">3000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfNDUtMS0xLTEtMA_a8e76f3d-5e88-4be4-9d59-1fa1608ca78e"
      unitRef="usd">-16897000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfNDUtMy0xLTEtMA_f4c5fb3d-697c-4106-8c33-6fc5429ad446"
      unitRef="usd">42216000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfNDYtMS0xLTEtMA_b751ad2b-2d05-4076-a785-9faa151dd924"
      unitRef="usd">58812000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i00df6877cb2d4b75a1a4abee0d94d57f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfNDYtMy0xLTEtMA_e34fde87-acc3-434a-bd01-2876a3ead491"
      unitRef="usd">16596000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfNDctMS0xLTEtMA_c5446f13-913a-4259-aa2d-df3b1cd9db38"
      unitRef="usd">41915000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfNDctMy0xLTEtMA_1365fce9-e88b-4d03-a44b-3707fac33eea"
      unitRef="usd">58812000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfNTEtMS0xLTEtMA_6e8e154a-f201-4490-9a1b-a0b03a850f6b"
      unitRef="usd">46000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfNTEtMy0xLTEtMA_af985ef1-c257-4dbf-88b3-75e50fbf710a"
      unitRef="usd">8000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfNTItMS0xLTEtMA_b7f30652-b0c4-44f0-a29f-6bb08a3a933e"
      unitRef="usd">82000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfNTItMy0xLTEtMA_fd587e07-7a93-4fec-82e6-8ab82597a6e9"
      unitRef="usd">325000</us-gaap:IncomeTaxesPaid>
    <apyx:NonCashTransferOfOtherAssetsToFixedAssets
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfNTUtMS0xLTEtMA_e59e705c-9975-4b30-8719-eae52e26dc30"
      unitRef="usd">0</apyx:NonCashTransferOfOtherAssetsToFixedAssets>
    <apyx:NonCashTransferOfOtherAssetsToFixedAssets
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfNTUtMy0xLTEtMA_e804d839-adcb-4a2a-9691-6980f6f3456d"
      unitRef="usd">42000</apyx:NonCashTransferOfOtherAssetsToFixedAssets>
    <apyx:NonCashTransfersOfInventoryToFromFixedAssets
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfNTYtMS0xLTEtMA_02132dbd-855c-479f-8e96-e6da776f287a"
      unitRef="usd">23000</apyx:NonCashTransfersOfInventoryToFromFixedAssets>
    <apyx:NonCashTransfersOfInventoryToFromFixedAssets
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV82Ny9mcmFnOmFlOTdmNmIzNDA4ODQzOGNhMWMzYTQ4NGFjOTM0ODk5L3RhYmxlOmRjYjlmNDlhNDM1NjQ2MzdhMTA3NjY5YjRiNDliMWJlL3RhYmxlcmFuZ2U6ZGNiOWY0OWE0MzU2NDYzN2ExMDc2NjliNGI0OWIxYmVfNTYtMy0xLTEtMA_20c8aace-793b-41e7-8c28-ae102cc734f1"
      unitRef="usd">277000</apyx:NonCashTransfersOfInventoryToFromFixedAssets>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83My9mcmFnOjg5NjA5ZGI5NzlmZDQ2YzM5MDQ5MmYyZTNjNjJiNWQ2L3RleHRyZWdpb246ODk2MDlkYjk3OWZkNDZjMzkwNDkyZjJlM2M2MmI1ZDZfMTI1NA_ff6d252f-7576-4b69-9099-0d0b5b0ad64d">DESCRIPTION OF BUSINESS&#160;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Apyx Medical Corporation (&#x201c;Company", "Apyx", "it" and similar terms) was incorporated in 1982, under the laws of the State of Delaware and has its principal executive office at 5115 Ulmerton Road, Clearwater, FL 33760.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is an advanced energy technology company with a passion for elevating people&#x2019;s lives through innovative products in the cosmetic and surgical markets. Known for its innovative Helium Plasma Technology, Apyx is solely focused on bringing transformative solutions to the physicians and patients they serve. It's Helium Plasma Technology is marketed and sold as Renuvion&#xae; in the cosmetic surgery market and J-Plasma&#xae; in the hospital surgical market. Renuvion&#xae; offers plastic surgeons, fascial plastic surgeons and cosmetic physicians a unique ability to provide controlled heat to the tissue to achieve their desired results. The J-Plasma&#xae; system allows surgeons to operate with a high level of precision, virtually eliminating unintended tissue trauma. The Company also leverages its deep expertise and decades of experience in unique waveforms through original equipment manufacturing (OEM) agreements with other medical device manufacturers.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMTY3ODQ_d12b6993-e47c-4028-b2f8-cbf4869903f0">SIGNIFICANT ACCOUNTING POLICIES&#160;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Consolidated Financial Statements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements include the accounts of Apyx, its wholly owned subsidiary, Apyx Bulgaria, EOOD, and its 51% owned subsidiary, Apyx SY Medical Devices (Ningbo) Co., Ltd. (collectively, "Apyx," or the &#x201c;Company&#x201d;). All significant intercompany transactions and balances have been eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates in the Preparation of Financial Statements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. The reported amounts of revenues and expenses during the reporting period may be affected by the estimates and assumptions the Company is required to make.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Holdings of highly liquid investments with original maturities of three months or less from the date of purchase are considered to be cash equivalents. As of December 31, 2020 and 2019, all of the Company&#x2019;s U.S. Treasury Bills have original maturities of three months or less and are included in cash and cash equivalents.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of trade accounts receivable. With respect to cash, the Company frequently maintains cash and cash equivalent balances in excess of federally insured limits; it has not experienced any losses in such accounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Trade Accounts Receivable and Allowance for Doubtful Accounts&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's standard credit terms for billings range from net 10 days to net 90 days, depending on the customer agreement. Accounts receivable are determined to be past due if payments are not made in accordance with such agreements and an allowance is generally recorded for accounts that become three months past due, or sooner if there are other indicators that the receivables may not be recovered. Customary collection efforts are initiated, and receivables are written off when the Company determines they are not collectible and abandons these collection efforts.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates the allowance for doubtful accounts on a regular basis for adequacy based upon its periodic review of the collectability of the receivables in light of historical experience, adverse situations that may affect its customers&#x2019; ability to pay and prevailing economic conditions. This evaluation is inherently subjective, as it requires estimates that are susceptible to significant revision as more information becomes available. Management believes that the allowances for doubtful accounts of approximately $0.3 million at December&#160;31, 2020 and 2019, are adequate to provide for possible bad debts.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are allocated to manufactured inventory based upon labor hours. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company monitors inventory usage to determine if the carrying value of any items should be adjusted due to lack of demand for the item and adjusts inventory for estimated obsolescence or unusable inventory equal to the difference between the cost of inventory and the estimated net realizable value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are recorded at cost. Depreciation and amortization are provided for using the straight-line method over the estimated useful lives of the assets. The amortization of leasehold improvements is based on the shorter of the lease term or the life of the improvement. Betterments and major improvements, which extend the life of the asset, are capitalized, whereas maintenance and repairs and routine improvements are expensed as incurred. The estimated useful lives are: buildings and improvements, 39 years; machinery and equipment, 3-10 years; furniture and fixtures, 5-10 years;  computer equipment and software, 3-5 years; and molds, 7-15 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Valuation of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews long-lived assets for recoverability if events or changes in circumstances indicate that the assets may have been impaired. This circumstance exists when the carrying amount of the asset exceeds the sum of the undiscounted cash flows expected to result from its use and eventual disposition. In those cases, an impairment loss is recognized to the extent that the assets&#x2019; carrying amount exceeds its fair value. Any impairment losses are not restored in the future if the fair value increases. At December&#160;31, 2020, the Company believes the remaining carrying values of its long-lived assets are recoverable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Product Warranties&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides a four year limited warranty on end-user sales of its Renuvion&#xae;/J-Plasma&#xae; generators, a two year warranty on mounting fixtures, and a one-year warranty on certain accessories. The Company estimates and provides for future costs for product warranties in cost of sales at the time revenue is recognized. The Company bases its product warranty costs on related material costs, repair labor costs and shipping costs. The Company estimates the future cost of product warranties by considering historical material, repair labor, and shipping costs, and applying the experience rates to the outstanding warranty period for products sold. It is reasonably possible that actual results could differ from those estimates. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration that the Company expects to receive for those goods or services. To recognize revenue, the Company (i) identifies the contract(s) with a customer; (ii) identifies the performance obligations in the contract; (iii) determines the transaction price; (iv) allocates the transaction price to the performance obligations in the contract; and (v) recognizes revenue when, or as, it satisfies the performance obligation(s). For sales of the Company's Advanced Energy products (Renuvion&#xae;/J-Plasma&#xae;), this is at a point in time when title has been transferred to the customer, which is generally at the time of shipment or receipt by customer for FOB destination terms. For sales of products under its OEM agreements, the Company recognizes revenue over time when no alternative use exists for the manufactured goods and the Company has rights to payment. Presently, the Company does not stock any significant completed goods under its OEM agreements, accordingly, the recognition of revenue under these agreements approximates point in time recognition. The following policies apply to its major categories of revenue transactions:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:63pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt"&gt;The majority of sales to customers are evidenced by firm purchase orders. Generally, title and the risks and rewards of ownership are transferred to the customer when the product is shipped. Payment by the customer is due under fixed payment terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:63pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt"&gt;Product returns are only accepted at the Company's discretion and in accordance with its &#x201c;Returned Goods Policy&#x201d;. Historically, the level of product returns has not been significant. Accruals for sales returns, rebates and allowances are made as a reduction of revenue based upon an analysis of historical customer returns and credits, rebates, discounts and current market conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:63pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt"&gt;The terms of sale to customers generally do not include any obligations to perform future services. Limited warranties are generally provided for sales and provisions for warranty are provided at the time of product sale based upon an analysis of historical data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:63pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt"&gt;In connection with the execution of OEM supply agreements, the Company may enter into an accompanying product development agreement. If the Company enters into a product development agreement, and development of the goods does not represent a performance obligation on a standalone basis, the Company defers the development fees billed to customers and the associated costs. At December 31, 2020 and 2019, respectively, the Company had recorded approximately $0.6&#160;million and $0.4 million of contract liabilities and $0.2&#160;million and $0.1 million of contract assets related to the deferral of revenues and expenses under these agreements. Recognition of the deferred billings and costs will occur as the Company performs on the accompanying supply arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Advertising Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Advertising costs are expensed as incurred. The amounts of advertising costs, including trade shows, were approximately $0.8 million and $1.5 million for the years ended December&#160;31, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for stock-based compensation in accordance with FASB ASC Topic 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation-Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. FASB ASC 718 requires recognizing compensation expense for all share-based payment awards made to employees, directors and non-employees based upon the awards&#x2019; grant date fair value. It accounts for forfeitures as they occur. The standard covers employee stock options, restricted stock and other equity awards. The Company utilizes a Black-Scholes model to estimate the grant date fair value of stock option awards. For employee and director awards, compensation expense is recognized on a straight-line basis over the vesting periods. For  non-employee awards, compensation expense is recorded for non-forfeitable, fully vested awards at the grant date. For other awards granted to non-employees, compensation cost is recognized as services are provided, which approximates a straight-line basis over the vesting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Litigation Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with authoritative guidance, the Company accrues a liability in its consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible, but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the consolidated financial statements. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded; actual results may differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income (Loss) Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company computes basic (loss) earnings attributable to common stockholders per share by dividing net (loss) income attributable to common stockholders by the weighted average number of common shares outstanding for the reporting period. Diluted (loss) earnings per share attributable to common stockholders gives effect to all potential dilutive shares outstanding during the period. The number of dilutive shares is calculated using the treasury stock method which reduces the effective number of shares by the amount of shares the Company could purchase with the proceeds of assumed exercises. Anti-dilutive units are excluded from the calculation of diluted shares. In periods of loss, all potentially dilutive units are anti-dilutive and are excluded from the calculation of diluted income (loss) per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses are charged to operations as incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilizes the liability method of accounting for income taxes as set forth in FASB ASC Topic 740, "Income Taxes".  Under the liability method, deferred taxes are determined based on temporary differences between the financial statement and tax bases of assets and liabilities using tax rates expected to be in effect during the years in which the deferred taxes reverse.  The Company accounts for interest and penalties on income taxes as income tax expense. A valuation allowances is recorded when it is more likely than not that a tax benefit will not be realized.  In determining the need for valuation allowances the Company considers projected future taxable income, the timing of reversals of temporary differences, and the availability of tax planning strategies.  As of December 31, 2020 and 2019, the Company recorded a valuation allowance on the net deferred tax asset. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses the realizability of deferred tax assets each reporting period and will be able to reduce the valuation allowance to the extent the financial results of continuing operations improve, and it becomes more likely than not that the deferred tax assets will be realizable. As Management expects the Company to continue to generate losses in the foreseeable future after 2020, the Company will continue to record a full valuation allowance on the net deferred tax assets as of December 31, 2020. As a result of the CARES ACT, during 2020, the Company released the valuation allowance on the Federal NOLs that can now be carried back to prior taxable years.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses the financial statement impact of an uncertain tax position taken or expected to be taken on an income tax return at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority.  An uncertain income tax position will not be recognized in the financial statements unless it is more likely than not of being sustained. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Foreign Currency Transactions&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional currency of Apyx Bulgaria is the U.S.&#160;dollar. The monetary assets and liabilities that are denominated in a currency other than U.S. dollar are remeasured into U.S.&#160;dollars at the exchange rate on the balance sheet date, while nonmonetary items are remeasured at historical rates. Revenue and expenses are remeasured at weighted average exchange rates during the period. Transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency are included in selling, general and administrative expenses in the Consolidated Statements of Operations and were not material for the years ended December 31, 2020 and 2019. &lt;/span&gt;&lt;/div&gt;RECENT ACCOUNTING PRONOUNCEMENTS&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments&#x2014;Credit Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Topic 326). The update changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, contract assets, held-to-maturity debt securities and loans, and requires entities to use a new forward-looking expected loss model that will result in the earlier recognition of allowance for losses. This update, as originally issued, was effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Topic 326),&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Derivatives and Hedging &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Topic 815), &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;and Leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Topic 842) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Effective Dates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which deferred the effective dates of these standards for Smaller Reporting Companies until fiscal years beginning after December 15, 2022. The Company currently expects to continue to qualify as a Smaller Reporting Company, based upon the current SEC definition and, as a result, will be utilizing the deferred elective date. While the Company is in the process of determining the effects of the adoption of the standard on the consolidated financial statements, it does not expect the impact to be material.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on the Company's consolidated financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMTY4NzA_28232f0a-37a6-4955-80ef-8a0acc7d758d">Consolidated Financial StatementsThe accompanying consolidated financial statements include the accounts of Apyx, its wholly owned subsidiary, Apyx Bulgaria, EOOD, and its 51% owned subsidiary, Apyx SY Medical Devices (Ningbo) Co., Ltd. (collectively, "Apyx," or the &#x201c;Company&#x201d;). All significant intercompany transactions and balances have been eliminated in consolidation.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i45882c1ec2804d9e9753f1f3e2754339_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMTA5OTUxMTY1MDMxNQ_57d44797-3b2d-49ee-a36f-ff35071f4587"
      unitRef="number">0.51</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:UseOfEstimates
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMTY3OTY_5d08ff91-a56b-48d3-96d4-f56e0003ff63">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates in the Preparation of Financial Statements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. The reported amounts of revenues and expenses during the reporting period may be affected by the estimates and assumptions the Company is required to make.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMTY4MDg_a98f1baa-7968-4a7d-b533-9fd9585b70fa">Cash and Cash EquivalentsHoldings of highly liquid investments with original maturities of three months or less from the date of purchase are considered to be cash equivalents. As of December 31, 2020 and 2019, all of the Company&#x2019;s U.S. Treasury Bills have original maturities of three months or less and are included in cash and cash equivalents.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMTY4MDY_2a732bb9-5daf-4a73-ba19-0a45ca8f7e30">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of trade accounts receivable. With respect to cash, the Company frequently maintains cash and cash equivalent balances in excess of federally insured limits; it has not experienced any losses in such accounts.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMTY4NjA_29bc863d-e662-4981-a046-e58658835642">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Trade Accounts Receivable and Allowance for Doubtful Accounts&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's standard credit terms for billings range from net 10 days to net 90 days, depending on the customer agreement. Accounts receivable are determined to be past due if payments are not made in accordance with such agreements and an allowance is generally recorded for accounts that become three months past due, or sooner if there are other indicators that the receivables may not be recovered. Customary collection efforts are initiated, and receivables are written off when the Company determines they are not collectible and abandons these collection efforts.&lt;/span&gt;&lt;/div&gt;The Company evaluates the allowance for doubtful accounts on a regular basis for adequacy based upon its periodic review of the collectability of the receivables in light of historical experience, adverse situations that may affect its customers&#x2019; ability to pay and prevailing economic conditions. This evaluation is inherently subjective, as it requires estimates that are susceptible to significant revision as more information becomes available.</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <apyx:SalesDiscountBillingTermsLowerLimit
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMzM5NA_ff81a243-8442-42fa-868e-e800f6bc2efb">P10D</apyx:SalesDiscountBillingTermsLowerLimit>
    <apyx:SalesDiscountBillingTermsUpperLimit
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMzQwNA_5f9d4959-3ac4-48fa-af75-66727c35cd00">P90D</apyx:SalesDiscountBillingTermsUpperLimit>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfNDQwMQ_83a318b9-5002-4931-b56d-aa0a8a1b4fab"
      unitRef="usd">300000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfNDQwMQ_f22477c2-aac3-44eb-908a-7cafc9abc348"
      unitRef="usd">300000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMTY3NDk_5ad8975d-0933-45f3-b17e-df92194c51c0">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are allocated to manufactured inventory based upon labor hours. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company monitors inventory usage to determine if the carrying value of any items should be adjusted due to lack of demand for the item and adjusts inventory for estimated obsolescence or unusable inventory equal to the difference between the cost of inventory and the estimated net realizable value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMTY4MjQ_b1d21de0-1edc-40ae-8a20-7b5e5e482712">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are recorded at cost. Depreciation and amortization are provided for using the straight-line method over the estimated useful lives of the assets. The amortization of leasehold improvements is based on the shorter of the lease term or the life of the improvement. Betterments and major improvements, which extend the life of the asset, are capitalized, whereas maintenance and repairs and routine improvements are expensed as incurred. The estimated useful lives are: buildings and improvements, 39 years; machinery and equipment, 3-10 years; furniture and fixtures, 5-10 years;  computer equipment and software, 3-5 years; and molds, 7-15 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i0bc128762b18423fb747675dee1c2b38_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMjE5OTAyMzI3ODkwMw_91e79db8-d291-4f37-ba9a-ed110c80f112">P39Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i1cbbd8dbe42a42989174fca0d2219d64_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMjE5OTAyMzI3OTAyMA_0fda99e4-57cf-45bf-913a-126bb7615bb1">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ided82545571a4ee3959a92c88503da8a_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMjE5OTAyMzI3OTAyNA_bde87ddc-bdf0-41a4-af46-33dbe11675c2">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="id16feebf7b354586bb519173e63e4a13_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMjE5OTAyMzI3ODk4MQ_96fc3343-3582-4b24-86b3-4a31f71239bd">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ia212175fe18e4aa78e12bf752ae2656e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMjE5OTAyMzI3ODk4NQ_848f591a-b00b-4ac0-907c-7b326fe6b65a">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i7f6eeb41de814d65b926757c9f6c1659_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMjE5OTAyMzI3OTA5Nw_7ba2d8ef-6dd3-4363-b33e-7c2910681957">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i9461cea186574f9d99826a2a0dc1e166_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMjE5OTAyMzI3OTEwMQ_1cad51a5-e4e6-46e8-a070-5cbec5b3b36f">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i373f3e4cf9074d1eaadacf5820f14dc7_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMjE5OTAyMzI3OTAwOA_acd1638f-abe7-49c6-bf9b-dd1ae88d843d">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i37622543d9574bb98c9c743b9e441331_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMjE5OTAyMzI3OTAxMg_d26ee61e-1275-4527-a3e9-42860a7db830">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMTY4MTc_de02e79a-fb4d-4238-907c-437c4ba6462e">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Valuation of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews long-lived assets for recoverability if events or changes in circumstances indicate that the assets may have been impaired. This circumstance exists when the carrying amount of the asset exceeds the sum of the undiscounted cash flows expected to result from its use and eventual disposition. In those cases, an impairment loss is recognized to the extent that the assets&#x2019; carrying amount exceeds its fair value. Any impairment losses are not restored in the future if the fair value increases. At December&#160;31, 2020, the Company believes the remaining carrying values of its long-lived assets are recoverable.&lt;/span&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:StandardProductWarrantyPolicy
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMTY4NzU_303ae309-bd21-4527-baba-524a5b72dd53">Product WarrantiesThe Company provides a four year limited warranty on end-user sales of its Renuvion&#xae;/J-Plasma&#xae; generators, a two year warranty on mounting fixtures, and a one-year warranty on certain accessories. The Company estimates and provides for future costs for product warranties in cost of sales at the time revenue is recognized. The Company bases its product warranty costs on related material costs, repair labor costs and shipping costs. The Company estimates the future cost of product warranties by considering historical material, repair labor, and shipping costs, and applying the experience rates to the outstanding warranty period for products sold. It is reasonably possible that actual results could differ from those estimates.</us-gaap:StandardProductWarrantyPolicy>
    <apyx:ProductWarranty
      contextRef="i0b779b72fb924855b2f72a574d145bd7_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMTA5OTUxMTY1MDM0NQ_1a5f9e34-f78c-4ce6-8ac4-dc43d2bf4dc9">P4Y</apyx:ProductWarranty>
    <apyx:ProductWarranty
      contextRef="i981157b059a44725985cef208243fc13_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMTA5OTUxMTY1MDM0NA_37d44102-fb6a-44a9-8426-6f4f5c253825">P2Y</apyx:ProductWarranty>
    <apyx:ProductWarranty
      contextRef="i8df0935c0bc549ebafb864ba67aab0d3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMTA5OTUxMTY1MDM1OA_d681a705-4a4c-405a-98a5-8b26beb5a05c">P1Y</apyx:ProductWarranty>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMTY4MDA_ee322f26-c8f0-478e-b284-e5b699c6a088">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration that the Company expects to receive for those goods or services. To recognize revenue, the Company (i) identifies the contract(s) with a customer; (ii) identifies the performance obligations in the contract; (iii) determines the transaction price; (iv) allocates the transaction price to the performance obligations in the contract; and (v) recognizes revenue when, or as, it satisfies the performance obligation(s). For sales of the Company's Advanced Energy products (Renuvion&#xae;/J-Plasma&#xae;), this is at a point in time when title has been transferred to the customer, which is generally at the time of shipment or receipt by customer for FOB destination terms. For sales of products under its OEM agreements, the Company recognizes revenue over time when no alternative use exists for the manufactured goods and the Company has rights to payment. Presently, the Company does not stock any significant completed goods under its OEM agreements, accordingly, the recognition of revenue under these agreements approximates point in time recognition. The following policies apply to its major categories of revenue transactions:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:63pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt"&gt;The majority of sales to customers are evidenced by firm purchase orders. Generally, title and the risks and rewards of ownership are transferred to the customer when the product is shipped. Payment by the customer is due under fixed payment terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:63pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt"&gt;Product returns are only accepted at the Company's discretion and in accordance with its &#x201c;Returned Goods Policy&#x201d;. Historically, the level of product returns has not been significant. Accruals for sales returns, rebates and allowances are made as a reduction of revenue based upon an analysis of historical customer returns and credits, rebates, discounts and current market conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:63pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt"&gt;The terms of sale to customers generally do not include any obligations to perform future services. Limited warranties are generally provided for sales and provisions for warranty are provided at the time of product sale based upon an analysis of historical data.&lt;/span&gt;&lt;/div&gt;&#x2022;In connection with the execution of OEM supply agreements, the Company may enter into an accompanying product development agreement. If the Company enters into a product development agreement, and development of the goods does not represent a performance obligation on a standalone basis, the Company defers the development fees billed to customers and the associated costs. At December 31, 2020 and 2019, respectively, the Company had recorded approximately $0.6&#160;million and $0.4 million of contract liabilities and $0.2&#160;million and $0.1 million of contract assets related to the deferral of revenues and expenses under these agreements. Recognition of the deferred billings and costs will occur as the Company performs on the accompanying supply arrangements.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfNDk0NzgwMjM0NzQ3MA_a693c448-ebb6-4c08-aa6e-9984c3a6335d"
      unitRef="usd">600000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMTA5NDg_727a48bd-0dce-443e-be1b-0f4eee51814b"
      unitRef="usd">400000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfNDk0NzgwMjM0NzQ4NA_4691ac86-9948-4fc8-9a25-d423abae148a"
      unitRef="usd">200000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMTA5Nzk_eb2895d3-8ca9-4ee3-bfc4-8e9c6ed25b23"
      unitRef="usd">100000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMTY4NjE_06d96eb3-0038-457b-a691-ea8e15dcb29b">Advertising CostsAdvertising costs are expensed as incurred.</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMTEyMTg_644a898d-6586-4e70-be0e-292ebfcb0e3e"
      unitRef="usd">800000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMTEyMjI_e2cf8a3e-75b1-4f01-9e97-810951b6bdad"
      unitRef="usd">1500000</us-gaap:AdvertisingExpense>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMTY4NTU_1328a765-b6d2-42e9-99c4-e1597c94d87c">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for stock-based compensation in accordance with FASB ASC Topic 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation-Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. FASB ASC 718 requires recognizing compensation expense for all share-based payment awards made to employees, directors and non-employees based upon the awards&#x2019; grant date fair value. It accounts for forfeitures as they occur. The standard covers employee stock options, restricted stock and other equity awards. The Company utilizes a Black-Scholes model to estimate the grant date fair value of stock option awards. For employee and director awards, compensation expense is recognized on a straight-line basis over the vesting periods. For  non-employee awards, compensation expense is recorded for non-forfeitable, fully vested awards at the grant date. For other awards granted to non-employees, compensation cost is recognized as services are provided, which approximates a straight-line basis over the vesting period.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2019, the Company began granting stock option awards deeper within the organization. It does not have sufficient experience with grants to these employees and has experienced challenges in developing reliable forfeiture estimates at the grant date. Accounting for revising the forfeiture estimates has been burdensome. Accounting Standards Codification 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation- Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, prescribes two methods for accounting for forfeitures on stock option awards, either the estimation method utilized by the Company previously, or by accounting for forfeitures as they occur. On January 1, 2020, the Company made an accounting policy election change and began accounting for forfeitures on stock option awards using actual forfeitures. This accounting policy election change was made on a retrospective basis. However, the changes to the current and prior period were determined to be immaterial and there have been no changes to previously reported results as a result of the change.&lt;/span&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:LegalCostsPolicyTextBlock
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMTY4NjQ_17cb336e-4df6-4e42-8027-17db37548aad">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Litigation Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with authoritative guidance, the Company accrues a liability in its consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible, but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the consolidated financial statements. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded; actual results may differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:LegalCostsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMTY4Mjc_97afdcdb-be94-4a1d-aaf9-5f5410f40665">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income (Loss) Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company computes basic (loss) earnings attributable to common stockholders per share by dividing net (loss) income attributable to common stockholders by the weighted average number of common shares outstanding for the reporting period. Diluted (loss) earnings per share attributable to common stockholders gives effect to all potential dilutive shares outstanding during the period. The number of dilutive shares is calculated using the treasury stock method which reduces the effective number of shares by the amount of shares the Company could purchase with the proceeds of assumed exercises. Anti-dilutive units are excluded from the calculation of diluted shares. In periods of loss, all potentially dilutive units are anti-dilutive and are excluded from the calculation of diluted income (loss) per share.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMTY3NjE_de85e4b6-cd1b-4213-95c8-37fd98ef0755">Research and Development CostsResearch and development expenses are charged to operations as incurred.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMTY3NzY_9cc5dbf5-05d0-4205-8d68-3a2b6e5dcf1f">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilizes the liability method of accounting for income taxes as set forth in FASB ASC Topic 740, "Income Taxes".  Under the liability method, deferred taxes are determined based on temporary differences between the financial statement and tax bases of assets and liabilities using tax rates expected to be in effect during the years in which the deferred taxes reverse.  The Company accounts for interest and penalties on income taxes as income tax expense. A valuation allowances is recorded when it is more likely than not that a tax benefit will not be realized.  In determining the need for valuation allowances the Company considers projected future taxable income, the timing of reversals of temporary differences, and the availability of tax planning strategies.  As of December 31, 2020 and 2019, the Company recorded a valuation allowance on the net deferred tax asset. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses the realizability of deferred tax assets each reporting period and will be able to reduce the valuation allowance to the extent the financial results of continuing operations improve, and it becomes more likely than not that the deferred tax assets will be realizable. As Management expects the Company to continue to generate losses in the foreseeable future after 2020, the Company will continue to record a full valuation allowance on the net deferred tax assets as of December 31, 2020. As a result of the CARES ACT, during 2020, the Company released the valuation allowance on the Federal NOLs that can now be carried back to prior taxable years.&lt;/span&gt;&lt;/div&gt;The Company assesses the financial statement impact of an uncertain tax position taken or expected to be taken on an income tax return at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority.  An uncertain income tax position will not be recognized in the financial statements unless it is more likely than not of being sustained.</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83Ni9mcmFnOmYxZjljMTE3NTlmMTQ2MDNhZmZmMGEyNDMzNjA3NDRkL3RleHRyZWdpb246ZjFmOWMxMTc1OWYxNDYwM2FmZmYwYTI0MzM2MDc0NGRfMTY3ODM_ad0e7065-8ee4-48b4-8f6a-437f2379a1b9">Foreign Currency TransactionsThe functional currency of Apyx Bulgaria is the U.S.&#160;dollar. The monetary assets and liabilities that are denominated in a currency other than U.S. dollar are remeasured into U.S.&#160;dollars at the exchange rate on the balance sheet date, while nonmonetary items are remeasured at historical rates. Revenue and expenses are remeasured at weighted average exchange rates during the period. Transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency are included in selling, general and administrative expenses in the Consolidated Statements of Operations and were not material for the years ended December 31, 2020 and 2019.</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:AccountingChangesAndErrorCorrectionsTextBlock
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNzIyL2ZyYWc6OTE2Y2MxZjkzOGFjNDc5ZGJmZDUxNGI0Y2RiZmZhZmUvdGV4dHJlZ2lvbjo5MTZjYzFmOTM4YWM0NzlkYmZkNTE0YjRjZGJmZmFmZV80OTQ3ODAyMzI3MjY3_904ba55e-f855-4afb-b9b0-87e58a469f93">CHANGE IN ACCOUNTING POLICY&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2019, the Company began granting stock option awards deeper within the organization. It does not have sufficient experience with grants to these employees and has experienced challenges in developing reliable forfeiture estimates at the grant date. Accounting for revising the forfeiture estimates has been burdensome. Accounting Standards Codification 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation- Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, prescribes two methods for accounting for forfeitures on stock option awards, either the estimation method utilized by the Company previously, or by accounting for forfeitures as they occur. On January 1, 2020, the Company made an accounting policy election change and began accounting for forfeitures on stock option awards using actual forfeitures. This accounting policy election change was made on a retrospective basis. However, the changes to the current and prior period were determined to be immaterial and there have been no changes to previously reported results as a result of the change.&lt;/span&gt;</us-gaap:AccountingChangesAndErrorCorrectionsTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV83OS9mcmFnOmNiZjRlY2NkM2VjMTRlNWU4OTQ3NDZhNmRhNGI0YmIxL3RleHRyZWdpb246Y2JmNGVjY2QzZWMxNGU1ZTg5NDc0NmE2ZGE0YjRiYjFfMjIzMw_942da197-8315-4c6f-879d-78adb25ae8a6">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments&#x2014;Credit Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Topic 326). The update changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, contract assets, held-to-maturity debt securities and loans, and requires entities to use a new forward-looking expected loss model that will result in the earlier recognition of allowance for losses. This update, as originally issued, was effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Topic 326),&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Derivatives and Hedging &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Topic 815), &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;and Leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Topic 842) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Effective Dates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which deferred the effective dates of these standards for Smaller Reporting Companies until fiscal years beginning after December 15, 2022. The Company currently expects to continue to qualify as a Smaller Reporting Company, based upon the current SEC definition and, as a result, will be utilizing the deferred elective date. While the Company is in the process of determining the effects of the adoption of the standard on the consolidated financial statements, it does not expect the impact to be material.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on the Company's consolidated financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV85MS9mcmFnOjhiNTA4Y2FkYTBhZTQ4YjNhNDZhYmQzYTE5ZDIwNWIyL3RleHRyZWdpb246OGI1MDhjYWRhMGFlNDhiM2E0NmFiZDNhMTlkMjA1YjJfMjI4MQ_302abc66-1726-48db-94ca-0eb9ea2bca78">DISPOSITION OF THE CORE BUSINESS&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 30, 2018, the Company closed on a definitive asset purchase agreement (the "Asset Purchase Agreement") with Specialty Surgical Instrumentation Inc., a Tennessee Corporation and wholly owned subsidiary of Symmetry Surgical Inc. (&#x201c;Symmetry&#x201d;), pursuant to which the Company divested and sold the Company's electrosurgical "Core" business segment and related intellectual property, including the Bovie&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; brand and trademarks, to Symmetry for gross proceeds of $97 million in cash.&lt;/span&gt;In connection with the Asset Purchase Agreement, the Company entered into an Electro Surgical Disposables and Accessories, Cauteries and Other Products Supply Agreement with Symmetry for a four-year term, whereby it will manufacture certain Core products and sell them to Symmetry at agreed upon prices. Any activity resulting from this agreement is netted and reported in the Consolidated Statements of Operations as other income (loss). Core activity for 2020 amounted to $9.4&#160;million with cost of sales equivalents of $8.1&#160;million and other related expenses of $0.8&#160;million for net other income of $0.5&#160;million.  Core activity in 2019 amounted to&#160;$9.4 million&#160;with cost of sales equivalents of&#160;$8.8 million&#160;and related operating expenses of&#160;$0.5 million for net other income of $0.1&#160;million.</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="i67552fb7889b46aebef782a87a2fa29c_D20180830-20180830"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV85MS9mcmFnOjhiNTA4Y2FkYTBhZTQ4YjNhNDZhYmQzYTE5ZDIwNWIyL3RleHRyZWdpb246OGI1MDhjYWRhMGFlNDhiM2E0NmFiZDNhMTlkMjA1YjJfNTA0_5861dab8-6c4d-4ce9-b920-fc31d2051e59"
      unitRef="usd">97000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <apyx:AssetPurchaseAgreementTerm
      contextRef="ice559c8f3fad43108151f29c47e8b650_D20180830-20180830"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV85MS9mcmFnOjhiNTA4Y2FkYTBhZTQ4YjNhNDZhYmQzYTE5ZDIwNWIyL3RleHRyZWdpb246OGI1MDhjYWRhMGFlNDhiM2E0NmFiZDNhMTlkMjA1YjJfMTA5OTUxMTYzMzY5OA_aec0783e-b7c1-4d5f-8fd0-2cd08abb0c64">P4Y</apyx:AssetPurchaseAgreementTerm>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i1f29cae9fd29439fa7f042f1814f46aa_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV85MS9mcmFnOjhiNTA4Y2FkYTBhZTQ4YjNhNDZhYmQzYTE5ZDIwNWIyL3RleHRyZWdpb246OGI1MDhjYWRhMGFlNDhiM2E0NmFiZDNhMTlkMjA1YjJfNTQ5NzU1ODE0NDcxNA_7d986ebe-8e36-449c-81d6-09858d0d573e"
      unitRef="usd">9400000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="i1f29cae9fd29439fa7f042f1814f46aa_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV85MS9mcmFnOjhiNTA4Y2FkYTBhZTQ4YjNhNDZhYmQzYTE5ZDIwNWIyL3RleHRyZWdpb246OGI1MDhjYWRhMGFlNDhiM2E0NmFiZDNhMTlkMjA1YjJfNTQ5NzU1ODE0NDcyOA_0e29ddae-0385-4566-a31f-3e8892c4777a"
      unitRef="usd">8100000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="i1f29cae9fd29439fa7f042f1814f46aa_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV85MS9mcmFnOjhiNTA4Y2FkYTBhZTQ4YjNhNDZhYmQzYTE5ZDIwNWIyL3RleHRyZWdpb246OGI1MDhjYWRhMGFlNDhiM2E0NmFiZDNhMTlkMjA1YjJfNTQ5NzU1ODE0NDc0Mg_4a94eab0-2049-4e17-9d39-e08b1bbf8dfc"
      unitRef="usd">800000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="i1f29cae9fd29439fa7f042f1814f46aa_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV85MS9mcmFnOjhiNTA4Y2FkYTBhZTQ4YjNhNDZhYmQzYTE5ZDIwNWIyL3RleHRyZWdpb246OGI1MDhjYWRhMGFlNDhiM2E0NmFiZDNhMTlkMjA1YjJfNTQ5NzU1ODE0NDc1Ng_bc46ded4-8a43-4669-99e9-72fcd6cec624"
      unitRef="usd">500000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="ibf67c4dec56341a2a59058b71b03ea9c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV85MS9mcmFnOjhiNTA4Y2FkYTBhZTQ4YjNhNDZhYmQzYTE5ZDIwNWIyL3RleHRyZWdpb246OGI1MDhjYWRhMGFlNDhiM2E0NmFiZDNhMTlkMjA1YjJfMTA2NA_d4dbb938-5978-44ec-a7f4-efbfa2ef9d95"
      unitRef="usd">9400000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="ibf67c4dec56341a2a59058b71b03ea9c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV85MS9mcmFnOjhiNTA4Y2FkYTBhZTQ4YjNhNDZhYmQzYTE5ZDIwNWIyL3RleHRyZWdpb246OGI1MDhjYWRhMGFlNDhiM2E0NmFiZDNhMTlkMjA1YjJfMTA4OQ_f9ba1353-c0be-454d-88e9-eab9b6476ca6"
      unitRef="usd">8800000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="ibf67c4dec56341a2a59058b71b03ea9c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV85MS9mcmFnOjhiNTA4Y2FkYTBhZTQ4YjNhNDZhYmQzYTE5ZDIwNWIyL3RleHRyZWdpb246OGI1MDhjYWRhMGFlNDhiM2E0NmFiZDNhMTlkMjA1YjJfMTEyNg_daa93bb5-1b8f-4a03-93d5-819452c0169c"
      unitRef="usd">500000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="ibf67c4dec56341a2a59058b71b03ea9c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV85MS9mcmFnOjhiNTA4Y2FkYTBhZTQ4YjNhNDZhYmQzYTE5ZDIwNWIyL3RleHRyZWdpb246OGI1MDhjYWRhMGFlNDhiM2E0NmFiZDNhMTlkMjA1YjJfNTQ5NzU1ODE0NDc3MA_fbac1de3-c998-4b43-bab6-0068396f6b31"
      unitRef="usd">100000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:MinorityInterestDisclosureTextBlock
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNzI5L2ZyYWc6ZTBlZjUzNzJjZTAzNDRhYmJlN2U3ZjJjZmUyZTY5ZjkvdGV4dHJlZ2lvbjplMGVmNTM3MmNlMDM0NGFiYmU3ZTdmMmNmZTJlNjlmOV80OTQ3ODAyMzI1Nzky_23b18923-e17b-4277-bfb8-105bc39971b9">INTEREST IN JOINT VENTURE INVESTMENT&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, the Company executed a joint venture agreement with its Chinese supplier ("China JV"). The agreement requires the Company to make a capital contribution into the newly formed entity of approximately&#160;$357,000, of which approximately $154,000 was contributed during the year ended December 31, 2020. As of the date of these consolidated financial statements, the joint venture has not commenced principal operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the Company's ownership interest in its 51% owned China JV were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.088%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended&lt;br/&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning interest in China JV&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contributions &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Apyx&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending interest in China JV&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:MinorityInterestDisclosureTextBlock>
    <apyx:NoncontrollingInterestRequiredCapitalContribution
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNzI5L2ZyYWc6ZTBlZjUzNzJjZTAzNDRhYmJlN2U3ZjJjZmUyZTY5ZjkvdGV4dHJlZ2lvbjplMGVmNTM3MmNlMDM0NGFiYmU3ZTdmMmNmZTJlNjlmOV8xMDk5NTExNjI4NTE4_e6aeeabd-e7a4-4890-9957-e6c6841c10e8"
      unitRef="usd">357000</apyx:NoncontrollingInterestRequiredCapitalContribution>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="i8e0b17e778314c9c90e0d88fd0f6dd2b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNzI5L2ZyYWc6ZTBlZjUzNzJjZTAzNDRhYmJlN2U3ZjJjZmUyZTY5ZjkvdGV4dHJlZ2lvbjplMGVmNTM3MmNlMDM0NGFiYmU3ZTdmMmNmZTJlNjlmOV8yMTk5MDIzMjU1OTAy_bf146f5d-658c-4616-8bfe-f122ac1756d2"
      unitRef="usd">154000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <apyx:NoncontrollingInterestTableTextBlock
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNzI5L2ZyYWc6ZTBlZjUzNzJjZTAzNDRhYmJlN2U3ZjJjZmUyZTY5ZjkvdGV4dHJlZ2lvbjplMGVmNTM3MmNlMDM0NGFiYmU3ZTdmMmNmZTJlNjlmOV80OTQ3ODAyMzI1Nzkz_8f504f5a-eb56-43e8-94d6-0128e52b8a5e">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the Company's ownership interest in its 51% owned China JV were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.088%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended&lt;br/&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning interest in China JV&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contributions &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Apyx&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending interest in China JV&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</apyx:NoncontrollingInterestTableTextBlock>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="i63baacc6f0574a6e8bf0b19a1687afb0_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNzI5L2ZyYWc6ZTBlZjUzNzJjZTAzNDRhYmJlN2U3ZjJjZmUyZTY5ZjkvdGV4dHJlZ2lvbjplMGVmNTM3MmNlMDM0NGFiYmU3ZTdmMmNmZTJlNjlmOV8yMTk5MDIzMjU2MTQy_fa68d5c9-dd1d-442b-8a37-ae9d45da6575"
      unitRef="number">0.51</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:MinorityInterest
      contextRef="id0a28971628c45e3b9e9d97e753d9756_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNzI5L2ZyYWc6ZTBlZjUzNzJjZTAzNDRhYmJlN2U3ZjJjZmUyZTY5ZjkvdGFibGU6OWFiNTdjOTZlODJkNGMwOWE0Nzg4ZDdkOWRmZTM2YTcvdGFibGVyYW5nZTo5YWI1N2M5NmU4MmQ0YzA5YTQ3ODhkN2Q5ZGZlMzZhN18yLTEtMS0xLTM3ODc_ace8bdf0-53c5-4061-9541-68547b61349d"
      unitRef="usd">0</us-gaap:MinorityInterest>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="i8e0b17e778314c9c90e0d88fd0f6dd2b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNzI5L2ZyYWc6ZTBlZjUzNzJjZTAzNDRhYmJlN2U3ZjJjZmUyZTY5ZjkvdGFibGU6OWFiNTdjOTZlODJkNGMwOWE0Nzg4ZDdkOWRmZTM2YTcvdGFibGVyYW5nZTo5YWI1N2M5NmU4MmQ0YzA5YTQ3ODhkN2Q5ZGZlMzZhN18zLTEtMS0xLTM3ODc_a0bf1291-2b48-4c0f-950b-048e48e1b34e"
      unitRef="usd">154000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i8e0b17e778314c9c90e0d88fd0f6dd2b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNzI5L2ZyYWc6ZTBlZjUzNzJjZTAzNDRhYmJlN2U3ZjJjZmUyZTY5ZjkvdGFibGU6OWFiNTdjOTZlODJkNGMwOWE0Nzg4ZDdkOWRmZTM2YTcvdGFibGVyYW5nZTo5YWI1N2M5NmU4MmQ0YzA5YTQ3ODhkN2Q5ZGZlMzZhN180LTEtMS0xLTM3ODc_43be2c47-6781-4791-a4ba-288305f8af78"
      unitRef="usd">-10000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:MinorityInterest
      contextRef="ie7edc49dacbe457c9d33e24e671deb98_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNzI5L2ZyYWc6ZTBlZjUzNzJjZTAzNDRhYmJlN2U3ZjJjZmUyZTY5ZjkvdGFibGU6OWFiNTdjOTZlODJkNGMwOWE0Nzg4ZDdkOWRmZTM2YTcvdGFibGVyYW5nZTo5YWI1N2M5NmU4MmQ0YzA5YTQ3ODhkN2Q5ZGZlMzZhN181LTEtMS0xLTM3ODc_c7801231-1ea7-496b-a130-699c07c75436"
      unitRef="usd">144000</us-gaap:MinorityInterest>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV85Ny9mcmFnOmZiNmQ0NzhlYTQyMzQ0NjVhYzdkMzYyYWZlODZiYmRjL3RleHRyZWdpb246ZmI2ZDQ3OGVhNDIzNDQ2NWFjN2QzNjJhZmU4NmJiZGNfNzI_fcbb0d87-1a4e-497a-bf74-540565420ca7">INVENTORIES&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: provision for obsolescence&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(388)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(392)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2020, the Company reassessed its forecasted product mix due to COVID-19, increased availability of newer handpiece designs, and improved timing of product registrations in some of our foreign markets. As a result, certain products were reduced to a lower carrying value, and some components were also written down as the Company determined to cease further production on these older models. The total impairment was approximately $400,000 and is included in cost of sales in the accompanying Consolidated Statement of Operations for 2020. Later in 2020, the Company's forecasts were revised, and it subsequently utilized a portion of the written down components and approximately $100,000 of the impairment was recovered through the sale of the corresponding manufactured handpieces.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV85Ny9mcmFnOmZiNmQ0NzhlYTQyMzQ0NjVhYzdkMzYyYWZlODZiYmRjL3RleHRyZWdpb246ZmI2ZDQ3OGVhNDIzNDQ2NWFjN2QzNjJhZmU4NmJiZGNfNzQ_6c82dae9-61a4-4348-9cd0-74c50e6eecf8">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: provision for obsolescence&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(388)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(392)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV85Ny9mcmFnOmZiNmQ0NzhlYTQyMzQ0NjVhYzdkMzYyYWZlODZiYmRjL3RhYmxlOmZiMjdiOGZkZmMwOTRjNzc4MGE4M2UyNWFkZGFlY2E2L3RhYmxlcmFuZ2U6ZmIyN2I4ZmRmYzA5NGM3NzgwYTgzZTI1YWRkYWVjYTZfMS0xLTEtMS0w_fe760009-9364-49e1-8376-b0142cfd1704"
      unitRef="usd">2243000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV85Ny9mcmFnOmZiNmQ0NzhlYTQyMzQ0NjVhYzdkMzYyYWZlODZiYmRjL3RhYmxlOmZiMjdiOGZkZmMwOTRjNzc4MGE4M2UyNWFkZGFlY2E2L3RhYmxlcmFuZ2U6ZmIyN2I4ZmRmYzA5NGM3NzgwYTgzZTI1YWRkYWVjYTZfMS0zLTEtMS0w_af07127e-0aeb-434f-9e7f-271f24d1fab1"
      unitRef="usd">2935000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV85Ny9mcmFnOmZiNmQ0NzhlYTQyMzQ0NjVhYzdkMzYyYWZlODZiYmRjL3RhYmxlOmZiMjdiOGZkZmMwOTRjNzc4MGE4M2UyNWFkZGFlY2E2L3RhYmxlcmFuZ2U6ZmIyN2I4ZmRmYzA5NGM3NzgwYTgzZTI1YWRkYWVjYTZfMi0xLTEtMS0w_bb2903e3-3c88-48ce-9112-d0ac90b909da"
      unitRef="usd">1109000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV85Ny9mcmFnOmZiNmQ0NzhlYTQyMzQ0NjVhYzdkMzYyYWZlODZiYmRjL3RhYmxlOmZiMjdiOGZkZmMwOTRjNzc4MGE4M2UyNWFkZGFlY2E2L3RhYmxlcmFuZ2U6ZmIyN2I4ZmRmYzA5NGM3NzgwYTgzZTI1YWRkYWVjYTZfMi0zLTEtMS0w_8410f60b-88a2-4029-ac6b-6f1c56c66064"
      unitRef="usd">1209000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV85Ny9mcmFnOmZiNmQ0NzhlYTQyMzQ0NjVhYzdkMzYyYWZlODZiYmRjL3RhYmxlOmZiMjdiOGZkZmMwOTRjNzc4MGE4M2UyNWFkZGFlY2E2L3RhYmxlcmFuZ2U6ZmIyN2I4ZmRmYzA5NGM3NzgwYTgzZTI1YWRkYWVjYTZfMy0xLTEtMS0w_e3019878-eb86-4537-b381-93a3b95808b9"
      unitRef="usd">1087000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV85Ny9mcmFnOmZiNmQ0NzhlYTQyMzQ0NjVhYzdkMzYyYWZlODZiYmRjL3RhYmxlOmZiMjdiOGZkZmMwOTRjNzc4MGE4M2UyNWFkZGFlY2E2L3RhYmxlcmFuZ2U6ZmIyN2I4ZmRmYzA5NGM3NzgwYTgzZTI1YWRkYWVjYTZfMy0zLTEtMS0w_88740204-1586-4667-904e-5c8221bcc47f"
      unitRef="usd">1316000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryGross
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV85Ny9mcmFnOmZiNmQ0NzhlYTQyMzQ0NjVhYzdkMzYyYWZlODZiYmRjL3RhYmxlOmZiMjdiOGZkZmMwOTRjNzc4MGE4M2UyNWFkZGFlY2E2L3RhYmxlcmFuZ2U6ZmIyN2I4ZmRmYzA5NGM3NzgwYTgzZTI1YWRkYWVjYTZfNC0xLTEtMS0w_128d9aac-a15d-4144-aec5-b03d96ad6029"
      unitRef="usd">4439000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV85Ny9mcmFnOmZiNmQ0NzhlYTQyMzQ0NjVhYzdkMzYyYWZlODZiYmRjL3RhYmxlOmZiMjdiOGZkZmMwOTRjNzc4MGE4M2UyNWFkZGFlY2E2L3RhYmxlcmFuZ2U6ZmIyN2I4ZmRmYzA5NGM3NzgwYTgzZTI1YWRkYWVjYTZfNC0zLTEtMS0w_e223459f-a4e1-4b6e-85d1-fe8832f807fe"
      unitRef="usd">5460000</us-gaap:InventoryGross>
    <us-gaap:InventoryValuationReserves
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV85Ny9mcmFnOmZiNmQ0NzhlYTQyMzQ0NjVhYzdkMzYyYWZlODZiYmRjL3RhYmxlOmZiMjdiOGZkZmMwOTRjNzc4MGE4M2UyNWFkZGFlY2E2L3RhYmxlcmFuZ2U6ZmIyN2I4ZmRmYzA5NGM3NzgwYTgzZTI1YWRkYWVjYTZfNS0xLTEtMS0w_1e5e5818-9445-4375-a067-368d7714461e"
      unitRef="usd">388000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV85Ny9mcmFnOmZiNmQ0NzhlYTQyMzQ0NjVhYzdkMzYyYWZlODZiYmRjL3RhYmxlOmZiMjdiOGZkZmMwOTRjNzc4MGE4M2UyNWFkZGFlY2E2L3RhYmxlcmFuZ2U6ZmIyN2I4ZmRmYzA5NGM3NzgwYTgzZTI1YWRkYWVjYTZfNS0zLTEtMS0w_279736fc-a0ee-4c94-b117-3693907b81ed"
      unitRef="usd">392000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryNet
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV85Ny9mcmFnOmZiNmQ0NzhlYTQyMzQ0NjVhYzdkMzYyYWZlODZiYmRjL3RhYmxlOmZiMjdiOGZkZmMwOTRjNzc4MGE4M2UyNWFkZGFlY2E2L3RhYmxlcmFuZ2U6ZmIyN2I4ZmRmYzA5NGM3NzgwYTgzZTI1YWRkYWVjYTZfNi0xLTEtMS0w_704a6085-cb1d-4344-875e-cc2944fc8014"
      unitRef="usd">4051000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV85Ny9mcmFnOmZiNmQ0NzhlYTQyMzQ0NjVhYzdkMzYyYWZlODZiYmRjL3RhYmxlOmZiMjdiOGZkZmMwOTRjNzc4MGE4M2UyNWFkZGFlY2E2L3RhYmxlcmFuZ2U6ZmIyN2I4ZmRmYzA5NGM3NzgwYTgzZTI1YWRkYWVjYTZfNi0zLTEtMS0w_98b8194f-05cd-4acf-9963-1b7dd91a2616"
      unitRef="usd">5068000</us-gaap:InventoryNet>
    <us-gaap:InventoryWriteDown
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV85Ny9mcmFnOmZiNmQ0NzhlYTQyMzQ0NjVhYzdkMzYyYWZlODZiYmRjL3RleHRyZWdpb246ZmI2ZDQ3OGVhNDIzNDQ2NWFjN2QzNjJhZmU4NmJiZGNfNDk0NzgwMjMyNjkwMw_9815fe3e-1fd1-4f52-95a5-a39c513bde3d"
      unitRef="usd">400000</us-gaap:InventoryWriteDown>
    <apyx:InventoryWriteDownReversals
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV85Ny9mcmFnOmZiNmQ0NzhlYTQyMzQ0NjVhYzdkMzYyYWZlODZiYmRjL3RleHRyZWdpb246ZmI2ZDQ3OGVhNDIzNDQ2NWFjN2QzNjJhZmU4NmJiZGNfNDk0NzgwMjMyNjkxMw_3d0ce480-ae5c-438f-babf-b91d2dfceee5"
      unitRef="usd">100000</apyx:InventoryWriteDownReversals>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDAvZnJhZzowMmUyN2NjNmEzYWY0MGNjYWE0N2ZkMTg0ODRiZGNjYS90ZXh0cmVnaW9uOjAyZTI3Y2M2YTNhZjQwY2NhYTQ3ZmQxODQ4NGJkY2NhXzM0MQ_6962a832-f553-442b-a336-4c0fa95fdce2">PROPERTY AND EQUIPMENT&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Molds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,813)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,403)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment in service&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total depreciation expense was $0.7 million for the years ended December&#160;31, 2020 and 2019. Depreciation expense is included within cost of goods sold and selling, general and administrative expense in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDAvZnJhZzowMmUyN2NjNmEzYWY0MGNjYWE0N2ZkMTg0ODRiZGNjYS90ZXh0cmVnaW9uOjAyZTI3Y2M2YTNhZjQwY2NhYTQ3ZmQxODQ4NGJkY2NhXzMzNg_0aa44c10-07b3-4fe6-86ea-4b55f3639150">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Molds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,813)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,403)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment in service&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7a54987fec4e4d109be138c336d48d57_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDAvZnJhZzowMmUyN2NjNmEzYWY0MGNjYWE0N2ZkMTg0ODRiZGNjYS90YWJsZTplMjBkMTMzMzMwZDE0ZGY1YTI0ZTBhNDQ3YjJhMDM1MC90YWJsZXJhbmdlOmUyMGQxMzMzMzBkMTRkZjVhMjRlMGE0NDdiMmEwMzUwXzEtMS0xLTEtMA_8450e626-41fb-462e-ac50-26e3fef4a0d7"
      unitRef="usd">1600000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iee3b318d7e9f4b0a847b69cbdeb233ce_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDAvZnJhZzowMmUyN2NjNmEzYWY0MGNjYWE0N2ZkMTg0ODRiZGNjYS90YWJsZTplMjBkMTMzMzMwZDE0ZGY1YTI0ZTBhNDQ3YjJhMDM1MC90YWJsZXJhbmdlOmUyMGQxMzMzMzBkMTRkZjVhMjRlMGE0NDdiMmEwMzUwXzEtMy0xLTEtMA_a4ba3cc9-9aea-4f4d-9822-5973e3533ce5"
      unitRef="usd">1600000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie3f4327a210e4a4da700fd1022432191_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDAvZnJhZzowMmUyN2NjNmEzYWY0MGNjYWE0N2ZkMTg0ODRiZGNjYS90YWJsZTplMjBkMTMzMzMwZDE0ZGY1YTI0ZTBhNDQ3YjJhMDM1MC90YWJsZXJhbmdlOmUyMGQxMzMzMzBkMTRkZjVhMjRlMGE0NDdiMmEwMzUwXzItMS0xLTEtMA_4945f298-c5d2-4a7f-b11a-0f1867003943"
      unitRef="usd">4454000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i19401a17feaf403f899024675a2ec439_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDAvZnJhZzowMmUyN2NjNmEzYWY0MGNjYWE0N2ZkMTg0ODRiZGNjYS90YWJsZTplMjBkMTMzMzMwZDE0ZGY1YTI0ZTBhNDQ3YjJhMDM1MC90YWJsZXJhbmdlOmUyMGQxMzMzMzBkMTRkZjVhMjRlMGE0NDdiMmEwMzUwXzItMy0xLTEtMA_e6046326-959e-4db6-b30c-12b2b49490f1"
      unitRef="usd">4423000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i4036b967bee44ae799da3bf97a2bdb7f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDAvZnJhZzowMmUyN2NjNmEzYWY0MGNjYWE0N2ZkMTg0ODRiZGNjYS90YWJsZTplMjBkMTMzMzMwZDE0ZGY1YTI0ZTBhNDQ3YjJhMDM1MC90YWJsZXJhbmdlOmUyMGQxMzMzMzBkMTRkZjVhMjRlMGE0NDdiMmEwMzUwXzMtMS0xLTEtMA_7e459c54-26b1-47fe-b7c4-6cd5e549851a"
      unitRef="usd">2113000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i22cf6c2b0fa640009153ca8537851d59_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDAvZnJhZzowMmUyN2NjNmEzYWY0MGNjYWE0N2ZkMTg0ODRiZGNjYS90YWJsZTplMjBkMTMzMzMwZDE0ZGY1YTI0ZTBhNDQ3YjJhMDM1MC90YWJsZXJhbmdlOmUyMGQxMzMzMzBkMTRkZjVhMjRlMGE0NDdiMmEwMzUwXzMtMy0xLTEtMA_0f3321d4-81ff-4354-898e-0d7306f2b7e4"
      unitRef="usd">2187000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i4fb285bd8adc40a4b2a0c9d050a1f420_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDAvZnJhZzowMmUyN2NjNmEzYWY0MGNjYWE0N2ZkMTg0ODRiZGNjYS90YWJsZTplMjBkMTMzMzMwZDE0ZGY1YTI0ZTBhNDQ3YjJhMDM1MC90YWJsZXJhbmdlOmUyMGQxMzMzMzBkMTRkZjVhMjRlMGE0NDdiMmEwMzUwXzQtMS0xLTEtMA_f47ceb02-764f-4049-951e-1c223a59605d"
      unitRef="usd">290000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0306c2a7b1164d41a4a0dca8f17a1e2a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDAvZnJhZzowMmUyN2NjNmEzYWY0MGNjYWE0N2ZkMTg0ODRiZGNjYS90YWJsZTplMjBkMTMzMzMwZDE0ZGY1YTI0ZTBhNDQ3YjJhMDM1MC90YWJsZXJhbmdlOmUyMGQxMzMzMzBkMTRkZjVhMjRlMGE0NDdiMmEwMzUwXzQtMy0xLTEtMA_814ecdd8-dbc8-4a77-af58-9d0b100db346"
      unitRef="usd">292000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i40e12307801b4ccb8c56cf5e4fd98ec4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDAvZnJhZzowMmUyN2NjNmEzYWY0MGNjYWE0N2ZkMTg0ODRiZGNjYS90YWJsZTplMjBkMTMzMzMwZDE0ZGY1YTI0ZTBhNDQ3YjJhMDM1MC90YWJsZXJhbmdlOmUyMGQxMzMzMzBkMTRkZjVhMjRlMGE0NDdiMmEwMzUwXzUtMS0xLTEtMA_98ea14be-206e-4133-9ff2-768babfe84c3"
      unitRef="usd">1505000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id798580ebbff4f89bc905e8051c3b2b2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDAvZnJhZzowMmUyN2NjNmEzYWY0MGNjYWE0N2ZkMTg0ODRiZGNjYS90YWJsZTplMjBkMTMzMzMwZDE0ZGY1YTI0ZTBhNDQ3YjJhMDM1MC90YWJsZXJhbmdlOmUyMGQxMzMzMzBkMTRkZjVhMjRlMGE0NDdiMmEwMzUwXzUtMy0xLTEtMA_5544933d-94b3-449c-8541-bee5e0a64ae1"
      unitRef="usd">1409000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie6680d593e9440dbbfd54f5193fbf907_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDAvZnJhZzowMmUyN2NjNmEzYWY0MGNjYWE0N2ZkMTg0ODRiZGNjYS90YWJsZTplMjBkMTMzMzMwZDE0ZGY1YTI0ZTBhNDQ3YjJhMDM1MC90YWJsZXJhbmdlOmUyMGQxMzMzMzBkMTRkZjVhMjRlMGE0NDdiMmEwMzUwXzYtMS0xLTEtMA_a7a50fdb-58dc-4409-bf3e-07ef42f29f8a"
      unitRef="usd">156000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i22cabb993e2b4682a7111b3d2814c1c0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDAvZnJhZzowMmUyN2NjNmEzYWY0MGNjYWE0N2ZkMTg0ODRiZGNjYS90YWJsZTplMjBkMTMzMzMwZDE0ZGY1YTI0ZTBhNDQ3YjJhMDM1MC90YWJsZXJhbmdlOmUyMGQxMzMzMzBkMTRkZjVhMjRlMGE0NDdiMmEwMzUwXzYtMy0xLTEtMA_b4bd636f-a5c4-4f9e-883e-677b505c6924"
      unitRef="usd">156000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i1e903bdd325546128d4b5baaaa0369ec_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDAvZnJhZzowMmUyN2NjNmEzYWY0MGNjYWE0N2ZkMTg0ODRiZGNjYS90YWJsZTplMjBkMTMzMzMwZDE0ZGY1YTI0ZTBhNDQ3YjJhMDM1MC90YWJsZXJhbmdlOmUyMGQxMzMzMzBkMTRkZjVhMjRlMGE0NDdiMmEwMzUwXzctMS0xLTEtMA_10b09b72-9dd6-4812-b070-c39fd059a5f5"
      unitRef="usd">813000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3f57e20923764c72859b130e5896e87f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDAvZnJhZzowMmUyN2NjNmEzYWY0MGNjYWE0N2ZkMTg0ODRiZGNjYS90YWJsZTplMjBkMTMzMzMwZDE0ZGY1YTI0ZTBhNDQ3YjJhMDM1MC90YWJsZXJhbmdlOmUyMGQxMzMzMzBkMTRkZjVhMjRlMGE0NDdiMmEwMzUwXzctMy0xLTEtMA_113a10d0-185c-467f-9ec3-835b7b9b8c57"
      unitRef="usd">805000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDAvZnJhZzowMmUyN2NjNmEzYWY0MGNjYWE0N2ZkMTg0ODRiZGNjYS90YWJsZTplMjBkMTMzMzMwZDE0ZGY1YTI0ZTBhNDQ3YjJhMDM1MC90YWJsZXJhbmdlOmUyMGQxMzMzMzBkMTRkZjVhMjRlMGE0NDdiMmEwMzUwXzgtMS0xLTEtMA_f5c9e591-48a3-416d-b463-6195286e9d52"
      unitRef="usd">10931000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDAvZnJhZzowMmUyN2NjNmEzYWY0MGNjYWE0N2ZkMTg0ODRiZGNjYS90YWJsZTplMjBkMTMzMzMwZDE0ZGY1YTI0ZTBhNDQ3YjJhMDM1MC90YWJsZXJhbmdlOmUyMGQxMzMzMzBkMTRkZjVhMjRlMGE0NDdiMmEwMzUwXzgtMy0xLTEtMA_f9be2228-18f6-4add-a9cf-994456fcd87d"
      unitRef="usd">10872000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDAvZnJhZzowMmUyN2NjNmEzYWY0MGNjYWE0N2ZkMTg0ODRiZGNjYS90YWJsZTplMjBkMTMzMzMwZDE0ZGY1YTI0ZTBhNDQ3YjJhMDM1MC90YWJsZXJhbmdlOmUyMGQxMzMzMzBkMTRkZjVhMjRlMGE0NDdiMmEwMzUwXzktMS0xLTEtMA_3f458d39-7338-4235-a1e5-1461808b56da"
      unitRef="usd">4813000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDAvZnJhZzowMmUyN2NjNmEzYWY0MGNjYWE0N2ZkMTg0ODRiZGNjYS90YWJsZTplMjBkMTMzMzMwZDE0ZGY1YTI0ZTBhNDQ3YjJhMDM1MC90YWJsZXJhbmdlOmUyMGQxMzMzMzBkMTRkZjVhMjRlMGE0NDdiMmEwMzUwXzktMy0xLTEtMA_55b5e1fb-0f39-4e9f-a574-d2c754d1761f"
      unitRef="usd">4403000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <apyx:Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDAvZnJhZzowMmUyN2NjNmEzYWY0MGNjYWE0N2ZkMTg0ODRiZGNjYS90YWJsZTplMjBkMTMzMzMwZDE0ZGY1YTI0ZTBhNDQ3YjJhMDM1MC90YWJsZXJhbmdlOmUyMGQxMzMzMzBkMTRkZjVhMjRlMGE0NDdiMmEwMzUwXzEwLTEtMS0xLTA_5f6d2b61-833e-4e5a-8fd6-ed7dccfce17a"
      unitRef="usd">6118000</apyx:Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations>
    <apyx:Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDAvZnJhZzowMmUyN2NjNmEzYWY0MGNjYWE0N2ZkMTg0ODRiZGNjYS90YWJsZTplMjBkMTMzMzMwZDE0ZGY1YTI0ZTBhNDQ3YjJhMDM1MC90YWJsZXJhbmdlOmUyMGQxMzMzMzBkMTRkZjVhMjRlMGE0NDdiMmEwMzUwXzEwLTMtMS0xLTA_84557429-16d7-4ed9-8399-0df98e35ad9e"
      unitRef="usd">6469000</apyx:Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDAvZnJhZzowMmUyN2NjNmEzYWY0MGNjYWE0N2ZkMTg0ODRiZGNjYS90YWJsZTplMjBkMTMzMzMwZDE0ZGY1YTI0ZTBhNDQ3YjJhMDM1MC90YWJsZXJhbmdlOmUyMGQxMzMzMzBkMTRkZjVhMjRlMGE0NDdiMmEwMzUwXzExLTEtMS0xLTA_ce5d8f74-c4b1-40be-8550-c3e8e89e0d0a"
      unitRef="usd">423000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDAvZnJhZzowMmUyN2NjNmEzYWY0MGNjYWE0N2ZkMTg0ODRiZGNjYS90YWJsZTplMjBkMTMzMzMwZDE0ZGY1YTI0ZTBhNDQ3YjJhMDM1MC90YWJsZXJhbmdlOmUyMGQxMzMzMzBkMTRkZjVhMjRlMGE0NDdiMmEwMzUwXzExLTMtMS0xLTA_7131cab5-a853-4e07-80f8-1b5ea78dc8ae"
      unitRef="usd">149000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDAvZnJhZzowMmUyN2NjNmEzYWY0MGNjYWE0N2ZkMTg0ODRiZGNjYS90YWJsZTplMjBkMTMzMzMwZDE0ZGY1YTI0ZTBhNDQ3YjJhMDM1MC90YWJsZXJhbmdlOmUyMGQxMzMzMzBkMTRkZjVhMjRlMGE0NDdiMmEwMzUwXzEyLTEtMS0xLTA_fe60a876-def6-4226-97ea-5a4e4fc1a436"
      unitRef="usd">6541000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDAvZnJhZzowMmUyN2NjNmEzYWY0MGNjYWE0N2ZkMTg0ODRiZGNjYS90YWJsZTplMjBkMTMzMzMwZDE0ZGY1YTI0ZTBhNDQ3YjJhMDM1MC90YWJsZXJhbmdlOmUyMGQxMzMzMzBkMTRkZjVhMjRlMGE0NDdiMmEwMzUwXzEyLTMtMS0xLTA_50f16a86-b8ea-42c0-8db9-018641db1f7c"
      unitRef="usd">6618000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDAvZnJhZzowMmUyN2NjNmEzYWY0MGNjYWE0N2ZkMTg0ODRiZGNjYS90ZXh0cmVnaW9uOjAyZTI3Y2M2YTNhZjQwY2NhYTQ3ZmQxODQ4NGJkY2NhXzE1MQ_9e77e0d4-16ed-4046-8737-3e3f6a024157"
      unitRef="usd">700000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDAvZnJhZzowMmUyN2NjNmEzYWY0MGNjYWE0N2ZkMTg0ODRiZGNjYS90ZXh0cmVnaW9uOjAyZTI3Y2M2YTNhZjQwY2NhYTQ3ZmQxODQ4NGJkY2NhXzE1MQ_e11e9955-fa01-446d-a2b5-a0a53492255b"
      unitRef="usd">700000</us-gaap:Depreciation>
    <us-gaap:LesseeFinanceLeasesTextBlock
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90ZXh0cmVnaW9uOjMxNWMzNTEzNmNlYTQxNTA4MDJkNWZlMmY5MGFjM2FjXzIxNjA_415d8d63-fec5-46c3-b437-24fefb0da9c6">LEASES&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not recognize leases with terms less than twelve months in duration, or that have variable only payments, in its Consolidated Balance Sheet as right-of-use assets and lease liabilities. The Company has adopted the practical expedient which allows for the Company to not separate lease and non-lease components of contracts. Accordingly, non-lease components are included in the measurement of the Company's lease liabilities and right-of-use assets. If the Company is aware of the implicit rate in leases, the Company determines the operating lease liability using the implicit rate. For those leases where the Company is not aware of the implicit rate in the lease, the Company utilizes an incremental borrowing rate of 4.00%, which is indicative of its collateralized borrowing rate. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases its facility in Sofia, Bulgaria and vehicles in Clearwater, Florida under non-cancelable operating lease agreements. The Company's lease on the Bulgaria facility includes rent escalation over the term of the lease. Rent expense on the lease is accounted for on a straight-line basis over the lease term. During 2019, the Bulgaria facility lease was extended for an additional 2 years. In accordance with operating lease guidance under Topic 842, the extension was accounted for as a lease modification and the right-of-use asset and lease liability were remeasured at the modification date. These operating leases have terms expiring through December 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Finance Leases&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2019, the Company entered into non-cancelable finance leases for certain computer equipment and a vehicle in Clearwater, Florida. These finance leases have terms expiring through August 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information about the Company&#x2019;s lease costs are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended &lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease costs &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease costs:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and non-cash information related to our leases are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.531%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended &lt;br/&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended &lt;br/&gt;December 31, 2019&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non cash information:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets capitalized and lease liabilities recognized upon adoption of Topic 842&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets capitalized and lease liabilities recognized upon lease remeasurement&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets capitalized and lease liabilities recognized upon execution of lease&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash information:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information about the Company&#x2019;s weighted average remaining lease terms and discount rate assumptions are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.160%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended &lt;br/&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended &lt;br/&gt;December 31, 2019&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.03%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.04%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of lease liabilities as of December 31, 2020 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less current portion of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(238)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90ZXh0cmVnaW9uOjMxNWMzNTEzNmNlYTQxNTA4MDJkNWZlMmY5MGFjM2FjXzIxNjk_5bc9c1d5-cf3d-4799-84e4-e603203c77a4">LEASES&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not recognize leases with terms less than twelve months in duration, or that have variable only payments, in its Consolidated Balance Sheet as right-of-use assets and lease liabilities. The Company has adopted the practical expedient which allows for the Company to not separate lease and non-lease components of contracts. Accordingly, non-lease components are included in the measurement of the Company's lease liabilities and right-of-use assets. If the Company is aware of the implicit rate in leases, the Company determines the operating lease liability using the implicit rate. For those leases where the Company is not aware of the implicit rate in the lease, the Company utilizes an incremental borrowing rate of 4.00%, which is indicative of its collateralized borrowing rate. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases its facility in Sofia, Bulgaria and vehicles in Clearwater, Florida under non-cancelable operating lease agreements. The Company's lease on the Bulgaria facility includes rent escalation over the term of the lease. Rent expense on the lease is accounted for on a straight-line basis over the lease term. During 2019, the Bulgaria facility lease was extended for an additional 2 years. In accordance with operating lease guidance under Topic 842, the extension was accounted for as a lease modification and the right-of-use asset and lease liability were remeasured at the modification date. These operating leases have terms expiring through December 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Finance Leases&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2019, the Company entered into non-cancelable finance leases for certain computer equipment and a vehicle in Clearwater, Florida. These finance leases have terms expiring through August 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information about the Company&#x2019;s lease costs are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended &lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease costs &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease costs:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and non-cash information related to our leases are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.531%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended &lt;br/&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended &lt;br/&gt;December 31, 2019&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non cash information:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets capitalized and lease liabilities recognized upon adoption of Topic 842&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets capitalized and lease liabilities recognized upon lease remeasurement&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets capitalized and lease liabilities recognized upon execution of lease&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash information:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information about the Company&#x2019;s weighted average remaining lease terms and discount rate assumptions are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.160%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended &lt;br/&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended &lt;br/&gt;December 31, 2019&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.03%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.04%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of lease liabilities as of December 31, 2020 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less current portion of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(238)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <apyx:LesseeDiscountRateIncrementalBorrowingRate
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90ZXh0cmVnaW9uOjMxNWMzNTEzNmNlYTQxNTA4MDJkNWZlMmY5MGFjM2FjXzQ5NDc4MDIzMjc0MDU_9e01f04f-62af-40b7-8815-1fb9fed1b454"
      unitRef="number">0.0400</apyx:LesseeDiscountRateIncrementalBorrowingRate>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i810adca1ebab41a5a9488ebb3154fda3_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90ZXh0cmVnaW9uOjMxNWMzNTEzNmNlYTQxNTA4MDJkNWZlMmY5MGFjM2FjXzEzMTI_e7395b44-1b74-4ea6-9b3c-e34a71bfa465">P2Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90ZXh0cmVnaW9uOjMxNWMzNTEzNmNlYTQxNTA4MDJkNWZlMmY5MGFjM2FjXzIxNzI_8fd87f67-597c-44b5-8de0-86cae190b9d0">Information about the Company&#x2019;s lease costs are as follows:&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended &lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease costs &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease costs:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and non-cash information related to our leases are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.531%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended &lt;br/&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended &lt;br/&gt;December 31, 2019&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non cash information:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets capitalized and lease liabilities recognized upon adoption of Topic 842&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets capitalized and lease liabilities recognized upon lease remeasurement&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets capitalized and lease liabilities recognized upon execution of lease&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash information:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information about the Company&#x2019;s weighted average remaining lease terms and discount rate assumptions are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.160%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended &lt;br/&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended &lt;br/&gt;December 31, 2019&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.03%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.04%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTphMDVmNjBhNDNjOTY0NTQzOTFlMGFmMzk5M2NkNTFiOC90YWJsZXJhbmdlOmEwNWY2MGE0M2M5NjQ1NDM5MWUwYWYzOTkzY2Q1MWI4XzItMS0xLTEtNDk4_9790dcfb-e32d-4ad2-817d-36f1335b48aa"
      unitRef="usd">124000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTphMDVmNjBhNDNjOTY0NTQzOTFlMGFmMzk5M2NkNTFiOC90YWJsZXJhbmdlOmEwNWY2MGE0M2M5NjQ1NDM5MWUwYWYzOTkzY2Q1MWI4XzItMS0xLTEtMA_d55179f9-3844-4e70-933c-371fb6c56d89"
      unitRef="usd">115000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTphMDVmNjBhNDNjOTY0NTQzOTFlMGFmMzk5M2NkNTFiOC90YWJsZXJhbmdlOmEwNWY2MGE0M2M5NjQ1NDM5MWUwYWYzOTkzY2Q1MWI4XzQtMS0xLTEtNDk4_c9784021-e88a-4ac9-bfc8-44363ea84924"
      unitRef="usd">216000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTphMDVmNjBhNDNjOTY0NTQzOTFlMGFmMzk5M2NkNTFiOC90YWJsZXJhbmdlOmEwNWY2MGE0M2M5NjQ1NDM5MWUwYWYzOTkzY2Q1MWI4XzQtMS0xLTEtMA_3a564c04-4c5e-4c36-b2f9-a367d936c406"
      unitRef="usd">57000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTphMDVmNjBhNDNjOTY0NTQzOTFlMGFmMzk5M2NkNTFiOC90YWJsZXJhbmdlOmEwNWY2MGE0M2M5NjQ1NDM5MWUwYWYzOTkzY2Q1MWI4XzUtMS0xLTEtNDk4_bcd21d35-5de9-49b3-bcf9-69f13e309dd0"
      unitRef="usd">22000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTphMDVmNjBhNDNjOTY0NTQzOTFlMGFmMzk5M2NkNTFiOC90YWJsZXJhbmdlOmEwNWY2MGE0M2M5NjQ1NDM5MWUwYWYzOTkzY2Q1MWI4XzUtMS0xLTEtMA_56e0fcc0-2d1d-4d6d-89f8-bec7155327f2"
      unitRef="usd">8000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:VariableLeaseCost
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTphMDVmNjBhNDNjOTY0NTQzOTFlMGFmMzk5M2NkNTFiOC90YWJsZXJhbmdlOmEwNWY2MGE0M2M5NjQ1NDM5MWUwYWYzOTkzY2Q1MWI4XzYtMS0xLTEtNDk4_8a77813b-4d0f-4821-ad92-81cc99f2cd9f"
      unitRef="usd">13000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTphMDVmNjBhNDNjOTY0NTQzOTFlMGFmMzk5M2NkNTFiOC90YWJsZXJhbmdlOmEwNWY2MGE0M2M5NjQ1NDM5MWUwYWYzOTkzY2Q1MWI4XzYtMS0xLTEtMA_30cef4a5-e5c7-4796-b0af-ef00a7e3aaac"
      unitRef="usd">16000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTphMDVmNjBhNDNjOTY0NTQzOTFlMGFmMzk5M2NkNTFiOC90YWJsZXJhbmdlOmEwNWY2MGE0M2M5NjQ1NDM5MWUwYWYzOTkzY2Q1MWI4XzctMS0xLTEtNDk4_4f73dc27-e6ed-4bf5-bbe5-8eb585d80dbc"
      unitRef="usd">375000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTphMDVmNjBhNDNjOTY0NTQzOTFlMGFmMzk5M2NkNTFiOC90YWJsZXJhbmdlOmEwNWY2MGE0M2M5NjQ1NDM5MWUwYWYzOTkzY2Q1MWI4XzctMS0xLTEtMA_52f35355-cc40-443a-a3e6-51bcaffbe841"
      unitRef="usd">196000</us-gaap:LeaseCost>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i0363bd7ae504408f83e9148242c28770_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTo2YjI0NzYwNDFhNGU0ZTRiOGRiMmI5YWExMDFjOTYxYy90YWJsZXJhbmdlOjZiMjQ3NjA0MWE0ZTRlNGI4ZGIyYjlhYTEwMWM5NjFjXzMtMS0xLTEtMzgxOA_dc0796b1-187b-412e-99c5-959c5f08a4e4"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i0363bd7ae504408f83e9148242c28770_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTo2YjI0NzYwNDFhNGU0ZTRiOGRiMmI5YWExMDFjOTYxYy90YWJsZXJhbmdlOjZiMjQ3NjA0MWE0ZTRlNGI4ZGIyYjlhYTEwMWM5NjFjXzMtMi0xLTEtMzgxOA_6f461003-9e01-4b66-bc56-953e1a9427f4"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i672dd521a5844f22a7fa22968f746eed_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTo2YjI0NzYwNDFhNGU0ZTRiOGRiMmI5YWExMDFjOTYxYy90YWJsZXJhbmdlOjZiMjQ3NjA0MWE0ZTRlNGI4ZGIyYjlhYTEwMWM5NjFjXzMtMS0xLTEtMA_f7352d48-e3ec-4792-9cdd-48dda9a86b2e"
      unitRef="usd">212000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i672dd521a5844f22a7fa22968f746eed_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTo2YjI0NzYwNDFhNGU0ZTRiOGRiMmI5YWExMDFjOTYxYy90YWJsZXJhbmdlOjZiMjQ3NjA0MWE0ZTRlNGI4ZGIyYjlhYTEwMWM5NjFjXzMtMi0xLTEtMA_fe1d59b4-605c-4f69-9962-aed107de7da5"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i2fc3ec19ac0e4ed4895cf47c5da6347f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTo2YjI0NzYwNDFhNGU0ZTRiOGRiMmI5YWExMDFjOTYxYy90YWJsZXJhbmdlOjZiMjQ3NjA0MWE0ZTRlNGI4ZGIyYjlhYTEwMWM5NjFjXzQtMS0xLTEtMzgxOA_ef707aad-2ab5-4910-9911-03e7da4f5dac"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i2fc3ec19ac0e4ed4895cf47c5da6347f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTo2YjI0NzYwNDFhNGU0ZTRiOGRiMmI5YWExMDFjOTYxYy90YWJsZXJhbmdlOjZiMjQ3NjA0MWE0ZTRlNGI4ZGIyYjlhYTEwMWM5NjFjXzQtMi0xLTEtMzgxOA_59c92f11-19c5-48db-b1af-02950495dba1"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i6241803215ac41d1bca740510e6f9f94_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTo2YjI0NzYwNDFhNGU0ZTRiOGRiMmI5YWExMDFjOTYxYy90YWJsZXJhbmdlOjZiMjQ3NjA0MWE0ZTRlNGI4ZGIyYjlhYTEwMWM5NjFjXzQtMS0xLTEtMA_89f72fd6-de19-4a2c-88c0-d07790ce1369"
      unitRef="usd">207000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i6241803215ac41d1bca740510e6f9f94_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTo2YjI0NzYwNDFhNGU0ZTRiOGRiMmI5YWExMDFjOTYxYy90YWJsZXJhbmdlOjZiMjQ3NjA0MWE0ZTRlNGI4ZGIyYjlhYTEwMWM5NjFjXzQtMi0xLTEtMA_e982ca0a-f7cb-4604-9623-88c5135659f8"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ia07cd0c04ff44e70938ff407067b900c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTo2YjI0NzYwNDFhNGU0ZTRiOGRiMmI5YWExMDFjOTYxYy90YWJsZXJhbmdlOjZiMjQ3NjA0MWE0ZTRlNGI4ZGIyYjlhYTEwMWM5NjFjXzUtMS0xLTEtMzgxOA_f7e2f4c8-99db-49e3-8abb-b1a71b3a2aaf"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="ia07cd0c04ff44e70938ff407067b900c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTo2YjI0NzYwNDFhNGU0ZTRiOGRiMmI5YWExMDFjOTYxYy90YWJsZXJhbmdlOjZiMjQ3NjA0MWE0ZTRlNGI4ZGIyYjlhYTEwMWM5NjFjXzUtMi0xLTEtMzgxOA_c8dd4ffc-9297-42dc-b43b-8ca95dd585d7"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i796972f9750c4ee3b870255ed2cedf91_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTo2YjI0NzYwNDFhNGU0ZTRiOGRiMmI5YWExMDFjOTYxYy90YWJsZXJhbmdlOjZiMjQ3NjA0MWE0ZTRlNGI4ZGIyYjlhYTEwMWM5NjFjXzUtMS0xLTEtMA_10a0530e-7c40-4de4-8333-4a2ed9eeeb55"
      unitRef="usd">28000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i796972f9750c4ee3b870255ed2cedf91_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTo2YjI0NzYwNDFhNGU0ZTRiOGRiMmI5YWExMDFjOTYxYy90YWJsZXJhbmdlOjZiMjQ3NjA0MWE0ZTRlNGI4ZGIyYjlhYTEwMWM5NjFjXzUtMi0xLTEtMA_ca62ea35-ea24-4e70-978b-ffe0cb0e6d2a"
      unitRef="usd">710000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:OperatingLeasePayments
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTo2YjI0NzYwNDFhNGU0ZTRiOGRiMmI5YWExMDFjOTYxYy90YWJsZXJhbmdlOjZiMjQ3NjA0MWE0ZTRlNGI4ZGIyYjlhYTEwMWM5NjFjXzgtMS0xLTEtMzgxOA_dcbad5f9-78ff-4fcb-8cac-2b0227abf1ed"
      unitRef="usd">110000</us-gaap:OperatingLeasePayments>
    <apyx:FinanceLeasePayments
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTo2YjI0NzYwNDFhNGU0ZTRiOGRiMmI5YWExMDFjOTYxYy90YWJsZXJhbmdlOjZiMjQ3NjA0MWE0ZTRlNGI4ZGIyYjlhYTEwMWM5NjFjXzgtMi0xLTEtMzgxOA_e922ddd6-7310-45ff-9099-48eab7e2dc91"
      unitRef="usd">251000</apyx:FinanceLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTo2YjI0NzYwNDFhNGU0ZTRiOGRiMmI5YWExMDFjOTYxYy90YWJsZXJhbmdlOjZiMjQ3NjA0MWE0ZTRlNGI4ZGIyYjlhYTEwMWM5NjFjXzgtMS0xLTEtMA_194ceb44-e57e-4e30-81e3-82442ccc3e76"
      unitRef="usd">106000</us-gaap:OperatingLeasePayments>
    <apyx:FinanceLeasePayments
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTo2YjI0NzYwNDFhNGU0ZTRiOGRiMmI5YWExMDFjOTYxYy90YWJsZXJhbmdlOjZiMjQ3NjA0MWE0ZTRlNGI4ZGIyYjlhYTEwMWM5NjFjXzgtMi0xLTEtMA_db0fb052-9516-4f54-b6eb-d91c77fb6550"
      unitRef="usd">68000</apyx:FinanceLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZToxZmJjYzZlZDc1ZTg0YWYwYmE5NzIyYzhkOGI5NzhiNi90YWJsZXJhbmdlOjFmYmNjNmVkNzVlODRhZjBiYTk3MjJjOGQ4Yjk3OGI2XzItMS0xLTEtMzgzMQ_bc68e691-47f4-49d2-9a5c-f6e496492f1c">P2Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZToxZmJjYzZlZDc1ZTg0YWYwYmE5NzIyYzhkOGI5NzhiNi90YWJsZXJhbmdlOjFmYmNjNmVkNzVlODRhZjBiYTk3MjJjOGQ4Yjk3OGI2XzItMi0xLTEtMzgzMQ_75a6f06d-ba1b-48ac-b5a0-1ffc68937d39">P1Y8M12D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZToxZmJjYzZlZDc1ZTg0YWYwYmE5NzIyYzhkOGI5NzhiNi90YWJsZXJhbmdlOjFmYmNjNmVkNzVlODRhZjBiYTk3MjJjOGQ4Yjk3OGI2XzItMS0xLTEtMA_c92cde3b-435c-419a-8022-facaabd30c31">P3Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZToxZmJjYzZlZDc1ZTg0YWYwYmE5NzIyYzhkOGI5NzhiNi90YWJsZXJhbmdlOjFmYmNjNmVkNzVlODRhZjBiYTk3MjJjOGQ4Yjk3OGI2XzItMi0xLTEtMA_ef971720-a460-4b96-8c93-0842c306c4dc">P2Y8M12D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZToxZmJjYzZlZDc1ZTg0YWYwYmE5NzIyYzhkOGI5NzhiNi90YWJsZXJhbmdlOjFmYmNjNmVkNzVlODRhZjBiYTk3MjJjOGQ4Yjk3OGI2XzMtMS0xLTEtMzgzMQ_ebcd1079-ab60-47ac-953f-9e79450dccde"
      unitRef="number">0.0403</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZToxZmJjYzZlZDc1ZTg0YWYwYmE5NzIyYzhkOGI5NzhiNi90YWJsZXJhbmdlOjFmYmNjNmVkNzVlODRhZjBiYTk3MjJjOGQ4Yjk3OGI2XzMtMi0xLTEtMzgzMQ_0565f976-3df9-4021-9f9d-271f86eb7029"
      unitRef="number">0.0400</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZToxZmJjYzZlZDc1ZTg0YWYwYmE5NzIyYzhkOGI5NzhiNi90YWJsZXJhbmdlOjFmYmNjNmVkNzVlODRhZjBiYTk3MjJjOGQ4Yjk3OGI2XzMtNC0xLTEtMzgyNw_388b9493-f01e-4eda-8fb8-ad6d7c7c0176"
      unitRef="number">0.0404</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZToxZmJjYzZlZDc1ZTg0YWYwYmE5NzIyYzhkOGI5NzhiNi90YWJsZXJhbmdlOjFmYmNjNmVkNzVlODRhZjBiYTk3MjJjOGQ4Yjk3OGI2XzMtNS0xLTEtMzgyOQ_9c5bd173-b29b-4a15-b82e-dc51f8a4056e"
      unitRef="number">0.0400</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90ZXh0cmVnaW9uOjMxNWMzNTEzNmNlYTQxNTA4MDJkNWZlMmY5MGFjM2FjXzIxNjI_be6c21e0-d0b4-4376-9a5a-1b8be6dbe3a9">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of lease liabilities as of December 31, 2020 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less current portion of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(238)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90ZXh0cmVnaW9uOjMxNWMzNTEzNmNlYTQxNTA4MDJkNWZlMmY5MGFjM2FjXzIxNjc_7b699c18-fc7b-4513-bdad-a66563fa24ab">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of lease liabilities as of December 31, 2020 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less current portion of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(238)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTpiNTAyMTJjZjg1YzM0ODIwOWYxNGMzYWI2MDcwN2JiYS90YWJsZXJhbmdlOmI1MDIxMmNmODVjMzQ4MjA5ZjE0YzNhYjYwNzA3YmJhXzItMS0xLTEtMA_1bdc0b26-47e7-49e6-806d-df53b4479b4f"
      unitRef="usd">134000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTpiNTAyMTJjZjg1YzM0ODIwOWYxNGMzYWI2MDcwN2JiYS90YWJsZXJhbmdlOmI1MDIxMmNmODVjMzQ4MjA5ZjE0YzNhYjYwNzA3YmJhXzItMi0xLTEtMA_d8a8aab8-2f09-4b9f-8b05-1c8449bfc338"
      unitRef="usd">236000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTpiNTAyMTJjZjg1YzM0ODIwOWYxNGMzYWI2MDcwN2JiYS90YWJsZXJhbmdlOmI1MDIxMmNmODVjMzQ4MjA5ZjE0YzNhYjYwNzA3YmJhXzMtMS0xLTEtMA_9654796b-eced-48ac-a720-13dd7e6274dc"
      unitRef="usd">131000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTpiNTAyMTJjZjg1YzM0ODIwOWYxNGMzYWI2MDcwN2JiYS90YWJsZXJhbmdlOmI1MDIxMmNmODVjMzQ4MjA5ZjE0YzNhYjYwNzA3YmJhXzMtMi0xLTEtMA_ad94ac79-14df-4a4c-8425-b36c2242ad69"
      unitRef="usd">183000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTpiNTAyMTJjZjg1YzM0ODIwOWYxNGMzYWI2MDcwN2JiYS90YWJsZXJhbmdlOmI1MDIxMmNmODVjMzQ4MjA5ZjE0YzNhYjYwNzA3YmJhXzQtMS0xLTEtMA_21fd6d14-3c37-41e1-8fe0-300b21b4aa66"
      unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTpiNTAyMTJjZjg1YzM0ODIwOWYxNGMzYWI2MDcwN2JiYS90YWJsZXJhbmdlOmI1MDIxMmNmODVjMzQ4MjA5ZjE0YzNhYjYwNzA3YmJhXzQtMi0xLTEtMA_30d9a4cb-927c-49b3-8e6a-cbdf9d23f500"
      unitRef="usd">18000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTpiNTAyMTJjZjg1YzM0ODIwOWYxNGMzYWI2MDcwN2JiYS90YWJsZXJhbmdlOmI1MDIxMmNmODVjMzQ4MjA5ZjE0YzNhYjYwNzA3YmJhXzctMS0xLTEtMA_aca1beb9-4f1c-4c3d-9d01-66cd07809332"
      unitRef="usd">265000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTpiNTAyMTJjZjg1YzM0ODIwOWYxNGMzYWI2MDcwN2JiYS90YWJsZXJhbmdlOmI1MDIxMmNmODVjMzQ4MjA5ZjE0YzNhYjYwNzA3YmJhXzctMi0xLTEtMA_93807528-90f5-49cc-8536-5eedf873a2e6"
      unitRef="usd">437000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTpiNTAyMTJjZjg1YzM0ODIwOWYxNGMzYWI2MDcwN2JiYS90YWJsZXJhbmdlOmI1MDIxMmNmODVjMzQ4MjA5ZjE0YzNhYjYwNzA3YmJhXzgtMS0xLTEtMA_df9e388d-a874-45f3-8aa7-6ec7a9a41bd1"
      unitRef="usd">10000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTpiNTAyMTJjZjg1YzM0ODIwOWYxNGMzYWI2MDcwN2JiYS90YWJsZXJhbmdlOmI1MDIxMmNmODVjMzQ4MjA5ZjE0YzNhYjYwNzA3YmJhXzgtMi0xLTEtMA_5f8e7941-3bf3-4c81-b514-95831067e26d"
      unitRef="usd">16000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTpiNTAyMTJjZjg1YzM0ODIwOWYxNGMzYWI2MDcwN2JiYS90YWJsZXJhbmdlOmI1MDIxMmNmODVjMzQ4MjA5ZjE0YzNhYjYwNzA3YmJhXzktMS0xLTEtMA_028c822e-cec7-421f-862a-82e433238feb"
      unitRef="usd">255000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTpiNTAyMTJjZjg1YzM0ODIwOWYxNGMzYWI2MDcwN2JiYS90YWJsZXJhbmdlOmI1MDIxMmNmODVjMzQ4MjA5ZjE0YzNhYjYwNzA3YmJhXzktMi0xLTEtMA_a4069214-1336-447d-b678-f84e087a83a0"
      unitRef="usd">421000</us-gaap:FinanceLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTpiNTAyMTJjZjg1YzM0ODIwOWYxNGMzYWI2MDcwN2JiYS90YWJsZXJhbmdlOmI1MDIxMmNmODVjMzQ4MjA5ZjE0YzNhYjYwNzA3YmJhXzEwLTEtMS0xLTA_8c37660e-a616-4a25-8637-fc4f10bb0f49"
      unitRef="usd">126000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTpiNTAyMTJjZjg1YzM0ODIwOWYxNGMzYWI2MDcwN2JiYS90YWJsZXJhbmdlOmI1MDIxMmNmODVjMzQ4MjA5ZjE0YzNhYjYwNzA3YmJhXzEwLTItMS0xLTA_e70efe33-6d0a-4208-a4e5-e60303ad53bd"
      unitRef="usd">238000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTpiNTAyMTJjZjg1YzM0ODIwOWYxNGMzYWI2MDcwN2JiYS90YWJsZXJhbmdlOmI1MDIxMmNmODVjMzQ4MjA5ZjE0YzNhYjYwNzA3YmJhXzExLTEtMS0xLTA_d1b9353f-e7c0-49fe-9dca-dd58df2ff7c0"
      unitRef="usd">129000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDMvZnJhZzozMTVjMzUxMzZjZWE0MTUwODAyZDVmZTJmOTBhYzNhYy90YWJsZTpiNTAyMTJjZjg1YzM0ODIwOWYxNGMzYWI2MDcwN2JiYS90YWJsZXJhbmdlOmI1MDIxMmNmODVjMzQ4MjA5ZjE0YzNhYjYwNzA3YmJhXzExLTItMS0xLTA_b10881a5-4f11-408c-b485-5f96be2a341a"
      unitRef="usd">183000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDYvZnJhZzo5NjQyNWFiNjYxODQ0MmRhOGExNDIzNzEyM2RkNDAxNi90ZXh0cmVnaW9uOjk2NDI1YWI2NjE4NDQyZGE4YTE0MjM3MTIzZGQ0MDE2XzE0MA_1c5a7bb1-fded-4fdd-98d3-7f5afed9e2d4">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.737%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued bonus&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued commissions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued product warranties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued product liability claim insurance deductibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Joint and several payroll liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales tax payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses and current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <apyx:AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDYvZnJhZzo5NjQyNWFiNjYxODQ0MmRhOGExNDIzNzEyM2RkNDAxNi90ZXh0cmVnaW9uOjk2NDI1YWI2NjE4NDQyZGE4YTE0MjM3MTIzZGQ0MDE2XzE0Mg_9adc989e-128d-426e-aa0d-04183cdab433">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.737%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued bonus&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued commissions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued product warranties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued product liability claim insurance deductibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Joint and several payroll liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales tax payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses and current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</apyx:AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:AccruedSalariesCurrent
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDYvZnJhZzo5NjQyNWFiNjYxODQ0MmRhOGExNDIzNzEyM2RkNDAxNi90YWJsZTpmNTdmZWU5YmYzZWY0MGNjODJiMWU1MjQ2NDg5MWUwYy90YWJsZXJhbmdlOmY1N2ZlZTliZjNlZjQwY2M4MmIxZTUyNDY0ODkxZTBjXzItMS0xLTEtMA_0e88d65d-8798-476d-8ee3-90b07a078fd9"
      unitRef="usd">808000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDYvZnJhZzo5NjQyNWFiNjYxODQ0MmRhOGExNDIzNzEyM2RkNDAxNi90YWJsZTpmNTdmZWU5YmYzZWY0MGNjODJiMWU1MjQ2NDg5MWUwYy90YWJsZXJhbmdlOmY1N2ZlZTliZjNlZjQwY2M4MmIxZTUyNDY0ODkxZTBjXzItMy0xLTEtMA_62ef4847-e882-4e20-b397-91fcb550ce52"
      unitRef="usd">694000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDYvZnJhZzo5NjQyNWFiNjYxODQ0MmRhOGExNDIzNzEyM2RkNDAxNi90YWJsZTpmNTdmZWU5YmYzZWY0MGNjODJiMWU1MjQ2NDg5MWUwYy90YWJsZXJhbmdlOmY1N2ZlZTliZjNlZjQwY2M4MmIxZTUyNDY0ODkxZTBjXzMtMS0xLTEtMA_477c15cf-f3dc-4fd3-962d-26eac5b3c3db"
      unitRef="usd">811000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDYvZnJhZzo5NjQyNWFiNjYxODQ0MmRhOGExNDIzNzEyM2RkNDAxNi90YWJsZTpmNTdmZWU5YmYzZWY0MGNjODJiMWU1MjQ2NDg5MWUwYy90YWJsZXJhbmdlOmY1N2ZlZTliZjNlZjQwY2M4MmIxZTUyNDY0ODkxZTBjXzMtMy0xLTEtMA_64f1dab6-2933-4689-bc0e-4f9c02756229"
      unitRef="usd">1306000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedSalesCommissionCurrent
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDYvZnJhZzo5NjQyNWFiNjYxODQ0MmRhOGExNDIzNzEyM2RkNDAxNi90YWJsZTpmNTdmZWU5YmYzZWY0MGNjODJiMWU1MjQ2NDg5MWUwYy90YWJsZXJhbmdlOmY1N2ZlZTliZjNlZjQwY2M4MmIxZTUyNDY0ODkxZTBjXzQtMS0xLTEtMA_3c0ae541-29be-40b3-ba32-8fee29ca8a7c"
      unitRef="usd">1001000</us-gaap:AccruedSalesCommissionCurrent>
    <us-gaap:AccruedSalesCommissionCurrent
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDYvZnJhZzo5NjQyNWFiNjYxODQ0MmRhOGExNDIzNzEyM2RkNDAxNi90YWJsZTpmNTdmZWU5YmYzZWY0MGNjODJiMWU1MjQ2NDg5MWUwYy90YWJsZXJhbmdlOmY1N2ZlZTliZjNlZjQwY2M4MmIxZTUyNDY0ODkxZTBjXzQtMy0xLTEtMA_b7766cc5-b480-422e-842b-fbf6a9020f56"
      unitRef="usd">877000</us-gaap:AccruedSalesCommissionCurrent>
    <us-gaap:ProductWarrantyAccrualClassifiedCurrent
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDYvZnJhZzo5NjQyNWFiNjYxODQ0MmRhOGExNDIzNzEyM2RkNDAxNi90YWJsZTpmNTdmZWU5YmYzZWY0MGNjODJiMWU1MjQ2NDg5MWUwYy90YWJsZXJhbmdlOmY1N2ZlZTliZjNlZjQwY2M4MmIxZTUyNDY0ODkxZTBjXzUtMS0xLTEtMA_f9a3764d-7c94-4d47-8b45-4dfe18206836"
      unitRef="usd">498000</us-gaap:ProductWarrantyAccrualClassifiedCurrent>
    <us-gaap:ProductWarrantyAccrualClassifiedCurrent
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDYvZnJhZzo5NjQyNWFiNjYxODQ0MmRhOGExNDIzNzEyM2RkNDAxNi90YWJsZTpmNTdmZWU5YmYzZWY0MGNjODJiMWU1MjQ2NDg5MWUwYy90YWJsZXJhbmdlOmY1N2ZlZTliZjNlZjQwY2M4MmIxZTUyNDY0ODkxZTBjXzUtMy0xLTEtMA_3aa560e2-6cac-4ed6-970a-822838956acf"
      unitRef="usd">452000</us-gaap:ProductWarrantyAccrualClassifiedCurrent>
    <us-gaap:AccruedInsuranceCurrent
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDYvZnJhZzo5NjQyNWFiNjYxODQ0MmRhOGExNDIzNzEyM2RkNDAxNi90YWJsZTpmNTdmZWU5YmYzZWY0MGNjODJiMWU1MjQ2NDg5MWUwYy90YWJsZXJhbmdlOmY1N2ZlZTliZjNlZjQwY2M4MmIxZTUyNDY0ODkxZTBjXzYtMS0xLTEtMA_7a9d3edf-00a4-484d-87b1-88d0cb56956c"
      unitRef="usd">435000</us-gaap:AccruedInsuranceCurrent>
    <us-gaap:AccruedInsuranceCurrent
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDYvZnJhZzo5NjQyNWFiNjYxODQ0MmRhOGExNDIzNzEyM2RkNDAxNi90YWJsZTpmNTdmZWU5YmYzZWY0MGNjODJiMWU1MjQ2NDg5MWUwYy90YWJsZXJhbmdlOmY1N2ZlZTliZjNlZjQwY2M4MmIxZTUyNDY0ODkxZTBjXzYtMy0xLTEtMA_1d0933ba-efe6-469c-82b9-fdf9775e2e6f"
      unitRef="usd">1170000</us-gaap:AccruedInsuranceCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDYvZnJhZzo5NjQyNWFiNjYxODQ0MmRhOGExNDIzNzEyM2RkNDAxNi90YWJsZTpmNTdmZWU5YmYzZWY0MGNjODJiMWU1MjQ2NDg5MWUwYy90YWJsZXJhbmdlOmY1N2ZlZTliZjNlZjQwY2M4MmIxZTUyNDY0ODkxZTBjXzctMS0xLTEtMA_29e5fa66-0e07-42ac-a8d0-801634d7cdae"
      unitRef="usd">222000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDYvZnJhZzo5NjQyNWFiNjYxODQ0MmRhOGExNDIzNzEyM2RkNDAxNi90YWJsZTpmNTdmZWU5YmYzZWY0MGNjODJiMWU1MjQ2NDg5MWUwYy90YWJsZXJhbmdlOmY1N2ZlZTliZjNlZjQwY2M4MmIxZTUyNDY0ODkxZTBjXzctMy0xLTEtMA_de28496d-397e-4426-a265-1dc523589bd8"
      unitRef="usd">1383000</us-gaap:AccruedProfessionalFeesCurrent>
    <apyx:JointAndSeveralPayrollLiability
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDYvZnJhZzo5NjQyNWFiNjYxODQ0MmRhOGExNDIzNzEyM2RkNDAxNi90YWJsZTpmNTdmZWU5YmYzZWY0MGNjODJiMWU1MjQ2NDg5MWUwYy90YWJsZXJhbmdlOmY1N2ZlZTliZjNlZjQwY2M4MmIxZTUyNDY0ODkxZTBjXzgtMS0xLTEtMA_b6abb2eb-2fb6-4d27-a97a-f9bf3d7d98c0"
      unitRef="usd">1027000</apyx:JointAndSeveralPayrollLiability>
    <apyx:JointAndSeveralPayrollLiability
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDYvZnJhZzo5NjQyNWFiNjYxODQ0MmRhOGExNDIzNzEyM2RkNDAxNi90YWJsZTpmNTdmZWU5YmYzZWY0MGNjODJiMWU1MjQ2NDg5MWUwYy90YWJsZXJhbmdlOmY1N2ZlZTliZjNlZjQwY2M4MmIxZTUyNDY0ODkxZTBjXzgtMy0xLTEtMA_ac416e34-20cc-4384-9c47-c9ec66364cb7"
      unitRef="usd">1045000</apyx:JointAndSeveralPayrollLiability>
    <apyx:UncertainTaxPositionsLiability
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDYvZnJhZzo5NjQyNWFiNjYxODQ0MmRhOGExNDIzNzEyM2RkNDAxNi90YWJsZTpmNTdmZWU5YmYzZWY0MGNjODJiMWU1MjQ2NDg5MWUwYy90YWJsZXJhbmdlOmY1N2ZlZTliZjNlZjQwY2M4MmIxZTUyNDY0ODkxZTBjXzktMS0xLTEtMA_0690a7b0-8d6a-42b3-bccb-0ab4ee135333"
      unitRef="usd">1658000</apyx:UncertainTaxPositionsLiability>
    <apyx:UncertainTaxPositionsLiability
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDYvZnJhZzo5NjQyNWFiNjYxODQ0MmRhOGExNDIzNzEyM2RkNDAxNi90YWJsZTpmNTdmZWU5YmYzZWY0MGNjODJiMWU1MjQ2NDg5MWUwYy90YWJsZXJhbmdlOmY1N2ZlZTliZjNlZjQwY2M4MmIxZTUyNDY0ODkxZTBjXzktMy0xLTEtMA_a481db5a-4c87-40b2-ba15-fa2063ab77fd"
      unitRef="usd">1491000</apyx:UncertainTaxPositionsLiability>
    <us-gaap:SalesAndExciseTaxPayableCurrent
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDYvZnJhZzo5NjQyNWFiNjYxODQ0MmRhOGExNDIzNzEyM2RkNDAxNi90YWJsZTpmNTdmZWU5YmYzZWY0MGNjODJiMWU1MjQ2NDg5MWUwYy90YWJsZXJhbmdlOmY1N2ZlZTliZjNlZjQwY2M4MmIxZTUyNDY0ODkxZTBjXzEwLTEtMS0xLTIxMjM_6839b413-3c6e-4628-9c16-26a9be5813ed"
      unitRef="usd">591000</us-gaap:SalesAndExciseTaxPayableCurrent>
    <us-gaap:SalesAndExciseTaxPayableCurrent
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDYvZnJhZzo5NjQyNWFiNjYxODQ0MmRhOGExNDIzNzEyM2RkNDAxNi90YWJsZTpmNTdmZWU5YmYzZWY0MGNjODJiMWU1MjQ2NDg5MWUwYy90YWJsZXJhbmdlOmY1N2ZlZTliZjNlZjQwY2M4MmIxZTUyNDY0ODkxZTBjXzEwLTMtMS0xLTIxMjM_3713ab88-9d97-4ce4-b622-14823a4fe1a6"
      unitRef="usd">492000</us-gaap:SalesAndExciseTaxPayableCurrent>
    <apyx:OtherAccruedExpensesAndLiabilitiesCurrent
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDYvZnJhZzo5NjQyNWFiNjYxODQ0MmRhOGExNDIzNzEyM2RkNDAxNi90YWJsZTpmNTdmZWU5YmYzZWY0MGNjODJiMWU1MjQ2NDg5MWUwYy90YWJsZXJhbmdlOmY1N2ZlZTliZjNlZjQwY2M4MmIxZTUyNDY0ODkxZTBjXzEwLTEtMS0xLTA_23ecdea7-6fc6-46be-b656-bca9aa52fc29"
      unitRef="usd">227000</apyx:OtherAccruedExpensesAndLiabilitiesCurrent>
    <apyx:OtherAccruedExpensesAndLiabilitiesCurrent
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDYvZnJhZzo5NjQyNWFiNjYxODQ0MmRhOGExNDIzNzEyM2RkNDAxNi90YWJsZTpmNTdmZWU5YmYzZWY0MGNjODJiMWU1MjQ2NDg5MWUwYy90YWJsZXJhbmdlOmY1N2ZlZTliZjNlZjQwY2M4MmIxZTUyNDY0ODkxZTBjXzEwLTMtMS0xLTA_67def09b-30e1-4f7b-9963-86bfd97612a3"
      unitRef="usd">486000</apyx:OtherAccruedExpensesAndLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDYvZnJhZzo5NjQyNWFiNjYxODQ0MmRhOGExNDIzNzEyM2RkNDAxNi90YWJsZTpmNTdmZWU5YmYzZWY0MGNjODJiMWU1MjQ2NDg5MWUwYy90YWJsZXJhbmdlOmY1N2ZlZTliZjNlZjQwY2M4MmIxZTUyNDY0ODkxZTBjXzExLTEtMS0xLTA_df72342b-87ed-41ee-bf54-75be41d6669c"
      unitRef="usd">7278000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDYvZnJhZzo5NjQyNWFiNjYxODQ0MmRhOGExNDIzNzEyM2RkNDAxNi90YWJsZTpmNTdmZWU5YmYzZWY0MGNjODJiMWU1MjQ2NDg5MWUwYy90YWJsZXJhbmdlOmY1N2ZlZTliZjNlZjQwY2M4MmIxZTUyNDY0ODkxZTBjXzExLTMtMS0xLTA_24e78c1c-d1ca-43f1-b316-5efac586a47a"
      unitRef="usd">9396000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ProductWarrantyDisclosureTextBlock
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDkvZnJhZzpmODk3MWM2ZmZlODk0MzA1OTcwZTcxNWVmMjU4ZmUyYS90ZXh0cmVnaW9uOmY4OTcxYzZmZmU4OTQzMDU5NzBlNzE1ZWYyNThmZTJhXzExOQ_00ffdc69-ca6a-4abb-9635-6f6869963d07">PRODUCT WARRANTIES&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product warranty activity consisted of the following for the years ended:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for product warranties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product warranty expenses incurred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(217)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued product warranties&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ProductWarrantyDisclosureTextBlock>
    <us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDkvZnJhZzpmODk3MWM2ZmZlODk0MzA1OTcwZTcxNWVmMjU4ZmUyYS90ZXh0cmVnaW9uOmY4OTcxYzZmZmU4OTQzMDU5NzBlNzE1ZWYyNThmZTJhXzExNw_909f89ad-0f61-48a6-b0c6-bc6810746e50">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product warranty activity consisted of the following for the years ended:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for product warranties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product warranty expenses incurred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(217)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued product warranties&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock>
    <us-gaap:StandardProductWarrantyAccrual
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDkvZnJhZzpmODk3MWM2ZmZlODk0MzA1OTcwZTcxNWVmMjU4ZmUyYS90YWJsZToxMTBhN2NlOGNhYmI0OTA4YTVmZGNjN2ZjNjY3ZTk2YS90YWJsZXJhbmdlOjExMGE3Y2U4Y2FiYjQ5MDhhNWZkY2M3ZmM2NjdlOTZhXzEtMS0xLTEtMA_1b2f86ac-3177-4675-a568-c81b2c719cb5"
      unitRef="usd">452000</us-gaap:StandardProductWarrantyAccrual>
    <us-gaap:StandardProductWarrantyAccrual
      contextRef="i00df6877cb2d4b75a1a4abee0d94d57f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDkvZnJhZzpmODk3MWM2ZmZlODk0MzA1OTcwZTcxNWVmMjU4ZmUyYS90YWJsZToxMTBhN2NlOGNhYmI0OTA4YTVmZGNjN2ZjNjY3ZTk2YS90YWJsZXJhbmdlOjExMGE3Y2U4Y2FiYjQ5MDhhNWZkY2M3ZmM2NjdlOTZhXzEtMy0xLTEtMA_49d3e50f-9bda-4347-86f6-f160ce305011"
      unitRef="usd">348000</us-gaap:StandardProductWarrantyAccrual>
    <us-gaap:StandardProductWarrantyAccrualWarrantiesIssued
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDkvZnJhZzpmODk3MWM2ZmZlODk0MzA1OTcwZTcxNWVmMjU4ZmUyYS90YWJsZToxMTBhN2NlOGNhYmI0OTA4YTVmZGNjN2ZjNjY3ZTk2YS90YWJsZXJhbmdlOjExMGE3Y2U4Y2FiYjQ5MDhhNWZkY2M3ZmM2NjdlOTZhXzItMS0xLTEtMA_8d73b33f-7dc0-4fb2-b7ed-f501cccd0a2b"
      unitRef="usd">215000</us-gaap:StandardProductWarrantyAccrualWarrantiesIssued>
    <us-gaap:StandardProductWarrantyAccrualWarrantiesIssued
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDkvZnJhZzpmODk3MWM2ZmZlODk0MzA1OTcwZTcxNWVmMjU4ZmUyYS90YWJsZToxMTBhN2NlOGNhYmI0OTA4YTVmZGNjN2ZjNjY3ZTk2YS90YWJsZXJhbmdlOjExMGE3Y2U4Y2FiYjQ5MDhhNWZkY2M3ZmM2NjdlOTZhXzItMy0xLTEtMA_dd582574-0713-4512-b474-0f650e5ef6b9"
      unitRef="usd">321000</us-gaap:StandardProductWarrantyAccrualWarrantiesIssued>
    <us-gaap:StandardProductWarrantyAccrualPayments
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDkvZnJhZzpmODk3MWM2ZmZlODk0MzA1OTcwZTcxNWVmMjU4ZmUyYS90YWJsZToxMTBhN2NlOGNhYmI0OTA4YTVmZGNjN2ZjNjY3ZTk2YS90YWJsZXJhbmdlOjExMGE3Y2U4Y2FiYjQ5MDhhNWZkY2M3ZmM2NjdlOTZhXzMtMS0xLTEtMA_952246c5-a5fa-4df1-af70-ebdffbc6adf8"
      unitRef="usd">169000</us-gaap:StandardProductWarrantyAccrualPayments>
    <us-gaap:StandardProductWarrantyAccrualPayments
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDkvZnJhZzpmODk3MWM2ZmZlODk0MzA1OTcwZTcxNWVmMjU4ZmUyYS90YWJsZToxMTBhN2NlOGNhYmI0OTA4YTVmZGNjN2ZjNjY3ZTk2YS90YWJsZXJhbmdlOjExMGE3Y2U4Y2FiYjQ5MDhhNWZkY2M3ZmM2NjdlOTZhXzMtMy0xLTEtMA_ebb36b23-b7ec-4dfc-adc8-328f22f7057b"
      unitRef="usd">217000</us-gaap:StandardProductWarrantyAccrualPayments>
    <us-gaap:StandardProductWarrantyAccrual
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDkvZnJhZzpmODk3MWM2ZmZlODk0MzA1OTcwZTcxNWVmMjU4ZmUyYS90YWJsZToxMTBhN2NlOGNhYmI0OTA4YTVmZGNjN2ZjNjY3ZTk2YS90YWJsZXJhbmdlOjExMGE3Y2U4Y2FiYjQ5MDhhNWZkY2M3ZmM2NjdlOTZhXzQtMS0xLTEtMA_e19d679d-9a31-4c51-84fd-74606167430a"
      unitRef="usd">498000</us-gaap:StandardProductWarrantyAccrual>
    <us-gaap:StandardProductWarrantyAccrual
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMDkvZnJhZzpmODk3MWM2ZmZlODk0MzA1OTcwZTcxNWVmMjU4ZmUyYS90YWJsZToxMTBhN2NlOGNhYmI0OTA4YTVmZGNjN2ZjNjY3ZTk2YS90YWJsZXJhbmdlOjExMGE3Y2U4Y2FiYjQ5MDhhNWZkY2M3ZmM2NjdlOTZhXzQtMy0xLTEtMA_19a46ba7-40bc-473b-8be4-08d9c729c7d9"
      unitRef="usd">452000</us-gaap:StandardProductWarrantyAccrual>
    <apyx:JointandSeveralPayrollLiabilityTextBlock
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMTIvZnJhZzo0ODQzMDJiZTNkMGE0ZDI3OWYzZTNhN2RmM2I2YTJjNS90ZXh0cmVnaW9uOjQ4NDMwMmJlM2QwYTRkMjc5ZjNlM2E3ZGYzYjZhMmM1Xzg2NA_bfc91baa-dc53-4bca-b36f-8b88c945d220">JOINT AND SEVERAL PAYROLL LIABILITYDuring 2017, 2018 and 2019, the Company improperly calculated and reported the amount of income to certain employees, and did not collect and remit the correct amount of its employees' portion of income and payroll taxes, related to stock option exercises as required by the IRS. Due to IRS statutory requirements, the Company has joint and several liability for the full amount that was not withheld and remitted to the proper taxing authorities. This amount of the liability was approximately $1.0&#160;million at December 31, 2020 and 2019. Included in other income (loss), net in the accompanying Consolidated Statements of Operations for 2019 is approximately $0.3&#160;million related to the liability. If the Company can establish that its employees have in fact paid these obligations, either presently or in the future, it will be relieved of its liability.</apyx:JointandSeveralPayrollLiabilityTextBlock>
    <apyx:JointAndSeveralPayrollLiability
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMTIvZnJhZzo0ODQzMDJiZTNkMGE0ZDI3OWYzZTNhN2RmM2I2YTJjNS90ZXh0cmVnaW9uOjQ4NDMwMmJlM2QwYTRkMjc5ZjNlM2E3ZGYzYjZhMmM1XzEwOTk1MTE2MzExOTI_1362ba98-3fa1-41c9-a9ae-54f7d29d70bb"
      unitRef="usd">1000000.0</apyx:JointAndSeveralPayrollLiability>
    <apyx:JointAndSeveralPayrollLiability
      contextRef="ib92bbe0f312c4b5ba37e35fb5203b324_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMTIvZnJhZzo0ODQzMDJiZTNkMGE0ZDI3OWYzZTNhN2RmM2I2YTJjNS90ZXh0cmVnaW9uOjQ4NDMwMmJlM2QwYTRkMjc5ZjNlM2E3ZGYzYjZhMmM1XzEwOTk1MTE2MzExOTI_ccb9531c-0002-45e9-90cb-aed51d7a198d"
      unitRef="usd">1000000.0</apyx:JointAndSeveralPayrollLiability>
    <apyx:JointAndSeveralPayrollExpense
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMTIvZnJhZzo0ODQzMDJiZTNkMGE0ZDI3OWYzZTNhN2RmM2I2YTJjNS90ZXh0cmVnaW9uOjQ4NDMwMmJlM2QwYTRkMjc5ZjNlM2E3ZGYzYjZhMmM1XzEwOTk1MTE2MzE0Njc_fcc679e3-d035-49e2-bb5b-faf4bd227368"
      unitRef="usd">300000</apyx:JointAndSeveralPayrollExpense>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMTUvZnJhZzo5MTcyZjJmY2ZmMzY0MDRlOWVmYzM4YzUwNWQyNTM4ZS90ZXh0cmVnaW9uOjkxNzJmMmZjZmYzNjQwNGU5ZWZjMzhjNTA1ZDI1MzhlXzQwOQ_275a9471-c777-49d6-ab1e-b69087d202e3">EARNINGS (LOSS) PER SHARE&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings (loss) per share (&#x201c;basic EPS&#x201d;) is computed by dividing the net income or loss by the weighted average number of common shares outstanding for the reporting period. Diluted earnings per share (&#x201c;diluted EPS&#x201d;) gives effect to all dilutive potential shares outstanding. As the Company is in a net loss position for all periods presented, all potential shares outstanding are anti-dilutive. The following table provides the computation of basic and diluted earnings (loss) per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Numerators:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net loss attributable to stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11,896)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(19,706)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average shares outstanding - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Loss per share - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Anti-dilutive instruments excluded from diluted loss per common share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMTUvZnJhZzo5MTcyZjJmY2ZmMzY0MDRlOWVmYzM4YzUwNWQyNTM4ZS90ZXh0cmVnaW9uOjkxNzJmMmZjZmYzNjQwNGU5ZWZjMzhjNTA1ZDI1MzhlXzQwMw_f985d748-249d-49b2-9b97-d662a3b1b7df">The following table provides the computation of basic and diluted earnings (loss) per share.&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Numerators:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net loss attributable to stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11,896)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(19,706)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average shares outstanding - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Loss per share - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Anti-dilutive instruments excluded from diluted loss per common share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMTUvZnJhZzo5MTcyZjJmY2ZmMzY0MDRlOWVmYzM4YzUwNWQyNTM4ZS90YWJsZTpiMmU0YzA3ZDliYjk0MjZmODU3ODMxYWU0OTExYjdjNS90YWJsZXJhbmdlOmIyZTRjMDdkOWJiOTQyNmY4NTc4MzFhZTQ5MTFiN2M1XzUtMS0xLTEtMA_1585dd87-3361-4f84-b9e8-4d151e5cb248"
      unitRef="usd">-11896000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMTUvZnJhZzo5MTcyZjJmY2ZmMzY0MDRlOWVmYzM4YzUwNWQyNTM4ZS90YWJsZTpiMmU0YzA3ZDliYjk0MjZmODU3ODMxYWU0OTExYjdjNS90YWJsZXJhbmdlOmIyZTRjMDdkOWJiOTQyNmY4NTc4MzFhZTQ5MTFiN2M1XzUtMy0xLTEtMA_c02ed9b7-f8ac-45f6-be8b-cb5a598a249b"
      unitRef="usd">-19706000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMTUvZnJhZzo5MTcyZjJmY2ZmMzY0MDRlOWVmYzM4YzUwNWQyNTM4ZS90YWJsZTpiMmU0YzA3ZDliYjk0MjZmODU3ODMxYWU0OTExYjdjNS90YWJsZXJhbmdlOmIyZTRjMDdkOWJiOTQyNmY4NTc4MzFhZTQ5MTFiN2M1XzIwLTEtMS0xLTA_ea06bd82-3756-4669-87c0-2e50d7fdb2f5"
      unitRef="shares">34212000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMTUvZnJhZzo5MTcyZjJmY2ZmMzY0MDRlOWVmYzM4YzUwNWQyNTM4ZS90YWJsZTpiMmU0YzA3ZDliYjk0MjZmODU3ODMxYWU0OTExYjdjNS90YWJsZXJhbmdlOmIyZTRjMDdkOWJiOTQyNmY4NTc4MzFhZTQ5MTFiN2M1XzIwLTMtMS0xLTA_837c523c-65aa-43ac-8326-df44910890ce"
      unitRef="shares">34069000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMTUvZnJhZzo5MTcyZjJmY2ZmMzY0MDRlOWVmYzM4YzUwNWQyNTM4ZS90YWJsZTpiMmU0YzA3ZDliYjk0MjZmODU3ODMxYWU0OTExYjdjNS90YWJsZXJhbmdlOmIyZTRjMDdkOWJiOTQyNmY4NTc4MzFhZTQ5MTFiN2M1XzM3LTEtMS0xLTA_b1a97deb-fb87-42c5-b9ad-248234c16d93"
      unitRef="usdPerShare">-0.35</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMTUvZnJhZzo5MTcyZjJmY2ZmMzY0MDRlOWVmYzM4YzUwNWQyNTM4ZS90YWJsZTpiMmU0YzA3ZDliYjk0MjZmODU3ODMxYWU0OTExYjdjNS90YWJsZXJhbmdlOmIyZTRjMDdkOWJiOTQyNmY4NTc4MzFhZTQ5MTFiN2M1XzM3LTMtMS0xLTA_2a45bf55-dce6-4518-b6ac-91f28346304d"
      unitRef="usdPerShare">-0.58</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i12dd582368554dba97b8aa9e153c5b2b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMTUvZnJhZzo5MTcyZjJmY2ZmMzY0MDRlOWVmYzM4YzUwNWQyNTM4ZS90YWJsZTpiMmU0YzA3ZDliYjk0MjZmODU3ODMxYWU0OTExYjdjNS90YWJsZXJhbmdlOmIyZTRjMDdkOWJiOTQyNmY4NTc4MzFhZTQ5MTFiN2M1XzU1LTEtMS0xLTA_dfa6506b-6153-4727-8dff-094d9408a92e"
      unitRef="shares">4939000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i47bce2e772fe46be81b0517aa210b5d9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMTUvZnJhZzo5MTcyZjJmY2ZmMzY0MDRlOWVmYzM4YzUwNWQyNTM4ZS90YWJsZTpiMmU0YzA3ZDliYjk0MjZmODU3ODMxYWU0OTExYjdjNS90YWJsZXJhbmdlOmIyZTRjMDdkOWJiOTQyNmY4NTc4MzFhZTQ5MTFiN2M1XzU1LTMtMS0xLTA_cd842f5f-b158-463c-aae6-7ffd432db77b"
      unitRef="shares">3967000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMTgvZnJhZzpmMmMwNTJkMjlmY2Q0M2FlOWUzZjhmZjRjY2NjZjNlNy90ZXh0cmVnaW9uOmYyYzA1MmQyOWZjZDQzYWU5ZTNmOGZmNGNjY2NmM2U3XzE0Mzc_8021c24d-313d-481b-b8e0-68f0e826a18c">FINANCIAL INSTRUMENTSCash and Cash Equivalents at December 31, 2020 and 2019, respectively, consisted of approximately $2,250,000 and $2,237,000 in cash and $39,665,000 and $56,575,000 in U.S. Treasury Securities with maturities of 3 months or less.</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:Cash
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMTgvZnJhZzpmMmMwNTJkMjlmY2Q0M2FlOWUzZjhmZjRjY2NjZjNlNy90ZXh0cmVnaW9uOmYyYzA1MmQyOWZjZDQzYWU5ZTNmOGZmNGNjY2NmM2U3XzEwOTk1MTE2MzA1MTY_8ab60cd7-b3bf-4c84-b9e5-76d48456d073"
      unitRef="usd">2250000</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMTgvZnJhZzpmMmMwNTJkMjlmY2Q0M2FlOWUzZjhmZjRjY2NjZjNlNy90ZXh0cmVnaW9uOmYyYzA1MmQyOWZjZDQzYWU5ZTNmOGZmNGNjY2NmM2U3XzExMw_e6bce8ee-da48-49a8-a418-62babfdc8b8c"
      unitRef="usd">2237000</us-gaap:Cash>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMTgvZnJhZzpmMmMwNTJkMjlmY2Q0M2FlOWUzZjhmZjRjY2NjZjNlNy90ZXh0cmVnaW9uOmYyYzA1MmQyOWZjZDQzYWU5ZTNmOGZmNGNjY2NmM2U3XzEwOTk1MTE2MzA1Mjg_ed55e8e8-4eb5-40fc-9afc-0d6229190d1a"
      unitRef="usd">39665000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMTgvZnJhZzpmMmMwNTJkMjlmY2Q0M2FlOWUzZjhmZjRjY2NjZjNlNy90ZXh0cmVnaW9uOmYyYzA1MmQyOWZjZDQzYWU5ZTNmOGZmNGNjY2NmM2U3XzEyOA_d082b763-949f-43bc-ab65-a7b459317102"
      unitRef="usd">56575000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90ZXh0cmVnaW9uOjdmMjM2M2MzYTgzMzRkYzA4MTM0MzYxMjZjYzY4NWU3XzI1ODg_f507d5b0-7fdb-44b0-a051-ed6fc0665ec1">INCOME TAXES&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of the provision for income taxes are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.964%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.757%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,682)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(120)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(205)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,839)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(130)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Release of valuation allowance due to CARES Act&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,664)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,503)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(130)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,989)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,004)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(741)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,029)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total provision for income tax&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,503)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(130)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Below is a reconciliation of the statutory federal income tax rate to the Company's effective tax rate:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.029%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes (net of federal benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;NOL carryback from CARES Act&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Major components of the Company&#x2019;s deferred tax assets (liabilities) are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.352%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss and credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,837)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,472)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets, net of valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(278)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(245)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(199)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(399)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(444)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 27, 2020, the U.S. government enacted the CARES Act to provide relief from COVID-19. The CARES Act includes a provision that allows companies to carryback net operating losses (NOL&#x2019;s) generated in the period 2018 through 2020 to prior years. In conjunction with the disposition of the Core business in 2018, the Company generated a significant amount of taxable income in 2018. Subsequent to this, the Company generated NOLs in 2019 and 2020. For the NOLs generated in 2019, the Company previously recorded a full valuation allowance on the deferred tax assets associated with the NOL due to realization not being probable under then existing tax law. The CARES Act makes these assets realizable and, as of the date of the CARES Act, the Company has recognized an income tax benefit of approximately $3.7&#160;million associated with the release of the valuation allowance on its Federal NOL deferred tax asset from 2019. Additionally, using the provisions of the CARES Act, the Company is carrying back its 2020 Federal NOL of approximately $3.7&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all positive and negative evidence regarding the realization of deferred tax assets, including past operating results and future sources of taxable income. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers the earnings of Apyx Bulgaria, EOOD to be indefinitely invested outside the United States on the basis of estimates that future domestic cash generation will be sufficient to meet future domestic cash needs and our specific plans for reinvestment of those subsidiary earnings. It has not recorded a deferred tax liability related to the U.S. Federal and State income taxes and foreign withholding taxes on the undistributed earnings of Apyx Bulgaria, EOOD indefinitely invested outside the United States. If it decides to repatriate the foreign earnings, the Company will need to adjust its income tax provision in the period it determines that the earnings will no longer be indefinitely invested outside the United States.&#160; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses the financial statement impact of an uncertain tax position taken or expected to be taken on an income tax return at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An uncertain income tax position will not be recognized in the financial statements unless it is more likely than not of being sustained. As of December 31, 2020 and 2019, the Company has recorded a liability of approximately $1.3 million related to uncertain tax positions and accrued approximately $0.4&#160;million and $0.2 million, respectively, of interest and penalties on these positions. It is expected that the change in unrecognized tax benefits within the next 12 months will not be significant.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a roll-forward of the Company's total gross unrecognized tax benefits, not including interest and penalties, for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:79.093%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.604%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.018%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Tax Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Beginning of year balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions of tax positions related to the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions of tax positions related to the prior year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decreases for tax positions related to prior year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;End of year balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The Company is subject to U.S. federal and state income tax examination.  The Company&#x2019;s 2017 through 2019 U.S. federal income tax returns are subject to examination by the Internal Revenue Service.  The Company&#x2019;s state income tax returns are subject to examination for the 2016 through 2019 tax years.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90ZXh0cmVnaW9uOjdmMjM2M2MzYTgzMzRkYzA4MTM0MzYxMjZjYzY4NWU3XzI1ODY_d57fadbc-d469-442b-a5bb-46ef1cb366d0">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of the provision for income taxes are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.964%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.757%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,682)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(120)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(205)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,839)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(130)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Release of valuation allowance due to CARES Act&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,664)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,503)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(130)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,989)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,004)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(741)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,029)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total provision for income tax&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,503)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(130)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo1MzU2YmE3MjBkMTI0MjZmODY3MGM2Yzk2MmE4NGM5NS90YWJsZXJhbmdlOjUzNTZiYTcyMGQxMjQyNmY4NjcwYzZjOTYyYTg0Yzk1XzItMS0xLTEtMA_e8f4ebe1-8489-4948-b383-ea0b9904ecb2"
      unitRef="usd">-3682000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo1MzU2YmE3MjBkMTI0MjZmODY3MGM2Yzk2MmE4NGM5NS90YWJsZXJhbmdlOjUzNTZiYTcyMGQxMjQyNmY4NjcwYzZjOTYyYTg0Yzk1XzItMy0xLTEtMA_32d4553c-927c-4b31-b0de-f2a76ed4fec0"
      unitRef="usd">-12000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo1MzU2YmE3MjBkMTI0MjZmODY3MGM2Yzk2MmE4NGM5NS90YWJsZXJhbmdlOjUzNTZiYTcyMGQxMjQyNmY4NjcwYzZjOTYyYTg0Yzk1XzMtMS0xLTEtMA_6b788fbf-d4e0-48e9-863b-8f81c7425f23"
      unitRef="usd">-120000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo1MzU2YmE3MjBkMTI0MjZmODY3MGM2Yzk2MmE4NGM5NS90YWJsZXJhbmdlOjUzNTZiYTcyMGQxMjQyNmY4NjcwYzZjOTYyYTg0Yzk1XzMtMy0xLTEtMA_e4fa0f4b-7a72-4f84-ab9a-dd634745e7d6"
      unitRef="usd">-205000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo1MzU2YmE3MjBkMTI0MjZmODY3MGM2Yzk2MmE4NGM5NS90YWJsZXJhbmdlOjUzNTZiYTcyMGQxMjQyNmY4NjcwYzZjOTYyYTg0Yzk1XzQtMS0xLTEtMA_05bdccbc-a66d-4942-846f-73237fed6849"
      unitRef="usd">-37000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo1MzU2YmE3MjBkMTI0MjZmODY3MGM2Yzk2MmE4NGM5NS90YWJsZXJhbmdlOjUzNTZiYTcyMGQxMjQyNmY4NjcwYzZjOTYyYTg0Yzk1XzQtMy0xLTEtMA_8a6034d3-e3f8-4a60-a337-13e4e4e08a67"
      unitRef="usd">87000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo1MzU2YmE3MjBkMTI0MjZmODY3MGM2Yzk2MmE4NGM5NS90YWJsZXJhbmdlOjUzNTZiYTcyMGQxMjQyNmY4NjcwYzZjOTYyYTg0Yzk1XzUtMS0xLTEtMA_80ba231e-675f-457b-8af8-ae5af2b60278"
      unitRef="usd">-3839000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo1MzU2YmE3MjBkMTI0MjZmODY3MGM2Yzk2MmE4NGM5NS90YWJsZXJhbmdlOjUzNTZiYTcyMGQxMjQyNmY4NjcwYzZjOTYyYTg0Yzk1XzUtMy0xLTEtMA_353c122f-c12f-41c8-867f-6f3dcde6fa11"
      unitRef="usd">-130000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <apyx:CARESActIncomeTaxExpenseBenefitValuationAllowance
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo1MzU2YmE3MjBkMTI0MjZmODY3MGM2Yzk2MmE4NGM5NS90YWJsZXJhbmdlOjUzNTZiYTcyMGQxMjQyNmY4NjcwYzZjOTYyYTg0Yzk1XzctMS0xLTEtMzg2NQ_1329db28-14b3-4df3-b708-d237614756ac"
      unitRef="usd">3664000</apyx:CARESActIncomeTaxExpenseBenefitValuationAllowance>
    <apyx:CARESActIncomeTaxExpenseBenefitValuationAllowance
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo1MzU2YmE3MjBkMTI0MjZmODY3MGM2Yzk2MmE4NGM5NS90YWJsZXJhbmdlOjUzNTZiYTcyMGQxMjQyNmY4NjcwYzZjOTYyYTg0Yzk1XzctMy0xLTEtMzg2Nw_545b6a32-7d95-4463-b763-fdbb91c1d1e4"
      unitRef="usd">0</apyx:CARESActIncomeTaxExpenseBenefitValuationAllowance>
    <apyx:CurrentIncomeTaxExpenseBenefitAfterValuationAllowance
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo1MzU2YmE3MjBkMTI0MjZmODY3MGM2Yzk2MmE4NGM5NS90YWJsZXJhbmdlOjUzNTZiYTcyMGQxMjQyNmY4NjcwYzZjOTYyYTg0Yzk1XzgtMS0xLTEtMzg2NQ_d32de340-ae0f-46c5-b70a-099fc47af10b"
      unitRef="usd">-7503000</apyx:CurrentIncomeTaxExpenseBenefitAfterValuationAllowance>
    <apyx:CurrentIncomeTaxExpenseBenefitAfterValuationAllowance
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo1MzU2YmE3MjBkMTI0MjZmODY3MGM2Yzk2MmE4NGM5NS90YWJsZXJhbmdlOjUzNTZiYTcyMGQxMjQyNmY4NjcwYzZjOTYyYTg0Yzk1XzgtMy0xLTEtMzg2Nw_448dcf26-7452-4954-af6c-527e418a6d53"
      unitRef="usd">-130000</apyx:CurrentIncomeTaxExpenseBenefitAfterValuationAllowance>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo1MzU2YmE3MjBkMTI0MjZmODY3MGM2Yzk2MmE4NGM5NS90YWJsZXJhbmdlOjUzNTZiYTcyMGQxMjQyNmY4NjcwYzZjOTYyYTg0Yzk1XzctMS0xLTEtMA_43770109-dee6-4073-b3f3-f0583fc7a2a0"
      unitRef="usd">-25000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo1MzU2YmE3MjBkMTI0MjZmODY3MGM2Yzk2MmE4NGM5NS90YWJsZXJhbmdlOjUzNTZiYTcyMGQxMjQyNmY4NjcwYzZjOTYyYTg0Yzk1XzctMy0xLTEtMA_4202c2c8-a029-4ae9-a5e3-02689347f40d"
      unitRef="usd">-3989000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo1MzU2YmE3MjBkMTI0MjZmODY3MGM2Yzk2MmE4NGM5NS90YWJsZXJhbmdlOjUzNTZiYTcyMGQxMjQyNmY4NjcwYzZjOTYyYTg0Yzk1XzgtMS0xLTEtMA_a1d6749b-05ff-41db-b49f-796c5ae8d94b"
      unitRef="usd">-1004000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo1MzU2YmE3MjBkMTI0MjZmODY3MGM2Yzk2MmE4NGM5NS90YWJsZXJhbmdlOjUzNTZiYTcyMGQxMjQyNmY4NjcwYzZjOTYyYTg0Yzk1XzgtMy0xLTEtMA_37a55291-206f-4f6f-a013-7bc2d4f2cf6e"
      unitRef="usd">-741000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo1MzU2YmE3MjBkMTI0MjZmODY3MGM2Yzk2MmE4NGM5NS90YWJsZXJhbmdlOjUzNTZiYTcyMGQxMjQyNmY4NjcwYzZjOTYyYTg0Yzk1XzEwLTEtMS0xLTA_b6f2d135-041e-4b4b-b6b0-90cef1d24f08"
      unitRef="usd">-1029000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo1MzU2YmE3MjBkMTI0MjZmODY3MGM2Yzk2MmE4NGM5NS90YWJsZXJhbmdlOjUzNTZiYTcyMGQxMjQyNmY4NjcwYzZjOTYyYTg0Yzk1XzEwLTMtMS0xLTA_fe863261-9e34-4ac4-b79e-92b23d64d28e"
      unitRef="usd">-4730000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <apyx:IncomeTaxExpenseBenefitValuationAllowance
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo1MzU2YmE3MjBkMTI0MjZmODY3MGM2Yzk2MmE4NGM5NS90YWJsZXJhbmdlOjUzNTZiYTcyMGQxMjQyNmY4NjcwYzZjOTYyYTg0Yzk1XzEyLTEtMS0xLTA_d1c8f555-eb05-43d8-affb-4702c12ba0fa"
      unitRef="usd">-1029000</apyx:IncomeTaxExpenseBenefitValuationAllowance>
    <apyx:IncomeTaxExpenseBenefitValuationAllowance
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo1MzU2YmE3MjBkMTI0MjZmODY3MGM2Yzk2MmE4NGM5NS90YWJsZXJhbmdlOjUzNTZiYTcyMGQxMjQyNmY4NjcwYzZjOTYyYTg0Yzk1XzEyLTMtMS0xLTA_87e9e19f-15b9-49dc-9818-c24a1da4f261"
      unitRef="usd">-4730000</apyx:IncomeTaxExpenseBenefitValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo1MzU2YmE3MjBkMTI0MjZmODY3MGM2Yzk2MmE4NGM5NS90YWJsZXJhbmdlOjUzNTZiYTcyMGQxMjQyNmY4NjcwYzZjOTYyYTg0Yzk1XzE0LTEtMS0xLTA_b6e1cb38-84cd-49b0-8de5-1dce7415bbfb"
      unitRef="usd">-7503000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo1MzU2YmE3MjBkMTI0MjZmODY3MGM2Yzk2MmE4NGM5NS90YWJsZXJhbmdlOjUzNTZiYTcyMGQxMjQyNmY4NjcwYzZjOTYyYTg0Yzk1XzE0LTMtMS0xLTA_5debeb81-835a-438a-818a-f95c00ac32a4"
      unitRef="usd">-130000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90ZXh0cmVnaW9uOjdmMjM2M2MzYTgzMzRkYzA4MTM0MzYxMjZjYzY4NWU3XzI1OTM_b0dad329-0858-4bbb-9a30-866b47ca327b">&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Below is a reconciliation of the statutory federal income tax rate to the Company's effective tax rate:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.029%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes (net of federal benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;NOL carryback from CARES Act&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTpmNGY2ZTZiMzJmMjQ0OGU5OWE4MzRjMmYwOTJhMjdmYi90YWJsZXJhbmdlOmY0ZjZlNmIzMmYyNDQ4ZTk5YTgzNGMyZjA5MmEyN2ZiXzItMS0xLTEtMA_e7c6aac3-770a-443c-9824-341690c1cd8b"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTpmNGY2ZTZiMzJmMjQ0OGU5OWE4MzRjMmYwOTJhMjdmYi90YWJsZXJhbmdlOmY0ZjZlNmIzMmYyNDQ4ZTk5YTgzNGMyZjA5MmEyN2ZiXzItMy0xLTEtMA_660ae1ff-d1c0-46e0-a199-0d938512c10a"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTpmNGY2ZTZiMzJmMjQ0OGU5OWE4MzRjMmYwOTJhMjdmYi90YWJsZXJhbmdlOmY0ZjZlNmIzMmYyNDQ4ZTk5YTgzNGMyZjA5MmEyN2ZiXzMtMS0xLTEtMA_25843662-d1b1-4994-94b1-7b31fc8b0f96"
      unitRef="number">0.051</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTpmNGY2ZTZiMzJmMjQ0OGU5OWE4MzRjMmYwOTJhMjdmYi90YWJsZXJhbmdlOmY0ZjZlNmIzMmYyNDQ4ZTk5YTgzNGMyZjA5MmEyN2ZiXzMtMy0xLTEtMA_d82593ab-5b7a-4f3f-8908-71469ab1b150"
      unitRef="number">0.043</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTpmNGY2ZTZiMzJmMjQ0OGU5OWE4MzRjMmYwOTJhMjdmYi90YWJsZXJhbmdlOmY0ZjZlNmIzMmYyNDQ4ZTk5YTgzNGMyZjA5MmEyN2ZiXzUtMS0xLTEtMA_9277d018-caf0-4739-8c3a-da52d55a299c"
      unitRef="number">-0.053</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTpmNGY2ZTZiMzJmMjQ0OGU5OWE4MzRjMmYwOTJhMjdmYi90YWJsZXJhbmdlOmY0ZjZlNmIzMmYyNDQ4ZTk5YTgzNGMyZjA5MmEyN2ZiXzUtMy0xLTEtMA_4108838c-5865-43c0-94f0-00954268923c"
      unitRef="number">-0.238</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <apyx:EffectiveIncomeTaxRateReconciliationCARESActNetOperatingLossCarryforwardsPercent
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTpmNGY2ZTZiMzJmMjQ0OGU5OWE4MzRjMmYwOTJhMjdmYi90YWJsZXJhbmdlOmY0ZjZlNmIzMmYyNDQ4ZTk5YTgzNGMyZjA5MmEyN2ZiXzctMS0xLTEtMzg3MQ_59e22906-5422-472a-87fd-9377f1c7e923"
      unitRef="number">0.189</apyx:EffectiveIncomeTaxRateReconciliationCARESActNetOperatingLossCarryforwardsPercent>
    <apyx:EffectiveIncomeTaxRateReconciliationCARESActNetOperatingLossCarryforwardsPercent
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTpmNGY2ZTZiMzJmMjQ0OGU5OWE4MzRjMmYwOTJhMjdmYi90YWJsZXJhbmdlOmY0ZjZlNmIzMmYyNDQ4ZTk5YTgzNGMyZjA5MmEyN2ZiXzctMy0xLTEtMzg3Mw_49e41035-c076-44e3-8439-950a6919fc0e"
      unitRef="number">0</apyx:EffectiveIncomeTaxRateReconciliationCARESActNetOperatingLossCarryforwardsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTpmNGY2ZTZiMzJmMjQ0OGU5OWE4MzRjMmYwOTJhMjdmYi90YWJsZXJhbmdlOmY0ZjZlNmIzMmYyNDQ4ZTk5YTgzNGMyZjA5MmEyN2ZiXzctMS0xLTEtMA_66b4fba0-04ed-4b5f-93fa-164e37a27874"
      unitRef="number">-0.010</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTpmNGY2ZTZiMzJmMjQ0OGU5OWE4MzRjMmYwOTJhMjdmYi90YWJsZXJhbmdlOmY0ZjZlNmIzMmYyNDQ4ZTk5YTgzNGMyZjA5MmEyN2ZiXzctMy0xLTEtMA_397e350a-e20a-452e-a15a-ee97f2e9d68f"
      unitRef="number">-0.008</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductions
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTpmNGY2ZTZiMzJmMjQ0OGU5OWE4MzRjMmYwOTJhMjdmYi90YWJsZXJhbmdlOmY0ZjZlNmIzMmYyNDQ4ZTk5YTgzNGMyZjA5MmEyN2ZiXzgtMS0xLTEtMA_51082198-d5ee-4e94-8e69-b535fa72a6a1"
      unitRef="number">0.387</us-gaap:EffectiveIncomeTaxRateReconciliationDeductions>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductions
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTpmNGY2ZTZiMzJmMjQ0OGU5OWE4MzRjMmYwOTJhMjdmYi90YWJsZXJhbmdlOmY0ZjZlNmIzMmYyNDQ4ZTk5YTgzNGMyZjA5MmEyN2ZiXzgtMy0xLTEtMA_32d84137-3535-4178-971c-9fcfbaad3042"
      unitRef="number">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationDeductions>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90ZXh0cmVnaW9uOjdmMjM2M2MzYTgzMzRkYzA4MTM0MzYxMjZjYzY4NWU3XzI1NjU_3cd1b758-9dfa-4f36-93f5-630137904b8e">Major components of the Company&#x2019;s deferred tax assets (liabilities) are as follows: &lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.352%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss and credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,837)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,472)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets, net of valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(278)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(245)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(199)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(399)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(444)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo0ZTI1NjdiZGNjMjg0NDYxOTQ5OTFiYmZhMDAxNjE3MS90YWJsZXJhbmdlOjRlMjU2N2JkY2MyODQ0NjE5NDk5MWJiZmEwMDE2MTcxXzItMS0xLTEtMA_17bf95a8-8b43-4a78-89a3-22d565c581bc"
      unitRef="usd">1888000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo0ZTI1NjdiZGNjMjg0NDYxOTQ5OTFiYmZhMDAxNjE3MS90YWJsZXJhbmdlOjRlMjU2N2JkY2MyODQ0NjE5NDk5MWJiZmEwMDE2MTcxXzItMy0xLTEtMA_3a745ca0-d32c-4df1-8667-30babb198f56"
      unitRef="usd">4779000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo0ZTI1NjdiZGNjMjg0NDYxOTQ5OTFiYmZhMDAxNjE3MS90YWJsZXJhbmdlOjRlMjU2N2JkY2MyODQ0NjE5NDk5MWJiZmEwMDE2MTcxXzMtMS0xLTEtMA_7e852fec-7034-4af2-b210-171accdb837b"
      unitRef="usd">1603000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo0ZTI1NjdiZGNjMjg0NDYxOTQ5OTFiYmZhMDAxNjE3MS90YWJsZXJhbmdlOjRlMjU2N2JkY2MyODQ0NjE5NDk5MWJiZmEwMDE2MTcxXzMtMy0xLTEtMA_be4fb0bd-dc30-4b57-bba8-860da8300b35"
      unitRef="usd">1004000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo0ZTI1NjdiZGNjMjg0NDYxOTQ5OTFiYmZhMDAxNjE3MS90YWJsZXJhbmdlOjRlMjU2N2JkY2MyODQ0NjE5NDk5MWJiZmEwMDE2MTcxXzYtMS0xLTEtMA_779390ba-0bf0-4b36-98cd-f80d70954141"
      unitRef="usd">745000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo0ZTI1NjdiZGNjMjg0NDYxOTQ5OTFiYmZhMDAxNjE3MS90YWJsZXJhbmdlOjRlMjU2N2JkY2MyODQ0NjE5NDk5MWJiZmEwMDE2MTcxXzYtMy0xLTEtMA_53a983f2-5b57-4938-be9e-60b5daf485b9"
      unitRef="usd">1133000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo0ZTI1NjdiZGNjMjg0NDYxOTQ5OTFiYmZhMDAxNjE3MS90YWJsZXJhbmdlOjRlMjU2N2JkY2MyODQ0NjE5NDk5MWJiZmEwMDE2MTcxXzctMS0xLTEtMA_c050e7b5-4fc5-4316-bf97-183d73901b72"
      unitRef="usd">4236000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo0ZTI1NjdiZGNjMjg0NDYxOTQ5OTFiYmZhMDAxNjE3MS90YWJsZXJhbmdlOjRlMjU2N2JkY2MyODQ0NjE5NDk5MWJiZmEwMDE2MTcxXzctMy0xLTEtMA_dbb97eac-a178-44c0-bbfa-173b1358e404"
      unitRef="usd">6916000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo0ZTI1NjdiZGNjMjg0NDYxOTQ5OTFiYmZhMDAxNjE3MS90YWJsZXJhbmdlOjRlMjU2N2JkY2MyODQ0NjE5NDk5MWJiZmEwMDE2MTcxXzgtMS0xLTEtMA_479f6525-aa0e-4daa-b32c-baa8f45ca281"
      unitRef="usd">3837000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo0ZTI1NjdiZGNjMjg0NDYxOTQ5OTFiYmZhMDAxNjE3MS90YWJsZXJhbmdlOjRlMjU2N2JkY2MyODQ0NjE5NDk5MWJiZmEwMDE2MTcxXzgtMy0xLTEtMA_99fe4e61-fc42-4852-9461-3d260843214b"
      unitRef="usd">6472000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo0ZTI1NjdiZGNjMjg0NDYxOTQ5OTFiYmZhMDAxNjE3MS90YWJsZXJhbmdlOjRlMjU2N2JkY2MyODQ0NjE5NDk5MWJiZmEwMDE2MTcxXzktMS0xLTEtMA_e1b6e50e-ab16-4cb6-bb78-1a8d78218d35"
      unitRef="usd">399000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo0ZTI1NjdiZGNjMjg0NDYxOTQ5OTFiYmZhMDAxNjE3MS90YWJsZXJhbmdlOjRlMjU2N2JkY2MyODQ0NjE5NDk5MWJiZmEwMDE2MTcxXzktMy0xLTEtMA_c3f7d0e9-418d-4a7c-89f7-d7e207bc9112"
      unitRef="usd">444000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo0ZTI1NjdiZGNjMjg0NDYxOTQ5OTFiYmZhMDAxNjE3MS90YWJsZXJhbmdlOjRlMjU2N2JkY2MyODQ0NjE5NDk5MWJiZmEwMDE2MTcxXzEyLTEtMS0xLTA_2ac815ab-2d11-4364-bcf2-33798c066e56"
      unitRef="usd">278000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo0ZTI1NjdiZGNjMjg0NDYxOTQ5OTFiYmZhMDAxNjE3MS90YWJsZXJhbmdlOjRlMjU2N2JkY2MyODQ0NjE5NDk5MWJiZmEwMDE2MTcxXzEyLTMtMS0xLTA_526e3968-51c4-4f72-b0eb-f6468eeed09c"
      unitRef="usd">245000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo0ZTI1NjdiZGNjMjg0NDYxOTQ5OTFiYmZhMDAxNjE3MS90YWJsZXJhbmdlOjRlMjU2N2JkY2MyODQ0NjE5NDk5MWJiZmEwMDE2MTcxXzE0LTEtMS0xLTA_bd62a931-34bc-4cd5-9fb5-a78b25e1ef6a"
      unitRef="usd">121000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo0ZTI1NjdiZGNjMjg0NDYxOTQ5OTFiYmZhMDAxNjE3MS90YWJsZXJhbmdlOjRlMjU2N2JkY2MyODQ0NjE5NDk5MWJiZmEwMDE2MTcxXzE0LTMtMS0xLTM4NzU_4562b58a-6aa8-4f02-addd-816712b45c49"
      unitRef="usd">199000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo0ZTI1NjdiZGNjMjg0NDYxOTQ5OTFiYmZhMDAxNjE3MS90YWJsZXJhbmdlOjRlMjU2N2JkY2MyODQ0NjE5NDk5MWJiZmEwMDE2MTcxXzE1LTEtMS0xLTA_9c2dc4a7-16e6-4088-9736-b846cd003d02"
      unitRef="usd">399000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo0ZTI1NjdiZGNjMjg0NDYxOTQ5OTFiYmZhMDAxNjE3MS90YWJsZXJhbmdlOjRlMjU2N2JkY2MyODQ0NjE5NDk5MWJiZmEwMDE2MTcxXzE1LTMtMS0xLTA_152c741a-e98d-4636-970d-8e5504cb559e"
      unitRef="usd">444000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo0ZTI1NjdiZGNjMjg0NDYxOTQ5OTFiYmZhMDAxNjE3MS90YWJsZXJhbmdlOjRlMjU2N2JkY2MyODQ0NjE5NDk5MWJiZmEwMDE2MTcxXzE2LTEtMS0xLTA_0128e8d2-9c07-4fbf-8ad1-5fcc70358a98"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTo0ZTI1NjdiZGNjMjg0NDYxOTQ5OTFiYmZhMDAxNjE3MS90YWJsZXJhbmdlOjRlMjU2N2JkY2MyODQ0NjE5NDk5MWJiZmEwMDE2MTcxXzE2LTMtMS0xLTA_9ac4503b-a17c-4a62-8055-93f7ad3a86ec"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <apyx:CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90ZXh0cmVnaW9uOjdmMjM2M2MzYTgzMzRkYzA4MTM0MzYxMjZjYzY4NWU3XzEwOTk1MTE2MzYzMzA_a7ab007b-f34d-4029-bfdc-4e118712e4bb"
      unitRef="usd">-3700000</apyx:CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards>
    <apyx:CARESActEffectiveIncomeTaxRateReconciliationFederalNetOperatingLossCarryforwardsAmount
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90ZXh0cmVnaW9uOjdmMjM2M2MzYTgzMzRkYzA4MTM0MzYxMjZjYzY4NWU3XzEwOTk1MTE2MzYzNDQ_bbd19a2a-10f4-468a-8de7-786d8bd031b8"
      unitRef="usd">3700000</apyx:CARESActEffectiveIncomeTaxRateReconciliationFederalNetOperatingLossCarryforwardsAmount>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90ZXh0cmVnaW9uOjdmMjM2M2MzYTgzMzRkYzA4MTM0MzYxMjZjYzY4NWU3XzE4Njc_0b4d5cf7-5417-4b0d-899a-a852f33b5d8c"
      unitRef="usd">1300000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90ZXh0cmVnaW9uOjdmMjM2M2MzYTgzMzRkYzA4MTM0MzYxMjZjYzY4NWU3XzE4Njc_10f811de-c644-48cf-9189-1b05638eb98a"
      unitRef="usd">1300000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90ZXh0cmVnaW9uOjdmMjM2M2MzYTgzMzRkYzA4MTM0MzYxMjZjYzY4NWU3XzcxNDY4MjU1ODkzOTg_df0c13b7-6e43-4446-a4a7-335b30df4d06"
      unitRef="usd">400000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90ZXh0cmVnaW9uOjdmMjM2M2MzYTgzMzRkYzA4MTM0MzYxMjZjYzY4NWU3XzE5MjI_1f83a5d8-9741-4711-ab84-43a76684d652"
      unitRef="usd">200000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90ZXh0cmVnaW9uOjdmMjM2M2MzYTgzMzRkYzA4MTM0MzYxMjZjYzY4NWU3XzI1ODM_aec17595-4541-4414-8a7c-40b6a2e8c212">&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a roll-forward of the Company's total gross unrecognized tax benefits, not including interest and penalties, for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:79.093%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.604%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.018%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Tax Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Beginning of year balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions of tax positions related to the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions of tax positions related to the prior year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decreases for tax positions related to prior year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;End of year balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTpiNGY4ZWE5MDE0MDg0MGZjYWRjZGFiMGZhMDE2MWI2Mi90YWJsZXJhbmdlOmI0ZjhlYTkwMTQwODQwZmNhZGNkYWIwZmEwMTYxYjYyXzEtMi0xLTEtMA_c9e20297-e213-43c8-91b5-5bcb81b9957a"
      unitRef="usd">1313000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i00df6877cb2d4b75a1a4abee0d94d57f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTpiNGY4ZWE5MDE0MDg0MGZjYWRjZGFiMGZhMDE2MWI2Mi90YWJsZXJhbmdlOmI0ZjhlYTkwMTQwODQwZmNhZGNkYWIwZmEwMTYxYjYyXzItNC0xLTEtNTM2Nw_0c15f714-c8f8-4463-8040-96547ea2a3db"
      unitRef="usd">1313000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTpiNGY4ZWE5MDE0MDg0MGZjYWRjZGFiMGZhMDE2MWI2Mi90YWJsZXJhbmdlOmI0ZjhlYTkwMTQwODQwZmNhZGNkYWIwZmEwMTYxYjYyXzItMi0xLTEtMA_15c0fc01-9f98-4a6b-9e1b-ccd782b4528d"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTpiNGY4ZWE5MDE0MDg0MGZjYWRjZGFiMGZhMDE2MWI2Mi90YWJsZXJhbmdlOmI0ZjhlYTkwMTQwODQwZmNhZGNkYWIwZmEwMTYxYjYyXzMtNC0xLTEtNTM2Nw_9f4dd9de-3219-4772-bc9c-a8fafcde6a7f"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTpiNGY4ZWE5MDE0MDg0MGZjYWRjZGFiMGZhMDE2MWI2Mi90YWJsZXJhbmdlOmI0ZjhlYTkwMTQwODQwZmNhZGNkYWIwZmEwMTYxYjYyXzMtMi0xLTEtMA_436c5a37-a0d0-408a-a79b-a36c1deed3ca"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTpiNGY4ZWE5MDE0MDg0MGZjYWRjZGFiMGZhMDE2MWI2Mi90YWJsZXJhbmdlOmI0ZjhlYTkwMTQwODQwZmNhZGNkYWIwZmEwMTYxYjYyXzQtNC0xLTEtNTM2Nw_66aaa0a2-b72a-41e7-97c2-55e831472092"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTpiNGY4ZWE5MDE0MDg0MGZjYWRjZGFiMGZhMDE2MWI2Mi90YWJsZXJhbmdlOmI0ZjhlYTkwMTQwODQwZmNhZGNkYWIwZmEwMTYxYjYyXzQtMi0xLTEtMA_05120607-d09d-422b-af3a-8301909490a2"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTpiNGY4ZWE5MDE0MDg0MGZjYWRjZGFiMGZhMDE2MWI2Mi90YWJsZXJhbmdlOmI0ZjhlYTkwMTQwODQwZmNhZGNkYWIwZmEwMTYxYjYyXzUtNC0xLTEtNTM2Nw_59db85ac-c53a-41b2-ac01-1ad88d3a2805"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTpiNGY4ZWE5MDE0MDg0MGZjYWRjZGFiMGZhMDE2MWI2Mi90YWJsZXJhbmdlOmI0ZjhlYTkwMTQwODQwZmNhZGNkYWIwZmEwMTYxYjYyXzUtMi0xLTEtMA_546730f4-28ea-401c-9558-4d52f4e15853"
      unitRef="usd">1313000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjEvZnJhZzo3ZjIzNjNjM2E4MzM0ZGMwODEzNDM2MTI2Y2M2ODVlNy90YWJsZTpiNGY4ZWE5MDE0MDg0MGZjYWRjZGFiMGZhMDE2MWI2Mi90YWJsZXJhbmdlOmI0ZjhlYTkwMTQwODQwZmNhZGNkYWIwZmEwMTYxYjYyXzYtNC0xLTEtNTM2Nw_736bcbb8-9c1b-462b-9f04-bdb783da2be1"
      unitRef="usd">1313000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjcvZnJhZzplY2EwOWM4ODg5MmE0Njk1ODc3MDBkMTEzNjIwYTBkNS90ZXh0cmVnaW9uOmVjYTA5Yzg4ODkyYTQ2OTU4NzcwMGQxMTM2MjBhMGQ1XzkzNA_3ad78e67-17f2-4177-ba5a-ea7b728664e4">RETIREMENT PLAN&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides a tax-qualified profit-sharing retirement plan under section 401(k) of the Internal Revenue Code for the benefit of eligible employees with an accumulation of funds for retirement on a tax-deferred basis and provides for annual discretionary contribution to individual trust funds.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All employees are eligible to participate upon completing three months of service. The employees may make voluntary contributions to the plan up to the maximum percentage allowed by the Internal Revenue Code. Vesting in employee matching contributions is graded and depends on the years of service. After three years from their date of hire, the employees are 100% vested. The Company makes matching contributions of 50% of the employee contributions up to a total of 3% of participant payroll. Matching contributions made by the Company totaled approximately $0.3 million for each of the years ended December&#160;31, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <apyx:DefinedContributionPlanEmployersMatchingContributionVestingPeriod
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjcvZnJhZzplY2EwOWM4ODg5MmE0Njk1ODc3MDBkMTEzNjIwYTBkNS90ZXh0cmVnaW9uOmVjYTA5Yzg4ODkyYTQ2OTU4NzcwMGQxMTM2MjBhMGQ1XzY0MQ_222b8728-1acc-43e9-af08-798fd7e778f2">P3Y</apyx:DefinedContributionPlanEmployersMatchingContributionVestingPeriod>
    <apyx:DefinedContributionPlanEmployersMatchingContributionVestingPercentageAfterThreeYears
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjcvZnJhZzplY2EwOWM4ODg5MmE0Njk1ODc3MDBkMTEzNjIwYTBkNS90ZXh0cmVnaW9uOmVjYTA5Yzg4ODkyYTQ2OTU4NzcwMGQxMTM2MjBhMGQ1XzY4Nw_ca936040-be55-475f-b1b3-cf451a01078f"
      unitRef="number">1</apyx:DefinedContributionPlanEmployersMatchingContributionVestingPercentageAfterThreeYears>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjcvZnJhZzplY2EwOWM4ODg5MmE0Njk1ODc3MDBkMTEzNjIwYTBkNS90ZXh0cmVnaW9uOmVjYTA5Yzg4ODkyYTQ2OTU4NzcwMGQxMTM2MjBhMGQ1Xzc0Mg_ab2b03e7-0b06-4ec0-929f-7455a6f84656"
      unitRef="number">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjcvZnJhZzplY2EwOWM4ODg5MmE0Njk1ODc3MDBkMTEzNjIwYTBkNS90ZXh0cmVnaW9uOmVjYTA5Yzg4ODkyYTQ2OTU4NzcwMGQxMTM2MjBhMGQ1Xzc5Mg_85a6945d-29f9-4805-9b85-ebbda268f926"
      unitRef="number">0.03</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjcvZnJhZzplY2EwOWM4ODg5MmE0Njk1ODc3MDBkMTEzNjIwYTBkNS90ZXh0cmVnaW9uOmVjYTA5Yzg4ODkyYTQ2OTU4NzcwMGQxMTM2MjBhMGQ1Xzg3MA_ddd509c3-1b55-4e4e-894e-43d035fb831d"
      unitRef="usd">300000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMjcvZnJhZzplY2EwOWM4ODg5MmE0Njk1ODc3MDBkMTEzNjIwYTBkNS90ZXh0cmVnaW9uOmVjYTA5Yzg4ODkyYTQ2OTU4NzcwMGQxMTM2MjBhMGQ1Xzg3MA_e6707246-b4c5-40ec-b37a-f9fdd9ae09f8"
      unitRef="usd">300000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzMvZnJhZzozNzkyMTk1YzY4ZDQ0OTdjYmFkYzZkNWRkNWM5NjBjYi90ZXh0cmVnaW9uOjM3OTIxOTVjNjhkNDQ5N2NiYWRjNmQ1ZGQ1Yzk2MGNiXzY1Ng_e5639371-b369-4176-8576-e85814387ec5">RELATED PARTY TRANSACTIONS&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Several relatives of Nikolay Shilev, Apyx Bulgaria&#x2019;s Managing Director, are considered related parties. Teodora Shileva, Mr. Shilev&#x2019;s spouse, is an employee of the Company working in the accounting department. Antoaneta Dimitrova Shileva-Tor&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;omanova, Mr. Shilev&#x2019;s sister, is the manager of human resources. Svetoslav Shilev, Mr. Shilev&#x2019;s son, is a quality manager in the quality assurance department. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, as part of the purchase of the Apyx Bulgaria manufacturing facility, Mr. Shilev was issued a note payable for $0.1 million, which was paid in full on October 20, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The partner in the Company's China joint venture is also a supplie&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;r of the Company. For the years ended December 31, 2020 and 2019, the Company made purchases from this supplier of approximately $1,441,000 and $2,643,000, respectively. At December 31, 2020 and 2019, respectively, the Company owed this supplier approximately $38,000 and $29,000, respective&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ly.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:NotesPayableRelatedPartiesNoncurrent
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzMvZnJhZzozNzkyMTk1YzY4ZDQ0OTdjYmFkYzZkNWRkNWM5NjBjYi90ZXh0cmVnaW9uOjM3OTIxOTVjNjhkNDQ5N2NiYWRjNmQ1ZGQ1Yzk2MGNiXzU3Mw_42b7ca02-268d-484f-b878-fcdb9c6c5b77"
      unitRef="usd">100000</us-gaap:NotesPayableRelatedPartiesNoncurrent>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="i8ae0b3b25b524ed89da35d0c86ded00e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzMvZnJhZzozNzkyMTk1YzY4ZDQ0OTdjYmFkYzZkNWRkNWM5NjBjYi90ZXh0cmVnaW9uOjM3OTIxOTVjNjhkNDQ5N2NiYWRjNmQ1ZGQ1Yzk2MGNiXzEwOTk1MTE2Mjk0NTM_3f053f04-759a-4e88-9d5c-87e75d92d4f8"
      unitRef="usd">1441000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="i42b2e2edfea349f6bef6deafaa0b9c9f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzMvZnJhZzozNzkyMTk1YzY4ZDQ0OTdjYmFkYzZkNWRkNWM5NjBjYi90ZXh0cmVnaW9uOjM3OTIxOTVjNjhkNDQ5N2NiYWRjNmQ1ZGQ1Yzk2MGNiXzEwOTk1MTE2Mjk0ODM_3b93a7bc-b87f-46de-8e7b-1659412bf9f8"
      unitRef="usd">2643000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="ie2101546a5f04f93a9393b9ac203e960_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzMvZnJhZzozNzkyMTk1YzY4ZDQ0OTdjYmFkYzZkNWRkNWM5NjBjYi90ZXh0cmVnaW9uOjM3OTIxOTVjNjhkNDQ5N2NiYWRjNmQ1ZGQ1Yzk2MGNiXzEwOTk1MTE2Mjk0NjU_ccfc1d86-48c6-46e2-8264-c796e93446c7"
      unitRef="usd">38000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="i324ce5f416944371b0b0f1514f0a8c83_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzMvZnJhZzozNzkyMTk1YzY4ZDQ0OTdjYmFkYzZkNWRkNWM5NjBjYi90ZXh0cmVnaW9uOjM3OTIxOTVjNjhkNDQ5N2NiYWRjNmQ1ZGQ1Yzk2MGNiXzEwOTk1MTE2Mjk0NzQ_8eaf31a9-c78c-445d-96ff-0601f5f46a19"
      unitRef="usd">29000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzYvZnJhZzoxZDA2ZDA3NjQ1MGI0NDE4ODI5MTgzYTBhYTI5ZmNlNC90ZXh0cmVnaW9uOjFkMDZkMDc2NDUwYjQ0MTg4MjkxODNhMGFhMjlmY2U0XzcwMTI_5ad9b86c-543d-4187-b296-caeb0e0163d0">COMMITMENTS AND CONTINGENCIES&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Litigation &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The medical device industry is characterized by frequent claims and litigation, and the Company may become subject to various claims, lawsuits and proceedings in the ordinary course of our business. Such claims may include claims by current or former employees, distributors and competitors, claims concerning the marketing and promotion of our products and product liability claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is involved in a number of legal actions relating to the use of our Helium Plasma technology. The outcomes of these legal actions are not within the Company&#x2019;s complete control and may not be known for prolonged periods of time. It believes that such claims are adequately covered by insurance; however, in the case of one of the Company&#x2019;s carriers, the Company is in a dispute regarding the total level of coverage available. Notwithstanding the foregoing, in the opinion of management, the Company has meritorious defenses, and such claims are not expected, individually or in the aggregate, to result in a material, adverse effect on its financial condition, results of operations and cash flows. However, in the event that damages exceed the aggregate coverage limits of the Company&#x2019;s policies or if its insurance carriers disclaim coverage, management believes it is possible that costs associated with these claims could have a material adverse impact on the consolidated financial condition, results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 17, 2019, a complaint (the &#x201c;Complaint&#x201d;) was filed in the United States District Court for the Middle District of Florida, against the Company and Charles D. Goodwin, the Company&#x2019;s President and Chief Executive Officer and a member of the Company&#x2019;s Board of Directors, alleging certain violations of the Securities Exchange Act of 1934, as amended.  On July 16, 2019, the Court appointed lead plaintiff for the putative class and approved the lead plaintiff&#x2019;s selection of counsel. On September 3, 2019, lead plaintiff filed an amended complaint (the &#x201c;Amended Complaint&#x201d;) with the Court. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Amended Complaint seeks class action status on behalf of all persons and entities that acquired the Company&#x2019;s securities between December 21, 2018 and April 1, 2019, and alleges violations by the Company and Goodwin of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended and Rule 10b-5 thereunder, primarily related to certain public statements concerning the Premarket Notification 510(k) submission made to the US Food and Drug Administration for a new indication for the Company&#x2019;s J-Plasma&#xae; technology for use in dermal resurfacing procedures.  On October 3, 2019, defendants filed a motion to dismiss the Amended Complaint, and on March 11, 2020, the Court denied that motion.  On July 10, 2020, the parties executed a settlement agreement, which was subject to Court approval. The Court preliminarily approved the settlement on July 21, 2020. The settlement agreement provides for the dismissal of the action with prejudice. On November 6, 2020, the Court issued its final order approving the settlement and dismissing the action and all claims contained in the Amended Complaint with prejudice. At December 31, 2020, the Company has settled and fully paid all obligations related to this matter. Included in selling, general and administrative expenses for the year ended December 31, 2019 is $1,000,000 for the matter. At December 31, 2019, the Company had accrued $820,000 for the matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accrues a liability in our consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is recorded. If a loss is reasonably possible, but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the consolidated financial statements. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded, actual results may differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Purchase Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020, the Company has purchase commitments for inventories totaling approximately $1.9&#160;million, substantially all of which is expected to be purchased by the end of 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;China Joint Venture&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Company's agreement in the China joint venture requires it to make a capital contribution into the newly formed entity of $357,000. As of the date of these consolidated financial statements, approximately $203,000 of its capital commitment remains to be funded.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentrations&lt;/span&gt;&lt;/div&gt;Sales to one customer within the OEM segment represented 10% and 11% of total sales for the year ended December 31, 2020 and 2019, respectively.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <apyx:LossContingencyAccrualTotalAccruedToDate
      contextRef="i33ad88dc3b434353b50eb3acfab694d4_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzYvZnJhZzoxZDA2ZDA3NjQ1MGI0NDE4ODI5MTgzYTBhYTI5ZmNlNC90ZXh0cmVnaW9uOjFkMDZkMDc2NDUwYjQ0MTg4MjkxODNhMGFhMjlmY2U0XzEwOTk1MTE2NTE1MTI_9ee52496-ab1b-4a0c-a3ab-a9a0fdcfd7a7"
      unitRef="usd">1000000</apyx:LossContingencyAccrualTotalAccruedToDate>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i33ad88dc3b434353b50eb3acfab694d4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzYvZnJhZzoxZDA2ZDA3NjQ1MGI0NDE4ODI5MTgzYTBhYTI5ZmNlNC90ZXh0cmVnaW9uOjFkMDZkMDc2NDUwYjQ0MTg4MjkxODNhMGFhMjlmY2U0XzEwOTk1MTE2NTE1MDI_93d805f9-9c27-4345-be55-b1d71c241a2d"
      unitRef="usd">820000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:PurchaseObligation
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzYvZnJhZzoxZDA2ZDA3NjQ1MGI0NDE4ODI5MTgzYTBhYTI5ZmNlNC90ZXh0cmVnaW9uOjFkMDZkMDc2NDUwYjQ0MTg4MjkxODNhMGFhMjlmY2U0XzEwOTk1MTE2NTA2Nzk_048c3282-bfa0-4a06-b5ba-b5b92847a258"
      unitRef="usd">1900000</us-gaap:PurchaseObligation>
    <apyx:NoncontrollingInterestRequiredCapitalContribution
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzYvZnJhZzoxZDA2ZDA3NjQ1MGI0NDE4ODI5MTgzYTBhYTI5ZmNlNC90ZXh0cmVnaW9uOjFkMDZkMDc2NDUwYjQ0MTg4MjkxODNhMGFhMjlmY2U0XzEwOTk1MTE2NTA2OTM_d43e19b8-8e5b-4882-933a-403de3657d43"
      unitRef="usd">357000</apyx:NoncontrollingInterestRequiredCapitalContribution>
    <apyx:PaymentsToAcquireInterestInJointVentureRemaining
      contextRef="i24f804d243d24666a8bc91f19e0bc3dc_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzYvZnJhZzoxZDA2ZDA3NjQ1MGI0NDE4ODI5MTgzYTBhYTI5ZmNlNC90ZXh0cmVnaW9uOjFkMDZkMDc2NDUwYjQ0MTg4MjkxODNhMGFhMjlmY2U0XzEwOTk1MTE2NTA3MDg_6cb6e084-0d0c-4c11-b919-9b58c430fee1"
      unitRef="usd">203000</apyx:PaymentsToAcquireInterestInJointVentureRemaining>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0a42214a67b14472a2d145b68faf883b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzYvZnJhZzoxZDA2ZDA3NjQ1MGI0NDE4ODI5MTgzYTBhYTI5ZmNlNC90ZXh0cmVnaW9uOjFkMDZkMDc2NDUwYjQ0MTg4MjkxODNhMGFhMjlmY2U0XzEwOTk1MTE2NTA3MDM_0f957672-7d79-438c-8a4c-3cbfeee999b6"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i1a14786bb32f4b7fbd8311532b5e461e_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzYvZnJhZzoxZDA2ZDA3NjQ1MGI0NDE4ODI5MTgzYTBhYTI5ZmNlNC90ZXh0cmVnaW9uOjFkMDZkMDc2NDUwYjQ0MTg4MjkxODNhMGFhMjlmY2U0XzY4NDc_53887b0a-c0db-4c06-9415-46b6be496607"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzY2MTI_026e854d-d6a4-42aa-8925-bdd42b2553bc">STOCK OPTIONS&#160;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 30, 2007, the Company's stockholders approved, and the Board of Directors adopted an amendment to the 2003 Executive and Employee Stock Option Plan (the &#x201c;Plan&#x201d;) to increase the maximum aggregate number of shares of common stock reserved for issuance under the Plan from 1.2 million shares (already reserved against outstanding options) to 1.7 million shares. Except for the increase in the number of shares covered by the Plan, the Plan remained otherwise unchanged. In 2001, the Board of Directors adopted the 2001 Executive and Employee Stock Option Plan which reserved for issuance 1.2 million stock options. Stock options to employees typically have a ten-year life and currently vest over periods between &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzEwOTk1MTE2MzcxMDk_cf9a545e-25f8-4790-a167-4803e9a50ffa"&gt;one&lt;/span&gt; and seven years. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2012, the Company's stockholders approved the 2012 Share Incentive Plan covering a total of 750,000 shares of common stock issuable upon exercise of options to be granted under the plan. At December&#160;31, 2020 approximately 60,000 are available to be issued in this plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2015, the Company's stockholders approved the 2015 Executive and Employee Stock Option Plan covering a total of 2,000,000 shares of common stock issuable upon exercise of options to be granted under the plan. At December&#160;31, 2020 approximately 230,000 are available to be issued in this plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2017, the Company's stockholders approved the 2017 Executive and Employee Stock Option Plan covering a total of 3,000,000 shares of common stock issuable upon exercise of options to be granted under the plan. At December&#160;31, 2020 approximately 70,000 are available to be issued in this plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2019, the Company's stockholders approved the 2019 Share Incentive Plan covering a total of 2,000,000 shares of common stock issuable upon exercise of options to be granted under the plan. At December&#160;31, 2020, all 2,000,000 are available to be issued in this plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 29, 2021, the Company granted employees appro&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ximately 700,000 options to purchase common shares of the Company's stock. All options granted were pursuant to the plans noted above. The options ves&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;t over a period of three years. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The status of the Company's stock options is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of options &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,254,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,379,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(410,635)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(256,785)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,966,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,376,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(112,965)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(291,850)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,938,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,484,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,376,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(665,510)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(151,850)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,044,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common shares required to be issued upon the exercise of stock options would be issued from authorized and unissued shares. Options are valued using the Black-Scholes model. For employee grants, the Company calculates expected life via the simplified method as it does not have sufficient history to determine actual expected life. For non-employee grants, the Company calculates expected life using a combination of past exercise behavior, the contractual term and expected remaining exercise behavior. Inputs used in the valuation models are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:83.625%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.116%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.072%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.116%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.674%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.116%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.072%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020 Grants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019 Grants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Option value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4.98&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$8.18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$7.15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$7.91&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.9%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.9%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.4%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized approximately $4,210,000 and $3,581,000 in stock-based compensation expense during the years ended December 31, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The intrinsic value of each option share is the difference between the fair value of our common stock and the exercise price of such option share to the extent it is &#x201c;in-the-money&#x201d;. Aggregate intrinsic value represents the value that would have been received by the holders of in-the-money options had they exercised their options on the last trading day of the year and sold the underlying shares at the closing stock price on such day. The intrinsic value calculation at December 31, 2020 is based on the $7.20 closing stock price of the Company's common stock on December&#160;31, 2020, the last trading day of 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, there were 4,530,049 stock options outstanding and expected to vest with an aggregate intrinsic value of approximately $10,250,000. These options have a weighted average exercise price of $5.26 and a weighted average remaining contractual term of approximately 7 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, there were 2,894,474 stock options outstanding and exercisable with an aggregate intrinsic value of approximately $9,800,000. These options have a weighted average exercise price of $3.89 and a weighted average remaining contractual term of approximately 6 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total intrinsic value of in the money options exercised during the years ended December 31, 2020 and 2019, was approximately $200,000 and $1,420,000, respectively. Intrinsic value of exercised shares is the total value of such shares on the date of exercise less the cash received from the option holder to exercise the options or other consideration paid. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total fair value of options granted during the years ended December 31, 2020 and 2019, was approximately $6,580,000 and $6,300,000, respectively. The weighted average fair value of options granted during the years ended December 31, 2020 and 2019, was $4.78 and $4.57, respectively. The total fair value of option shares vested during the years ended December 31, 2020 and 2019, was approximately $2,510,000 and $2,130,000, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company allows employees to exercise stock-based awards by surrendering stock-based awards with an intrinsic value equal to the cumulative exercise price of the stock-based awards being exercised, referred to as net settlements. These surrenders are included in stock options exercised in the options rollforward above. During the years ended December 31, 2020 and 2019, the Company received 39,448 and 125,948 options as payment in the exercise of 47,088 and 222,601 options, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, there was approximately $5,910,000 of total unrecognized stock-based compensation expense, related to unvested stock options granted under the plans above. This expense is expected to be recognized over a weighted-average period of approximately 1 year.&lt;/span&gt;&lt;/div&gt;During October 2015, the Company granted 225,922 restricted stock units that vest ratably over a period of 5 years. As of December 31, 2020, all of the restricted stock units had vested.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i6ccc3072ced640849dd9bbd33abe34e5_I20011231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzMwMQ_3b30e80a-0642-4ba2-bdc8-ef20a07fbbff"
      unitRef="shares">1200000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="id2069ea94eb1477bb94891296fd7ccf0_I20071030"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzM2MQ_4b3f8304-b45e-451e-933b-086534d7d9a2"
      unitRef="shares">1700000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i6ccc3072ced640849dd9bbd33abe34e5_I20011231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzU5OA_3b30e80a-0642-4ba2-bdc8-ef20a07fbbff"
      unitRef="shares">1200000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzEwOTk1MTE2MzcxMDE_401b01c7-9b18-4af9-8e20-bb1062014f92">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i7ec1168e4e6e457abbce2a3267321f39_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzcyMQ_e154b7dc-d1ea-474b-ba54-63b9f9a55010">P7Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i1c9befc04c0e430b8f6bffceacc59a9d_I20120731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzgyMA_30a8a42e-5a49-46da-998c-a08f2434769e"
      unitRef="shares">750000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i8f01e109bd104360a674e88733aec92b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzcxNDY4MjU1ODk1NDg_73ee8d16-1e67-42a7-b882-b48e5ff52b8f"
      unitRef="shares">60000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="ief0094005e77442fa9d4b4c6c22a8df0_I20150731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzEwODg_4b356ec3-c660-4a0e-a4ff-27f360e703a6"
      unitRef="shares">2000000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ib4bc94f07ff84f97b245be704259861e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzcxNDY4MjU1ODk1NTY_3c7acb19-3289-4bc6-9a97-9583af76ff96"
      unitRef="shares">230000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i74bbca955e6f4c6e8758ac942298fe99_I20170831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzEzNTg_0459598c-f67b-45cf-8c3c-98bc7bf076ef"
      unitRef="shares">3000000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i04da05110f984d449da3c74c6a62b472_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzEwOTk1MTE2MzY1MTM_ddde27af-f9dd-42d1-a555-53b6436187dd"
      unitRef="shares">70000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i865b7f7fe4ac4cfba2d0d6c0001de126_I20190831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzE2MDg_6f17ccb9-57cc-4e71-941f-8621a24a8515"
      unitRef="shares">2000000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i8dcd8a8a5fd54b70a6dd5754aceae3b0_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzE3MDk_e19f0e5d-7d69-4696-ad38-32b2acef23fc"
      unitRef="shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ib625f4dfee414563bb1127dd3c30d6a0_D20200129-20200129"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzcxNDY4MjU1ODk1NjU_a117964c-6738-4725-9293-ea58a79c530b"
      unitRef="shares">700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ib625f4dfee414563bb1127dd3c30d6a0_D20200129-20200129"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzE5NzQ_df56b11f-8cc0-4c02-8c28-cbb18705cd2a">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzY2MTk_66bad38f-31aa-41dd-862d-d7dac4cfc49b">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The status of the Company's stock options is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of options &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,254,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,379,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(410,635)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(256,785)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,966,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,376,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(112,965)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(291,850)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,938,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i00df6877cb2d4b75a1a4abee0d94d57f_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTo5N2QzNWVmOGUwYjU0YTIzYjIzYzFlYzJkM2Q3ZmMyNy90YWJsZXJhbmdlOjk3ZDM1ZWY4ZTBiNTRhMjNiMjNjMWVjMmQzZDdmYzI3XzEzLTEtMS0xLTA_9d5c6b8d-1c79-46de-b43f-983348bac51e"
      unitRef="shares">3254779</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i00df6877cb2d4b75a1a4abee0d94d57f_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTo5N2QzNWVmOGUwYjU0YTIzYjIzYzFlYzJkM2Q3ZmMyNy90YWJsZXJhbmdlOjk3ZDM1ZWY4ZTBiNTRhMjNiMjNjMWVjMmQzZDdmYzI3XzEzLTMtMS0xLTA_9df9bf4b-828a-43b4-b539-b660babf782a"
      unitRef="usdPerShare">3.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTo5N2QzNWVmOGUwYjU0YTIzYjIzYzFlYzJkM2Q3ZmMyNy90YWJsZXJhbmdlOjk3ZDM1ZWY4ZTBiNTRhMjNiMjNjMWVjMmQzZDdmYzI3XzE0LTEtMS0xLTA_4726e49b-3a1f-4741-bb29-c90bf57721b4"
      unitRef="shares">1379500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTo5N2QzNWVmOGUwYjU0YTIzYjIzYzFlYzJkM2Q3ZmMyNy90YWJsZXJhbmdlOjk3ZDM1ZWY4ZTBiNTRhMjNiMjNjMWVjMmQzZDdmYzI3XzE0LTMtMS0xLTA_f1edce44-f2bc-4db9-ae01-e82c4033cab2"
      unitRef="usdPerShare">7.70</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTo5N2QzNWVmOGUwYjU0YTIzYjIzYzFlYzJkM2Q3ZmMyNy90YWJsZXJhbmdlOjk3ZDM1ZWY4ZTBiNTRhMjNiMjNjMWVjMmQzZDdmYzI3XzE1LTEtMS0xLTA_59443ff0-e8cd-49e8-b5f5-170fa3c4de6a"
      unitRef="shares">410635</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTo5N2QzNWVmOGUwYjU0YTIzYjIzYzFlYzJkM2Q3ZmMyNy90YWJsZXJhbmdlOjk3ZDM1ZWY4ZTBiNTRhMjNiMjNjMWVjMmQzZDdmYzI3XzE1LTMtMS0xLTA_279131cc-161a-4642-ae11-ecca24eea09a"
      unitRef="usdPerShare">2.99</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTo5N2QzNWVmOGUwYjU0YTIzYjIzYzFlYzJkM2Q3ZmMyNy90YWJsZXJhbmdlOjk3ZDM1ZWY4ZTBiNTRhMjNiMjNjMWVjMmQzZDdmYzI3XzE2LTEtMS0xLTA_8c98c665-d653-41dc-a7ff-3d8dcf367dee"
      unitRef="shares">256785</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTo5N2QzNWVmOGUwYjU0YTIzYjIzYzFlYzJkM2Q3ZmMyNy90YWJsZXJhbmdlOjk3ZDM1ZWY4ZTBiNTRhMjNiMjNjMWVjMmQzZDdmYzI3XzE2LTMtMS0xLTA_06165120-a5f2-495c-a0e0-9f34abde1b35"
      unitRef="usdPerShare">4.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTo5N2QzNWVmOGUwYjU0YTIzYjIzYzFlYzJkM2Q3ZmMyNy90YWJsZXJhbmdlOjk3ZDM1ZWY4ZTBiNTRhMjNiMjNjMWVjMmQzZDdmYzI3XzE3LTEtMS0xLTA_7dfe439a-de2e-425a-93a1-188d4c2e7586"
      unitRef="shares">3966858</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTo5N2QzNWVmOGUwYjU0YTIzYjIzYzFlYzJkM2Q3ZmMyNy90YWJsZXJhbmdlOjk3ZDM1ZWY4ZTBiNTRhMjNiMjNjMWVjMmQzZDdmYzI3XzE3LTMtMS0xLTA_6b116e71-2915-4777-9f3a-63a8940ee31e"
      unitRef="usdPerShare">4.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTo5N2QzNWVmOGUwYjU0YTIzYjIzYzFlYzJkM2Q3ZmMyNy90YWJsZXJhbmdlOjk3ZDM1ZWY4ZTBiNTRhMjNiMjNjMWVjMmQzZDdmYzI3XzE4LTEtMS0xLTQwMzg_c3d7bb8c-a8f1-4aa6-8296-981cffaa43fc"
      unitRef="shares">1376900</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTo5N2QzNWVmOGUwYjU0YTIzYjIzYzFlYzJkM2Q3ZmMyNy90YWJsZXJhbmdlOjk3ZDM1ZWY4ZTBiNTRhMjNiMjNjMWVjMmQzZDdmYzI3XzE4LTMtMS0xLTQwMzg_fd5e4110-e3b9-457b-bfde-c96c6d3a7ca9"
      unitRef="usdPerShare">7.94</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTo5N2QzNWVmOGUwYjU0YTIzYjIzYzFlYzJkM2Q3ZmMyNy90YWJsZXJhbmdlOjk3ZDM1ZWY4ZTBiNTRhMjNiMjNjMWVjMmQzZDdmYzI3XzE5LTEtMS0xLTQwMzg_7e18ae41-7c7d-4441-84e8-1d98474fb3fd"
      unitRef="shares">112965</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTo5N2QzNWVmOGUwYjU0YTIzYjIzYzFlYzJkM2Q3ZmMyNy90YWJsZXJhbmdlOjk3ZDM1ZWY4ZTBiNTRhMjNiMjNjMWVjMmQzZDdmYzI3XzE5LTMtMS0xLTQwMzg_4ec7bef9-b29c-44dd-8459-4a21aa3cd19c"
      unitRef="usdPerShare">3.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTo5N2QzNWVmOGUwYjU0YTIzYjIzYzFlYzJkM2Q3ZmMyNy90YWJsZXJhbmdlOjk3ZDM1ZWY4ZTBiNTRhMjNiMjNjMWVjMmQzZDdmYzI3XzIwLTEtMS0xLTQwMzg_9d64c211-70ff-455c-9988-a59d57f1596d"
      unitRef="shares">291850</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTo5N2QzNWVmOGUwYjU0YTIzYjIzYzFlYzJkM2Q3ZmMyNy90YWJsZXJhbmdlOjk3ZDM1ZWY4ZTBiNTRhMjNiMjNjMWVjMmQzZDdmYzI3XzIwLTMtMS0xLTQwMzg_86e6aa62-0ec0-45ff-824e-98bde3192a19"
      unitRef="usdPerShare">7.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTo5N2QzNWVmOGUwYjU0YTIzYjIzYzFlYzJkM2Q3ZmMyNy90YWJsZXJhbmdlOjk3ZDM1ZWY4ZTBiNTRhMjNiMjNjMWVjMmQzZDdmYzI3XzIxLTEtMS0xLTQwMzg_c659a264-f880-4caf-a6fb-9a6d485e57c3"
      unitRef="shares">4938943</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTo5N2QzNWVmOGUwYjU0YTIzYjIzYzFlYzJkM2Q3ZmMyNy90YWJsZXJhbmdlOjk3ZDM1ZWY4ZTBiNTRhMjNiMjNjMWVjMmQzZDdmYzI3XzIxLTMtMS0xLTQwMzg_f5c53839-fc19-4cc8-ab19-7bd981a19c10"
      unitRef="usdPerShare">5.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzY2MDM_6e8b07b9-c211-49b7-bace-01b6f96113f9">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,484,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,376,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(665,510)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(151,850)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,044,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTo5YjFlMDQyZjNhYTA0MTY1YWI5ZWExNDI3ZGE3MzdlZS90YWJsZXJhbmdlOjliMWUwNDJmM2FhMDQxNjVhYjllYTE0MjdkYTczN2VlXzEtMS0xLTEtMA_9ff8d066-29c1-413f-8229-483997718f85"
      unitRef="shares">1484929</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i9020d4fc4c274bc28ceac88534fe42fd_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTo5YjFlMDQyZjNhYTA0MTY1YWI5ZWExNDI3ZGE3MzdlZS90YWJsZXJhbmdlOjliMWUwNDJmM2FhMDQxNjVhYjllYTE0MjdkYTczN2VlXzEtMy0xLTEtMA_46d9eda4-8f39-451c-97a4-a1412226169b"
      unitRef="usdPerShare">4.11</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTo5YjFlMDQyZjNhYTA0MTY1YWI5ZWExNDI3ZGE3MzdlZS90YWJsZXJhbmdlOjliMWUwNDJmM2FhMDQxNjVhYjllYTE0MjdkYTczN2VlXzItMS0xLTEtMA_a9e6656d-7647-4f3e-b6a9-93a16b239eec"
      unitRef="shares">1376900</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTo5YjFlMDQyZjNhYTA0MTY1YWI5ZWExNDI3ZGE3MzdlZS90YWJsZXJhbmdlOjliMWUwNDJmM2FhMDQxNjVhYjllYTE0MjdkYTczN2VlXzItMy0xLTEtMA_11a5cc08-1549-4572-a0ff-a03e319a6aca"
      unitRef="usdPerShare">4.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTo5YjFlMDQyZjNhYTA0MTY1YWI5ZWExNDI3ZGE3MzdlZS90YWJsZXJhbmdlOjliMWUwNDJmM2FhMDQxNjVhYjllYTE0MjdkYTczN2VlXzMtMS0xLTEtMA_05c4aa5a-a07e-49b6-8543-9d5fcc25f082"
      unitRef="shares">665510</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTo5YjFlMDQyZjNhYTA0MTY1YWI5ZWExNDI3ZGE3MzdlZS90YWJsZXJhbmdlOjliMWUwNDJmM2FhMDQxNjVhYjllYTE0MjdkYTczN2VlXzMtMy0xLTEtMA_281305f2-8d26-4078-8ff9-706133b01051"
      unitRef="usdPerShare">3.77</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTo5YjFlMDQyZjNhYTA0MTY1YWI5ZWExNDI3ZGE3MzdlZS90YWJsZXJhbmdlOjliMWUwNDJmM2FhMDQxNjVhYjllYTE0MjdkYTczN2VlXzQtMS0xLTEtMA_341bc8a8-bc79-4667-a035-7e4f77768cef"
      unitRef="shares">151850</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTo5YjFlMDQyZjNhYTA0MTY1YWI5ZWExNDI3ZGE3MzdlZS90YWJsZXJhbmdlOjliMWUwNDJmM2FhMDQxNjVhYjllYTE0MjdkYTczN2VlXzQtMy0xLTEtMA_bb007caf-7b0b-4256-83a4-17ecc324d293"
      unitRef="usdPerShare">4.53</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTo5YjFlMDQyZjNhYTA0MTY1YWI5ZWExNDI3ZGE3MzdlZS90YWJsZXJhbmdlOjliMWUwNDJmM2FhMDQxNjVhYjllYTE0MjdkYTczN2VlXzUtMS0xLTEtMA_ee91d0d2-a90f-49ab-a831-5414165a452d"
      unitRef="shares">2044469</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTo5YjFlMDQyZjNhYTA0MTY1YWI5ZWExNDI3ZGE3MzdlZS90YWJsZXJhbmdlOjliMWUwNDJmM2FhMDQxNjVhYjllYTE0MjdkYTczN2VlXzUtMy0xLTEtMA_3e11cd9a-dcf1-4e83-a2a3-acf34d440376"
      unitRef="usdPerShare">4.61</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzY2MTY_9a973f6f-36cd-4a8d-a346-ba5201e0d746">Inputs used in the valuation models are as follows:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:83.625%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.116%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.072%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.116%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.674%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.116%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.072%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020 Grants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019 Grants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Option value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4.98&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$8.18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$7.15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$7.91&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.9%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.9%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.4%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i79cf41051ed34d12a5fa5d78feeeef12_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTplZTI0ZDQ2Mjk4ZmM0ZTViODY4Mzg4ZjI3Njc4NTkxMy90YWJsZXJhbmdlOmVlMjRkNDYyOThmYzRlNWI4NjgzODhmMjc2Nzg1OTEzXzEtMS0xLTEtMA_179b21d1-6562-4dfd-b1fb-90099f6cdfd1"
      unitRef="usdPerShare">4.98</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i7ec1168e4e6e457abbce2a3267321f39_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTplZTI0ZDQ2Mjk4ZmM0ZTViODY4Mzg4ZjI3Njc4NTkxMy90YWJsZXJhbmdlOmVlMjRkNDYyOThmYzRlNWI4NjgzODhmMjc2Nzg1OTEzXzEtMy0xLTEtMA_61e476b0-b5a8-48af-ab72-e2523c20a1dc"
      unitRef="usdPerShare">8.18</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i7505016b032b4f8aaffab34edef82f38_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTplZTI0ZDQ2Mjk4ZmM0ZTViODY4Mzg4ZjI3Njc4NTkxMy90YWJsZXJhbmdlOmVlMjRkNDYyOThmYzRlNWI4NjgzODhmMjc2Nzg1OTEzXzEtNS0xLTEtMA_761fb2f1-b2f8-4795-abba-9a20d37cde78"
      unitRef="usdPerShare">7.15</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="iffb306c7379244eab19d37d41fd043d9_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTplZTI0ZDQ2Mjk4ZmM0ZTViODY4Mzg4ZjI3Njc4NTkxMy90YWJsZXJhbmdlOmVlMjRkNDYyOThmYzRlNWI4NjgzODhmMjc2Nzg1OTEzXzEtNy0xLTEtMA_60dfabe3-fdaa-401f-aab8-45ea22b90406"
      unitRef="usdPerShare">7.91</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i79cf41051ed34d12a5fa5d78feeeef12_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTplZTI0ZDQ2Mjk4ZmM0ZTViODY4Mzg4ZjI3Njc4NTkxMy90YWJsZXJhbmdlOmVlMjRkNDYyOThmYzRlNWI4NjgzODhmMjc2Nzg1OTEzXzItMS0xLTEtMA_3ee13c8c-d539-4ca0-a8de-9d21f231c200"
      unitRef="number">0.003</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i7ec1168e4e6e457abbce2a3267321f39_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTplZTI0ZDQ2Mjk4ZmM0ZTViODY4Mzg4ZjI3Njc4NTkxMy90YWJsZXJhbmdlOmVlMjRkNDYyOThmYzRlNWI4NjgzODhmMjc2Nzg1OTEzXzItMy0xLTEtMA_3dc97125-81f3-4a1d-9553-2a7e5a7a1cbd"
      unitRef="number">0.017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i7505016b032b4f8aaffab34edef82f38_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTplZTI0ZDQ2Mjk4ZmM0ZTViODY4Mzg4ZjI3Njc4NTkxMy90YWJsZXJhbmdlOmVlMjRkNDYyOThmYzRlNWI4NjgzODhmMjc2Nzg1OTEzXzItNS0xLTEtMA_f3897f39-deb7-4439-b2f1-7eed276b04bb"
      unitRef="number">0.017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="iffb306c7379244eab19d37d41fd043d9_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTplZTI0ZDQ2Mjk4ZmM0ZTViODY4Mzg4ZjI3Njc4NTkxMy90YWJsZXJhbmdlOmVlMjRkNDYyOThmYzRlNWI4NjgzODhmMjc2Nzg1OTEzXzItNy0xLTEtMA_e110c8ab-ecfd-4c10-8372-506bc1e4a573"
      unitRef="number">0.026</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTplZTI0ZDQ2Mjk4ZmM0ZTViODY4Mzg4ZjI3Njc4NTkxMy90YWJsZXJhbmdlOmVlMjRkNDYyOThmYzRlNWI4NjgzODhmMjc2Nzg1OTEzXzMtMS0xLTEtMA_8d43910b-928d-4a63-b9fe-6ea5c17f66b8"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTplZTI0ZDQ2Mjk4ZmM0ZTViODY4Mzg4ZjI3Njc4NTkxMy90YWJsZXJhbmdlOmVlMjRkNDYyOThmYzRlNWI4NjgzODhmMjc2Nzg1OTEzXzMtNS0xLTEtMA_83bfc096-a0f2-4659-9300-23676be17d35"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTplZTI0ZDQ2Mjk4ZmM0ZTViODY4Mzg4ZjI3Njc4NTkxMy90YWJsZXJhbmdlOmVlMjRkNDYyOThmYzRlNWI4NjgzODhmMjc2Nzg1OTEzXzQtMS0xLTEtMA_f7961bc6-3114-4f6f-983a-d897c50c799f"
      unitRef="number">0.659</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTplZTI0ZDQ2Mjk4ZmM0ZTViODY4Mzg4ZjI3Njc4NTkxMy90YWJsZXJhbmdlOmVlMjRkNDYyOThmYzRlNWI4NjgzODhmMjc2Nzg1OTEzXzQtMy0xLTEtMA_8b599fd9-4925-4a0c-8b8c-50ad9ce8d2fc"
      unitRef="number">0.701</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTplZTI0ZDQ2Mjk4ZmM0ZTViODY4Mzg4ZjI3Njc4NTkxMy90YWJsZXJhbmdlOmVlMjRkNDYyOThmYzRlNWI4NjgzODhmMjc2Nzg1OTEzXzQtNS0xLTEtMA_61336c39-2cc7-42a5-89c8-c4fb12bb7d64"
      unitRef="number">0.649</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTplZTI0ZDQ2Mjk4ZmM0ZTViODY4Mzg4ZjI3Njc4NTkxMy90YWJsZXJhbmdlOmVlMjRkNDYyOThmYzRlNWI4NjgzODhmMjc2Nzg1OTEzXzQtNy0xLTEtMA_df728e78-6365-4cf8-b1b6-9928489bd17d"
      unitRef="number">0.664</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTplZTI0ZDQ2Mjk4ZmM0ZTViODY4Mzg4ZjI3Njc4NTkxMy90YWJsZXJhbmdlOmVlMjRkNDYyOThmYzRlNWI4NjgzODhmMjc2Nzg1OTEzXzUtMS0xLTEtMA_145925ab-69c0-4073-907b-cdf004883bfa">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i7505016b032b4f8aaffab34edef82f38_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTplZTI0ZDQ2Mjk4ZmM0ZTViODY4Mzg4ZjI3Njc4NTkxMy90YWJsZXJhbmdlOmVlMjRkNDYyOThmYzRlNWI4NjgzODhmMjc2Nzg1OTEzXzUtNS0xLTEtMA_73bba24d-5f93-49ba-ad9d-35f32ea1e773">P4Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="iffb306c7379244eab19d37d41fd043d9_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90YWJsZTplZTI0ZDQ2Mjk4ZmM0ZTViODY4Mzg4ZjI3Njc4NTkxMy90YWJsZXJhbmdlOmVlMjRkNDYyOThmYzRlNWI4NjgzODhmMjc2Nzg1OTEzXzUtNy0xLTEtNDA0Mg_1a119525-e860-4aa3-8227-20ba996ce7c2">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzcxNDY4MjU1ODk1NzQ_779bc2cb-53cb-4485-8c34-94fc04b55711"
      unitRef="usd">4210000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzcxNDY4MjU1ODk1ODY_afa4d552-1be4-445d-b94a-26fee5f5739d"
      unitRef="usd">3581000</us-gaap:AllocatedShareBasedCompensationExpense>
    <apyx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueClosingStockPrice
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzcxNDY4MjU1ODk1OTg_1127b5d6-b038-4bd1-85ce-2c53ad871306"
      unitRef="usdPerShare">7.20</apyx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueClosingStockPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzcxNDY4MjU1ODk2MDU_cb455611-10c0-4913-b174-77df8fabc8a3"
      unitRef="shares">4530049</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzcxNDY4MjU1ODk2MTY_2ee04b44-8338-4661-a86f-7005c67e729f"
      unitRef="usd">10250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzcxNDY4MjU1ODk2Mjk_0c2e67d9-ea0d-47b3-8ca5-2f684c0d56c7"
      unitRef="usdPerShare">5.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzcxNDY4MjU1ODk4NDE_60d20782-be36-487d-a13e-4b892e8fdbf7">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzcxNDY4MjU1ODk2MzY_06725718-d8e7-4d79-b2a3-bade934ffc43"
      unitRef="shares">2894474</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzcxNDY4MjU1ODk2NDc_47cfd6ae-d418-4c63-966b-ef707c91d3d4"
      unitRef="usd">9800000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzcxNDY4MjU1ODk2NTk_6ee35647-ef62-4a1e-b5bf-a8bb4984c387"
      unitRef="usdPerShare">3.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzcxNDY4MjU1ODk4Mjk_3220beb8-94de-438b-bdc6-fbf6629c1412">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzcxNDY4MjU1ODk2NjY_895b0109-2880-4e3c-bea1-431add61a15f"
      unitRef="usd">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzcxNDY4MjU1ODk2NzY_ab57f547-1e41-4de8-81b1-6dd282b7fe96"
      unitRef="usd">1420000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <apyx:ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzcxNDY4MjU1ODk2ODg_676903a7-7621-49b2-ad45-28464f4fdfd6"
      unitRef="usd">6580000</apyx:ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue>
    <apyx:ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzcxNDY4MjU1ODk3MDA_b9d0239d-3043-4597-8156-27c396ca79dd"
      unitRef="usd">6300000</apyx:ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzcxNDY4MjU1ODk3MTI_b205fe79-7f7b-46c8-b500-708a9fac5a79"
      unitRef="usdPerShare">4.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzcxNDY4MjU1ODk3MTk_b2b587e2-fb7a-4e5b-bcdd-6200ac0209d9"
      unitRef="usdPerShare">4.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzcxNDY4MjU1ODk3MjY_6e264374-d7c2-44f6-9dbc-698e261415a6"
      unitRef="usd">2510000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzcxNDY4MjU1ODk3Mzg_5f108e8a-36b8-4663-ab6b-6d6b3e5b1ac5"
      unitRef="usd">2130000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzcxNDY4MjU1ODk3NTA_d94d2f97-289c-44a4-9670-29833f55724d"
      unitRef="shares">39448</apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived>
    <apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzcxNDY4MjU1ODk3NTg_4cf68c8c-5abc-43a6-b6c7-2e7a563851cc"
      unitRef="shares">125948</apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived>
    <apyx:StockIssuedDuringPeriodSharesStockSwaps
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzcxNDY4MjU1ODk3Njc_ff9487a2-daf7-47e8-8609-250ba94ccd5a"
      unitRef="shares">47088</apyx:StockIssuedDuringPeriodSharesStockSwaps>
    <apyx:StockIssuedDuringPeriodSharesStockSwaps
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzcxNDY4MjU1ODk3NzU_1e1e1303-1433-4ecc-b304-2f4c4dece3e4"
      unitRef="shares">222601</apyx:StockIssuedDuringPeriodSharesStockSwaps>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i96df8138377f4df5b064ec7bcc292732_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzcxNDY4MjU1ODk3ODQ_d9a02ecc-f3d3-4cb7-b69a-ab4c7f10de15"
      unitRef="usd">5910000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzYyNDI_c0c246e0-f10d-4dac-b836-67f5f0da1d1b">P1Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <apyx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedToDate
      contextRef="i938276f948f8476088fcafef6b8fa346_I20151031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzYyODg_f8de7a14-5f44-40eb-bc36-4f1b5997a3d4"
      unitRef="shares">225922</apyx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedToDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ic7261616081a40bbad79158817e1fdf0_D20151001-20151031"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzYzNTA_e90496b0-0278-4eb6-a6c5-e070589daa07">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90ZXh0cmVnaW9uOjRjYmQ3MGIwNzQ2NDQ5MDNhZmJiZDY2NDllMTQxODM0XzE1OTE_00a08c18-54ca-44fe-bc21-b7931f5e797b">GEOGRAPHIC AND SEGMENT INFORMATION&#160;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are aggregated into reportable segments only if they exhibit similar economic characteristics. In addition to similar economic characteristics, the Company also considers the following factors in determining the reportable segments: the nature of business activities, the management structure directly accountable to its chief operating decision maker for operating and administrative activities, availability of discrete financial information and information presented to the Board of Directors and investors. Asset information is not reviewed by the chief operating decision maker by segment and is not available by segment, accordingly, the Company has not presented a measure of assets by segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's reportable segments are disclosed as principally organized and managed as&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;two operating segments: Advanced Energy and OEM. "Corporate &amp;amp; Other" includes certain unallocated corporate and administrative costs which were not specifically attributed to any reportable segment. The OEM segment is primarily development and manufacturing contract and product driven, all related expenses are recorded as cost of sales, therefore no segment specific operating expenses are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized financial information with respect to reportable segments is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Advanced Energy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OEM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate (Other)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,793)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,083)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Advanced Energy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OEM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate (Other)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,045)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,960)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,869)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other losses, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(351)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(351)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;International sales in 2020 and 2019, were 32.1% and 30.6% of sales, respectively. Substantially all of these sales are denominated in U.S. dollars. Revenue by geographic region, based on the "ship to" location on the invoice are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Sales by Domestic and International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90ZXh0cmVnaW9uOjRjYmQ3MGIwNzQ2NDQ5MDNhZmJiZDY2NDllMTQxODM0XzgzNA_17238bc4-be7c-482e-9690-d046eced7381"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90ZXh0cmVnaW9uOjRjYmQ3MGIwNzQ2NDQ5MDNhZmJiZDY2NDllMTQxODM0XzE1ODY_1ad90d60-41b5-4cb3-96e5-af4f2b7c2db1">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized financial information with respect to reportable segments is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Advanced Energy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OEM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate (Other)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,793)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,083)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Advanced Energy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OEM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate (Other)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,045)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,960)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,869)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other losses, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(351)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(351)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i594539d6cfd54e88904eebbf46eef99a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTphMWYxOWY3NmNiOTY0ZDQwOTc5ODFlYTlhODZlMTZkZS90YWJsZXJhbmdlOmExZjE5Zjc2Y2I5NjRkNDA5Nzk4MWVhOWE4NmUxNmRlXzItMS0xLTEtMA_a1229e14-b5dc-4b71-81ec-f9c0cff4b942"
      unitRef="usd">22214000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5a77d1947a3942e4b0d3b8009af417c4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTphMWYxOWY3NmNiOTY0ZDQwOTc5ODFlYTlhODZlMTZkZS90YWJsZXJhbmdlOmExZjE5Zjc2Y2I5NjRkNDA5Nzk4MWVhOWE4NmUxNmRlXzItMy0xLTEtMA_f21c2ca9-135f-456a-9abb-593f51ac722c"
      unitRef="usd">5497000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5a90fc59d66d4c82b190fa272723dc6d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTphMWYxOWY3NmNiOTY0ZDQwOTc5ODFlYTlhODZlMTZkZS90YWJsZXJhbmdlOmExZjE5Zjc2Y2I5NjRkNDA5Nzk4MWVhOWE4NmUxNmRlXzItNS0xLTEtMA_ce1e9150-d88d-4b12-96a3-f7083a9cc543"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTphMWYxOWY3NmNiOTY0ZDQwOTc5ODFlYTlhODZlMTZkZS90YWJsZXJhbmdlOmExZjE5Zjc2Y2I5NjRkNDA5Nzk4MWVhOWE4NmUxNmRlXzItNy0xLTEtMA_251e7e63-e5f1-40b2-a5a9-d8b56c6e79fb"
      unitRef="usd">27711000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingIncomeLoss
      contextRef="i594539d6cfd54e88904eebbf46eef99a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTphMWYxOWY3NmNiOTY0ZDQwOTc5ODFlYTlhODZlMTZkZS90YWJsZXJhbmdlOmExZjE5Zjc2Y2I5NjRkNDA5Nzk4MWVhOWE4NmUxNmRlXzE1LTEtMS0xLTA_b7d9e4fa-1b5a-40a6-b577-f726bb9d492c"
      unitRef="usd">-7128000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5a77d1947a3942e4b0d3b8009af417c4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTphMWYxOWY3NmNiOTY0ZDQwOTc5ODFlYTlhODZlMTZkZS90YWJsZXJhbmdlOmExZjE5Zjc2Y2I5NjRkNDA5Nzk4MWVhOWE4NmUxNmRlXzE1LTMtMS0xLTA_59719d3a-9d5a-44d8-b5fe-612e963eb4d2"
      unitRef="usd">1838000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5a90fc59d66d4c82b190fa272723dc6d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTphMWYxOWY3NmNiOTY0ZDQwOTc5ODFlYTlhODZlMTZkZS90YWJsZXJhbmdlOmExZjE5Zjc2Y2I5NjRkNDA5Nzk4MWVhOWE4NmUxNmRlXzE1LTUtMS0xLTA_f0f5ec7d-0f18-4e81-87db-c1a23587dceb"
      unitRef="usd">-14793000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTphMWYxOWY3NmNiOTY0ZDQwOTc5ODFlYTlhODZlMTZkZS90YWJsZXJhbmdlOmExZjE5Zjc2Y2I5NjRkNDA5Nzk4MWVhOWE4NmUxNmRlXzE1LTctMS0xLTA_3a230f04-31f9-45d8-a7ca-09327aa096ff"
      unitRef="usd">-20083000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTphMWYxOWY3NmNiOTY0ZDQwOTc5ODFlYTlhODZlMTZkZS90YWJsZXJhbmdlOmExZjE5Zjc2Y2I5NjRkNDA5Nzk4MWVhOWE4NmUxNmRlXzE1LTctMS0xLTA_da81baf8-76ae-40ec-9b58-9738333a2341"
      unitRef="usd">-20083000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOperating
      contextRef="i594539d6cfd54e88904eebbf46eef99a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTphMWYxOWY3NmNiOTY0ZDQwOTc5ODFlYTlhODZlMTZkZS90YWJsZXJhbmdlOmExZjE5Zjc2Y2I5NjRkNDA5Nzk4MWVhOWE4NmUxNmRlXzE4LTEtMS0xLTA_2d6ecef8-0543-4ab1-92c5-28ace258f7d5"
      unitRef="usd">0</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="i5a77d1947a3942e4b0d3b8009af417c4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTphMWYxOWY3NmNiOTY0ZDQwOTc5ODFlYTlhODZlMTZkZS90YWJsZXJhbmdlOmExZjE5Zjc2Y2I5NjRkNDA5Nzk4MWVhOWE4NmUxNmRlXzE4LTMtMS0xLTA_f89ee430-89ea-49bf-9345-08fcf7ea3d3a"
      unitRef="usd">0</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTphMWYxOWY3NmNiOTY0ZDQwOTc5ODFlYTlhODZlMTZkZS90YWJsZXJhbmdlOmExZjE5Zjc2Y2I5NjRkNDA5Nzk4MWVhOWE4NmUxNmRlXzE4LTUtMS0xLTA_c7657e66-8386-4e7e-824d-a561df032472"
      unitRef="usd">241000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTphMWYxOWY3NmNiOTY0ZDQwOTc5ODFlYTlhODZlMTZkZS90YWJsZXJhbmdlOmExZjE5Zjc2Y2I5NjRkNDA5Nzk4MWVhOWE4NmUxNmRlXzE4LTctMS0xLTA_fa61c3b4-a22e-473a-b7db-ae73ac46c69d"
      unitRef="usd">241000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestExpense
      contextRef="i594539d6cfd54e88904eebbf46eef99a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTphMWYxOWY3NmNiOTY0ZDQwOTc5ODFlYTlhODZlMTZkZS90YWJsZXJhbmdlOmExZjE5Zjc2Y2I5NjRkNDA5Nzk4MWVhOWE4NmUxNmRlXzE5LTEtMS0xLTA_3bc434ee-bd92-4621-a48c-6747f60db05a"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i5a77d1947a3942e4b0d3b8009af417c4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTphMWYxOWY3NmNiOTY0ZDQwOTc5ODFlYTlhODZlMTZkZS90YWJsZXJhbmdlOmExZjE5Zjc2Y2I5NjRkNDA5Nzk4MWVhOWE4NmUxNmRlXzE5LTMtMS0xLTA_5f4b2ae7-3163-41c1-9fb6-2be133eff3df"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i5a90fc59d66d4c82b190fa272723dc6d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTphMWYxOWY3NmNiOTY0ZDQwOTc5ODFlYTlhODZlMTZkZS90YWJsZXJhbmdlOmExZjE5Zjc2Y2I5NjRkNDA5Nzk4MWVhOWE4NmUxNmRlXzE5LTUtMS0xLTA_bfabd677-0a23-4b3c-97ad-f4d916bae130"
      unitRef="usd">46000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTphMWYxOWY3NmNiOTY0ZDQwOTc5ODFlYTlhODZlMTZkZS90YWJsZXJhbmdlOmExZjE5Zjc2Y2I5NjRkNDA5Nzk4MWVhOWE4NmUxNmRlXzE5LTctMS0xLTA_02a9075c-042d-43f2-9055-ab37b3f42478"
      unitRef="usd">46000</us-gaap:InterestExpense>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i594539d6cfd54e88904eebbf46eef99a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTphMWYxOWY3NmNiOTY0ZDQwOTc5ODFlYTlhODZlMTZkZS90YWJsZXJhbmdlOmExZjE5Zjc2Y2I5NjRkNDA5Nzk4MWVhOWE4NmUxNmRlXzIwLTEtMS0xLTA_e3ede33c-e886-4962-afe3-fec4f1f550a8"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i5a77d1947a3942e4b0d3b8009af417c4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTphMWYxOWY3NmNiOTY0ZDQwOTc5ODFlYTlhODZlMTZkZS90YWJsZXJhbmdlOmExZjE5Zjc2Y2I5NjRkNDA5Nzk4MWVhOWE4NmUxNmRlXzIwLTMtMS0xLTA_2a5de15f-8663-423a-bec3-cc5fe2807f3d"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i5a90fc59d66d4c82b190fa272723dc6d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTphMWYxOWY3NmNiOTY0ZDQwOTc5ODFlYTlhODZlMTZkZS90YWJsZXJhbmdlOmExZjE5Zjc2Y2I5NjRkNDA5Nzk4MWVhOWE4NmUxNmRlXzIwLTUtMS0xLTA_8dc32d98-f7da-4aa1-9159-93b384c7533e"
      unitRef="usd">479000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTphMWYxOWY3NmNiOTY0ZDQwOTc5ODFlYTlhODZlMTZkZS90YWJsZXJhbmdlOmExZjE5Zjc2Y2I5NjRkNDA5Nzk4MWVhOWE4NmUxNmRlXzIwLTctMS0xLTA_6563f329-231d-48c4-bbd1-1cd2d686f44a"
      unitRef="usd">479000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i594539d6cfd54e88904eebbf46eef99a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTphMWYxOWY3NmNiOTY0ZDQwOTc5ODFlYTlhODZlMTZkZS90YWJsZXJhbmdlOmExZjE5Zjc2Y2I5NjRkNDA5Nzk4MWVhOWE4NmUxNmRlXzI1LTEtMS0xLTA_466066f8-ce12-435f-9f9a-b023a30919c8"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5a77d1947a3942e4b0d3b8009af417c4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTphMWYxOWY3NmNiOTY0ZDQwOTc5ODFlYTlhODZlMTZkZS90YWJsZXJhbmdlOmExZjE5Zjc2Y2I5NjRkNDA5Nzk4MWVhOWE4NmUxNmRlXzI1LTMtMS0xLTA_ff084000-854e-4820-b34f-95b783045885"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5a90fc59d66d4c82b190fa272723dc6d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTphMWYxOWY3NmNiOTY0ZDQwOTc5ODFlYTlhODZlMTZkZS90YWJsZXJhbmdlOmExZjE5Zjc2Y2I5NjRkNDA5Nzk4MWVhOWE4NmUxNmRlXzI1LTUtMS0xLTA_69726d54-e84e-4aeb-ae6f-994004a1653f"
      unitRef="usd">-7503000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTphMWYxOWY3NmNiOTY0ZDQwOTc5ODFlYTlhODZlMTZkZS90YWJsZXJhbmdlOmExZjE5Zjc2Y2I5NjRkNDA5Nzk4MWVhOWE4NmUxNmRlXzI1LTctMS0xLTA_99315a5c-5cd5-4383-95e3-61b64312278f"
      unitRef="usd">-7503000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0d507772bdc84e94aa1f1e2764c3a5b4_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiYzcwZmI0OWU3M2Q0NjYzYTA0MjI5NmIyOTFjYmRhYy90YWJsZXJhbmdlOmJjNzBmYjQ5ZTczZDQ2NjNhMDQyMjk2YjI5MWNiZGFjXzItMS0xLTEtMA_bf43f2fc-1872-435f-a030-436e487663e0"
      unitRef="usd">22676000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iacc05ae73fc84dee92f50cd7192ca9e1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiYzcwZmI0OWU3M2Q0NjYzYTA0MjI5NmIyOTFjYmRhYy90YWJsZXJhbmdlOmJjNzBmYjQ5ZTczZDQ2NjNhMDQyMjk2YjI5MWNiZGFjXzItMy0xLTEtMA_c6cfd732-27eb-4884-9a79-b6cb40cd646d"
      unitRef="usd">5559000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ief62b70f9e3643ea9918e4763977575f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiYzcwZmI0OWU3M2Q0NjYzYTA0MjI5NmIyOTFjYmRhYy90YWJsZXJhbmdlOmJjNzBmYjQ5ZTczZDQ2NjNhMDQyMjk2YjI5MWNiZGFjXzItNS0xLTEtMA_7beb252d-6317-45a8-877d-002fae361510"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiYzcwZmI0OWU3M2Q0NjYzYTA0MjI5NmIyOTFjYmRhYy90YWJsZXJhbmdlOmJjNzBmYjQ5ZTczZDQ2NjNhMDQyMjk2YjI5MWNiZGFjXzItNy0xLTEtMA_e46fab52-816a-4334-aa9b-09b1626dca9a"
      unitRef="usd">28235000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0d507772bdc84e94aa1f1e2764c3a5b4_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiYzcwZmI0OWU3M2Q0NjYzYTA0MjI5NmIyOTFjYmRhYy90YWJsZXJhbmdlOmJjNzBmYjQ5ZTczZDQ2NjNhMDQyMjk2YjI5MWNiZGFjXzE0LTEtMS0xLTA_fb070948-e315-44fc-97f1-1dd87885d986"
      unitRef="usd">-8045000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iacc05ae73fc84dee92f50cd7192ca9e1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiYzcwZmI0OWU3M2Q0NjYzYTA0MjI5NmIyOTFjYmRhYy90YWJsZXJhbmdlOmJjNzBmYjQ5ZTczZDQ2NjNhMDQyMjk2YjI5MWNiZGFjXzE0LTMtMS0xLTA_6e0b71ca-1897-48ef-a0a5-2a73648e26e3"
      unitRef="usd">2136000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ief62b70f9e3643ea9918e4763977575f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiYzcwZmI0OWU3M2Q0NjYzYTA0MjI5NmIyOTFjYmRhYy90YWJsZXJhbmdlOmJjNzBmYjQ5ZTczZDQ2NjNhMDQyMjk2YjI5MWNiZGFjXzE0LTUtMS0xLTA_836238b4-6e77-4f60-a4d0-91b79c00a717"
      unitRef="usd">-14960000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiYzcwZmI0OWU3M2Q0NjYzYTA0MjI5NmIyOTFjYmRhYy90YWJsZXJhbmdlOmJjNzBmYjQ5ZTczZDQ2NjNhMDQyMjk2YjI5MWNiZGFjXzE0LTctMS0xLTA_f73228c6-30b2-4c16-920d-6c052219dc8a"
      unitRef="usd">-20869000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOperating
      contextRef="i0d507772bdc84e94aa1f1e2764c3a5b4_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiYzcwZmI0OWU3M2Q0NjYzYTA0MjI5NmIyOTFjYmRhYy90YWJsZXJhbmdlOmJjNzBmYjQ5ZTczZDQ2NjNhMDQyMjk2YjI5MWNiZGFjXzE3LTEtMS0xLTA_9c62f480-b103-4c9a-b1d1-2d1b23d1b07c"
      unitRef="usd">0</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="iacc05ae73fc84dee92f50cd7192ca9e1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiYzcwZmI0OWU3M2Q0NjYzYTA0MjI5NmIyOTFjYmRhYy90YWJsZXJhbmdlOmJjNzBmYjQ5ZTczZDQ2NjNhMDQyMjk2YjI5MWNiZGFjXzE3LTMtMS0xLTA_64a39da5-4e90-4e5b-a685-c26b07462b31"
      unitRef="usd">0</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="ief62b70f9e3643ea9918e4763977575f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiYzcwZmI0OWU3M2Q0NjYzYTA0MjI5NmIyOTFjYmRhYy90YWJsZXJhbmdlOmJjNzBmYjQ5ZTczZDQ2NjNhMDQyMjk2YjI5MWNiZGFjXzE3LTUtMS0xLTA_7ac238fc-7811-4916-8208-3242df98da94"
      unitRef="usd">1392000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiYzcwZmI0OWU3M2Q0NjYzYTA0MjI5NmIyOTFjYmRhYy90YWJsZXJhbmdlOmJjNzBmYjQ5ZTczZDQ2NjNhMDQyMjk2YjI5MWNiZGFjXzE3LTctMS0xLTA_bde7e918-744a-401e-84e1-d47b3b62e215"
      unitRef="usd">1392000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestExpense
      contextRef="i0d507772bdc84e94aa1f1e2764c3a5b4_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiYzcwZmI0OWU3M2Q0NjYzYTA0MjI5NmIyOTFjYmRhYy90YWJsZXJhbmdlOmJjNzBmYjQ5ZTczZDQ2NjNhMDQyMjk2YjI5MWNiZGFjXzE4LTEtMS0xLTA_958dfd29-764d-4d5d-a4ac-c9940c03ff7e"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="iacc05ae73fc84dee92f50cd7192ca9e1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiYzcwZmI0OWU3M2Q0NjYzYTA0MjI5NmIyOTFjYmRhYy90YWJsZXJhbmdlOmJjNzBmYjQ5ZTczZDQ2NjNhMDQyMjk2YjI5MWNiZGFjXzE4LTMtMS0xLTA_9ce6dc2c-a519-42c1-8de0-b7194f1e554e"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ief62b70f9e3643ea9918e4763977575f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiYzcwZmI0OWU3M2Q0NjYzYTA0MjI5NmIyOTFjYmRhYy90YWJsZXJhbmdlOmJjNzBmYjQ5ZTczZDQ2NjNhMDQyMjk2YjI5MWNiZGFjXzE4LTUtMS0xLTA_7af29c3a-1aec-4010-b27b-7c707c86cf17"
      unitRef="usd">8000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiYzcwZmI0OWU3M2Q0NjYzYTA0MjI5NmIyOTFjYmRhYy90YWJsZXJhbmdlOmJjNzBmYjQ5ZTczZDQ2NjNhMDQyMjk2YjI5MWNiZGFjXzE4LTctMS0xLTA_e9887aa2-758b-446c-9122-26f3f211473d"
      unitRef="usd">8000</us-gaap:InterestExpense>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i0d507772bdc84e94aa1f1e2764c3a5b4_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiYzcwZmI0OWU3M2Q0NjYzYTA0MjI5NmIyOTFjYmRhYy90YWJsZXJhbmdlOmJjNzBmYjQ5ZTczZDQ2NjNhMDQyMjk2YjI5MWNiZGFjXzE5LTEtMS0xLTA_86b1af30-80bf-4cf8-8aaa-4453c53c5958"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="iacc05ae73fc84dee92f50cd7192ca9e1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiYzcwZmI0OWU3M2Q0NjYzYTA0MjI5NmIyOTFjYmRhYy90YWJsZXJhbmdlOmJjNzBmYjQ5ZTczZDQ2NjNhMDQyMjk2YjI5MWNiZGFjXzE5LTMtMS0xLTA_9fd85b7a-5845-482d-9cb4-b8e4bd6ee046"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ief62b70f9e3643ea9918e4763977575f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiYzcwZmI0OWU3M2Q0NjYzYTA0MjI5NmIyOTFjYmRhYy90YWJsZXJhbmdlOmJjNzBmYjQ5ZTczZDQ2NjNhMDQyMjk2YjI5MWNiZGFjXzE5LTUtMS0xLTA_41b154e5-90d0-4160-88d0-08f51fd5d165"
      unitRef="usd">-351000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiYzcwZmI0OWU3M2Q0NjYzYTA0MjI5NmIyOTFjYmRhYy90YWJsZXJhbmdlOmJjNzBmYjQ5ZTczZDQ2NjNhMDQyMjk2YjI5MWNiZGFjXzE5LTctMS0xLTA_2ddf3f4a-5495-4468-82d1-d270c7625b9d"
      unitRef="usd">-351000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0d507772bdc84e94aa1f1e2764c3a5b4_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiYzcwZmI0OWU3M2Q0NjYzYTA0MjI5NmIyOTFjYmRhYy90YWJsZXJhbmdlOmJjNzBmYjQ5ZTczZDQ2NjNhMDQyMjk2YjI5MWNiZGFjXzIzLTEtMS0xLTA_d72479d3-d03b-4ddc-8172-807866ea2e93"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iacc05ae73fc84dee92f50cd7192ca9e1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiYzcwZmI0OWU3M2Q0NjYzYTA0MjI5NmIyOTFjYmRhYy90YWJsZXJhbmdlOmJjNzBmYjQ5ZTczZDQ2NjNhMDQyMjk2YjI5MWNiZGFjXzIzLTMtMS0xLTA_76babc4d-6e3b-4cdd-bbc9-d33b44173612"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ief62b70f9e3643ea9918e4763977575f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiYzcwZmI0OWU3M2Q0NjYzYTA0MjI5NmIyOTFjYmRhYy90YWJsZXJhbmdlOmJjNzBmYjQ5ZTczZDQ2NjNhMDQyMjk2YjI5MWNiZGFjXzIzLTUtMS0xLTA_0e0ec093-37e0-4ac0-800e-2f67e06aa26d"
      unitRef="usd">-130000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiYzcwZmI0OWU3M2Q0NjYzYTA0MjI5NmIyOTFjYmRhYy90YWJsZXJhbmdlOmJjNzBmYjQ5ZTczZDQ2NjNhMDQyMjk2YjI5MWNiZGFjXzIzLTctMS0xLTA_6bef245b-c8be-4d54-961b-798903398762"
      unitRef="usd">-130000</us-gaap:IncomeTaxExpenseBenefit>
    <apyx:TotalRevenuePercent
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90ZXh0cmVnaW9uOjRjYmQ3MGIwNzQ2NDQ5MDNhZmJiZDY2NDllMTQxODM0XzEzNzY_c45c08bf-5000-439e-ab7c-50412641938f"
      unitRef="number">0.321</apyx:TotalRevenuePercent>
    <apyx:TotalRevenuePercent
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90ZXh0cmVnaW9uOjRjYmQ3MGIwNzQ2NDQ5MDNhZmJiZDY2NDllMTQxODM0XzEzODA_7c4436b1-97c8-4ff4-81cd-a2584a35078c"
      unitRef="number">0.306</apyx:TotalRevenuePercent>
    <us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90ZXh0cmVnaW9uOjRjYmQ3MGIwNzQ2NDQ5MDNhZmJiZDY2NDllMTQxODM0XzE1ODk_e8b35215-7654-45ed-ae0d-992029b78e01">Revenue by geographic region, based on the "ship to" location on the invoice are as follows:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Sales by Domestic and International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i661eca8a002a4cb2af895f3f5c9a5ec2_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiNDgzYmFiZGQ2ZDQ0ODgxOThmYzU0MmY4Y2Q1NDBmMS90YWJsZXJhbmdlOmI0ODNiYWJkZDZkNDQ4ODE5OGZjNTQyZjhjZDU0MGYxXzMtMS0xLTEtMA_e6405a64-5e7b-4d2b-b2a5-8f0057c63d45"
      unitRef="usd">18812000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idd1b12aeda3f4c229577e1cc6e8722a7_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiNDgzYmFiZGQ2ZDQ0ODgxOThmYzU0MmY4Y2Q1NDBmMS90YWJsZXJhbmdlOmI0ODNiYWJkZDZkNDQ4ODE5OGZjNTQyZjhjZDU0MGYxXzMtMy0xLTEtMA_3c76059a-0c26-4257-957a-6c080150adac"
      unitRef="usd">19584000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie7e4bbf7a2034449bae0430f14b14d54_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiNDgzYmFiZGQ2ZDQ0ODgxOThmYzU0MmY4Y2Q1NDBmMS90YWJsZXJhbmdlOmI0ODNiYWJkZDZkNDQ4ODE5OGZjNTQyZjhjZDU0MGYxXzQtMS0xLTEtMA_a048a9c8-a6a7-4277-952f-0ae4d8ab364e"
      unitRef="usd">8899000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i515759e8c6ae472bb639c3e78b1b52f8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiNDgzYmFiZGQ2ZDQ0ODgxOThmYzU0MmY4Y2Q1NDBmMS90YWJsZXJhbmdlOmI0ODNiYWJkZDZkNDQ4ODE5OGZjNTQyZjhjZDU0MGYxXzQtMy0xLTEtMA_f2d27b51-9cff-4739-a958-cdf809fb68eb"
      unitRef="usd">8651000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id55f6de3007948b69061635a4640b62b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiNDgzYmFiZGQ2ZDQ0ODgxOThmYzU0MmY4Y2Q1NDBmMS90YWJsZXJhbmdlOmI0ODNiYWJkZDZkNDQ4ODE5OGZjNTQyZjhjZDU0MGYxXzUtMS0xLTEtMA_5a7fe1d4-cd29-4ce0-ac62-fb28c289faab"
      unitRef="usd">27711000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xNDUvZnJhZzo0Y2JkNzBiMDc0NjQ0OTAzYWZiYmQ2NjQ5ZTE0MTgzNC90YWJsZTpiNDgzYmFiZGQ2ZDQ0ODgxOThmYzU0MmY4Y2Q1NDBmMS90YWJsZXJhbmdlOmI0ODNiYWJkZDZkNDQ4ODE5OGZjNTQyZjhjZDU0MGYxXzUtMy0xLTEtMA_e46fab52-816a-4334-aa9b-09b1626dca9a"
      unitRef="usd">28235000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663395623160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 29, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-12183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">APYX MEDICAL CORPORATION<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">11-2644611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">5115 Ulmerton Road<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Clearwater<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">384-2323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $.001 Par Value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">APYX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 189.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,317,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000719135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663476952152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 41,915<span></span>
</td>
<td class="nump">$ 58,812<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade accounts receivable, net of allowance of $300 and $273</a></td>
<td class="nump">8,399<span></span>
</td>
<td class="nump">7,987<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Income tax receivables</a></td>
<td class="nump">7,654<span></span>
</td>
<td class="nump">426<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">1,275<span></span>
</td>
<td class="nump">1,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net of provision for obsolescence of $388 and $392</a></td>
<td class="nump">4,051<span></span>
</td>
<td class="nump">5,068<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,795<span></span>
</td>
<td class="nump">3,207<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">66,089<span></span>
</td>
<td class="nump">76,733<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">6,541<span></span>
</td>
<td class="nump">6,618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">237<span></span>
</td>
<td class="nump">350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right-of-use assets</a></td>
<td class="nump">437<span></span>
</td>
<td class="nump">653<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">807<span></span>
</td>
<td class="nump">391<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">74,111<span></span>
</td>
<td class="nump">84,745<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,511<span></span>
</td>
<td class="nump">2,438<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">7,278<span></span>
</td>
<td class="nump">9,396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">126<span></span>
</td>
<td class="nump">108<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current portion of finance lease liabilities</a></td>
<td class="nump">238<span></span>
</td>
<td class="nump">229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Related party note payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">9,153<span></span>
</td>
<td class="nump">12,311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">129<span></span>
</td>
<td class="nump">235<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term finance lease liabilities</a></td>
<td class="nump">183<span></span>
</td>
<td class="nump">421<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contract liabilities</a></td>
<td class="nump">621<span></span>
</td>
<td class="nump">405<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">166<span></span>
</td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">10,252<span></span>
</td>
<td class="nump">13,486<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS AND CONTINGENCIES (NOTE 18)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 75,000,000 shares authorized; 34,289,222 issued and outstanding as of December 31, 2020, and 34,312,527 issued and 34,169,952 outstanding as of December 31, 2019</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">61,066<span></span>
</td>
<td class="nump">56,708<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">2,621<span></span>
</td>
<td class="nump">14,517<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">63,721<span></span>
</td>
<td class="nump">71,259<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interest</a></td>
<td class="nump">138<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">63,859<span></span>
</td>
<td class="nump">71,259<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 74,111<span></span>
</td>
<td class="nump">$ 84,745<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.5(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663487303128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowances for doubtful accounts</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_ProvisionForObsolescenceInventory', window );">Provision for obsolescence</a></td>
<td class="nump">$ 388<span></span>
</td>
<td class="nump">$ 392<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">34,289,222<span></span>
</td>
<td class="nump">34,169,952<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">34,289,222<span></span>
</td>
<td class="nump">34,312,527<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_ProvisionForObsolescenceInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Provision For Obsolescence, Inventory</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_ProvisionForObsolescenceInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121599878&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663485918488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">$ 27,711<span></span>
</td>
<td class="nump">$ 28,235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">10,207<span></span>
</td>
<td class="nump">9,141<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">17,504<span></span>
</td>
<td class="nump">19,094<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Other costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">3,920<span></span>
</td>
<td class="nump">3,731<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional services</a></td>
<td class="nump">7,350<span></span>
</td>
<td class="nump">8,507<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Salaries and related costs</a></td>
<td class="nump">14,630<span></span>
</td>
<td class="nump">14,025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">11,687<span></span>
</td>
<td class="nump">13,700<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total other costs and expenses</a></td>
<td class="nump">37,587<span></span>
</td>
<td class="nump">39,963<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(20,083)<span></span>
</td>
<td class="num">(20,869)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest income</a></td>
<td class="nump">241<span></span>
</td>
<td class="nump">1,392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(46)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other income (loss), net</a></td>
<td class="nump">479<span></span>
</td>
<td class="num">(351)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">674<span></span>
</td>
<td class="nump">1,033<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss from operations before income taxes</a></td>
<td class="num">(19,409)<span></span>
</td>
<td class="num">(19,836)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="num">(7,503)<span></span>
</td>
<td class="num">(130)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(11,906)<span></span>
</td>
<td class="num">(19,706)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to non-controlling interest</a></td>
<td class="num">(10)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to stockholders</a></td>
<td class="num">$ (11,896)<span></span>
</td>
<td class="num">$ (19,706)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and Diluted (in dollars per share)</a></td>
<td class="num">$ (0.35)<span></span>
</td>
<td class="num">$ (0.58)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of shares outstanding - basic and diluted (in shares)</a></td>
<td class="nump">34,212<span></span>
</td>
<td class="nump">34,069<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=118262090&amp;loc=SL114874205-224268<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesAndWages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesAndWages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663398807896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Non-controlling interest equity</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 87,177<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">$ 52,920<span></span>
</td>
<td class="nump">$ 34,223<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued on stock options exercised for cash (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued on stock options exercised for cash</a></td>
<td class="nump">207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="nump">3,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_StockSwapToAcquireOptionsShares', window );">Shares issued on net settlement of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vested restricted stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(19,706)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,706)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="nump">71,259<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">56,708<span></span>
</td>
<td class="nump">14,517<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Contributions from non-controlling interest</a></td>
<td class="nump">148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued on stock options exercised for cash (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued on stock options exercised for cash</a></td>
<td class="nump">148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="nump">4,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_StockSwapToAcquireOptionsShares', window );">Shares issued on net settlement of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vested restricted stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(11,906)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,896)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">$ 63,859<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">$ 61,066<span></span>
</td>
<td class="nump">$ 2,621<span></span>
</td>
<td class="nump">$ 138<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_StockSwapToAcquireOptionsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock swap to acquire options shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_StockSwapToAcquireOptionsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569655-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663398403656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (11,906)<span></span>
</td>
<td class="num">$ (19,706)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">887<span></span>
</td>
<td class="nump">754<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_ProvisionForInventoryObsolescence', window );">Provision for inventory obsolescence</a></td>
<td class="nump">506<span></span>
</td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductWarrantyExpense', window );">Provision for product warranties</a></td>
<td class="nump">215<span></span>
</td>
<td class="nump">321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="nump">4,210<span></span>
</td>
<td class="nump">3,581<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Realized and unrealized gains on short term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(164)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision (benefit) for allowance for doubtful accounts</a></td>
<td class="nump">262<span></span>
</td>
<td class="num">(163)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in current assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Trade receivables</a></td>
<td class="num">(558)<span></span>
</td>
<td class="num">(3,970)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable', window );">Income tax receivables</a></td>
<td class="num">(7,228)<span></span>
</td>
<td class="nump">180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="nump">615<span></span>
</td>
<td class="num">(2,367)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(965)<span></span>
</td>
<td class="nump">1,054<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="num">(2,090)<span></span>
</td>
<td class="nump">2,370<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(16,066)<span></span>
</td>
<td class="num">(18,475)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(581)<span></span>
</td>
<td class="num">(1,301)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(18,884)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">80,726<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(581)<span></span>
</td>
<td class="nump">60,541<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised', window );">Proceeds from stock option exercises</a></td>
<td class="nump">148<span></span>
</td>
<td class="nump">207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayment of related party note payable</a></td>
<td class="num">(140)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_RepaymentofFinanceLeaseLiabilities', window );">Repayment of finance lease liabilities</a></td>
<td class="num">(229)<span></span>
</td>
<td class="num">(60)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMinorityShareholders', window );">Contributions from non-controlling interests</a></td>
<td class="nump">148<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(73)<span></span>
</td>
<td class="nump">147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rates on cash</a></td>
<td class="num">(177)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="num">(16,897)<span></span>
</td>
<td class="nump">42,216<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of year</a></td>
<td class="nump">58,812<span></span>
</td>
<td class="nump">16,596<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance</a></td>
<td class="nump">41,915<span></span>
</td>
<td class="nump">58,812<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Cash paid for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest expense</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non cash operating and investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_NonCashTransferOfOtherAssetsToFixedAssets', window );">Transfer of other assets to fixed assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_NonCashTransfersOfInventoryToFromFixedAssets', window );">Transfer of inventory to fixed assets</a></td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">$ 277<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_NonCashTransferOfOtherAssetsToFixedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non Cash, Transfer Of Other Assets To Fixed Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_NonCashTransferOfOtherAssetsToFixedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_NonCashTransfersOfInventoryToFromFixedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non Cash, Transfers Of Inventory To (From) Fixed Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_NonCashTransfersOfInventoryToFromFixedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Stock Options Exercised And Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_ProvisionForInventoryObsolescence">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Provision For Inventory Obsolescence</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_ProvisionForInventoryObsolescence</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_RepaymentofFinanceLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repayment of Finance Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_RepaymentofFinanceLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2443-110228<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expense charged against earnings for the period pertaining to standard and extended warranties on the entity's goods and services granted to customers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph ((c)(3,4))<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663394715000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">DESCRIPTION OF BUSINESS</a></td>
<td class="text">DESCRIPTION OF BUSINESS&#160;<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apyx Medical Corporation (&#8220;Company", "Apyx", "it" and similar terms) was incorporated in 1982, under the laws of the State of Delaware and has its principal executive office at 5115 Ulmerton Road, Clearwater, FL 33760.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is an advanced energy technology company with a passion for elevating people&#8217;s lives through innovative products in the cosmetic and surgical markets. Known for its innovative Helium Plasma Technology, Apyx is solely focused on bringing transformative solutions to the physicians and patients they serve. It's Helium Plasma Technology is marketed and sold as Renuvion&#174; in the cosmetic surgery market and J-Plasma&#174; in the hospital surgical market. Renuvion&#174; offers plastic surgeons, fascial plastic surgeons and cosmetic physicians a unique ability to provide controlled heat to the tissue to achieve their desired results. The J-Plasma&#174; system allows surgeons to operate with a high level of precision, virtually eliminating unintended tissue trauma. The Company also leverages its deep expertise and decades of experience in unique waveforms through original equipment manufacturing (OEM) agreements with other medical device manufacturers.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663393041096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">SIGNIFICANT ACCOUNTING POLICIES&#160;<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Financial Statements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements include the accounts of Apyx, its wholly owned subsidiary, Apyx Bulgaria, EOOD, and its 51% owned subsidiary, Apyx SY Medical Devices (Ningbo) Co., Ltd. (collectively, "Apyx," or the &#8220;Company&#8221;). All significant intercompany transactions and balances have been eliminated in consolidation. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates in the Preparation of Financial Statements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. The reported amounts of revenues and expenses during the reporting period may be affected by the estimates and assumptions the Company is required to make.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Holdings of highly liquid investments with original maturities of three months or less from the date of purchase are considered to be cash equivalents. As of December 31, 2020 and 2019, all of the Company&#8217;s U.S. Treasury Bills have original maturities of three months or less and are included in cash and cash equivalents.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of trade accounts receivable. With respect to cash, the Company frequently maintains cash and cash equivalent balances in excess of federally insured limits; it has not experienced any losses in such accounts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trade Accounts Receivable and Allowance for Doubtful Accounts</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's standard credit terms for billings range from net 10 days to net 90 days, depending on the customer agreement. Accounts receivable are determined to be past due if payments are not made in accordance with such agreements and an allowance is generally recorded for accounts that become three months past due, or sooner if there are other indicators that the receivables may not be recovered. Customary collection efforts are initiated, and receivables are written off when the Company determines they are not collectible and abandons these collection efforts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the allowance for doubtful accounts on a regular basis for adequacy based upon its periodic review of the collectability of the receivables in light of historical experience, adverse situations that may affect its customers&#8217; ability to pay and prevailing economic conditions. This evaluation is inherently subjective, as it requires estimates that are susceptible to significant revision as more information becomes available. Management believes that the allowances for doubtful accounts of approximately $0.3 million at December&#160;31, 2020 and 2019, are adequate to provide for possible bad debts.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are allocated to manufactured inventory based upon labor hours. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company monitors inventory usage to determine if the carrying value of any items should be adjusted due to lack of demand for the item and adjusts inventory for estimated obsolescence or unusable inventory equal to the difference between the cost of inventory and the estimated net realizable value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Depreciation and amortization are provided for using the straight-line method over the estimated useful lives of the assets. The amortization of leasehold improvements is based on the shorter of the lease term or the life of the improvement. Betterments and major improvements, which extend the life of the asset, are capitalized, whereas maintenance and repairs and routine improvements are expensed as incurred. The estimated useful lives are: buildings and improvements, 39 years; machinery and equipment, 3-10 years; furniture and fixtures, 5-10 years;  computer equipment and software, 3-5 years; and molds, 7-15 years.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Valuation of Long-Lived Assets</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews long-lived assets for recoverability if events or changes in circumstances indicate that the assets may have been impaired. This circumstance exists when the carrying amount of the asset exceeds the sum of the undiscounted cash flows expected to result from its use and eventual disposition. In those cases, an impairment loss is recognized to the extent that the assets&#8217; carrying amount exceeds its fair value. Any impairment losses are not restored in the future if the fair value increases. At December&#160;31, 2020, the Company believes the remaining carrying values of its long-lived assets are recoverable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Warranties</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides a four year limited warranty on end-user sales of its Renuvion&#174;/J-Plasma&#174; generators, a two year warranty on mounting fixtures, and a one-year warranty on certain accessories. The Company estimates and provides for future costs for product warranties in cost of sales at the time revenue is recognized. The Company bases its product warranty costs on related material costs, repair labor costs and shipping costs. The Company estimates the future cost of product warranties by considering historical material, repair labor, and shipping costs, and applying the experience rates to the outstanding warranty period for products sold. It is reasonably possible that actual results could differ from those estimates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration that the Company expects to receive for those goods or services. To recognize revenue, the Company (i) identifies the contract(s) with a customer; (ii) identifies the performance obligations in the contract; (iii) determines the transaction price; (iv) allocates the transaction price to the performance obligations in the contract; and (v) recognizes revenue when, or as, it satisfies the performance obligation(s). For sales of the Company's Advanced Energy products (Renuvion&#174;/J-Plasma&#174;), this is at a point in time when title has been transferred to the customer, which is generally at the time of shipment or receipt by customer for FOB destination terms. For sales of products under its OEM agreements, the Company recognizes revenue over time when no alternative use exists for the manufactured goods and the Company has rights to payment. Presently, the Company does not stock any significant completed goods under its OEM agreements, accordingly, the recognition of revenue under these agreements approximates point in time recognition. The following policies apply to its major categories of revenue transactions:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">The majority of sales to customers are evidenced by firm purchase orders. Generally, title and the risks and rewards of ownership are transferred to the customer when the product is shipped. Payment by the customer is due under fixed payment terms.</span></div><div style="margin-bottom:3pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Product returns are only accepted at the Company's discretion and in accordance with its &#8220;Returned Goods Policy&#8221;. Historically, the level of product returns has not been significant. Accruals for sales returns, rebates and allowances are made as a reduction of revenue based upon an analysis of historical customer returns and credits, rebates, discounts and current market conditions.</span></div><div style="margin-bottom:3pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">The terms of sale to customers generally do not include any obligations to perform future services. Limited warranties are generally provided for sales and provisions for warranty are provided at the time of product sale based upon an analysis of historical data.</span></div><div style="margin-bottom:3pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">In connection with the execution of OEM supply agreements, the Company may enter into an accompanying product development agreement. If the Company enters into a product development agreement, and development of the goods does not represent a performance obligation on a standalone basis, the Company defers the development fees billed to customers and the associated costs. At December 31, 2020 and 2019, respectively, the Company had recorded approximately $0.6&#160;million and $0.4 million of contract liabilities and $0.2&#160;million and $0.1 million of contract assets related to the deferral of revenues and expenses under these agreements. Recognition of the deferred billings and costs will occur as the Company performs on the accompanying supply arrangements. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Advertising Costs</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising costs are expensed as incurred. The amounts of advertising costs, including trade shows, were approximately $0.8 million and $1.5 million for the years ended December&#160;31, 2020 and 2019, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for stock-based compensation in accordance with FASB ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation-Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. FASB ASC 718 requires recognizing compensation expense for all share-based payment awards made to employees, directors and non-employees based upon the awards&#8217; grant date fair value. It accounts for forfeitures as they occur. The standard covers employee stock options, restricted stock and other equity awards. The Company utilizes a Black-Scholes model to estimate the grant date fair value of stock option awards. For employee and director awards, compensation expense is recognized on a straight-line basis over the vesting periods. For  non-employee awards, compensation expense is recorded for non-forfeitable, fully vested awards at the grant date. For other awards granted to non-employees, compensation cost is recognized as services are provided, which approximates a straight-line basis over the vesting period.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation Contingencies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with authoritative guidance, the Company accrues a liability in its consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible, but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the consolidated financial statements. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded; actual results may differ from those estimates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income (Loss) Per Share</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company computes basic (loss) earnings attributable to common stockholders per share by dividing net (loss) income attributable to common stockholders by the weighted average number of common shares outstanding for the reporting period. Diluted (loss) earnings per share attributable to common stockholders gives effect to all potential dilutive shares outstanding during the period. The number of dilutive shares is calculated using the treasury stock method which reduces the effective number of shares by the amount of shares the Company could purchase with the proceeds of assumed exercises. Anti-dilutive units are excluded from the calculation of diluted shares. In periods of loss, all potentially dilutive units are anti-dilutive and are excluded from the calculation of diluted income (loss) per share.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses are charged to operations as incurred. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the liability method of accounting for income taxes as set forth in FASB ASC Topic 740, "Income Taxes".  Under the liability method, deferred taxes are determined based on temporary differences between the financial statement and tax bases of assets and liabilities using tax rates expected to be in effect during the years in which the deferred taxes reverse.  The Company accounts for interest and penalties on income taxes as income tax expense. A valuation allowances is recorded when it is more likely than not that a tax benefit will not be realized.  In determining the need for valuation allowances the Company considers projected future taxable income, the timing of reversals of temporary differences, and the availability of tax planning strategies.  As of December 31, 2020 and 2019, the Company recorded a valuation allowance on the net deferred tax asset. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the realizability of deferred tax assets each reporting period and will be able to reduce the valuation allowance to the extent the financial results of continuing operations improve, and it becomes more likely than not that the deferred tax assets will be realizable. As Management expects the Company to continue to generate losses in the foreseeable future after 2020, the Company will continue to record a full valuation allowance on the net deferred tax assets as of December 31, 2020. As a result of the CARES ACT, during 2020, the Company released the valuation allowance on the Federal NOLs that can now be carried back to prior taxable years.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the financial statement impact of an uncertain tax position taken or expected to be taken on an income tax return at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority.  An uncertain income tax position will not be recognized in the financial statements unless it is more likely than not of being sustained. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Transactions</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency of Apyx Bulgaria is the U.S.&#160;dollar. The monetary assets and liabilities that are denominated in a currency other than U.S. dollar are remeasured into U.S.&#160;dollars at the exchange rate on the balance sheet date, while nonmonetary items are remeasured at historical rates. Revenue and expenses are remeasured at weighted average exchange rates during the period. Transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency are included in selling, general and administrative expenses in the Consolidated Statements of Operations and were not material for the years ended December 31, 2020 and 2019. </span></div>RECENT ACCOUNTING PRONOUNCEMENTS<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments&#8212;Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 326). The update changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, contract assets, held-to-maturity debt securities and loans, and requires entities to use a new forward-looking expected loss model that will result in the earlier recognition of allowance for losses. This update, as originally issued, was effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 326),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Derivatives and Hedging </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 815), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">and Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 842) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Effective Dates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which deferred the effective dates of these standards for Smaller Reporting Companies until fiscal years beginning after December 15, 2022. The Company currently expects to continue to qualify as a Smaller Reporting Company, based upon the current SEC definition and, as a result, will be utilizing the deferred elective date. While the Company is in the process of determining the effects of the adoption of the standard on the consolidated financial statements, it does not expect the impact to be material.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on the Company's consolidated financial statements or disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663393261800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CHANGE IN ACCOUNTING POLICY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes and Error Corrections [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock', window );">CHANGE IN ACCOUNTING POLICY</a></td>
<td class="text">CHANGE IN ACCOUNTING POLICY<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, the Company began granting stock option awards deeper within the organization. It does not have sufficient experience with grants to these employees and has experienced challenges in developing reliable forfeiture estimates at the grant date. Accounting for revising the forfeiture estimates has been burdensome. Accounting Standards Codification 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation- Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, prescribes two methods for accounting for forfeitures on stock option awards, either the estimation method utilized by the Company previously, or by accounting for forfeitures as they occur. On January 1, 2020, the Company made an accounting policy election change and began accounting for forfeitures on stock option awards using actual forfeitures. This accounting policy election change was made on a retrospective basis. However, the changes to the current and prior period were determined to be immaterial and there have been no changes to previously reported results as a result of the change.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting accounting changes and error corrections. It includes the conveyance of information necessary for a user of the Company's financial information to understand all aspects and required disclosure information concerning all changes and error corrections reported in the Company's financial statements for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663393050424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RECENT ACCOUNTING PRONOUNCEMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract', window );"><strong>Accounting Standards Update and Change in Accounting Principle [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">RECENT ACCOUNTING PRONOUNCEMENTS</a></td>
<td class="text">SIGNIFICANT ACCOUNTING POLICIES&#160;<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Financial Statements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements include the accounts of Apyx, its wholly owned subsidiary, Apyx Bulgaria, EOOD, and its 51% owned subsidiary, Apyx SY Medical Devices (Ningbo) Co., Ltd. (collectively, "Apyx," or the &#8220;Company&#8221;). All significant intercompany transactions and balances have been eliminated in consolidation. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates in the Preparation of Financial Statements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. The reported amounts of revenues and expenses during the reporting period may be affected by the estimates and assumptions the Company is required to make.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Holdings of highly liquid investments with original maturities of three months or less from the date of purchase are considered to be cash equivalents. As of December 31, 2020 and 2019, all of the Company&#8217;s U.S. Treasury Bills have original maturities of three months or less and are included in cash and cash equivalents.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of trade accounts receivable. With respect to cash, the Company frequently maintains cash and cash equivalent balances in excess of federally insured limits; it has not experienced any losses in such accounts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trade Accounts Receivable and Allowance for Doubtful Accounts</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's standard credit terms for billings range from net 10 days to net 90 days, depending on the customer agreement. Accounts receivable are determined to be past due if payments are not made in accordance with such agreements and an allowance is generally recorded for accounts that become three months past due, or sooner if there are other indicators that the receivables may not be recovered. Customary collection efforts are initiated, and receivables are written off when the Company determines they are not collectible and abandons these collection efforts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the allowance for doubtful accounts on a regular basis for adequacy based upon its periodic review of the collectability of the receivables in light of historical experience, adverse situations that may affect its customers&#8217; ability to pay and prevailing economic conditions. This evaluation is inherently subjective, as it requires estimates that are susceptible to significant revision as more information becomes available. Management believes that the allowances for doubtful accounts of approximately $0.3 million at December&#160;31, 2020 and 2019, are adequate to provide for possible bad debts.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are allocated to manufactured inventory based upon labor hours. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company monitors inventory usage to determine if the carrying value of any items should be adjusted due to lack of demand for the item and adjusts inventory for estimated obsolescence or unusable inventory equal to the difference between the cost of inventory and the estimated net realizable value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Depreciation and amortization are provided for using the straight-line method over the estimated useful lives of the assets. The amortization of leasehold improvements is based on the shorter of the lease term or the life of the improvement. Betterments and major improvements, which extend the life of the asset, are capitalized, whereas maintenance and repairs and routine improvements are expensed as incurred. The estimated useful lives are: buildings and improvements, 39 years; machinery and equipment, 3-10 years; furniture and fixtures, 5-10 years;  computer equipment and software, 3-5 years; and molds, 7-15 years.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Valuation of Long-Lived Assets</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews long-lived assets for recoverability if events or changes in circumstances indicate that the assets may have been impaired. This circumstance exists when the carrying amount of the asset exceeds the sum of the undiscounted cash flows expected to result from its use and eventual disposition. In those cases, an impairment loss is recognized to the extent that the assets&#8217; carrying amount exceeds its fair value. Any impairment losses are not restored in the future if the fair value increases. At December&#160;31, 2020, the Company believes the remaining carrying values of its long-lived assets are recoverable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Warranties</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides a four year limited warranty on end-user sales of its Renuvion&#174;/J-Plasma&#174; generators, a two year warranty on mounting fixtures, and a one-year warranty on certain accessories. The Company estimates and provides for future costs for product warranties in cost of sales at the time revenue is recognized. The Company bases its product warranty costs on related material costs, repair labor costs and shipping costs. The Company estimates the future cost of product warranties by considering historical material, repair labor, and shipping costs, and applying the experience rates to the outstanding warranty period for products sold. It is reasonably possible that actual results could differ from those estimates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration that the Company expects to receive for those goods or services. To recognize revenue, the Company (i) identifies the contract(s) with a customer; (ii) identifies the performance obligations in the contract; (iii) determines the transaction price; (iv) allocates the transaction price to the performance obligations in the contract; and (v) recognizes revenue when, or as, it satisfies the performance obligation(s). For sales of the Company's Advanced Energy products (Renuvion&#174;/J-Plasma&#174;), this is at a point in time when title has been transferred to the customer, which is generally at the time of shipment or receipt by customer for FOB destination terms. For sales of products under its OEM agreements, the Company recognizes revenue over time when no alternative use exists for the manufactured goods and the Company has rights to payment. Presently, the Company does not stock any significant completed goods under its OEM agreements, accordingly, the recognition of revenue under these agreements approximates point in time recognition. The following policies apply to its major categories of revenue transactions:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">The majority of sales to customers are evidenced by firm purchase orders. Generally, title and the risks and rewards of ownership are transferred to the customer when the product is shipped. Payment by the customer is due under fixed payment terms.</span></div><div style="margin-bottom:3pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Product returns are only accepted at the Company's discretion and in accordance with its &#8220;Returned Goods Policy&#8221;. Historically, the level of product returns has not been significant. Accruals for sales returns, rebates and allowances are made as a reduction of revenue based upon an analysis of historical customer returns and credits, rebates, discounts and current market conditions.</span></div><div style="margin-bottom:3pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">The terms of sale to customers generally do not include any obligations to perform future services. Limited warranties are generally provided for sales and provisions for warranty are provided at the time of product sale based upon an analysis of historical data.</span></div><div style="margin-bottom:3pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">In connection with the execution of OEM supply agreements, the Company may enter into an accompanying product development agreement. If the Company enters into a product development agreement, and development of the goods does not represent a performance obligation on a standalone basis, the Company defers the development fees billed to customers and the associated costs. At December 31, 2020 and 2019, respectively, the Company had recorded approximately $0.6&#160;million and $0.4 million of contract liabilities and $0.2&#160;million and $0.1 million of contract assets related to the deferral of revenues and expenses under these agreements. Recognition of the deferred billings and costs will occur as the Company performs on the accompanying supply arrangements. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Advertising Costs</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising costs are expensed as incurred. The amounts of advertising costs, including trade shows, were approximately $0.8 million and $1.5 million for the years ended December&#160;31, 2020 and 2019, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for stock-based compensation in accordance with FASB ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation-Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. FASB ASC 718 requires recognizing compensation expense for all share-based payment awards made to employees, directors and non-employees based upon the awards&#8217; grant date fair value. It accounts for forfeitures as they occur. The standard covers employee stock options, restricted stock and other equity awards. The Company utilizes a Black-Scholes model to estimate the grant date fair value of stock option awards. For employee and director awards, compensation expense is recognized on a straight-line basis over the vesting periods. For  non-employee awards, compensation expense is recorded for non-forfeitable, fully vested awards at the grant date. For other awards granted to non-employees, compensation cost is recognized as services are provided, which approximates a straight-line basis over the vesting period.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation Contingencies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with authoritative guidance, the Company accrues a liability in its consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible, but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the consolidated financial statements. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded; actual results may differ from those estimates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income (Loss) Per Share</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company computes basic (loss) earnings attributable to common stockholders per share by dividing net (loss) income attributable to common stockholders by the weighted average number of common shares outstanding for the reporting period. Diluted (loss) earnings per share attributable to common stockholders gives effect to all potential dilutive shares outstanding during the period. The number of dilutive shares is calculated using the treasury stock method which reduces the effective number of shares by the amount of shares the Company could purchase with the proceeds of assumed exercises. Anti-dilutive units are excluded from the calculation of diluted shares. In periods of loss, all potentially dilutive units are anti-dilutive and are excluded from the calculation of diluted income (loss) per share.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses are charged to operations as incurred. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the liability method of accounting for income taxes as set forth in FASB ASC Topic 740, "Income Taxes".  Under the liability method, deferred taxes are determined based on temporary differences between the financial statement and tax bases of assets and liabilities using tax rates expected to be in effect during the years in which the deferred taxes reverse.  The Company accounts for interest and penalties on income taxes as income tax expense. A valuation allowances is recorded when it is more likely than not that a tax benefit will not be realized.  In determining the need for valuation allowances the Company considers projected future taxable income, the timing of reversals of temporary differences, and the availability of tax planning strategies.  As of December 31, 2020 and 2019, the Company recorded a valuation allowance on the net deferred tax asset. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the realizability of deferred tax assets each reporting period and will be able to reduce the valuation allowance to the extent the financial results of continuing operations improve, and it becomes more likely than not that the deferred tax assets will be realizable. As Management expects the Company to continue to generate losses in the foreseeable future after 2020, the Company will continue to record a full valuation allowance on the net deferred tax assets as of December 31, 2020. As a result of the CARES ACT, during 2020, the Company released the valuation allowance on the Federal NOLs that can now be carried back to prior taxable years.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the financial statement impact of an uncertain tax position taken or expected to be taken on an income tax return at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority.  An uncertain income tax position will not be recognized in the financial statements unless it is more likely than not of being sustained. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Transactions</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency of Apyx Bulgaria is the U.S.&#160;dollar. The monetary assets and liabilities that are denominated in a currency other than U.S. dollar are remeasured into U.S.&#160;dollars at the exchange rate on the balance sheet date, while nonmonetary items are remeasured at historical rates. Revenue and expenses are remeasured at weighted average exchange rates during the period. Transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency are included in selling, general and administrative expenses in the Consolidated Statements of Operations and were not material for the years ended December 31, 2020 and 2019. </span></div>RECENT ACCOUNTING PRONOUNCEMENTS<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments&#8212;Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 326). The update changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, contract assets, held-to-maturity debt securities and loans, and requires entities to use a new forward-looking expected loss model that will result in the earlier recognition of allowance for losses. This update, as originally issued, was effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 326),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Derivatives and Hedging </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 815), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">and Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 842) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Effective Dates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which deferred the effective dates of these standards for Smaller Reporting Companies until fiscal years beginning after December 15, 2022. The Company currently expects to continue to qualify as a Smaller Reporting Company, based upon the current SEC definition and, as a result, will be utilizing the deferred elective date. While the Company is in the process of determining the effects of the adoption of the standard on the consolidated financial statements, it does not expect the impact to be material.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on the Company's consolidated financial statements or disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663398927992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DISPOSITION OF THE CORE BUSINESS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">DISPOSITION OF THE CORE BUSINESS</a></td>
<td class="text">DISPOSITION OF THE CORE BUSINESS<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2018, the Company closed on a definitive asset purchase agreement (the "Asset Purchase Agreement") with Specialty Surgical Instrumentation Inc., a Tennessee Corporation and wholly owned subsidiary of Symmetry Surgical Inc. (&#8220;Symmetry&#8221;), pursuant to which the Company divested and sold the Company's electrosurgical "Core" business segment and related intellectual property, including the Bovie</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> brand and trademarks, to Symmetry for gross proceeds of $97 million in cash.</span>In connection with the Asset Purchase Agreement, the Company entered into an Electro Surgical Disposables and Accessories, Cauteries and Other Products Supply Agreement with Symmetry for a four-year term, whereby it will manufacture certain Core products and sell them to Symmetry at agreed upon prices. Any activity resulting from this agreement is netted and reported in the Consolidated Statements of Operations as other income (loss). Core activity for 2020 amounted to $9.4&#160;million with cost of sales equivalents of $8.1&#160;million and other related expenses of $0.8&#160;million for net other income of $0.5&#160;million.  Core activity in 2019 amounted to&#160;$9.4 million&#160;with cost of sales equivalents of&#160;$8.8 million&#160;and related operating expenses of&#160;$0.5 million for net other income of $0.1&#160;million.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663394406056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTEREST IN JOINT VENTURE INVESTMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDisclosureTextBlock', window );">INTEREST IN JOINT VENTURE INVESTMENT</a></td>
<td class="text">INTEREST IN JOINT VENTURE INVESTMENT<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Company executed a joint venture agreement with its Chinese supplier ("China JV"). The agreement requires the Company to make a capital contribution into the newly formed entity of approximately&#160;$357,000, of which approximately $154,000 was contributed during the year ended December 31, 2020. As of the date of these consolidated financial statements, the joint venture has not commenced principal operations. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the Company's ownership interest in its 51% owned China JV were as follows:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.712%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.088%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended<br/>December 31, 2020</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning interest in China JV</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contributions </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Apyx</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending interest in China JV</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663398927992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text">INVENTORIES<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,243&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,935&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,087&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross inventories</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,439&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,460&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: provision for obsolescence</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(388)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(392)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,051&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,068&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, the Company reassessed its forecasted product mix due to COVID-19, increased availability of newer handpiece designs, and improved timing of product registrations in some of our foreign markets. As a result, certain products were reduced to a lower carrying value, and some components were also written down as the Company determined to cease further production on these older models. The total impairment was approximately $400,000 and is included in cost of sales in the accompanying Consolidated Statement of Operations for 2020. Later in 2020, the Company's forecasts were revised, and it subsequently utilized a portion of the written down components and approximately $100,000 of the impairment was recovered through the sale of the corresponding manufactured handpieces.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663393050424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text">PROPERTY AND EQUIPMENT<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">813&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">805&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,931&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,872&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,813)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,403)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment in service</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,118&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,469&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,541&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,618&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total depreciation expense was $0.7 million for the years ended December&#160;31, 2020 and 2019. Depreciation expense is included within cost of goods sold and selling, general and administrative expense in the Consolidated Statements of Operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663394732328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASES<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not recognize leases with terms less than twelve months in duration, or that have variable only payments, in its Consolidated Balance Sheet as right-of-use assets and lease liabilities. The Company has adopted the practical expedient which allows for the Company to not separate lease and non-lease components of contracts. Accordingly, non-lease components are included in the measurement of the Company's lease liabilities and right-of-use assets. If the Company is aware of the implicit rate in leases, the Company determines the operating lease liability using the implicit rate. For those leases where the Company is not aware of the implicit rate in the lease, the Company utilizes an incremental borrowing rate of 4.00%, which is indicative of its collateralized borrowing rate. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases its facility in Sofia, Bulgaria and vehicles in Clearwater, Florida under non-cancelable operating lease agreements. The Company's lease on the Bulgaria facility includes rent escalation over the term of the lease. Rent expense on the lease is accounted for on a straight-line basis over the lease term. During 2019, the Bulgaria facility lease was extended for an additional 2 years. In accordance with operating lease guidance under Topic 842, the extension was accounted for as a lease modification and the right-of-use asset and lease liability were remeasured at the modification date. These operating leases have terms expiring through December 2022. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance Leases</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, the Company entered into non-cancelable finance leases for certain computer equipment and a vehicle in Clearwater, Florida. These finance leases have terms expiring through August 2023. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about the Company&#8217;s lease costs are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.274%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended <br/>December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease costs:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease costs</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and non-cash information related to our leases are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.531%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended <br/>December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended <br/>December 31, 2019<br/></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non cash information:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets capitalized and lease liabilities recognized upon adoption of Topic 842</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets capitalized and lease liabilities recognized upon lease remeasurement</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets capitalized and lease liabilities recognized upon execution of lease</span></td><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">710&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash information:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about the Company&#8217;s weighted average remaining lease terms and discount rate assumptions are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.160%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended <br/>December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended <br/>December 31, 2019<br/></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.03%</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.04%</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of December 31, 2020 are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:76.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.191%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion of lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(238)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASES<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not recognize leases with terms less than twelve months in duration, or that have variable only payments, in its Consolidated Balance Sheet as right-of-use assets and lease liabilities. The Company has adopted the practical expedient which allows for the Company to not separate lease and non-lease components of contracts. Accordingly, non-lease components are included in the measurement of the Company's lease liabilities and right-of-use assets. If the Company is aware of the implicit rate in leases, the Company determines the operating lease liability using the implicit rate. For those leases where the Company is not aware of the implicit rate in the lease, the Company utilizes an incremental borrowing rate of 4.00%, which is indicative of its collateralized borrowing rate. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases its facility in Sofia, Bulgaria and vehicles in Clearwater, Florida under non-cancelable operating lease agreements. The Company's lease on the Bulgaria facility includes rent escalation over the term of the lease. Rent expense on the lease is accounted for on a straight-line basis over the lease term. During 2019, the Bulgaria facility lease was extended for an additional 2 years. In accordance with operating lease guidance under Topic 842, the extension was accounted for as a lease modification and the right-of-use asset and lease liability were remeasured at the modification date. These operating leases have terms expiring through December 2022. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance Leases</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, the Company entered into non-cancelable finance leases for certain computer equipment and a vehicle in Clearwater, Florida. These finance leases have terms expiring through August 2023. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about the Company&#8217;s lease costs are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.274%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended <br/>December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease costs:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease costs</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and non-cash information related to our leases are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.531%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended <br/>December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended <br/>December 31, 2019<br/></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non cash information:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets capitalized and lease liabilities recognized upon adoption of Topic 842</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets capitalized and lease liabilities recognized upon lease remeasurement</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets capitalized and lease liabilities recognized upon execution of lease</span></td><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">710&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash information:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about the Company&#8217;s weighted average remaining lease terms and discount rate assumptions are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.160%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended <br/>December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended <br/>December 31, 2019<br/></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.03%</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.04%</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of December 31, 2020 are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:76.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.191%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion of lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(238)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663394428184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</a></td>
<td class="text">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:64.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.737%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.739%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">808&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">694&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued bonus</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,306&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued commissions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product warranties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product liability claim insurance deductibles</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,170&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,383&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joint and several payroll liability</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,027&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,045&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,658&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,491&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales tax payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses and current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,278&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,396&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663504532968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PRODUCT WARRANTIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductWarrantiesDisclosuresAbstract', window );"><strong>Product Warranties Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductWarrantyDisclosureTextBlock', window );">PRODUCT WARRANTIES</a></td>
<td class="text">PRODUCT WARRANTIES<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product warranty activity consisted of the following for the years ended:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:72.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.695%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for product warranties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product warranty expenses incurred</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(169)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(217)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product warranties</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantiesDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantiesDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for standard and extended product warranties and other product guarantee contracts, including a tabular reconciliation of the changes in the guarantor's aggregate product warranty liability for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -URI http://asc.fasb.org/topic&amp;trid=2155896<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663393048456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>JOINT AND SEVERAL PAYROLL LIABILITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_JointandSeveralPayrollLiabilityTextBlock', window );">JOINT AND SEVERAL PAYROLL LIABILITY</a></td>
<td class="text">JOINT AND SEVERAL PAYROLL LIABILITYDuring 2017, 2018 and 2019, the Company improperly calculated and reported the amount of income to certain employees, and did not collect and remit the correct amount of its employees' portion of income and payroll taxes, related to stock option exercises as required by the IRS. Due to IRS statutory requirements, the Company has joint and several liability for the full amount that was not withheld and remitted to the proper taxing authorities. This amount of the liability was approximately $1.0&#160;million at December 31, 2020 and 2019. Included in other income (loss), net in the accompanying Consolidated Statements of Operations for 2019 is approximately $0.3&#160;million related to the liability. If the Company can establish that its employees have in fact paid these obligations, either presently or in the future, it will be relieved of its liability.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_JointandSeveralPayrollLiabilityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Joint and Several Payroll Liability [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_JointandSeveralPayrollLiabilityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663395312536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">EARNINGS (LOSS) PER SHARE</a></td>
<td class="text">EARNINGS (LOSS) PER SHARE<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings (loss) per share (&#8220;basic EPS&#8221;) is computed by dividing the net income or loss by the weighted average number of common shares outstanding for the reporting period. Diluted earnings per share (&#8220;diluted EPS&#8221;) gives effect to all dilutive potential shares outstanding. As the Company is in a net loss position for all periods presented, all potential shares outstanding are anti-dilutive. The following table provides the computation of basic and diluted earnings (loss) per share.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:72.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.695%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Numerators:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to stockholders</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,896)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19,706)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average shares outstanding - basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,069&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss per share - basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.58)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Anti-dilutive instruments excluded from diluted loss per common share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,939&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663394695032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">FINANCIAL INSTRUMENTS</a></td>
<td class="text">FINANCIAL INSTRUMENTSCash and Cash Equivalents at December 31, 2020 and 2019, respectively, consisted of approximately $2,250,000 and $2,237,000 in cash and $39,665,000 and $56,575,000 in U.S. Treasury Securities with maturities of 3 months or less.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663489675288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXES<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of the provision for income taxes are as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.964%"><tr><td style="width:1.0%"/><td style="width:66.757%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.547%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,682)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(205)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,839)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(130)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Release of valuation allowance due to CARES Act</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,664)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,503)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(130)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,989)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,004)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(741)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,029)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,730)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,029&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,730&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total provision for income tax</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,503)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(130)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a reconciliation of the statutory federal income tax rate to the Company's effective tax rate:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.029%"><tr><td style="width:1.0%"/><td style="width:67.053%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.438%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.569%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.440%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal tax provision</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes (net of federal benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOL carryback from CARES Act</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Major components of the Company&#8217;s deferred tax assets (liabilities) are as follows: </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.352%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss and credit carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,888&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,603&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,916&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,837)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,472)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets, net of valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(278)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(245)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(199)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(399)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(444)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the U.S. government enacted the CARES Act to provide relief from COVID-19. The CARES Act includes a provision that allows companies to carryback net operating losses (NOL&#8217;s) generated in the period 2018 through 2020 to prior years. In conjunction with the disposition of the Core business in 2018, the Company generated a significant amount of taxable income in 2018. Subsequent to this, the Company generated NOLs in 2019 and 2020. For the NOLs generated in 2019, the Company previously recorded a full valuation allowance on the deferred tax assets associated with the NOL due to realization not being probable under then existing tax law. The CARES Act makes these assets realizable and, as of the date of the CARES Act, the Company has recognized an income tax benefit of approximately $3.7&#160;million associated with the release of the valuation allowance on its Federal NOL deferred tax asset from 2019. Additionally, using the provisions of the CARES Act, the Company is carrying back its 2020 Federal NOL of approximately $3.7&#160;million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all positive and negative evidence regarding the realization of deferred tax assets, including past operating results and future sources of taxable income. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers the earnings of Apyx Bulgaria, EOOD to be indefinitely invested outside the United States on the basis of estimates that future domestic cash generation will be sufficient to meet future domestic cash needs and our specific plans for reinvestment of those subsidiary earnings. It has not recorded a deferred tax liability related to the U.S. Federal and State income taxes and foreign withholding taxes on the undistributed earnings of Apyx Bulgaria, EOOD indefinitely invested outside the United States. If it decides to repatriate the foreign earnings, the Company will need to adjust its income tax provision in the period it determines that the earnings will no longer be indefinitely invested outside the United States.&#160; </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the financial statement impact of an uncertain tax position taken or expected to be taken on an income tax return at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An uncertain income tax position will not be recognized in the financial statements unless it is more likely than not of being sustained. As of December 31, 2020 and 2019, the Company has recorded a liability of approximately $1.3 million related to uncertain tax positions and accrued approximately $0.4&#160;million and $0.2 million, respectively, of interest and penalties on these positions. It is expected that the change in unrecognized tax benefits within the next 12 months will not be significant.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a roll-forward of the Company's total gross unrecognized tax benefits, not including interest and penalties, for the years ended December 31:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:79.093%"><tr><td style="width:1.0%"/><td style="width:58.604%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.018%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.569%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.570%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Tax Benefits</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning of year balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,313&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,313&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions of tax positions related to the current year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions of tax positions related to the prior year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases for tax positions related to prior year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">End of year balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,313&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,313&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The Company is subject to U.S. federal and state income tax examination.  The Company&#8217;s 2017 through 2019 U.S. federal income tax returns are subject to examination by the Internal Revenue Service.  The Company&#8217;s state income tax returns are subject to examination for the 2016 through 2019 tax years.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663565160360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RETIREMENT PLAN<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">RETIREMENT PLAN</a></td>
<td class="text">RETIREMENT PLAN<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides a tax-qualified profit-sharing retirement plan under section 401(k) of the Internal Revenue Code for the benefit of eligible employees with an accumulation of funds for retirement on a tax-deferred basis and provides for annual discretionary contribution to individual trust funds.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All employees are eligible to participate upon completing three months of service. The employees may make voluntary contributions to the plan up to the maximum percentage allowed by the Internal Revenue Code. Vesting in employee matching contributions is graded and depends on the years of service. After three years from their date of hire, the employees are 100% vested. The Company makes matching contributions of 50% of the employee contributions up to a total of 3% of participant payroll. Matching contributions made by the Company totaled approximately $0.3 million for each of the years ended December&#160;31, 2020 and 2019, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663398223864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text">RELATED PARTY TRANSACTIONS<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several relatives of Nikolay Shilev, Apyx Bulgaria&#8217;s Managing Director, are considered related parties. Teodora Shileva, Mr. Shilev&#8217;s spouse, is an employee of the Company working in the accounting department. Antoaneta Dimitrova Shileva-Tor</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">omanova, Mr. Shilev&#8217;s sister, is the manager of human resources. Svetoslav Shilev, Mr. Shilev&#8217;s son, is a quality manager in the quality assurance department. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as part of the purchase of the Apyx Bulgaria manufacturing facility, Mr. Shilev was issued a note payable for $0.1 million, which was paid in full on October 20, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The partner in the Company's China joint venture is also a supplie</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r of the Company. For the years ended December 31, 2020 and 2019, the Company made purchases from this supplier of approximately $1,441,000 and $2,643,000, respectively. At December 31, 2020 and 2019, respectively, the Company owed this supplier approximately $38,000 and $29,000, respective</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ly.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663393347160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The medical device industry is characterized by frequent claims and litigation, and the Company may become subject to various claims, lawsuits and proceedings in the ordinary course of our business. Such claims may include claims by current or former employees, distributors and competitors, claims concerning the marketing and promotion of our products and product liability claims.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is involved in a number of legal actions relating to the use of our Helium Plasma technology. The outcomes of these legal actions are not within the Company&#8217;s complete control and may not be known for prolonged periods of time. It believes that such claims are adequately covered by insurance; however, in the case of one of the Company&#8217;s carriers, the Company is in a dispute regarding the total level of coverage available. Notwithstanding the foregoing, in the opinion of management, the Company has meritorious defenses, and such claims are not expected, individually or in the aggregate, to result in a material, adverse effect on its financial condition, results of operations and cash flows. However, in the event that damages exceed the aggregate coverage limits of the Company&#8217;s policies or if its insurance carriers disclaim coverage, management believes it is possible that costs associated with these claims could have a material adverse impact on the consolidated financial condition, results of operations and cash flows.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 17, 2019, a complaint (the &#8220;Complaint&#8221;) was filed in the United States District Court for the Middle District of Florida, against the Company and Charles D. Goodwin, the Company&#8217;s President and Chief Executive Officer and a member of the Company&#8217;s Board of Directors, alleging certain violations of the Securities Exchange Act of 1934, as amended.  On July 16, 2019, the Court appointed lead plaintiff for the putative class and approved the lead plaintiff&#8217;s selection of counsel. On September 3, 2019, lead plaintiff filed an amended complaint (the &#8220;Amended Complaint&#8221;) with the Court. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Complaint seeks class action status on behalf of all persons and entities that acquired the Company&#8217;s securities between December 21, 2018 and April 1, 2019, and alleges violations by the Company and Goodwin of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended and Rule 10b-5 thereunder, primarily related to certain public statements concerning the Premarket Notification 510(k) submission made to the US Food and Drug Administration for a new indication for the Company&#8217;s J-Plasma&#174; technology for use in dermal resurfacing procedures.  On October 3, 2019, defendants filed a motion to dismiss the Amended Complaint, and on March 11, 2020, the Court denied that motion.  On July 10, 2020, the parties executed a settlement agreement, which was subject to Court approval. The Court preliminarily approved the settlement on July 21, 2020. The settlement agreement provides for the dismissal of the action with prejudice. On November 6, 2020, the Court issued its final order approving the settlement and dismissing the action and all claims contained in the Amended Complaint with prejudice. At December 31, 2020, the Company has settled and fully paid all obligations related to this matter. Included in selling, general and administrative expenses for the year ended December 31, 2019 is $1,000,000 for the matter. At December 31, 2019, the Company had accrued $820,000 for the matter.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accrues a liability in our consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is recorded. If a loss is reasonably possible, but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the consolidated financial statements. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded, actual results may differ from these estimates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchase Commitments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, the Company has purchase commitments for inventories totaling approximately $1.9&#160;million, substantially all of which is expected to be purchased by the end of 2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">China Joint Venture</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Company's agreement in the China joint venture requires it to make a capital contribution into the newly formed entity of $357,000. As of the date of these consolidated financial statements, approximately $203,000 of its capital commitment remains to be funded.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations</span></div>Sales to one customer within the OEM segment represented 10% and 11% of total sales for the year ended December 31, 2020 and 2019, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663398861592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK OPTIONS</a></td>
<td class="text">STOCK OPTIONS&#160;<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 30, 2007, the Company's stockholders approved, and the Board of Directors adopted an amendment to the 2003 Executive and Employee Stock Option Plan (the &#8220;Plan&#8221;) to increase the maximum aggregate number of shares of common stock reserved for issuance under the Plan from 1.2 million shares (already reserved against outstanding options) to 1.7 million shares. Except for the increase in the number of shares covered by the Plan, the Plan remained otherwise unchanged. In 2001, the Board of Directors adopted the 2001 Executive and Employee Stock Option Plan which reserved for issuance 1.2 million stock options. Stock options to employees typically have a ten-year life and currently vest over periods between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRiNDZjOGI3MWQ3ZDRhMjdiMjc3YjZkYjUyZjY4ZThlL3NlYzpkYjQ2YzhiNzFkN2Q0YTI3YjI3N2I2ZGI1MmY2OGU4ZV8xMzkvZnJhZzpjNWM3NjM4NTE2MmQ0YTUzYTI1ZDIyNzFkMzUyYThlMi90ZXh0cmVnaW9uOmM1Yzc2Mzg1MTYyZDRhNTNhMjVkMjI3MWQzNTJhOGUyXzEwOTk1MTE2MzcxMDk_cf9a545e-25f8-4790-a167-4803e9a50ffa">one</span> and seven years. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2012, the Company's stockholders approved the 2012 Share Incentive Plan covering a total of 750,000 shares of common stock issuable upon exercise of options to be granted under the plan. At December&#160;31, 2020 approximately 60,000 are available to be issued in this plan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2015, the Company's stockholders approved the 2015 Executive and Employee Stock Option Plan covering a total of 2,000,000 shares of common stock issuable upon exercise of options to be granted under the plan. At December&#160;31, 2020 approximately 230,000 are available to be issued in this plan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2017, the Company's stockholders approved the 2017 Executive and Employee Stock Option Plan covering a total of 3,000,000 shares of common stock issuable upon exercise of options to be granted under the plan. At December&#160;31, 2020 approximately 70,000 are available to be issued in this plan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Company's stockholders approved the 2019 Share Incentive Plan covering a total of 2,000,000 shares of common stock issuable upon exercise of options to be granted under the plan. At December&#160;31, 2020, all 2,000,000 are available to be issued in this plan.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 29, 2021, the Company granted employees appro</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ximately 700,000 options to purchase common shares of the Company's stock. All options granted were pursuant to the plans noted above. The options ves</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t over a period of three years. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The status of the Company's stock options is summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of options </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,254,779&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,379,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(410,635)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(256,785)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,966,858&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,376,900&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112,965)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(291,850)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,938,943&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average grant date fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,484,929&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,376,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(665,510)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(151,850)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,044,469&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common shares required to be issued upon the exercise of stock options would be issued from authorized and unissued shares. Options are valued using the Black-Scholes model. For employee grants, the Company calculates expected life via the simplified method as it does not have sufficient history to determine actual expected life. For non-employee grants, the Company calculates expected life using a combination of past exercise behavior, the contractual term and expected remaining exercise behavior. Inputs used in the valuation models are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:83.625%"><tr><td style="width:1.0%"/><td style="width:60.613%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.116%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.072%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.116%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.674%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.116%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.072%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.121%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 Grants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019 Grants</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option value</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4.98</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$8.18</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$7.15</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$7.91</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.9%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.1%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.9%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.4%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized approximately $4,210,000 and $3,581,000 in stock-based compensation expense during the years ended December 31, 2020 and 2019, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intrinsic value of each option share is the difference between the fair value of our common stock and the exercise price of such option share to the extent it is &#8220;in-the-money&#8221;. Aggregate intrinsic value represents the value that would have been received by the holders of in-the-money options had they exercised their options on the last trading day of the year and sold the underlying shares at the closing stock price on such day. The intrinsic value calculation at December 31, 2020 is based on the $7.20 closing stock price of the Company's common stock on December&#160;31, 2020, the last trading day of 2020. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, there were 4,530,049 stock options outstanding and expected to vest with an aggregate intrinsic value of approximately $10,250,000. These options have a weighted average exercise price of $5.26 and a weighted average remaining contractual term of approximately 7 years. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, there were 2,894,474 stock options outstanding and exercisable with an aggregate intrinsic value of approximately $9,800,000. These options have a weighted average exercise price of $3.89 and a weighted average remaining contractual term of approximately 6 years. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of in the money options exercised during the years ended December 31, 2020 and 2019, was approximately $200,000 and $1,420,000, respectively. Intrinsic value of exercised shares is the total value of such shares on the date of exercise less the cash received from the option holder to exercise the options or other consideration paid. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of options granted during the years ended December 31, 2020 and 2019, was approximately $6,580,000 and $6,300,000, respectively. The weighted average fair value of options granted during the years ended December 31, 2020 and 2019, was $4.78 and $4.57, respectively. The total fair value of option shares vested during the years ended December 31, 2020 and 2019, was approximately $2,510,000 and $2,130,000, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allows employees to exercise stock-based awards by surrendering stock-based awards with an intrinsic value equal to the cumulative exercise price of the stock-based awards being exercised, referred to as net settlements. These surrenders are included in stock options exercised in the options rollforward above. During the years ended December 31, 2020 and 2019, the Company received 39,448 and 125,948 options as payment in the exercise of 47,088 and 222,601 options, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, there was approximately $5,910,000 of total unrecognized stock-based compensation expense, related to unvested stock options granted under the plans above. This expense is expected to be recognized over a weighted-average period of approximately 1 year.</span></div>During October 2015, the Company granted 225,922 restricted stock units that vest ratably over a period of 5 years. As of December 31, 2020, all of the restricted stock units had vested.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663393402632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC AND SEGMENT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">GEOGRAPHIC AND SEGMENT INFORMATION</a></td>
<td class="text">GEOGRAPHIC AND SEGMENT INFORMATION&#160;<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are aggregated into reportable segments only if they exhibit similar economic characteristics. In addition to similar economic characteristics, the Company also considers the following factors in determining the reportable segments: the nature of business activities, the management structure directly accountable to its chief operating decision maker for operating and administrative activities, availability of discrete financial information and information presented to the Board of Directors and investors. Asset information is not reviewed by the chief operating decision maker by segment and is not available by segment, accordingly, the Company has not presented a measure of assets by segment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's reportable segments are disclosed as principally organized and managed as</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">two operating segments: Advanced Energy and OEM. "Corporate &amp; Other" includes certain unallocated corporate and administrative costs which were not specifically attributed to any reportable segment. The OEM segment is primarily development and manufacturing contract and product driven, all related expenses are recorded as cost of sales, therefore no segment specific operating expenses are incurred.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information with respect to reportable segments is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate (Other)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,214&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,497&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,711&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,128)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,838&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,793)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,083)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate (Other)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,676&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,559&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,235&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,045)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,960)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,869)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other losses, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(351)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(351)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">International sales in 2020 and 2019, were 32.1% and 30.6% of sales, respectively. Substantially all of these sales are denominated in U.S. dollars. Revenue by geographic region, based on the "ship to" location on the invoice are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales by Domestic and International</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,812&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,584&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,899&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,651&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,711&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,235&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663394985512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidated Financial Statements</a></td>
<td class="text">Consolidated Financial StatementsThe accompanying consolidated financial statements include the accounts of Apyx, its wholly owned subsidiary, Apyx Bulgaria, EOOD, and its 51% owned subsidiary, Apyx SY Medical Devices (Ningbo) Co., Ltd. (collectively, "Apyx," or the &#8220;Company&#8221;). All significant intercompany transactions and balances have been eliminated in consolidation.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates in the Preparation of Financial Statements</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates in the Preparation of Financial Statements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. The reported amounts of revenues and expenses during the reporting period may be affected by the estimates and assumptions the Company is required to make.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">Cash and Cash EquivalentsHoldings of highly liquid investments with original maturities of three months or less from the date of purchase are considered to be cash equivalents. As of December 31, 2020 and 2019, all of the Company&#8217;s U.S. Treasury Bills have original maturities of three months or less and are included in cash and cash equivalents.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of trade accounts receivable. With respect to cash, the Company frequently maintains cash and cash equivalent balances in excess of federally insured limits; it has not experienced any losses in such accounts.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Trade Accounts Receivable and Allowance for Doubtful Accounts</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trade Accounts Receivable and Allowance for Doubtful Accounts</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's standard credit terms for billings range from net 10 days to net 90 days, depending on the customer agreement. Accounts receivable are determined to be past due if payments are not made in accordance with such agreements and an allowance is generally recorded for accounts that become three months past due, or sooner if there are other indicators that the receivables may not be recovered. Customary collection efforts are initiated, and receivables are written off when the Company determines they are not collectible and abandons these collection efforts.</span></div>The Company evaluates the allowance for doubtful accounts on a regular basis for adequacy based upon its periodic review of the collectability of the receivables in light of historical experience, adverse situations that may affect its customers&#8217; ability to pay and prevailing economic conditions. This evaluation is inherently subjective, as it requires estimates that are susceptible to significant revision as more information becomes available.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are allocated to manufactured inventory based upon labor hours. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company monitors inventory usage to determine if the carrying value of any items should be adjusted due to lack of demand for the item and adjusts inventory for estimated obsolescence or unusable inventory equal to the difference between the cost of inventory and the estimated net realizable value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Depreciation and amortization are provided for using the straight-line method over the estimated useful lives of the assets. The amortization of leasehold improvements is based on the shorter of the lease term or the life of the improvement. Betterments and major improvements, which extend the life of the asset, are capitalized, whereas maintenance and repairs and routine improvements are expensed as incurred. The estimated useful lives are: buildings and improvements, 39 years; machinery and equipment, 3-10 years; furniture and fixtures, 5-10 years;  computer equipment and software, 3-5 years; and molds, 7-15 years.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Valuation of Long-Lived Assets</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Valuation of Long-Lived Assets</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews long-lived assets for recoverability if events or changes in circumstances indicate that the assets may have been impaired. This circumstance exists when the carrying amount of the asset exceeds the sum of the undiscounted cash flows expected to result from its use and eventual disposition. In those cases, an impairment loss is recognized to the extent that the assets&#8217; carrying amount exceeds its fair value. Any impairment losses are not restored in the future if the fair value increases. At December&#160;31, 2020, the Company believes the remaining carrying values of its long-lived assets are recoverable.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StandardProductWarrantyPolicy', window );">Product Warranties</a></td>
<td class="text">Product WarrantiesThe Company provides a four year limited warranty on end-user sales of its Renuvion&#174;/J-Plasma&#174; generators, a two year warranty on mounting fixtures, and a one-year warranty on certain accessories. The Company estimates and provides for future costs for product warranties in cost of sales at the time revenue is recognized. The Company bases its product warranty costs on related material costs, repair labor costs and shipping costs. The Company estimates the future cost of product warranties by considering historical material, repair labor, and shipping costs, and applying the experience rates to the outstanding warranty period for products sold. It is reasonably possible that actual results could differ from those estimates.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration that the Company expects to receive for those goods or services. To recognize revenue, the Company (i) identifies the contract(s) with a customer; (ii) identifies the performance obligations in the contract; (iii) determines the transaction price; (iv) allocates the transaction price to the performance obligations in the contract; and (v) recognizes revenue when, or as, it satisfies the performance obligation(s). For sales of the Company's Advanced Energy products (Renuvion&#174;/J-Plasma&#174;), this is at a point in time when title has been transferred to the customer, which is generally at the time of shipment or receipt by customer for FOB destination terms. For sales of products under its OEM agreements, the Company recognizes revenue over time when no alternative use exists for the manufactured goods and the Company has rights to payment. Presently, the Company does not stock any significant completed goods under its OEM agreements, accordingly, the recognition of revenue under these agreements approximates point in time recognition. The following policies apply to its major categories of revenue transactions:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">The majority of sales to customers are evidenced by firm purchase orders. Generally, title and the risks and rewards of ownership are transferred to the customer when the product is shipped. Payment by the customer is due under fixed payment terms.</span></div><div style="margin-bottom:3pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Product returns are only accepted at the Company's discretion and in accordance with its &#8220;Returned Goods Policy&#8221;. Historically, the level of product returns has not been significant. Accruals for sales returns, rebates and allowances are made as a reduction of revenue based upon an analysis of historical customer returns and credits, rebates, discounts and current market conditions.</span></div><div style="margin-bottom:3pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">The terms of sale to customers generally do not include any obligations to perform future services. Limited warranties are generally provided for sales and provisions for warranty are provided at the time of product sale based upon an analysis of historical data.</span></div>&#8226;In connection with the execution of OEM supply agreements, the Company may enter into an accompanying product development agreement. If the Company enters into a product development agreement, and development of the goods does not represent a performance obligation on a standalone basis, the Company defers the development fees billed to customers and the associated costs. At December 31, 2020 and 2019, respectively, the Company had recorded approximately $0.6&#160;million and $0.4 million of contract liabilities and $0.2&#160;million and $0.1 million of contract assets related to the deferral of revenues and expenses under these agreements. Recognition of the deferred billings and costs will occur as the Company performs on the accompanying supply arrangements.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Costs</a></td>
<td class="text">Advertising CostsAdvertising costs are expensed as incurred.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for stock-based compensation in accordance with FASB ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation-Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. FASB ASC 718 requires recognizing compensation expense for all share-based payment awards made to employees, directors and non-employees based upon the awards&#8217; grant date fair value. It accounts for forfeitures as they occur. The standard covers employee stock options, restricted stock and other equity awards. The Company utilizes a Black-Scholes model to estimate the grant date fair value of stock option awards. For employee and director awards, compensation expense is recognized on a straight-line basis over the vesting periods. For  non-employee awards, compensation expense is recorded for non-forfeitable, fully vested awards at the grant date. For other awards granted to non-employees, compensation cost is recognized as services are provided, which approximates a straight-line basis over the vesting period.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, the Company began granting stock option awards deeper within the organization. It does not have sufficient experience with grants to these employees and has experienced challenges in developing reliable forfeiture estimates at the grant date. Accounting for revising the forfeiture estimates has been burdensome. Accounting Standards Codification 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation- Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, prescribes two methods for accounting for forfeitures on stock option awards, either the estimation method utilized by the Company previously, or by accounting for forfeitures as they occur. On January 1, 2020, the Company made an accounting policy election change and began accounting for forfeitures on stock option awards using actual forfeitures. This accounting policy election change was made on a retrospective basis. However, the changes to the current and prior period were determined to be immaterial and there have been no changes to previously reported results as a result of the change.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalCostsPolicyTextBlock', window );">Litigation Contingencies</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation Contingencies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with authoritative guidance, the Company accrues a liability in its consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible, but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the consolidated financial statements. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded; actual results may differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Income (Loss) Per Share</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income (Loss) Per Share</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company computes basic (loss) earnings attributable to common stockholders per share by dividing net (loss) income attributable to common stockholders by the weighted average number of common shares outstanding for the reporting period. Diluted (loss) earnings per share attributable to common stockholders gives effect to all potential dilutive shares outstanding during the period. The number of dilutive shares is calculated using the treasury stock method which reduces the effective number of shares by the amount of shares the Company could purchase with the proceeds of assumed exercises. Anti-dilutive units are excluded from the calculation of diluted shares. In periods of loss, all potentially dilutive units are anti-dilutive and are excluded from the calculation of diluted income (loss) per share.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text">Research and Development CostsResearch and development expenses are charged to operations as incurred.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the liability method of accounting for income taxes as set forth in FASB ASC Topic 740, "Income Taxes".  Under the liability method, deferred taxes are determined based on temporary differences between the financial statement and tax bases of assets and liabilities using tax rates expected to be in effect during the years in which the deferred taxes reverse.  The Company accounts for interest and penalties on income taxes as income tax expense. A valuation allowances is recorded when it is more likely than not that a tax benefit will not be realized.  In determining the need for valuation allowances the Company considers projected future taxable income, the timing of reversals of temporary differences, and the availability of tax planning strategies.  As of December 31, 2020 and 2019, the Company recorded a valuation allowance on the net deferred tax asset. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the realizability of deferred tax assets each reporting period and will be able to reduce the valuation allowance to the extent the financial results of continuing operations improve, and it becomes more likely than not that the deferred tax assets will be realizable. As Management expects the Company to continue to generate losses in the foreseeable future after 2020, the Company will continue to record a full valuation allowance on the net deferred tax assets as of December 31, 2020. As a result of the CARES ACT, during 2020, the Company released the valuation allowance on the Federal NOLs that can now be carried back to prior taxable years.</span></div>The Company assesses the financial statement impact of an uncertain tax position taken or expected to be taken on an income tax return at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority.  An uncertain income tax position will not be recognized in the financial statements unless it is more likely than not of being sustained.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Transactions</a></td>
<td class="text">Foreign Currency TransactionsThe functional currency of Apyx Bulgaria is the U.S.&#160;dollar. The monetary assets and liabilities that are denominated in a currency other than U.S. dollar are remeasured into U.S.&#160;dollars at the exchange rate on the balance sheet date, while nonmonetary items are remeasured at historical rates. Revenue and expenses are remeasured at weighted average exchange rates during the period. Transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency are included in selling, general and administrative expenses in the Consolidated Statements of Operations and were not material for the years ended December 31, 2020 and 2019.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments&#8212;Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 326). The update changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, contract assets, held-to-maturity debt securities and loans, and requires entities to use a new forward-looking expected loss model that will result in the earlier recognition of allowance for losses. This update, as originally issued, was effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 326),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Derivatives and Hedging </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 815), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">and Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 842) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Effective Dates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which deferred the effective dates of these standards for Smaller Reporting Companies until fiscal years beginning after December 15, 2022. The Company currently expects to continue to qualify as a Smaller Reporting Company, based upon the current SEC definition and, as a result, will be utilizing the deferred elective date. While the Company is in the process of determining the effects of the adoption of the standard on the consolidated financial statements, it does not expect the impact to be material.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on the Company's consolidated financial statements or disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=27011672&amp;loc=d3e149975-122751<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StandardProductWarrantyPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for standard warranties including the methodology for measuring the liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StandardProductWarrantyPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663393316440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTEREST IN JOINT VENTURE INVESTMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_NoncontrollingInterestTableTextBlock', window );">Schedule of Noncontrolling Interest</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the Company's ownership interest in its 51% owned China JV were as follows:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.712%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.088%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended<br/>December 31, 2020</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning interest in China JV</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contributions </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Apyx</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending interest in China JV</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_NoncontrollingInterestTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest Table Text Block</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_NoncontrollingInterestTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663393070904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,243&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,935&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,087&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross inventories</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,439&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,460&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: provision for obsolescence</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(388)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(392)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,051&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,068&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663393402632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">813&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">805&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,931&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,872&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,813)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,403)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment in service</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,118&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,469&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,541&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,618&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663394730088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease Costs</a></td>
<td class="text">Information about the Company&#8217;s lease costs are as follows:<div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.274%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended <br/>December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease costs:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease costs</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and non-cash information related to our leases are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.531%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended <br/>December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended <br/>December 31, 2019<br/></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non cash information:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets capitalized and lease liabilities recognized upon adoption of Topic 842</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets capitalized and lease liabilities recognized upon lease remeasurement</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets capitalized and lease liabilities recognized upon execution of lease</span></td><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">710&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash information:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about the Company&#8217;s weighted average remaining lease terms and discount rate assumptions are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.160%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended <br/>December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended <br/>December 31, 2019<br/></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.03%</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.04%</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Maturity of Finance Lease Liabilities</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of December 31, 2020 are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:76.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.191%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion of lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(238)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Maturities of Operating Lease Liabilities</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of December 31, 2020 are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:76.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.191%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion of lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(238)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663489463896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:64.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.737%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.739%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">808&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">694&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued bonus</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,306&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued commissions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product warranties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product liability claim insurance deductibles</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,170&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,383&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joint and several payroll liability</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,027&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,045&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,658&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,491&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales tax payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses and current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,278&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,396&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Expenses And Other Current Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663395706056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PRODUCT WARRANTIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductWarrantiesDisclosuresAbstract', window );"><strong>Product Warranties Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock', window );">Schedule of Product Warranty Activity</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product warranty activity consisted of the following for the years ended:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:72.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.695%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for product warranties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product warranty expenses incurred</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(169)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(217)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product warranties</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantiesDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantiesDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663394502248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and Diluted Earnings (Loss) Per Share</a></td>
<td class="text">The following table provides the computation of basic and diluted earnings (loss) per share.<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:72.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.695%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Numerators:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to stockholders</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,896)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19,706)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average shares outstanding - basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,069&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss per share - basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.58)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Anti-dilutive instruments excluded from diluted loss per common share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,939&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663397029208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Components Of Provision For Income Taxes</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of the provision for income taxes are as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.964%"><tr><td style="width:1.0%"/><td style="width:66.757%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.547%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,682)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(205)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,839)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(130)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Release of valuation allowance due to CARES Act</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,664)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,503)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(130)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,989)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,004)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(741)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,029)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,730)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,029&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,730&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total provision for income tax</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,503)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(130)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Statutory Federal Income Tax Rate</a></td>
<td class="text"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a reconciliation of the statutory federal income tax rate to the Company's effective tax rate:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.029%"><tr><td style="width:1.0%"/><td style="width:67.053%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.438%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.569%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.440%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal tax provision</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes (net of federal benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOL carryback from CARES Act</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Deferred Tax Assets (Liabilities)</a></td>
<td class="text">Major components of the Company&#8217;s deferred tax assets (liabilities) are as follows: <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.352%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss and credit carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,888&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,603&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,916&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,837)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,472)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets, net of valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(278)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(245)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(199)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(399)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(444)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Unrecognized Tax Benefits Roll-Forward</a></td>
<td class="text"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a roll-forward of the Company's total gross unrecognized tax benefits, not including interest and penalties, for the years ended December 31:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:79.093%"><tr><td style="width:1.0%"/><td style="width:58.604%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.018%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.569%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.570%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Tax Benefits</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning of year balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,313&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,313&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions of tax positions related to the current year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions of tax positions related to the prior year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases for tax positions related to prior year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">End of year balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,313&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,313&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=121610041&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663395711608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Options And Stock Awards</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The status of the Company's stock options is summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of options </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,254,779&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,379,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(410,635)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(256,785)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,966,858&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,376,900&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112,965)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(291,850)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,938,943&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock', window );">Number of Weighted Average Grant-Date Fair Values of Options</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average grant date fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,484,929&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,376,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(665,510)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(151,850)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,044,469&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Option Fair Value Assumptions</a></td>
<td class="text">Inputs used in the valuation models are as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:83.625%"><tr><td style="width:1.0%"/><td style="width:60.613%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.116%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.072%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.116%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.674%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.116%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.072%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.121%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 Grants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019 Grants</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option value</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4.98</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$8.18</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$7.15</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$7.91</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.9%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.1%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.9%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.4%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663394706328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC AND SEGMENT INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Reporting Information by Segment</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information with respect to reportable segments is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate (Other)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,214&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,497&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,711&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,128)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,838&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,793)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,083)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate (Other)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,676&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,559&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,235&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,045)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,960)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,869)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other losses, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(351)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(351)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock', window );">Schedule of Revenue by Geographic Area</a></td>
<td class="text">Revenue by geographic region, based on the "ship to" location on the invoice are as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales by Domestic and International</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,812&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,584&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,899&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,651&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,711&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,235&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663477577112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_SalesDiscountBillingTermsLowerLimit', window );">Credit terms, billing term, lower limit</a></td>
<td class="text">10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_SalesDiscountBillingTermsUpperLimit', window );">Credit terms, billing term, upper limit</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowances for doubtful accounts</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="nump">600<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expense</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=apyx_ApyxSYMedicalDevicesNingboCoLtdMember', window );">Apyx SY Medical Devices (Ningbo) Co., Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage</a></td>
<td class="nump">51.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Building and improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives</a></td>
<td class="text">39 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=apyx_ComputerEquipmentandSoftwareMember', window );">Computer equipment and software | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=apyx_ComputerEquipmentandSoftwareMember', window );">Computer equipment and software | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ToolsDiesAndMoldsMember', window );">Molds | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ToolsDiesAndMoldsMember', window );">Molds | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=apyx_RenuvionJPlasmaGeneratorsMember', window );">Renuvion/J-Plasma generators</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_ProductWarranty', window );">Product warranty</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=apyx_MountingFixturesMember', window );">Mounting Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_ProductWarranty', window );">Product warranty</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=apyx_AccessoriesMember', window );">Accessories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_ProductWarranty', window );">Product warranty</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_ProductWarranty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Product Warranty</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_ProductWarranty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_SalesDiscountBillingTermsLowerLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales Discount, Billing Terms, Lower Limit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_SalesDiscountBillingTermsLowerLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_SalesDiscountBillingTermsUpperLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales Discount, Billing Terms, Upper Limit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_SalesDiscountBillingTermsUpperLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121599878&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=apyx_ApyxSYMedicalDevicesNingboCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=apyx_ApyxSYMedicalDevicesNingboCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=apyx_ComputerEquipmentandSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=apyx_ComputerEquipmentandSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ToolsDiesAndMoldsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ToolsDiesAndMoldsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=apyx_RenuvionJPlasmaGeneratorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=apyx_RenuvionJPlasmaGeneratorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=apyx_MountingFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=apyx_MountingFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=apyx_AccessoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=apyx_AccessoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663477301000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DISPOSITION OF THE CORE BUSINESS - (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from the disposition of Core business</a></td>
<td class="nump">$ 97.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apyx_SymmetrySurgicalInc.Member', window );">Symmetry Surgical Inc. | Electro Surgical Disposables and Accessories, Cauteries and Other Products Supply Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_AssetPurchaseAgreementTerm', window );">Asset purchase agreement, term</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.4<span></span>
</td>
<td class="nump">$ 9.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold', window );">Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.1<span></span>
</td>
<td class="nump">8.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense', window );">Operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss', window );">Net other income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_AssetPurchaseAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Purchase Agreement, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_AssetPurchaseAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apyx_SymmetrySurgicalInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apyx_SymmetrySurgicalInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663505511224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTEREST IN JOINT VENTURE INVESTMENT - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_NoncontrollingInterestRequiredCapitalContribution', window );">Required capital contribution</a></td>
<td class="nump">$ 357<span></span>
</td>
<td class="nump">$ 357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Contributions from non-controlling interest</a></td>
<td class="nump">148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember', window );">China joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Contributions from non-controlling interest</a></td>
<td class="nump">$ 154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_NoncontrollingInterestRequiredCapitalContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Required Capital Contribution</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_NoncontrollingInterestRequiredCapitalContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569655-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663476948040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTEREST IN JOINT VENTURE INVESTMENT - Changes in Ownership Interest (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInMinorityInterestRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Beginning interest in China JV</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Contributions</a></td>
<td class="nump">148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to Apyx</a></td>
<td class="num">(10)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Ending interest in China JV</a></td>
<td class="nump">138<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember', window );">China joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInMinorityInterestRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Beginning interest in China JV</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Contributions</a></td>
<td class="nump">154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to Apyx</a></td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Ending interest in China JV</a></td>
<td class="nump">$ 144<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=apyx_ChineseSupplierMember', window );">Chinese Supplier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Ownership interest</a></td>
<td class="nump">51.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInMinorityInterestRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInMinorityInterestRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569655-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=apyx_ChineseSupplierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=apyx_ChineseSupplierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663399066392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 2,243<span></span>
</td>
<td class="nump">$ 2,935<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">1,109<span></span>
</td>
<td class="nump">1,209<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">1,087<span></span>
</td>
<td class="nump">1,316<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Gross inventories</a></td>
<td class="nump">4,439<span></span>
</td>
<td class="nump">5,460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Less: provision for obsolescence</a></td>
<td class="num">(388)<span></span>
</td>
<td class="num">(392)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">4,051<span></span>
</td>
<td class="nump">$ 5,068<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-down</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_InventoryWriteDownReversals', window );">Inventory write down reversals</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_InventoryWriteDownReversals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory Write Down Reversals</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_InventoryWriteDownReversals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663398904584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">$ 10,931<span></span>
</td>
<td class="nump">$ 10,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(4,813)<span></span>
</td>
<td class="num">(4,403)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations', window );">Property and equipment in service</a></td>
<td class="nump">6,118<span></span>
</td>
<td class="nump">6,469<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment', window );">Construction in progress</a></td>
<td class="nump">423<span></span>
</td>
<td class="nump">149<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">6,541<span></span>
</td>
<td class="nump">6,618<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">700<span></span>
</td>
<td class="nump">700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Building and improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">4,454<span></span>
</td>
<td class="nump">4,423<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">2,113<span></span>
</td>
<td class="nump">2,187<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">290<span></span>
</td>
<td class="nump">292<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=apyx_ComputerEquipmentandSoftwareMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">1,505<span></span>
</td>
<td class="nump">1,409<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">156<span></span>
</td>
<td class="nump">156<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ToolsDiesAndMoldsMember', window );">Molds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">$ 813<span></span>
</td>
<td class="nump">$ 805<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net property, plant and equipment of continuing and discontinued operations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=apyx_ComputerEquipmentandSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=apyx_ComputerEquipmentandSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ToolsDiesAndMoldsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ToolsDiesAndMoldsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663396989016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_LesseeDiscountRateIncrementalBorrowingRate', window );">Discount rate</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=apyx_SophiaBulgariaMember', window );">Sophia, Bulgaria</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_LesseeDiscountRateIncrementalBorrowingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Discount Rate, Incremental Borrowing Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_LesseeDiscountRateIncrementalBorrowingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=apyx_SophiaBulgariaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=apyx_SophiaBulgariaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663477158024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Lease Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 124<span></span>
</td>
<td class="nump">$ 115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of right-of-use assets</a></td>
<td class="nump">216<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease costs</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease costs</a></td>
<td class="nump">$ 375<span></span>
</td>
<td class="nump">$ 196<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663476969368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Cash and Non-Cash Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_OperatingLeaseCostsAbstract', window );"><strong>Operating</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for lease liabilities</a></td>
<td class="nump">$ 110<span></span>
</td>
<td class="nump">$ 106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_FinanceLeaseCostsAbstract', window );"><strong>Finance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_FinanceLeasePayments', window );">Cash paid for lease liabilities</a></td>
<td class="nump">251<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_LeaseArrangementsAxis=apyx_LeaseRemeasurementMember', window );">Lease Remeasurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_OperatingLeaseCostsAbstract', window );"><strong>Operating</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets capitalized and lease liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_FinanceLeaseCostsAbstract', window );"><strong>Finance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Right-of-use assets capitalized and lease liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_LeaseArrangementsAxis=apyx_LeaseExecutionMember', window );">Lease Execution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_OperatingLeaseCostsAbstract', window );"><strong>Operating</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets capitalized and lease liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_FinanceLeaseCostsAbstract', window );"><strong>Finance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Right-of-use assets capitalized and lease liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">710<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Topic 842</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_OperatingLeaseCostsAbstract', window );"><strong>Operating</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets capitalized and lease liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">212<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_FinanceLeaseCostsAbstract', window );"><strong>Finance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Right-of-use assets capitalized and lease liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_FinanceLeaseCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Costs [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_FinanceLeaseCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_FinanceLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_FinanceLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_OperatingLeaseCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Costs [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_OperatingLeaseCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_LeaseArrangementsAxis=apyx_LeaseRemeasurementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_LeaseArrangementsAxis=apyx_LeaseRemeasurementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_LeaseArrangementsAxis=apyx_LeaseExecutionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_LeaseArrangementsAxis=apyx_LeaseExecutionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663396982504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Lease Terms and Discount Rates (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_OperatingLeaseCostsAbstract', window );"><strong>Operating</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">4.03%<span></span>
</td>
<td class="nump">4.04%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_FinanceLeaseCostsAbstract', window );"><strong>Finance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_FinanceLeaseCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Costs [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_FinanceLeaseCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_OperatingLeaseCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Costs [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_OperatingLeaseCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663398466040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Maturities of Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less current portion of lease liabilities</a></td>
<td class="num">(126)<span></span>
</td>
<td class="num">$ (108)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">129<span></span>
</td>
<td class="nump">235<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(16)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Less current portion of lease liabilities</a></td>
<td class="num">(238)<span></span>
</td>
<td class="num">(229)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term finance lease liabilities</a></td>
<td class="nump">$ 183<span></span>
</td>
<td class="nump">$ 421<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663476918488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued payroll</a></td>
<td class="nump">$ 808<span></span>
</td>
<td class="nump">$ 694<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Accrued bonus</a></td>
<td class="nump">811<span></span>
</td>
<td class="nump">1,306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalesCommissionCurrent', window );">Accrued commissions</a></td>
<td class="nump">1,001<span></span>
</td>
<td class="nump">877<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrualClassifiedCurrent', window );">Accrued product warranties</a></td>
<td class="nump">498<span></span>
</td>
<td class="nump">452<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedInsuranceCurrent', window );">Accrued product liability claim insurance deductibles</a></td>
<td class="nump">435<span></span>
</td>
<td class="nump">1,170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">222<span></span>
</td>
<td class="nump">1,383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_JointAndSeveralPayrollLiability', window );">Joint and several payroll liability</a></td>
<td class="nump">1,027<span></span>
</td>
<td class="nump">1,045<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_UncertainTaxPositionsLiability', window );">Uncertain tax positions</a></td>
<td class="nump">1,658<span></span>
</td>
<td class="nump">1,491<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesAndExciseTaxPayableCurrent', window );">Sales tax payable</a></td>
<td class="nump">591<span></span>
</td>
<td class="nump">492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_OtherAccruedExpensesAndLiabilitiesCurrent', window );">Other accrued expenses and current liabilities</a></td>
<td class="nump">227<span></span>
</td>
<td class="nump">486<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 7,278<span></span>
</td>
<td class="nump">$ 9,396<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_JointAndSeveralPayrollLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Joint And Several Payroll Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_JointAndSeveralPayrollLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_OtherAccruedExpensesAndLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Accrued Expenses And Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_OtherAccruedExpensesAndLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_UncertainTaxPositionsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Uncertain Tax Positions Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_UncertainTaxPositionsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedInsuranceCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedInsuranceCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalesCommissionCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalesCommissionCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrualClassifiedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12524-110249<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68070138&amp;loc=d3e11281-110244<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrualClassifiedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesAndExciseTaxPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesAndExciseTaxPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663396298248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PRODUCT WARRANTIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInStandardProductWarrantyAccrualRollForward', window );"><strong>Movement in Standard Product Warranty Accrual [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StandardProductWarrantyAccrual', window );">Beginning balance</a></td>
<td class="nump">$ 452<span></span>
</td>
<td class="nump">$ 348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StandardProductWarrantyAccrualWarrantiesIssued', window );">Provision for product warranties</a></td>
<td class="nump">215<span></span>
</td>
<td class="nump">321<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StandardProductWarrantyAccrualPayments', window );">Product warranty expenses incurred</a></td>
<td class="num">(169)<span></span>
</td>
<td class="num">(217)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StandardProductWarrantyAccrual', window );">Accrued product warranties</a></td>
<td class="nump">$ 498<span></span>
</td>
<td class="nump">$ 452<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInStandardProductWarrantyAccrualRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInStandardProductWarrantyAccrualRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StandardProductWarrantyAccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount as of the balance sheet date of the aggregate standard product warranty liability. Does not include the balance for the extended product warranty liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(1),(c)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StandardProductWarrantyAccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StandardProductWarrantyAccrualPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the standard product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard product warranty. Excludes extended product warranties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph ((c)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StandardProductWarrantyAccrualPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StandardProductWarrantyAccrualWarrantiesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in the standard product warranty accrual from warranties issued. Excludes extended product warranties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph ((c)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StandardProductWarrantyAccrualWarrantiesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663391565048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>JOINT AND SEVERAL PAYROLL LIABILITY (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_JointAndSeveralPayrollLiability', window );">Joint and several payroll liability</a></td>
<td class="nump">$ 1,045<span></span>
</td>
<td class="nump">$ 1,027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_JointAndSeveralPayrollExpense', window );">Joint and several payroll expense</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_JointAndSeveralPayrollLiability', window );">Joint and several payroll liability</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_JointAndSeveralPayrollExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Joint And Several Payroll Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_JointAndSeveralPayrollExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_JointAndSeveralPayrollLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Joint And Several Payroll Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_JointAndSeveralPayrollLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663395615192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Numerators:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to stockholders</a></td>
<td class="num">$ (11,896)<span></span>
</td>
<td class="num">$ (19,706)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of shares outstanding - basic and diluted (in shares)</a></td>
<td class="nump">34,212<span></span>
</td>
<td class="nump">34,069<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Loss per share - basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.35)<span></span>
</td>
<td class="num">$ (0.58)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_OptionOnSecuritiesMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Anti-dilutive instruments excluded from diluted loss per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Options (in shares)</a></td>
<td class="nump">4,939<span></span>
</td>
<td class="nump">3,967<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_OptionOnSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_OptionOnSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663498347512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 2,250<span></span>
</td>
<td class="nump">$ 2,237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">US Treasury securities</a></td>
<td class="nump">$ 39,665<span></span>
</td>
<td class="nump">$ 56,575<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663391539992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Components of Provision For Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">$ (3,682)<span></span>
</td>
<td class="num">$ (12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="num">(120)<span></span>
</td>
<td class="num">(205)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="num">(37)<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current income tax expense (benefit)</a></td>
<td class="num">(3,839)<span></span>
</td>
<td class="num">(130)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_CARESActIncomeTaxExpenseBenefitValuationAllowance', window );">Release of valuation allowance due to CARES Act</a></td>
<td class="num">(3,664)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_CurrentIncomeTaxExpenseBenefitAfterValuationAllowance', window );">Current income tax expense (benefit), after valuation allowance</a></td>
<td class="num">(7,503)<span></span>
</td>
<td class="num">(130)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(3,989)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(1,004)<span></span>
</td>
<td class="num">(741)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax expense (benefit)</a></td>
<td class="num">(1,029)<span></span>
</td>
<td class="num">(4,730)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_IncomeTaxExpenseBenefitValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">1,029<span></span>
</td>
<td class="nump">4,730<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total provision for income tax</a></td>
<td class="num">$ (7,503)<span></span>
</td>
<td class="num">$ (130)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_CARESActIncomeTaxExpenseBenefitValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>CARES Act, Income Tax Expense (Benefit), Valuation Allowance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_CARESActIncomeTaxExpenseBenefitValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_CurrentIncomeTaxExpenseBenefitAfterValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current Income Tax Expense (Benefit), After Valuation Allowance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_CurrentIncomeTaxExpenseBenefitAfterValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_IncomeTaxExpenseBenefitValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax Expense (Benefit), Valuation Allowance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_IncomeTaxExpenseBenefitValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663395366264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Reconciliation of Statutory Federal Income Tax Rate to Effective Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation of the statutory federal income tax rate to our effective tax rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal tax provision</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes (net of federal benefit)</a></td>
<td class="nump">5.10%<span></span>
</td>
<td class="nump">4.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(5.30%)<span></span>
</td>
<td class="num">(23.80%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_EffectiveIncomeTaxRateReconciliationCARESActNetOperatingLossCarryforwardsPercent', window );">NOL carryback from CARES Act</a></td>
<td class="nump">18.90%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions', window );">Total</a></td>
<td class="nump">38.70%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_EffectiveIncomeTaxRateReconciliationCARESActNetOperatingLossCarryforwardsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, CARES Act, Net Operating Loss Carryforwards, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_EffectiveIncomeTaxRateReconciliationCARESActNetOperatingLossCarryforwardsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations attributable to deduction. Includes, but is not limited to, dividend deduction, deduction for dividend paid to employee stock ownership plan (ESOP), Medicare prescription drug benefit subsidy deduction, and other deductions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663477392808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES - Deferred Tax Assets (Liabilities) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Loss and credit carryforwards</a></td>
<td class="nump">$ 1,888<span></span>
</td>
<td class="nump">$ 4,779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">1,603<span></span>
</td>
<td class="nump">1,004<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">745<span></span>
</td>
<td class="nump">1,133<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">4,236<span></span>
</td>
<td class="nump">6,916<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(3,837)<span></span>
</td>
<td class="num">(6,472)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets, net of valuation allowance</a></td>
<td class="nump">399<span></span>
</td>
<td class="nump">444<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="num">(278)<span></span>
</td>
<td class="num">(245)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(121)<span></span>
</td>
<td class="num">(199)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(399)<span></span>
</td>
<td class="num">(444)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663398459368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards', window );">Income tax benefit</a></td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_CARESActEffectiveIncomeTaxRateReconciliationFederalNetOperatingLossCarryforwardsAmount', window );">Net operating loss carryback</a></td>
<td class="nump">3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">1,313<span></span>
</td>
<td class="nump">$ 1,313<span></span>
</td>
<td class="nump">$ 1,313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest and penalties</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_CARESActEffectiveIncomeTaxRateReconciliationFederalNetOperatingLossCarryforwardsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>CARES Act, Effective Income Tax Rate Reconciliation, Federal Net Operating Loss Carryforwards, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_CARESActEffectiveIncomeTaxRateReconciliationFederalNetOperatingLossCarryforwardsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>CARES Act, Income Tax Expense (Benefit), Release Of Valuation Allowance, Federal Net Operating Loss Carryforwards</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663398807688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Unrecognized Tax Benefits Roll-Forward (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Gross Unrealized Tax Benefits</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning of year balance</a></td>
<td class="nump">$ 1,313<span></span>
</td>
<td class="nump">$ 1,313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions of tax positions related to the current year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions of tax positions related to the prior year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Decreases for tax positions related to prior year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">End of year balance</a></td>
<td class="nump">$ 1,313<span></span>
</td>
<td class="nump">$ 1,313<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663393185464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RETIREMENT PLAN - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_DefinedContributionPlanEmployersMatchingContributionVestingPeriod', window );">Defined contribution plan, vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_DefinedContributionPlanEmployersMatchingContributionVestingPercentageAfterThreeYears', window );">Defined contribution plan, vesting percentage after 3 years</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Defined contribution plan, employer matching contribution</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Defined contribution plan, percent of employees' gross pay</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Company matching contributions</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DefinedContributionPlanEmployersMatchingContributionVestingPercentageAfterThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Contribution Plan, Employers Matching Contribution, Vesting Percentage After Three Years</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DefinedContributionPlanEmployersMatchingContributionVestingPercentageAfterThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DefinedContributionPlanEmployersMatchingContributionVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Contribution Plan, Employers Matching Contribution, Vesting Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DefinedContributionPlanEmployersMatchingContributionVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663391840552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesNoncurrent', window );">Note payable issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_CoVenturerMember', window );">Co-venturer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty', window );">Purchases from supplier</a></td>
<td class="nump">$ 1,441<span></span>
</td>
<td class="nump">2,643<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to supplier</a></td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableRelatedPartiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount for notes payable (written promise to pay), payable to related parties, which are due after one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.23)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableRelatedPartiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_CoVenturerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=us-gaap_CoVenturerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663398421816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Purchase commitments</a></td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_NoncontrollingInterestRequiredCapitalContribution', window );">Required capital contribution</a></td>
<td class="nump">$ 357<span></span>
</td>
<td class="nump">$ 357<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember', window );">Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_LossContingencyAccrualTotalAccruedToDate', window );">Total loss contingency accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Cost accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 820<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=apyx_LargestCustomerMember', window );">Largest Customer | Sales | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration receivable risk</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_CorporateJointVentureMember', window );">China joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_PaymentsToAcquireInterestInJointVentureRemaining', window );">Remaining payments to acquire interest in joint venture</a></td>
<td class="nump">$ 203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_LossContingencyAccrualTotalAccruedToDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency Accrual, Total Accrued To Date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_LossContingencyAccrualTotalAccruedToDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_NoncontrollingInterestRequiredCapitalContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Required Capital Contribution</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_NoncontrollingInterestRequiredCapitalContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_PaymentsToAcquireInterestInJointVentureRemaining">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Interest In Joint Venture, Remaining</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_PaymentsToAcquireInterestInJointVentureRemaining</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=apyx_LargestCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=apyx_LargestCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_CorporateJointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=us-gaap_CorporateJointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663390431432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTIONS - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 29, 2020</div></th>
<th class="th"><div>Oct. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Aug. 31, 2019</div></th>
<th class="th"><div>Aug. 31, 2017</div></th>
<th class="th"><div>Jul. 31, 2015</div></th>
<th class="th"><div>Jul. 31, 2012</div></th>
<th class="th"><div>Oct. 30, 2007</div></th>
<th class="th"><div>Dec. 31, 2001</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Option expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Option vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,376,900<span></span>
</td>
<td class="nump">1,379,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,210<span></span>
</td>
<td class="nump">$ 3,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueClosingStockPrice', window );">Closing stock price for computation of intrinsic value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Stock options outstanding and expected to vest (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,530,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value of all stock options outstanding and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Stock options outstanding and expected to vest, weighted average exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Stock options outstanding and exercisable, weighted average remaining contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Stock options outstanding and exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,894,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value of currently exercisable stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">1,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue', window );">Intrinsic value of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,580<span></span>
</td>
<td class="nump">$ 6,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of options granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.78<span></span>
</td>
<td class="nump">$ 4.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of option shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,510<span></span>
</td>
<td class="nump">$ 2,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived', window );">Shares received in stock swaps (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,448<span></span>
</td>
<td class="nump">125,948<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_StockIssuedDuringPeriodSharesStockSwaps', window );">Shares issued in stock swaps (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,088<span></span>
</td>
<td class="nump">222,601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock-based compensation cost, recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Option vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Option vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Option vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedToDate', window );">Grants to date (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=apyx_A2001ExecutiveandEmployeeStockOptionPlanMember', window );">2001 Executive and Employee Stock Option Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Shares authorized under common stock option plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=apyx_A2003ExecutiveandEmployeeStockOptionPlanMember', window );">2003 Executive and Employee Stock Option Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Shares authorized under common stock option plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=apyx_TwoThousandTwelveShareIncentivePlanMember', window );">2012 Share Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Shares authorized under common stock option plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remaining shares for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=apyx_TwoThousandFifteenExecutiveAndEmployeeStockOptionPlanMember', window );">2015 Executive and Employee Stock Option Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Shares authorized under common stock option plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remaining shares for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=apyx_A2017ExecutiveandEmployeeStockOptionPlanMember', window );">2017 Executive and Employee Stock Option Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Shares authorized under common stock option plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remaining shares for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=apyx_A2019ShareIncentivePlanMember', window );">2019 Share Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Shares authorized under common stock option plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remaining shares for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedToDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Non-Option Equity Instruments, Granted To Date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedToDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Options, Grants In Period, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueClosingStockPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Options, Intrinsic Value, Closing Stock Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueClosingStockPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_StockIssuedDuringPeriodSharesStockSwaps">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Stock Swaps</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_StockIssuedDuringPeriodSharesStockSwaps</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Stock Swaps Equity Instruments Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=apyx_A2001ExecutiveandEmployeeStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=apyx_A2001ExecutiveandEmployeeStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=apyx_A2003ExecutiveandEmployeeStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=apyx_A2003ExecutiveandEmployeeStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=apyx_TwoThousandTwelveShareIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=apyx_TwoThousandTwelveShareIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=apyx_TwoThousandFifteenExecutiveAndEmployeeStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=apyx_TwoThousandFifteenExecutiveAndEmployeeStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=apyx_A2017ExecutiveandEmployeeStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=apyx_A2017ExecutiveandEmployeeStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=apyx_A2019ShareIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=apyx_A2019ShareIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663398058216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTIONS - Summary of Stock Options (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 29, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,966,858<span></span>
</td>
<td class="nump">3,254,779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">1,376,900<span></span>
</td>
<td class="nump">1,379,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(112,965)<span></span>
</td>
<td class="num">(410,635)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Cancelled and forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(291,850)<span></span>
</td>
<td class="num">(256,785)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,938,943<span></span>
</td>
<td class="nump">3,966,858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning of period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.67<span></span>
</td>
<td class="nump">$ 3.18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.94<span></span>
</td>
<td class="nump">7.70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.37<span></span>
</td>
<td class="nump">2.99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Cancelled and forfeited (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.19<span></span>
</td>
<td class="nump">4.76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, end of period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.46<span></span>
</td>
<td class="nump">$ 4.67<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663477600152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTIONS - Summary of Nonvested Stock Options (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 29, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward', window );"><strong>Number of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Options Non-vested at beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,484,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options Non-vested, Granted (in shares)</a></td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">1,376,900<span></span>
</td>
<td class="nump">1,379,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of Options Non-vested, Vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(665,510)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Number of Options Non-vested, Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(151,850)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Options Non-vested at end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,044,469<span></span>
</td>
<td class="nump">1,484,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract', window );"><strong>Weighted average grant date fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Non-vested Options at beginning of period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Non-vested Options, Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.78<span></span>
</td>
<td class="nump">$ 4.57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Non-vested Options, Vested (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Non-vested Options, Forfeited (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Non-vested Options at end of period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.61<span></span>
</td>
<td class="nump">$ 4.11<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663567094520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTIONS STOCK OPTIONS - Fair Value Assumptions (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Option value (in dollars per share)</a></td>
<td class="nump">$ 7.94<span></span>
</td>
<td class="nump">$ 7.70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility - minimum</a></td>
<td class="nump">65.90%<span></span>
</td>
<td class="nump">64.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility - maximum</a></td>
<td class="nump">70.10%<span></span>
</td>
<td class="nump">66.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Option value (in dollars per share)</a></td>
<td class="nump">$ 4.98<span></span>
</td>
<td class="nump">$ 7.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Option value (in dollars per share)</a></td>
<td class="nump">$ 8.18<span></span>
</td>
<td class="nump">$ 7.91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663394864904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC AND SEGMENT INFORMATION - Narrative (Details) - segment<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_TotalRevenuePercent', window );">International sales</a></td>
<td class="nump">32.10%<span></span>
</td>
<td class="nump">30.60%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_TotalRevenuePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total Revenue, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_TotalRevenuePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663481638648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC AND SEGMENT INFORMATION - Reportable Segment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">$ 27,711<span></span>
</td>
<td class="nump">$ 28,235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="num">(20,083)<span></span>
</td>
<td class="num">(20,869)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest income</a></td>
<td class="nump">241<span></span>
</td>
<td class="nump">1,392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(46)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other income (loss), net</a></td>
<td class="nump">479<span></span>
</td>
<td class="num">(351)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">7,503<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Advanced Energy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">22,214<span></span>
</td>
<td class="nump">22,676<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="num">(7,128)<span></span>
</td>
<td class="num">(8,045)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other income (loss), net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | OEM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">5,497<span></span>
</td>
<td class="nump">5,559<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="nump">1,838<span></span>
</td>
<td class="nump">2,136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other income (loss), net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate (Other)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="num">(14,793)<span></span>
</td>
<td class="num">(14,960)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(46)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other income (loss), net</a></td>
<td class="nump">479<span></span>
</td>
<td class="num">(351)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">$ 7,503<span></span>
</td>
<td class="nump">$ 130<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=apyx_AdvancedEnergyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=apyx_AdvancedEnergyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=apyx_OEMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=apyx_OEMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139663394813992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC AND SEGMENT INFORMATION - Geographic (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">$ 27,711<span></span>
</td>
<td class="nump">$ 28,235<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">Domestic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">18,812<span></span>
</td>
<td class="nump">19,584<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">$ 8,899<span></span>
</td>
<td class="nump">$ 8,651<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>83
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( .R#?U('04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " #L@W]2,)_O$^X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M2L0P$(9?17)O)VE@A=#M1?&D(+B@> N3V=U@TX9DI-VWMZV[740?P&-F_GSS
M#4R-T6"?Z#GUD1)[RC=C:+ML,&[%D3D:@(Q'"C:74Z*;FOL^!<O3,QT@6ORP
M!X)*R@T$8NLL6YB!15R)HJD=&DQDN4]GO,,5'S]3N\ < K44J.,,JE0@FGEB
M/(UM#5? #&-*(7\7R*W$I?HG=NF ."?'[-?4, SEH)?<M(."MZ?'EV7=PG>9
M;8<T_<K>\"G25EPFO^J[^]V#:"I9J4+J0JN=VABMC+Q]GUU_^%V%0^_\WO]C
MXXM@4\.ONVB^ %!+ P04    " #L@W]2F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M .R#?U)\^!V_P04  !88   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MI5G;<MLV$'U.OP*CR4,R8UD$J)LSLF9DR6[5^*)*3E*WTP>(A"2.24 %0<O^
M^RXHBE0\U)(SS4/$"_;@<'=Q%E@/=DH_QQLA#'F-0AE?-C;&;+^T6K&W$1&/
MS]562'BS4CKB!F[UNA5OM>!^:A2%+>8XW5;$ ]D8#M)G,ST<J,2$@10S3>(D
MBKA^NQ*AVETV:./P8!ZL-\8^: T'6[X6"V&^;6<:[EHYBA]$0L:!DD2+U65C
M1+],W*XU2$=\#\0N/KHF]E.62CW;FZE_V7 L(Q$*SU@(#C\O8BS"T"(!CW\S
MT$8^IS4\OCZ@WZ0?#Q^SY+$8J_!'X)O-9:/?(+Y8\20T<[7[360?U+%XG@KC
M]'^RVX]MMQO$2V*CHLP8&$2!W/_RU\P11P:N<\* 90;LG0$]-8.;&;AU#=J9
M03OUS/Y34C],N.'#@58[HNUH0+,7J3-3:_C\0-JX+XR&MP'8F>%8O0A-FN3;
M8D(^??Q,/I) DKL@#"$H\:!E8 H[L.5E<%=[.'8"CC)RIZ39Q.1:^L+_&: %
MW'*"[$#PBJ&($^&=$Y>>$>8PIX30&#>_X_J<L(O4G):83W#SWQ,)LSMEL__T
M-6[N;C?%<U%W_SU:QD9#RO^#0+9SR'8*V3[E(.4EL! ->7S;BK*(X>;4:7Y%
M6'1R%IUZ+$92)CPD<[%5VI31P7&,3@1"IYO3Z:(PXT1KR^8FB#U@\R2XMAE)
M8(V4^@A':S8I:[H4X=7+>?7JN6DF=*!\E%,%4K8N?OGPH2(W^SFW?LU$TAQT
M/97ETV'$L58\C+$X7N2<+E"<:VD"\P9A# 6Y3Z*ET&5<< P'HD?[+L*&.H5:
M.G7XS,4ZL"L8G'7/H]+H50"-9D]_DKOKR70\NB7CA_GL83YZG#[<8RR/-)W6
M83F5GM(0/VY#>486!A*-*$W&*I%&O\&O7TX=1Y]<8R1909+5(?G(7\G4A[0+
M5H&7,D4"70%):9-UV^TNQ98J+;2:NG48CGQ?BS@^.UR06QA''F2Y[W#(#J4=
M\BV,A#9V=2F.E4A:E "*B_A[IF-[!Y%^5#M9RA*'&X>@ESO(%HVQ*TH#Q37]
M/;L\$6=:O032*W<DCGESBU$KR@3%E?T]M9F*#=2+OX+MZ=6!([INKXNI,2U*
M!<45/@WB"#;SIZG@ #W6PX@4=8'B8GZK; V=;93$1+@"Q.VWF\QEJ P758'B
MDOX8&"@(:D4H^[3\3!;"2S1XJY06CC16400K<6&4]WQ&/IX[#B4SV"Q\YR&Z
M$6%%R6"XTD,U]0.Y)HNW:*G",HH5 +948$R*LL!PX3ZXB5R_>ALNU^)D\:H
MNA\M)J,_,$Y%%6"UJL /./@UGR7(%023QY!I/IG&<5*>:A68]PJC5L@_JR7_
MWU4(Y1+.Q.DN1)<>BBJ0<$*%RK-:*G_8V^[W9FEJ@: FY<1PQ"<18\P*A6>U
M%'XJH63L3_)V5\L/5$N9X8@5S J!9[4$/@T=&4/=62M=JA,5./=*-KGG"8 !
M$'\/B#$L9)[A*ITQ7$0\#,E5$L/KN#R6.$[%R8D5<L]PI<X(7<,F96VSZU=
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M%X4=9G"5$VD,X/U""/TV,;=%_>=@^!]02P,$%     @ [(-_4O@;;+4H!0
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M>S! 0_1]N4!G7\Z1W%'!),I*M-KQ@Z1E*B_0ET_7TY$",.U^E!PA;FL(8H'
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M.WP6.IQPNLT_8SQ0SFF2'VX(%H8G >+^BE+^<B*_C)0?YP;_ %!+ P04
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M%=7-K6"D:1EU"<B:"\7^V@N^V#7397M!R?-Q+W"NS7B4^J,VWND<1W7>"O[
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M/Y"C#B/H $:VHE@1LZ9O>L1 'AKLD[D-CX\9. D ''700/AXT7HC_YLJ4S=
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M?)NJ-K1BEE@,("\G8[*' I7/9M-L8\P<LA)DV4R-6"&" B?F-"[Q0<MCF0
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MWDIA$F='>D<_C0NQJW5MN[39_I-*F0Z^+.[09FYEN"+0%:3XE%?QAEI#V-*
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MDM3-=OK7;;QI@N9LC2<%"\N*/AEHV8'L.V/\:<,)^H_0_%]02P,$%     @
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M0^,5Z'RME#MLO(/NS9S\ U!+ P04    " #L@W]2SYSM=!X$  !P"   &0
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MWIN"'S,I\ A"!/A]:HQ?OI""YF?TV=]02P,$%     @ [(-_4B9&XYHI P
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M4Z)V#G2?*V7WBDO0[][Y'U!+ P04    " #L@W]2IW80;J@#  #M!P  &0
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MC]%Z _Y>&$.'C0]PG/#C?P!02P,$%     @ [(-_4H<$7>*3 P  [ <  !D
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M4DET/!J ]W-K0W-#"ZP_#Y_]!U!+ P04    " #L@W]2#:!^J)X#  #_!P
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MSF4)TSV 4X8_A+@AU^A2!_^2&VMK-)=B,K-@L%U<=#XF=S)9G=1AC_=-\.E
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MR!'^*U.*G,A5$(2+(&'+JI*/W7A3:ZDL9_<AE8<A,"2G#&"P,X HYM>GNV<
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MP34KY<+JDW=:0UC!D5N!J ,PK!%:JL*PN6C70M1,U0+-_J6#4U$01D^*; <
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M%N,9M$"S8.IP6P; 48N6&=&V)7T:,'U5&O2U@ZBL\[(K[+2Z6Q^W^>?J1/]
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MBZ%#LXS33O >KX= ?TNJE_9"J^(?F2[(_,IJQ(T?H48^SGZ+/C\H3X7MJE+
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M0R_@^<RY-GRA">(?.7KQ'U!+ P04    " #L@W]2U:$V5YD"  !Z!0  &0
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M'%'9!(IOI30'PS9HG]OA7U!+ P04    " #L@W]2(*)Q**H"  !V!0  &0
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M-_"PF$P7#XO-@G8_;MA6H/XT] V16P@_;8BF-5%TA2B,X*LLS$'#O,@P^S^
M3ZI;Z=%)^C1Z%_$>TUOHA#<0!5'P#EZG/8J.P^M<P5NR5Y<<L"*#29JJB@D-
M/R9;;10]GI_O4,0M1>PHXBL4:ZJIK!((<E<S8 ;S%RHPW=!^,P=4,*N4PL+
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MSM5-/P!=Z;]RK"J\YM;*DH*]F='*1.T2Z/M&*7MT7(-F"4_^ %!+ P04
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M;"]W;W)K<VAE971S+W-H965T,S4N>&ULI5=K;]LV%/TKA)=N-N#:>MF2W<2
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M.M[-<$'W*13:@+[/.%?;B0ZPNZ&-_@502P,$%     @ [(-_4N=FX&WM P
M90D  !D   !X;"]W;W)K<VAE971S+W-H965T,S<N>&ULK59;;^LV#/XKA%<,
M"6 TOB9.EP1(VYR>//2"IMLP#'M0;"8VCBUEDI*T^_6C9,<GZR7=@#U8EBSR
M(T7R,S7:"_E-Y8@:GJN2J[&3:[VYZ/54FF/%U+G8(*>=E9 5T[24ZY[:2&29
M5:K*7N!Y_5[%"NY,1O;;@YR,Q%:7!<<'"6I;54R^7&(I]F/'=PX?'HMUKLV'
MWF2T86M<H/YY\R!IU6M1LJ)"K@K!0>)J[$S]B\O8R%N!7PK<JZ,YF),LA?AF
M%O-L['C&(2PQU0:!T6N'5UB6!HC<^+/!=%J31O%X?D#_8L].9UDRA5>B_+7(
M=#YV$@<R7+%MJ1_%_BLVY[$.IJ)4=H1]+1O%#J1;I475*),'5<'K-WMNXG"D
MD'@?* 2-0F#]K@U9+Z^99I.1%'N01IK0S,0>U6J3<P4W25EH2;L%Z>G)S>S^
MYG'Z\'5^!=.[:UC,;FYG=T\PO_MR_W@[?9K?WT'GB2U+5-U13Y-!H]9+&_#+
M&CSX -P/X%9PG2N8\0RS?P+TR-/6W>#@[F5P$O$:TW,(?1<"+_!.X(7M\4.+
M%WZ M\ U59B&1]P(J0N^AM^G2Z4E%<L?)^"C%CZR\-%'\,2A;%LBB-61B3FO
MR62J<OD"C0_OA?<DNN'KA=JP%,<.$5*AW*$S65AV%7]A!JN",YX6K(3BR.*^
MT#G126V(%Z %38U?)L6@:D\4% J8@I4HB;/J GY#)@%-"H$2@-4299L$Z,PY
MZ%QL%>.9ZL(TVY%1DIQQE.L7N)_=PI609(-IA,Z]SE%VX4EH<FO!J*[@#(+
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MM#D<TMB/_:9DSP[L;TOSO73UCEI?132P#5Y!*K9<UUVP_=K>(:9UZ_PN7E]
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MA.<*I6QL7 8G'7/EY?+3P_)$BZ+:O7\16HNL.IPRFC!I)YC?QT+HMQ,;H/X
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MZNEQBF+9%H;B6[NO5ESI[6>/B?X^H3 !^G[-N3H8)D'UQ0O_ %!+ P04
M" #L@W]28J[AF&<#  !?"P  &0   'AL+W=O<FMS:&5E=',O<VAE970T,2YX
M;6S%5MMNVS@0_15":-$6V$877U/8!FS'BW6Q<8,XR3X4?:"EL<6-1*HD%2=_
MOT-)EAQ'$E)L@+[8(C7GS)DA9S2CO9#W*@30Y#&.N!I;H=;)%]M6?@@Q56<B
M 8YOMD+&5.-2[FR52*!!!HHCVW.<OAU3QJW)*-N[DI.12'7$.%Q)HM(XIO)I
M!I'8CRW7.FQ<LUVHS88]&25T!VO0M\F5Q)5=L@0L!JZ8X$3"=FQ-W2]SMV\
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M/K##;Z3H4#_-Y[-09+_@4&#M'O 3(5E4!"L&$8WS?_Q:"%$)@-Z) %0$H&:
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MQ1),642BMP"^UE&)06LQ(^1$G)#P C3@-X "%.PA-/YP.^PYZ#0J;QL6KW$
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M9@'.;X70AXZY;+NW-?X-4$L#!!0    ( .R#?U+',)<F4@,  '@,   9
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M6_5I@+E>H)ZO&9.'@3Y\%A\;HW]02P,$%     @ [(-_4C1(L0:% P  .0L
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MP6,.Q":.$?^ZQ93M^A:TOA^\D.5*Z@?VH+=&2SS!\G4]YFIF%RIS$N-$$)8
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M,N7@FQ&YHEP!P]1(!HT;0R3+85)NM"A</UX*;;J[6V9F_J*T!\SS5 A]V-@
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MI3N>':;Z34)A O3^ANLC7DT,0?W*#7\#4$L#!!0    ( .R#?U(;[^5)8 ,
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MV9J'8?Z/S&@&"M_U5"1XC&&7-I_DCJG[AIC[>R70?YNT^L&.(G@EI/O*)<3
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M-(_$3;KZRLH):8!!&F7Z?[ JQSH#$.292.,R6"*(PZ3X2Y_*0E0"H-L2@,H
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MIFDL/2NC6O5/Y!.1S)GT$0'NGT%UW#5]UI=/5I3/P%]_R)3@0K X^]L""&\
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MAOM1=6QT$=MUL6_5IQUY2'?5*R=B=I72ASV9VC_JQ8K=6:9ELFW+(#YJ.4/
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M[;+0PQ6$.:"_;SE7QXU)T([K^#=02P,$%     @ [(-_4H#U#)^[!   UA4
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M+13!!F]3N6*[.R@-M31?R%)AKFA7QCH6"K="LJP$*P49H<4=OY6%. "X[3,
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MKDO]HQ_<\TZM;$S(0@&RA0!,D^'O;4S(0L%+/L$A^]#G-B9DH> UG^F,,G$
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M/S[+SC;]6SX;_YJW> %02P$"% ,4    " #L@W]2!T%-8H$   "Q    $
M            @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( .R#
M?U(PG^\3[@   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E
M+GAM;%!+ 0(4 Q0    ( .R#?U*97)PC$ 8  )PG   3              "
M <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ [(-_4GSX';_!
M!0  %A@  !@              ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q
M+GAM;%!+ 0(4 Q0    ( .R#?U*>M,!<<P8  "\:   8              "
M@00.  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " #L@W]2
M6%"'8>\"   H"   &               @(&M%   >&PO=V]R:W-H965T<R]S
M:&5E=#,N>&UL4$L! A0#%     @ [(-_4O@;;+4H!0  GA(  !@
M     ("!TA<  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    (
M .R#?U*V/&'VK 0  *@3   8              " @3 =  !X;"]W;W)K<VAE
M971S+W-H965T-2YX;6Q02P$"% ,4    " #L@W]2QD?CO"0'  !:'0  &
M            @($2(@  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#
M%     @ [(-_4H%@4N%N!   2PD  !@              ("!;"D  'AL+W=O
M<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( .R#?U+.KAR/K1<   M#
M   8              " @1 N  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q0
M2P$"% ,4    " #L@W]2$JNT9[$#  !N"   &               @('S10
M>&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ [(-_4DF3_H'*
M%P  !T,  !D              ("!VDD  'AL+W=O<FMS:&5E=',O<VAE970Q
M,"YX;6Q02P$"% ,4    " #L@W]2<E:T:R0#  "0!@  &0
M@(';80  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( .R#
M?U)=X+ZT9P,  #\'   9              " @39E  !X;"]W;W)K<VAE971S
M+W-H965T,3(N>&UL4$L! A0#%     @ [(-_4L^<[70>!   < @  !D
M         ("!U&@  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4
M    " #L@W]2A\Y617T#  "!!P  &0              @($I;0  >&PO=V]R
M:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( .R#?U)*.O.YN 8  )@>
M   9              " @=UP  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL
M4$L! A0#%     @ [(-_4B9&XYHI P   P<  !D              ("!S'<
M 'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " #L@W]2;C)
M+8D"  "'!0  &0              @($L>P  >&PO=V]R:W-H965T<R]S:&5E
M=#$W+GAM;%!+ 0(4 Q0    ( .R#?U*G=A!NJ ,  .T'   9
M  " @>Q]  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @
M[(-_4H<$7>*3 P  [ <  !D              ("!RX$  'AL+W=O<FMS:&5E
M=',O<VAE970Q.2YX;6Q02P$"% ,4    " #L@W]2Z'Y\#'0"  !7!0  &0
M            @(&5A0  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4
M Q0    ( .R#?U)]SH# S@@  "H6   9              " @4"(  !X;"]W
M;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ [(-_4@V@?JB> P
M_P<  !D              ("!19$  'AL+W=O<FMS:&5E=',O<VAE970R,BYX
M;6Q02P$"% ,4    " #L@W]2W*H6$+T#   ^"   &0              @($:
ME0  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( .R#?U(L
M\.FMGPD  "07   9              " @0Z9  !X;"]W;W)K<VAE971S+W-H
M965T,C0N>&UL4$L! A0#%     @ [(-_4F<UZ,#)"0  \QT  !D
M     ("!Y*(  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .R#?U)<]0UF' ,  )L&   9              "
M@<C0  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ [(-_
M4L9+9-M#!   *PT  !D              ("!&]0  'AL+W=O<FMS:&5E=',O
M<VAE970S,2YX;6Q02P$"% ,4    " #L@W]2XPT;>CT#  #I!@  &0
M        @(&5V   >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0
M   ( .R#?U*0UHK,G (  ) %   9              " @0G<  !X;"]W;W)K
M<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ [(-_4F?T?!L) P  1 8
M !D              ("!W-X  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q0
M2P$"% ,4    " #L@W]2@KB9D$<%  !H#0  &0              @($<X@
M>&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( .R#?U(0P:;X
M+ 0  *T)   9              " @9KG  !X;"]W;W)K<VAE971S+W-H965T
M,S8N>&UL4$L! A0#%     @ [(-_4N=FX&WM P  90D  !D
M ("!_>L  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " #L
M@W]2(?G79CP%   ,&@  &0              @($A\   >&PO=V]R:W-H965T
M<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( .R#?U(G/7@B9P,  +\)   9
M          " @93U  !X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#
M%     @ [(-_4BT[JT*A @  _08  !D              ("!,OD  'AL+W=O
M<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " #L@W]28J[AF&<#  !?
M"P  &0              @($*_   >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM
M;%!+ 0(4 Q0    ( .R#?U+(_@4D% ,   H)   9              " @:C_
M  !X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ [(-_4N=6
MH51:!   ]!(  !D              ("!\P(! 'AL+W=O<FMS:&5E=',O<VAE
M970T,RYX;6Q02P$"% ,4    " #L@W]2<HY&TD0"   *!@  &0
M    @(&$!P$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    (
M .R#?U(9'H$XNP(  (<'   9              " @?\) 0!X;"]W;W)K<VAE
M971S+W-H965T-#4N>&UL4$L! A0#%     @ [(-_4KQY@T=! P  3 T  !D
M             ("!\0P! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"
M% ,4    " #L@W]2$#?F95L"  !G!P  &0              @(%I$ $ >&PO
M=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( .R#?U+',)<F4@,
M '@,   9              " @?L2 0!X;"]W;W)K<VAE971S+W-H965T-#@N
M>&UL4$L! A0#%     @ [(-_4C1(L0:% P  .0L  !D              ("!
MA!8! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    " #L@W]2
MX?3)H<,"   A!P  &0              @(% &@$ >&PO=V]R:W-H965T<R]S
M:&5E=#4P+GAM;%!+ 0(4 Q0    ( .R#?U*2> 8YI@(  "4'   9
M      " @3H= 0!X;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%
M  @ [(-_4@F <?@D P  60@  !D              ("!%R ! 'AL+W=O<FMS
M:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    " #L@W]2-OFODCP"   0!0
M&0              @(%R(P$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+
M 0(4 Q0    ( .R#?U(X*:56>P,  /$+   9              " @>4E 0!X
M;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%     @ [(-_4IP>&#?Z
M @  :0D  !D              ("!ERD! 'AL+W=O<FMS:&5E=',O<VAE970U
M-2YX;6Q02P$"% ,4    " #L@W]25[ZN!#L#  "J"@  &0
M@('(+ $ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( .R#
M?U(HFJ9PLP(  #H'   9              " @3HP 0!X;"]W;W)K<VAE971S
M+W-H965T-3<N>&UL4$L! A0#%     @ [(-_4DVAL;O" @    @  !D
M         ("!)#,! 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"% ,4
M    " #L@W]27Y,4E\("  #=!P  &0              @($=-@$ >&PO=V]R
M:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( .R#?U+5I-1IK (  /$&
M   9              " @18Y 0!X;"]W;W)K<VAE971S+W-H965T-C N>&UL
M4$L! A0#%     @ [(-_4AOOY4E@ P  50H  !D              ("!^3L!
M 'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"% ,4    " #L@W]2S2%U
M!QT'  !Z)P  &0              @(&0/P$ >&PO=V]R:W-H965T<R]S:&5E
M=#8R+GAM;%!+ 0(4 Q0    ( .R#?U(%R:E-6P,  . +   9
M  " @>1& 0!X;"]W;W)K<VAE971S+W-H965T-C,N>&UL4$L! A0#%     @
M[(-_4DKH^Y=" P  >@P  !D              ("!=DH! 'AL+W=O<FMS:&5E
M=',O<VAE970V-"YX;6Q02P$"% ,4    " #L@W]2228G'Z$#   [#@  &0
M            @('O30$ >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4
M Q0    ( .R#?U*/_QK@9@(  +H%   9              " @<=1 0!X;"]W
M;W)K<VAE971S+W-H965T-C8N>&UL4$L! A0#%     @ [(-_4H#U#)^[!
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M96QS+RYR96QS4$L! A0#%     @ [(-_4F4HR_BK!0  Y"P   \
M     ( !@V ! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( .R#?U(6W6L4
M)@(  &,H   :              "  5MF 0!X;"]?<F5L<R]W;W)K8F]O:RYX
M;6PN<F5L<U!+ 0(4 Q0    ( .R#?U+A[%X1] $  *(G   3
M  "  ;EH 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !, $P RQ0  -YJ
$ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>106</ContextCount>
  <ElementCount>408</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>46</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - DESCRIPTION OF BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/DESCRIPTIONOFBUSINESS</Role>
      <ShortName>DESCRIPTION OF BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2102102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2105103 - Disclosure - CHANGE IN ACCOUNTING POLICY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/CHANGEINACCOUNTINGPOLICY</Role>
      <ShortName>CHANGE IN ACCOUNTING POLICY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2106104 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/RECENTACCOUNTINGPRONOUNCEMENTS</Role>
      <ShortName>RECENT ACCOUNTING PRONOUNCEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2107105 - Disclosure - DISPOSITION OF THE CORE BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESS</Role>
      <ShortName>DISPOSITION OF THE CORE BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2109106 - Disclosure - INTEREST IN JOINT VENTURE INVESTMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENT</Role>
      <ShortName>INTEREST IN JOINT VENTURE INVESTMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2113107 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/INVENTORIES</Role>
      <ShortName>INVENTORIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2116108 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/PROPERTYANDEQUIPMENT</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2119109 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/LEASES</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2126110 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2129111 - Disclosure - PRODUCT WARRANTIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/PRODUCTWARRANTIES</Role>
      <ShortName>PRODUCT WARRANTIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2132112 - Disclosure - JOINT AND SEVERAL PAYROLL LIABILITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/JOINTANDSEVERALPAYROLLLIABILITY</Role>
      <ShortName>JOINT AND SEVERAL PAYROLL LIABILITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2134113 - Disclosure - EARNINGS (LOSS) PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/EARNINGSLOSSPERSHARE</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2137114 - Disclosure - FINANCIAL INSTRUMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/FINANCIALINSTRUMENTS</Role>
      <ShortName>FINANCIAL INSTRUMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2139115 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/INCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2146116 - Disclosure - RETIREMENT PLAN</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/RETIREMENTPLAN</Role>
      <ShortName>RETIREMENT PLAN</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2148117 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONS</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2150118 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2152119 - Disclosure - STOCK OPTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/STOCKOPTIONS</Role>
      <ShortName>STOCK OPTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2158120 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATION</Role>
      <ShortName>GEOGRAPHIC AND SEGMENT INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2203201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2310301 - Disclosure - INTEREST IN JOINT VENTURE INVESTMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTTables</Role>
      <ShortName>INTEREST IN JOINT VENTURE INVESTMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENT</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2314302 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/INVENTORIESTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/INVENTORIES</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2317303 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/PROPERTYANDEQUIPMENTTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/PROPERTYANDEQUIPMENT</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2320304 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/LEASESTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/LEASES</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2327305 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2330306 - Disclosure - PRODUCT WARRANTIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/PRODUCTWARRANTIESTables</Role>
      <ShortName>PRODUCT WARRANTIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/PRODUCTWARRANTIES</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2335307 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/EARNINGSLOSSPERSHARETables</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/EARNINGSLOSSPERSHARE</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2340308 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/INCOMETAXESTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/INCOMETAXES</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2353309 - Disclosure - STOCK OPTIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/STOCKOPTIONSTables</Role>
      <ShortName>STOCK OPTIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/STOCKOPTIONS</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2359310 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONTables</Role>
      <ShortName>GEOGRAPHIC AND SEGMENT INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATION</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2404401 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2408402 - Disclosure - DISPOSITION OF THE CORE BUSINESS - (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESSDetails</Role>
      <ShortName>DISPOSITION OF THE CORE BUSINESS - (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESS</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2411403 - Disclosure - INTEREST IN JOINT VENTURE INVESTMENT - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails</Role>
      <ShortName>INTEREST IN JOINT VENTURE INVESTMENT - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2412404 - Disclosure - INTEREST IN JOINT VENTURE INVESTMENT - Changes in Ownership Interest (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTChangesinOwnershipInterestDetails</Role>
      <ShortName>INTEREST IN JOINT VENTURE INVESTMENT - Changes in Ownership Interest (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2415405 - Disclosure - INVENTORIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/INVENTORIESDetails</Role>
      <ShortName>INVENTORIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/INVENTORIESTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2418406 - Disclosure - PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2421407 - Disclosure - LEASES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/LEASESNarrativeDetails</Role>
      <ShortName>LEASES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2422408 - Disclosure - LEASES - Lease Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/LEASESLeaseCostDetails</Role>
      <ShortName>LEASES - Lease Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2423409 - Disclosure - LEASES - Cash and Non-Cash Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/LEASESCashandNonCashInformationDetails</Role>
      <ShortName>LEASES - Cash and Non-Cash Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2424410 - Disclosure - LEASES - Lease Terms and Discount Rates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/LEASESLeaseTermsandDiscountRatesDetails</Role>
      <ShortName>LEASES - Lease Terms and Discount Rates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2425411 - Disclosure - LEASES - Maturities of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails</Role>
      <ShortName>LEASES - Maturities of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2428412 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2431413 - Disclosure - PRODUCT WARRANTIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/PRODUCTWARRANTIESDetails</Role>
      <ShortName>PRODUCT WARRANTIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/PRODUCTWARRANTIESTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2433414 - Disclosure - JOINT AND SEVERAL PAYROLL LIABILITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/JOINTANDSEVERALPAYROLLLIABILITYDetails</Role>
      <ShortName>JOINT AND SEVERAL PAYROLL LIABILITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/JOINTANDSEVERALPAYROLLLIABILITY</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2436415 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/EARNINGSLOSSPERSHARETables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2438416 - Disclosure - FINANCIAL INSTRUMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/FINANCIALINSTRUMENTSDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/FINANCIALINSTRUMENTS</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2441417 - Disclosure - INCOME TAXES - Components of Provision For Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails</Role>
      <ShortName>INCOME TAXES - Components of Provision For Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2442418 - Disclosure - INCOME TAXES - Reconciliation of Statutory Federal Income Tax Rate to Effective Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/INCOMETAXESReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails</Role>
      <ShortName>INCOME TAXES - Reconciliation of Statutory Federal Income Tax Rate to Effective Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2443419 - Disclosure - INCOME TAXES - Deferred Tax Assets (Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails</Role>
      <ShortName>INCOME TAXES - Deferred Tax Assets (Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2444420 - Disclosure - INCOME TAXES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/INCOMETAXESNarrativeDetails</Role>
      <ShortName>INCOME TAXES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2445421 - Disclosure - INCOME TAXES - Unrecognized Tax Benefits Roll-Forward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/INCOMETAXESUnrecognizedTaxBenefitsRollForwardDetails</Role>
      <ShortName>INCOME TAXES - Unrecognized Tax Benefits Roll-Forward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2447422 - Disclosure - RETIREMENT PLAN - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/RETIREMENTPLANNarrativeDetails</Role>
      <ShortName>RETIREMENT PLAN - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2449423 - Disclosure - RELATED PARTY TRANSACTIONS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2451424 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2454425 - Disclosure - STOCK OPTIONS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails</Role>
      <ShortName>STOCK OPTIONS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2455426 - Disclosure - STOCK OPTIONS - Summary of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/STOCKOPTIONSSummaryofStockOptionsDetails</Role>
      <ShortName>STOCK OPTIONS - Summary of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2456427 - Disclosure - STOCK OPTIONS - Summary of Nonvested Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/STOCKOPTIONSSummaryofNonvestedStockOptionsDetails</Role>
      <ShortName>STOCK OPTIONS - Summary of Nonvested Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2457428 - Disclosure - STOCK OPTIONS STOCK OPTIONS - Fair Value Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/STOCKOPTIONSSTOCKOPTIONSFairValueAssumptionsDetails</Role>
      <ShortName>STOCK OPTIONS STOCK OPTIONS - Fair Value Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2460429 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails</Role>
      <ShortName>GEOGRAPHIC AND SEGMENT INFORMATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2461430 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Reportable Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails</Role>
      <ShortName>GEOGRAPHIC AND SEGMENT INFORMATION - Reportable Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="apyx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2462431 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Geographic (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails</Role>
      <ShortName>GEOGRAPHIC AND SEGMENT INFORMATION - Geographic (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="apyx-20201231.htm">apyx-20201231.htm</File>
    <File>a2020q410-qexhibit311.htm</File>
    <File>a2020q410-qexhibit312.htm</File>
    <File>a2020q410-qexhibit321.htm</File>
    <File>a2020q410-qexhibit322.htm</File>
    <File>apyx-20201231.xsd</File>
    <File>apyx-20201231_cal.xml</File>
    <File>apyx-20201231_def.xml</File>
    <File>apyx-20201231_lab.xml</File>
    <File>apyx-20201231_pre.xml</File>
    <File>rsmconsent.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>apyx-20201231_g1.jpg</File>
    <File>apyx-20201231_g2.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>89
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "apyx-20201231.htm": {
   "axisCustom": 1,
   "axisStandard": 18,
   "contextCount": 106,
   "dts": {
    "calculationLink": {
     "local": [
      "apyx-20201231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "apyx-20201231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "apyx-20201231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "apyx-20201231_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "apyx-20201231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "apyx-20201231.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 505,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 1,
    "http://xbrl.sec.gov/dei/2020-01-31": 4,
    "total": 5
   },
   "keyCustom": 39,
   "keyStandard": 369,
   "memberCustom": 20,
   "memberStandard": 25,
   "nsprefix": "apyx",
   "nsuri": "http://apyxmedical.com/20201231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://apyxmedical.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106104 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS",
     "role": "http://apyxmedical.com/role/RECENTACCOUNTINGPRONOUNCEMENTS",
     "shortName": "RECENT ACCOUNTING PRONOUNCEMENTS",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107105 - Disclosure - DISPOSITION OF THE CORE BUSINESS",
     "role": "http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESS",
     "shortName": "DISPOSITION OF THE CORE BUSINESS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109106 - Disclosure - INTEREST IN JOINT VENTURE INVESTMENT",
     "role": "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENT",
     "shortName": "INTEREST IN JOINT VENTURE INVESTMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113107 - Disclosure - INVENTORIES",
     "role": "http://apyxmedical.com/role/INVENTORIES",
     "shortName": "INVENTORIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116108 - Disclosure - PROPERTY AND EQUIPMENT",
     "role": "http://apyxmedical.com/role/PROPERTYANDEQUIPMENT",
     "shortName": "PROPERTY AND EQUIPMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119109 - Disclosure - LEASES",
     "role": "http://apyxmedical.com/role/LEASES",
     "shortName": "LEASES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126110 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
     "role": "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProductWarrantyDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129111 - Disclosure - PRODUCT WARRANTIES",
     "role": "http://apyxmedical.com/role/PRODUCTWARRANTIES",
     "shortName": "PRODUCT WARRANTIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProductWarrantyDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "apyx:JointandSeveralPayrollLiabilityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132112 - Disclosure - JOINT AND SEVERAL PAYROLL LIABILITY",
     "role": "http://apyxmedical.com/role/JOINTANDSEVERALPAYROLLLIABILITY",
     "shortName": "JOINT AND SEVERAL PAYROLL LIABILITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "apyx:JointandSeveralPayrollLiabilityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2134113 - Disclosure - EARNINGS (LOSS) PER SHARE",
     "role": "http://apyxmedical.com/role/EARNINGSLOSSPERSHARE",
     "shortName": "EARNINGS (LOSS) PER SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "i96df8138377f4df5b064ec7bcc292732_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "i96df8138377f4df5b064ec7bcc292732_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2137114 - Disclosure - FINANCIAL INSTRUMENTS",
     "role": "http://apyxmedical.com/role/FINANCIALINSTRUMENTS",
     "shortName": "FINANCIAL INSTRUMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2139115 - Disclosure - INCOME TAXES",
     "role": "http://apyxmedical.com/role/INCOMETAXES",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2146116 - Disclosure - RETIREMENT PLAN",
     "role": "http://apyxmedical.com/role/RETIREMENTPLAN",
     "shortName": "RETIREMENT PLAN",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2148117 - Disclosure - RELATED PARTY TRANSACTIONS",
     "role": "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2150118 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2152119 - Disclosure - STOCK OPTIONS",
     "role": "http://apyxmedical.com/role/STOCKOPTIONS",
     "shortName": "STOCK OPTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2158120 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION",
     "role": "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATION",
     "shortName": "GEOGRAPHIC AND SEGMENT INFORMATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2203201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "apyx:NoncontrollingInterestTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2310301 - Disclosure - INTEREST IN JOINT VENTURE INVESTMENT (Tables)",
     "role": "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTTables",
     "shortName": "INTEREST IN JOINT VENTURE INVESTMENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "apyx:NoncontrollingInterestTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2314302 - Disclosure - INVENTORIES (Tables)",
     "role": "http://apyxmedical.com/role/INVENTORIESTables",
     "shortName": "INVENTORIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "i96df8138377f4df5b064ec7bcc292732_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "i96df8138377f4df5b064ec7bcc292732_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "apyx:ProvisionForObsolescenceInventory",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317303 - Disclosure - PROPERTY AND EQUIPMENT (Tables)",
     "role": "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTTables",
     "shortName": "PROPERTY AND EQUIPMENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2320304 - Disclosure - LEASES (Tables)",
     "role": "http://apyxmedical.com/role/LEASESTables",
     "shortName": "LEASES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "apyx:AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2327305 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)",
     "role": "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "apyx:AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2330306 - Disclosure - PRODUCT WARRANTIES (Tables)",
     "role": "http://apyxmedical.com/role/PRODUCTWARRANTIESTables",
     "shortName": "PRODUCT WARRANTIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2335307 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)",
     "role": "http://apyxmedical.com/role/EARNINGSLOSSPERSHARETables",
     "shortName": "EARNINGS (LOSS) PER SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2340308 - Disclosure - INCOME TAXES (Tables)",
     "role": "http://apyxmedical.com/role/INCOMETAXESTables",
     "shortName": "INCOME TAXES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2353309 - Disclosure - STOCK OPTIONS (Tables)",
     "role": "http://apyxmedical.com/role/STOCKOPTIONSTables",
     "shortName": "STOCK OPTIONS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2359310 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION (Tables)",
     "role": "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONTables",
     "shortName": "GEOGRAPHIC AND SEGMENT INFORMATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "apyx:SalesDiscountBillingTermsLowerLimit",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404401 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)",
     "role": "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "apyx:SalesDiscountBillingTermsLowerLimit",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "i67552fb7889b46aebef782a87a2fa29c_D20180830-20180830",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromDivestitureOfBusinesses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408402 - Disclosure - DISPOSITION OF THE CORE BUSINESS - (Details)",
     "role": "http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESSDetails",
     "shortName": "DISPOSITION OF THE CORE BUSINESS - (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "i67552fb7889b46aebef782a87a2fa29c_D20180830-20180830",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromDivestitureOfBusinesses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "i96df8138377f4df5b064ec7bcc292732_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "apyx:NoncontrollingInterestRequiredCapitalContribution",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411403 - Disclosure - INTEREST IN JOINT VENTURE INVESTMENT - Narrative (Details)",
     "role": "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails",
     "shortName": "INTEREST IN JOINT VENTURE INVESTMENT - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "i9020d4fc4c274bc28ceac88534fe42fd_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412404 - Disclosure - INTEREST IN JOINT VENTURE INVESTMENT - Changes in Ownership Interest (Details)",
     "role": "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTChangesinOwnershipInterestDetails",
     "shortName": "INTEREST IN JOINT VENTURE INVESTMENT - Changes in Ownership Interest (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "apyx:NoncontrollingInterestTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "i8e0b17e778314c9c90e0d88fd0f6dd2b_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "i96df8138377f4df5b064ec7bcc292732_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415405 - Disclosure - INVENTORIES (Details)",
     "role": "http://apyxmedical.com/role/INVENTORIESDetails",
     "shortName": "INVENTORIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "i96df8138377f4df5b064ec7bcc292732_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "i96df8138377f4df5b064ec7bcc292732_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418406 - Disclosure - PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details)",
     "role": "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails",
     "shortName": "PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "i96df8138377f4df5b064ec7bcc292732_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "apyx:LesseeDiscountRateIncrementalBorrowingRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421407 - Disclosure - LEASES - Narrative (Details)",
     "role": "http://apyxmedical.com/role/LEASESNarrativeDetails",
     "shortName": "LEASES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "apyx:LesseeDiscountRateIncrementalBorrowingRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422408 - Disclosure - LEASES - Lease Cost (Details)",
     "role": "http://apyxmedical.com/role/LEASESLeaseCostDetails",
     "shortName": "LEASES - Lease Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423409 - Disclosure - LEASES - Cash and Non-Cash Information (Details)",
     "role": "http://apyxmedical.com/role/LEASESCashandNonCashInformationDetails",
     "shortName": "LEASES - Cash and Non-Cash Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "i96df8138377f4df5b064ec7bcc292732_I20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424410 - Disclosure - LEASES - Lease Terms and Discount Rates (Details)",
     "role": "http://apyxmedical.com/role/LEASESLeaseTermsandDiscountRatesDetails",
     "shortName": "LEASES - Lease Terms and Discount Rates (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "i96df8138377f4df5b064ec7bcc292732_I20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "i96df8138377f4df5b064ec7bcc292732_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425411 - Disclosure - LEASES - Maturities of Lease Liabilities (Details)",
     "role": "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails",
     "shortName": "LEASES - Maturities of Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "i96df8138377f4df5b064ec7bcc292732_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "apyx:AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "i96df8138377f4df5b064ec7bcc292732_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedSalariesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428412 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)",
     "role": "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "apyx:AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "i96df8138377f4df5b064ec7bcc292732_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedSalariesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "i96fdd56f4a934deb9be8b429dd443450_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY",
     "role": "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "i96fdd56f4a934deb9be8b429dd443450_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "i9020d4fc4c274bc28ceac88534fe42fd_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StandardProductWarrantyAccrual",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431413 - Disclosure - PRODUCT WARRANTIES (Details)",
     "role": "http://apyxmedical.com/role/PRODUCTWARRANTIESDetails",
     "shortName": "PRODUCT WARRANTIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "i00df6877cb2d4b75a1a4abee0d94d57f_I20181231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:StandardProductWarrantyAccrual",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "apyx:AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "i9020d4fc4c274bc28ceac88534fe42fd_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "apyx:JointAndSeveralPayrollLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433414 - Disclosure - JOINT AND SEVERAL PAYROLL LIABILITY (Details)",
     "role": "http://apyxmedical.com/role/JOINTANDSEVERALPAYROLLLIABILITYDetails",
     "shortName": "JOINT AND SEVERAL PAYROLL LIABILITY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "i8fe2ec49386740bc980e091b7b21fce3_D20190101-20191231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "apyx:JointAndSeveralPayrollExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436415 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)",
     "role": "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails",
     "shortName": "EARNINGS (LOSS) PER SHARE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "i12dd582368554dba97b8aa9e153c5b2b_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "i96df8138377f4df5b064ec7bcc292732_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438416 - Disclosure - FINANCIAL INSTRUMENTS (Details)",
     "role": "http://apyxmedical.com/role/FINANCIALINSTRUMENTSDetails",
     "shortName": "FINANCIAL INSTRUMENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "i96df8138377f4df5b064ec7bcc292732_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441417 - Disclosure - INCOME TAXES - Components of Provision For Income Taxes (Details)",
     "role": "http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails",
     "shortName": "INCOME TAXES - Components of Provision For Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442418 - Disclosure - INCOME TAXES - Reconciliation of Statutory Federal Income Tax Rate to Effective Rate (Details)",
     "role": "http://apyxmedical.com/role/INCOMETAXESReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails",
     "shortName": "INCOME TAXES - Reconciliation of Statutory Federal Income Tax Rate to Effective Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "i96df8138377f4df5b064ec7bcc292732_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443419 - Disclosure - INCOME TAXES - Deferred Tax Assets (Liabilities) (Details)",
     "role": "http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails",
     "shortName": "INCOME TAXES - Deferred Tax Assets (Liabilities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "i96df8138377f4df5b064ec7bcc292732_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "apyx:CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444420 - Disclosure - INCOME TAXES - Narrative (Details)",
     "role": "http://apyxmedical.com/role/INCOMETAXESNarrativeDetails",
     "shortName": "INCOME TAXES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "apyx:CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "i9020d4fc4c274bc28ceac88534fe42fd_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445421 - Disclosure - INCOME TAXES - Unrecognized Tax Benefits Roll-Forward (Details)",
     "role": "http://apyxmedical.com/role/INCOMETAXESUnrecognizedTaxBenefitsRollForwardDetails",
     "shortName": "INCOME TAXES - Unrecognized Tax Benefits Roll-Forward (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "apyx:DefinedContributionPlanEmployersMatchingContributionVestingPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447422 - Disclosure - RETIREMENT PLAN - Narrative (Details)",
     "role": "http://apyxmedical.com/role/RETIREMENTPLANNarrativeDetails",
     "shortName": "RETIREMENT PLAN - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "apyx:DefinedContributionPlanEmployersMatchingContributionVestingPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "i9020d4fc4c274bc28ceac88534fe42fd_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NotesPayableRelatedPartiesNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449423 - Disclosure - RELATED PARTY TRANSACTIONS - Narrative (Details)",
     "role": "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails",
     "shortName": "RELATED PARTY TRANSACTIONS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "i9020d4fc4c274bc28ceac88534fe42fd_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NotesPayableRelatedPartiesNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "i96df8138377f4df5b064ec7bcc292732_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PurchaseObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451424 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "role": "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "i96df8138377f4df5b064ec7bcc292732_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PurchaseObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454425 - Disclosure - STOCK OPTIONS - Narrative (Details)",
     "role": "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails",
     "shortName": "STOCK OPTIONS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "i9020d4fc4c274bc28ceac88534fe42fd_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455426 - Disclosure - STOCK OPTIONS - Summary of Stock Options (Details)",
     "role": "http://apyxmedical.com/role/STOCKOPTIONSSummaryofStockOptionsDetails",
     "shortName": "STOCK OPTIONS - Summary of Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "i00df6877cb2d4b75a1a4abee0d94d57f_I20181231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "i9020d4fc4c274bc28ceac88534fe42fd_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456427 - Disclosure - STOCK OPTIONS - Summary of Nonvested Stock Options (Details)",
     "role": "http://apyxmedical.com/role/STOCKOPTIONSSummaryofNonvestedStockOptionsDetails",
     "shortName": "STOCK OPTIONS - Summary of Nonvested Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2457428 - Disclosure - STOCK OPTIONS STOCK OPTIONS - Fair Value Assumptions (Details)",
     "role": "http://apyxmedical.com/role/STOCKOPTIONSSTOCKOPTIONSFairValueAssumptionsDetails",
     "shortName": "STOCK OPTIONS STOCK OPTIONS - Fair Value Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2460429 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Narrative (Details)",
     "role": "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails",
     "shortName": "GEOGRAPHIC AND SEGMENT INFORMATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2461430 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Reportable Segment (Details)",
     "role": "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails",
     "shortName": "GEOGRAPHIC AND SEGMENT INFORMATION - Reportable Segment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "i594539d6cfd54e88904eebbf46eef99a_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2462431 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Geographic (Details)",
     "role": "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails",
     "shortName": "GEOGRAPHIC AND SEGMENT INFORMATION - Geographic (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "i661eca8a002a4cb2af895f3f5c9a5ec2_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - DESCRIPTION OF BUSINESS",
     "role": "http://apyxmedical.com/role/DESCRIPTIONOFBUSINESS",
     "shortName": "DESCRIPTION OF BUSINESS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountingChangesAndErrorCorrectionsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2105103 - Disclosure - CHANGE IN ACCOUNTING POLICY",
     "role": "http://apyxmedical.com/role/CHANGEINACCOUNTINGPOLICY",
     "shortName": "CHANGE IN ACCOUNTING POLICY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20201231.htm",
      "contextRef": "id55f6de3007948b69061635a4640b62b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountingChangesAndErrorCorrectionsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 46,
   "tag": {
    "apyx_A2001ExecutiveandEmployeeStockOptionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2001 Executive and Employee Stock Option Plan [Member]",
        "label": "2001 Executive and Employee Stock Option Plan [Member]",
        "terseLabel": "2001 Executive and Employee Stock Option Plan"
       }
      }
     },
     "localname": "A2001ExecutiveandEmployeeStockOptionPlanMember",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_A2003ExecutiveandEmployeeStockOptionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2003 Executive and Employee Stock Option Plan [Member]",
        "label": "2003 Executive and Employee Stock Option Plan [Member]",
        "terseLabel": "2003 Executive and Employee Stock Option Plan"
       }
      }
     },
     "localname": "A2003ExecutiveandEmployeeStockOptionPlanMember",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_A2017ExecutiveandEmployeeStockOptionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2017 Executive and Employee Stock Option Plan [Member]",
        "label": "2017 Executive and Employee Stock Option Plan [Member]",
        "terseLabel": "2017 Executive and Employee Stock Option Plan"
       }
      }
     },
     "localname": "A2017ExecutiveandEmployeeStockOptionPlanMember",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_A2019ShareIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2019 Share Incentive Plan [Member]",
        "label": "2019 Share Incentive Plan [Member]",
        "terseLabel": "2019 Share Incentive Plan"
       }
      }
     },
     "localname": "A2019ShareIncentivePlanMember",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_AccessoriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accessories [Member]",
        "label": "Accessories [Member]",
        "terseLabel": "Accessories"
       }
      }
     },
     "localname": "AccessoriesMember",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Expenses And Other Current Liabilities",
        "label": "Accrued Expenses And Other Current Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "apyx_AdvancedEnergyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advanced Energy [Member]",
        "label": "Advanced Energy [Member]",
        "terseLabel": "Advanced Energy"
       }
      }
     },
     "localname": "AdvancedEnergyMember",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_ApyxSYMedicalDevicesNingboCoLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Apyx SY Medical Devices (Ningbo) Co., Ltd",
        "label": "Apyx SY Medical Devices (Ningbo) Co., Ltd [Member]",
        "terseLabel": "Apyx SY Medical Devices (Ningbo) Co., Ltd"
       }
      }
     },
     "localname": "ApyxSYMedicalDevicesNingboCoLtdMember",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_AssetPurchaseAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Purchase Agreement, Term",
        "label": "Asset Purchase Agreement, Term",
        "terseLabel": "Asset purchase agreement, term"
       }
      }
     },
     "localname": "AssetPurchaseAgreementTerm",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESSDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "apyx_CARESActEffectiveIncomeTaxRateReconciliationFederalNetOperatingLossCarryforwardsAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CARES Act, Effective Income Tax Rate Reconciliation, Federal Net Operating Loss Carryforwards, Amount",
        "label": "CARES Act, Effective Income Tax Rate Reconciliation, Federal Net Operating Loss Carryforwards, Amount",
        "terseLabel": "Net operating loss carryback"
       }
      }
     },
     "localname": "CARESActEffectiveIncomeTaxRateReconciliationFederalNetOperatingLossCarryforwardsAmount",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CARES Act, Income Tax Expense (Benefit), Release Of Valuation Allowance, Federal Net Operating Loss Carryforwards",
        "label": "CARES Act, Income Tax Expense (Benefit), Release Of Valuation Allowance, Federal Net Operating Loss Carryforwards",
        "negatedTerseLabel": "Income tax benefit"
       }
      }
     },
     "localname": "CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_CARESActIncomeTaxExpenseBenefitValuationAllowance": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "apyx_CurrentIncomeTaxExpenseBenefitAfterValuationAllowance",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CARES Act, Income Tax Expense (Benefit), Valuation Allowance",
        "label": "CARES Act, Income Tax Expense (Benefit), Valuation Allowance",
        "negatedTerseLabel": "Release of valuation allowance due to CARES Act"
       }
      }
     },
     "localname": "CARESActIncomeTaxExpenseBenefitValuationAllowance",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_ChineseSupplierMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chinese Supplier",
        "label": "Chinese Supplier [Member]",
        "terseLabel": "Chinese Supplier"
       }
      }
     },
     "localname": "ChineseSupplierMember",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTChangesinOwnershipInterestDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_ComputerEquipmentandSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer Equipment and Software [Member]",
        "label": "Computer Equipment and Software [Member]",
        "terseLabel": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentandSoftwareMember",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails",
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_CurrentIncomeTaxExpenseBenefitAfterValuationAllowance": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current Income Tax Expense (Benefit), After Valuation Allowance",
        "label": "Current Income Tax Expense (Benefit), After Valuation Allowance",
        "totalLabel": "Current income tax expense (benefit), after valuation allowance"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitAfterValuationAllowance",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_DefinedContributionPlanEmployersMatchingContributionVestingPercentageAfterThreeYears": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Contribution Plan, Employers Matching Contribution, Vesting Percentage After Three Years",
        "label": "Defined Contribution Plan, Employers Matching Contribution, Vesting Percentage After Three Years",
        "terseLabel": "Defined contribution plan, vesting percentage after 3 years"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployersMatchingContributionVestingPercentageAfterThreeYears",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/RETIREMENTPLANNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "apyx_DefinedContributionPlanEmployersMatchingContributionVestingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Contribution Plan, Employers Matching Contribution, Vesting Period",
        "label": "Defined Contribution Plan, Employers Matching Contribution, Vesting Period",
        "terseLabel": "Defined contribution plan, vesting period"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployersMatchingContributionVestingPeriod",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/RETIREMENTPLANNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "apyx_EffectiveIncomeTaxRateReconciliationCARESActNetOperatingLossCarryforwardsPercent": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/INCOMETAXESReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateReconciliationDeductions",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, CARES Act, Net Operating Loss Carryforwards, Percent",
        "label": "Effective Income Tax Rate Reconciliation, CARES Act, Net Operating Loss Carryforwards, Percent",
        "terseLabel": "NOL carryback from CARES Act"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationCARESActNetOperatingLossCarryforwardsPercent",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Electro Surgical Disposables And Accessories, Cauteries And Other Products Supply Agreement [Member]",
        "label": "Electro Surgical Disposables And Accessories, Cauteries And Other Products Supply Agreement [Member]",
        "terseLabel": "Electro Surgical Disposables and Accessories, Cauteries and Other Products Supply Agreement"
       }
      }
     },
     "localname": "ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_FinanceLeaseCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Lease, Costs [Abstract]",
        "label": "Finance Lease, Costs [Abstract]",
        "terseLabel": "Finance"
       }
      }
     },
     "localname": "FinanceLeaseCostsAbstract",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/LEASESCashandNonCashInformationDetails",
      "http://apyxmedical.com/role/LEASESLeaseTermsandDiscountRatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "apyx_FinanceLeasePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Lease, Payments",
        "label": "Finance Lease, Payments",
        "terseLabel": "Cash paid for lease liabilities"
       }
      }
     },
     "localname": "FinanceLeasePayments",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/LEASESCashandNonCashInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_IncomeTaxExpenseBenefitValuationAllowance": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Expense (Benefit), Valuation Allowance",
        "label": "Income Tax Expense (Benefit), Valuation Allowance",
        "negatedTerseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitValuationAllowance",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_InventoryWriteDownReversals": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory Write Down Reversals",
        "label": "Inventory Write Down Reversals",
        "terseLabel": "Inventory write down reversals"
       }
      }
     },
     "localname": "InventoryWriteDownReversals",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/INVENTORIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_JointAndSeveralPayrollExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Joint And Several Payroll Expense",
        "label": "Joint And Several Payroll Expense",
        "terseLabel": "Joint and several payroll expense"
       }
      }
     },
     "localname": "JointAndSeveralPayrollExpense",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/JOINTANDSEVERALPAYROLLLIABILITYDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_JointAndSeveralPayrollLiability": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Joint And Several Payroll Liability",
        "label": "Joint And Several Payroll Liability",
        "terseLabel": "Joint and several payroll liability"
       }
      }
     },
     "localname": "JointAndSeveralPayrollLiability",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails",
      "http://apyxmedical.com/role/JOINTANDSEVERALPAYROLLLIABILITYDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_JointandSeveralPayrollLiabilityTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Joint and Several Payroll Liability [Text Block]",
        "label": "Joint and Several Payroll Liability [Text Block]",
        "terseLabel": "JOINT AND SEVERAL PAYROLL LIABILITY"
       }
      }
     },
     "localname": "JointandSeveralPayrollLiabilityTextBlock",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/JOINTANDSEVERALPAYROLLLIABILITY"
     ],
     "xbrltype": "textBlockItemType"
    },
    "apyx_LargestCustomerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Largest Customer [Member]",
        "label": "Largest Customer [Member]",
        "terseLabel": "Largest Customer"
       }
      }
     },
     "localname": "LargestCustomerMember",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_LeaseArrangementsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Arrangements [Axis]",
        "label": "Lease Arrangements [Axis]",
        "terseLabel": "Lease Arrangements [Axis]"
       }
      }
     },
     "localname": "LeaseArrangementsAxis",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/LEASESCashandNonCashInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "apyx_LeaseArrangementsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Lease Arrangements [Axis]",
        "label": "Lease Arrangements [Domain]",
        "terseLabel": "Lease Arrangements [Domain]"
       }
      }
     },
     "localname": "LeaseArrangementsDomain",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/LEASESCashandNonCashInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_LeaseExecutionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Execution [Member]",
        "label": "Lease Execution [Member]",
        "terseLabel": "Lease Execution"
       }
      }
     },
     "localname": "LeaseExecutionMember",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/LEASESCashandNonCashInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_LeaseRemeasurementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Remeasurement [Member]",
        "label": "Lease Remeasurement [Member]",
        "terseLabel": "Lease Remeasurement"
       }
      }
     },
     "localname": "LeaseRemeasurementMember",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/LEASESCashandNonCashInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_LesseeDiscountRateIncrementalBorrowingRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Discount Rate, Incremental Borrowing Rate",
        "label": "Lessee, Discount Rate, Incremental Borrowing Rate",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "LesseeDiscountRateIncrementalBorrowingRate",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "apyx_LossContingencyAccrualTotalAccruedToDate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency Accrual, Total Accrued To Date",
        "label": "Loss Contingency Accrual, Total Accrued To Date",
        "terseLabel": "Total loss contingency accrued"
       }
      }
     },
     "localname": "LossContingencyAccrualTotalAccruedToDate",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_MountingFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mounting Fixtures [Member]",
        "label": "Mounting Fixtures [Member]",
        "terseLabel": "Mounting Fixtures"
       }
      }
     },
     "localname": "MountingFixturesMember",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net property, plant and equipment of continuing and discontinued operations",
        "label": "Net property, plant and equipment of continuing and discontinued operations",
        "totalLabel": "Property and equipment in service"
       }
      }
     },
     "localname": "Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_NonCashTransferOfOtherAssetsToFixedAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Cash, Transfer Of Other Assets To Fixed Assets",
        "label": "Non Cash, Transfer Of Other Assets To Fixed Assets",
        "terseLabel": "Transfer of other assets to fixed assets"
       }
      }
     },
     "localname": "NonCashTransferOfOtherAssetsToFixedAssets",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_NonCashTransfersOfInventoryToFromFixedAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Cash, Transfers Of Inventory To (From) Fixed Assets",
        "label": "Non Cash, Transfers Of Inventory To (From) Fixed Assets",
        "terseLabel": "Transfer of inventory to fixed assets"
       }
      }
     },
     "localname": "NonCashTransfersOfInventoryToFromFixedAssets",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_NoncontrollingInterestRequiredCapitalContribution": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling Interest, Required Capital Contribution",
        "label": "Noncontrolling Interest, Required Capital Contribution",
        "terseLabel": "Required capital contribution"
       }
      }
     },
     "localname": "NoncontrollingInterestRequiredCapitalContribution",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_NoncontrollingInterestTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling Interest Table Text Block",
        "label": "Noncontrolling Interest [Table Text Block]",
        "terseLabel": "Schedule of Noncontrolling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestTableTextBlock",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "apyx_OEMMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OEM [Member]",
        "terseLabel": "OEM"
       }
      }
     },
     "localname": "OEMMember",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_OperatingLeaseCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Costs [Abstract]",
        "label": "Operating Lease, Costs [Abstract]",
        "terseLabel": "Operating"
       }
      }
     },
     "localname": "OperatingLeaseCostsAbstract",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/LEASESCashandNonCashInformationDetails",
      "http://apyxmedical.com/role/LEASESLeaseTermsandDiscountRatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "apyx_OtherAccruedExpensesAndLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Accrued Expenses And Liabilities, Current",
        "label": "Other Accrued Expenses And Liabilities, Current",
        "terseLabel": "Other accrued expenses and current liabilities"
       }
      }
     },
     "localname": "OtherAccruedExpensesAndLiabilitiesCurrent",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_PaymentsToAcquireInterestInJointVentureRemaining": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments To Acquire Interest In Joint Venture, Remaining",
        "label": "Payments To Acquire Interest In Joint Venture, Remaining",
        "terseLabel": "Remaining payments to acquire interest in joint venture"
       }
      }
     },
     "localname": "PaymentsToAcquireInterestInJointVentureRemaining",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Stock Options Exercised And Warrants Exercised",
        "label": "Proceeds From Stock Options Exercised And Warrants Exercised",
        "terseLabel": "Proceeds from stock option exercises"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercisedAndWarrantsExercised",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_ProductWarranty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Warranty",
        "label": "Product Warranty",
        "terseLabel": "Product warranty"
       }
      }
     },
     "localname": "ProductWarranty",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "apyx_ProvisionForInventoryObsolescence": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provision For Inventory Obsolescence",
        "label": "Provision For Inventory Obsolescence",
        "terseLabel": "Provision for inventory obsolescence"
       }
      }
     },
     "localname": "ProvisionForInventoryObsolescence",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_ProvisionForObsolescenceInventory": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provision For Obsolescence, Inventory",
        "label": "Provision For Obsolescence, Inventory",
        "terseLabel": "Provision for obsolescence"
       }
      }
     },
     "localname": "ProvisionForObsolescenceInventory",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_RenuvionJPlasmaGeneratorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Renuvion/J-Plasma Generators [Member]",
        "label": "Renuvion/J-Plasma Generators [Member]",
        "terseLabel": "Renuvion/J-Plasma generators"
       }
      }
     },
     "localname": "RenuvionJPlasmaGeneratorsMember",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_RepaymentofFinanceLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayment of Finance Lease Liabilities",
        "label": "Repayment of Finance Lease Liabilities",
        "negatedTerseLabel": "Repayment of finance lease liabilities"
       }
      }
     },
     "localname": "RepaymentofFinanceLeaseLiabilities",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_SalesDiscountBillingTermsLowerLimit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Discount, Billing Terms, Lower Limit",
        "label": "Sales Discount, Billing Terms, Lower Limit",
        "terseLabel": "Credit terms, billing term, lower limit"
       }
      }
     },
     "localname": "SalesDiscountBillingTermsLowerLimit",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "apyx_SalesDiscountBillingTermsUpperLimit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Discount, Billing Terms, Upper Limit",
        "label": "Sales Discount, Billing Terms, Upper Limit",
        "terseLabel": "Credit terms, billing term, upper limit"
       }
      }
     },
     "localname": "SalesDiscountBillingTermsUpperLimit",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "apyx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedToDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Non-Option Equity Instruments, Granted To Date",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Non-Option Equity Instruments, Granted To Date",
        "terseLabel": "Grants to date (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedToDate",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "apyx_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Options, Grants In Period, Fair Value",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Options, Grants In Period, Fair Value",
        "terseLabel": "Intrinsic value of options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueClosingStockPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Options, Intrinsic Value, Closing Stock Price",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Options, Intrinsic Value, Closing Stock Price",
        "terseLabel": "Closing stock price for computation of intrinsic value (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueClosingStockPrice",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "apyx_SophiaBulgariaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sophia, Bulgaria [Member]",
        "label": "Sophia, Bulgaria [Member]",
        "terseLabel": "Sophia, Bulgaria"
       }
      }
     },
     "localname": "SophiaBulgariaMember",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_StockIssuedDuringPeriodSharesStockSwaps": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Stock Swaps",
        "label": "Stock Issued During Period, Shares, Stock Swaps",
        "terseLabel": "Shares issued in stock swaps (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockSwaps",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Stock Swaps Equity Instruments Received",
        "label": "Stock Issued During Period, Shares, Stock Swaps Equity Instruments Received",
        "terseLabel": "Shares received in stock swaps (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "apyx_StockSwapToAcquireOptionsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock swap to acquire options shares.",
        "label": "Stock swap to acquire options, Shares",
        "terseLabel": "Shares issued on net settlement of stock options (in shares)"
       }
      }
     },
     "localname": "StockSwapToAcquireOptionsShares",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "apyx_SymmetrySurgicalInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Symmetry Surgical Inc. [Member]",
        "label": "Symmetry Surgical Inc. [Member]",
        "terseLabel": "Symmetry Surgical Inc."
       }
      }
     },
     "localname": "SymmetrySurgicalInc.Member",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_TotalRevenuePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total Revenue, Percent",
        "label": "Total Revenue, Percent",
        "terseLabel": "International sales"
       }
      }
     },
     "localname": "TotalRevenuePercent",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "apyx_TwoThousandFifteenExecutiveAndEmployeeStockOptionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "2015 Executive and Employee Stock Option Plan [Member]",
        "terseLabel": "2015 Executive and Employee Stock Option Plan"
       }
      }
     },
     "localname": "TwoThousandFifteenExecutiveAndEmployeeStockOptionPlanMember",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_TwoThousandTwelveShareIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "2012 Share Incentive Plan [Member]",
        "terseLabel": "2012 Share Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandTwelveShareIncentivePlanMember",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_UncertainTaxPositionsLiability": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Uncertain Tax Positions Liability",
        "label": "Uncertain Tax Positions Liability",
        "terseLabel": "Uncertain tax positions"
       }
      }
     },
     "localname": "UncertainTaxPositionsLiability",
     "nsuri": "http://apyxmedical.com/20201231",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "Domestic"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r517",
      "r518",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r517",
      "r518",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r154",
      "r167",
      "r168",
      "r169",
      "r170",
      "r172",
      "r174",
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r154",
      "r167",
      "r168",
      "r169",
      "r170",
      "r172",
      "r174",
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r185",
      "r262",
      "r266",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r282",
      "r283",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r478",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails",
      "http://apyxmedical.com/role/STOCKOPTIONSSTOCKOPTIONSFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r282",
      "r283",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r478",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails",
      "http://apyxmedical.com/role/STOCKOPTIONSSTOCKOPTIONSFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r185",
      "r262",
      "r266",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTChangesinOwnershipInterestDetails",
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTChangesinOwnershipInterestDetails",
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r268",
      "r282",
      "r283",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r478",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails",
      "http://apyxmedical.com/role/STOCKOPTIONSSTOCKOPTIONSFairValueAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r268",
      "r282",
      "r283",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r478",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails",
      "http://apyxmedical.com/role/STOCKOPTIONSSTOCKOPTIONSFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAdjustmentMember": {
     "auth_ref": [
      "r110",
      "r111",
      "r112",
      "r113",
      "r114",
      "r115",
      "r118",
      "r119",
      "r120",
      "r122",
      "r123",
      "r125",
      "r126",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period, Adjustment [Member]",
        "verboseLabel": "Adjustments"
       }
      }
     },
     "localname": "RestatementAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/JOINTANDSEVERALPAYROLLLIABILITYDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [
      "r110",
      "r111",
      "r112",
      "r113",
      "r114",
      "r115",
      "r118",
      "r119",
      "r120",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r134",
      "r205",
      "r206",
      "r319",
      "r357",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]",
        "terseLabel": "Revision of Prior Period [Axis]"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/JOINTANDSEVERALPAYROLLLIABILITYDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [
      "r110",
      "r111",
      "r112",
      "r113",
      "r114",
      "r115",
      "r118",
      "r119",
      "r120",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r134",
      "r205",
      "r206",
      "r319",
      "r357",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Domain]",
        "terseLabel": "Revision of Prior Period [Domain]"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/JOINTANDSEVERALPAYROLLLIABILITYDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r182",
      "r183",
      "r262",
      "r265",
      "r479",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails",
      "http://apyxmedical.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r182",
      "r183",
      "r262",
      "r265",
      "r479",
      "r500",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails",
      "http://apyxmedical.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Changes and Error Corrections [Abstract]",
        "terseLabel": "Accounting Changes and Error Corrections [Abstract]"
       }
      }
     },
     "localname": "AccountingChangesAndErrorCorrectionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingChangesAndErrorCorrectionsTextBlock": {
     "auth_ref": [
      "r124",
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting accounting changes and error corrections. It includes the conveyance of information necessary for a user of the Company's financial information to understand all aspects and required disclosure information concerning all changes and error corrections reported in the Company's financial statements for the period.",
        "label": "Accounting Changes and Error Corrections [Text Block]",
        "terseLabel": "CHANGE IN ACCOUNTING POLICY"
       }
      }
     },
     "localname": "AccountingChangesAndErrorCorrectionsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CHANGEINACCOUNTINGPOLICY"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "Topic 842"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/LEASESCashandNonCashInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r19",
      "r33",
      "r187",
      "r188"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Trade accounts receivable, net of allowance of $300 and $273"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedBonusesCurrent": {
     "auth_ref": [
      "r23",
      "r24",
      "r53"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Bonuses, Current",
        "terseLabel": "Accrued bonus"
       }
      }
     },
     "localname": "AccruedBonusesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedInsuranceCurrent": {
     "auth_ref": [
      "r23",
      "r24",
      "r53"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Insurance, Current",
        "terseLabel": "Accrued product liability claim insurance deductibles"
       }
      }
     },
     "localname": "AccruedInsuranceCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails",
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r23",
      "r24",
      "r53"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalariesCurrent": {
     "auth_ref": [
      "r23",
      "r24",
      "r53"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Salaries, Current",
        "terseLabel": "Accrued payroll"
       }
      }
     },
     "localname": "AccruedSalariesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalesCommissionCurrent": {
     "auth_ref": [
      "r23",
      "r24",
      "r53"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Sales Commission, Current",
        "terseLabel": "Accrued commissions"
       }
      }
     },
     "localname": "AccruedSalesCommissionCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r47",
      "r221"
     ],
     "calculation": {
      "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r34",
      "r319"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r110",
      "r111",
      "r113",
      "r316",
      "r317",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r114",
      "r115",
      "r116",
      "r117",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r354",
      "r355",
      "r356",
      "r357",
      "r436",
      "r437",
      "r438",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Accounting Standards Update [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/LEASESCashandNonCashInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r285",
      "r287",
      "r322",
      "r323"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Advertising Costs"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r326"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising expense"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r287",
      "r309",
      "r321"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r193",
      "r207",
      "r208",
      "r210"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "terseLabel": "Allowances for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Options (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r103",
      "r162",
      "r169",
      "r176",
      "r200",
      "r373",
      "r381",
      "r391",
      "r453",
      "r466"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r21",
      "r22",
      "r66",
      "r103",
      "r200",
      "r373",
      "r381",
      "r391"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r288",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BuildingAndBuildingImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Building and Building Improvements [Member]",
        "terseLabel": "Building and improvements"
       }
      }
     },
     "localname": "BuildingAndBuildingImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails",
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r16",
      "r109",
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "DESCRIPTION OF BUSINESS"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/DESCRIPTIONOFBUSINESS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r44",
      "r495",
      "r496"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/FINANCIALINSTRUMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r17",
      "r44",
      "r96"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r26",
      "r97",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r89",
      "r96",
      "r99"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance",
        "periodStartLabel": "Cash and cash equivalents, beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r89",
      "r392"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Non cash operating and investing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CoVenturerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other venturer from the perspective of the entity in the corporate joint venture.",
        "label": "Co-venturer [Member]",
        "terseLabel": "Co-venturer"
       }
      }
     },
     "localname": "CoVenturerMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r57",
      "r235",
      "r459",
      "r471"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES (NOTE 18)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r232",
      "r233",
      "r234",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r110",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r32",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 75,000,000 shares authorized; 34,289,222 issued and outstanding as of December 31, 2020, and 34,312,527 issued and 34,169,952 outstanding as of December 31, 2019"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r143",
      "r144",
      "r185",
      "r389",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r143",
      "r144",
      "r185",
      "r389",
      "r390",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r143",
      "r144",
      "r185",
      "r389",
      "r390",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r143",
      "r144",
      "r185",
      "r389",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration receivable risk"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r143",
      "r144",
      "r185",
      "r389",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r101",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Consolidated Financial Statements"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r250",
      "r252",
      "r263"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "terseLabel": "Contract assets"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r250",
      "r251",
      "r263"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r250",
      "r251",
      "r263"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateJointVentureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporation owned and operated by a small group of ventures to accomplish a mutually beneficial venture or project.",
        "label": "Corporate Joint Venture [Member]",
        "terseLabel": "China joint venture"
       }
      }
     },
     "localname": "CorporateJointVentureMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTChangesinOwnershipInterestDetails",
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r167",
      "r168",
      "r169",
      "r170",
      "r172",
      "r178",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Corporate (Other)"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r79",
      "r435"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Other costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r104",
      "r350",
      "r360"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r106",
      "r350"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r104",
      "r350",
      "r360",
      "r362"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "apyx_CurrentIncomeTaxExpenseBenefitAfterValuationAllowance",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Current income tax expense (benefit)"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r104",
      "r350",
      "r360"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r142",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r104",
      "r351",
      "r360"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r94",
      "r104",
      "r351",
      "r360",
      "r361",
      "r362"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Deferred income tax expense (benefit)"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r29",
      "r30",
      "r341",
      "r454",
      "r465"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r104",
      "r351",
      "r360"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r342"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r344"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r344"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets, net of valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r348",
      "r349"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r348",
      "r349"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r343"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r348",
      "r349"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r348",
      "r349"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Property and equipment"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Company matching contributions"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/RETIREMENTPLANNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Defined contribution plan, percent of employees' gross pay"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/RETIREMENTPLANNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Defined contribution plan, employer matching contribution"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/RETIREMENTPLANNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r94",
      "r219"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r94",
      "r157"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "STOCK OPTIONS"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]",
        "terseLabel": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": {
     "auth_ref": [
      "r9",
      "r14"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": {
     "auth_ref": [
      "r9"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Operating Expense",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": {
     "auth_ref": [
      "r9"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Operating Income (Loss)",
        "terseLabel": "Net other income"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r0",
      "r1",
      "r10",
      "r224"
     ],
     "calculation": {
      "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment",
        "verboseLabel": "Construction in progress"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": {
     "auth_ref": [
      "r9",
      "r14"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Revenue",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r15",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "DISPOSITION OF THE CORE BUSINESS"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r49",
      "r107",
      "r423"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Related Parties, Current",
        "terseLabel": "Related party note payable"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r107",
      "r423",
      "r458",
      "r472"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.",
        "label": "Due to Related Parties",
        "verboseLabel": "Due to supplier"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Loss per share"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "netLabel": "Basic and Diluted (in dollars per share)",
        "verboseLabel": "Loss per share - basic and diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted, Other Disclosures [Abstract]",
        "terseLabel": "Anti-dilutive instruments excluded from diluted loss per common share:"
       }
      }
     },
     "localname": "EarningsPerShareDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r101",
      "r131",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Income (Loss) Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share Reconciliation [Abstract]",
        "terseLabel": "Numerators:"
       }
      }
     },
     "localname": "EarningsPerShareReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r131",
      "r132",
      "r133",
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "EARNINGS (LOSS) PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHARE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r392"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rates on cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "terseLabel": "Reconciliation of the statutory federal income tax rate to our effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r332",
      "r363"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INCOMETAXESReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateReconciliationDeductions",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal tax provision"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r332",
      "r363"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INCOMETAXESReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateReconciliationDeductions",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationDeductions": {
     "auth_ref": [
      "r332",
      "r363"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INCOMETAXESReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations attributable to deduction. Includes, but is not limited to, dividend deduction, deduction for dividend paid to employee stock ownership plan (ESOP), Medicare prescription drug benefit subsidy deduction, and other deductions.",
        "label": "Effective Income Tax Rate Reconciliation, Deduction, Percent",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDeductions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r332",
      "r363"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INCOMETAXESReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateReconciliationDeductions",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r332",
      "r363"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INCOMETAXESReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateReconciliationDeductions",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State taxes (net of federal benefit)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized stock-based compensation cost, recognition period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r310"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r110",
      "r111",
      "r113",
      "r115",
      "r123",
      "r126",
      "r137",
      "r204",
      "r247",
      "r248",
      "r316",
      "r317",
      "r318",
      "r356",
      "r357",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r484",
      "r485",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Error Corrections and Prior Period Adjustments Restatement [Line Items]",
        "terseLabel": "Error Corrections and Prior Period Adjustments Restatement [Line Items]"
       }
      }
     },
     "localname": "ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/JOINTANDSEVERALPAYROLLLIABILITYDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r101",
      "r387",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r405",
      "r409",
      "r418"
     ],
     "calculation": {
      "http://apyxmedical.com/role/LEASESLeaseCostDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Interest on lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/LEASESLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Finance"
       }
      }
     },
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r404",
      "r417"
     ],
     "calculation": {
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "totalLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r404"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "negatedTerseLabel": "Less current portion of lease liabilities",
        "terseLabel": "Current portion of finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.",
        "label": "Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]",
        "terseLabel": "Maturity of Finance Lease Liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r404"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Long-term finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Payment, Due",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r417"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less imputed interest"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r403"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Finance lease right-of-use assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r405",
      "r409",
      "r418"
     ],
     "calculation": {
      "http://apyxmedical.com/role/LEASESLeaseCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Amortization of right-of-use assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/LEASESLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r415",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/LEASESLeaseTermsandDiscountRatesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r414",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/LEASESLeaseTermsandDiscountRatesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r101",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Transactions"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails",
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets": {
     "auth_ref": [
      "r94",
      "r218",
      "r223"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property",
        "negatedTerseLabel": "Loss on disposal of property and equipment"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnInvestments": {
     "auth_ref": [
      "r81",
      "r94",
      "r198"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) on investment.",
        "label": "Gain (Loss) on Investments",
        "negatedTerseLabel": "Realized and unrealized gains on short term investments"
       }
      }
     },
     "localname": "GainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r77",
      "r103",
      "r162",
      "r168",
      "r172",
      "r175",
      "r178",
      "r200",
      "r391"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r101",
      "r217",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Valuation of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r71",
      "r162",
      "r168",
      "r172",
      "r175",
      "r178",
      "r451",
      "r460",
      "r463",
      "r475"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss from operations before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Statement of Operations"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r1",
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r8",
      "r11",
      "r12",
      "r13",
      "r14",
      "r226",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r333",
      "r339",
      "r346",
      "r358",
      "r364",
      "r366",
      "r367",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r104",
      "r125",
      "r126",
      "r160",
      "r331",
      "r359",
      "r365",
      "r476"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      },
      "http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Income tax benefit",
        "terseLabel": "Income tax benefit",
        "totalLabel": "Total provision for income tax"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails",
      "http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r69",
      "r101",
      "r329",
      "r330",
      "r339",
      "r340",
      "r345",
      "r352",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r91",
      "r98"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesReceivable": {
     "auth_ref": [
      "r59",
      "r457",
      "r473"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.",
        "label": "Income Taxes Receivable, Current",
        "terseLabel": "Income tax receivables"
       }
      }
     },
     "localname": "IncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Trade receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.",
        "label": "Increase (Decrease) in Income Taxes Receivable",
        "negatedTerseLabel": "Income tax receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInIncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in current assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r70",
      "r156",
      "r400",
      "r401",
      "r462"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeOperating": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.",
        "label": "Interest Income, Operating",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeOperating",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r87",
      "r90",
      "r98"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INVENTORIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INVENTORIESDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INVENTORIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INVENTORIESDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "totalLabel": "Gross inventories"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INVENTORIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r18",
      "r64"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://apyxmedical.com/role/INVENTORIESDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories, net of provision for obsolescence of $388 and $392",
        "totalLabel": "Inventories, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://apyxmedical.com/role/INVENTORIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r25",
      "r65",
      "r101",
      "r136",
      "r211",
      "r213",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INVENTORIESDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INVENTORIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r64",
      "r108",
      "r214"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INVENTORIESDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "Inventory Valuation Reserves",
        "negatedTerseLabel": "Less: provision for obsolescence"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INVENTORIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INVENTORIESDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INVENTORIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r212"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Inventory write-down"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INVENTORIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r199",
      "r452",
      "r464",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "FINANCIAL INSTRUMENTS"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/FINANCIALINSTRUMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LandMember": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Part of earth's surface not covered by water.",
        "label": "Land [Member]",
        "terseLabel": "Land"
       }
      }
     },
     "localname": "LandMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r416",
      "r418"
     ],
     "calculation": {
      "http://apyxmedical.com/role/LEASESLeaseCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease costs"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/LEASESLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Lease Costs"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdsAndLeaseholdImprovementsMember": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets held by a lessee under a capital lease and any addition or improvement to assets held under a lease arrangement (including addition or improvement to assets held by lessee under an operating lease arrangement).",
        "label": "Leaseholds and Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdsAndLeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LegalCostsPolicyTextBlock": {
     "auth_ref": [
      "r100",
      "r101",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.",
        "label": "Legal Costs, Policy [Policy Text Block]",
        "terseLabel": "Litigation Contingencies"
       }
      }
     },
     "localname": "LegalCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.",
        "label": "Lessee, Finance Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeFinanceLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/LEASES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/LEASESCashandNonCashInformationDetails",
      "http://apyxmedical.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/LEASESCashandNonCashInformationDetails",
      "http://apyxmedical.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Maturities of Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r417"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/LEASES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r51",
      "r103",
      "r170",
      "r200",
      "r374",
      "r381",
      "r382",
      "r391"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r38",
      "r103",
      "r200",
      "r391",
      "r456",
      "r469"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r54",
      "r103",
      "r200",
      "r374",
      "r381",
      "r382",
      "r391"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationStatusAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Axis]",
        "terseLabel": "Litigation Status [Axis]"
       }
      }
     },
     "localname": "LitigationStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Domain]",
        "terseLabel": "Litigation Status [Domain]"
       }
      }
     },
     "localname": "LitigationStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r235"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Cost accrued"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment [Member]",
        "terseLabel": "Machinery and equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails",
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r20",
      "r52"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "US Treasury securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/FINANCIALINSTRUMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r60",
      "r103",
      "r200",
      "r391",
      "r455",
      "r468"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending interest in China JV",
        "periodStartLabel": "Beginning interest in China JV",
        "terseLabel": "Non-controlling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTChangesinOwnershipInterestDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDisclosureTextBlock": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.",
        "label": "Noncontrolling Interest Disclosure [Text Block]",
        "terseLabel": "INTEREST IN JOINT VENTURE INVESTMENT"
       }
      }
     },
     "localname": "MinorityInterestDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MinorityInterestLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Noncontrolling Interest [Line Items]",
        "terseLabel": "Noncontrolling Interest [Line Items]"
       }
      }
     },
     "localname": "MinorityInterestLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTChangesinOwnershipInterestDetails",
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.",
        "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners",
        "terseLabel": "Ownership interest"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTChangesinOwnershipInterestDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "terseLabel": "Ownership percentage"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MinorityInterestTable": {
     "auth_ref": [
      "r60",
      "r78",
      "r370",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of noncontrolling interest disclosure which includes the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.",
        "label": "Noncontrolling Interest [Table]",
        "terseLabel": "Noncontrolling Interest [Table]"
       }
      }
     },
     "localname": "MinorityInterestTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTChangesinOwnershipInterestDetails",
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MovementInMinorityInterestRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]",
        "terseLabel": "Stockholders' Equity Attributable to Noncontrolling Interest [Abstract]"
       }
      }
     },
     "localname": "MovementInMinorityInterestRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTChangesinOwnershipInterestDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MovementInStandardProductWarrantyAccrualRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Movement in Standard Product Warranty Accrual [Roll Forward]",
        "terseLabel": "Movement in Standard Product Warranty Accrual [Roll Forward]"
       }
      }
     },
     "localname": "MovementInStandardProductWarrantyAccrualRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/PRODUCTWARRANTIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r89",
      "r92",
      "r95"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r14",
      "r67",
      "r68",
      "r72",
      "r95",
      "r103",
      "r114",
      "r118",
      "r119",
      "r120",
      "r121",
      "r125",
      "r126",
      "r128",
      "r162",
      "r168",
      "r172",
      "r175",
      "r178",
      "r200",
      "r391",
      "r461",
      "r474"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss attributable to stockholders",
        "totalLabel": "Net loss attributable to stockholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r67",
      "r68",
      "r125",
      "r126",
      "r377",
      "r384"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss attributable to non-controlling interest",
        "verboseLabel": "Net loss attributable to Apyx"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTChangesinOwnershipInterestDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update and Change in Accounting Principle [Abstract]",
        "terseLabel": "Accounting Standards Update and Change in Accounting Principle [Abstract]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "International"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling Interest [Abstract]"
       }
      }
     },
     "localname": "NoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": {
     "auth_ref": [
      "r249",
      "r372",
      "r379"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Increase from Subsidiary Equity Issuance",
        "terseLabel": "Contributions from non-controlling interest",
        "verboseLabel": "Contributions"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTChangesinOwnershipInterestDetails",
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r110",
      "r111",
      "r113",
      "r248",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non-controlling interest equity"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NotesPayableRelatedPartiesNoncurrent": {
     "auth_ref": [
      "r55",
      "r107",
      "r423"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount for notes payable (written promise to pay), payable to related parties, which are due after one year (or one business cycle).",
        "label": "Notes Payable, Related Parties, Noncurrent",
        "terseLabel": "Note payable issued"
       }
      }
     },
     "localname": "NotesPayableRelatedPartiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total other costs and expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r162",
      "r168",
      "r172",
      "r175",
      "r178"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations",
        "verboseLabel": "Income (loss) from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r410",
      "r418"
     ],
     "calculation": {
      "http://apyxmedical.com/role/LEASESLeaseCostDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease costs"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/LEASESLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Operating"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r404"
     ],
     "calculation": {
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r404"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "negatedTerseLabel": "Less current portion of lease liabilities",
        "terseLabel": "Current portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r404"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r406",
      "r412"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/LEASESCashandNonCashInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r403"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r415",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/LEASESLeaseTermsandDiscountRatesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r414",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/LEASESLeaseTermsandDiscountRatesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r167",
      "r168",
      "r169",
      "r170",
      "r172",
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OptionOnSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of a security at a specified price during a specified period or at a specified date.",
        "label": "Option on Securities [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "OptionOnSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Commitments [Line Items]",
        "terseLabel": "Other Commitments [Line Items]"
       }
      }
     },
     "localname": "OtherCommitmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table]",
        "terseLabel": "Other Commitments [Table]"
       }
      }
     },
     "localname": "OtherCommitmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "totalLabel": "Total other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income (Expense), Net",
        "terseLabel": "Other income (loss), net"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Net, Current",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r197"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedTerseLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PendingLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.",
        "label": "Pending Litigation [Member]",
        "terseLabel": "Pending Litigation"
       }
      }
     },
     "localname": "PendingLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r268",
      "r269",
      "r270",
      "r271",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "RETIREMENT PLAN"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/RETIREMENTPLAN"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r288",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r21",
      "r42",
      "r43"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "auth_ref": [
      "r83"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.",
        "label": "Proceeds from Divestiture of Businesses",
        "terseLabel": "Proceeds from the disposition of Core business"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMinorityShareholders": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.",
        "label": "Proceeds from Noncontrolling Interests",
        "terseLabel": "Contributions from non-controlling interests"
       }
      }
     },
     "localname": "ProceedsFromMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductWarrantiesDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Warranties Disclosures [Abstract]",
        "terseLabel": "Product Warranties Disclosures [Abstract]"
       }
      }
     },
     "localname": "ProductWarrantiesDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ProductWarrantyAccrualClassifiedCurrent": {
     "auth_ref": [
      "r53",
      "r238",
      "r239"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Product Warranty Accrual, Current",
        "terseLabel": "Accrued product warranties"
       }
      }
     },
     "localname": "ProductWarrantyAccrualClassifiedCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductWarrantyDisclosureTextBlock": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for standard and extended product warranties and other product guarantee contracts, including a tabular reconciliation of the changes in the guarantor's aggregate product warranty liability for the reporting period.",
        "label": "Product Warranty Disclosure [Text Block]",
        "terseLabel": "PRODUCT WARRANTIES"
       }
      }
     },
     "localname": "ProductWarrantyDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/PRODUCTWARRANTIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProductWarrantyExpense": {
     "auth_ref": [
      "r93",
      "r242"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expense charged against earnings for the period pertaining to standard and extended warranties on the entity's goods and services granted to customers.",
        "label": "Product Warranty Expense",
        "terseLabel": "Provision for product warranties"
       }
      }
     },
     "localname": "ProductWarrantyExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfessionalFees": {
     "auth_ref": [
      "r497",
      "r498"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.",
        "label": "Professional Fees",
        "terseLabel": "Professional services"
       }
      }
     },
     "localname": "ProfessionalFees",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r14",
      "r67",
      "r68",
      "r88",
      "r103",
      "r114",
      "r125",
      "r126",
      "r162",
      "r168",
      "r172",
      "r175",
      "r178",
      "r200",
      "r371",
      "r376",
      "r378",
      "r384",
      "r385",
      "r391",
      "r463"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r47",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails",
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r229",
      "r502",
      "r503",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "PROPERTY AND EQUIPMENT"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/PROPERTYANDEQUIPMENT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r46",
      "r220"
     ],
     "calculation": {
      "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails",
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r27",
      "r28",
      "r222",
      "r470"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r45",
      "r101",
      "r222",
      "r502",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r27",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r27",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails",
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r74",
      "r209"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Provision (benefit) for allowance for doubtful accounts"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.",
        "label": "Purchase Obligation",
        "terseLabel": "Purchase commitments"
       }
      }
     },
     "localname": "PurchaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Gross Unrealized Tax Benefits"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r272",
      "r422",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESSDetails",
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTChangesinOwnershipInterestDetails",
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r272",
      "r422",
      "r423",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESSDetails",
      "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESSDetails",
      "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Purchases from Related Party",
        "terseLabel": "Purchases from supplier"
       }
      }
     },
     "localname": "RelatedPartyTransactionPurchasesFromRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r272",
      "r422",
      "r425",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESSDetails",
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTChangesinOwnershipInterestDetails",
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r420",
      "r421",
      "r423",
      "r426",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfRelatedPartyDebt": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.",
        "label": "Repayments of Related Party Debt",
        "negatedTerseLabel": "Repayment of related party note payable"
       }
      }
     },
     "localname": "RepaymentsOfRelatedPartyDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r327",
      "r514"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r101",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r35",
      "r248",
      "r319",
      "r467",
      "r488",
      "r493"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r110",
      "r111",
      "r113",
      "r115",
      "r123",
      "r126",
      "r204",
      "r316",
      "r317",
      "r318",
      "r356",
      "r357",
      "r484",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r153",
      "r154",
      "r167",
      "r173",
      "r174",
      "r181",
      "r182",
      "r185",
      "r261",
      "r262",
      "r435"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Sales"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r102",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r413",
      "r418"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "Right-of-use assets capitalized and lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/LEASESCashandNonCashInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r413",
      "r418"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets capitalized and lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/LEASESCashandNonCashInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalariesAndWages": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.",
        "label": "Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold",
        "terseLabel": "Salaries and related costs"
       }
      }
     },
     "localname": "SalariesAndWages",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesAndExciseTaxPayableCurrent": {
     "auth_ref": [
      "r24",
      "r49"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Sales and Excise Tax Payable, Current",
        "terseLabel": "Sales tax payable"
       }
      }
     },
     "localname": "SalesAndExciseTaxPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r143",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Sales"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Components Of Provision For Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Deferred Tax Assets (Liabilities)"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Basic and Diluted Earnings (Loss) Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHARETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Statutory Federal Income Tax Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable": {
     "auth_ref": [
      "r112",
      "r118",
      "r119",
      "r122",
      "r123",
      "r125",
      "r126",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of prior period adjustments to correct an error in previously issued financial statements. The disclosure may include, but is not limited to: (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustment (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made. This table can be used to disclose the amounts as previously reported and the effect of the correction or other adjustment on per line item or per share amount basis. This table uses as its line items financial statement line items that are affected by prior period adjustments.",
        "label": "Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]",
        "terseLabel": "Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]"
       }
      }
     },
     "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/JOINTANDSEVERALPAYROLLLIABILITYDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r25",
      "r39",
      "r40",
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INVENTORIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability.",
        "label": "Schedule of Product Warranty Liability [Table Text Block]",
        "terseLabel": "Schedule of Product Warranty Activity"
       }
      }
     },
     "localname": "ScheduleOfProductWarrantyLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/PRODUCTWARRANTIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r47",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails",
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r105",
      "r424",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock": {
     "auth_ref": [
      "r76",
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]",
        "terseLabel": "Schedule of Revenue by Geographic Area"
       }
      }
     },
     "localname": "ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r162",
      "r165",
      "r171",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r162",
      "r165",
      "r171",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of Reporting Information by Segment"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r288",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails",
      "http://apyxmedical.com/role/STOCKOPTIONSSTOCKOPTIONSFairValueAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r294",
      "r299",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Options And Stock Awards"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Option Fair Value Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r338",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Unrecognized Tax Benefits Roll-Forward"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r149",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r167",
      "r168",
      "r169",
      "r170",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r178",
      "r185",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r149",
      "r151",
      "r152",
      "r162",
      "r166",
      "r172",
      "r176",
      "r177",
      "r178",
      "r179",
      "r181",
      "r184",
      "r185",
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "GEOGRAPHIC AND SEGMENT INFORMATION"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "verboseLabel": "Option vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSSTOCKOPTIONSFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility - maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSSTOCKOPTIONSFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility - minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSSTOCKOPTIONSFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSSTOCKOPTIONSFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails",
      "http://apyxmedical.com/role/STOCKOPTIONSSTOCKOPTIONSFairValueAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Remaining shares for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r301"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Cancelled and forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSSummaryofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Cancelled and forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSSummaryofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)",
        "verboseLabel": "Number of Options Non-vested, Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails",
      "http://apyxmedical.com/role/STOCKOPTIONSSummaryofNonvestedStockOptionsDetails",
      "http://apyxmedical.com/role/STOCKOPTIONSSummaryofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value, Non-vested Options, Granted (in dollars per share)",
        "verboseLabel": "Weighted average grant date fair value of options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails",
      "http://apyxmedical.com/role/STOCKOPTIONSSummaryofNonvestedStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]",
        "terseLabel": "Number of Weighted Average Grant-Date Fair Values of Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r296",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, end of period (in shares)",
        "periodStartLabel": "Outstanding, beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSSummaryofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSSummaryofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, end of period (in dollars per share)",
        "periodStartLabel": "Outstanding, beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSSummaryofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSSummaryofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Stock options outstanding and exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r302"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of all stock options outstanding and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Stock options outstanding and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Stock options outstanding and expected to vest, weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r286",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSSummaryofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)",
        "verboseLabel": "Option value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSSTOCKOPTIONSFairValueAssumptionsDetails",
      "http://apyxmedical.com/role/STOCKOPTIONSSummaryofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r101",
      "r288",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding",
        "terseLabel": "Shares authorized under common stock option plans (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Option expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r306",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSSTOCKOPTIONSFairValueAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r311"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of currently exercisable stock options"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares",
        "periodEndLabel": "Number of Options Non-vested at end of period (in shares)",
        "periodStartLabel": "Number of Options Non-vested at beginning of period (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSSummaryofNonvestedStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of options"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSSummaryofNonvestedStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options forfeited.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares",
        "negatedTerseLabel": "Number of Options Non-vested, Forfeited (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSSummaryofNonvestedStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options forfeited.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value, Non-vested Options, Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSSummaryofNonvestedStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average grant date fair value, Non-vested Options at end of period (in dollars per share)",
        "periodStartLabel": "Weighted average grant date fair value, Non-vested Options at beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSSummaryofNonvestedStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted average grant date fair value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSSummaryofNonvestedStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Stock options outstanding and exercisable, weighted average remaining contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r293"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of option shares vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares",
        "negatedTerseLabel": "Number of Options Non-vested, Vested (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSSummaryofNonvestedStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value, Non-vested Options, Vested (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSSummaryofNonvestedStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES",
        "verboseLabel": "RECENT ACCOUNTING PRONOUNCEMENTS"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/RECENTACCOUNTINGPRONOUNCEMENTS",
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StandardProductWarrantyAccrual": {
     "auth_ref": [
      "r244"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount as of the balance sheet date of the aggregate standard product warranty liability. Does not include the balance for the extended product warranty liability.",
        "label": "Standard Product Warranty Accrual",
        "periodEndLabel": "Accrued product warranties",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "StandardProductWarrantyAccrual",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/PRODUCTWARRANTIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StandardProductWarrantyAccrualPayments": {
     "auth_ref": [
      "r240"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in the standard product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard product warranty. Excludes extended product warranties.",
        "label": "Standard Product Warranty Accrual, Decrease for Payments",
        "negatedLabel": "Product warranty expenses incurred"
       }
      }
     },
     "localname": "StandardProductWarrantyAccrualPayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/PRODUCTWARRANTIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StandardProductWarrantyAccrualWarrantiesIssued": {
     "auth_ref": [
      "r241"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in the standard product warranty accrual from warranties issued. Excludes extended product warranties.",
        "label": "Standard Product Warranty Accrual, Increase for Warranties Issued",
        "terseLabel": "Provision for product warranties"
       }
      }
     },
     "localname": "StandardProductWarrantyAccrualWarrantiesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/PRODUCTWARRANTIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StandardProductWarrantyPolicy": {
     "auth_ref": [
      "r101",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for standard warranties including the methodology for measuring the liability.",
        "label": "Standard Product Warranty, Policy [Policy Text Block]",
        "terseLabel": "Product Warranties"
       }
      }
     },
     "localname": "StandardProductWarrantyPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r2",
      "r149",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r167",
      "r168",
      "r169",
      "r170",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r178",
      "r185",
      "r216",
      "r225",
      "r230",
      "r231",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r58",
      "r110",
      "r111",
      "r113",
      "r115",
      "r123",
      "r126",
      "r137",
      "r204",
      "r247",
      "r248",
      "r316",
      "r317",
      "r318",
      "r356",
      "r357",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r484",
      "r485",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Balance Sheet"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r110",
      "r111",
      "r113",
      "r137",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r31",
      "r32",
      "r247",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Vested restricted stock issued (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r31",
      "r32",
      "r247",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Shares issued on stock options exercised for cash (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r31",
      "r32",
      "r247",
      "r248",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSSummaryofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r58",
      "r247",
      "r248"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Shares issued on stock options exercised for cash"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r32",
      "r36",
      "r37",
      "r103",
      "r195",
      "r200",
      "r391"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r103",
      "r110",
      "r111",
      "r113",
      "r115",
      "r123",
      "r200",
      "r204",
      "r248",
      "r316",
      "r317",
      "r318",
      "r356",
      "r357",
      "r369",
      "r370",
      "r383",
      "r391",
      "r393",
      "r394",
      "r398",
      "r485",
      "r486"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Cash paid for:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r347"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Loss and credit carryforwards"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ToolsDiesAndMoldsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used to cut, shape, and form metal and other materials into goods for sale.",
        "label": "Tools, Dies and Molds [Member]",
        "terseLabel": "Molds"
       }
      }
     },
     "localname": "ToolsDiesAndMoldsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails",
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r189",
      "r190",
      "r191",
      "r192",
      "r194",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Trade Accounts Receivable and Allowance for Doubtful Accounts"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r114",
      "r115",
      "r116",
      "r117",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r354",
      "r355",
      "r356",
      "r357",
      "r436",
      "r437",
      "r438",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Adjustments for Change in Accounting Principle [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/LEASESCashandNonCashInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r328",
      "r335"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "End of year balance",
        "periodStartLabel": "Beginning of year balance",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESNarrativeDetails",
      "http://apyxmedical.com/role/INCOMETAXESUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r336"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "terseLabel": "Decreases for tax positions related to prior year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r334"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Accrued interest and penalties"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r337"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Additions of tax positions related to the current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r336"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Additions of tax positions related to the prior year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r138",
      "r139",
      "r140",
      "r141",
      "r145",
      "r146",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates in the Preparation of Financial Statements"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r411",
      "r418"
     ],
     "calculation": {
      "http://apyxmedical.com/role/LEASESLeaseCostDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease costs"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/LEASESLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted average number of shares outstanding - basic and diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18726-107790"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "27",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e22044-107793"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "http://asc.fasb.org/topic&trid=2122394"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/subtopic&trid=2122178"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8475-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e4975-111524"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=SL6953423-111524"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5212-111524"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5033-111524"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5093-111524"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27405-111563"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=27011672&loc=d3e149975-122751"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=68070138&loc=d3e11281-110244"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12524-110249"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "((c)(2))",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "((c)(3))",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "((c)(3,4))",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1),(c)(5)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "460",
   "URI": "http://asc.fasb.org/topic&trid=2155896"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130533-203044"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121610041&loc=d3e36027-109320"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569655-111683"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121329987&loc=SL77916155-209984"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.5(c))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(k)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262090&loc=SL114874205-224268"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r515": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r516": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r517": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r518": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r519": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r521": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r522": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.23)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.19)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(c),9(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>90
<FILENAME>0000719135-21-000029-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000719135-21-000029-xbrl.zip
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MS3FZ16RZ7%V&YPW,[M,!IF"Q3)%Z0M%*JGD*:[2:E6:9QN <SROX.U1Y!)=
MTRJZ8RZ-6K(,6" 8$[R5NL%I"1%[:V!LA<CK_#I9Y H& *<&@OQH13@AMS,6
M*[VP%7+-=05DG![6O1V"K*\ T%;!W GV>6.PMW,8G*RES$O0P8$M85;J%"(3
M76@7G\PQXT9XV  &<JH$I9<)('6JI)V1.9DE(%(B4_H>21LJ;7/T(XHU6A7X
MR8P.183'EKT"7"(!_!68.+T*9SR]$%X(G^<DMX(N;P3]5^*U[QKTH^);\562
M_DT+W))_1A2W N<"7A3+U@/%:P/%&(CF>1ODL"!I\'4=]RW@#CJ[#5R^.\ =
M-ML#6H<38;%2R*&OB-\&6)V*=<ASNWT7JII3 ;"4(Q5U6.<&#D!D<VD]/<)*
MI-X/"?H;8EWE9B,4]^@K"_$-@NHE;U.C!,DB%JN5C/R)B,VG5D:2&TD3D(5<
M\,4B)4^YI1+N-ZOU]=Z3J;8" 3F0-W7*.& ?YHI3#<"T?! W4@ ]"F&Q6C'P
MUU20(6@:_47T.%K>=71/=P?=)2VO@WMK;KN#\>U9<6NH8WO,940(YE:GG.B?
M6Z"?I"K!FINH@AA +_E4*NF6) _N&Y8VG$>C!UJQ5]9,5_2/KS)7Y82R'"]4
M%ED@.1.&VD0^ "]Z+T0*E:* =[2(C#82F4#0%YC&AI,9B/YYHSK<'517G'TZ
MYRKWQ$8Y%W%,YW5S9,O>HQ^OQ<@61%U\O5]2>A2C(TC6%L)UJG.W.8)M2@F_
MMA8DRN-OOURQ::7V_<84Q4I4QP$TP+,%8K0[0*SHM4CQ7:C0>W\I!WW+O7A\
M *F2'M!AF!L"Q$KQO<=KHJW#<SK(A2]+AT:_YZC=</UJO<M+HL+<@.ANV94A
MXZ5,^,.*=/V$ZG41SXS;:XU"%.GW $'3,+\0):TOF9*70I4'%[?,'[TTCT?]
MKK_K]7<.]7_L7<^?>T;5AJG?\!C1ZBIH;RB-P/< S7)'$E^'QB&+G3;V6B;X
M!W"9)-(Y(;Y2-*8:0H3:(XGXO)-70#@XVE(-P+\DSJO]*'[/)<+W>R]/_8](
M]O7_7^E^L#QXIZ#WL%;^ISW$1&_IH10 3%GBKU^M%H)?4LTN])^OVEZY^@/9
MZHCJ03 LWX**DXU[*)!'Z&C%-QFPTKOH MQ!EM8+X6"A&FR> #58)3^9ZG3N
MOK.\YR\*=N^=ZQUJ?VS ,'5@07A2!)K\H7H)NWI10&4ZUVHNJ(JF_*+\;<"4
M/"J23.FE0.MBI@ORY&N@!@@?(B[L1L0VM\0&75DHGSB=C8I+",Z_N)7V4\!4
MF 867_',BE'UQP%H/U-\.9*I7T+?Z6!.E0*RHP06?)8W(H;#YJ ]H$L1SN#_
MJ')?WI=H^OL2+1?=;>OM-X?#[L;F=C/8V/8UM]UF?]CY_EZ[S?9^[[N[#8+F
ML+^YZZK;EE_?8HV1*YOQ]&VM6ZLZE.@>=;(K%JRS  '^=@(+F/QX&O#W9TZP
MM7R=91^Y ?]V@[J_YW.-[7(M'C;-BNQV::;OE^MZXBE-S'L<28?1PBVF^F*O
M!RKSGS=W)9HKER4>L AM6H(' G^MSZ--2W8D[H0M\X>SK%K6W<O55S/S]+/Q
MQ!;\LX$N);'E)=^&&T&/2D#+5^5[5,"M6XN9+JYMCHJ?(N9BXSW&4C>T;[KP
M*5"?N\U=-MU$VWBIL/PLKFCZRZ)'_P502P,$%     @ [(-_4MN2HT!,"
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M].>J9Q7[:\X5,S->93?(58ELDQU -@BZVW1G50A7';[J[J86@EX4US656][
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M]6:539=;G_%P[;.^![8WTH?_ %!+ P04    " #L@W]2Q1N-?^T$  !W%@
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MQ-'RG5LWG+MB<8P!I.*!3)Y2H5C*8LP">%\)61&T07'P]N"#?69/X8S&.N7
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MI^=G%Z?GG\=GYZ?VV4D_^6@=)*<W0_CN+_/TIA\?W+R_.##_TD]/]N':?>O
MW#?//NP;W<&I>?CALWWVQ=<_FF?CTZ_4/3VAUP=?/YL'-U0_.SDZ/]C=M@_.
M>^.S#]WQV<E?X^[Y07SXH8O?7;(/[^/PPV>W^W7?.#U/!N*WDS\N#C[ 7L][
M5Z<G>];IS=[5X>Z7\X,/?\$]%^J>+_ L)ST[R:Y/S[_$AU]/QUUSW^E^^$N'
M?9F'NW_TNR?LO'L"S_[:U<]V>^;A%W_\\62O[![KUQ]/MK_9GD^H2<..YSC
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M@\!BW_8%#%Q+GX.CE^9LJ0[>[5AZO9#ZY9&G62!C*FX=J *F^/'1)QI:!K-
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MNDMH'Z1D/FY?^!T /X@K'&$M@WP6?NS&:3P8#981=1AGONG8CN.!Y.;<"IR
M!";FKH+X)CY9H<Y/H@ZY7EK4,=R(\S#R0@M3G-PP= "FGL5=B]O$L)85==Z/
M0"<O03>""]_'U_C7]Z3*BNE,8 XQ#=/PG(@;/F *\7RTN"//,0DW7<?E*\Q9
M\9P[_#21"RS'-ACW#9NY3AB8H--Z-(A<:KA.L&R8(^P1-$)'8&'65Y"4'6=1
M>45ROF(\CZH[L%V#<F+XK@,:<L""P#==8H*F# :LX;H+@#X_3._SA9@+B3Z6
M9T6@V] HT#V;&9P01FCD^*8> 3>BW@*@SP_)K9,L2XK=F!=P83=+V$K=>23:
MN";86!8+@.N$8>#3@'JV%0;<M@W+,E9HL])U9J"-'GI>$'IF!$J.[3M.:$:>
M21SD/+83LJ7C-D*D'/%T= GW_@F7%@/R@:>RZ',I_7:!;QB.%^I.0&S;,YW
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M$Y=CQ59H!,1P0?F-0GWQ,KQV,/9?<$&CL/""9'0QG9A^X!FNZ5/;X>A #%@
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MH'\V(#W>>GIYR?PPZTFTZXM%ZZ>5!?4@GFU,6E![WS@WHL .4#8;-O!L9G8
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M,CJV95" 761V/(MSA_DZ9S9?V]I).,FO@ ?GKP<S(0,.\T^@<P.O7TP5^LD
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M;\!E/02LCZY/[8BGHTMX#FACGOW;K2/ U^?Y6-TK[ORS(U>?O*.?%;+89^K
M-J:?D*'GN4#/:E$_0+A>(U)4&3X3OZC*!;6A]C$  <;_'4TDP(N:6\:KVL4$
MWK;/25D=8@F&_(C+7#15222JTADOXEP4$$F#73APIUY4AN[0!9]=%<WN8"V9
ME\(K;.P#-FN A3Q!+C#,.155P+($XS+.2UFBR[$C0RI1%5Y$%(G#%JHMYF0T
M(,)[2Y(B$^OEH,0)G&.<#S'P@FV_5&44*"6$R5BP^"%6#2RJ,[HBEZ*\N*&
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MO+!O4L25KIEBCIKRES7^;/1;,<Q3PV?57GK!4D2742ERA=N@*$''J-M:"04
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M:%X1J$H[ /6*%Y,KK=_RXBNW^KC5>7")P2=X9BQFP.#X4]$]10W):C=Y5/E
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M(05O#=E3&7=%'X<[M3*0FXCO9.!/928K=RXRF@3Q'-6" 4;RR$"%=:ND6)S
ML'-HPL8+9!T$8]S5WG"1AI76QDX3X;MS8A"^[53F8/6J294+6V]YBI'?3HQ5
MP7&9&(L4/IT5BV5+TO(:3^0T-:.S1'(!ES,E9@9U)LSEJ?"* E]K?F2C*ZNC
MFG8,E2,6-^W#LI'LSE1-^A$/H\AU!4M1/<K**N-FPHU>;VIBSAF^!Y*(F)X!
M'XB0TR(\@RM5D82I?+CI7*6)](B6S&J+(X7FZTU6Q$0-%CX'>"0 C:0<,T$
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M>0H?.G0J)R.<F*%;WQ./G_1C791UG+E.J"U%_89I;-'!AJ2#HY)^EK5KB)
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MX*JXFH*0(I!D _K2RU>"<+9TA98<\>YQ7>#N/9\8ICF1BG-] H+.8[IQY:I
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MZPAYA)&!0R49MW*4,FB$^B[/<]N804N ?3$?ZV#;;].) :O@FA;U[%S+RZ&
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M3^5@HMMR68-!K!>XK7H@]DA,27Y'O)UQ%H/S;,P'X662XK28@=TEC>E0),T
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M^UVCR@YTMEPTGG=TA1WH;"U/H/4;<'=E)P#=E9T =%=V M!=>7\"L+V@LUO
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M,_GMG51-]-1RSRX;P?X57+3;KY)^%\)_T2]LDE\8;X\O3%=@P=C-1MMIKRT
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MA@4DT_%#,Y#D1<^Z=541B]W-44EKD?-="S,E\XYMGO;/'R6._7C[]G^<(NO
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M>S%S[^U>RTKK_24]E[5H(#W,C>TDD,Z0+UEZ#2;&YM@F"?SZ*VW;V [0P=C
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MNS[]G9FHWC-/-&1Q!6D'*#0>:*H4D!(;[2'CGHJ-3=%04E1(?Y_9(<7>?#7
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M;2!T=9>8:L!C\).[F:75B)3^B5,IHVA&T8</"<\HNBR*SHBVH XSX2T0EAA
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M9"_R'IC *!#,>(H<YUS95#$.BRJE3LT!/K4D&%E]UZ.^<[?##)?41_7E6!A
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MER(QKN8[JJS+]JF%A,T(0XX$JU8D6(:@.T+0PN$N4\0X;BP@W$A 4V9C+7$
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M]ON\^>?>Q7\O=K^U#[Z@YL$NCO/'6A=?/@D7$.:! !*L3P4@'# X*."E%ZD
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MR61W"35/]JL?#L?U3X>3,X)\#EL%TC(OFE?>#S.Z+8-N\Z>O(D!L+?0@>$X
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M\-=&T?,Y6=C#<<Q2!#\<:DSVM);/^3R7V]8^+U!.%=D&,0QH(A6@%#$@.;=
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M_7'^/HIUK]>>"G7K4J9YLUQJLURX@!?7-4=."*"ET(!JJN-F2>(/:H1#P?C
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M-M_$2>F[J]4J;?<L"6H>H,>@G7%V*9Q=*$&KI1<\$ >8EQ)0XRE0CBF @HY
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M&XR FIBV,5)EY7+V/.=WRF?CDW^28O3%)XZ&X]/N!%V.Q2U;7WX#D+T? 4?
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MWS9^<N;]K )UL@A8C2^O9[&Y*\F]3B#U##>@%2#O,$5ZJM:&_Y6%K?4PQW;
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M&L"0Y\[FS3$_(.^>[6P<: LF$9.!:.-SPI7-B G*$.>H]E(ZR1GHX_Q.O,O
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M4#?BCQ<V0!%"[$Y *2%R68P\%DVT_&@T#]%5QU5EH"Y@BM1M"C0TCLH4@R)
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M=%<MM$I.QQA8G0 *6GLI#=)QL1% O[P$BKW!9R=Q>5^ QW2,8RV&[XJ.]TB
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MWW4".','P1J3.)D3JKD'QRC7Q(2<$\$3D0F>)E;GRX5#FHI,Y5DNF Y<:V7
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MZ:4_H E[M1KB_(:F\.K1FL)C*KWW;[L#/; ^P@:-5Z<-=[OBZ8OV[C_'X&2
M([)_O ^\W-[]=+:S"?RZ^4]_?_?/_@XX,GL7P*OGRSS=_MKYW+[H[&Y==/HP
MA]WW7SN[&[R]^>=)Y_-^#]XGVN_>'K?3M\?_O=C^VCG>. #IZZ3+& G>"@+D
MQ8CA()U3<#J#29Q6-EON N]#FE,EG?:,\Y!ZHW@"<B'A2AD-(USJV_TS3K7D
MP\%A<ZZ=XY,# 7K14B>(#0RT;JX4D=QSXK.$I0FS>:[Y\KD*"1N=PD&((&'W
ME5$NY<*;/ CCX._E<_UK:^/CUL=+]N>E?]_5R+Q*!BX)T^)0;R?$Q07F0@I+
M37#2,&Z-EC1D*9@*$ANQ)JHT0RZ_Y_:-67R/S9(0I$XQ#L#!P)$ZR:Q+7));
M*3A/7CVV=+[&V(Z:K@]O/F^Y(8P[&$Y:H&F'AP,8I=6+C!65:VOB1_TQ_&8\
M!OT(,YV<^1ZHS3Z\XP@5<<M-"ZVXUHH:7D]:1QJ^\$6/NK&%_7#0.V^=ZO.H
M1]?PB2[HTP4]^X?NH9QN?3SR?M(":S_&),@PD"EH9@U,#T^@[HX3:_5@X&ZO
M.^GZ\7JKOI0C>%2[X2F.B<K\-%HA8,I%+>^ZF)U\=M2U1RW=ZPW/QC.CI!I@
M,HP[,?:G&A95;D1\,Y Y*?YEX;O@II5& 9(#O@5FLF'M<(2QEM[YVM7?UR,_
M-UU*@Z,/7YJ.HI6!X]5F\Z_QY?7&N5RQ.^NM[85GT4C2B+-;C=GMG_:ZM@NG
MC.N"=Q=GO+;PD/-XVD MX_CK825HE^9QWIJ.\;>7QEUOO8T;.AS/:>C(PR26
M9H9[?//L\)=QA,4)3B?P_HNX#;B1Q;;!\9KA:#0\PSG% 6#4:[T,< + XKQ?
MCS%=R)\LM%1,69@.)A]@0MOSJ?Y1S11_/_,S2/KBE-=[T=FT\-GV!:PA:6]^
M O<QH2'A@62I1L!]DQ,IJ2 T&!6\HX8+_NHU7[^B)>G_KI5\'7T#!RP?;7N@
M Y0U(%6Q>@<< * =MT0LZZW[45NK:(3/+*5682H]AY7>KM!*R8,G'[0M!!:(
ME(_#T-5KK3^FO4-435&2?O% -3T?]=@;>&YTAG2RUGH+LP;=!%+#^5&4Y185
M5*]0:$MB41^.?.$E+FBCF?@>%N)L]N+:I*(J '6'PA\MKEYAB@R_^$(OH3BN
M9&0<;+WU(7ZW=%J'-4D91;Z-,@>('#4;U@RWT-&-^@(WK67T&+XV&[]X$-\"
MOO9TA&M"QWOMF@D77\=P')Q[X<+C>^"X\9(!IPZR^"8?0-)$.ZNI-]IPJH4&
M:2N],8P*'IQF]8NO6N0&J,+^!G8&Q@Z^Q2> /?)GNK<+ZWIQ<G4+WK-]X'.F
MA.&<4)-SPKW.B#+,$C"?=0YV,6@V\>IUNFS!%]$9,"8&D91&+IIET0Y<IOK#
M:;?XM."1W>$I'+;D:4$[D3[&2,M(+8MDB;\H!^D/73=$:5W6M^.SE\V;*VR_
M\]89&A:H5J/]Y%I@>$9[JCZDBP(>F')\B6W'A9E:F+? 3]U18=*,AM/#HUED
M"@-2Z7-6$66(Y#H%L:J+N5H+7!)AE4H F>E'T>:.%OZ". _E#I14@11J_6BB
M8UCQRAX6NM(;UZB-BN*61KZ)WC:FA[!S2&WL>5#;U0?TX/$AV.@WP_%D%T_V
M10>&+K8/9' R#UE.A,H16]H((IU/B,RL]E0E1KGD4L /;U="L"YG.;>9E,:9
M-->:,\VL2,)R8&A[4*CI*+_-<#JIL]W_^__(E.:_5W80!ND+'U@CFT4/_+>;
M8TB7(^LWQMI+6N,"B/%T.(X6R6\CWXO>P.]G73<YJI)U:D^5B17)_!%MQL,>
M,/ZUC]08RD;9\DC\Q-G2?M7^/!I5LSG5AYZ8D=<G1 >8[&^Z=Z;/QZ_^O; F
M\/NKP3,&;U]>^_62YH:XW??&X;XAKG9UG/ V^EU<LAX=PJI+ D"J*7^#J31B
M,1-O=L[Q1GY..S'U)GJ8IV/_6_7#[]6-?G<03RT^=$4R^7R7P:V-.UVF*)3C
MEQ^OQX^6$H:*SS*QGN;\VH^3=7KM9S<-2\5Z3M.'&?;;9GM+PL:M)3G9I:]>
MD5]9G.HCY1%>LL@B!>R!/=':BLY5Y+69*<KHVD+JV .45=Z8;CJ3 3\?%VNN
M/JH=>*!YQ!%_ZTY@Z?9;D&IBJ'(XA5'=^-<'GMN-,_EM221_1Y';M6F$-U',
M"C(06H?7EMV^J'V@ZBX"XWOEPF.0^\Y2-"(*A^L2:[_I/)]X^OVWK?'99-#_
M:(K?I;K3Q0 B^I KE"7_??YCF25_U(;/.L>8$=\YWMG=2SJ[[R]V=M_VP%_L
MMR].1#OMG'1VWW9W+F7);YUU/N^EF!'?3MNB<_R>=C;;HOWYT]G>YST8X^1B
M+WU/VY^W.?B<,V"^SN8)/U"Y2IP-AGB6.L0@38FDN2,L"Y0Q8;C4V-@HY7=,
MDO]6V?R]-4.-S'BV,N-'LTD;F?%P,J.]<0 BG>8J*,(DQRN+/"&*,4M83H/)
MK,B<5" QZ%U[+#RHQ/C9/MACL-C;>AB[L+1^^Q'[^E;/_7O'N)M]&\\[7\_%
MBF]_'5L4[X*OR/ZYAO2?CZIZG@KIWHW8>K[S!YS33O@T]AM((W4J:K34G;34
M^T7+UJI<\B2EQ$NIP;*UV++32L(YRYC7DL=>@"F]8R_ ^[5?&]9?;=:_=UNT
M8?V'97U$F]<BXS8!V]0*#W^PC)@4[%7-LMPIEEF>9*]>B\M%40_.]_=DA3X5
MBV@[9G-@Q=?@<H;TC^!//6U)^6U+?#8B]$&MIXK$MHI$RT9LWDEL?EJTF(QU
M*75,$.&\(EP91HP%P9FI0!D<H'(N 8OIAWL1W2\^9",XGJG@>%#;JQ$<]R,X
ML.='YI-@;4)21QWA+G-$JB")\3:G0K T#^FKUS^,LO/S<"B?4M#OGZI\[_;[
MU><C")^GO+MW0ZFBC>;:X_NDW-ZB>21UGDO*#(BX)! N4TJT4WA?:JU2(;5.
MA5>O[]H"OHDGO20>OW>;IN'Q^^)QC!PEU@>N!?'"Y@C1D!&3Z$!\2!*=>Z:U
MML#ACQ Q?@GWEP6RV#?DB=V2$-A@O/Z$#7HV$OG>K:Y&$G^?)+:+UA8/.7,V
MS8F/('4F"&*,%T1Z(Z1P,G$&9#'+[YIF\O"\\8"QK$;"-1+N\6W.1L+]J(3#
MJ%D:F&!"$&MY@DD)FFCF,R*HL3H$XR6G8&NJ.QJ;*RS?K@#*_8&:Z<<IY'RC
MQT<SG"F+_^C6*FMC"2MB6@U;P^FHJB>_5$E[3?7W<ZAR%'1=L.M+#K^['#%9
M%TJLTK W?\;D U1Z/M@>9,GU']^ATO/[$TFS'W)DKR[I^AD=H.Y>&-KZT:*W
M9B_K>TG5HG)X>I<[]U+(>A,AW4&KKWB=Y*R,XV4MN[RU_H9%WR5A__GL3T,6
MCX8T\!B.;P?L[&7#^X?*7+Z))GZD!N;!7_ D)GGW%SPM17XCT7ZX B?9ZM.H
M]A'J]$K,Y#G0LVM-3Q&X"2&3R^JB&8Y?D^RQ.DNX0U N81DS+M=>))PG,DCF
M%>42@912F>?)-UP[U%NF7/C1T(%47 [5+948[!C$R_-N>[#UU1[IP:%_.QPM
MEL?^50$W/I/@WC"%<9/.Q=Y99_/M4>?=IV1_]T-WY]V';KN_+?8^;\'X;S'H
M]W7V3!7<.]Z'-;QGG>.-I WO@N=ZG7?;'.9WOG?<.]K;W3IK?\:@'V*YM>?!
MO8O#KSL;!\XFN<H,)53FAG":>J*4%40)^#,D$GMZOGH=L=?2WYN<D494/ %1
M4<^@;03%=PN*[H*@R +/@"@806!UPDV6$6-%!H*">:H53_/PR(+B#KYF(U.>
MA$S)\M0YD5(M)/9I274>=)JJ3(:<9]Z[.]\)-H;&(Q@:&P<A9R)U7!+/O,6,
MM90HZQSATCFMM,Q,ZK'(^8XU.XV!T0B#.PF#QL!8*0'1G0L(3YU0AI,L$2 @
M0J; "\E2HKVC2>Y\[K1X1./B)40L[R?X4WQCUD<!0>Z_,P4$0W!7Y'\\'RE]
M'QOP;(1[&BR8!E1IFWCNP510P@:>6^%TQG@>FD#3$Q/O[Y<#33[D2:ZU(ZDV
M@G!%$Q#QE)*$H73G 4[:?J>(OP=.>OALV$:>-?+L4>198ZS>BS1;C(8)954:
M0'Q1#):#'VN(H3J0)%781E8XH^F3E&;W<:/;2,1&(EYVW['O2L)2*K3EU&'^
M>,X301.?!144;V)YJRS]YK$\J4*>!I<1YZDB7*>62&D3XI(\5XGUE&4*NP7<
M$;BLL>$:B?7\)%9CPZV4%)L''+V2J=6))B&WAO LX41E*4-1)B@3F5!!/CW[
MK<E%6PI'^J_>3JMDM/CUVW'=G[> ?X%R7">Y=8E-> @<&P$H)N&G)$^RW*@D
ML4UL\8E)\D_+L<60^S1P*XE2X(ASY4&0:Q-=\IP:IE.MP_=*\Y]I?C9"J!%"
M34#PB8B@Q8"@E<[!V5JB4I43GCI+#&>&2*N5< [!0/)5%D%W3YYKI-7SE5:Y
MRE2>!I6+Q'+OF9%YD@KA76J]"XHVP;I5EDSS8!U-=")8XDD>X3N<YT0RQC!L
MYYWRWALA7KU.[XIZV]A$C91YJE*FL7[NU?H!RT=GJ==,$*_3JM->+@T)P2?6
M)#YSJ7[U.J?)J@F9,EI6O;"B8A&-G<<M;KUAQ:O]AJ<QR^]XPS,*K;[YCKKT
M.^SZ:G[U):3PQH,]U5V'H8(?[V5T*Q;;,[*^[F</GHUE]L -T?_6YY@9/F[,
MKCN978>7B[>-=B(HDLL0" \VQILL24V2IKDV@7J'38[O:GK="S<\)L!L(YD:
MR72+9-*GYU\7>BTU0NE[A=)B)-RK-'7.921G-"%<@&12B5*$2Z]-[E-G%7WU
M.A7TB0FEGY@9VPBVER?8[AW_NC&Y[M?DVCB@BEMO."=>Y)YP4$)$4LPU2#E/
MK;7,YQF86\E/ \-NS*U&*CT1J=286_=N;H'_9Y)@$I$2)6@&_I_@Q&3>$*>H
MS?-@,B&25Z^S^VIJ^5/DT?WB[]_ZW$_DO;3H-CX'XM=F.)VT)D>^]6;8A[F<
MQ_20_/=QJQ@"TUQAK_1AK*C7W0'L;1G6F_A1?QR38%UW;.&L)BU0]C%3=MJ/
M\(LO#-&?K:?R06#GJ<A7:=A'0?1_J#W(&D3_!M'_*>[E#R#Z-[#G+V#9#1I^
M0Q8-&OYLW9^_Q9QM8=>0<Y"[W]8QY,X([BM+*S<ZZ9UI'YZWBUZYRER0E$D&
M3AYW09@DX][FQMI4I3E+#[;G=Q^UJ@&8BOW-34>XR3='"ZL#VRC.ZT-U7/'#
M73@L^K2=]:_[_3^/]R[V>_N;EN[O'L+O]\[V^ENB<P%.]\71"<P;?H:Y=)>=
M];?]O7[GN-/_YZ1S\4]O!]:U?_Q'=V_WA+6/_X3UON=[QR<,GD__>[%=O["]
M:+\_,#:3/E.4<#@XPI4#UUT+2T+FN<HX0HK85Z_3]=F%;7G\KQN.^.D<40]6
M-?QP7_S07>"'7.@L))DC1E-#N-26&*$30D, 3E$L=TR]>DW7\_ODAY_6)^09
ML!4PC>/!<IOFW-A46J^ME(+QX'D:'+)5%?5M%,U**)J- ZM2ZSP#?F((IDJ5
M)C))4Z >J[5Q++%P7*_93U(R#4,T>N81]0P"3ZJ<YFE"-,\2PHW*B+2*D43R
M]/]G[\N?&LF1_?^5"O:]]YV-0*RN*DF]+XCP -./B;;=#>[I@5\(704&'ZR/
MYOCKOZDJGV :# 8*J-UH!NPZI%1FZI.I/"S#B>4NPUR_WF/>4?SW+6ML[@AA
M"9_%FQ+GVZ>=G6'PZ*T]'DA.SSGY4KO<]HC>>T#NK[X7:#8Y!46TE/ '2'CU
MIF7EC0VEPA72)DBY "2I8I8BY87B,786ML2U3;Z!V:W#T/\N6?X1+$^7V,=*
MAE\%P\^;3CA.8MC9$L1<JA#'E""5*H>H(*E,O!&8JHSA;P=_+\/P2^3;O$O9
M6 +OE=O!*TI';6LB'5>UBR,FI5$<4%Z*20C5<V #I48B[1(GK+"8A% ]D Y>
M;@<K8?ER.WAIAI_BGZOZMR-E8^.(8,A0!9:_)C$RDGKD; S[@>:P7?@';0<+
MXJ_"#8%%FIUA%KCT^(BL7UC6CTKLF&>Y+[[?]_Z.,B)5/1CVX+^-,+,&O/;W
M5M>>O5%F._S[!-OV7QW]0PWKI]7+VH_J=:VQ<UUKPQ@:WRYKC0JO;O]Y5OMQ
MV(+WQ=7/?YQ6:8@?W+VLG>X>&9]82GRHVFLXX@Q@A-*Q1L1(^,H9S[1:BSS(
MY'E8XM[0_]HMLH+%6UB7H5RTR:+9(P%T599(E-K0JC4F(.Q..Z23)$Y8JBG7
MYM:B%3$&<K2JH6#GN"SG7!5/G7U^*WQI90&-SQ2^J-2&P.(QT8LBV6!$/4N(
MG7I8B-W2CWU8A.+CO68C#GW1B+#LB9^R$K/V ;#JM]U.-#CI#N&I[F$Q"V_1
M1UX&\#PM@&>L0V#K]+^VHY]VY3/$$;V&#/Y2XF 7($^HNOUK[GO?B4L/F/^[
M25IZG$/S=@;E+^V)<?[2]M#7X,V-"]_ZZ:LPC)/WDM)TW@1$>E5M_'EZ>'I,
M#JZKN+Z]>U'_<7!9^UR]/OBQ2ZO;]J)&_VP>[-^P9=LPCNW=RVJ[UJYOA_=^
MX]732GQXNH.S=YP>7-2N*^R@_>?)C<-K8IS%AB:("R]"*><$R1 @ LO(#.="
M&9ZN;1)VVV_SY*+\]VY.+]!=I%11I8I:1D4MM)I+U;1"U323;2FUU-I(1%.L
M0B!!BJ3!,2)6<JY,:AF3@%'8BM._GT\U+0T9T^Q_;PTRTCMM%+K<7!>JWU(-
M+8&40EI5XZ);:J&EM%!U%B"I) 84E!CDK7=YR*P.T4V$.2=\0D46SD38D\OK
M+!;V)U?/*67NA;;^4M8>*6O3'5\[Q;45"A%8*,0UMTAR&B/#$DLII]J%7H=$
MWHXI>CU9^R!^(/:H37W!7$L%TUZJP\Q26_U)S_M2 2VE@.::K5*2NL01CIAE
M G'B"9*IQXAA;"@Q7.LD676;PI?<\$MY7/6&7TK<8R1NNN4S[!3L\P;!TE@$
M9CU#TB<:6>-2Y2A+8XS#EE\@87L;!U %&<:[<&HTN@/=&@5.G(\4P%.<'$]S
M0)?*>0E85.KFI72SG45#VFIBO%&(IP1TLV4.*8<)2A+KL)!8,4;!.$CB%9EC
M+W$V5(IIH3!4*9[+BN<4.BDFL8BI1 JG,4 G:Y&,68)B[V'Q!-/4AYA[)MZ*
M>'X$5TK8MZ)F^WP8$D*;(>#*]P<?S+?R6]'PPO?.."77NYU+"Y=6VN&O4CLM
MI9WFBG>#^>:9E YI*7AH2Q!ZA&N!$E@]#28?,8Z$XMVWE-.MR,[2@?)6A6[A
M[E\*VZJ$;0H%XE2&O&N"F $YXU829&+"D8HE(S@1GB:A,='M2(E7$;:/X#+X
M"OLZ8-SHIVX-_<*TB]*!\*J6R?ON?OU26NAL=LO'5%I)J4<6%@1Q2E(D$ZJ1
MI)XS1IE,O0F=B$I_02F5RR"&4B:7E<F9D J.$T4!"A#&$L2Y<,@D0J)4<H^E
MT))IO+;)Z:K"ETHGP:J<!';8ZP4$<=[M9=*W,@Q1VC KP E;^>J4JFDIU;1S
MD:FE##)4CJ1E(DFP1SH)[70TC0$O,(%2RU."C<$I#^%>M"!F2RE?+[;CE]+U
M6.G:G4B7%]BGGC&4.*P!C6.)-/<Q\@EFF&D7,^-"^L3MT(K2*?!<^WJW<XRR
MVOO+;.H/A%QWMPG[L/ENJR=0L?5W<>!1K=NQI0Y_C Z_G$5(CAC%0EE-+RQ&
M7*4>*6<U<BZ6+J5I"A\'A*16:[VM0%*>(WVWU'>EOGMM?;<0KI;:[@G:;HI8
M#<%2$AV'>#.".)86&2YC%*<J,9YJQHE>9?K/ZVN[.XK_S15%7_#W?'' U94+
M7,%](_GDH0K8>;??# /ZU/,M&-E//^T[^M_SI=)&2X"GMV@#U!X.[KYE49/4
MURBNQOD\+69_AN'F6L#PQ$HCB!..:RH,%<(DSL0T3:27_HC@9&U\UTEO6J_K
MV"/3\_H,Z12F^$FW+O15?^U?\^77FIWQD#C=$('R-XEV)VG2]-E(DXL"Z-)N
M+V/+3R" OA>N@C'IPHPE.NF%#>(?]Z^16-O,ZB(&HVTK["U9%+A^D R]$(O>
MJJ*5L6CEZ\'?475G>W>K\B7:JN]]K>]5&KOU6N$'7JLW=O:C1AT&7=NO?]G=
MKC1VMJ,_=FN5VM8NS&6_ 1]4=VJ-_0AE2P(JT+M%\CB1@3O4UP.^?(W)1P1O
M1/GF=OOG,Q<(K=@L2*?_55\%KJ]T''S2 _I^F;HJ0F7A5K<_[!6H6.C!&/?$
MM=-O5[4??S1KIP>7]>UON-K>.ZE_WKFL;>]>UZYWKJIT[ZRV7;D,I8'GBX6>
M4;B&!)Q3.]WAM>UO5X>?=_A! [#3:955&[O7AY_A>=L[%# ,#F64;*R%,02E
M+E0)2)U#2CJ&1!KKU#OEJ>,Y(LU8M!*2/H5)M;?<:.HLUYYK+;2T-)&68)NP
M6[5%*UM;>]^!_W?^_KI3VP?!J-2VHWKC_W;VHJWO>WL@!M&7W<KONU]V&[L[
M^W=V5[F?Y6_@B7Q![QWM<Q6LU>=7EY]&K+=S>>X[?=\'9JP/3GQOY">>X<B"
M5:Y]!68\/E+:62651X1*8$::>*0U=@ASP,[6:<,96U2X]G4 U&AI(S]:VTAW
M7-0-JSLY ITM5@MLU6_V0_0T;,-PU:@\;4#BCRY0>[L*YO.5K)4Q>TS)VH1O
M<$577ULVWA#L<<WF?_U=S)YIL \KV_M.NOPN6R&WN6R%W)6UCG_5,K&W2E>_
M=KO*-TT^HHI8;W=E&<D%$_%?"O1X;SS75SW8<>YR<'T0?W?IM7ZLUWK$1_NZ
MI7L HHH77O$XG#QR5K=K#=<^_/$]/F@?7!_^.,#5S[73^O:?S>J/[Z0*XZAM
M'\?P^\7$P3UQ5A^0&CUL'39:S</36NOP]-O% :WR:GOW\K#Q_:JV?8#KVV?P
M^^^G-^KF8B^E2V*'I% 2<9' ;]XSI+#!0F,A4Z?6-B5>MG#%2X8TW]]]K%0P
M[UW!/*KY5*E@GDO!7$T43$)]RB47"!0-1=Q3C Q3 BF26A/'V/J8KFTF:MG"
MW&\P/KMP"F0,RTRW,_QH,=BOAUY^#]0N=<OC=,M<35LNA"6Q35'*G W>:L M
M"76()J#]8\,L<P; "WER4L@S15^OPHHOI?/16_]LV<K.L.VZ@]'WI> ^B^#.
M@ *>$J=-@JAB#/%$*F0L]B#"RF(JXH2&)L1DG>%5%<5_ 4CP%G=^VVVWF_T^
MT/4A^_\[5R0KJ7_[$$4"Y@6HD0GI2X7R&(4R5_"66:Q]S DH% -J!!N&C&8T
M5+WU5%DMM0C5[=<Q7A(+O+ROXN/)W<IM]U*X5B!<T]W:")$DUL8ABA4C'BHC
M2$X-2DV:Z+!Z:9P S!9+%F@KK?0E#T]Z73>T@^A"]WJZ\P'3IE_!9/^:T_Q'
M3O*K;"ET:ZNE0;>D3>]*[?(8[?)]=NM.E68BX0X)JSCBC@LD#8_AM]0327$B
M62C_J(I4.KLTX@N* 4IY?29YG:(!IG6<8$]18K5%W+L$*8%#=20JF51QHFT*
M\AK3 LGK.[3<QVA@'%-X%=F6;K:C9J<_[(74+I"3<$'3M!X$%-ZY?EFM"W]W
M3.12GSQ&GQS,[O]"*\>\2Q'&&O9_R4,L@B%(2H>MB1/0*#:4?UZRVEIIN!=X
MTU[685;*VU/E;;I_$Q<:'AB-?.H3Q!-E8>LV"J4N54+$GOHD=,I>)^)V3>/2
MGE_M#I[ZS$>E6U'J2W/^Q;;OKS.4_\.7)WJ/TRIS/5:H\G&JDP1ACT/-U-!>
M%C9P)#%)&'?".NW7-BDMDE506O%O%A"4$KPB"9[B N>IY*!H$5/"(\YI@C1-
M8D2<C2F+I3).9F?R3Z];45KVBP3MSVZS,\BR!OL>Q@6@8)0N,;7Q2SO^^<[H
ML_S<; TJ';>?K\#7? &*6,'Y+>B7N48J)M'&4&\030W8'8X*I)70*%4F94XX
M);,:8.N8OL(Y8FGIO];&7HK=<XC=U4SS0TX2SSBBV%K$F>1(62Z05=XF"4NX
M-2(3._X*#K:/8.Y_[U@8C0XIS?HR&A>&*HW]5]OC)PO2T)=?Q\M1ZIK'Z9KY
MQBF)PEH8L/I=$DHUAR@\:PW"VG#O"8L98T'7)'%YF/^>!?B9T4(IP*L5X!FP
MP"5Q)M:A]9H(8;04&4UBX"B*$Z8-:.30?VV=JR*EU#Q#R?7"H8@LJC5'$'D=
MLZ>T77OGZF=%AP49R<$HV;FTS;X/NB:G?.EK?(R>F6V9LGM9/:T>)9(IPPE#
MS"8>\21T@+8D0331RO@8EM"#LHF?KFH6B_NS8H4;KWP45O@8PKJBP+]26%<M
MK-4Y866"P/XO042= F1@/4<FH101+BG3L%A$9U&Z3S[?6Z&P?@3O0E8^,M*+
M:@\NJ#I8.AV>"S1DADFV&+=+?,Z4]2S5T5.Q0^6(,F^=#RW84QL"F(P'510G
MR%BMM(YI:D/R,%WV&*'T,;PI>7TB;BCE]87@0^4H$<ZG6!G$L">(I\(@I1*&
M9&)2 !,)H9H!=)!O*-7_7;@4&MV!;BV&#G>6+2Y[NI4]C@J,Q98-(RLU_5,U
M_7R;MU10%C+#I0C= X@'9);&'(G8>$Y<DB3*KFV*=2J>?/Y3F-9'*_((E8JT
M5*0% LFE(GT%13J%S)1[(2VQR!&K$6<I08:1!,4^U3:6B>9"KVVJ=::>#)H+
MHT@?V$/N5H>X7[=S>VC;,K6VN43SN!>L;#_30XF\6@^E&VGU16R7=#82\O,V
M"!6\HTH/VX<M^!U7KRNDWK 7APU[6?OQ5[MZ"O>TOU^%EH]S'6K:!QRNNP0Q
M;\/W\/NWZ^KV][AV_7L+E ,!X;^J-4Y"J\FLY6/]VU%H]N9LHI#5(>!%&S!M
M@;0H ;Y*@I'KL+C9+DF[.+%886Y -YO$2Y5H#4I8IS95)+[5+NGK7GW[^U8C
M^E'9VZO4'M02Z5[^?7"WI'L'^US=DB;G.O;$NV'+U],;/#B)]RA8IZ27Y\/:
MQ9'"*I5*.X33A" N=8(,ML$EFDB"!4]\C!=U2GI%1;>XB=+7^1I'5U'8U'YF
MU0WN[)<4P$KVR977O7[D.\Z[M]%#B9/X,3V4!-V(1;+ZMD1D(U'\67HHQ<\S
MV(<]]FVE"&5/7*)5TNZ2K9+>;DN?;,]Z8%>D)9H?O7F"+-?GZ#&GWJ,]88$N
M>R4;^'</&KL3=+_1K5 78MDS@@_K+5EZ_J4SY"8B'8"JU3VWN-18@=P>CT.B
MN=NC>UEM_'Y2H[56_7/MY*"]B^N-"C]H_-4^_%P[K='#T]KI 3MLG-')/6.W
MQ^G.9?7S#CN@W_D!_:,)8XZKVR<GM1\P)UIEA^TJK9W"=8W#@%YGTP>(H:E,
MM$6,"(%X(F*DXT0B*^$;*XBR)EYE9;'"^(;O.?4OE5FIS&XH,XQ=FD@AK*%@
MEXM8$\VU\1X[Q5TLTDR9R5*9O;0RFZ92\%#5+,8I4L8%%VXH:YJD"4I!4UG/
M<(P)6=MD?%694,5KB'1_2$3A<"6(P<]FJ"J2^1165'#Y0\1Q/\K5]WC-]&.R
M)+O]_M"[4E,MI:GF6D!*)YAA+$7"68QX&I*^POE]"BK*6NNPIF9MDY(E\\/+
M/(RW)+\R]=1;KIA,!$BL51)[K(@1AI(4]JL@OT2-Y/?I9E(IOT^5WYG"32Z6
M-!8<84$8XC$!^>7ASS2)L8]]FA@%2(,6*8_J(SBI;IUE3$(LFYTLM-)]L'2,
MWXJ+)[[JJ[;O#/JE'EI*#\UU8U0QI3RQP6F3ZM"^@2"="HR\<6EJ;*)=&@K(
M)>J6'KIU;E&F9+Q%F7UA#%'*[&-E=HH=O#$L,90%Q&^#S%JDG96(49E2"M(;
MBPS[W\ZE>A69_0@^B(>W>RICALN8X0(E7Y2>Y6?3V7.]+CU1+A'*(:490=S&
M!$F>.B1X$D"RX SKE33,*DQH<)EC4>K+PNK+,JR@D/IRIN&)TCPQ.JMG!AA7
M,(.D\1QAZ905%/XYM9*P@L+HRWM@\CA.%:;J?ZUB7^K*Q^9^/"K0?54Y(X2^
M@9P1^N(Y(]."SOK.@LZ%"==O[(YSPW!].X39_]D\;-3.0-/@P^U=5O]Q< U_
M@\;: _VR2P\:?Y[6;H;KGW[CM>WJ1;7]9ZM*OUT<-/;.8'QQR/FJTAUV^/G@
M&L9Z4FU7R=_7Q[16.3*I5<1HC9R-&8)=0R,PPU-02U):Q6-'*;Z9-H(!?6/-
M8\)@GU'4FE@P*S$U#G,I4WXSO/_/^FZM$55JV]'^SE\[>Y4OT=?*P5[]RY?H
MRV[E]]TONXV#Y\DC*6):P>+DEGM)NKD][(4@4V!PL1Y^RJPZ0MC0U[.,@ZUN
M&V9S%37;8*V?^U[K*@*=;(<M'1(5PK4]?][MA3_"Y;H-V\4@)# T.[;;]M&@
M&XV+0_OV>:M[Y7U_/;O/P9;0Z0Z" FUY.Q@]J]T<9 ^RW5XO^W3ZP$%_^HC_
M%X67AGE.7Q4>,.XG,="7X3T]GX\31M$?@#!&W?/L)G_I>Z&*6C_2?;CH/\-F
M#ZXR5]FK=_?V-Z+M839V^!WNU(/AH-N[&E^9^>3FR7,"SSF]U=UBVKERG,"1
M#F%PHSD-3G3P??0S*EPT!R<GON6F9!B-.]R5DSY,*JR5'@Y.NKTL$W4C:IPT
M^S-$"E=/WQH>KL_A[DL 90,/:_=?SV\GQZLNB9]\.!6Z<U%OG)%J8X=60Q9>
M8_>(,-B2M)*(I1HL8F(5TDI[%/-4.*J<P,8L!>J-HL9XG#)"+3>QT4QX%J>P
M^6-F&.5W@/IR<9]A<:TU*F;$(M@B*.*Q5TAA:Y#V+@9PIHF2H2;QQNUNA7?@
M>=A?6F']0;_,9E-$05XG^GTCVNW8UM"!F@'EG-?#&6G2WUK=?O^?ZU''#\)W
MF6*W-E=U00-M=3L9I,]T*YAU@UPE!@54!T65;4#]3.>%%T7-IVBAIQZY/)%C
M1T6S2G[-^1773NU1:FTBE&?(818CKCQ%!E0( )N4&T!V@B5R;1-OW-5%:\R>
M,[OSW+X%G)G.[:X6\)3O!^.IV3_)]\TY- #;[T\?.#6%]P &:&9@I.^C+MQQ
MG+/C>N2;&8^?]^";S@#8L-L;<W<Z' Q[?AV>"ALQ[-#&A\$U@1/<&'I,1W?;
M4(N6-+]&V' $X#C=$"$M<]PXXU-&E^9//TJC'#EL9FX<&=YX>HLV()##P=VW
M+,KY? V<&GJPS))C]N<REFD\L4Q/>M,\MV./3,_K,Z13F.(GW;K05_VU?\VG
MQS8[XR$E#,9\DV)WTB5-GXTNN?<#M%(W5YZ?AAT'6+N9^0]T8<82G?2"3O['
M_0LDUC:SK/4@/5M!G</V\+__T@\RI%Z(/Q?[%"I?#_Z.JCO;NUM@3V[5][[6
M]RJ-W7JM\ ,/SI#]J%&'0=?VZU]VMRN-G>WHC]U:I;:U"W/9;\ 'U9U:8S]"
MV9)DAO<B82RNJX>]6GF0'=T+R9C]K[ZW?Z(+5!6D\7U2^J?:L/"L/^';PW;U
M^@!7M_=:]1]_M0^NJ_S@^OM%[<>WJUJCR@]OP8&SR]KUG^UJ^_#T$*ZNG7Z[
MJ'W^'A_^.#RM7I^<UAH5 M""P.^MOZ^_7=2_'5$1:\4%05:$/#;E$J0-"55J
M%99@D&#JV4WW#E@NWL1$I#2F7!*I8L=BEG(LB'>:I3?=.SN5O=IN[?-^]-N7
M^O[^/Z.O.WO1_O]5]G9>L#C(O6-^;6E9O,G^KOL@ W[$LR,X'P470C\P;_3;
M__Q#4HK_;;+K=K[N9W^3?_\S0/6 \X>#W!T"DVL&7WT&DG)K(#,0 #F%9XX]
M)OE@@C\H0.=CN'28V1R@_.'R-E S>R\8",-!/SA-9VM:Y/ZC\ D,L-EU&]%V
MLY4-8#*!VR-WHTMFQWX,D E 89H&OQ%@2@U +KL./H_.NV$/:NK6@J%L1)7^
MO+,K!+!&.IMQ-L\QSLH&'9Z;#[4_!I/>K><?_^(M41A_"'-!XT%M1"]66N:F
M_LHX!(R=$:F+56'F%71:]>(H53)V@DM$09^!3C,4*:,$<DE"-3-@<;KTEDYS
M5*18IA1SPE6LI(^]H5YJ*6/)$W93IS7FJKKD-5?.0T:6\_V1VS,(GQY[-G,!
MS;VE-V3BIE!O/%@MWE<?YBYG\KV3+:O(O.DJ,L]V['E_99H[0X[5&RUB<@!R
M&NV$.DUS'KAERIB\\:H]S9FJ/>N1O[3^?#"SD3L]T \IYK-,)$'!>>*!A7T>
M-.,'5/UY5Y2[40'H%515L7OIJ <%?6700 ^ZO?ZGAS#BDQ+Q'\*AC\Y$><%!
M/BM3%2].J21"4=1+D?IM/%"]C,UE/1CTFF:86P/CV(N3;@L$\JX4CP+%%C]L
MLG>%%A<A!OAA,WCA9-4^S!=^6Z+R.O#3;N9O^@),59SXX$>Z)T;5UIO5]G=\
M<%V!<;6:!Z=GN'IZV*YO?V?U[>KEP8_ON-[8N3PX==FI[7RU]=VKP\;>:77;
MG=5__-FL-^#9[0->:UA>O?[CY+#Q#<;S1[-&PZGM][FR8[&,G9,",1:*YZ:2
M(Z.\1-R1F/C8&LI#WBI9EPNJK=^5!O=\:0_W9#>4JJ+0JF(%.;*EJGAA53%-
M);"8>J>,0*G4%G'0^LAX:9 UL8Z5U)0K ZI"K0M<!%6Q$DQV(QZ#\$SKO*[-
MLB"IHH"6U=-&65H5)1%*(I1$*(E0$J$D0DF$D@@E$4HBE$0HB5 $(KR'$XD?
M-P,3%X3EH=M15N^E"/;#B'2G;R\GUNI/ A[LU1LO7R5?O5H655I/LPC&^G0)
M;P0SENZ_I=Q_NQ>S#:Z]QHEQDB(FX@3Q)%%("HL1]3%V(G6&IG$HZK].R:JJ
MB12H?E(IZ"OUXY>"7C1!GS9@EDS8F#*+DEB'[AW:(LEH@ES*N2)8*FQ])NAX
M03G;H@EZ>0SPAD=90OF2""412B*41"B)4!*A)$))A)(()1%*(I1$*(E0$J$X
M1'@/!T)?LFH.DRS4!YS]/-D-7#02+%T3_YV$J8]+7ZSV/"L<%(RCU7]=,N@N
MYS4NG=</<%Y7V>PIE2%:"><-2HT4B%,;(Z.T0Y1+RK@EB5,LJT!XNZ/KP[LZ
M%>]XJM1%[UL7/?'(K=1%+Z>+I@=I5//8I'&,G/5):$XKD4FT18JD5#*>,,Q=
MT$7Q[6Y%!=)%)7Q^=\>(;_ 9)1>61"B)4!*A)$))A)(()1%*(I1$*(E0$N'5
MB? >SCXJL[6GHV:G/^@-\[X]_G+4""CM==N34L.M\5G); WOQQ4.?&C8??&>
M48I62817T2^+JXMF'C^1]PLJL*JI9VT6;]7ZFTS\5^DU"R;^'M-K"'4NEI0E
M,HZY,UH)([56GL3,QF:U>71!\X\5_[ZWP[QYY,Y(Z_\!2G]K6G?^=K. 2M9>
M<JW,MEFJJA:9/;!TJ4YBG!B4D- /5U"!I$M3A!5WBF.I%055P=<5>W*RS2\4
MQW,=6S[4T5N*?9,+8SWU0M#4\\1X20R.B=":$FQBIU:955>*_>N(_?1LT#K)
M:1JGR)!8(IXPB[3V"1)IZCBCS@AAUC;9NDI$X<6^!($E$4HBE$0HB5 2H23"
M<Q'A7UG1_,W;/8;'+3IO?7Y?M^&E6A%_G#[$R6KZ$,NUS:?W(1YW@"Y;$9>M
MB,M6Q/.2^'C=]IJ=BOG&*S4JWNW\]/U!=JRSV]GV9E#IN*KNG?EL7]GYS[ Y
MN)KZ N#++; $=;/3Z.E@-U;Z?3_H;S?[MM7M#XO4Y_AX9/R?MZOMZD6M\>=9
M];0%5WS#5?H'&/_?KP]/3]J'IWNG![1V>GA::]6N;O0$;1]<'5Q7X+G?KNH_
M#D\/M[]=@^$?'S9J[?KGPW;M<RW<VZ[2[^SOZQU<O;9'$E-B*7>($>80E\0@
M(SU&B4RQES311-J;34&-%PF32DBK/4^$UC9)L7-&FR3FRMQJ=#P5C-W:?F/O
M>R89]W;S?%767[RG+FX;>B\Y-K=T_R1+P<I^"3SZ4[>R@TD]F&N?& 6NSZX,
MOK'UJ.?[Y]X&B-*Z6@^KT&_VP\DE:'I]?M[K7C;;>@#?1?^U1/\*E;A4$B:9
M$"EW:6QPPKT5QEJJJ&#T:/?)_O@PS[7BQ-R_N&A=U!MGI-K8H=5P3^/@2 (S
M8.L$,LRDB-N\04V,1.*XY''BL&!KFW2=QG@=>/B6KRSCB:46&9;0\=1R2P4W
MEDKKM94R9CSUG*8N+/(3O:\??9$OJQ='/C$6,)A'3G.)N-(2:4XD@KU,F]0!
M;@/U&=:5B<7KVNQ$=JP="B;$TUUUNI]N#7L]/^,S_X#+/B_;I\=''E -\  L
MOS<QXCBU2&GX@5U"J2(*.Z+7-IE:3Y+XS0AWN?@+%_^J7CER6%(#6SY27($N
M9\:BL-4C+0R/%2."8+JV&2?KL;ACO4'HOV_L;T0-,*$!A%Y%4QI'%\W!201K
M-/X;MGH6M6'U3^#W7M3R_?[&;2=)]#2OR,@\_QB.$;$2QP@EJW",)*STBI1>
MD=(K<H=7Y'5\&_%&]&K.C=#BKZ$O"^B@"._)HQ/8X>GN=>VT=EJE.[QZ7<6'
MGZL7]>V=Z]IVE58;N_2 5FE]^Z_;F^VI:U?A+OC_]4'C^+IZO7<&FR^O-JH8
M/H%WP BO#WCM1]AL=TE]^_@HC;%P &]1J,V-.(??-(X)\BY)+09(Y2VYZ:!0
M&&O PQ1;;KB45*?*8I(*RK5,$\IN.BAV:UOUZD[4J/R]\Q2_Q$+OP/UCF1][
MJHP $,]CP05/ \@GTH-68V H.N?D)![GN7APWYYX-VSY>AJ"9[J=H#CKZ80S
M=R[/?:?O?_<=GS8'F8K]V"QZ<.1BD6H',-#Q1 &+4H-T;(!9$Y\2:U@"YOU-
MEGL])]9T5</6.#CQT7FO^[/9#QP+Y@& T[#2T4!?PCM##2'=A\];K>Y%_].=
M>U!;]XX!U8Q@(:$PDM%'H7SRC6#>R2Z5]\^>0,JLW#*0H:7/^_[3^)=_CX\2
MFYUL,ME--^-[X"TC&"7C#97P@*1&QZVCQX] UD8&LFX$&^7?)0F@8''GUWB#
MW/G=KQY+^$;,DT<]]M??)?'=+WW28!],@Y<^)B]$+LI4S+(G?FH.X&WV(053
M=CL@;MTA/-7U;U7&6&ZZN0B]](3OPD[9]&;]V-GF&#:8)6;Y@%R5MTN0S)__
M &(4(@?CM>7JEU(T<D(]+DWK=F7_$$+:[[::KLCM!YXTR$*D#;YZ6L\#N>L/
M#S37K3=<(_&!$WV3A<D>.+=?5B9;?;>O24FRAY^<Y3ILQ&RWC*KB9"0\TJ#*
M,Q*ZI'K]G1ZT=UCU]/<SN&:4D0 S^%R%,9S1:GN'USY7XUL9":??KVN-P^9!
MPUY5/W^#<8PR$D[MQ<$US+=Q< 7&&89GA+8_HVR$G4&U<N1ERKWQ!$DNP1:#
M-46&28:\QD8IS+TU-"0D)/)V=Z\"52M[SY432PVUE(9:09NR.XHFEFIHQ6KH
M:J*&&'4\CIE%B@J+N&$$&>P\2JD6B7<\]1:O;2[H,%@@'50(6^2M ,?]@1[X
M]Y(.7G"<M5"+90M0Z;@O75OJLJ?JLNHLI$J,D#(U*7+<8\2E5T@FS""92F(%
MIW%*6=!EMP,='J[,RISN LONLR.04G97*[M3'.)YJG'*#1):4,13R9$V2B/G
M$L8%C[UPR=HFQ4\I(_^V$[/?G0>KVX,_.^^EP_M;A"*C)2@5V=,4V;=9$()C
MXZP-H99)XH)?AR+)DQ0)1IE(O4LD5VN;[':5B0(95!^F6_L#A?9E(4@IJL\J
MJE/,(76"&7<,>99*Q.$OI!D3B##/X?\8OA=KF_+)!6'>N0/D*0;)@\X.WY"F
M>"LG.G=$R97:9"EM\GUVXY?8:%@BCQ(1IXC'PB"I0:]H'^N4F@13(<.!CEQ0
M6&YI&^;!<O.&G!,?61<\N^>B%/@5"?S,T4G,+*$T1? 3!)Y8B6#U4I2DS%GG
MDU03LK9)V K<C:\D[BO!%3=2N$B\5!>FMUNONO UK]_;R=:>;WG=S_*H?NK6
M*+5!AWAPW;$^<D,?#;K15F5O9S^JV$%Y!O:<R/1>0*K/KRX_98L!:W''[O37
M>!DKXU4L]ZNE]BL[!:C7Q[3V[8@PJIRA$A%N&.(N9<@(+)&C3"2$BSC1-HLZ
M2GB1'>WE(=EK.JAF9?O:][HNJZ]1BO5+BO75C%A?',4\-HEF% FG8L1Y$L0:
M?J3.&$4L<<3SM<W_^8>DA/[[8]<W?E;?]ITX_2TJE<+ZLG(=\TN[MA**&I1Z
MYHEZYO@F?'",PB)SC+3'8/(FH=N[P!IAI5++A4X)-FN;8CW&[.GG6P\3IC=T
M\O5AM</JO5NE"G@Y%3 /-3B7SJ8T08+'%'$5<Z33Q**8"L^)U(F+V5.]7J^H
M  K@\BI@:MZ;&&0AHJ\*[2';]JD'E>G*UH&E&W79S-)W[D$I1ES>6$!':U >
MVJW8"5HYXDP(6!F%G/<)XE@P9%C*4(ICR5(K--5X;9,6.LRX]'X6PQ1Y<-!-
M*=;/ZP0%L09%:ZF52&.J$-=>(1U[AC!-I&)<I!R[K+V;7$'P3<&MCX^20/#X
M3,:W&XE<6)_L354WERE5*KP5>V,K1YHXV,"403A.0_"1,\B$*L]")3;67CK%
MS=HF6<?X*0>Y9:9!@>7[^6(&2R%^"7]JY8@)'<=4A?5)0(A3^*$Q84@82QU/
MJ4T3V-P%)T46X;+?X*M[F)XEZOJ]J\]7A4>E,EV%,MVYR!3IJ,6W25+J"(L1
MYL0C;CA HL1@I+#U*7&4IUAFD(@^9P+&6_7[E-D7K^04*E7!JE1!=:(*4B\3
M1A."E&<<<6TY,D)YI*BAS"7<40F;+U\797)&F9Q1GBJ^@#K^ZW9&Q@<[82PJ
M-,U"J<I([6?:EJYF$:HC5J9Q'"-O<(PX<Q+I-#6("TPMH4;C5-^%4(L6I%T>
M0KYF"D8IWH41[RGJE,(K3U2*2&Q"26=GD9)$(DNY)D[S%!#I7:BS:.+]OM#E
M\\5!%G"0!5BZ%4:'OL%G%& !WJY555IF+PQ<&MV!;MW96NV1SI!1?S4&9'#=
M86B>]F!78N$(]/#Z_H^B0;%A;>%/5$KWZ4J +)X_2?&A':1$DMM0P])@))V/
M$7'6"P[HUJ0K2/-[C+2\L@U;:K]2^[U\.$ZIXE:EXJ:V>NR\\482)&&#0IQ)
MC<!4URA5L<586T8U7VWQKM=0<"L PO_*VMANCMN>W^@YO;B[^^FP/VBF5VN_
M[$#](IVA=]+4P[+]]!,9VM,#O^?AC;;9:F;.K[(U=*-Z9+#3CE&%L(PEXL88
MI#2#?3])#!=6,RK,HM;0]Z[^O7;="^CRK)WT[[[5O8B:_4A'O;GU'W>7[@_T
M8#CH]JZB-,_3F#&#HAZP32@?%BX,C:EUY^K_]2,_9J_)-0_M/!W?:CP=K/MG
M:#.MX@U,U:/:3(L-'+/GZ-P,ZO89VDS'B7J6P?('=Z]^:5?$O2X1=>O2M]&1
M^,#K7K33<=Y%<]V:9W?>I])FQ@Q8(H"CX(1[8"OKE?G#WQ/ERK[7J\P?SW;$
MB5?Q*;$>[RTR\4Z;LC,,BFZU3K7=VA\WT?%#,'%EW&QS?PR*YBZ>F)Z(OE&\
MG-N>Y^W:YP-Z"#9D]?I/P,S?,#PWKO\(]^^=PGLNZHT_PWC;!\T;MF?[ !^>
M'K9J[=UKN.ZJMOT-YG 6![P-MBK,J1*#W7I5HX?-FYU_A4TT6)A(A-)9G(?F
MFY)RQ#B!U;7$.FE 'P$L6=$I\7,&*+Z& /WWH\J7E+'2*])(3W1TE1JI(!II
MFH>6)%A[DJ;($8L13SQ&FBB%L(-%C@FU!.M2(SU1(Q4BM[_0R#%+-PVX$1[Y
M6\</@F-F[(HQN<_[EO/U06K[[>8#ORA69(_1RXMSA'V_5,C+*>2Y3L8TEIPE
M"06%; CB2G&D./PF#(,M5AJ<JF1M,]ZXG1C\*JW)BJIRR^H"KXCS2FWRNMID
M"N^<I+%BVJ#8"# X4Y8BJ;!$@O!$:0,J)L9KFWSC=C!'J4W*0@>E_[/,=%M5
MU,PSH=8[XF8>LN%LG>C.,5PPSL:&BRK]OA_T?Y$;4^Y!#]J#YKIC*BJ$PR$9
M1J<8<<$4DI9IY'1,@0$T5<H&1+N"@,)WNOV4"7=/TC)/1[.EEBFHEIDI TJP
ME$Q:%,LD)-A:#'8SZ!N,5<Q#*5#*0,M0MB%+-5.BW,*@W#?HJZW5OT16]WI7
M8391VNNVG]A9\Z-X55;EH\WRNA^T]XR:\=7\H'[N>_!9Y_A+M]_?"JN7=GL7
MNN?Z7WTOQ.24F\]RF\]<?TU6_784*T\I+"F"[88"S*4:29$ZI)@0*;'"PPZT
MMDGDQI,+/+QO7TOIN7U=S^V]+3Y+S?/JFN=J1O-<'''E ?VR&%DL$L2Y9TAR
ML+)5C'6BB$HM]BMK ?J^E4_IX[R/BO7!B>^57LW">C6S]:FXD(G3!N5:'I\]
M'M>%Z"C#4Z,QPMP[Q$V< IQ+-2()*%FAJ9 BI HN"(XJ?0JEZ_*MNRY+5;(R
MH%8Y8DIX!H ,>1I"OV/JD28Q_.F52*E7+I'IVB8NW9-%P69OT#.7U?-YB@ON
M8T>WOT8,Y;9WPVQLI79=4KO.]42*"0;K5DGD8N\1]XHCZ1.%3,SB5 NJ$TW6
M-IG<$"NR?S]B&/NS>N8^MNIYC8#+4O4\0?7, #OJ)"=,( :Z!G$B)%*"6*12
M"Z:C=@QS&H!=J7D*"OV*=XI<$J$D0DF$YR?"O06N[JYB-?GR!=4EG<$5SU\_
MZU; 6LC-:&H#\&'0]/T/7SJK=OK]B%D'&"V&'=^E67I%$OS#,4H8!D2@,#?2
MYTBOV1EZ5PG'JED;(DNTB#'FFB6 \11EJ8X3RQE NINEMJKZM-N#9[3/@7T[
M@_ZX9M6H%%5VK"?^W0<TF*]75GU#9RL6_=::+M@_(]WS\$64=D/ 8?]3=(OC
MYS@\?#D:>087YRI:C5B2AUI6Y]U^,USPJ>=;.F#.4?FI$0Z>N6M4  M/;]$&
M\,MP</<MMRK'O#Q*R<2.RQO4F?EY,JG8?:Z//3(]K\^03F&PGW3K0E_UU_XU
M7PZLV1D_/&'P]IMSOW.&:?IL,\PQ(K!?MY>M]B< GKX7KH(QZ<*,)3KI!4WW
MCZ8S/+'2".*$XYJ"G22$29R):9I(+_V16-O,5%00EZV@)$%T_O=?^K8:?SU.
MNU6-*..TRM>#OZ/JSO;N5N5+M%7?^UK?JS1VZ[7"#[Q6;^SL1XTZ#+JV7_^R
MNUUI[&Q'?^S6*K6M79C+?@,^J.[4&OL1RI8DTXF+Q.J&YLGWEE0982WEL>""
MIRZ5A$@/R\T<E\XY>5//8OA,&*P\)I[+U&E,$^I4HKP@!G.QMFR)OH6CNE>;
M/T]I/U 6&SA7&,O6]A-D@R:/*\+WRW)Y=(/%#RZ7M\1W,7O<4^\=+"UZ;;^"
M'#ED3_S4',#;[$-..'<[@$^Z0WBJZ]]=M.%!TRU@L;BYHH3!+GA@W;TE2NN]
M78)$92F]%7G%MF^C^4]/";=XOC9(*VRT4Z@V2$\]*7XK36!"6&X$NCJRP&[-
M09[:,0[1?4I8Z'MK<K!HBL5VK2_1PD E 5$S&9(5N$MC@Q/NK3" N!45C![M
MWM6WY<'M6AKZ<BMCL=D@\$H;2/QN^AG@PT9P#+GFX6>X[_08U[8/+NN-;W&]
M\4?SH'UX4MVN7-9.=UCU5C^#O5;U]#NMT3_/X+E7]>UO&*Z+:]MG<?7'G\W#
M]LY%=7L'WFLO;]24),*D*M822<,9XEK ;THS1*F+D]C&DA@;.HM*>3NTZ%5B
MOU=YPESJH_>JCT#;.)Y:;JG@QE)IO;92QHRGGM/4!7VTN)-*J8]>0Q_-G(=K
MP6.K,7*,6@1["0F=) 1BV&ACB))IG&2M4$5!$N&* R3?=C?!_4'7GB&C^]YE
MQQ6^T\\<91\L6:18H.O6*1[\,OYLU%-J:V:M*ATW:C'5WS_1/?][6,W9"[:Z
M_5([+J<=Y\H["B]CFGJ+!&8<T%I*D:$$(R*(MM89X 43T%JRH+]>T1I%E[D=
M188WI>070?*GN,AXGAIL''*6X9!+)I QP6Q+L-.286Q8'"0?8UYXR2\#D$HB
ME*[6%\R=?H?E*U8)A^_9^3*ZEWO74GO7P1QJ%8HIL-\1-J&$HPEQ;M(ZE$KL
M1"BP1CA9VP2[O_ 6?5E=YDUAUE)R'R6Y4]09,ZTD RLS#H S)!@AXY5'"3:Q
MTRF7L5$!=1)6D!+@Q<$:;S!J($L 7A0)7#;A>S,.NL^];K]?JKRE5-Y<T1:+
M8^R%B1'L5:$2+$F0295 1#(G ,80(V@X@* L>0,]K5[+__:1I?X5@$XI]8^2
M^IE.)\8H >N$=,C Y=QB9$PHU228(2R6GF.^MIFL*_+&I;X0'I="HZ!5M>%X
MNU;=W56FBH%Q?E'[OE1]#U%]<\5/N%!I$M,8:8T]XDYK9$+LA=%:IB$6@\I0
M_&0=EO@)Q:5*UTR1A?@5($LIQ$\7XBE^40I6RB<$P2)2Q&5,D>+P)W,TP9(S
M2K@)^(4+6F0A+GTTC_;1K$>CQK<_5]M&["-;<L]UHE3S92S$<LKN;!:Q>&(2
M'P-8T88DB%N3@+$&9AO1T@E)B70A%H*I)T>(E@Z:=RG6CT8[I5BO7JRG&,:R
M5#CL%>(@P2$5Q2*I4H&<\!2#UE6$!,\K7U6 4^F!*2C&F<M>G:E!\[@4UH>:
M@<5[1ADB5A23X*V$B'WM=<]A.%=91J[_S[!Y'DJO?[ 4BI=Q7]Z)!6:JG(V7
MXVM+=P:5CML9KT@)$Y:""3M7&43(+(#*$06T1F)M$'6$(,X2CHQ-*6),*&EQ
M K9!LK9)Q>O7PB^S'PKFKBR%]F6%MCH1VI@FGJE$HIA8CG@J*#+8&Y0F/)'>
M>X=#&V^Z( :T0$); K*BV"]O!9!]Q)C]XN"O,O[W$6H;SV(MXQ*J%2.(P4:+
MN'4Q4JF)D1;2T-@3GR9Z;9-04N13I?)HN*A8JQ30QPGH&%=5>>WZ^Q&/$VIB
MJ5&BM01LA2D"IG1(DD00:GAL>8C27W >4B A+82?I]!88L'1[XQSM#SC+08"
MF;3,F5%SI89;3L.160BB+'66:X%(XA/$L0P=<EB"C.2)=1@SA^GBT]ZE+<?R
MH/>=R?:*P4LIVRN1[:E7B,34"DXT\BH<^28A,UA@0"X^CC&W)HZ57WSD^U9D
MNQ#>DD+#FIH?/"3G\+XIC]9W5(*?P2*Z[C"4SA_/X&F*L'!D6[K2XPH)5.P=
MXL6S%ZY]K^MT_^3> *&9;:.,%5IZYZ"SJ! 617KI*%(6"[!Y38JD=@3%J;4"
M,["&E5S;S-H;T7^OMG?B"B2HX'5O2UU:ZM)7RGLM=>E+Z=(I"E?:\A@S$Y)?
M+>(ZH4CB. [-Z(1V3,LD="+Z&+JT/.(MB5 2H21"2822""41GHL(D];)M[K$
M_JH_Y>FP/VBF5VN_[*M\[WWW0I,7P-99Q\MZ)ZKJGCV)J BMSRA>SSKS?M_8
MWXB.NX!=.B'J,/(= %K!-1:Z]E;V=O:CBAU$@VYTWNO^;#H?]7RKZ=,H[77;
MT5;]K]UM1-1&U)B[O-FQK:&#L>O\MGX \X,3/<B31/N1S?H! Y@.3\Z:. 7Z
MY#FEYSYT4NT<1ZTN0.]^]%NM_F7<./B?T;'OA.]AA,U.-DBXO-EUH9F;A+^!
MPL<GV?3R,3>[O>C*ZUY_(]KM! OB=-C);8N+YN D>T!@FU&+WVF[XIZ/S+ /
M1.SWPXO"T]=G.QG/C$-'?5CV9@K0#^BGLYX<V8/T9=9,LYFY\<=/V8CVAZ;O
M_S,,Q(8A#DZ:_;N>#!,?OUUE,?9A7AO1'S"G<$/V]1P]PH7S#SOO^9_-[K#?
MNH*%LP'DA@&GPU9K4>9NU,UINJ@],_RG:YO9FR:D@Q%$;NC#/'H>N/\Z?UZG
M.XB,#TL(JV\R(F1=<<,]G<A?-OO9^F9'ROKB)O.T]5G@BQ/?]^-WCQX>'@1D
M6 ^-H4<KY6! DU4;/V*>!">ZG\T=UN@ZS+XS7I'P?I.7$0^/T.<PVDLP% <>
MJ/5?2]BBCVIE/F.4QFL9"\%O#RAQH,^O+C]E4X693HZ(1D721U71]WS+Z[ZO
MI[?+'OSA82%T"XS8^EC00E.UV;8RTT.FY(V:MX]OE;YS46^<D6IC)UP-UU:.
MM- &%M:@E'&'.*8*F=2!X>H)D8)0SXU9VV0;M\N5Y*8JJ/)6)F0+Y*>7K].8
M@>^0R"9(P&C9<HF[)9VY-@[2OQ%5P%8-SX!'7*U'08<=YWIRK(C[]\A+LY]K
MY'!CII7#^S.-.CN(UQ:8Y>1D)TV]#>W>)P*S!Z/> ZW0L<U6,R/Z0R3C1L>E
MCRX?M>UO1\8XHC35B."4(YY(C:3S @F9.&D<9L3(!\C'QO+0ZLU#LL:,U $G
M]@%>]?I!]J,<D/S,MCM 1<<Z^\,' !:40@\^Z;FQ9,]NO2"6"ZMUY(@LVY)U
M?Q9D]7Q_V!KD3373X6 (P*??'?:L[]_&,!M1N4BC10IT!UC9 1)FA*J MHE^
M'[9@79IZ/=JIU[<#*C*!=+ @3="%04DV.S]]/VP!W>$@/"F'X.%+%^T/0"7U
MQQ#,Z'XS>S)<GZG8?@Z@1VOD8#G@"PNJNG\R!H$YK 7V@=?VARD@TN8(9;:]
MO^/6CO<N7WU8]:A_#DH4[HO D(*- M0>,$@^Z,PZR':.;C\\WL#XF[IW-2$#
M(.Q!!K8"_)L!FPM#" ,<;66;88:!1W;(>(,)P\G(,0/5_(A' 9H#MV1[Z$FW
MY49 <DHXX!3 E[VF&8:GW[=&2ZX.S#&%_3#;BUQNO?3\N8;7A<&&R\?C&[]X
M?F_-5B>0/-RI76#Y;'N=0:13@VG>P,G>.O"]=C!*<EZ88\+\T5VPFCK' +67
MY[R-7!]_=!D/&C.S.[/5;'8 A36!)?N!1ID,-.$ZFUL, >18WQOHL%1A[<9V
MY !L&%#&/3!V0*)&;&[\^//.#2NDYT$RX<-\25NZ=PQK-38ELZ4&7= &SD*M
MYAFL)H+/.BC(6?[8/I 5Q@"O&9Z'AP]#;V1S-<&8/X-E"B\*PJ*'(,$]D,"I
M-G^AM2 /6HN7'M7#.*0RN]2STCI>\9'X!<-WUMH<R? "/NK# UN9>V&RNE&^
MNF'%<R,:>"RWHR<+#/@^TV4W&MD#.,_] S?M_['Q.]+%4_7[)/S^R,/7A\#V
M\0GL]\Z4B@#7Q^V^/C+TYK53>X0-=[%-!8HY$8B;$+ZHE$8ZM.ICS,1.VI<(
M2BK7\NEK"1:3),1Y9!,.II.T*5)$*D0,CA,FO5$RI+MMW.YV<>N#:.QFF(%5
MB_>F'$9I:WO#H!(>KP->C6\F-OQ7W]&M$))1Z;A=&!K8,H-*/K$/S%OVLK9]
MP*NGWTE]^^RZWC@^<BFVA!F!$A^ZKG.>(!U2'!B+#<,.E@\G:YMXXZY25Q,7
M%C#.V]@F2A;YM?J)JZ>[1R253,-^@93@!'%!"-)&@B)B6B2)Y"Z):6"+VS5<
MQ]IF/;@/SG//6O V JAHCHB<,<OYF/HCXPP,QXD:RLQ% #Y3A#PV:2S G^/L
MP&0XL[JS[OI^9OZ-L%4'^"TB%!!49W#2GP-B,P<S&]&*#)N<%+5A&X"D78%;
M<YZ?]^V)=\.6KZ=W</9>M]7Z(_=&-H)KI@%O_[W5M6<?CHEW0;]5C[2W1,0J
M1CP.3,P)1S+4\@L4U]1+2PE=BSR(^GE8:1#\M3=HG*;=<" 0+(%F.%3MP9]H
MY).>GEEFB/__!:=$R-P\#DTZ[I:@]4Q&IF[!Q7*[GKF PN.S0]3(=X(=,6-\
M?+I3J-I@Q38[XY"[4#EC]$F(L;M12,/Z\'8@?'90/Z%\'I,'=&[I\[[_-/[E
MW^.#_F8GHU9VT\WH.WC+OR^:;G#R2:@-K%B(+AT%0XP>GW]+-K+ TQN!A/EW
ML=Q(,+_S:[Q!'O4=W<!$/NK.7PV6B(TX42L?+-Z(V>.>>M]@Q=U?SS[VGC"6
M@N4>94_\U 0!;-J'I!=F>UAW"$]U_5M)9K^8[ITYFJJHE!G102RD0]91* I;
M7CC* !4#.UXTWO+FR/+4U/M'%=-<X3/N##3^519=KA\+%:H? ,RC"J0^F XE
ME0.5B7H:^Q<Z17.Q,OC= TP(AQH!V@3<$1G=^F5C@>=/3KJ'D]YWXM%]DR^3
MBE;G"WW;&47GS=IG>/>/G;BZO8.KV\>X^AE&\V/O]/#S'TWX_23+"OJQ2ZO-
M&QE%[5U\>'K2.FB<750;W^ ]WRX.V[63P\^ULX,?NQ=91E'CX/+@].#J[^N=
M0;4YK>2N/.Q&2B!/"4.<68D4,3&*C362&*5B$=RHZXRLJFWP@[>7-Y!V66JV
MCZ#9,'9I(H6PACIN1*R)YMIXCYWB+A9IIMEDJ=E>7;/M#FI;N6:K-:JT=G&$
M+8E303BR,@V]0A.&).88J23FPFNJF3-O2;L]0^VTXDGF. AW'$0W<_IV(^[)
M#GN]$%42<.Y3[*D/6LC[!8..'Y@Z?O>)5"_$>O?WLH!+(/,?O6Y[*U_]KUF(
M5SBN&K-)J367U)HS>)#$%J<6EE&E2H8$<X.4)P99&_IU&1Y3Z5:68%Z6[B^N
MQ,O44V^Y8C(1(.-62>PQF ;"4)):SX+$$S62^,<7BR@E_A4DOGH3)ZF4.Z><
M1XP2A;@()?^MLDC+5*?6^42+M(A2_PP>O>()[</QT#1E\UG;;[W/4MMO' U]
M#6M?:L8G:\89+,198F/-!-+8X5#.5B,ME$$:/B?.>\>L7G6QG0+YP$IY+S(6
M*N5]%?+^[2822A*M-=: ?P35B!,OD!*6HCCVDA$N*%:TB#+_(3Q#VWXD"7ED
MU5U0Z(DPJ#01WP0,FC!#J1:?02W.P" <$XH3+)##RB%.*2"@E&DD6=CT%%>@
M+HMH');R_JY@4"GOSR?OWV_"H%@Y(V-MD8U9@$&&(AV\PD0[*1W35.*XB#+_
M$4*\=CJN0,%=9>7ILO+T2U?Q+T,I7F!'F$& ,4\$"Q6*J/2P&V!BD8ICB;B+
M:<H]B67,GB6,HG UITLM6FK1 FC1,M3V;6C1@YNX6K#$6&,D4I88Q!.PI56*
M.3+.",F<IL:3]Z9)Y\L(9ZF._YI+!%Y47'@F&7(D)3SD/8[]?9\R=U_SIQ_E
M*8Y$:.:NT83Q]!9M8&[#P=VW+$JJ?&%-D"6M<C6?&#K[\Z0W35$[]LB 27R&
M= J#_:1;%_JJO_:O^4S29F?\\ 06_];<[YQAFC[;#'/^<:&R3K;:G[("M^$J
M&),NS%BBDU[0MO]H.L,3*XT@3CBNJ3!4"),X ^ GD5[Z([&VF>63![-L*RCJ
M3DB\TP^JZO5"G';+E,PK,WT]^#NJ[FSO;E6^1%OUO:_UO4ICMUXK_,!K]<;.
M?M2HPZ!K^_4ON]N5QLYV],=NK5+;VH6Y[#?@@^I.K;$?H6Q)0+-XMTBL)C+P
MY@NQ_>\-)9IOT-@Y*0Q6'A//9>HTI@EU*E%>$(.YF"_@UNR'ZH2G/B];GM45
M3&?J"O9OU!6,_"7,I).];B.*9IXT+CH>RFJ)F=KB1,T_]58AMWZD>WYV$#.O
M&)=ERXJ1=.#N/?_3P\)&^[[WLVG]'4.X->H'O&F<N@\C3N:''QZ05T5?5!/_
M!O?\DK5^S7<YO+I/]1 JUA[#K2\IJ!%)-J(<O=S^^<PU0;[Z3J@'6>FXK(']
MUVY_ *O?[&5EY":NY6;?MKK]8:] %4'L"-Z>MP[HSD7]1Y77MX_C:GL'UT[/
M2'W;LNKV[V?5!L#<T]V+@\;O9[7]&Q5!VG^='C0J\<'U,=Q[=G70^$;KC>^\
M=FTOJI^_758!DE9/?S^!W\G?UV?7M<H1TTY(GPA$1$H1)T(@HV.-O!9&4)DD
MW//<%LGT:258$L1;F\24I5XICC56EJ5<<*EB[3C1Z<T"(GL[C=V]3#='7[]4
M:K>QX(H*S=Q6A?>.]+5%Z/X"FZ-&$J&.">@A])\A##!M>A>^ $Y&_1/=RRL3
MCWD\JT8[:B'0][EIR3'Y[>R?X^(GM[3I5M?YB0*<*?+O@1C- '-\^[S5O?(^
M+R44ZG%J:X?M86M21SF%%XY+X$Y&$JI@9<.>5+7-"_5F55/&$POWZ ZL6RLT
ME[#A]FXGE,H-ZYE5ILUJA'9#A=8FW!(N!,;J#_)WOD(I[!<KH]EJS5 ^[%V3
M!0E!#SJ88,WSL-5EA4Q#FY"6SYM% )+UXQI/L#K]\7896&OZR+:^RAI(1#_!
M3NH,;A*]/PDSS3CJ?/QG6U\VV\-VJ+4;,"&8)7D)_K"^=^S7@<,VHK]\WLNB
MV9D, AXVL"?AP_DW Y<<]W16AQ.8Q?ES'_AK5+4X+Z\S.Z]*,(BBE6\M,]X3
M6$3[R0U[%V ]]WUGKG#^=J@<[-W6S R^ LEV\CGV^M71'&<O&-$B/\G\<)O/
M :Y^.Z*4&@F[#"*@31!G7H%ABR42"F"K\$+(E*YMYKR<+?G-K2/OY  <T>Q-
M>IN<@/+)J[K.B\Z=WK;.,%1G6FVDRV[MCQ4RR$C(,AYO!&H<!&),/'.(?CSV
MX;6+(ZL52T)RI_%QC+B(4V2(8<BF/"8:U@;X9VV38'S+L?;?45[>>V/6>ABU
MTKE#'P%GO18'S;19_143+>*A$?/4T^S+C\PQ%E>/C[2A!C,O$#8X0=Q;C!15
M*1(\CG622I[$R=IFO(AA1M!ILFW-<T>^-^I1,;F7YA6Z.D[YT"P2 XM(8 3%
M8X> +Q3B$L=(&1DC;XS3-)&IHL BMWWU&8=,(%E X?HJ%![<B*J+%4H;P,T8
M+HTU4,8^3ZHS_-2(K66JR=[#9=NS8'[VHL*U!7II1CMFU<J1<RX.!BDB)NQ>
MGGLD%?S@S&$6IT8RXEXT.+=<^I=:>I\(+"A/D.$6EAY[BPP3&J4J=4YI$-A4
MAE+"RU0R#U:TU_9DO%$MJD":^]\6]$"8K4M\PYY>>%"W$C\F8V_ CRE>S8^Y
MEZ<W?(4MY:K1@XGD*UY$U^5U=7PR?UV[/KNJ-LY(*#Q\N/T-UQON]*#]Q]G!
M]>%9[<<>_*O&M=/?3P^:-XL95UF]L7M9;_QU6CL].:MM?XMKM-8,)_2U]C=R
M"-)S<'U&JY]K38#_I'9\Y..$*28(R$ZB@NLR03*&'U[&DG FA;?Q3=>EC&.#
MC4B]B277@3\Y+ ^U+ 5KP2E\VW7Y)3MG^EK9:QQ$C;U*;;^R%<[+]E_0BWGO
MH%];@!9[K_;]S^S 9WQPG]E0M>99MZ6OHOV39LO_7)_O,C4YOZGJCCX.D&D;
MC'D[Z/;6,Q-^W% ,5-HX^2=#7*'35,-W7;>G1P_6ZU&UMS'Z8WHL=-X=]OUZ
M5A5ZQ@,U7Q(ZNNCVSD9.JO"QMC;L6>$3Y\/K@F=S(ZIT!EW=\0,-8VPW![WN
MS\F[4:,[R4,JU'EA>$+W+MHTP2#N9;3)77RP KZ7.52&\$?8(O)&=W#G3S_H
M]EOZYV05%STOU+O/RF]G+NO!U>21([J./]9]T&59\\Y9\BZBWTN1Z15Z>KW4
MU'8[D1X5%\CZ @>"C_G_');W9*:_ZIQHAM4;IK %#;/3!O@M:XPTN_31A0YN
MVW[6*"742_?!!LJB) (X*5@KC!J,K_\U']_,5@NZI-;MC,I,%0>GOO@.^YU5
M+XXX-<)J3!'8O0YL89XB(X5$J75&V<3&1HB 4\DO6EY<G#0!E%YDO-;,.GQE
M[;1A_>N@V$-9_-!;/6O5_7[%+G@9@ZAUINIOVH!@ZZ39T=%IM]D91#^!ZT+7
MR: X6_W@4>H/S\];35_(_:1W8^N<-EN_H__!+YNO90Z1L1+JCUW[67Q*1H+>
MT[JP2;"K##,T!A.$>R>5TRQVV$K Z0YCOV3NZB^5RQW8_>MX<B&/;?::B:+!
M'T[1S+1(/CW#M4;UB*4X9B%$5L1*(^ZE1,K%%@&@%[%3%#8&&2)F.2?K>(%S
M?^G&2Z#FJ*?>I5XSKM+$^&"[Z51K#&I.I4MF.9:<\1R<$;K7,*.8%L:&72A%
M'!8)22\,(DFL.*$FS?PF=#WA;"%GW'!T1)7!+Y73?+>F6565'77/ZZ;'*R9/
M@;-BGN@8F#Z%&2HP:XW2EF+F58)7D"&U/?2-[CS*&556JW3< KSST9FM=OK]
MR-K4$B>3T&D0?B2>(DD3CJQ0B5>,\\0"^&%R-3J(46Y]G'*2*,Y9"-0T."4Q
MX2G6TDJV@@2/D@F69(+K;T<2M@%&M()5EQ;Q<"ZDDC1%.,$DA>5*-%&@<=2]
MZN8U[=F'^70?#;8?ZNY-WH"[5[Z:NQ>VEG8S<WZ$YHMY /NQ[UB0TB)Z? _&
MHGEYN%VA\(_53K^1ZN==7-O>X?7MW;C:.+X^:/Q^ L^)#]NU5FWKIFC^<5;=
M/H1_EM:VOU_ ^S'<PT'T+NO;M9/JYS]@S"UXZW?\=SA+:>P>Q=HI(Q.+8L[
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MFEE/YO-NOY\'Y8=!VFX_Z*-^OPOS#T>46<9$+BX3'3=L.5BPGWZ&E!-*-F'
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MQ!G(SW#5-$E2E0+O.X,49II?(46T 5$ J#4.:-NI',Z_HAP=:#URMQ&64Y?
M5J,X'9><"'2^D,6D(7QL8'QIEI?/1 [,J['@T"R99T_-S4BF8WSHTNU]Y[Y/
M%*N!T=.AJ7SCI32P=L%OM!=+.Q388U1^UAT1/CW[$,E(>$F0$"]0FG 9:B(]
M'I!8^D!UXVK!@T48HMKXPC-^(H3D3(>2^HDGC!<K&:M0)XM'B@_'%]-) <P'
M#).64OZY7H]2ZDKY!"E)LN$PNRR>+UMW&S[IO@*,KYO5_1R-#KU^P/R[G(P.
M7+#.O8T?-A9]2H.-'XQF?5>P'1DKT%7P'1GKO='UAN?-=ZJXQG><BX]V]"@X
M*D^GS(3>Q(GXW24#C6Y.AGMEM4>Q>56:52OJ"-QRSK<)?F\-BZV+)M\^Y"HB
ME7#,,3/:XYHRZ2?2UR),#/PGH:SK['7?P=>+X?O30_?]_I_LZ.,G_GYTY+X_
M_3L]V3_C8$7S]_C.CPJ>]^G+T6*MP-'?PZ./;SX=[Y]=G9P.1F=?WPR/WQWR
MXX_G7T_V!R.8'SL&2_SD].#KPL%Y*J*8@8]/ C]@A.M$DYABO537C:($#/%$
M4PR^1LO')3IAL\+V__XK9)0M!:&?*#7N!#U&@3T:&FX"PWTAXU@9)CT6"(_1
MQ(LZZ'E$T-/L^P34<!'$+HE]&1(>8JGF6#!BF,\\Q5Q)M7KV(NS3S4+/+4HM
M=0*[1F!]UW<I+)W'8IZ$4B:)C#UNM$E"EG@A"BR-*H'=1/OS3F!_F, >-[:"
M", R8 DE\ ,$5D0^"&PL2229JSVAM!&A[2^QW%VOTXZ=K; 1Z$F2V',#)3P1
M,<X-EK0&UM.<)MKEGHXZZ'E$T-.R%5P-*L9X)-%2$NY2L!5D#"#D&\E8'+G<
M#6SOX>4<D7L/LFQ%X&8'SU6]28M/),F-<7(YN5OHYOI9;R'LK46]<=4"9I-Q
M&6]CI2QFN6ZM?4M<PE>P@H=(9%-,WL!"SF".L [G;H!S<[5L/&.HIT)%M(\5
MNI1TB0RU(9$&3QB6%MPB]]D+M[]\0N)_GHX D:<SU5MBQ?<%4CJLV &L:.7-
M:A4)RGP2PMH2+JDFD>][A$EA?"DD53'V.^\OGQ??"%;<*7[R%(3P^X(CG1!N
MOQ"V8B*PH)' :IK:Q()P[F'/\80288QF&-WD<7R/0K@; O0]88^=G/#M$.,[
M8QH=8NP 8C1JVU#JJE#&Q*A$@XE/71)Z@A'?#6)%#9>^\)Z]8/WEOFPW08Q'
M$,K8P1R4@SH)6:>?4VW&VKE*S7!]P9CHNZ:_\X"WZ5(Q7TV>:5D,[A4(ZS7>
MKY:X \+; ^%<O;M0@[5$W9A$+,1\[\ C<908$ACI*RJ2((C#ENVP$?/IIGO
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M33=6-/%;J'<*JT@[:+L!M,W5B:7<!_=$QB2(E(L]03P2N2(F2B>NRT,,T$J
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M[X..N&8)>*$LC!3H-LE)% B7L"CTO,3W!>-X7BWJ<;[&KK\=FVRZ6G?')@_
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MY@OADYURS*O:PG=RS%?,^_'!S ,[Y@?E>G2@<SO0\=L.N1<K[L$JD5A'C/"
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MW=9:E%>",#TN/6/YMK@ N$C1R@5@:]1.[0K6>L?^K0%* '= I"IZ56SEH#2
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MO:-;[M*7V[J(5# [C(IF-I9F\_++[,G'JR)NRB\5"]>'5X#[=&-M-&'$6I7
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M<)#U*UK;6NW?ZO6-930.WSJ','")16%.C1J,$<)M_9C#L>H#R; DX.>RU!Y
MOYZ5=ZD;MGRMBO8C@."(JH?U 5:0"+:X6@MPYD<(#P'<L%7S)@,@(X!721Y+
ML9/AU>AB6OS\VU4.XK/W\NC0UL*QK69,V0#7%NS)[0$E7+RAD;JL[.+DV; L
M)-+J\3!78O&J/S>4V)S+"OAS<UZ6ZRHD/J/&=EM I1R+[2?FLK(=*=R#U?AM
MLYY15A7N6M 1V* 3']:KJ]_5E5$6"SE6Y6I:\\KEZ*+DS**H2E_90=0561HV
M:\U^8N2HYBI0%-CV()EB!R94 K.B47OP#N"CL?/R:I(5*KLP")NV.@M,M2I?
MB72OJE?V+ G^VW==!^1S6+40!4KXMOKAW'2;16OF-@7_R\)F6K9SG6<&C>WC
M8 QZ5GJO39CS81;;6XM952-G;":7M<8'RP3!'W[! EGG31$;NX;G>78YL14G
M/?]_JGZ.>56^J2:?Y3PT=XKIL&Y%(:M%Q;?!JL[-\%V6#V'@VI1+6Y%"+)-B
M\<*&CY \RS*[V!5;UI.?566LZ_KEV9=T5 HG('"K@$[-F-(6UIF5@JH%<HXI
MD$+S*X875<)7KCCK,R>>6_%P7GH:L^2W/)M>K&#_^GDM,VMQ;6?\@170P([$
M(-B%+1B7(S:NI$U+4.HBD3WGS?\#F?EEOZRKU738*FDY3\0&>_PY E[6:S8_
M3PN!<X!FGYK,^ =P9 ZNKP'8JC,A7WA+V3W+^;6_UZ^.8)85M Y@);-1JHK2
MI#V0!38M<-Y)VS%] J-IS.UOV$;U>]::1BTE>(Z=CAN[Z-L*;(U=](A-G*53
MV#_0LJ&]]1VNUYS:K6R:WR5@96[WMZ.6YEYE<P!<%7T[XP7[8KDI)TK&WM][
MAW\X?TN0^;+XHL1.2]-$V@+%>=76;B+386F0&#),04=I>S,:Y5CR$:N3@5I,
M%:C^"]L!ONKO8Z4 !NU7C@INA?6; ;;:_:*>,.53]T8%*NG#DCFM*-:E]$I)
MJ.!H;IS6D"AOD%7QQ;&QG?Y@@"-4&-BRM :%;QL>];#=H!DV6*5J.IP5,[10
MD\\KG[9=6H-"W9EX45OF0%"0>8EU+(N9OJW0QELV*A=)@B#0?M^LW\W>5*>3
M2@<$6 75E)C8-$J9 UVT7ZPA!C[IK\,K -QYLB_Q0F&&%2> 7:+KAJ,#[.N5
M@%K/[:R!+'JJ)E5+T;UQ^F5B>Y+8,9:O[35:<V8RE%.IC0:K(QS4_K80JPW$
MXM(![V!]4&L.XAJ@.5ZVD 4GG%IT!+L R8#J9(+2 D-ZAQ;@ 'C-M/AOAN.M
ML,E;52)F$SG9:_JL6L; ]6Q%39#ZH'G'65J68:X=3!C%T:][Y2TK%0 ^^^VD
M[_R1@<U7SLJ&4E[B'I%E]-?3> A"50T RTC_]/+UWC\>,URO.(7^XQ";^[WU
M8:5E9.[9@,DBEJ".+AG]96,+-5;/+(2VX*16!Q$/YIW4EBL6-8J^,A;7:'E;
MMS@%QT<-9AAI; 5BVW \FTZL^5#*$6@B7 *<B,4-].4P.-+R71H0M:(/5P+W
M&)CQ4DBH*%VJTL1O&OB5L&#G$T_3H:U"6?E5Z!>5SQW*Z5@-;$UG6-))RS+K
ME]6WYK0? "L/V2]MQ[O9X>2M2:TLI%\A=+4X=9>V*KPPP^PW9CS]C%_\[/Q.
M7@]E,9*.U)\1\71M$A=7 -2C-2JZ'@;2=97[6\8EZDCL A\!DKW,K[(_TL14
MINE^V8\+UZX,757/+_WARDW[ZVWEU"!E>W71U;8VK<#:P?99208NA"T FUIB
M(RD'!ON>?);#SZ;N)%M@[T9@ZUPF"/(SOP#[3B,;5)QA1EF!+>H4"I/5Q1K(
M>U4@MY<,:WN"_.N5HP:E^5"^*P'EB)&X6HWTRWG)89$UDVLY2&6U;CE3[*7K
MV/*E43(JOPKH4;(C-D4;FV$?C/2\;." A%P0G7F9,&4]\>J1EI0'6# <6((X
M!V.=.6^!$B8OUP]8T<RLLFH*,X6SMSHD?X$. 2C8<S.#A6&1U;T"TXNT<M9&
MZ#+(2YGKTFLJIU2YV*,ZZ%TZU8]86ZPM"_#C5$80]IR59\@K?0%PQ,"4Q,V&
MFB/G&DY;,T:$,VBM[.+%N%ICE]4=(;"X?0.35W-(?SAV3L!2K#8JO#*BT2*;
M12FCYW8\X-TK@@2-LSZ_V8&EH4LWH[H$1E6[&:4-?0SN:1T'I?#VNF![SRGM
M'MOS$N=2^BPK:=A?'/@,FU?O<@ L:ML_8K%#X3=J$>^R4-@J["M.>8+?^7KO
M!\F&'5,I&P(4\?YL(Z[T5)I*[7:[IS0-_@!C QV1NN% X^J40M0<2"DYHIIF
MLU^%G<LG5Z05]ED*AUR4MK6<&??SCVH:"E@F+^:Z)H#63XM2O[]*<S R_D#;
MY; 8XN /QW!Y69B^=*C'MH=],9GA\J7=1FAW-$[2?#2;VU6U%=<*T(/R;P^N
MD3NT&IO!V-K@+6\%GPH3/T@+L$[V1MC9Y(\_7B]$[%I..-Z/7<[@:I*.\4P"
MJ+,R0V%FN9;+]KK:OP7)LD'A<A880VA1HIS06W,Q:4O^DFFT-#R<:I?:,TOM
M";O4GBT82Y?:LT6I/:NU3 V/==SS.Z'L7]EP\M5Y,XW!MYT84!EO#,A/JCXA
ML+\N3?;JU)$;(* U'N>"7JH'=(2(CY!7C:S.,FF#9MF  ;_YO]='OS5O L.-
MHV>#+GL5W%L%]S-HKP)D,\>^LBS9\LCJYA)S?;86^X8 V6P X12O!A).QW5'
M/KMCU&]YW'"U#?DV*J"]!^[W6AK5ZGSK!4^*,F8W:Z]DYLQ6U(B]I9'+"YM!
M4W4ZQS[NYC_34FLO[+P'-YSEW_O. ;B-)1.TML)ZC;U;.+.P>C5XNP[S@Z\V
MA-=;,G9V3?"(T6_-KKWU,\[&I D*K<T96SN3_BI+HN:K%KG#TN)9R.M:2;5C
M;#,"GG[^L_/FWV_ Y07['$,4&!1^!0B*L5X<-ICEV WM#9@_SD%A\\(.&\OH
M-$?FJ?V>EHG3&L,*-FG\*CX_M;;S/+=4;Z<7Z&L4V&6M,3_ARU_-9(!ZU'D%
MKCNV>'J9&WP7>&B+=+-/7CW&)NEM/DA<Y[_-?)89,>W,ZUUA:4,3WY"*?YFV
MR=:,83;/5>PP>\4*Q'F=7<+(]Z:301-\FLEFF7(S/[NDM>.YN!K5J)=>/$\^
M[%)3CMAV#ILE/,C6/D79@P]'4G<7J]KHO3UX:5_]C1YBW]A;;;''ZKW5:SR4
M:QR4E;EJ]9[L-1Y(Y<<7[6VJ\2P"&R-)'T<KP#71G#4U0'Y<,$=XO24PTFM<
M47>6T]&2SBI?82:?\QDXY:Y &9X%#^_D8I*U\KKJ=)N\:HTYO]F98YLGF\]5
M6A35EFL9#52@\-&UZL''$Z-F[3%U*L_'&<9?T1V^LGFG$A6,RL8ZK;8C7E6;
MGW[;V@A[M;NX-(VY;;UF-E6VBAJEC4V26&<9-475@Q:>[")M5D?,ZJ2L5D+.
M+)PZE[U6I>A4?#,;YKK'V>BLQ0IK-N$NRV?;JK'90[<!]K+A8U)MN4QFSVUO
MO,X_9Z_>#GA=A:Z1$GLY$M)F#2[IX=F89^EZ_W][W_Z=-I(E_*_4Z9G=3?K(
M&/%V,M/G$,?IN">.L[9G>N:G/04JC"9"HO6PX_GK]]Y;I1<(#!B#!/6=_:9C
M$*6J6_?]E#[ )"Z2&;L8CV -$G_^HHA/FN\Z%Z"Q0"@'Y)*G@;39JPL2X$R2
M0Z4<BP1/DFJ.7&J@HJ:)0+,RR>(8V 38I!'OF3SS>] %:+9L&F=-M1IY35<9
M_TAQW!6+3$7@A7Q9+DT,X6<9OII0/@%P!S("-,OZ9YC[ZE U4I :,3G'9\N
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M@/?3V,L\:R+2&^3.$TM\YJV2GB4\*:X2^WML%P5 IJ&63>X?4-8D7<UO)N8
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M%-9ZFLDO2-L"+B@]R>974("0>@;#*Y^R65D9![Q,82KNX1=WVY2=#SE-#J6
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MZYH]]N8V](;?V;DWF0HWX*'MN6^78,4JMWN(>-(H)9XP/@$M(PS8R/,9%@+
M=0^=R$+T2>^3@2("O !19.0YCO<(:S%@F(!=R!^FO@=H-0G>+;PJM9=6&S8[
M]0(;%WWG"T P8%3O'VTK'"OM*/LKJ;:\JZ<_X8, L#I<_).YR.*>KKO3SL,B
M^[]C/\7@>W$R %[[_82/8+/ON//(GX*?3G-GFMANO'BG"6^?/?O"$XY&KX=1
M!&A+ %\@#'E'&()/P9YX:?;"QKX8_?6G/]G6H-49]@9=T^I:+=[H#AK=[J!C
M#=J-4:<G>N+_NEA!!*(>6>$YO!"0)_C+*5_,?7:/:=U"3.M_^]<_V=7%Q\OS
M_A=V?GWS[?JF?W=Y_;4(_[)(Q?U[P"M%8FBYJ$]";_JN712CQY):@E!"G3Z
M&>T3AT\#\2[^Q_M8F;)=VBW]:-8B@;<H/.YV:\WF&:*R,DG4\@K+:X3E,^:1
M_*[9JG4:W85?UVOFAM]U6^V-?KELLV:K5F\T]KO92JC=50/J 6]V-=IZQIVP
M1O[0!H_N.:/H>1XM<[-J'VNDR_[J>18H3RND%ZT!BU+2<.7O[$K>V+D=^IX+
M&N_P/]N]M6I!XTY"8_7)?8<.":PTSX%!>U7UD^MX%C6JZ"=?C"J;9%P7A?K
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M+ONNW6QNO6"ST:LU&IUM%FSNN^W]BO587_E$'',]&K$G/@S9Q8^I+1L@L(]
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MY9+(_DJZ1M[5TY_P0> Y4;CX)W-I.=MVK)CUE6ZGVYAQ V;^=^RGT+P7)P.
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M6J<<:*;[1Q-HZ@])N^=X1R.XI9"LG/Y$N%:<14JUP/GOGQ'$^ZXM6XOA_$_
M_C=IW'@SQW3^-V4Y7[T'E6I"3*=;-%C@"!2!5L44 <UP]L=P>OCOAGDZ>/@!
M%-.KM^O-WLGW0IYSX=@3V\UQE%LX#1RRSSK_A8X7NE?T.WPC<O8I5<P;?H_'
MR..S'Y8]6#6^=![!WH$)SW"EWLG?LGK0D^)'O:WPH^HI0.V**4![-4R.GAGU
M.LB,_@_IQ6PT>C\6L:,C4X%6835)JFVCMT6&4S4%J+6AS_)(/2%'SW :+6(X
MP4E3J4"2W5Q2_^+(%VS?K&)-3A'_07PO4VZH.,;M23.OG+2.6#EI;>@UU<I)
ME7E%L *S2+E$YI\-PL?&V2F?/OVP1##T[2F^QAO!4I%OAY)U?$R_F5<\$O_I
MK?R)+8)],YAY740F."WC,GTYL&/>'_.W8A=PH[X!@ZD,'S'K-?/GG]?HP[D"
MQ]!>E++RA@6*A-F6?EO0)H .OJO3F?"),F#&W,= Z<<:^]7SK$=LU7C)+B93
MQWLB$=V_]P4):X/)3+U$H3?;TJ-YV)S"/&8_";"0QDHL1&LCQ\QQS$ZCU^C5
MS3/00WIG#>(XO3]:J)#DF4Y=,IU;,>7*%DC8"_EC?Q4NSH\!NG0$#T3,<I(8
MBMF0Q&@@E>,/!B)\Q%SH7.M9^/PWL"& I5T\"O_ -1E3FDIG1^E6 81J;LB?
MM&=%\Z<Y_J32Q^Z .X$I-!DL581^XT"C_A.3/.E,LYF]R_77@J_9EKRFE>$U
M+ZZ=UQK1P7&<)?Z9;OTT0!TFX2<\9B>S+(=B2&K8WXV@:BAK*1\";2I4ZE%'
M>C6JYAU>)8Z4.65O8]_-[D3X:[.B]HM8D59^CIL5<<EC?,5>[J7G1TR6^81>
MPI>ZFB\=B8K4T2J2YDL;\Z70LZRQY[O!X&E6/X)OV&?YU398T;XYT6NDVI10
M1=J+4T@GVZS%M\O-?99O<.L!](FP\%Z&GB6\T2 *X"6!THK@(THY#L?V<)].
M91*U.CS^8C;168E-Z.#X86L=G>[IP/(<$8;"EX3^A?[-1KXWF9E,<GRP^'#L
M /AXS?Y^VS?8ER_?RJ<R/L_R5U$;^]%]%(3 [TMBONX#M@U3-Y70.N,F.B,&
MQ?YH9<*(C3B*^ 7($!7&VV@0V);-_?UF599;;:R^V=EHUDR=BG!@[2[\8()M
M"A,WU+G\ \GZYO8*5(,YS:!\W70/7G@WS4TI[QBE=T4HCZ,@(<'Z1]+<R9PM
MNL0,PFGD!Q&7W4IOQ9 ^:]8;)'FY/^"N"$ZN?SCBB?6'1+@@NU]K=%X52*6A
MA=01D$IC2Z127OM_10A4_P1;8U:5D^L-+=>/@5DU5I;K9_7.$F9564J/ 5!=
M7I6<X'@UJX;6K(Z"6:VL62UG5ELT0JHFU\VZ6;O\>OMS12L+]P&R?WZX^<(N
MW2#DZ*7]Z TC3&_*@>_@.2RBS>WYYTW19M]L=F]H<\=_>*XW>6(7/T+AT@B7
MV^%83/B6\*AJM(1X=-[_HMG/R_'HG#O#R)$B\(OM?A_PX)BYT\>+3YH[O1RK
M/HJ1[=JO@515HSM$JB_]#YI5O1RIOO"!<#23,FO?;BXTD]H6/GV3\_.D!%R,
M4]L;)/?<[W8('IH6]3/[1#D@.)_OT0['M?6W7)FC_LRNN,OO9;N2(3R/[@J<
M?CCT)E- "QYZ_A/COL]=^=!! ^-G1J3Q1I$$=L[^(//EXZF,0-] )NY]!#![
M.SN2<A3YKAV,514/SJ)4R40^XVS*??*2^)FVD?_])[-3?Y^.Q(0'I[X73,4P
MC& Y_#/RIUX@I_XH)TS 3!.?-!MI>_"XPUWLBC'/FDV#\8"IJDC<G87U0]EM
M+5B?F;V"A2]^#,>( YDWM')OP"-[.-/RT099I&9Q!M'@W[ JNI <FP]LQPZ?
M&*6MX?KP7*#.M'VTTK,9X]F,G<6S&=>8XWE6_RG^U2M,="SOT,:][T7/9UPT
MG[$LV[^]_/5K_^[O-Q>+)\567CA^RT0#,F.9Y5#CK/!HDFQJO['>KBQ%9J9D
MC4&J6)'SQ&C^LB6'(JLI6/#V 4@-@(=,TK7A[0,QYLXH3OPEPI$/&'+&<N3"
MKVA!'H5CSX=3PU>VR\X=P?U'$+Z^P3X!&&V+LU@H4_:O_*=* 387RZC*#0IM
M=6IGC>;61WHV:^U>>^NKMNJU9K.U_65!$O6V,7YTC6GN2TQ$1=[[L!+GN)J<
MVSY]^L&N9.THB)-DQL.F!88*BC/ZF:G(8UN%BCMX]*7HL%)UY1[1H=AI\.'I
MW1HWOVZ]Z"N=B%9\9X?PMN$*9SP-3EEAIY@7XOQND59)%Y0]\"P#V\6V6 S.
MDEW0TNNH_E54"=KH][,MZC!R/K;%")0U4-S05&;7HY$]!)L=;?R/H/4-0\_7
M]_!:#9V^^;8[M*<@=>=NX*T6OEKX5@7+-Q"^2<O(2G&7@Q&XU01_9>)N4JQ^
MLET._!W8NV+JAH;VJR"S+W@0^4IMN15#7X3<?]+ ?F6E90Z_7Z:T'&Z<^3F7
MZHJ^T]0YBH[3 8Z.4/[1@7"\Q]@O.O(<^ OCEU/A!QA&]-S8=:I>YJ<^6"09
M6\Z@&/(I'\HM4(Q/?HI-" -XQ*)!H%89?:/=>G<3WVC3K'5;F[D;EW_7;KZ"
MQ[5RF^ULT^6ZNNZ^([VJV)7ZE4_$SOJRE1$ =W;H[ X",AA8*@!\!"99E)>W
MCD&^DIFQ!\MFWZ_<.J_87\PE=JX%ZYC[I730S")VJW*>INW;!N5AUANX9OI?
M/]Y<_,ZN^G^[N?R8R738DSC;IQ7/;1]6B;7F#Q[WK3W+MOU!(]<ES2P2<=OV
MFNU7ORF&0M^U?%CIBG_W;0M;XAT6\ZY>F&"?S/M5B7&3B/;G_LV7BUL*HUY?
M?_S]\NL+PJB5 -(*7MC7"6YJ=KXM=KY7^;Z]K(.]/ZHY^F&JXW?]FSZ[O;CZ
M<.R,?#Z<QK8<^=%,O?I,_<61[;T_JAGYW&]VU6WX-9[41RO/AK=VM))QQ W4
MBM^N/W^5KKXC]O#] ]0(IMU\6H7(@> W;^PR<O1I_UZ5'CU><52^#>NC'8,2
M\:7_^\W%U_,+]EN-_=[_\O&J__5XE0GM4M:JPQ?^*&=1(4%PQX(%M0I1H4</
MGF-?79Y_[E]\8;]>W/1__7SW+\VN-;L^7G9]90_'7#CL5^%S^/25 @<Z%T_S
MZHW2.6[ZE[^RV]_[7S_VOVA&K1GU\3+J<Y_;]^SVD;L6=S27KM"C!\^EKRZ_
M?KV\8!_Z__IR?7/R^>+KC5:J-:\^8EY]9;NN+=@'_@3O._DLW-=*R-D5]UI8
MF+S+SK.E:3+;7=QD]G3@64_PGW$X<7[Y?U!+ P04    " #L@W]2U9:&,0<2
M  !ZN@  $0   &%P>7@M,C R,#$R,S$N>'-D[5U1<^(X$G[?7Z'C:;?JF& @
MR22UF2O'F Q[!#C;F=EYNG)L :XU%BO;2;A??RW9!H.Q;)-DX<ZIVIH-H/Y:
MZD]J=4NR_.L_7A8N>L+4=XAWTY ^M1H(>Q:Q'6]VTW@P^LW/C7]\^>FG7__6
M;/Y^JPU1CUCA GL!4B@V VRC9R>8H^\V]O] 4TH6Z#NA?SA/9K/YA0LI9+FB
MSFP>H':K+>W^2J\[%]+5]+'5;5Y>V.UF%W?:3;/=MIH7EY?MSL7YI3W%YW^?
M75]VK"OKL2,UNU=MW.S:5U+3_(R[S?/61;MKMZR696(.^N)?^]8<+TP$#?/\
MZQ?_IC$/@N7UV=GS\_.GY\XG0F=G[59+.OO]?JCSHHVXK.MX?VR5?GFD;E*^
M<\9^?C1]G!0WEZN7=7'V88%MQS+=3Q99@$2[);4[4E*803D"<,?S ].SUN >
M\;QPL5_ #NA9L%KB,RC4A%*8.M9:KEAH6X 5L(.U3+I6YV?1CPUD!@%U'L,
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MZ$X?CG5]HFKZ5UE32W*U5U0\FB KSCB[! ;]S(!^00"%.%;-6:@4"P@ Q.'
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MD8KG.Q9?<U5<F/"\&<_')M01Y+WOKO>M?7[<,Z)U^\J;<_YXNLYP#-*G9''
M_EP!R,GZ>CY^^6F.&:1Z*Y[XF"[WZG$25! AE <XV>!JM5C@@*[TD,[8Z47P
M@)\*_(5 XNA>(Y//R2^.7SKYBPJ_02/LX-IV -*/-\P/7,W@L9.9N[E:G,J7
M!SB-W!T<!DZ_V!/Z5A23F.XMH90\@]TTX8"L ''D.9I-+R%$R>O7N#.>R#2
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MSLJ:LJF0P;.<>AQ@EJW0!F+-E-\6&'>3 -RY?-OJSX;"V9$>,1V22+P$_K7
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M32$,RI0'*CPW@DKPSEN#>[Z(.F:>I32/LKR;\A>' Z0&;BMKOO+GY<7HZ2>
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MT3CC=2JH+L?T\K2D*P%4B 6_N1HB=Z^&@-#>]+^6SVZT5DG0+KO2-Z94.(V
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M/-H_?G=PMO>?Z[WNO/OGFW-N*9CYJ@PQR1P5]8Y:F97#_W$#DEK.C&#<]I;
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MHXDCO7?$*VJ(=JB705KA*O68;0%N\Y=YGV%P!6_0O+AI2O>/_OC3_M5HW%S
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M,'GN8@L-JI"6P5@)*ERJHRBT0EVVV->;X1E$60EL2.;E&A/.<Z=:,[</8&9
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M]%K&DQ1](C_3;8L8H2[C8&2*6^7S:=<11@P.O*,./K5P]/=O%F"^C 607"R
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MB^WB1H<1S5;XZ=5%H1:[%9F-V#0O!XZ]"!8@F(Z]#^IHM027S,C\;%@.ZE[
MS/@^'X6N7HF\@JR#^M!)=/?M'P0M?F/8&R1F7['!CY@_F2KLX!?:Z)'9=VZM
M0=Q([KKF9QMIX(R?0C\WJ9;L0 HA5-//(O@J]A)(EJO@935A3<"\NT=3\\Y*
M"BT=XS6;YC=VB3<2V0#T82+#D)+X9[*-(0:7/F4T3*9O$]?(:W^GJT64?UD4
M1WU"N"%%$>SX883OK4]^9V148?NJOP>WP,D87F).BE!#K4>**XZ+[YG4(^1'
M!P72S7?-A-7WYC := .4+3FS520:Y?O",TCC#NX*3_S'S/%C!]8A,S5U8NO/
M2YO;UM10&2R FD<K@R?TN3A6\*)MXJ?1=!0]@07@4&6K04??Q.MPB$>3G1"R
M'0X9W#4(_J @8]D-G+E;@GW]&L%=Z[U@[GK2PGTBN#/?1/GKJN&$M-]R3"'4
M$7$8>8)\F.@2[SY=*I.B>.5DR5\.!,KOY>:&G,+Q\9:<\=\3O\^$3T^KA$N)
M@>X#..<OM"%T'SXO;;+/G\61+' C] GZ4$Q;MUAX_H>D2<0[G>WK;/CW; 3-
M(2N2FHW(ALK@C0U%L<GI+\+3[Q7'3K*1K&Q;;TXCG%0+>2<:FAWS[:*6629=
MDZD'YQ2U4&C5X]59 [?Y& W3^S(:<DEQ9 ,6@,NN@5&7<[WZKV';Q+]@B=,.
M73#'9[?H>O9V<K"^FC]BML<#[%>++7!+.] ,O/I/JS!Q]10%?;C8T"Y[OFJB
MY]P@7;MKG?(;CD_D'_HDGK\W&_NJ\PSU-62S+Q1V:H:,G%7?'"\*+*Z20+]"
MO"6TO&*,KD)Y)]''2S"S'JT&F+!TN:J1AU/2Y?#5S3_BTN_3]89].(<#G="I
M9WO3+3[L83<7LC!]"Q2P0JOPU=[OTW.,>9\8"CN%4]H]$IZ=N2:0PDQRRQN_
M4RW@9_SA46P@2')7>ZI@ [XF?%Y:MBX'SB%;4RT,468O:>.S__'\2AX^C!2(
M6FCQ5[N=NG?RX^2G]W!:M+G"UQED\(GV!C=<4MLMIC#9.&5J>,VO*:,\<J>:
M-LB[_(.N+T[$_QG2]U3JAE3$U0GX.<2UIL49%<-]VJPP9>^&93$!=#N#ZCY4
M4CX5=O3Q]"1B$C16!W[7NT?QWMG=S]OFE]:^L7MP).F=)C1DKMBK3W\H0\EN
MJE,R*B@H+@B@J+]^ (76%O<7Z)C%OG57=N.MZQ9=3!52N@W?0:XL \0*>Q%.
M,6\P^/?+"'RLZ_.-4179C@31:/<9]3-!2L^-OC;B4O:X&4EA7C'Y ]011UH7
MDX>.-25H7_@%;X"M?H)MSA!W$/-5L$MLSM@$AG*C0NS="ZR[W0(\0%,5A56W
MG*\MX_KS9\)+=<[%FSL8MDV!E*?D^W3+P_N,*EZW#VJN5U=%.41YZ:N; 8[%
M&0T/7ZU^M]L0\NB!J6'Y<*( 5F2J,>Z-A]F?$\#!BB=Y)$_/>;>[4]QFY[)_
MI3=0W]X?KJC3<OIEHW5CD&=-_S)Z>E$E3K7ID*/ER>?7H,;FRX6?[B>DM[;?
ME5->'X@7?+.K[G +-^!-QET#&;O?.\SQE4-,MM@5 G4THEC\<=LH0"C1FL-E
MB^_\\V/W8^#3Y +@(;+1_='-2R:#?*N1<%HZ+T+@#%R%LI8',RJ _9E^<,OI
M1TUL=J+N:D^'%-,)'<E :7K6&BHU)PX^5J"Z3P]A8T60+2]X-W/0;JAV_W(P
M,?)12QNM@ATE,%,9M+[?_C<5J"7'YYP:5I%QO[=&&$W[23G8%_1MEG%BJ;5V
M(2S!J:X$=>Z6Y.[A:,60=R8AAYW'^A%ET%=H; F,G#&GV?(H9W(DE1ETB3(>
M<A+'G+3(37RX\/G1RNR8!2H7UKB]<\?;:UWLCL&4G%8@7&8(?KJ_N%[IZ[B+
MJEO5Y"_06ZU;',+:2_E[*MDZ( :O4)Z.[H4N<&_9IUR9*QI5^\XN\Q-6V?$*
MW51BZ9\QK7DS.&-R)8D9)$L18MQS8$Z,]250>0C0IE(RK9%:$FEV9T<'/95*
M=K*[MU0MR3F>0F>D"%8GSR4<\])ML[)\^/H$%S0*#FFS!!?@0BHLZDQA2-@.
M!5F#3[0GU@._Q^_EKVRO,&%G/QGK!-N39F&WX9UP]=_G<F<-DB^),E2'/+<:
M8_5F*U^2'& JHWVAP4:>,WT@EY0IE.)$3YG[+S64+NS;WV4)T_]4E@C&'BR_
M^&]E"<2#F(' "R5)^39K(N[%C*S7-C9YB4^RP*U%!SBW55PQW^)-+&S O_CN
MRN76_*O2Q.4I!UV_AP69TI]G#JS!CM"?D-^S<SI-3S]X-';B.R)SXBR.-W2O
M=+5#COQJ$OV-D:7Y>)J/[!QP6J%LY[Z] Z_8C>_G;K*%\PC8'$00@]NT"X=Z
MA1T!&BY0%<8VH98S]0VR?6"5PCT'*F9HBQT7,<K0>W_#XCH<3#]'D&F-B'11
M#7('576%/+]]#8F_Z!7RZ51OX+M&[$0/.5H4<=(_1RWBSE.M*N3/RL;US< W
M6N],QUZ-K49H0$*NCD)L;DE657VXH7=,%L2K=PVP#-GR@@NFRU] RVTWK==B
MMF$?*"2?-F^\EW^PB$G*U"YLD04 FK;5@]BXY';C?JIMX@/XNI=Q.3\'\^ )
MH[GGGH,-[_3[=S>.]-NX)*I.AM2P (GFI1?=B(T@>#CC)D_2[//+"RU#QG0F
MH^^G9W*T EC^J:&>0O?F/E+N M7_O= 'B20X-X.YR,.W)M,_/'L&+AZIV<[I
MRW=L@N(OAJ\O%T'N9;^/D7Z2+]]K.QT56!/P8B ^8O-+S*?@$)KTJK6U@=^L
M&W;#4E".!"F2F@F$/"]!;"';Z_FHS4L&]8F#V]/L64Y]^K'GK1CP&V<V_-,8
MB" SJ_J6H&%TV?42ET>LYY%O7*VEXHTL0 !B0C/PX0[L<#+^RX4/PXUH*P1D
M@NI+;P#VEY5<*M8OL"3V@A=M4&9C.T3M0QFU,>\1)X@>8;5L-LD*X%Q\O7@I
M^,<0[2?B\RKTPL+:=FU%[HUG7\Q<Y-A!]$+%VI"9RVU"T'[,E+R'*L<X(3_H
MM:<#F=T-2?#"K,,?DF-Z+ZJW>FSJ<B._RA0'.SS -BF(JKW2EG3Q^T6[N.11
M]N#%JX4K'#(3-FZ(1K?ELM--"^3Q+HR7M<$ D?(L&'O2L5"Q\=?Y(,*H=F%N
MK\L>.'!(*LHI"N=S(I*[['OG&2(_%;)73EFGD\E?9L;PX&@?=Z%"+OLDGSHU
MP@VLXNF]F9<A3276Z"QV$#M%^J)TAZ!3'Q W@>[PNL:>UZ?ZNMI-9="91V@;
MU%+/$@<#&96O$ZR!TJN>JNYD1G9YL@"3ZMP^O_>JX(4(#&(_[9I+G_F:<";T
M]14A%!I]@MSOOS.[F9!?MU5GR>SS^664EG89NO4<JPO"2P>Q .LQ.*-U+!^,
M[!IP^<C7]) :F:S.*QRKR5#\ 9A#\_A6 2[A/-0W!ZF-7-C15HBX!+5IO%IJ
M1]2"/T#TS8<XL./FQKM9^W]10.<,98[:J3([\&]SW\W$"XH4I>8TS=\4YA2?
M<,>\_HZ*7:LG3^$\R'?1DJY^ ]!D1XZ0N.&E,^UOHEHF4E\@&@M#48WE?_S&
M"#MYR-H*NPCZ%+:'^:[S$GB"$G+5RVYG#UG( D@[;N]39S#U)"J3G>5 #U/&
M)G/#GYV:?Q,2/AS;/L=Q"_MR$CJCB_8*ETGY*UI%0?)C08&BOA8 U>\1!@<:
M'?0'ZP]\ JI.GW2V_[5BL_@":=B*&^>FV?$W,IQ%-^8;)@/IT]A""AC8QAZ)
MF9 WL 93HSCL+DPIC^U-I% \_M\(EP/2.BU:2O -#<IRO1Q0Y6?\R?./WS$M
M+O4SU'"R:,<T%YH<-!?1*T)^YG]W.8>#1]EYLX;*?,,[B;E9V(W6HI^'?= 6
M4)QHAU9[$UWD;.HS"_^"U^#Z7PV=0T/?;\=LB(B/QC'F57<>8+J91TG!2FDL
M@-.<5I0%+7]KG@H=H 2"3QK?C5,+T]4SU^=/>&S_FFN5*V=L3F]S'U<XT? >
MJ"!T%CPBV)Q21![R>-R;%NT?]@B^5/:#!>A YZ K4+V''T4*\0F=?JUA,8DL
MQ[9](_"T(":H;WZ,5<SSJ&Z6=PPX4G>/;_4%,HS>OHCV(7)OF>&IOA3O;:C,
MW'I2+ OPI-\:^B%@CT+<(6H]8T/W8$QW\[ZBE]=?1UGYPW3J1WR$WPB8ER9+
MO5A9UM)7!_A)F4<%OZ,9!ENS\Y)<:VWAH7._XG.[F+$2XC)IS_5J<R7_S)..
MU-MB%<,LPGR0K;OAFRQ EX]63RHDW3W\OD.6>5E($J4A=A'&6Q\01!!MLPCL
M732V77^-]?WK,K VE((TT2]Y% [!BU0ZVV45#/O%CY13Q1-D[^6*W!_)!#U^
M'2Y;%'6C(8GDL8_11SO>0ZLJ9?V>I#Q]N6[?UMKR,7U5708O]DMSK1'-@R&P
M .$7=Q]H(8(T'.<E%\(O[WUI>$G_Q1E(6VI&"WW'>[Q;KPA1A<H/CJ@J['TF
M7@SIZM)>1/]F@QS*G-KK2*N!*U1W^^V!C[<)]PW+AEA',.99@,/8D77TT[%]
M3WI!^+_?6,1N!;4YV1Z9*]46>UY<Q>Z/7+(_L@#<>5+(3K,"?,QD2P=X',U;
MA2?6?ZX=@7F/:[X_^1JQE3.I_:JPK^=R;..L\_ND"5B,SEYZXH/01/N(W+"8
M2837*A.WP ((^Z?CVN$7AHEU)=+UR5F_T];MPC'7O@*;2_,R,%]<[YJ=6U+S
M)3KO?E'730.I0Z0S*.R\\IXEV3[H0YSLQRZI2)"9KK[4S 'RV+)@"_!(QPR8
M8\7ZDMFI%@%:&&PN^<>+='H:\"%D(68BAAWO\0GT&S'WTK5((I<$#>N^):F_
M#_'B031"-BXP;$+QIS\M1:6,6BOH8*99 ,GMN\H]5U9;.#BS0I962;1$S'X@
MWWVQ\_=N+%0$PJ6/ ]%\GL!M>(.+9+EV9DJ>\Z#MG#'E(Q9_E7:[OIOT!@^E
MG\,>WPK^O(==P:Y4D5=]0QL0H#[QKQ:]GD<XU\:/RJ("M;<IS]!N!.W,=TK
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M"'P#LNN+=F5+*E^8F%*;.6'N&O91K23YU>%,A]V68[0\U.NYHA(5/ M@F]-
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MC!%%N/G?W6D9XW/"&<3WO!''_Y#A6*9AMK[9$6$#5WPO.WS_1.#9D L)9 ^
MDV-H(BPB/PSAN+(RA&</;8-DSW\IT>YL1:<KLU4!/(O.]>%/?T#LIXGEBP5W
M'.+3:@[S:&XX@K[.*-)T8U3B#-R/</96Q8.W+ODKJ1]B&E0$\8WL3) T5H6.
M]D(#K14LF+?7J=K@1L03)_Z5KJ#2/>1^I>BQOSN_,>P5LO]O=2R$]\)YV-]6
M/J=3W--IW:T/=O^(>SW#W$!LE<##V9GJ-G BH@F!CZ!?"6<^(4VO'2?ER* 2
M!L_NMMLP.>TPL%K\-.>J)=>.0B!\A[)!!K_R5(6N340.P^J /L'5= 0/.W3
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M_6A^\&;>#%RFP:^2E@1<@,BU[-R'U2<R'R11*,C7GN+/=^X8R:G1:MR7IEB
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M5\ +Z7L4Y*^)11@C->8+?\-840B8XKY?CFP8:OPO@JP%EV$!NFX3/!AO-UF
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ME^@F;!D=_@?[AY51PM6HE,0R;XU.P+1KORKPMI_P3BXSL-[6<4[09^KB"@O
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M+3+WU,1K[,NZ,T[#M]*L3&-_ENT$,1^+DG_VKGW&R$R+\,JD189-C"&REW>
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ML3\^:[/"F-T<"T#A'W!N \'&_7^KY?KWW)NE "#Q1C-S[T-&9-ZHU?4CAGE
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M4G1?3U_I^(7>^T<0W7,GF&^KZO:D%^6TQDT0%K*61CCY?0''0J#-!9(+,2R
MXHJU!ZF8\"Q)Z.DY3/\,\P2?UCU@SO/]['=W[JPQIEGY))A"PG6+RKK%GL6H
M4/]H6C#?RP*T&?I8\^.G?!(4FJ4]-M!K>7!UIB0F"!^ /KB^0IG8^<@"',9P
M&=@0)?*FPGN]\YP$A",[6(#XA.,"]5M""YHA_&S3O'G\_>?1S+6A;?F(A_R"
MTAPEHL^Y&I +'VSP-N9"=&;<H-2YB/CSDP!-YS7L:]!A'![]^D'I1PC-;(&1
MOAVB^ESU-O5"/75F!RW#2((?*"NJ( 97[\.)P9.=S\QZL "R'Q +(%06["*T
M@%!^AT"DKGHZZOOG%:]OTFO!;94E5Z,DH$9-U:URX[ )5QW*;R=+&C#EKU%]
MH!AS(/4 LXWHDAWJ,CWBFJM7_/3(G@4 EG[ BP68D+7AA?K1GQ(@=$G4$4^#
M_=,3_@<9N;BH@+YYKK'@6<[M.@VF9"3? WA.E.>Y/_/WK]*Q8Y40X'97K?&?
M*?YDQ]\]UJ[1_FRX5(AX/,&>9ENRUG+SB;;PCV:&12=%0N^^ UT9H\@&%.$+
M]LVWB)[A>$*2PX<&^%3;[Z><U*I_C'H(31>^%.OZ:?&*I4OZT[*2H#-O$4-W
M 70?]"_5&URK[L=;.AP/"W!ZNE%0'XGQZH/XM#?A WX8':;KAAS'!BV2!_^Y
MW7$#"FM)Z!"P#;W6&=)."6JO6\5^/FZ[I+=C\ARQ:_P;D7\1[WBK#/*DQ?JC
MZE/-V]9/?F6B+ZJ+M6*<D&'!&PL^ZH;)#-'CQ4Y'0M8[^A]1Y7A@1,8PY6?F
MM\KXC2F+^>C/26:7-M0Z%4_$Z*_I?UFF["BTF72Y*S2;+!>O5(E1Y60[%V<_
MF.-S.%W_H=N<VU0V>>]*NS; C]41L6_S7UAK*FIV3M8I%'V:3:'MBJ6:B<.0
M-"6Z#!N95)I (PF$U0'EFTT7'F[>V#4+&:S@04R*E?E_NV0ET\N7 XO+1R50
M:I%<ZC_$XAZ>AI9OA6VRIP@SZ9<0%*!L-\D"\)HO4 /@UEF9CY2Q9IH&P.?/
MP=\*V )VXN'^WK W_#'=0*QB2J[^SV>K2VR#F7?FWXW0!GA8$N]*EQP_H3(@
M[SI0VN+X\*"68\82D98Z/6I;&V#**3VH6)4E5#"/8D\@7 9OE.CUWR\R!<HH
M;MN1#N^$T/=[H;LJ2RY6,7]EUF110=UT9!\9I%+"_)E/GZ:B^P.P@IS,ZLWM
MN]DZT@WG]$^5/C_+4YB]]^:"]HICZ5WN,2@77%*R&<O=)K.685X\<G@%IC!(
M><S5_5)R2= +K8M^J<5'OUY)=IP^9&VFV6.ILH8^8\PL/^<+-&KB==]&U[X8
MNSYAUKN*SI^U6+TD9O$H[L@-:9[7H(.,SA /Z*J,BK@>K?T)G0;:W 3MG;J=
M05/DQQK"U_S0EY;I->$F1CHPBXU_J#6 'F?VV*BR5Z9I2KDE7\'U:X]V23CW
MZTGF-F8=G;#PNBZ'7#9M1T9,:AJ;\>S]!9;H!_LF!]&_V:Y\KMOM[7CZXV!)
M48>]VGG<W.A#Y.R;RW?]EQA7Y3#0&!!XL@:3Y-%FZ++6ALNCE5**2HUTX&;P
M8CXCJW$N0B93A0B/2]=^]VQN_QKHM7QGQ>0G5&-I]AU3!V$W3F?JKB632,%;
MF6,Q$'@H%4DR)8#H8LS]"?<KD2[C7VFQ;@WF1]^A$D?')PO\89"BHD##XHJ2
M\@@=5U?A%C[G;M-K #C -(P95O]0[%73#5Y@,484/8>=JVD2DH%+?99 .#)/
M"W"2P:SG4_^G2--_N*MMJ*V';WV?^CDG+UO;[,)75*%KMN<8.=#L0F:/4Y=C
M977&9D5;*A^J052N_X7^AF%FRS$LL=57EVX22!XX#%.CV?@ NP(-B=95 6P1
MF68=S>C1CT3^6@.&X;H\Z3O)DS;0R(]'DM%Z%11@]Y"6IKVYL$]4-<@40Z%S
M!+T(24^L]%EAA&G?C$+*4>?UB3=U5Z"AHEP]VX_JQ_@VGKWW2O1QQ0:+=DE/
M'MS!#LFU@89L)&H(_5T?ROMZ?U1P?_JX[R;;^$D@UE]*KW ZL=U^GB6YUM<[
MWTNO<V@AVD.WN[@*V!0$-XNC,_4&.+[[0?A)N!\=S +$Q$U-T ZQY=_"?*%]
ME>L_Y.5OVD@SIK+SV%QM18Y6"R*@.=-ZO^VND;5W(^*P!5L5'D%F+$FM.GCU
MG$^U<GE(*S\3N+2?FU 8.U51?]H5WQ4S;I7G-'Q27^!=]H_]6W%ZX)T0X)VX
MA=Y.(K\;5N".RFLOK\5TA%=UJN?MIL-Z_"*G]2V?0R#+>58[O;:=3]C&!_G'
MWR?^5LL!Z.)$N6;'/D<SF?+D\MKMMH[=B'I,*.V"Y'!YQO7"<TX?!;_I;^GR
MY_4T-?05B L6YD]W"T-,=&16W/AU]96WT/4LP%!9O ',OX4TV'J^O"<3&.JH
MQ^R@4"&9 3)DKK0 %?-U<2ZS@7KLB/UM&3UF(EH=7H-R3X%\P2U9R!W*/?Q(
M?K@STT_.AIGLAWKOD&)./( G".OEE[OV5A0R7[^8=+OX)!VC U+^IT4'9(-I
MW.NVUW!Q)S.B1*=T$VG$]5K4'1/_?3Q:+R%CB6V2KZ"[Z8^)V6S$.[IM?4=-
MHU,943+L$3V3?5"O1*2"OA]7[QZ>M7W+"0J\DAJ/VZ+S=JM>-*/.Z@$#$Z!6
MBYL31-7<"^F8LZ#'!R]D 8H /+'U+0#8+IH869)VHUF%*9&JT9"=/;0Z&,7S
M4^N1UMLV1BG_-LP=P4T_J<%-V+G5,W;%^@.=AH:J,>VY%QO9JMT1^DM(@GM)
M4/A%TDXJNI]--2;$*".:;8@GMDNFX#%+.1VF_^]=_8+PS[(!]LNYGNG-GZ^N
MBGM0_DI8W\XC2(?K?.P" !T(EPNXB9IRB+BDO-M"B>QQ^+UL:_NKR6C&W!*\
M<D6:D_J!#DLV\5$T3)A3M^M[;/S+[9[<3!N3:QVJ@)L),$WV]\,893(&Z3:N
M%9V;6Z!'>)&,I:TZC(5_#SD@ 8&:Y32Y@@? (_B,+(6/A/A.N=AC;_5.*8Y;
MMY^+Y,Y9@P&$SI, 25]:?MZ2ASQ-O'4Y_/W'&$UIDB>9?1H.[(3O96RIEQK*
MQ^M7\,8[7LV$3W\C":Y)KSK-,8%DB4[\3I!,J97,Y2 /F<&&)..=% 9X!G Z
M+Q,]OG&[R,['U)#N:N%'H@"QB6O.,KB32W*OK^KX>F\C9JK^C#=-_E<.8,8;
M67/6;AK- WU2L4Q+?M_8SOWC5)1I6Z4J*,O5R*(O6_CKB[G"U(B>C_K=23G<
M]F6WZ=-$O>#U +&I0ZM (V1G=>F[UND2;QY-[3W'5G3L<#A@F4#C!/EFZ;&I
M2"V1)4NG1[,F'K*8^XR[,?"@VKT!2.A+!Z&GQ34F7S A/G7+S'U=S-".$E7[
MRILXZ/$>@Q(60+**O5UKC$</4L$D4W+.;'O J9P?&T6.2O,>O[9],*+F_FNG
M6P*&C"ULP-DVVM[.TMH>7/E%MT)X(HYH<_<=L_ELA<R)G[(-#3'$>?8CK,'2
MBIV+<SX6#W,]AT@PX/8OAE1Z)>(-\/@9<N(D#7:-W_"ZR W_@\3BNVIG$)Y5
MR$)UX35IZL$@/Y\DHP+]<06(WN;G<T&W92V,<@LN5'-\V!XI_]4R4.1(I40L
M"?TVGZ[L(N%2VKSY#+#@X/X.-'D125L)(URE5E@R8GIM^M&>TMB3]_4]O17!
MTK#0YUWZH+;>I&P6@,?9@06X<9L%(._!T*WAZA]F$NM _,;'I*QJ-1=6>]&V
MI)0*S8X-NKB&DA-=&NIEM;TX2O$+HX8P!0>PS.!$%H!P $&N N$CG[)-JR.*
M!0 DL #A:'6&^0_$/(YI"-S4!&WG76 !4!B*#*:=XE>7PWC/%,1F#(WZE!B]
M;%&>@1N&J3;M]XB/!:X>E5\YL*#S@GF(\2% #&_U96VM>7BU1P0]XCZ3L[U1
MW\ V_L>E<50W5?[M(8'#)@T#YOE6$"OQPMJ)Q1W4*1114\..^TU#MD.UG^,0
MO&+K:^GO]@1._PHT_ONP)5<WF8U?)OS,2F>#Q9>:H'39B/>:IB&5#_93(?/K
M835R7WQ4;*I[E&_R"'BMEH40OJY\]\\1"81FF':2I_$5(<QS%EEU%8]*2A^$
M%AY=26+31<\05]OH5:@DZC%B^&O$HKH)$I:TPI[U%55_+69[2DX_)%MVM0J&
M6X+[=T.-Q^&M5)/8HC*B^,QEDGY!CRXP5)J>"R3;6H&HPNS%JA=G ::6-Q,:
M*;E>) 1%"='%D'4WN]?/0#,-Y#:T;/*2+A5X?%H:\(M+IGB;Q>0353(N[H&+
M0'HPA-9RQ)82EBWZ#%B ENZ_+OXQ?,JP["VE%=Q.!O-1 M_CC3L*>2]8@&JY
M#<WYQKISY43OX*VQ1[_FQDG\[X]DZ?];1;IE)38(P0O$HT* >LQ^F-GH[9[F
MGNMB\OM:31ZD1,PP):JO,K(/215G<-M<^5AF _,"\;;H1CC_>#CK ]6;[?78
MQ$TAZ._1)UF 09MU%D!/TT.Y-^"O>(WY* ]=Y]>$SB%N/42,+;( 07!.9'?N
M*O+Z7RKB5NQX]HN=V>8GH/ZAX5E# V9-&=3* IR'*[9.K&^QIQ)SQ6>^&3B4
MT*1UV??25A<98?3,P.K,9;4=9 2B_B95F$)KF2C!1-9(]*CV'D$_J;VDU#LW
M@_@6.;W15@OKT/'S63M5;VN5A#Q?W48OIR.EY:8"FG:_%_DV/6S)P"*ZZ#U)
M0K*S/K.Z83JJC]VTN4>-I;><K0B%D5-_#.4YFEF&37.MWI5Y SL@ N=O<)HH
MT7OI>;TKR:3*OZC#V2 !VOW6B'R0O$0_%1;.:#'O\!U#))(JX5<:?UC67M2A
M6*!_D</"J.SO0](@;"723G[+&:'Z+HM@.LR*+B%LK\R,D+^*^E@HT=VWCR-N
M$><;*9E>V0A=C!G27L3T/=:O?#L"\P<VZ0DZ78(1N6WJ.N83\P/7OSH&GCGP
M&=$DL@S:NLS&HHF$?%#_:"\S %.+2.QF%MN!-ADP+!V9^@6=D<:(=+5R^#@5
M>H(V(C-4M$5I=;Z')5TI0@*=B3K-S#K#I+:)L>%2),]<,0N08$9IHW=EM0C=
M1LQNLP"K0XCHC55^TJ5DFCCY4E=P)<H$H]9A\8S?A/U,*=YEZZA(@EY]U3&S
M<D)_;/&&\*)A Q:]?@B2I?=&OI=Y/@.8C(AA@!4JA&8)3!$[R848.G0A0#Z#
MC# A[FV+_NR(LXS C)8%98(^H8T)Z)62:5G?#)BV[):T_4Q9UZN9MF()7](C
MZ95P9_.G>',7?-3^A* HY8,9"WL-H?I!DRO*FN[\(O3X\&U$F)8#?VME;MB@
MDY.HZS@BG2XT(WJ0\8$NAK>/\B=/- OD_:35[[E&^T,5I"MK4\$G/](:W1PN
M\N1*[IEZP N 5\X%=$GC)(&LNO%P,KT& ZG6 O)'-4]G8]]^F:&S #K%''^@
M=?;1O_'-[9J;*.6.Q. /DIV_=/ ERZ%#!@L(;MINWI>I9VQ1]R%-_*NH,DAD
M2*B&Q\GP/<D%+UX,#FH(H=A*_VP9+%1YRI/L?<*V[AOR_2/&H'_>GYGH\T$$
MX+W.Z7]+1(<+_V8QL5HUTCT(APE.UJDC41JL;PR+0C$_ND<W[-?MI]]'BR9N
MH:^@BT!V4,Y?@";UE1.G1[SS]6N?JQW]?)VW><W530<&Y)V$UR+?/*X=I&%G
MF<_:*87GVE@ A]G-]]!:.4\_S ;$H=Q(AY_632?_4WG20C<GA[L2>AMVKJ8$
MV;"WB:<#%Z)3_^8T<BTJ>]"VLK"G)IE-MQ.UI);=QL?(45;JSC[T2IGI,IZB
M^?4KWA$Q_M.?N,I\OT44&349++G7ZJ7W2_LN#VYM#.+MPI XNTY#IZUG3$MO
M.C)"^?#U>=.ZRMKJQ,)+A;_O,;083(E!"*.A=UF )N$A%N!7+XBY2XX%$-"C
MRQ>@&(<568#)XRP T9-,8UO*.VLH#KB!GMPWCFVQ,.VE*[  8K-+TDM_L=0+
M+$"P,IM8I'U&T'=#F9<2J$5)+  634\"S?T%&(L9"<SC'?@Q3;IQGM6'[4/-
M0PY\X<'!)_J)@QC@2Q;@"4Y_$C&4W6C#6Q-%>IQL51NQIELG97MC\ V7$'6N
MUJFNZ1S^V^12OIG":.?CLHKDS=4=E "*J"%?:G."&PZI]K/VLK%F3G+R4A0W
MW?Y)QL"N_+QSQ5]Y\B]K"^V!-+$ HEI\G82)EGN&CH<0#Z#R,3W:WUO]2O\@
MB55\:4M#5^8&EZ4/^H0;HL!]J^?JBC\\Q"?>N+A%/=8GFE[#,W\QV.7&4(6C
MK#%#4VA+3<)= W5L]7B->&;"\A)F$IC<!QD8WED)P8\LQR<8]+N^R+1%B??=
M"5_YUF2[9&B'^.\K (WO#"JYV9&UATY)6.JF-JN67'QO["F\X8Y(?_(OL)$<
M%L!,$<JY9R]6C][) E@6(RDT-L1TTI$B9&FB C08+A^\IFN;9?WHU$*(VFW"
M),)7OYW4O@[U&AG5\77E;SXN\^M[6L\?:F;W%/9K-O!OHO^R)58FCFB<<I\$
M'FI(_Y&GG]?R[,>,P?GK5VYBSUY->>F!M(WJWTE1"^IZOBVC)74R>'%,72M/
MKX3. &/)R0+Q]I=44\0-^H;RE#V[ERJ@"6E]W3K\I/F&H'^IA]W_^0"F8OZ2
M;5>8_ \@3,>%L0 ^.4N_NXP>8JZ#Z=*_;\&2[_,3^"NT!HC10(B.1P0<PRN6
M;=(T86/0KVZNM$@P$=,!C"!6T!@@@MP/]M>!^L']_D_(V'\8AD[Z36)+1=,$
M]\0R1-QBVCJ>$,LLMVV4F^\@[2'EI<H0/T=.PN31VWGD_$]<LV9JOKP[1GHR
M\#BB:RLHO +#K]P"*W#.&(Z1E3TPGUK(S$><43W=08G85,N.[W8/KX44K\ZQ
M  7@W/;GM[YE^7QWZHM?Q\1L(EXU0J'@G(G[-O]Y<='/YM^9M&QBR3<26PV"
MZ8MSPLEGD[4.$T:9\D2SA/21QP;^5ULJ>59L\B>N?4(U8FZ\&-.:T.]=?>IB
M>\S*ZH^OS8'IN2\!]*" 3MI9LO3JU?B<J?#0C?BF%:],%@ 6_/CAFL 3-M--
MHL9@;/$RO%\;-6['EP$GR^FNG-3**-"R8$M0^(XCNF6=;$7D^'@7R/_2+03_
M"P;7OT;WDHC_1O? _R]T;PW]!N&P3I&Q$68!"GL0"]GHZCS2D<,L@'L.4X4B
M1DR]P@(@_J.8!(R]_B\4?_T9;09/2:[*NQ!8@%;+X%<2KV27ARB^'Y]=WS<A
MC#',%AR+JLT;D<9CA@V8!I!0S.H("Z"?CGX_==M+3*Y1MU#8+#;&2C(K>7D!
MAN"Q(P=T"EU5_3(N);LV4!&VN.27@BJW_AKQGI#?Q0B$ D @F7Y]S-,A(80G
MGD\7"^DSX.W\SK]IS4_)FWK:SP)T3M#C03/PU$KH!>C&/ L@D4!!7;.!#R;1
M7S)BM7L?:-;,QX!GS+[)>I ^$->*\]_FW/BL.\I?5&$*"KPR!WR%EDFOS)WW
MC;-SQ"5TC&P4C>B=Z[Q0W?@&[L?TEEU**ELK\]GQ"YK9P8%W/E>^JT8UI_3?
MNH ^>>^YMZOQJ+Z../_O#1ZD)6@S]3CLO(*^V%Y3HQA]50!<Z3MI?<@;7T14
M"<.&NI[[F9SY]4G%D?.52QG,W5JVZ^75!%6UZ:++3;WCX#5K:/MDV_3%6;+C
ME),+_TY=^!SVLY8@65F#:Q(FK;LK@/QHS*V3;JS2-:]).<_[X'>WF;<9MY0N
MMK[G?V^:T,Y\6F#FN72K0,]7OYS!N?@@)_1?B6S^+QC_:ZN8_\&'?IC9 ]VP
MK-%A 9Y-4 WY81U__4V I"#[.3?HSNS='DWEWHMH;T5,(J@F8$7VZ2+VDE[^
MYTE?U1*AB^.8$E 9/Y>BX!:K$TXG7I]%XE!3KB0]K4J1@:TGILTF)E]:OH/3
M+Z-MXH63\RQOR5M;)$Z"N)801VMT7#,=H^?TC]@EOAKB@8TA/S'N</O1L UU
MQ[X20"$RI2YJ5T9&)%2 M6*B%B.CJ<[J>$R3M20^ZHT20YXGIDYX:N.:1L=(
M'W77D#],7[( /5PL$FWW8NQ655\\TZ"8 6[R"=3T+=.Y$_\^HR*9O0:<SN/+
MO._^E5[L_UO&/XEI0]-PT",U%V&>RBW88"7G\+<I'>=[%HF*U2=BFN,ZSF_H
M?\'@S7W4F4&RO"S WJ]LXJ),L7O&B[Z7^3FWP,I?<3M)PS$D^Y;2F$"Z@><O
M.BD=<QWQEW]00C1^)7@S#EH"F8<>LNFM,W!;\1@+ $H8_8'!!8#8_&P<&07Z
MJTGF A,$@I62VPM7 M0RAZR;/41()'F]<R*VP0?W3PXP8.5Z<=B+3=\C9C)'
MZE+?PD,:YX=*%2/^<#8.#S,JKRM@<MK^=:.4_F6Z0)A897-O\;QF*&F5!<CL
MAHS&!>;X"#19_EA)2 H)*<U;_B9?-S7W_>+Y , ^\QQ)P"XR!.N0^'CSOM*3
MZ[=D]35AP@QP9KN'N9U@(B1'X/S40&H.,V3>A9\J!&QRW5\_,DTH#S^%\%5:
MT&:S5"<$65M#24U4M">$\8U]5IIQS86'"@:*:8D[<I$++SXQM^!>)@/E*@+8
MXN%QJV#FRDUS9AQ5D9?]'EYC)Y,=3MF>BMG#33'=-HTT-=EK*@C@ 4C[$(QI
MIBS !I0L<7PZB'29!:"HL !.<-@BXF"-;7X<33+84\]L46Q$Z0EB\C: X5S#
MAJJ5[&E#B_<3#*1N.+F&\@:)M+L=P;B)+OZ"OA?"/9E3W9^219;;I(,E,,*V
MN=+WWMCN5#"AKZ92>1AQ ;)XDOZVKSUQ;\]FN>O8-5[:RQFFC%Z9OVQ6BC L
MWVO@JYZ+Z_'5FVG70E^^ !P!Y'Q!%S1.N@T*;N G,RCT\14RW>9A6%LGZH11
MYP9%EI,&.>Z+_U=-S_\=_W?\+QC<<Q,MKN2+DLW8W70C(C)X10ETX(=MQK)*
MDF=-PI4$66D]GG7AA'.3NYLO= !X2/QL*=G4"^?D>V,F)^B[.?G>291Y$ELX
MQ;XF?V0!;+78RC/K.0X%F>BMQZ><&SW9U@'FM_Y_V'OOL*:Z;E\T5A141 %I
M$A4$! $5$9&2%Q$0$! 0(C4B*DU$>@N)BHC4" @H")%FI :D"0(!0I$N-1!Z
M[Y!00B#M+M[W['/O]_KM>[ZS]W/W^>/N/];SP'S6REISS#''^/W&F'-,[0P1
MBASE"N.K."-#^6161XZ%V7T?M'89U_"@P]P\QZVQ#X_N+M79.64>0$D8\.^M
M"L;6C_9W3T+I%\"1"=<RO)4T/B]HT>3N\6_?NL)5HLZ<? W?K+89P=EG3[M?
ME,2;;D'+*2I#/-[F\95_9C/2?OWI,]XL+ @*.CR3.7_;>5Q=-/IVC0GWD6B#
M!P?T8%+(FEM5\N WR/WI)$903; %V4+^M?\Q?ND_#H[C>!ZCF$2TSDB$N'6Z
M0V-FK'GH>Z%1]5E9/F2-$=R7,[38AZ[XF?I0;X],NNYAV=QGYMXO+A]J-_44
M?%MS1J+!U0Q"VA@%)+(A2P4,&"@/,&1B5==3JY8?4^_E_D3%^I1OX2[33&@B
M=/L^I@K]= G9[JVT!TU%4[=IN=7\Z;,H9TV0D%)9A_*Z=3?L(K+F&F2J_RER
MZ0( I5+8=Y*KP#P\[.OAIB&%\Z0UMPQ^7?_=M"U&;7N<O,AD!Y/!XRX-LCQ4
M ^U.N*PKQD$APF5_:5R\M)P$:#IT2$(\N1IZ@ 7BU-M=1W^3!0I$DM@!5A+M
MU(![ZK*MV/$61^%V81QP:G1:M1][WI7!.X9]!,^X8_)8\;P,II\%^KUK**J?
M2SURYQ1=<+<T Y(> Q,RM A0YV"!5#OC^Q99("751A8H^ M]=VT_L@9'/0!T
MI.DJ\C<]HDZ$JJ8$L4!H>]52V/8 !4)749C ,3B8NYL0I'!,[32F<"(9Q@1N
M <#?&,\H"R1*:.0VW#PB2Z>I;9:S0.T=!2S0^#QN=_<!C.3"W&,%^!,]Q&<'
M!0-DQL#03V[MJQ=$#HSMO7<2U8Y#AS)?5"BQ0.>8\2R0=0%R;F\5\AJ^ZW/*
MTJ33Z(8*O*I8)\]RA29PU5 #/KZ$3@8+X\926" N)B_](1GV>B/I5.V6@%>,
M3Q])U]?!K?O*BV/W<VM?^2X=> [[74@53I0&8(Y\HH:Q0#::0+=-*[RJ*)%L
M1R4-G[%3M)KOU9L:1QLM!*#^R=#8_RX]>7(]3VG/)=SZ,G_ ,]QZX1+R[X-@
M/, "U=Q3%6N\]HPN-ZXXR5RZMF6(;FT?;:ZZG(I:HO_?(NM$[P=N-2W*#DD+
MKA\Y\",?E68UMQ7F2MTVVE_])RD?'(< (PBB/_LF1U6O,R6^__DCHP!>[\GY
MX];8)?[)YP<,'CJ1:O/F_&;2QI/,"29=LGE7AW5ZZ_*MB#JV<6*G>U_^E,=;
MB*?(TW">C+D%S(?>L*U-K8VC&G KVBGF, ?9=**CFJD2)X7D_;;TK1=T?Z+G
M.=M/?&JKKS(HMW_?"T0G-AI[\XLP/)87\\LHE[US]L7N221/>=8:E^MIQCY8
MBAT+]%J*R14!T<0QB307(J1X/$ZORF" \G1M^HY=V]-9%39]%LB8,(NE\V"8
M#E!&/9+27BE4]<EQPN9P-@;9],FGJ3GIL(Y,AT'K^NC?96F]!7PF4?@:(TWU
M@F.R(%DL_O/]?N)<U\(%L5@79;>/O#XBH/B/#4,Z0[:*^]"P%B(-S#S\F 42
M/S#!2>-9@6SD=57%\P?BN_'MAJ_T1.KP#YWTBVPOV".^ -T@BW?_&?7R13:X
M$'7' 57WO\24(HB$,N+A-TP^KV/%3K\-#_B%K)B&CE2<HO0POD/'C\0+'R8I
M1UE2ZV-.)02"R/,OPH- I*YW[H&U4W;B+[>#<IW,@T/D+7(-3"J_]W@*8JYT
M>'J>C=;FV[S8&.TT6O/8+2]6IUR+;!<5VIAE$)V<0\-,L-%Y8&;?$^[#3X[]
M4.)3.RNSV93@_7@)_K7Y@.I@/Q2U@",9&D2:!YYTF="5OGCR74FY2>&>95H=
M<DUJ)DMJ_NP+O+'I79@*4JXA3K*B-)&.2O<8I4H$-RKQ'G3A)B[L4QQT3R>^
M[,:L3)IO8O<"&F<"U[93-J3B:\J?85S>"4]JQ2YGF*P,"GVW78X%ZU"-0L5?
MX/7,:N!%]" A$Y_E:P@B_20C"W$:[A=RCC12=*:7LA)PRF@O1WVC^.%HH6/3
M''N&0C<7F/"GJWE7!W_*+(O']2VPG=!0EC&<?.#&?]_MD,@KJ8U$B@2C_ MY
M>CG^A>JY80R%_B%,MV_HP"E,D9S7"1;(\_OH+WJ_[/KWH<Q._8S3T&>8PC>-
M61$WOX33 )*'35;YGWP/F\P"/5TE/ERG.)%X8P-2!^_#?,),*M>D<XNYO=_>
M"BLW.Z1IY/H>5J'X3M@5=A,ZY4WGMIC T"]R$@\N:I7$(Q+'?4[I_8&9ED,G
M>^VLG.5DN/',3_=[OLU[']O5^^EZ<WN$6-_2//(W:Q8@3CO)'/ ;7>:?D.6R
M%Y;*[_)8-FTG*@V>3:^_Z'11K43WN[;(6D9J R<9K$//P.HS/C(EP(&C0G#Q
M";OXYH(W2VIP]\:!#,90.H,GC-.39X/ZJ?SUUR;CH(Q?I+E)R89TWVD/Q$2G
MGNFQE/>OTA]Q_>K.'C?(^C<.IBQ'J:-.8Q$=Z,,V9*U@YZN+;6J;UY^&^Z6[
M:?,V:O-]$DEIO^O=:"TUX?*;7] !1ET?-S6XC%Q2 0AUZ@RV^<;.4"''S1)P
M0KJQMUW'9 &/0^_TZYP<1#"B'4:Z:_ 6?:I*W@=6L],>,1[F+'<OX?9,7$/?
M]).[!4H1&9@'Q^YYLE4B7A$FV98 0RYN0J(QJ[ZP0%T.3A1$16M?Q WY- ''
MYM%LI><\XD:)[MZ[M4K)!G?^E:J#_]F++LU(Q4V-58DC^SNRD/.6Q;.]<Y B
M*/W3J;I5&O^F 4,JKF('IY=&O[XC,B$)=]MD9X0R@A#R+%#M))7G2\9R36*=
M,+@A'ICW0Q*,5@S!PZ=)Q<P:=]II'MPO,@FC2T(BXZY!2P^>WE?WP^-'=>.4
MMBXRK1DY[%ZJ$J<E/SMS'YESUVOD1AKV@$5_+W1@#E$#&!N25M^?(7'$)281
M(L#6T!%);&,D-:(_SR/)4MWL)883$9'S;+05JY?,>4,B3HL%<AZ- ),RF/L6
MN@?:?RT2^SQRKS?T>SAP;T='3CZR>0L9D5 B3%H%Z.L%4[-;.A&8P(^FQ.A-
M&X"]]@IS[0!.:#\ &F)L +^<GS'*?"VUX+=MRSP,_"N&MP5<H2Z.<0C:L[G=
MKL"8P62KMG#0^?QVX8R6-C6)9HML:H<#[#(_#3DG9:UD7?_W%E@&8"\#.36V
MP3P6U.A-NSG9)2CM+/PRM85TC5"7+-F9YU+L()MWQL$6E\!5P'= T.0%U@?P
MIEZ[N_52'-<!(%$*H5O9_8ZQ9$^%8H5N3?(7Q008I./'YW7"+4(K?X"O O#W
M!P) '[^*?8$W6Z"9,BBJMTOUZ XO%D)R<F>!Z@E=/5!QPF7P.IFQ-+=3#)Z"
MN:X;T)5*QUP8'% T5;[LKPS9W[\A0%H#;%F'[&C<RO]W'EJ<Y[#P65I.*7WK
M'"IZ*%"Q>M_>+ZD%F>893O[:"L]F\C'LR/U/N0TU'MHCQ!']HVON:"[DDL3H
M#CLADE#P]X9Y'^08OA.A56_*%*TTVQ&A<2&:6"!VIBS\<#'Y5!A<FI&;H\*H
MDW9GI'@>,P0D9QL+167XS]*!>38FSCB$W+Z/8X$F-SM^%YW4J9"_1)>W4SC_
M?,,!$-VKP8+UCK\_VN(3PSR<1O*^7_RH>Z*OB+]D_'$1[LJ#G2@).!,=% #3
M<,MY(B:SD$8;^($W1-H$-$YAECEVJYJ1,365-U:M?^5!&U3Y2XU%NP9OV?XH
M46MR.-?4'+GT>DM4 AN[N'/BS*4SX:'T=!;H51"SK0_,1G>UG< >)4JCWU3<
M:A?NXJGSBG=ZM9!&-:P9RNX/W@?: ]..?V*$E;6U0*#*)B8OZ413WE.6X/$N
MKM))=5#>M8J3=363T=<D?U9/71)YI[8* Y2XP&#YT"BXBJM>%2.)"_4PM3AM
M_.6QDOOI!B7?T&-(HE9U@Q2Y9-<DO7I.UXRI01?IY46(!GFP0">(NC;G8M9"
M#.\47-YJOL*Y,^=4*(?/ZA'*S?%D@>30^\RZLN*U4G8&_SR"S)1G&\#1!QQ8
MH 03%L@5QBC$_LJB;P(_6\0"M4FR0-^QS %"]NY1<?C9;;G T\Q5V?@95(?C
M/P$BU[' =X_%P=:>6Y\!.F ]R0+I+$LM%G)NF2<'=]A 4/LVKP"NKH,SGYW,
M2:1-CM+EMFH&&0_;@!M?AS*J:M(;QH3N5,\8<1H*O!H*/\$-KK0>A<6.DHQQ
M;XU\8B9C@X.Z;CZE*V ^VZ^_DQ'?"W5YVCC%B1^I%,(=*^![VV A;58?GC77
MZ6:Q! \*"'#-'!FRMMY=IN4JHG=U_;)W5']T:ZNO:+2V>)ZCI-0"CBJ.6V*!
M[,B!$T%]E7F#TH1@^"61I.5IRXRV[IBIM&,+U^2BF,V!>.AP7[:0BH*1A<AT
M9G>LV5<MKV?,5H"OZ ^[3,0EVDW 3EM;^L#PI7L>EQ8$L0WF35X_6V7S]GU@
MS=D0YMQ^ 9I3+2 -2 WL,#'GD@^G >[!#W-GP^3ET:'M\#\@*R^DANRQK[$?
M'DHUKYA:16W>RW^?*77>>\:G]"W$%O9J1+3(7@8A/']M07/?_$)?I,K6K6:G
M*3!1CGDXTW<\X-HBC KS]LRSN/E%NTBP*]>#^U$,QXO]'YCC@OG7+_I TC?N
M=38^E-!9@%HEIV4&I9F8-8P$K_?/=1:*9&H9O\JYI+:1\<:N-/9\"%&1*U J
MI<9(<;]P0Q4!4(#WS ZOD4-DJ_@ZYV,#SAL=Q^_\6GC>\/WV:O[]VY>[V^[6
ML4!%X<C0*G'L#WQ?I%ATIC"FN2]]KJW6BG. LS^1\@J)0AZRB3?^I#N1Q!77
M>&]V)CZ\7A&\T:G60;M-G>39.(T J$B-,E,<AV>!B%*ZW8\3GWR<N)^HDZ2M
M!*]5J.[?7.<^0XG*WERH$K^,SU'Q2BOL!1L$YBP:Z:T4[7+QPMVR"Z IIB1U
MAS#N@D>>\/FV[J2>WM_B(6*+NER]+;)3&&NXTDO5R'$DF%-R_3-'[Q!.E196
MMJXK0*/Z"R_O1#MMH)GL460#VBG W ?3V1RNR13_0)=:GTO6*!)]:BH<<6$_
MDG 2]K&7XJLBK".3/0*+5G6ZDMEFJ.;!+I7RB[XGAQI<JWJ>+!U;$'^;1"JA
MP?LA/]:GUB:7AU_2LY.QOMI*&;_6<CH&5OLQ $231@V,XA4*VV8=_2R1 Z?J
M2F;6;?:8?-@I>B*NN-)0V8>[#$R@> @W+A\AZC1RH#R1E[B))2YUAC02'^S_
M]G73/BP:.?\.VQU*IX&U^A^>YRGLA7?DU9I0BA[N+ $&VG?VP9_GZFK1N1>9
M>E4$)KX/MR/C2$_#]G90+Q#HB0%81G N<L.R=UL+YA+# OV #ZQMH\A,K7($
M'K?F">/$+2ZX,,3B<':+Y$#*:<"_9E$#6""8,7+^:C$-8JWI2??90>1LN'6,
MZQ(VU'8KU2=__Z_(^U M:!K(IAHXP+4*T/< (%;FU)']"VF/W;XN&S)*D5M
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MXKG# TO&D4S1VQFP+<!J#=[8O(+;^@X'.O!\$C<\O4;OW%Z& 5VIN0B8KPK
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ML4Q. .;+DSJ8'("?88?\O6%31X*RB4QB+*G$0J9ASW_:Z/H82?2(VJ>8W'L
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M4(O!>.0+A7*3RLY <_+5; PQQSF8:Z^P]\[^/8<W8YW6G)@GI*',5]YHZG$
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MY3RX/W._$-B14<OXP+S &0[;![\PX7!^W66FF'=K5IF1)3O<;/!EQ@@_$(0
M0T<!1*K# H4B]%,F<,'Q[C9V)GU/N2(/;@X*C?E%*T>SI5[.NS."*DII+PWI
MC.^=RFZFV,UE<!O"C@<H_G>8XM\+4\#4H1V0?Q:%F)%E3&"HZ)D Q)\<>7=/
M5[/'_RPB$#):HD#_-%L'H[$K,%\53Q8OP?[6L&/]%[<FF_P?X-;?Z!<96(0X
M7(#T"2%(RBMTL4UOE&O/;[(]TNC_J6!H00^ I"0R)!*V<66 !1K+ KK]%ILP
M]S6.]W7B^\^)"/4(OP)3(Z]-U?>_!\#!_^3!C$UE")T&<P/W22&5:!T9O\6_
MM?X66)>:*9?8208S [!E;/_>,[ \\]\CY'0Z8>/ ^.CVJ0W<SB: 'O_@6?]8
M+^#Q7N63425E6[C=RLA3J&PZ($) (K7J*07U'T@F-(Z#EV/)(F/HP#12XQN9
MHKFBKS/1GA:)YV.W%%O@=32H PO$*48%O"N$J,#D@-*=IK,DS[_&MY7I'"Z=
MNN?*\S G?2E ]^\WQ9+%EP?(^+J^7&>%B)F"H#>'NIW/E"#HVV]?-HX-9]=(
MI.?[^/S(<EIA>YNSE4AK\:LJ_.H3:(B^VRN;YRFU/>A1"HVY^NUG@-F':(.^
M+),(!=V*/I?4PNYE\:J*#\N1(\1KT5JJ+_\09?)LPJIQ5'$#%%/$R@)&K54@
M08+##GK^L!QMK@KA) D/Q.SW) Y++A R@B,6E,Y=Z$JRLY=*EJ.IPO>0.9<Y
M)EL"]FE$I!2B3BS<^!1ZQ_3Y;)SX#^&;6%/5%R<@]DQA*H<6%3:6*U)+/(H;
M*,J]LF>_5,/,2GN=YY.'9BBWNE[.(-AA^&42K/8:4XCTY5-YP&L[>*3^_#/1
MZH/:L&S%ZMG/U2 0**^Y2NIT9-P54W,-9Z9=]_BE;$Y!7$@0MZ&UX<C_F<4-
M=61,X ;VK3!W+UPQSX*C3=SH9>[*6>7'MQ<XG[#M%Z[;1RR9^Y*H/Z=G989^
M"R[R7MK*8[970=#J/9TK'F5ANE\<7QZ*7!':V3A6MB>^8/. ]EHY8X**(:'Q
M8/X*$=?Q#I[YJ 4!..Z*PG#<R!_7H\47(J_XGE8[,W6"<^;4\IX_5[-NU?IG
MYVKA3;M]"+5C<=HYML.^>W=T05.3M*:HAMO6L93O0NT\J2DF1%B@JAW/RUBQ
M:3UK2-1Z::"RYP0XV&_*O/&-9V(;IQ'JI>OCRQ%OF8NV;XR']=56I.9'V7<7
MW%==G/,*.XAQ (P%%X]E0.I*V\0'M/'T#2Q3"2;2QC'83-:)$'I;;R;T(%/H
MN):MMG6&I8K 3D^HW=$;O1?H)PHHO "G/W"+BLDD7KWA%35>>;K?=IG+O.5B
M:(#FM@[3T6D&]7:45QE&=KDO@ ZCJ_ECK?)N(1V0PW6<AD*.>\^HAH+RC(*,
MEGC4GHB#CGV)O2@O(+,Q\>Y>KM&7F-C:2LXQK6H&<G*UCD/VR)SAAT[41_^O
M5WA#FT$(!S#XG65$ZQ^3N7[!U;!^A0GQ!JE$_V']9H.#U,=O[7KD;X?N:D8W
MWS'^D-/\)=BR>=A7R$'$(:KQ&.3UPU_*T@_.A+TIJX@_ZNY]IJ-#:NR9\J=C
M+X1 !WS[AYJ33U_O]HZ?\AK/-\[I^9(+;AVDNH\=!8^[O/) L<\=#T#K=(T=
MK\MQ:W7351)>:C4+6;E/T-;@(9^(B7%>";BA(_E3BKS%9#^P>Y21UC)/]L!@
MVXQ#LJ!:6O6>R=:;=V:%JYQNS';RXHRJKL$U \?%:U'</N4/R[J6DN^;E"O/
M3@=!QHRN<#;@V%U<Q'NPXC_*8S%ER9IQ9I;32?U3!:KI,3#MZ,Z93]FJ"<(R
M=J:=$?($(TG&06 ZF,#EI,7#E9&NI]A/:GQS4_%J@3!_S0X19ML0P\P6R!&M
M6LB+JN.DC7?;IR8ZGZV^Y',I:J,U[?.+E2Z<>U5Y<:2T$+\F/>4ZO;&]Z*X:
MG+.[ 8GMKPU(<!0PS!>I#^!V)$GP"0NM*EHM(<Q-_PJB[0)7,QN=H\EVZ4W5
M]QPDGX]U1\/(R3ZXRE>9Q=.F[4X7JA>_W9*XO54S47YITXJ]X&NYG$ /(U=1
MO8QZV(H%JN8,B8:#J4WC!KS95P;GM[(IGROB2N#I+2AC0545LB4FK$(N8 S'
MO;!S, ,<^]7!VVW 4CP]JLRTL43C,6%N+=Q1#5.H>EGAL-4SU-R-$9^5SY'V
MC\QLHM33W[KEI#\Z'G#9B- !SD?5&U#-(85Y@920BF%CM?8([^_3J/=L[QN5
M/]5UK@^]V<"F+*Z;%PT+1'_9 3OI.Z9S$XRG4+_!H6ST;^M!JEK$62"O[<*9
M=? D/0+PC4SE/@0?%:]'A@2OG"#<[TY*'G$X9\:C;:H>^T!M'&5HO?A;;G@[
M+W13\FZ&R4BZ,<)^/,C\?6^*&.I?\IA2D/^1>(Y"WL^EKZ[^J]XY;<$'N4VI
MF@+_NT\%--(.T)^3O1M=@E7/]%;8(GE3 NRR$N];2]F/[X6(76LX#O*U;4/<
MVD7+)S#,VZMAN"5EY$:RY%JALHJ CYV$FCA&';?//'U1HEDO;3D!<+Y7=_[X
M_ZJ,3M,F=L!@'/RV.(P!-2()Q_A^'34XW]M6]W8P([:_L&R[/$Z4*6_ Y%L=
M*V6<S!5D,@!Y\E@W:;ALAK;H>V\5RMH:;$.''E(A->6R+Y25'#Y3_?6#M3N7
M%;9YO<9>H]P+2^066AO)N5D2.1;.PPFBT=_^[?RGW10NIS19=@E'RFX0V%PI
MSO4!Z_9X6@PH#X9E1H7]',$DM+% ;Y2HTBS0K45-%@CGS +50[\96F1M&GU+
MI W$?_NRZ0IS[:"*5*L*4YT_?PD;CY <U>R*TXQU=E8[Q%]FVY'KP6UXOV1J
MI>U_'%-J%T>-I\"H)I-'_;;,^RHX,Q9NY"XE.]?W_*R?<C%N>\("X4_3>5F@
M5,\TY.BNIF0/2.3V^F6:Z3&66@:,_;YCOY-Q5%O<J]$-_2(7&F64;@(F-2(/
MX.:2[$>WEG'4+(K.!<;#TG5<95A_-]-D2UB!!3KB3;)@AO0!*HX E"@T[7=A
M_J5,-DN GY:DH01_[[7A;[^"?92*RC%E>F_E4ZZR0+$!C1&_?WO_F2#I\4B)
M'E'7KR:&OT"7#FAKV$G&9)*;ODT>PH_O'L15>'%M] 2SA05BK[#!6B^:$UYN
M5&J95,:T?2__R%<1L>";,_J/O?4_SU..-9&Z@*O\Z"_I N7Y%SL(^?-3"_P%
M=G-# ',8CV1R(#MO=.)6!Y%D$Y7XI2C2LUK8%=E@@7T*Z7VIAMNJ&G[+W%5_
M+NYH_$LLX09'J5+XD:,O:L89;'=^C8L<5+G6KN39^(5+P[E3X^'@LZ5.T2*
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M]$U\37GZ3E#;:UV5VA:[BWL,$^W/E(>OS\/"(:2\W0H8-QL J/QBM_ZH/ 4
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M.P<WR,TO@1X&V'/O"=P.KSR:OEN$-@2KS_A0P3%A 28*CO?6=P076_C[%+=
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M;O(DGKL<G@\[)0_\\DW_C"8%]548-;M6R<%6FQ<4G!'?27F],*KZN,!"&%F
M?/26\5_&6=<_"!0CMTZ8E&LK4\R50G+D1FH<%!2@B\5[5B%YN:WC9:NBNKKF
M*V+1^P6RC(F.O)T\J=#KH2Y%7X1O'@=<@""[L.,)![\(U0M146:T_6Y]7*9V
M7)KDXV97NP.<</2#DD91#KYL2TB>7I$HO?R=K];;KO**O ]#JI]<8,5[D%B@
M"U&1?@PG@*;Z$\ G\1;FMY )R 0(NO/Z,PDKOC$I6:\EL0P"&QU5S4(V_RQ,
M ^>#8GWPS&U&0=FS!+X:GTGAS9OBC]@&CU1KM;6>H\P>G5-0Y2Q*>F1O-^Q;
MQU59X];?]O-!JBRJ2Y5LF8[FI]R%-RKY"1.(+U/E'WFFT0[(7&5%I>4=WJD/
MCRT6\B#ZTY2LFVE B6"2:5F=C 1) Z^AJN7>G:_)Z]8W92UZ;/#\OMU.Q!)_
MXJ<R$;6)VV6'7*&D7C+B!#";E28PX 8U%9T/:"]:+2T.7W_0?\? ?;I*]B8]
M;Z3D!^[<;AZF/XH)>4;0)/N?&=E3K3X6'M?Z'%W/!4>^&CM;5" ;<.DF$9/X
MN4FOJ6N$O>_'M,I5\!7DV6D6@]X30$759D267^_!/5MWMI+U-"E46&]5<71(
MT,1]5>;G*@_YK]^\6<DD.EJ<I>[V\X>F:9G1J>;3<5<99#&8;P]'VXN'4Z1K
MXJ%1-]:,WCAH3?K>"(Q19C)_?29204UH)H=@>5!+Z)R3Z]@24^2%)BAQ*YIE
MOW?4K@_MK0T]9-,PPEY#]^Q0]?L?[)S-9B'K4?0\U>S2A) L<."-44D@+4RE
M OVI8@9QK;YBJ0C#J*O*;7EQ/.[1/DT.CP^NZJ"'T(>$/<=%)OLNY->&<4^;
M_9Z99ZNL.K/@%6VH=G7EB^I\<:1.B+-+7%R$F86:5-QT'R;IM%[@T&GZA8?8
M".".RNF@-><^ 9"%O$D\R!G@O[85=BK2'F>L[()#A38<_TU,^+]78Y!'_SM2
M/*WMO\9C/7.SO;!HIM<BT<?C6OH7 SHZ-[\);N\8PG.38$F47T?=Q+5E"<86
M&$\991IHIS]ZL9M>W'SVT?G(N$(1AT+5)KFJUR)J.F&QJS[B)+X:,/GL!E62
MW  UE0/H .?.HCG@_Z1=2-G^>%CC<),+43EUR]4"?Z\%$FU$':BZ?@/8\JAV
MT$<X5YW>G!Y^<\?0:#KQ3I719,JDZKGFSJ@4/@ X+^EPFR 4M2DS#P\[C@J3
MEUDPM:](-9H0KJ#GS%(=J$LY<BFZJFOQJ@4^:UV1&S^2K3(Y+8U*LZ9RGIMO
M7)+-I)0VU=-]9S%8A+<Q3=;.1QRV,K&HS8$X36Q17,9'ED.%<U7^7Q\'OWY@
M2-M]@<%+O@19 )I-0RD2XO#0)WA0*,QYWKC01B/R_=#>JF" ,*9'&V5S=%6M
MX>VP:Z11O=VXO1%+??E$U<(1CZ_\.Y'A ^?GQ+.ARY1;I*?]BJP$Y1- "TH
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M$:Z^OJZL67'E]E*'S ]U(UBL$C_/ L[P8U8@[5C"[<I\YUQ36Q!=H47IT(+
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MDQ11*DS2"P66F](H#Q?,[&@,21,2>J;60E6Z9BT7;]1B?KOML3<@QA+:0>7
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M_J*WZ8Y#4QUS<?C6/ETK9"T 1:*JDD1;)XA?;_JR[D6HF/7HV^3K 7^%P%5
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MW^2*3<O!_%UZ"EWAZ5QJ@AR< 1YKB_FE89;92:S&% WV3^B-LZ"]=*/VVR<
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M^_D!]:BT@M([N%EH)%XZ967(^V*\!9;R,79JN09)<#C=-WQQA]J7;%0/%&'
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MB":DYR> 0!VB J'9,!0B0H'J9(]?/:RCLJY[ 6J-$T$Y8P0L [;T$8P19V'
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M%GSQS'_222<R,PV\ZEY(9399T]&L7--FR^R)OX; KDYS5&:S2OR& [ FS$*
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MM363[ %^U)=SWSKP_"+[\1;24$S"8D A;\H;0O9R\S37,YF<&-R7:'?!W3V
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M]U3-#"7A_%?-*O-$E&__L_'VOYF,]64-V#CJC]*JMK9L?=^8XHSJ>.6P4@H
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M?):/>]:ZUKW6O:[#]UKK6FOH@_1Q@,] 5U\78&)F GY@? #Z1V#+,0=W.T?
M$6!<3/01X 3 S/3Y^OR7^?/%RO+Y+QLK*PLK.QL[^T^)@W,3(W&PLV_BWL3)
M]?EB_+>9FVOSYYO/E?P7*3,;"PL;%P<[!]?_^*+7 _R;6.K9+%F8) %F?B86
M?B9Z,P!AM)'MI^8Q ?]],3&SL+*Q<S":P<TH4,[':#X+"Z/1;(P6,W(#&/D
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M[*L3\.V$5_?!QS$MA:B)Z:0\VU>VSF5D*592_NN;X1//3\&Z=AT;KJ(#H-1
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MXO7,B)0%?B>QJ+5"E_?9TH$!%MC!7W1RSB1D?:L2:OY60;(/)7B< =+D*2&
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MR:QXXKC2WRMB[A.]<OF#?#;KW@P\WL;[+'YE7+Y).>7];8G4Z8U6^1Y=4F3
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M9'?^QT0[_=W5<CTB=Z)GJ? MSYP54QT84F9<L% 1TUYP_7;]JU3C)W805=A
M%FRYQ=-F;'GTTZF,2/DW1_F^]?:_UJ"%D5_I5V#P3P>O_1)WY;[HEC<"DN'=
M&,I>(HM1TP>4 $70UW/Q:J/.MA,SG\.NC'XW[$KY5V%7D#(X14B>QCG"0'Y+
M(Y#Z>,IUT,:U$6$#HK)O]W^JXF!:-5(^(VTN7O;VH5S>)2?[R(T<$HJ:C62A
M]4DPA^'=%\A$/7WBF3N*+.^<*[?[^TAI7>@Z)!UT^D:)C@6I:+K.G/H(.IZ
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MER#MRSYUBM0TA [Y,IABG+S#E11)G,Z<7%:\N_[V0X]PQ=MQZ97R@RG6 AS
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M##B[G]RW[37N3TPA&%*X=+#<:2I!>W0IDGB@7D-L0<57;.*S!;,1V&KU?68
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M6.79%#@U/L>K\^4\^+8V<7,B:A9MH<4U_\6G0$%)N;H(YE1P4#.=\_2[E*A
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M3XVUN,@RI)?$5 H["\T51&V!$XF-_<@8^/13R"9#,:YQT '5E<1DN&C 2SI
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M4L@1F)X%=;XE6@PIN]7RLS;^?V%2X=)KLQ7!KS^6M4XX1D+:E _(DJ],^83
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ME<J:U"@YZ<C=>D%Y:AE,="* #C!^HB%9'7%RPBW34B'+NN1(F^\DZ9O:QBN
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MG4\J, Z)=OFBATY95BOSMG6JZI&]09#=_/0V,O?UQ'M.MIRDKQ;))#2QAR2
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M=[_Q9Y__:@/,6.!?NE"#_QQ,&C$C?B//@<4T\+=R(OSE,<>?'[WL7/N+H$Y
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M#:FHH *FX>#4$1<5YQ,8HOQVO!*5AWR<KCQGCNOO1]V#GR:(+"V6JF*4(^O
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MQ+ OA9)?;+_]F>:=H7$PY<TN0[UU OL!KXE$:8 QG?!R@"X[B]>\VB;./0U
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M(8FB'%?TDG"5??]1MMZ3F6>G>D^\C@RQ1%TL UEQ^%)G@3PZ(97$M /G!AP
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M'1VCXN6#0G0[7_^RX#+F-?Y^@42YV$^XS,O!!N%F2R@;/09.M%#&]C'#AXD
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M"G6M#YI%%FI<2\?7X_L2X6D8O8D:R<;TG%6B'J]NQJ<9K._1^W7NS&QL[?1
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MI/JL&^GCRX;^ZM0 ?XO?M/":3[DN[XT=E2]^7+F&.!FV<^+_' M4CV:9LRN
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M"!>)4(DJ?>;S><[QQ:(Y;?ZKO\?JC^%SM<6]JTEUW;J9))3L5\^3RDJKOPB
M=LXP5PY/W>@\PLO=GM9%@'[YGUSK&/4+*X, ]$J@PJ&EEG4V;V]04^OK%$;5
MIFK![<.E[!7$0H+8F^OOQEGDZ5GV%HA7VV:#[6CZ(>B%8QPT^U4X3,$4MPO5
MVET7T1*?KI_S>'G1)_>IG,?HK)/LP\Q'C9E>?;4;!R]PZYK6&#L$4I]A.71
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MIGR&@P[R9K-;W-. CPMW2YKG+^73TV^8I)_;?#@Z_)Z\:/(_ %!+ P04
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MTUDQQS.J&BC2OQ?E+S]E%,]+SH_B @>O4#_!YC*H?@5=#_KNWWX4[)=__Q<
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M&=!]&6@"%/M4< *%(Z1:!5Q S)5D"5<@'B8($:/C_1IMCDVKKJX?+N\N[Q_
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MRT>NZN:;U'&,95;9\QG[))F?/N ?ES_4;)"_YS,NTOD$880C@AVHYEMJBX5
M[#$7"D&<"$4)<Q)AXI!HM3JV[[I$:^9SZ+&KYVCTSIGU;[_$6V>*5H&")>0R
MIK &#=[5L'L\A65$4Y^.A%[#@WH/1EQLNPQF-W=3'_F\BYRS='Z!\_Q59'E9
M_>A)G4*?)(1'ONL(&))$:@[&*BQ0G<=*$":(Q)Q&@8GFM+0U-J4I"S6H+X:6
M@ %=0VRXY]O&L)[N],2;9;51JE+!!.LXST"%M#]]T:"C3U5I:VY0+=&P>UM!
M=&XY,03D-INF]'65LR6,?8XXIY#Y+I-2X5&8$,9A@@D.D4M]'ANEUSG4T-@4
M8ST4HF-0R#:5>NK0!T&6I6'%S1FH4(*O]7^M9+$Y1HF5()+MMMXFFN2 Q0?#
M2@Y=WS5P%A?\(BOFDQ@GQ$.A@#3"%")7<!ASY,* ABB) IK$"9G,594=/1E8
M/MGHNU\^W^*P5]4@*\]L4XG/\.-?,:;WM7?BP?+G76_3*%1]!I=N&=IOM&CS
M\('#/[=LVHWGW+[@Q#P+]5RAF,2NYS!$ N@G'H&(8 )C52*"B8 &A"#7424B
M]+_'G1;&^5UF9;*B\KNLCB?6:#NF4EC2J?>QGD22Y8]V%39^>8R3[AD2MNVV
MDA5AV<C;9$+8MO%@]H.="SNN%V9/3]FLS+)YB_.;O%P>8'_@Z8(W>9XGD72T
M&4]\Z) 0081<#&.?^)#$,8H\'(<<&05D:[0Y-G^\@ERE4CY3A:3 BX);QMRQ
M;#K%>:'"\*KX.\/P.YTNT%Q2[)=8VPN*%:?W%:<2L"H_5T$&)>95JO@>EQ/U
M*>IU,5&CV6&7$O5YV%E(-+CUA!22:R>8KZ5-30X6RMP@B!R8^"* R&<(QDG"
M(4Y8X >4)FY@E(/E<%-CDZ J4V+WDE2'.=5T/WIARK8?4I*TD>)@A;/GE)*M
M7/2>5W)_:\,GEVRU>F^&R?8[WN;HR<<L%[PLN%ZHC @_GM.\?$)Q-;LMH^G_
MY"JQ%&?G+]+?>N1-FO';/*5\@IU0("<*H8O#!"+F,4@<!\G^(RR6XN2XCE$R
MVS>U9FPZ=Z%"^:93Z02H*9:H3..L%U?K;5\;/9W]:5X&RU+>YPF*-4ZJ%#<K
M5H!\K2I>SD###*BI65:' "4YXSETT4L?C^F QFD&_52'.7KIN[X/?O0#JMM8
M_AGG?_&YRCU]SZ5WD*[754Y<ZOLA1= 5*N5BX LYT@H!710&C 9^1$1H,M*V
MM#6V<?#+/7C(.2X6^2LHEF#-QKLV:O5&HYX(LSQ6K%""%4P+R18UV.A35=N:
M&U3S-.S>5B2=6T[P_<EQK2,'M.X/7D@A:X3M(T[S<NW"G7B)C\*(N=#C0HJ-
MXW*(X\"#?A![)!%.[)B)C2V@8U,JA:Q>#\U$4VBN.HD,7DH;.GCI-CK8P %_
MXV[[B7SKRMQU-[I\'TJ;>_:8+79*[\ZP#:S#^[D6&=_KPMILKV-*</9?BZ*N
MCY*=,Y:JQO!4'1J]FEW@YW2.I_NAWZGLM44ZEP-@_B+=Y J8JIKZ."N?4N*;
M< _%A$4!#(4?0.22!!*:1% $0>1C1T2,F560LPQX;*-/5>:QTBBZ9HUA=G+;
MW:PW]HRI\RR/0>>W5Q=G^T>8U3=_!JYF-"_#H426ET%!8,VF'M.H#T1\KYG8
M;6,>-IG[0#VPDP]^J':[C3^70G ZOQ&7/^@W]57<X3F_D;B*;^K_JUS.TO-6
MX._D^)>G5(Z!Z@_G,[;YB[4K)S%U8^J[+G0BQY<3G9!"PL,0(H\S^2N/>IY6
MAF:+&,<VRE0FJOD-KXT$N;2R -)IIA*ZV6ACHU/U!I@W[BK+8\JJEQK[@#)0
M=9("?5;^+UC#?@969E5_5-L#V[];NZ&_$<=B3_0YR-B .>BX8I'G[:'$9E,C
MW2>?A*$3,!\'T*$QER,(]2!V0CF1"?TX%I''J$_,2IA8QZPE6(,6/6G;\WZ3
ME'['^WTDF]DC&GP&W[#^B?:C?\H]Y_^?[2N_V=[QB6/8U>Q%MICEK]=\/N&A
MSWG@^5!E"H8H\G@5BXXY$<0+?#D6<;,#H:N'CVW.T6 K]S)GO/1KG_/L)54%
MR\KUD(P4$DQ!N<IO)__Z/^686^K%__03S_3<Z!K+ 7-<WXU"M1,F!W7B8:E7
MH0L1(B'S0DHX<4S.]W1F>8"C/=LLGT";WIC8E0S+P]<2UAFX[K/ Z3YS^STR
MN_;\@8_)[EJV>S1VSS5=TP[*1RVX2NUUD<WF.:;S/]/YMR9[D)QT3!<J<ZLJ
M9"/_GZH"-G&(BX,8N]!%G$KOW",P)M2%1#C(YU'BN2PQRSQHC&%LJEH6?C1-
M-6C.O)X66.;3LF34Z*N<@@U^\%T: !H+SL#2!M 8H8[N]YETL#.%_>8=-(<Q
M<.K!SCSM9A_L_J@.M0:7&OIG+F?%'[+O,P4@+_"TF(1!P+#\OY#B6/HGL2L]
M%1(S&,88HS@(>8*T!.Y80V-3L254\%UA!4R"!7F#UJ""7ANY[1K6)V5#^3:@
MA D43G#7,UL&!0=[8FV@BH,=V3.K.*A!26O)P;;[AZLYJ&'%1M%!G>N[QJW(
MY\SE5'%Y5'P2."@.?=^70Y?C0(03#\;"BZ1J"M^AA.+ ,ZHGN-O$V%1R#6&3
MK,$T+&2'1=U CE.XL1UZL4;+Y1%:.D12'+*\W]B'G58&CE8X9.5N?,'!*[NF
M;) (E==5QB"DQ5^W/%>_P(\JAEG.Z4(_BF$BB/S&D?P7H13!. Y=UV4>XF9;
M^VV-C>UKW\ JG2'*TY?R3$ N<9OF9&CA6$\!^F+.LA9LDJ9PGH$5TCX3+QRG
MH]^,"RWM#9QJX;CENSD6-.XQS^5^SQ^5O_@[SQYS_/PMI7CZ(7O"Z6R"6(B8
M'\8PI &#R",!Q'Y$8>)PER$71TAO'M7:RM@$8QTA^%IA-,CO?IC-=H7HC2/+
MTF!&CU'.]Z/FGYKZ_7 #@V6 /VKC>B+XXQ</?%AJM8]7;_@SY(B ^0(ZB9!S
M!A%&,$E\!!.<^ %%L9\(HRQ0O2$;FZI4VZ)JOE'#K LT#G0(:J?C]-R5-^D.
MRP+60T3&RCH[01=],CZ*,TP[X'Z.0TN'..WME-+!!CKJNDJZI1[^*9WQ*_G/
M8D(BS".7!C @I#Q(Y,*8XQC&3!#,48B99Y:59J>)L2GM$B'XJC""$J2F ]="
MI*9@GD2/;>4S8\9<NPX:WZL([;8RK)H<M')'%@Y?V6'#JTS<NZ8I5>THY 1!
M3 F&F#,LIVB! Y-0.#".O$2Z9"X*J)8#=KB)L7W?)<CUP;HPJL'5PJ7&SM;)
M#%G^Q.V18["1=3)) VUAF9-EMGO5RD/KOM7^.X?;L6I%OK%7U7ZEF<PQGDXN
M9_-T_OI'-EW([L]?/Z93*2D3'"9Q$+  >LQ5"3XQA7'@^A %G%$<1T%$M"I
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M7,%D3T-#URDY;.N>:B0M%YLI0)'/)\NRK;_S[#''S]^4,)W_2(N)%_.04QK
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MSM^;G6DH08SW5,,Z1R>=:]AX4%>E>U0I0.5T[C:;IO1U-3&+ \:<D&'((I1
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M'L$8QQA&P@D]Y(@D1F;IM(^W.38)_/WRYO>[\]O_?74!SJ\_@/O+WS]?7C^
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M<K!^]A+M9L?V8=>QQW4>.5Y#+_/:UG&?'<.?]#M"PSFP0J]EC:CCEVMF&]1
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M2A53Q)V$<QT:GQME'FR/&N/KLTMC?G1D_^#D,Z>>L2/14'@'9DV?4+MKS@[
MS*N6K$O[TVK$#D#F0OMUR#,\J7?</^^^;K;+_VTD7GD5'Y2#+%8FJ)5F@*;Z
M?]*$D1Q2J203H\0[#FW-C<>N:G?0O;D>I3N.\+:C*T\H!F:G:\(=T<'2@+(=
MEW $5>TX:NYE13LN_>[5[+ARRU 6.=+?,J);KWX\ZB?=_[DL%P6%!$I! "ZX
M %#  E"(8I 6G!09%C!+B1N+W&QK?BQR+$MF;(V,J?J+K(UUG/AT06Q+'%Z
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M4A<UD,<\:QA1_KKY7FT&OEM_-O).="O.B+@)]_BT6:U^WFS-_N""RY@E$B6
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ME;761;_7]EDJ^'<CV<U2WO )S$/VT#@)W_:Z/E8$]W8#DPGB]OIX+([;?_'
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M\KO\+/GSMMIW?/NGR9R5XF=MKHE\?ZYC;1_4>;'9^V_FI5BD*H<9S2@@@F
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MW6L=J@0!MTWZ<^-2O4"NG(IJKZI;]G[Y(UN?*/ND8"]V34K,/I$\IVNOSYZ
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M?73$)[J31IYNS?7S*P[ZK*E(FDT$W76K_76R7$AH1/P*/0O$U ABP1C@7!0
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M-%&0Z6$-:11G) LX)LSIX.5\DW,;[KWJG1=(\EF ;\<.?B$=F2X\H.G,(?8
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M5N+;/2O^U:QB"$K3("0(QG& (-9?',@YB6&*-:\G@69SY;1X/-?@W+C[F;W
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M 4H#Y2^>)2['_<)9,OQ?YFLT]MQA482FMP;-%6@@N0(U*'6F;N>K]V?UU>M
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MDLO1>QU#ZAH>#VC8#",-1T@[8W!+0/DXF<W]Z'\-+Y<VE8O,B<0%B=F45:"
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M:R;CV1O(DRG<&71]] V9B)(;COWT^S%R=O9$N5?B(#-#O\+STL=!4$5L"H8
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MWA[E#!$=L*-O\;,??X)35+0GX[+8\E\)P'_Q(UAF]UZW"RW_@#;L_1_<^>3
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MK"7EA4M6>L*%#D2"-\1E0TEVB490SM%4R=_HWC5?/O,MS.)T>%E$<)6^D1A
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MN^DA]QFC6 21)-J;7*.M$-#R#%HD$IEV^%\&/.PV.@>??$6+89@.3L%N6-J
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MW-UM">TWG%T+,)O,Y>Q*>C\ .J_#GS%(H2-#)0_<X1%"T:<''TG6*CHKE G
M^P!E$T'K1K"XBZQ^% @N YR""Z$T -'"%QNWE'AHQ(QRWE*9I8BV>B_WAD/3
M+<%P:WG] $ <1*IE"D(2'UA)0H-,0C "89.RS-8&7G^60'L!Z$9@MY5T&HBU
MK%W/DT%*EWF(.3@"S*$+IZ@@CBE.O$+]SI2F4"?<O!65_8:9^\1A)W)K)RRS
MOL16@8NHOAVJ<V2=M"[A!M.6)*D-VK4,7/UY%XT$EOO$VE9R:%7178<M8Q(R
M,!#$4$%+7K<B%LT#DFUPTJ2(?[X>IIH(*/<)K5VDTKC6NA.HU*518%*!""@M
M G -Q$<J26*)"15]^>=7PUHK@>0^X;:C;!K-K3\X/#S]_>CMT7]^//IP=G1V
M\.'MR?G?CDX/?S\]/?IP_O[XX,WQ^^/SXZ.S77+K-W]X%[GU.RZEH]QZQ%YI
M^S<[&*>#&*<+/[HS#T9)K6-I !F%(5*SB!C$KXR*(FL6@-8IZ'^&IH[:E<]6
MK[A^ V+Z3BD#6I>C2>F*>HY,?H.__L^!,T*"$D!R,L@*5TS+[#1)VNIDO!0T
M5?%&=Z2WWW!Q5YAZHK/Y_VWOV[K;2FXUW^>_8*;NEY=92VVK^_A,6_:2E63R
MQ%57FQ.9]"$IQSZ_?E 4=3%%2IOD+NZBDH=T;-DF<?F  E HH*KR3MW?+8=X
M[O6B:->O.*KOV\36$3R@<(EYX35$7B:_V;+0OD3_F<LH@Z8ZR"J5^ H></FT
M;V4OJ^5^Y>,_++ZDV2H4?61&2WD_6!!EEL60!1A:QM5E'< DBUE0UA3C%,.C
MZK:E?$\"VO5GNR#DER?@QU#%J3NS ]Y'[OP=1W5G-5]+/H=64A:_IN0A._0[
MPBH/-L8 BD@\@(7& ['*=7?=B*[8T2=W[69H+7=9M=8\9DDR4%T*U)ERP'_+
M@>=HO25$:U7ED>AF<MKU7[L@8D,\=JCH&[B)6G'QVW1R,W]@@GITK<6EJ[)F
M0]B,.;*E%@@FRB%[9YFM\H!L(S7#WKA7AL\!@F\'/6@#R,+TZ]?Q?(YJN6>&
M"NJMC*!CV9XL0\;#VAL(D5%BG*'*U$319JJ&O3BO[XP.540#J/HXF\:;L/B;
M*]L^%C]7@GIS[9"I/$[QGJVLBT=5X+GE('BB93(UBHYR*:Q)++DJ-Y4=Z1OV
MKKP6TFHHIP',K0SHW61^,ROEXSLV3(Z&YY)A,.M05"Z =P83'NNSX-YZ:JI4
M ;?0,^R]=V7O=9#PV\$06DA.2__KKG]/#V=[<LY(+@@$;3(()AAX32F03(F0
MN4R/KG(!^3Q9P]YN5T94'ZH8>M[@?T['DP7*YU,J\Z*N46+XZ=</=_249>MD
MYA )4R"$BV"#M. HY51%8VEZL5[0Y8N&O:ON&RB]BW9HF/P%_>:LS+"_<C\^
M3N?CHICY RLF6YXD#T"S]"!,3& QZ@/")"-6*F)D-Y0\_SW#WC!7 4F/@FW@
MC%IF""B?\Q]A/$^%I5N9W7E&1Y.,U#G0A(BRT1D](S42>-2*9X$90ZY2.7J!
MKDZXLJ>"JQK*&-K_+.OW3\OZCTKY=UQ9-!DOC<5S-S*T&.I08MP"LX1J%TO_
M!>ODBCI_9;<")#D5^%24=P,>ZNFM]KTY,*\T3QD<T6@.GN-Q+-&5V!"]B4$R
M2JO<1VZEJ!NN3K6R?: &>NL'[??Z[>/EA[=_>7/UM[/+R[.+?7NDGGY('Q=H
M+Y#6UPW9+P6<7YI&'N!C(N?>.P1-%ACY:DR0+$<,Q1",CC%YP:N\1^Y"7,_E
MQ4T],T)8%'1V$ W3('C9%Q1H0!E$(R+/V:@J>W-?)FW@N[2^L?-"=?%0W33:
M O#$T/?O6]KV457\4<T^I"[("D(&)[('ESVJ7AC$F*6ZZ#]9HFS0\0AF6<<K
M?0I?4KRY3A_RF@W<IYIKK3#:.ZXSM4"IC&AFQ>"XS,"MU3HK'5V=VX]="3T!
MC[4+KI[D<#7U=BK^ZX!6I:V?5<6#56T]Z@(U1DPV&E,P'<OD$I49."XB*,$P
M>LZ*<5^EE?H8+NS]]'LJ3SG>33XMW"2Z6=Q\67@YO;[^?3K[)_Z%$>$A!%U2
MB)11'LQ+<,(1,-%2A\9@F:GBTO>@]00<V2[H6G=DM;770&GA><9&1B:BN500
M5*2E=:L,5$G(E\7X4DA%;:XRT/!YLH:%7754K!^G_:EH;\!]2[/Q-"(EL\41
M8/=@T>_F\YL41YPX32-CX&-*($@J>V;*0 MNK'1,I<"JM!SL1N:P77EMP?(@
M%3;O%^_W'D>5A30D +.^K 0L5UT$C<]P%V)44><A@+G3XNEJC7UM 7(OE1WZ
MO/H81W04T5!J!& &5;JKE0!;"DS>\N"1%^M4E=4!/1S1U3K]VH+>3BHZ\(@^
MG\1J.>Y_?GAW<75V\?;3^5_/+\_^_'CV]\L/?_YY]XKE[_NDNB]]9!\9[TYD
M'^'-C<\I><<28&9B2[4#?8\-"5((2F16_E<GWZWTAG#9,N2VM@P]E'F,39:3
M%,!HG9%QI<!)IP$C5#0W%3$(Z+8PO>LWMOO*9A<,/.W/ZEO8C=;47C#< RIL
M'3_Y"-YGJ(=_)@LC!<<SCGN$1W823)88%%$BM!',Y%!E\6[%AW\/9>?SV6PZ
M>S-%&(=E:QI^V4<\'&<?ET?D6?Q_-_-%"0\NTQPUNHP4EA7ID9094V<\]$4N
MQ2)/T7P"+].T42HL!Z)SE=+;X:2WZ^IV0=KVFX2CJ'3 O',^6XP>T7[V8SP?
M:6>R-\OWW,: 0$; <H8N/"=I+8T1!=H!C?C1CY"(OUM'X8;O'A9.QU;[M!\=
MM .?M].RQ'NDN.$B9 F)$E]JWQ8LS0)()I02:4F.75+#70%T^^W#0.A@'6[&
MPAX";0<-#V;R/GWU:3;2D;H0C00AJ 9A% -#.,=0D4@M+)6TTPW3SHYEC8XF
M$+*/9K?XBT/$O#=:, WPTYZ*GEV][?P1UQ@,IW?XR_F(.\PWI,F@G$*_*U4"
M;Z5 J^-2I.Q4K/.8ZR"JAZW9#W30'5_?0[?BO_2L*?CH><H&,BU/<Y5.)1^W
M$*U.,CK-\:#H7IHX\,58M;CJB/K>Y4W9+L)O$TBKUP8C*JV6D3.PTN@R<#J#
M<YF 9LFQY(GV)AP H]77#.NSF@+1/H)OM-IU?G9Y\>[BCT]_?OCTZ>/YY:?_
M.+L\WZ>VM?%S^JADO4Q@3W6K<S>;C">?YXBH3U\0D_>EA+*#/KJ8P3"10&C4
MLK=)HI9=]D$&QG*="&,+00?'6VN?^ZAZRP0C3I3QS])AZ(C9BDU>(F%9928<
M<[K*8X.M% U\</6!B"?13R_2/R%OLG]+_3.?5LNS5&RLWXXFJTP,AD%6;OF.
M0H-Q1@!U"5- RZG755[ZUO(OC]*+M6_XS<W' 4_3M^/KFS(&_M=^;)E$5"1K
M<$%2$"12L!9_90+)" D3B:UR0[DGO:WZIAW0]$SANYKF3LAS'7#5]]S'U?)=
M-2_UML)-N3)"*E/0Y=F&L%9!>5L&6@>J$@^)UMD]7M]YG4T6XUC@/OZ>/J5P
M,UL^P#W_$:YO4)Z_HT6^F7[]=G.KO*<6<ULGT8KEX!2%)*PH!3X*3I41X"%0
MR[+RBE1Y*=TO&XVZNEVPM]W5'5W/#?29'LCS;S\W?\#RWH,*&PR7!H@A# 0>
M.^!HF;1OHY%6!LU4G6&3]7AJY5[R^%!='TC0"&Z:-:$+]S6M[G:84EE3$E"Z
M)4FD/(,K\\U2TI$+JA2Q_'AV\$#8L&!N!D&=D+VG.AN YX=O2P%.'GA970^6
M:QIB9(9@=.&#2O Z$V#"\F!(#*D.++<1U"(<]U7[M((.&L#2@3;[4(8G)++
MA0'K@P3A4WF78Q1*U#%FC;6BSMS_OAAHY=KVU.. _1#1@"6L,W*9PG02QM?C
M6Q#<)29644*4HT S=2 8+RT8A@+C406972#Q*#<&F\EKT>/6ALX+1?@>]-@
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M.\<9_;G045I7I7WE&9J&?9-]E%-O+_&WB*3"R,K,F!'92*_!)RI!$,_!1^8
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MYV\_.GYC6XU >VIW6EO4#?B@S7R=+9:+D/&'90UX&B5B- DN 5=EG&%2')S
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MA!1E59 7D@"54266B=6\RM2LP\@^>(I UV__[?&W/SSLM%J0[*F'&,N595E
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MK!<LBP,C+3A/1BK@M@S*%-: $4*!E'B01<F]65\]N:7GKC*AG7"M7QFNFT-
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M!#1*F8-P7I@JSVBVT-,2;O91]+1_J3< GC?3&3IBMT@7T\F*DQ4CV7I'G&!
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M'VFN_J#\IPQA^]__X_\#4$L#!!0    ( .R#?U*EH7))X0(  .0(   .
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M:&EB:70S,3$N:'1M4$L! A0#%     @ [(-_4MN2HT!,"   =RH  !D
M         ( !AP@  &$R,#(P<30Q,"UQ97AH:6)I=#,Q,BYH=&U02P$"% ,4
M    " #L@W]2?OU2B?@$  #L%@  &0              @ $*$0  83(P,C!Q
M-#$P+7%E>&AI8FET,S(Q+FAT;5!+ 0(4 Q0    ( .R#?U+%&XU_[00  '<6
M   9              "  3D6  !A,C R,'$T,3 M<65X:&EB:70S,C(N:'1M
M4$L! A0#%     @ [(-_4AV"SA[&>P( $X,; !$              ( !71L
M &%P>7@M,C R,#$R,S$N:'1M4$L! A0#%     @ [(-_4M66AC$'$@  >KH
M !$              ( !4I<" &%P>7@M,C R,#$R,S$N>'-D4$L! A0#%
M  @ [(-_4B-ICIAM)P  !)$! !4              ( !B*D" &%P>7@M,C R
M,#$R,S%?8V%L+GAM;%!+ 0(4 Q0    ( .R#?U+JRNH;N$0  (6Y @ 5
M          "  2C1 @!A<'EX+3(P,C Q,C,Q7V1E9BYX;6Q02P$"% ,4
M" #L@W]2;+9((&81 0!,/ $ %               @ $3%@, 87!Y>"TR,#(P
M,3(S,5]G,2YJ<&=02P$"% ,4    " #L@W]2CF[P9XLF 0#P]0$ %
M        @ &K)P0 87!Y>"TR,#(P,3(S,5]G,BYJ<&=02P$"% ,4    " #L
M@W]2"*GE)U#K  !DUPD %0              @ %H3@4 87!Y>"TR,#(P,3(S
M,5]L86(N>&UL4$L! A0#%     @ [(-_4N:@KO^AAP  *24& !4
M     ( !ZSD& &%P>7@M,C R,#$R,S%?<')E+GAM;%!+ 0(4 Q0    ( .R#
M?U*EH7))X0(  .0(   .              "  ;_!!@!R<VUC;VYS96YT+FAT
7;5!+!08     #0 - &8#  #,Q 8    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
